STUDYID|DOMAIN|USUBJID|TRSEQ|TRGRPID|TRREFID|TRSPID|TRLNKID|TRLNKGRP|TRTESTCD|TRTEST|TRORRES|TRORRESU|TRSTRESC|TRSTRESN|TRSTRESU|TRSTAT|TRREASND|TRNAM|TRMETHOD|TRLOBXFL|TRBLFL|TREVAL|TREVALID|TRACPTFL|VISITNUM|VISIT|VISITDY|TAETORD|EPOCH|TRDTC|TRDY
TRIAL STUDY 134XCP|TR|28FBEC95-59B8-4821-BD7A-125E2C87D71C|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||LOG10 ELISA UNIT|NONPALPABLE||MSEC|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|N|NA|CHILD|PATHOLOGIST 2|U|1||38||BASELINE|1963-05-25|
TRIAL STUDY 134XCP|TR|28FBEC95-59B8-4821-BD7A-125E2C87D71C|2||||||VDIAM|VIABLE DIAMETER||KHZ|NON-PATHOLOGICAL||GENEQ/ML|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|N|2||58||FOLLOW-UP|1960-11-17|
TRIAL STUDY 134XCP|TR|28FBEC95-59B8-4821-BD7A-125E2C87D71C|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||CG|DIFFUSELY INCREASED||DEG/MM|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|NA|U|FRIEND|MICROSCOPIST|Y|3||39||OPEN LABEL TREATMENT|1971-06-30|
TRIAL STUDY 134XCP|TR|28FBEC95-59B8-4821-BD7A-125E2C87D71C|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||PKAT/L|FURTHER ENLARGEMENT||UG/DL|NOT DONE|||MRI WITHOUT CONTRAST|Y|NA|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|4||88||RUN-IN|1961-10-08|
TRIAL STUDY 134XCP|TR|28FBEC95-59B8-4821-BD7A-125E2C87D71C|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||CMHG|PALPABLE||U/CL|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|U|Y|CHILD|ADJUDICATOR|U|5||7||CONTINUATION TREATMENT|1968-03-17|
TRIAL STUDY 134XCP|TR|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||G/M2/DAY|ABSENT||MBQ|NOT DONE|||CONTRAST ENHANCED PET SCAN|U|NA|PARENT|MICROSCOPIST 3|Y|1||38||WASHOUT|1968-01-09|
TRIAL STUDY 134XCP|TR|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|2||||||PALPSTAT|PALPABLE STATE||HOMEOPATHIC DILUTION|TUMOR MERGED||NMOL/L/H|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|N|INVESTIGATOR|NEUROLOGIST|U|2||58||BASELINE|1960-12-23|
TRIAL STUDY 134XCP|TR|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|3||||||CALCFIND|CALCIFICATION INDICATOR||UG/KG|FURTHER ENLARGEMENT FROM NADIR||L/L|NOT DONE|||PHOTOMETRIC CLOT DETECTION|NA|Y|SIBLING|MICROSCOPIST 1|Y|3||39||OPEN LABEL TREATMENT|1963-08-19|
TRIAL STUDY 134XCP|TR|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MAC50|UNEQUIVOCAL||UG/ANIMAL|NOT DONE|||ICP-MS|NA|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|4||88||SCREENING|1972-04-27|
TRIAL STUDY 134XCP|TR|312DF5BA-05C3-49B4-AEDF-DC5F794D12C1|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||U.CARR|DECREASED||DRUM|NOT DONE|||CHROMATOGRAPHY|NA|U|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|5||7||OPEN LABEL TREATMENT|1970-07-11|
TRIAL STUDY 134XCP|TR|1117C221-3530-45CB-82B2-B831C4DAD86B|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PT_BR|ENLARGEMENT||FIU|NOT DONE|||MIGET|Y|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||BLINDED TREATMENT|1962-01-15|
TRIAL STUDY 134XCP|TR|1117C221-3530-45CB-82B2-B831C4DAD86B|2||||||CALCFIND|CALCIFICATION INDICATOR||V/SEC|NONPALPABLE||COPIES/ML|NOT DONE|||ENDPOINT DILUTION ASSAY|N|U|PARENT|ADJUDICATOR 3|N|2||58||RUN-IN|1961-06-03|
TRIAL STUDY 134XCP|TR|1117C221-3530-45CB-82B2-B831C4DAD86B|3||||||LDIAM|LONGEST DIAMETER||NEEDLE GAUGE|PALPABLE||CD/M2|NOT DONE|||AUTOMATED COUNT|U|N|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|3||39||FOLLOW-UP|1960-07-05|
TRIAL STUDY 134XCP|TR|1117C221-3530-45CB-82B2-B831C4DAD86B|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MM/2H|TUMOR MERGED||MEQ/UG|NOT DONE|||MICRONEUTRALIZATION ASSAY|NA|U|INTERVIEWER|ONCOLOGIST 1|N|4||88||SCREENING|1960-11-08|
TRIAL STUDY 134XCP|TR|1117C221-3530-45CB-82B2-B831C4DAD86B|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||EJACULATE U|PRESENT||TESLA|NOT DONE|||PET SCAN|Y|NA|INVESTIGATOR|ADJUDICATOR|U|5||7||BLINDED TREATMENT|1970-03-21|
TRIAL STUDY 134XCP|TR|3ACFF838-5B16-4898-9640-A60C85096F64|1||||||AREA|AREA||NGEQ/L|INCREASED||ENZYME U/L|NOT DONE|||RULER MEASUREMENT METHOD|N|N|ADJUDICATOR|PATHOLOGIST 1|NA|1||38||CONTINUATION TREATMENT|1967-04-27|
TRIAL STUDY 134XCP|TR|3ACFF838-5B16-4898-9640-A60C85096F64|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MEQ/DL|PALPABLE||AMFI|NOT DONE|||FLAME PHOTOMETRY|NA|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1961-03-10|
TRIAL STUDY 134XCP|TR|3ACFF838-5B16-4898-9640-A60C85096F64|3||||||SUMDIAM|SUM OF DIAMETER||10^9 ORGANISMS/ML|PRESENT||PMOL|NOT DONE|||IMMUNOPRECIPITATION|N|N|CHILD|CLINICAL PATHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1964-06-23|
TRIAL STUDY 134XCP|TR|3ACFF838-5B16-4898-9640-A60C85096F64|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||KHZ|NONPALPABLE||MPL U|NOT DONE|||FLOCCULATION|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|4||88||TREATMENT|1969-11-20|
TRIAL STUDY 134XCP|TR|3ACFF838-5B16-4898-9640-A60C85096F64|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||S*KPA|ENLARGEMENT FROM NADIR||NG/DL|NOT DONE|||IRON HEMATOXYLIN STAIN|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|U|5||7||BLINDED TREATMENT|1970-08-30|
TRIAL STUDY 134XCP|TR|308F422A-B02B-4C76-86E7-834AAC127FE3|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MCI/KG|FOCALLY INCREASED||SFC/10^6 PBMC|NOT DONE|||CALCULATION|NA|NA|SIBLING|ONCOLOGIST 2|Y|1||38||FOLLOW-UP|1963-11-02|
TRIAL STUDY 134XCP|TR|308F422A-B02B-4C76-86E7-834AAC127FE3|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MG/DOSE|EQUIVOCAL||CCID 50/ML|NOT DONE|||AUTOREFRACTION|U|N|SIBLING|RATER 2|Y|2||58||OPEN LABEL TREATMENT|1960-03-28|
TRIAL STUDY 134XCP|TR|308F422A-B02B-4C76-86E7-834AAC127FE3|3||||||LESFLIND|LESION FAILURE INDICATOR||MG/KG/WEEK|FURTHER ENLARGEMENT FROM NADIR||CI/G|NOT DONE|||OSCILLOMETRY|N|U|CHILD|MICROSCOPIST 2|Y|3||39||BLINDED TREATMENT|1961-07-16|
TRIAL STUDY 134XCP|TR|308F422A-B02B-4C76-86E7-834AAC127FE3|4||||||LESFLIND|LESION FAILURE INDICATOR||10^6 U|ENLARGEMENT||COPIES/UG|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|4||88||RUN-IN|1972-12-09|
TRIAL STUDY 134XCP|TR|308F422A-B02B-4C76-86E7-834AAC127FE3|5||||||LESSCIND|LESION SUCCESS INDICATOR||AMFI|DECREASED||ABSORBANCE U/ML|NOT DONE|||LIQUID SCINTILLATION COUNTING|U|U|CAREGIVER|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1967-04-11|
TRIAL STUDY 134XCP|TR|34A3AA01-3595-42C2-95C3-44E3AF77B28D|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PMOL/10^9 CELLS|NORMAL||LOG10 CFU/ML|NOT DONE|||RYAN BLUE STAIN|N|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|1||38||SCREENING|1972-05-29|
TRIAL STUDY 134XCP|TR|34A3AA01-3595-42C2-95C3-44E3AF77B28D|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UKAT|ENLARGEMENT||KA_U/DL|NOT DONE|||MULTIPLE BREATH WASHOUT|NA|N|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|2||58||BASELINE|1962-03-18|
TRIAL STUDY 134XCP|TR|34A3AA01-3595-42C2-95C3-44E3AF77B28D|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML*CMH2O|FOCALLY INCREASED||10^10/L|NOT DONE|||IHC|U|N|VENDOR|UROLOGIST|U|3||39||OBSERVATION|1967-09-17|
TRIAL STUDY 134XCP|TR|34A3AA01-3595-42C2-95C3-44E3AF77B28D|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||/10^4|PATHOLOGICAL||AMFI|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|Y|NA|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|U|4||88||WASHOUT|1961-01-20|
TRIAL STUDY 134XCP|TR|34A3AA01-3595-42C2-95C3-44E3AF77B28D|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MIU/L|PALPABLE||10^3 CFU|NOT DONE|||EPSILOMETER|N|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|NA|5||7||BASELINE|1964-09-17|
TRIAL STUDY 134XCP|TR|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DIOPTER|NONPALPABLE||ML/M2|NOT DONE|||CLIP|Y|U|VENDOR|PEDIATRIC NEUROLOGIST|N|1||38||TREATMENT|1961-07-11|
TRIAL STUDY 134XCP|TR|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||GBQ/G|ENLARGEMENT FROM NADIR||CAN|NOT DONE|||SXA SCAN|Y|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|2||58||OBSERVATION|1965-11-13|
TRIAL STUDY 134XCP|TR|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|3||||||LNSTATE|LYMPH NODE STATE||CI|ABSENT||AMPULE|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|U|NA|INVESTIGATOR|PHYSIOTHERAPIST|N|3||39||RUN-IN|1968-08-19|
TRIAL STUDY 134XCP|TR|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NEBULE|FURTHER ENLARGEMENT FROM NADIR||BQ/UG|NOT DONE|||OSCILLOMETRY|NA|NA|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|4||88||CONTINUATION TREATMENT|1964-01-24|
TRIAL STUDY 134XCP|TR|05A82CB3-4A6B-42B9-9B5F-7D48C263EC70|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||HOUNSFIELD UNIT|TUMOR MERGED||FRAMES/S|NOT DONE|||AURAMINE STAIN|NA|U|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|5||7||FOLLOW-UP|1963-05-29|
TRIAL STUDY 134XCP|TR|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||IU/G HB|DECREASED||S/H|NOT DONE|||STRESS ECHOCARDIOGRAPHY|N|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1||38||WASHOUT|1968-04-27|
TRIAL STUDY 134XCP|TR|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||NMOL/MOL|DECREASED||PL|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|U|N|STUDY SUBJECT|PHYSIOTHERAPIST|U|2||58||INDUCTION TREATMENT|1965-05-06|
TRIAL STUDY 134XCP|TR|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UIU/L|FURTHER ENLARGEMENT||DEG2|NOT DONE|||GC/MS-EI|NA|U|SIGNIFICANT OTHER|RADIOLOGIST|N|3||39||INDUCTION TREATMENT|1964-10-30|
TRIAL STUDY 134XCP|TR|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|4||||||SUMDIAM|SUM OF DIAMETER||KBQ|EQUIVOCAL||10^9 CFU/G|NOT DONE|||FARR ASSAY|N|NA|GUARDIAN|CARDIOLOGIST|N|4||88||CONTINUATION TREATMENT|1960-10-14|
TRIAL STUDY 134XCP|TR|85B73C68-6C9D-4E57-A8E1-E2221AE61E30|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML/BREATH|NONPALPABLE||PMOL/L/H|NOT DONE|||MICROARRAY|NA|U|HEALTH CARE PROFESSIONAL|READER|U|5||7||OPEN LABEL TREATMENT|1966-01-20|
TRIAL STUDY 134XCP|TR|ECA054C6-EA0F-4D7B-905C-849EA4592624|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||PFU/ANIMAL|ENLARGEMENT||PHERESIS UNIT|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|N|DOMESTIC PARTNER|INTERNIST|Y|1||38||INDUCTION TREATMENT|1968-11-12|
TRIAL STUDY 134XCP|TR|ECA054C6-EA0F-4D7B-905C-849EA4592624|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||10^6 RNA COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||ML/MIN/MMHG|NOT DONE|||ACRIDINE ORANGE STAIN|Y|N|ADJUDICATOR|ENDOCRINOLOGIST|U|2||58||FOLLOW-UP|1964-08-22|
TRIAL STUDY 134XCP|TR|ECA054C6-EA0F-4D7B-905C-849EA4592624|3||||||LNSTATE|LYMPH NODE STATE||G/ANIMAL/DAY|NORMAL||VG/DOSE|NOT DONE|||CLIP|NA|Y|CAREGIVER|HEMATOLOGIST|N|3||39||SCREENING|1964-11-12|
TRIAL STUDY 134XCP|TR|ECA054C6-EA0F-4D7B-905C-849EA4592624|4||||||CALCFIND|CALCIFICATION INDICATOR||DYN|ABSENT||BLOCKS|NOT DONE|||JAEGER EYE CHART|N|U|DOMESTIC PARTNER|ONCOLOGIST 2|Y|4||88||RUN-IN|1961-07-11|
TRIAL STUDY 134XCP|TR|ECA054C6-EA0F-4D7B-905C-849EA4592624|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||ANTIBODY UNIT|FURTHER ENLARGEMENT||/4.0 ML|NOT DONE|||ICC|N|NA|DOMESTIC PARTNER|ONCOLOGIST|N|5||7||RUN-IN|1971-01-05|
TRIAL STUDY 134XCP|TR|83823CA3-1C1D-455E-BE49-DC5E3651A939|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||% INHIBITION|INCREASED||H*%|NOT DONE|||HPLC/IEX|U|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|1||38||SCREENING|1964-07-30|
TRIAL STUDY 134XCP|TR|83823CA3-1C1D-455E-BE49-DC5E3651A939|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MET|UNEQUIVOCAL||LOG10 CFU/ML|NOT DONE|||ANTIBIOTIC AGAR SCREEN|NA|N|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|2||58||WASHOUT|1972-12-06|
TRIAL STUDY 134XCP|TR|83823CA3-1C1D-455E-BE49-DC5E3651A939|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||NG/L|PATHOLOGICAL||VIAL|NOT DONE|||HPLC/MS|Y|U|CAREGIVER|READER|N|3||39||BASELINE|1966-09-19|
TRIAL STUDY 134XCP|TR|83823CA3-1C1D-455E-BE49-DC5E3651A939|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||ANTI-XA IU/ML|UNEQUIVOCAL||100 IU/ML|NOT DONE|||RAJI CELL RIA|U|N|SPOUSE|READER 3|Y|4||88||LONG-TERM FOLLOW-UP|1970-09-26|
TRIAL STUDY 134XCP|TR|83823CA3-1C1D-455E-BE49-DC5E3651A939|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||/7.5 ML|NON-PATHOLOGICAL||UKAT/10^12 RBC|NOT DONE|||FUNDUS PHOTOGRAPHY|N|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1964-04-18|
TRIAL STUDY 134XCP|TR|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML/MIN/MMHG|FURTHER ENLARGEMENT FROM NADIR||RATIO|NOT DONE|||HEMAGGLUTINATION ASSAY|N|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|NA|1||38||SCREENING|1971-06-28|
TRIAL STUDY 134XCP|TR|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||KUSP|INCREASED||PMOL|NOT DONE|||NUCLEIC ACID BASED METHOD|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||INDUCTION TREATMENT|1964-04-17|
TRIAL STUDY 134XCP|TR|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MG/ANIMAL|FURTHER ENLARGEMENT||MG/KG/MIN|NOT DONE|||CLINICAL EVALUATION|U|NA|PROXY|RADIOLOGIST|N|3||39||BLINDED TREATMENT|1972-03-20|
TRIAL STUDY 134XCP|TR|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||FMOL/L|TUMOR MERGED||G/KG|NOT DONE|||MAMMOGRAPHY|N|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1963-09-30|
TRIAL STUDY 134XCP|TR|C04E8E9E-71C7-4595-AD9D-01A86B1AC5BB|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||BQ/UL|ENLARGEMENT FROM NADIR||NEWTON|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|N|DOMESTIC PARTNER|READER 2|N|5||7||FOLLOW-UP|1962-09-19|
TRIAL STUDY 134XCP|TR|9C24F018-315A-4B9C-B89B-F54CA26452E7|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||UV*SEC|NONPALPABLE||MMOL/MIN/KPA|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|U|Y|CLINICAL STUDY SPONSOR|INTERNIST|N|1||38||INDUCTION TREATMENT|1969-10-16|
TRIAL STUDY 134XCP|TR|9C24F018-315A-4B9C-B89B-F54CA26452E7|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||BU/ML|DECREASED||V|NOT DONE|||KLEIHAUER-BETKE|N|NA|STUDY SUBJECT|READER|U|2||58||TREATMENT|1965-12-06|
TRIAL STUDY 134XCP|TR|9C24F018-315A-4B9C-B89B-F54CA26452E7|3||||||LESFLIND|LESION FAILURE INDICATOR||CMH2O*S/ML|ABSENT||GPL U/ML|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|U|N|INTERVIEWER|INTERNIST|Y|3||39||FOLLOW-UP|1969-05-16|
TRIAL STUDY 134XCP|TR|9C24F018-315A-4B9C-B89B-F54CA26452E7|4||||||LESSCIND|LESION SUCCESS INDICATOR||MM/SEC|NON-PATHOLOGICAL||ML/MMHG|NOT DONE|||DUCTOGRAPHY|N|NA|INDEPENDENT ASSESSOR|READER|NA|4||88||FOLLOW-UP|1968-11-30|
TRIAL STUDY 134XCP|TR|9C24F018-315A-4B9C-B89B-F54CA26452E7|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||L/MIN/M2|NON-PATHOLOGICAL||MBQ|NOT DONE|||SICKLE CELL SOLUBILITY TEST|U|U|PROXY|PATHOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1966-06-21|
TRIAL STUDY 134XCP|TR|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|1||||||LPERP|LONGEST PERPENDICULAR||MPH|DIFFUSELY INCREASED||NU/CL|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1961-01-22|
TRIAL STUDY 134XCP|TR|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|2||||||VOLUME|VOLUME||CAN|PATHOLOGICAL||CAN|NOT DONE|||MOUSE PROTECTION ASSAY|NA|Y|ADJUDICATOR|NEUROLOGIST 1|NA|2||58||BASELINE|1961-01-28|
TRIAL STUDY 134XCP|TR|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ARBITRARY U|FURTHER ENLARGEMENT||MPH|NOT DONE|||ANGIOGRAPHY|N|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1961-10-26|
TRIAL STUDY 134XCP|TR|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|4||||||LMBFLIND|LIMB FAILURE INDICATOR||MBQ|FURTHER ENLARGEMENT||/H|NOT DONE|||LYMPHANGIOGRAPHY|U|U|VENDOR|NEUROLOGIST 2|N|4||88||WASHOUT|1962-01-06|
TRIAL STUDY 134XCP|TR|AA9CE1A1-EAEF-4C04-A6BC-B56469AA236A|5||||||SUMVOL|SUM OF VOLUME||KPA/L/SEC|ENLARGEMENT||HZ/S|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|NA|DOMESTIC PARTNER|ONCOLOGIST 2|N|5||7||SCREENING|1964-09-08|
TRIAL STUDY 134XCP|TR|8D48F229-F38B-4335-B8A7-0AA24C928707|1||||||PALPSTAT|PALPABLE STATE||NFIU|FURTHER ENLARGEMENT FROM NADIR||VIAL|NOT DONE|||KLEIHAUER-BETKE|N|N|PARENT|ONCOLOGIST 1|Y|1||38||RUN-IN|1969-01-17|
TRIAL STUDY 134XCP|TR|8D48F229-F38B-4335-B8A7-0AA24C928707|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||IU/KG|NORMAL||MET*MIN|NOT DONE|||HEMOCYTOMETRY|U|Y|FRIEND|PATHOLOGIST 1|U|2||58||WASHOUT|1971-05-07|
TRIAL STUDY 134XCP|TR|8D48F229-F38B-4335-B8A7-0AA24C928707|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||% INHIBITION|ENLARGEMENT||FOZ_US|NOT DONE|||NEPHELOMETRY|U|N|VENDOR|CLINICAL PATHOLOGIST|N|3||39||FOLLOW-UP|1960-06-08|
TRIAL STUDY 134XCP|TR|8D48F229-F38B-4335-B8A7-0AA24C928707|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CMOL/L|ABSENT||DEG/MM|NOT DONE|||LC/MS|Y|U|DOMESTIC PARTNER|RADIOLOGIST 1|N|4||88||RUN-IN|1961-08-07|
TRIAL STUDY 134XCP|TR|8D48F229-F38B-4335-B8A7-0AA24C928707|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||10^12 IU/L|ENLARGEMENT||PMOL/10^9 CELLS|NOT DONE|||COMPLEMENT FIXATION|Y|NA|INTERVIEWER|RATER|N|5||7||CONTINUATION TREATMENT|1972-01-27|
TRIAL STUDY 134XCP|TR|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MG/KG/DOSE|PALPABLE||PG/DL|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|U|U|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|1||38||BASELINE|1962-05-23|
TRIAL STUDY 134XCP|TR|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|2||||||RADIODEN|RADIODENSITY||ANSON U|FOCALLY INCREASED||U/MG|NOT DONE|||IMPEDANCE CONDUCTIVITY|N|N|SIBLING|ADJUDICATOR 3|Y|2||58||INDUCTION TREATMENT|1967-12-29|
TRIAL STUDY 134XCP|TR|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MJOULE/CM2|PALPABLE||KA_U/DL|NOT DONE|||NO INFORMATION|N|Y|SPOUSE|ONCOLOGIST|U|3||39||WASHOUT|1966-08-05|
TRIAL STUDY 134XCP|TR|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MOL/ML|FOCALLY INCREASED||PMOL/G|NOT DONE|||HANSEL STAIN|N|N|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|4||88||OBSERVATION|1965-04-14|
TRIAL STUDY 134XCP|TR|F89F5FD5-AF3D-435F-9ABC-58BCB89FC3C6|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||CMH2O/ML|ENLARGEMENT||10^9/G|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|N|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|5||7||SCREENING|1962-01-26|
TRIAL STUDY 134XCP|TR|C882CB1F-C0DE-4BE5-B762-611333949C74|1||||||PALPSTAT|PALPABLE STATE||U/M2/H|FOCALLY INCREASED||CI/G|NOT DONE|||HPLC-UV|U|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1973-05-05|
TRIAL STUDY 134XCP|TR|C882CB1F-C0DE-4BE5-B762-611333949C74|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UL/DOSE|INCREASED||IU/MG|NOT DONE|||AUDIOMETRY|NA|Y|CHILD|ENDOCRINOLOGIST|NA|2||58||SCREENING|1969-08-29|
TRIAL STUDY 134XCP|TR|C882CB1F-C0DE-4BE5-B762-611333949C74|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||DPM/0.5 ML|DECREASED||IU/KG/H|NOT DONE|||ACRIDINE ORANGE STAIN|U|N|ADJUDICATION COMMITTEE|READER 3|U|3||39||LONG-TERM FOLLOW-UP|1968-06-26|
TRIAL STUDY 134XCP|TR|C882CB1F-C0DE-4BE5-B762-611333949C74|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MET|INCREASED||ENZYME U/L|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|NA|PROXY|ADJUDICATOR|U|4||88||OBSERVATION|1973-01-29|
TRIAL STUDY 134XCP|TR|C882CB1F-C0DE-4BE5-B762-611333949C74|5||||||ORSTATE|ORGAN STATE||UG/CM2|UNCHANGED||NFIU|NOT DONE|||CENTRIFUGATION|N|U|ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|U|5||7||BASELINE|1964-09-17|
TRIAL STUDY 134XCP|TR|7F3C3801-607B-4141-AA83-383FDFFD7152|1||||||VOLUME|VOLUME||UG/KG/H|NONPALPABLE||DAMOL/L|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|U|GUARDIAN|MICROSCOPIST 1|U|1||38||TREATMENT|1971-12-26|
TRIAL STUDY 134XCP|TR|7F3C3801-607B-4141-AA83-383FDFFD7152|2||||||BNLNUM|NUMBER OF BONE LESIONS||GAUSS|PRESENT||EJACULATE U|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|NA|U|HEALTH CARE PROFESSIONAL|READER|U|2||58||BLINDED TREATMENT|1972-06-03|
TRIAL STUDY 134XCP|TR|7F3C3801-607B-4141-AA83-383FDFFD7152|3||||||RADIODEN|RADIODENSITY||GPL U|UNEQUIVOCAL||MCI/KG|NOT DONE|||EEG|N|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1960-04-12|
TRIAL STUDY 134XCP|TR|7F3C3801-607B-4141-AA83-383FDFFD7152|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||U.CARR|PATHOLOGICAL||P|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|4||88||SCREENING|1962-01-16|
TRIAL STUDY 134XCP|TR|7F3C3801-607B-4141-AA83-383FDFFD7152|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||ML/KG|ENLARGEMENT FROM NADIR||DAYS/MONTH|NOT DONE|||KLEIHAUER-BETKE|N|N|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|U|5||7||OPEN LABEL TREATMENT|1968-01-06|
TRIAL STUDY 134XCP|TR|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MG/M2|PRESENT||MPL U/ML|NOT DONE|||PEAK FLOWMETRY|U|N|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1966-11-07|
TRIAL STUDY 134XCP|TR|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/VF|EQUIVOCAL||10^6/HPF|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|Y|N|CAREGIVER|NEUROLOGIST 2|NA|2||58||FOLLOW-UP|1967-04-22|
TRIAL STUDY 134XCP|TR|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||G/L|ENLARGEMENT FROM NADIR||TESLA|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|Y|ADJUDICATOR|RADIOLOGIST|N|3||39||WASHOUT|1962-02-20|
TRIAL STUDY 134XCP|TR|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||U/L|FURTHER ENLARGEMENT||ML/MMHG|NOT DONE|||MAMMOGRAPHY|U|N|CAREGIVER|RATER 1|Y|4||88||OBSERVATION|1971-07-15|
TRIAL STUDY 134XCP|TR|0DD4FBE8-5D91-4E48-AD35-06597F95E5BB|5||||||SUMDIAM|SUM OF DIAMETER||IU/G HB|DIFFUSELY INCREASED||MG/L FEU|NOT DONE|||MULTI-SLICE SPIRAL CT|U|NA|STUDY SUBJECT|ONCOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1967-02-24|
TRIAL STUDY 134XCP|TR|67025219-DBC0-4222-9D04-7F23EE3D5806|1||||||LMBFLIND|LIMB FAILURE INDICATOR||G/U|ENLARGEMENT FROM NADIR||MS/MMHG|NOT DONE|||PH METER MEASUREMENT METHOD|NA|N|SPOUSE|CARDIOLOGIST|Y|1||38||FOLLOW-UP|1972-03-29|
TRIAL STUDY 134XCP|TR|67025219-DBC0-4222-9D04-7F23EE3D5806|2||||||PALPSTAT|PALPABLE STATE||UG/DAY|DECREASED||10^9/L|NOT DONE|||WHOLE EXOME SEQUENCING|N|U|GUARDIAN|RATER 1|NA|2||58||BLINDED TREATMENT|1970-07-09|
TRIAL STUDY 134XCP|TR|67025219-DBC0-4222-9D04-7F23EE3D5806|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ENZYME U|NONPALPABLE||BREATHS/MIN|NOT DONE|||CT SCAN WITHOUT CONTRAST|NA|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|3||39||RUN-IN|1973-01-01|
TRIAL STUDY 134XCP|TR|67025219-DBC0-4222-9D04-7F23EE3D5806|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||FIU|FURTHER ENLARGEMENT FROM NADIR||MPS U|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|4||88||BLINDED TREATMENT|1965-02-05|
TRIAL STUDY 134XCP|TR|67025219-DBC0-4222-9D04-7F23EE3D5806|5||||||VDIAM|VIABLE DIAMETER||MOL/G|ENLARGEMENT||MMHG/SEC|NOT DONE|||DIFFUSION TENSOR MRI|Y|U|GUARDIAN|PATHOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1969-07-08|
TRIAL STUDY 134XCP|TR|A865B860-E5F2-423D-8110-58EBF7E470F3|1||||||BNLNUM|NUMBER OF BONE LESIONS||AG|PATHOLOGICAL||MMHG/SEC|NOT DONE|||X-RAY|N|U|INTERVIEWER|MICROSCOPIST 2|Y|1||38||TREATMENT|1973-07-13|
TRIAL STUDY 134XCP|TR|A865B860-E5F2-423D-8110-58EBF7E470F3|2||||||LESFLIND|LESION FAILURE INDICATOR||PFU/DOSE|INCREASED||UM/DAY|NOT DONE|||GRADIENT DIFFUSION|U|U|NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|2||58||INDUCTION TREATMENT|1967-04-19|
TRIAL STUDY 134XCP|TR|A865B860-E5F2-423D-8110-58EBF7E470F3|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||GY/MIN|UNEQUIVOCAL||G/L|NOT DONE|||ICP-MS|N|U|SIGNIFICANT OTHER|PATHOLOGIST 1|U|3||39||WASHOUT|1973-06-13|
TRIAL STUDY 134XCP|TR|A865B860-E5F2-423D-8110-58EBF7E470F3|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||DISK|PALPABLE||ML/CM H2O|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|4||88||BASELINE|1972-01-29|
TRIAL STUDY 134XCP|TR|A865B860-E5F2-423D-8110-58EBF7E470F3|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6 CFU|ABSENT||OD UNIT|NOT DONE|||FLOW CYTOMETRY|N|N|CAREGIVER|RADIOLOGIST 1|U|5||7||CONTINUATION TREATMENT|1960-10-28|
TRIAL STUDY 134XCP|TR|E78B2C0E-81D6-4898-B78A-FE136029AEA4|1||||||AREA|AREA||TRACE|PATHOLOGICAL||SEC|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|Y|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1969-11-28|
TRIAL STUDY 134XCP|TR|E78B2C0E-81D6-4898-B78A-FE136029AEA4|2||||||LNSTATE|LYMPH NODE STATE||10^7 TCID 50/DOSE|DECREASED||PMOL/L/H|NOT DONE|||MECHANICAL CLOT DETECTION|NA|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|2||58||SCREENING|1972-03-31|
TRIAL STUDY 134XCP|TR|E78B2C0E-81D6-4898-B78A-FE136029AEA4|3||||||LPERP|LONGEST PERPENDICULAR||PACKAGE|TUMOR MERGED||MMOL/DAY|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|NA|Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|3||39||TREATMENT|1972-06-06|
TRIAL STUDY 134XCP|TR|E78B2C0E-81D6-4898-B78A-FE136029AEA4|4||||||LNSTATE|LYMPH NODE STATE||MILE|FURTHER ENLARGEMENT FROM NADIR||MGEQ|NOT DONE|||ENDPOINT DILUTION ASSAY|NA|U|CAREGIVER|READER 3|N|4||88||CONTINUATION TREATMENT|1973-06-24|
TRIAL STUDY 134XCP|TR|E78B2C0E-81D6-4898-B78A-FE136029AEA4|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||GBQ/G|TUMOR MERGED||KDA|NOT DONE|||AURAMINE STAIN|U|Y|INVESTIGATOR|CLINICAL PATHOLOGIST|Y|5||7||SCREENING|1967-03-19|
TRIAL STUDY 134XCP|TR|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|1||||||LESSCIND|LESION SUCCESS INDICATOR||BE/ML|NORMAL||ML/MIN|NOT DONE|||DISK DIFFUSION|Y|Y|INVESTIGATOR|NEUROLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-05-26|
TRIAL STUDY 134XCP|TR|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|2||||||AREA|AREA||UOSM|DIFFUSELY INCREASED||UEQ/L|NOT DONE|||AUSCULTATION|Y|U|INTERVIEWER|RADIOLOGIST 2|U|2||58||WASHOUT|1969-03-03|
TRIAL STUDY 134XCP|TR|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||LOG EID 50/DOSE|NONPALPABLE||S^-1(%O2)^-1|NOT DONE|||ELECTROMYOGRAPHY|NA|Y|INTERVIEWER|HEMATOLOGIST|N|3||39||CONTINUATION TREATMENT|1960-08-06|
TRIAL STUDY 134XCP|TR|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MBP|EQUIVOCAL||PG/DL|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|NA|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|4||88||SCREENING|1966-06-09|
TRIAL STUDY 134XCP|TR|512B0190-2ABD-4477-BBAA-B5C8A57B1D53|5||||||LNSTATE|LYMPH NODE STATE||10^12 IU/L|NONPALPABLE||DAYS|NOT DONE|||GRADIENT DIFFUSION|Y|NA|FRIEND|ADJUDICATOR|Y|5||7||FOLLOW-UP|1972-03-30|
TRIAL STUDY 134XCP|TR|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||IU/L|ABSENT||LINEAR FT*LB|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|U|N|FAMILY MEMBER|RADIOLOGIST|U|1||38||BLINDED TREATMENT|1962-06-23|
TRIAL STUDY 134XCP|TR|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|2||||||AREA|AREA||10^3 CFU|NORMAL||10^6 RNA COPIES/ML|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|Y|INVESTIGATOR|RADIOLOGIST 2|U|2||58||SCREENING|1961-11-30|
TRIAL STUDY 134XCP|TR|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MS/MMHG|ABSENT||G/CAGE/DAY|NOT DONE|||POLYGRAPHY|N|U|GUARDIAN|PEDIATRIC NEUROLOGIST|N|3||39||CONTINUATION TREATMENT|1968-01-09|
TRIAL STUDY 134XCP|TR|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|4||||||LDIAM|LONGEST DIAMETER||TAMPON|DECREASED||DL|NOT DONE|||SPIROMETRY|N|N|PARENT|OPHTHALMOLOGIST|N|4||88||SCREENING|1961-05-26|
TRIAL STUDY 134XCP|TR|C0642FE2-8A9A-4CFA-80C1-71B884E4D8BF|5||||||BNLNUM|NUMBER OF BONE LESIONS||10^3/HPF|PRESENT||ML/CAGE/WK|NOT DONE|||PUPILLOMETRY|NA|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|5||7||LONG-TERM FOLLOW-UP|1971-09-08|
TRIAL STUDY 134XCP|TR|55210E20-F6B9-446F-994D-2D9149E33BAF|1||||||CALCFIND|CALCIFICATION INDICATOR||OHM|PALPABLE||MG/G/H|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|U|NA|CAREGIVER|CLINICAL PATHOLOGIST|Y|1||38||TREATMENT|1962-01-08|
TRIAL STUDY 134XCP|TR|55210E20-F6B9-446F-994D-2D9149E33BAF|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||APL U|NONPALPABLE||ANSON U|NOT DONE|||KARYOTYPING|U|U|SIGNIFICANT OTHER|PATHOLOGIST 1|N|2||58||BLINDED TREATMENT|1960-05-28|
TRIAL STUDY 134XCP|TR|55210E20-F6B9-446F-994D-2D9149E33BAF|3||||||NEWCONF|NEW TUMOR CONFIRMED||%/S|UNEQUIVOCAL||CM|NOT DONE|||SMEAR|U|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||SCREENING|1971-03-28|
TRIAL STUDY 134XCP|TR|55210E20-F6B9-446F-994D-2D9149E33BAF|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PM|FOCALLY INCREASED||/H|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|Y|CHILD|ADJUDICATOR|Y|4||88||INDUCTION TREATMENT|1968-12-22|
TRIAL STUDY 134XCP|TR|55210E20-F6B9-446F-994D-2D9149E33BAF|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UG|NONPALPABLE||CONTAINER|NOT DONE|||MICROBIAL CULTURE, LIQUID|N|Y|INTERVIEWER|OPHTHALMOLOGIST|N|5||7||WASHOUT|1972-04-08|
TRIAL STUDY 134XCP|TR|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||PG/L|UNEQUIVOCAL||10^5/HPF|NOT DONE|||LIGHT MICROSCOPY|NA|NA|INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|1||38||BASELINE|1961-04-04|
TRIAL STUDY 134XCP|TR|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|2||||||LESFLIND|LESION FAILURE INDICATOR||ML/KG|FOCALLY INCREASED||FMOL/L/SEC|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|U|U|SIBLING|UROLOGIST|U|2||58||SCREENING|1966-10-04|
TRIAL STUDY 134XCP|TR|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|3||||||BNLNUM|NUMBER OF BONE LESIONS||BAR|DIFFUSELY INCREASED||U/MG|NOT DONE|||HPLC/MS/MS|Y|N|PROXY|RATER 2|U|3||39||BASELINE|1967-10-06|
TRIAL STUDY 134XCP|TR|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|4||||||SUMDIAM|SUM OF DIAMETER||FOZ_BR|ENLARGEMENT FROM NADIR||PKAT/L|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|Y|CHILD|RADIOLOGIST|NA|4||88||SCREENING|1960-11-20|
TRIAL STUDY 134XCP|TR|1BE8ACB9-BEE8-4AFD-B384-D4C860B12450|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||ML*CMH2O|ABSENT||UL/KG/DAY|NOT DONE|||PHYSICAL EXAMINATION|N|U|GUARDIAN|PATHOLOGIST|NA|5||7||WASHOUT|1962-07-14|
TRIAL STUDY 134XCP|TR|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|1||||||BNLNUM|NUMBER OF BONE LESIONS||OZ EQ|TUMOR MERGED||/2500 WBC|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|U|N|FAMILY MEMBER|MICROSCOPIST 2|NA|1||38||OPEN LABEL TREATMENT|1961-03-02|
TRIAL STUDY 134XCP|TR|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||PG/L|EQUIVOCAL||VG/DOSE|NOT DONE|||PERFUSION MRI|N|N|INTERVIEWER|READER 2|N|2||58||SCREENING|1963-04-01|
TRIAL STUDY 134XCP|TR|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|3||||||PALPSTAT|PALPABLE STATE||NU/CL|DIFFUSELY INCREASED||NKAT/L|NOT DONE|||FLUORIMETRY|U|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3||39||BLINDED TREATMENT|1966-05-27|
TRIAL STUDY 134XCP|TR|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MBP|EQUIVOCAL||DAMOL/L|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|NA|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|4||88||INDUCTION TREATMENT|1964-10-02|
TRIAL STUDY 134XCP|TR|68F4DB07-31EC-4ECA-92BF-7D6986E4B33A|5||||||RADIODEN|RADIODENSITY||UMOL/MIN|FURTHER ENLARGEMENT FROM NADIR||DIP|NOT DONE|||ELECTROPHORESIS|NA|Y|SIBLING|RADIOLOGIST|Y|5||7||BLINDED TREATMENT|1971-02-04|
TRIAL STUDY 134XCP|TR|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|1||||||CALCFIND|CALCIFICATION INDICATOR||P|PATHOLOGICAL||FMOL/L|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1966-05-13|
TRIAL STUDY 134XCP|TR|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||EVENTS|FURTHER ENLARGEMENT FROM NADIR||U/G/H|NOT DONE|||CHROMOGENIC ASSAY|NA|N|FAMILY MEMBER|RATER 2|Y|2||58||OPEN LABEL TREATMENT|1969-02-01|
TRIAL STUDY 134XCP|TR|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ANTI-XA IU|PATHOLOGICAL||PKAT|NOT DONE|||ENZYMATIC COLORIMETRY|U|N|ADJUDICATION COMMITTEE|READER 1|N|3||39||INDUCTION TREATMENT|1968-10-23|
TRIAL STUDY 134XCP|TR|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|4||||||LESSCIND|LESION SUCCESS INDICATOR||BAG|DECREASED||CM H2O|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|4||88||RUN-IN|1964-02-28|
TRIAL STUDY 134XCP|TR|C46B45B7-0CC3-4997-A6B9-DAA58B8D33D7|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||/100 HPFS|PALPABLE||VG/DOSE|NOT DONE|||CT SCAN|NA|U|CHILD|MICROSCOPIST|Y|5||7||WASHOUT|1970-09-25|
TRIAL STUDY 134XCP|TR|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||M2|NONPALPABLE||VG/DOSE|NOT DONE|||IMMUNORADIOMETRIC ASSAY|Y|N|ADJUDICATOR|CARDIOLOGIST|NA|1||38||SCREENING|1966-08-14|
TRIAL STUDY 134XCP|TR|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||HOUNSFIELD UNIT|UNEQUIVOCAL||CCID 50/ML|NOT DONE|||NUCLEAR RADIOLOGY|U|N|SPOUSE|OTOLARYNGOLOGIST|NA|2||58||BASELINE|1972-03-19|
TRIAL STUDY 134XCP|TR|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||LOG10 TCID 50/ML|TUMOR MERGED||KUSP|NOT DONE|||CELL BASED BIOASSAY|N|Y|FRIEND|PEDIATRIC NEUROLOGIST|Y|3||39||SCREENING|1965-11-26|
TRIAL STUDY 134XCP|TR|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|4||||||PALPSTAT|PALPABLE STATE||TSP|TUMOR MERGED||ML/MIN/MMHG|NOT DONE|||FLUORESCENT SPOT TEST|N|U|STUDY SUBJECT|ADJUDICATOR 3|N|4||88||CONTINUATION TREATMENT|1968-03-17|
TRIAL STUDY 134XCP|TR|1616C5D6-32D7-4A5D-A025-59DE09E55B0D|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^6 ORGANISMS/ML|ABSENT||UG/ANIMAL|NOT DONE|||SLOAN LETTER EYE CHART 100%|NA|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||FOLLOW-UP|1967-09-23|
TRIAL STUDY 134XCP|TR|CAD0ED37-954A-4935-8A7E-589EC108E141|1||||||SUMDIAM|SUM OF DIAMETER||100 IU/ML|PRESENT||IU/DAY|NOT DONE|||CORONARY ANGIOGRAPHY|N|NA|FRIEND|ONCOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1963-07-18|
TRIAL STUDY 134XCP|TR|CAD0ED37-954A-4935-8A7E-589EC108E141|2||||||LNSTATE|LYMPH NODE STATE||L/S|EQUIVOCAL||BEATS/MIN|NOT DONE|||DIGITAL PCR ARRAY|U|N|GUARDIAN|RADIOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1961-11-27|
TRIAL STUDY 134XCP|TR|CAD0ED37-954A-4935-8A7E-589EC108E141|3||||||LPERP|LONGEST PERPENDICULAR||MG/DAY|INCREASED||TUBERCULIN UNIT|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|U|N|GUARDIAN|ONCOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1971-02-05|
TRIAL STUDY 134XCP|TR|CAD0ED37-954A-4935-8A7E-589EC108E141|4||||||BNLNUM|NUMBER OF BONE LESIONS||/MBP|FURTHER ENLARGEMENT FROM NADIR||PACKAGE|NOT DONE|||CELLULOSE TAPE|NA|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|4||88||SCREENING|1968-03-30|
TRIAL STUDY 134XCP|TR|CAD0ED37-954A-4935-8A7E-589EC108E141|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MU/G|NON-PATHOLOGICAL||V/SEC|NOT DONE|||HPLC/MS/MS|N|N|FAMILY MEMBER|MICROSCOPIST|N|5||7||OBSERVATION|1972-04-27|
TRIAL STUDY 134XCP|TR|BC9A31E2-100C-4AC3-8910-A04309854590|1||||||LPERP|LONGEST PERPENDICULAR||GPELISA UNIT/ML|FOCALLY INCREASED||BQ/ML|NOT DONE|||PET SCAN|N|N|VENDOR|PHYSIOTHERAPIST|U|1||38||LONG-TERM FOLLOW-UP|1960-12-15|
TRIAL STUDY 134XCP|TR|BC9A31E2-100C-4AC3-8910-A04309854590|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U/L|FOCALLY INCREASED||AMOL|NOT DONE|||CHROMOGENIC ASSAY|N|N|ADJUDICATOR|CARDIOLOGIST|Y|2||58||INDUCTION TREATMENT|1961-01-06|
TRIAL STUDY 134XCP|TR|BC9A31E2-100C-4AC3-8910-A04309854590|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UKAT/10^12 RBC|NON-PATHOLOGICAL||NEEDLE GAUGE|NOT DONE|||LC/MS|U|U|DOMESTIC PARTNER|NEUROLOGIST|U|3||39||OPEN LABEL TREATMENT|1966-02-01|
TRIAL STUDY 134XCP|TR|BC9A31E2-100C-4AC3-8910-A04309854590|4||||||RADIODEN|RADIODENSITY||PMOL/DL|EQUIVOCAL||UKAT/L|NOT DONE|||MOUSE PROTECTION ASSAY|NA|U|SIGNIFICANT OTHER|PATHOLOGIST|N|4||88||OBSERVATION|1965-03-28|
TRIAL STUDY 134XCP|TR|BC9A31E2-100C-4AC3-8910-A04309854590|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ML/BREATH|DIFFUSELY INCREASED||10^3 ORGANISMS|NOT DONE|||LC-FL|Y|U|STUDY SUBJECT|UROLOGIST|U|5||7||SCREENING|1963-11-19|
TRIAL STUDY 134XCP|TR|13A424BB-CC85-41EC-BDED-165A29532DFF|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MG/KG/H|UNEQUIVOCAL||ML*CMH2O|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||SCREENING|1962-01-04|
TRIAL STUDY 134XCP|TR|13A424BB-CC85-41EC-BDED-165A29532DFF|2||||||LMBFLIND|LIMB FAILURE INDICATOR||CM|INCREASED||GPL U/ML|NOT DONE|||TRYPAN BLUE STAIN|N|NA|CAREGIVER|NEUROLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1966-07-27|
TRIAL STUDY 134XCP|TR|13A424BB-CC85-41EC-BDED-165A29532DFF|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||/5X10^4 WBC|FOCALLY INCREASED||NEBULE|NOT DONE|||ORCHIDOMETERY|NA|Y|INVESTIGATOR|PATHOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1971-08-25|
TRIAL STUDY 134XCP|TR|13A424BB-CC85-41EC-BDED-165A29532DFF|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MMOL2/L2|FURTHER ENLARGEMENT FROM NADIR||SBE/ML|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|NA|SPOUSE|ADJUDICATOR|Y|4||88||INDUCTION TREATMENT|1962-05-08|
TRIAL STUDY 134XCP|TR|13A424BB-CC85-41EC-BDED-165A29532DFF|5||||||VDIAM|VIABLE DIAMETER||10^6/L|PALPABLE||NMOL/MOL|NOT DONE|||X-RAY|Y|U|ADJUDICATOR|NEUROLOGIST|NA|5||7||WASHOUT|1960-09-28|
TRIAL STUDY 134XCP|TR|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|1||||||SUMDIAM|SUM OF DIAMETER||F|PALPABLE||10^6 U|NOT DONE|||TOLUIDINE BLUE STAIN|N|N|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||INDUCTION TREATMENT|1965-10-30|
TRIAL STUDY 134XCP|TR|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|2||||||PALPSTAT|PALPABLE STATE||MOSM|FURTHER ENLARGEMENT||10^7/L|NOT DONE|||LC-FL|Y|U|STUDY SUBJECT|NEUROLOGIST|U|2||58||CONTINUATION TREATMENT|1966-12-23|
TRIAL STUDY 134XCP|TR|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NU/CL|NONPALPABLE||PMOL/10^10 CELLS|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|U|N|PARENT|READER 2|N|3||39||BLINDED TREATMENT|1960-05-21|
TRIAL STUDY 134XCP|TR|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|4||||||LESFLIND|LESION FAILURE INDICATOR||DEG|ENLARGEMENT||SHOCK WAVE|NOT DONE|||CT SCAN|U|Y|ADJUDICATOR|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1969-02-26|
TRIAL STUDY 134XCP|TR|154D9D23-8ABD-4B69-90A1-A3D96F4743F3|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||BQ/G|ABSENT||G/CAGE/DAY|NOT DONE|||FLUORESCENT SPOT TEST|NA|U|CHILD|FORENSIC PATHOLOGIST|Y|5||7||FOLLOW-UP|1972-03-14|
TRIAL STUDY 134XCP|TR|059FE504-DEE4-4E24-AA80-3C64264636BF|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MS2|UNCHANGED||UM/DAY|NOT DONE|||IMMUNOPRECIPITATION|U|NA|GUARDIAN|PATHOLOGIST|Y|1||38||WASHOUT|1966-11-28|
TRIAL STUDY 134XCP|TR|059FE504-DEE4-4E24-AA80-3C64264636BF|2||||||LDIAM|LONGEST DIAMETER||MCI|ENLARGEMENT||MN|NOT DONE|||POLYGRAPHY|NA|NA|STUDY SUBJECT|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1960-03-13|
TRIAL STUDY 134XCP|TR|059FE504-DEE4-4E24-AA80-3C64264636BF|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||GENEQ|PRESENT||G/KG|NOT DONE|||MALDI-TOF|U|N|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||WASHOUT|1971-02-26|
TRIAL STUDY 134XCP|TR|059FE504-DEE4-4E24-AA80-3C64264636BF|4||||||VSLPIND|VESSEL PATENCY INDICATOR||10^6 IU/ML|NON-PATHOLOGICAL||V/V|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|4||88||WASHOUT|1968-02-28|
TRIAL STUDY 134XCP|TR|059FE504-DEE4-4E24-AA80-3C64264636BF|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||IU/G|FURTHER ENLARGEMENT||SCM|NOT DONE|||ETDRS EYE CHART|NA|U|FAMILY MEMBER|RATER|U|5||7||RUN-IN|1960-02-10|
TRIAL STUDY 134XCP|TR|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||PMOL/L/H|UNCHANGED||DNA COPIES/UG|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|N|CAREGIVER|HEMATOLOGIST|Y|1||38||FOLLOW-UP|1969-09-18|
TRIAL STUDY 134XCP|TR|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PSEC|TUMOR MERGED||ML/M2/H|NOT DONE|||AGAR PROPORTION|U|Y|GUARDIAN|OTOLARYNGOLOGIST|Y|2||58||CONTINUATION TREATMENT|1971-11-05|
TRIAL STUDY 134XCP|TR|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MBQ/UL|NORMAL||IU/DAY|NOT DONE|||CLOT DETECTION|N|NA|SIGNIFICANT OTHER|PATHOLOGIST 2|U|3||39||INDUCTION TREATMENT|1965-09-03|
TRIAL STUDY 134XCP|TR|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||EU|DECREASED||CI/UG|NOT DONE|||WEBER GREEN STAIN|U|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|4||88||FOLLOW-UP|1971-05-22|
TRIAL STUDY 134XCP|TR|3F806ADA-68C3-42AD-9DB7-2CA8E3A9F236|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||CAL|FOCALLY INCREASED||ML/BREATH|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|U|NA|FAMILY MEMBER|CARDIOLOGIST|U|5||7||SCREENING|1970-07-29|
TRIAL STUDY 134XCP|TR|69BCF810-6748-43AA-BDFC-64EE1536CB47|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||L/H/M2|ENLARGEMENT FROM NADIR||UMOL/MOL|NOT DONE|||PUPILLOMETRY|Y|U|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|1||38||OBSERVATION|1965-11-24|
TRIAL STUDY 134XCP|TR|69BCF810-6748-43AA-BDFC-64EE1536CB47|2||||||PALPSTAT|PALPABLE STATE||AMOL|FOCALLY INCREASED||U/KG|NOT DONE|||SPIROMETRY|N|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|2||58||CONTINUATION TREATMENT|1966-02-07|
TRIAL STUDY 134XCP|TR|69BCF810-6748-43AA-BDFC-64EE1536CB47|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PPTH|DIFFUSELY INCREASED||10^4 CFU|NOT DONE|||IMMUNORADIOMETRIC ASSAY|U|NA|CAREGIVER|UROLOGIST|Y|3||39||CONTINUATION TREATMENT|1965-08-21|
TRIAL STUDY 134XCP|TR|69BCF810-6748-43AA-BDFC-64EE1536CB47|4||||||LESFLIND|LESION FAILURE INDICATOR||OZ|INCREASED||DEG/S|NOT DONE|||EPSILOMETER|U|NA|GUARDIAN|PATHOLOGIST 2|U|4||88||OBSERVATION|1967-08-14|
TRIAL STUDY 134XCP|TR|69BCF810-6748-43AA-BDFC-64EE1536CB47|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UEQ/L|EQUIVOCAL||LOG10 TCID 50/UL|NOT DONE|||LANDOLT RING|U|U|CLINICAL RESEARCH COORDINATOR|READER 1|NA|5||7||INDUCTION TREATMENT|1960-03-04|
TRIAL STUDY 134XCP|TR|DCE71DE9-8DFB-4796-BC41-21930EC21925|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||FG|PATHOLOGICAL||CMH2O*S/ML|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|Y|Y|PARENT|RADIOLOGIST 1|U|1||38||INDUCTION TREATMENT|1971-08-02|
TRIAL STUDY 134XCP|TR|DCE71DE9-8DFB-4796-BC41-21930EC21925|2||||||LDIAM|LONGEST DIAMETER||10^3 CFU/G|NON-PATHOLOGICAL||MOL/ML|NOT DONE|||MALDI-TOF|U|Y|ADJUDICATION COMMITTEE|READER 1|U|2||58||FOLLOW-UP|1972-03-25|
TRIAL STUDY 134XCP|TR|DCE71DE9-8DFB-4796-BC41-21930EC21925|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||OD UNIT|ABSENT||ML|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|N|NA|PROXY|PATHOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1970-11-29|
TRIAL STUDY 134XCP|TR|DCE71DE9-8DFB-4796-BC41-21930EC21925|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||TUBE|DECREASED||KPA|NOT DONE|||SCINTIGRAPHY|NA|NA|CAREGIVER|MICROSCOPIST|N|4||88||BASELINE|1966-04-29|
TRIAL STUDY 134XCP|TR|DCE71DE9-8DFB-4796-BC41-21930EC21925|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CIGAR|NONPALPABLE||/VF|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|U|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1969-06-18|
TRIAL STUDY 134XCP|TR|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|1||||||NEWCONF|NEW TUMOR CONFIRMED||10^3/HPF|FURTHER ENLARGEMENT FROM NADIR||ML/BEAT|NOT DONE|||CALCULATION|Y|NA|GUARDIAN|RATER|Y|1||38||BASELINE|1970-11-22|
TRIAL STUDY 134XCP|TR|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MCI|FURTHER ENLARGEMENT||LOG EID 50/DOSE|NOT DONE|||SURFACE PLASMON RESONANCE|NA|N|ADJUDICATOR|MICROSCOPIST 1|Y|2||58||WASHOUT|1969-10-13|
TRIAL STUDY 134XCP|TR|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MG/MOL|ENLARGEMENT||ML/KG/MIN|NOT DONE|||PALPATION|U|N|GUARDIAN|ADJUDICATOR 1|N|3||39||LONG-TERM FOLLOW-UP|1961-05-17|
TRIAL STUDY 134XCP|TR|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|4||||||TUMSTATE|TUMOR STATE||U/MG|INCREASED||UG/DL|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|NA|Y|FAMILY MEMBER|NEUROLOGIST 2|N|4||88||BASELINE|1962-12-28|
TRIAL STUDY 134XCP|TR|9EE46F65-A7A1-4D18-A685-BC2EF905CC19|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||LOG10 TCID 50/ML|FURTHER ENLARGEMENT||G/DL|NOT DONE|||SPIRAL CT|U|N|INVESTIGATOR|RADIOLOGIST 1|N|5||7||TREATMENT|1968-11-15|
TRIAL STUDY 134XCP|TR|97D06076-FE6B-4C77-BD5C-2E665F707C7A|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PFU/ANIMAL|FURTHER ENLARGEMENT||MG/KG/DOSE|NOT DONE|||BAC ACGH|NA|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|1||38||BLINDED TREATMENT|1967-03-07|
TRIAL STUDY 134XCP|TR|97D06076-FE6B-4C77-BD5C-2E665F707C7A|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UG/DAY|ABSENT||POINT|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|N|U|GUARDIAN|RATER 1|Y|2||58||TREATMENT|1963-06-10|
TRIAL STUDY 134XCP|TR|97D06076-FE6B-4C77-BD5C-2E665F707C7A|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||U/G/DAY|NON-PATHOLOGICAL||10^3 ORGANISMS|NOT DONE|||AGAR PROPORTION|U|Y|GUARDIAN|PHYSIOTHERAPIST|NA|3||39||INDUCTION TREATMENT|1966-09-17|
TRIAL STUDY 134XCP|TR|97D06076-FE6B-4C77-BD5C-2E665F707C7A|4||||||AREA|AREA||U/MMOL|FURTHER ENLARGEMENT||MM3/MM2/YEAR|NOT DONE|||LIGHT MICROSCOPY|Y|Y|SIGNIFICANT OTHER|RADIOLOGIST|NA|4||88||SCREENING|1963-10-06|
TRIAL STUDY 134XCP|TR|97D06076-FE6B-4C77-BD5C-2E665F707C7A|5||||||VSLPIND|VESSEL PATENCY INDICATOR||/MBP|ABSENT||G/G/DAY|NOT DONE|||FLOW MICROSCOPY|N|Y|INDEPENDENT ASSESSOR|RATER 1|N|5||7||LONG-TERM FOLLOW-UP|1966-01-31|
TRIAL STUDY 134XCP|TR|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|1||||||PALPSTAT|PALPABLE STATE||BOX|EQUIVOCAL||UG/DL|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|1||38||BASELINE|1968-06-27|
TRIAL STUDY 134XCP|TR|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||FOZ_US|NONPALPABLE||TRANSDUCING UNIT/ML|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|NA|INVESTIGATOR|MICROSCOPIST 2|U|2||58||SCREENING|1968-09-20|
TRIAL STUDY 134XCP|TR|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||G/CAGE|FOCALLY INCREASED||UG/DL|NOT DONE|||OBSERVATION|Y|NA|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1967-09-04|
TRIAL STUDY 134XCP|TR|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||UG/ML/H|TUMOR MERGED||/MONTH|NOT DONE|||LISSAMINE GREEN STAIN|U|NA|PARENT|READER 2|U|4||88||RUN-IN|1969-04-28|
TRIAL STUDY 134XCP|TR|E9E6E2D8-33F9-4769-B5F3-06ADB2926A9F|5||||||LESFLIND|LESION FAILURE INDICATOR||UG/M2/H|PRESENT||UMOL/L/MIN|NOT DONE|||PET/MRI SCAN|NA|U|SPOUSE|ADJUDICATOR 1|Y|5||7||OPEN LABEL TREATMENT|1965-01-18|
TRIAL STUDY 134XCP|TR|D5A1EB38-77EA-49A5-84CA-740A83D258AF|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||UL|ENLARGEMENT||M3|NOT DONE|||OPHTHALMOSCOPY|Y|N|INVESTIGATOR|READER 2|N|1||38||LONG-TERM FOLLOW-UP|1967-05-20|
TRIAL STUDY 134XCP|TR|D5A1EB38-77EA-49A5-84CA-740A83D258AF|2||||||LESFLIND|LESION FAILURE INDICATOR||U/L|UNCHANGED||DAGU/ML|NOT DONE|||FLOCCULATION|U|N|SPOUSE|MICROSCOPIST 3|N|2||58||LONG-TERM FOLLOW-UP|1966-01-08|
TRIAL STUDY 134XCP|TR|D5A1EB38-77EA-49A5-84CA-740A83D258AF|3||||||NEWCONF|NEW TUMOR CONFIRMED||U/KG/DAY|FOCALLY INCREASED||10^3 ORGANISMS/G|NOT DONE|||LEAD CITRATE STAIN|NA|N|INDEPENDENT ASSESSOR|NEUROLOGIST|N|3||39||TREATMENT|1965-01-08|
TRIAL STUDY 134XCP|TR|D5A1EB38-77EA-49A5-84CA-740A83D258AF|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||IU/L|FOCALLY INCREASED||MG/KG/H|NOT DONE|||PANENDOSCOPY|N|NA|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|4||88||BLINDED TREATMENT|1963-02-13|
TRIAL STUDY 134XCP|TR|D5A1EB38-77EA-49A5-84CA-740A83D258AF|5||||||CALCFIND|CALCIFICATION INDICATOR||MG/KG/H|UNCHANGED||PG/DL|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|U|N|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|5||7||WASHOUT|1966-06-27|
TRIAL STUDY 134XCP|TR|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|1||||||VOLUME|VOLUME||PMOL/10^9 CELLS|FURTHER ENLARGEMENT FROM NADIR||PT_US|NOT DONE|||OBSERVATION|NA|N|INTERVIEWER|OTOLARYNGOLOGIST|U|1||38||WASHOUT|1967-04-23|
TRIAL STUDY 134XCP|TR|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||NMOL/L/MIN|NORMAL||CCID 50/DOSE|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|NA|N|CHILD|ADJUDICATOR 3|N|2||58||OBSERVATION|1960-12-17|
TRIAL STUDY 134XCP|TR|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||G/M2|NON-PATHOLOGICAL||YD|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|N|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1967-08-02|
TRIAL STUDY 134XCP|TR|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|4||||||CALCFIND|CALCIFICATION INDICATOR||NMOL/L/MIN|UNCHANGED||UG/ML/H|NOT DONE|||FLAME PHOTOMETRY|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|4||88||BASELINE|1969-03-14|
TRIAL STUDY 134XCP|TR|5255639E-AC65-4DA8-85EF-4ABD53BAAED5|5||||||LMBFLIND|LIMB FAILURE INDICATOR||M|ABSENT||GRAVITATIONAL UNIT|NOT DONE|||CONTRAST ENHANCED CT SCAN|U|U|PROXY|NEUROLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1970-10-15|
TRIAL STUDY 134XCP|TR|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CCID 50/DOSE|UNEQUIVOCAL||LOG10 PFU|NOT DONE|||SPIRAL CT|NA|N|PROXY|ADJUDICATOR 1|N|1||38||RUN-IN|1967-11-23|
TRIAL STUDY 134XCP|TR|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BREATHS/30S|ENLARGEMENT||ML/(MIN*100ML)|NOT DONE|||MYELOPEROXIDASE STAIN|Y|NA|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|2||58||LONG-TERM FOLLOW-UP|1971-03-09|
TRIAL STUDY 134XCP|TR|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ML/DAY|TUMOR MERGED||KAT|NOT DONE|||PHASE CONTRAST MICROSCOPY|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER|NA|3||39||SCREENING|1972-08-05|
TRIAL STUDY 134XCP|TR|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||APL U|TUMOR MERGED||L/MIN/M2|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|U|Y|PARENT|PATHOLOGIST 1|U|4||88||WASHOUT|1970-05-03|
TRIAL STUDY 134XCP|TR|99F8DAA7-F186-487C-9E5D-43E9DBFB48C6|5||||||LDIAM|LONGEST DIAMETER||NMOL BCE/MMOL|NORMAL||LOG10 TCID 50/UL|NOT DONE|||CHROMATOGRAPHY|Y|U|ADJUDICATOR|RATER|Y|5||7||RUN-IN|1964-03-30|
TRIAL STUDY 134XCP|TR|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||UG/G/MIN|DECREASED||PRESSOR UNITS|NOT DONE|||CONTRAST ENHANCED X-RAY|Y|N|DOMESTIC PARTNER|RATER 1|U|1||38||OBSERVATION|1969-02-05|
TRIAL STUDY 134XCP|TR|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|2||||||RADIODEN|RADIODENSITY||HOURS|PRESENT||FMOL/L/SEC|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||CONTINUATION TREATMENT|1969-11-26|
TRIAL STUDY 134XCP|TR|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|3||||||PALPSTAT|PALPABLE STATE||PSEC|NON-PATHOLOGICAL||ML/DAY|NOT DONE|||SPIROMETRY|N|U|SIBLING|RATER 1|NA|3||39||INDUCTION TREATMENT|1963-02-16|
TRIAL STUDY 134XCP|TR|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|4||||||NEWCONF|NEW TUMOR CONFIRMED||U/M2/MIN|UNEQUIVOCAL||UMOL/H/MMOL|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|Y|NA|STUDY SUBJECT|ONCOLOGIST|NA|4||88||TREATMENT|1972-01-22|
TRIAL STUDY 134XCP|TR|88A1099B-F69D-4B6F-90CE-DAAE629CEACE|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||OZ EQ|PATHOLOGICAL||/200 HPFS|NOT DONE|||CLIP SEQUENCING|NA|NA|FRIEND|ONCOLOGIST|U|5||7||WASHOUT|1969-11-29|
TRIAL STUDY 134XCP|TR|640DDEF5-748A-4F92-A13D-15D1C7CE0800|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UCI|EQUIVOCAL||OI50|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|Y|Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|Y|1||38||FOLLOW-UP|1963-04-28|
TRIAL STUDY 134XCP|TR|640DDEF5-748A-4F92-A13D-15D1C7CE0800|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||LX|TUMOR MERGED||GY/MIN|NOT DONE|||ULTRASOUND|NA|NA|DOMESTIC PARTNER|RATER|N|2||58||WASHOUT|1969-12-09|
TRIAL STUDY 134XCP|TR|640DDEF5-748A-4F92-A13D-15D1C7CE0800|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UG/DOSE|NONPALPABLE||L/L|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|N|Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|U|3||39||FOLLOW-UP|1961-01-14|
TRIAL STUDY 134XCP|TR|640DDEF5-748A-4F92-A13D-15D1C7CE0800|4||||||VSLPIND|VESSEL PATENCY INDICATOR||MNFI|NON-PATHOLOGICAL||PFU/ANIMAL|NOT DONE|||TRICHROME STAIN|Y|Y|SIBLING|READER 2|N|4||88||TREATMENT|1966-05-21|
TRIAL STUDY 134XCP|TR|640DDEF5-748A-4F92-A13D-15D1C7CE0800|5||||||SUMVOL|SUM OF VOLUME||PMOL/10^10 CELLS|INCREASED||RATIO|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|NA|Y|ADJUDICATION COMMITTEE|RATER 1|Y|5||7||OPEN LABEL TREATMENT|1972-03-16|
TRIAL STUDY 134XCP|TR|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|1||||||VOLUME|VOLUME||TITER|INCREASED||UV|NOT DONE|||TARGETED GENOME SEQUENCING|Y|N|NON-HEALTH CARE PROFESSIONAL|READER|Y|1||38||BLINDED TREATMENT|1965-03-27|
TRIAL STUDY 134XCP|TR|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||/LPF|INCREASED||GAUSS|NOT DONE|||HPLC-UV|N|N|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|2||58||INDUCTION TREATMENT|1960-03-18|
TRIAL STUDY 134XCP|TR|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|3||||||LDIAM|LONGEST DIAMETER||PG|NORMAL||PMOL/10^10 CELLS|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|NA|N|SIBLING|ONCOLOGIST 2|U|3||39||TREATMENT|1961-05-02|
TRIAL STUDY 134XCP|TR|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||ML/BREATH|NORMAL||CI/UG|NOT DONE|||RADIOGRAPHY|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|NA|4||88||OPEN LABEL TREATMENT|1961-11-22|
TRIAL STUDY 134XCP|TR|FB4290D9-A5F8-472C-8AAC-28D8A59D8FED|5||||||LNSTATE|LYMPH NODE STATE||MET*H|NORMAL||ML/M2/MIN|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|NA|DOMESTIC PARTNER|PATHOLOGIST|U|5||7||RUN-IN|1960-08-13|
TRIAL STUDY 134XCP|TR|EBC7BF7B-18C6-463C-8500-027B2A6966DB|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||LOG10 COPIES/ML|FURTHER ENLARGEMENT||MEQ/DAY|NOT DONE|||SCANNING ELECTRON MICROSCOPY|N|Y|CAREGIVER|CARDIOLOGIST|N|1||38||BLINDED TREATMENT|1962-09-16|
TRIAL STUDY 134XCP|TR|EBC7BF7B-18C6-463C-8500-027B2A6966DB|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MHZ|ENLARGEMENT FROM NADIR||LOG10 CCID 50/DOSE|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|Y|SIGNIFICANT OTHER|INTERNIST|N|2||58||TREATMENT|1969-12-06|
TRIAL STUDY 134XCP|TR|EBC7BF7B-18C6-463C-8500-027B2A6966DB|3||||||TUMSTATE|TUMOR STATE||ELISA UNIT/DOSE|UNEQUIVOCAL||S^-1(%O2)^-1|NOT DONE|||HIGH RESOLUTION CT|N|NA|DOMESTIC PARTNER|READER 3|NA|3||39||BASELINE|1966-05-26|
TRIAL STUDY 134XCP|TR|EBC7BF7B-18C6-463C-8500-027B2A6966DB|4||||||RADIODEN|RADIODENSITY||TSP|ENLARGEMENT||10^6 ORGANISMS/MG|NOT DONE|||NEPHELOMETRY|N|NA|FAMILY MEMBER|RADIOLOGIST 1|Y|4||88||WASHOUT|1973-03-25|
TRIAL STUDY 134XCP|TR|EBC7BF7B-18C6-463C-8500-027B2A6966DB|5||||||RADIODEN|RADIODENSITY||CI/UL|FOCALLY INCREASED||BOTTLE|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|U|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|5||7||OBSERVATION|1967-10-11|
TRIAL STUDY 134XCP|TR|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MET|DECREASED||UM/DAY|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|N|FAMILY MEMBER|READER|U|1||38||CONTINUATION TREATMENT|1971-12-28|
TRIAL STUDY 134XCP|TR|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MG/DOSE|ENLARGEMENT FROM NADIR||10^8/L|NOT DONE|||MALDI-TOF|N|N|CAREGIVER|ONCOLOGIST 2|N|2||58||OPEN LABEL TREATMENT|1960-08-09|
TRIAL STUDY 134XCP|TR|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||CI/UG|TUMOR MERGED||/SEC|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|U|Y|CHILD|NEUROLOGIST|Y|3||39||INDUCTION TREATMENT|1968-03-01|
TRIAL STUDY 134XCP|TR|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DAGU/ML|NON-PATHOLOGICAL||10^8/L|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|U|NA|INTERVIEWER|ADJUDICATOR|U|4||88||FOLLOW-UP|1961-06-02|
TRIAL STUDY 134XCP|TR|3167BE9B-E72D-4011-BD2C-CB4F9F27FE2C|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||10^10/L|ENLARGEMENT FROM NADIR||L/S/KPA|NOT DONE|||TOLUIDINE BLUE STAIN|N|Y|PARENT|OPTOMETRIST|U|5||7||OPEN LABEL TREATMENT|1965-07-18|
TRIAL STUDY 134XCP|TR|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||U/G|DECREASED||BEATS/MIN|NOT DONE|||FLOW MICROSCOPY|N|NA|DOMESTIC PARTNER|READER 3|U|1||38||TREATMENT|1967-09-13|
TRIAL STUDY 134XCP|TR|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|2||||||ORVERLN|ORGAN VERTICAL LENGTH||UG/ANIMAL|INCREASED||BAR|NOT DONE|||PH METER MEASUREMENT METHOD|NA|U|GUARDIAN|RATER 2|U|2||58||OBSERVATION|1970-11-13|
TRIAL STUDY 134XCP|TR|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||/MM|ABSENT||10^4/HPF|NOT DONE|||HILLMEN COLOR CHART|Y|U|STUDY SUBJECT|READER 2|U|3||39||BASELINE|1967-04-03|
TRIAL STUDY 134XCP|TR|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||APL U|ENLARGEMENT FROM NADIR||ML/DAY|NOT DONE|||IMMUNOPRECIPITATION|NA|NA|GUARDIAN|ADJUDICATOR|NA|4||88||RUN-IN|1972-01-17|
TRIAL STUDY 134XCP|TR|61A831EB-7AFF-47B7-A0D5-9727CC6EB9CD|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||IMPLANT|PRESENT||CCID 50/ML|NOT DONE|||EIA|U|N|ADJUDICATOR|ADJUDICATOR|U|5||7||SCREENING|1970-08-10|
TRIAL STUDY 134XCP|TR|74741526-F925-4AA5-9BE3-F3B3884BEE68|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ATM|UNEQUIVOCAL||COAT|NOT DONE|||THIN SMEAR|Y|U|ADJUDICATION COMMITTEE|ONCOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1969-02-25|
TRIAL STUDY 134XCP|TR|74741526-F925-4AA5-9BE3-F3B3884BEE68|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PMOL/10^9 CELLS|NORMAL||NCI|NOT DONE|||FLUORIMETRY|U|NA|SPOUSE|RATER|NA|2||58||FOLLOW-UP|1969-10-26|
TRIAL STUDY 134XCP|TR|74741526-F925-4AA5-9BE3-F3B3884BEE68|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CIGARETTE|NORMAL||BOTTLE|NOT DONE|||PET/CT SCAN|U|Y|INVESTIGATOR|PATHOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1960-03-29|
TRIAL STUDY 134XCP|TR|74741526-F925-4AA5-9BE3-F3B3884BEE68|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||H/WK|FURTHER ENLARGEMENT FROM NADIR||10^9 ORGANISMS|NOT DONE|||VIRUS PLAQUE ASSAY|NA|Y|STUDY SUBJECT|CLINICAL PATHOLOGIST|N|4||88||OBSERVATION|1961-02-20|
TRIAL STUDY 134XCP|TR|74741526-F925-4AA5-9BE3-F3B3884BEE68|5||||||VSLPIND|VESSEL PATENCY INDICATOR||BQ/UL|INCREASED||PA|NOT DONE|||CRYOSCOPY|N|Y|VENDOR|READER|NA|5||7||BASELINE|1963-11-26|
TRIAL STUDY 134XCP|TR|25088C28-0FA3-4005-90C3-CCF9C6FF5851|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||PNU/ML|ENLARGEMENT||/MM2|NOT DONE|||U-HPLC/MS/MS|Y|Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|1||38||BASELINE|1967-03-25|
TRIAL STUDY 134XCP|TR|25088C28-0FA3-4005-90C3-CCF9C6FF5851|2||||||DIAMETER|DIAMETER||L/KG|NONPALPABLE||MCI/KG|NOT DONE|||HPLC-UV|N|NA|INTERVIEWER|PATHOLOGIST 2|U|2||58||RUN-IN|1969-03-15|
TRIAL STUDY 134XCP|TR|25088C28-0FA3-4005-90C3-CCF9C6FF5851|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UG/DAY|UNEQUIVOCAL||10^12/L|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|Y|NA|INTERVIEWER|MICROSCOPIST 2|N|3||39||OPEN LABEL TREATMENT|1966-10-30|
TRIAL STUDY 134XCP|TR|25088C28-0FA3-4005-90C3-CCF9C6FF5851|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||KPA/L/SEC|UNEQUIVOCAL||UV*SEC|NOT DONE|||CLIP|Y|Y|STUDY SUBJECT|RADIOLOGIST|NA|4||88||BLINDED TREATMENT|1963-06-29|
TRIAL STUDY 134XCP|TR|25088C28-0FA3-4005-90C3-CCF9C6FF5851|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||M|INCREASED||VOXEL|NOT DONE|||GC/MS/MS|NA|N|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|5||7||INDUCTION TREATMENT|1973-07-25|
TRIAL STUDY 134XCP|TR|9BF13738-0A50-46E6-A3DA-AC956A361B97|1||||||VOLUME|VOLUME||10^3/HPF|PATHOLOGICAL||MG/M2/MIN|NOT DONE|||POTENTIOMETRY|N|NA|SIBLING|NEUROLOGIST 1|NA|1||38||RUN-IN|1960-03-04|
TRIAL STUDY 134XCP|TR|9BF13738-0A50-46E6-A3DA-AC956A361B97|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||10^7 PFU|PATHOLOGICAL||GRAIN|NOT DONE|||WHOLE EXOME SEQUENCING|NA|U|STUDY SUBJECT|ADJUDICATOR 2|U|2||58||LONG-TERM FOLLOW-UP|1962-01-27|
TRIAL STUDY 134XCP|TR|9BF13738-0A50-46E6-A3DA-AC956A361B97|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^9 ORGANISMS/ML|FOCALLY INCREASED||CD/M2|NOT DONE|||WRIGHT-GIEMSA STAIN|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|3||39||FOLLOW-UP|1963-06-26|
TRIAL STUDY 134XCP|TR|9BF13738-0A50-46E6-A3DA-AC956A361B97|4||||||DIAMETER|DIAMETER||10^9 ORGANISMS/ML|ENLARGEMENT||OD UNIT|NOT DONE|||DUCTOGRAPHY|Y|NA|FAMILY MEMBER|MICROSCOPIST 1|N|4||88||SCREENING|1963-06-05|
TRIAL STUDY 134XCP|TR|9BF13738-0A50-46E6-A3DA-AC956A361B97|5||||||SUMVOL|SUM OF VOLUME||UMOL/MIN|NONPALPABLE||ML/G/DAY|NOT DONE|||WESTERN BLOT|Y|NA|SPOUSE|NEUROLOGIST 2|NA|5||7||LONG-TERM FOLLOW-UP|1963-03-20|
TRIAL STUDY 134XCP|TR|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||10^9/G|UNEQUIVOCAL||BU|NOT DONE|||TOLUIDINE BLUE STAIN|NA|U|NON-HEALTH CARE PROFESSIONAL|RATER|Y|1||38||BLINDED TREATMENT|1960-08-30|
TRIAL STUDY 134XCP|TR|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UG/L/H|NON-PATHOLOGICAL||ATM|NOT DONE|||DYNAMIC LIGHT SCATTERING|Y|U|DOMESTIC PARTNER|ADJUDICATOR 2|NA|2||58||BASELINE|1963-04-29|
TRIAL STUDY 134XCP|TR|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|3||||||SUMVOL|SUM OF VOLUME||GRAVITATIONAL UNIT|PALPABLE||CG|NOT DONE|||IMMUNORADIOMETRIC ASSAY|Y|U|INTERVIEWER|MICROSCOPIST 3|N|3||39||WASHOUT|1967-02-04|
TRIAL STUDY 134XCP|TR|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||PLUG|PALPABLE||UG/M2/MIN|NOT DONE|||WESTERGREN|NA|U|PARENT|PHYSIOTHERAPIST|NA|4||88||OPEN LABEL TREATMENT|1964-03-07|
TRIAL STUDY 134XCP|TR|C7432A9E-BB47-46D1-92F6-FED7FBC627A0|5||||||PALPSTAT|PALPABLE STATE||UMOL/DL|NORMAL||MMOL/S|NOT DONE|||HEMAGGLUTINATION ASSAY|Y|Y|PROXY|INTERNIST|NA|5||7||BLINDED TREATMENT|1965-02-28|
TRIAL STUDY 134XCP|TR|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||TCID 50/DOSE|FURTHER ENLARGEMENT FROM NADIR||FFU|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|N|NA|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|1||38||OBSERVATION|1961-07-05|
TRIAL STUDY 134XCP|TR|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ML/DAY|ENLARGEMENT||GY|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y|SPOUSE|MICROSCOPIST 3|NA|2||58||LONG-TERM FOLLOW-UP|1961-08-11|
TRIAL STUDY 134XCP|TR|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||NKAT/L|UNCHANGED||10^4 CFU/ML|NOT DONE|||FREEZING POINT DEPRESSION|U|NA|FRIEND|MICROSCOPIST 3|Y|3||39||OBSERVATION|1968-10-16|
TRIAL STUDY 134XCP|TR|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|4||||||ORSTATE|ORGAN STATE||MIN|ENLARGEMENT||/CMH2O|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|NA|CAREGIVER|RATER 2|NA|4||88||WASHOUT|1962-03-09|
TRIAL STUDY 134XCP|TR|F6EBFB06-3EEF-4621-BDA3-36FD6D4799BF|5||||||SUMDIAM|SUM OF DIAMETER||MCI/KG|FURTHER ENLARGEMENT||BAU/ML|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|NA|CHILD|CLINICAL PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1966-05-31|
TRIAL STUDY 134XCP|TR|5AEA7EE9-1095-4967-B833-7665B6A71B31|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||GTT|INCREASED||BLOCKS|NOT DONE|||MULTIPLE BREATH WASHOUT|Y|U|INTERVIEWER|INTERNIST|U|1||38||BLINDED TREATMENT|1968-09-11|
TRIAL STUDY 134XCP|TR|5AEA7EE9-1095-4967-B833-7665B6A71B31|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||/200 HPFS|ENLARGEMENT||ABSORBANCE U/ML|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|NA|STUDY SUBJECT|ADJUDICATOR 3|Y|2||58||TREATMENT|1972-01-15|
TRIAL STUDY 134XCP|TR|5AEA7EE9-1095-4967-B833-7665B6A71B31|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||PA|FOCALLY INCREASED||10^6/G|NOT DONE|||MAPH|U|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|3||39||CONTINUATION TREATMENT|1960-03-17|
TRIAL STUDY 134XCP|TR|5AEA7EE9-1095-4967-B833-7665B6A71B31|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MEQ/MMOL|FOCALLY INCREASED||OI50|NOT DONE|||SPIROMETRY|NA|Y|FAMILY MEMBER|ONCOLOGIST 1|Y|4||88||BASELINE|1967-09-15|
TRIAL STUDY 134XCP|TR|5AEA7EE9-1095-4967-B833-7665B6A71B31|5||||||TUMSTATE|TUMOR STATE||OD UNIT|NON-PATHOLOGICAL||MG/L|NOT DONE|||IMMUNOTURBIDIMETRY|U|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1961-08-27|
TRIAL STUDY 134XCP|TR|241CD521-D0BD-40BB-ABA2-B8C8E500B491|1||||||CALCFIND|CALCIFICATION INDICATOR||PPM|INCREASED||/10^3|NOT DONE|||PHOROPTER|Y|U|GUARDIAN|ADJUDICATOR|Y|1||38||BASELINE|1967-06-10|
TRIAL STUDY 134XCP|TR|241CD521-D0BD-40BB-ABA2-B8C8E500B491|2||||||LESFLIND|LESION FAILURE INDICATOR||U/M2/MIN|ENLARGEMENT||CMH2O/ML|NOT DONE|||REVERSE TRANSCRIPTASE PCR|N|U|SIBLING|NEUROLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1965-06-28|
TRIAL STUDY 134XCP|TR|241CD521-D0BD-40BB-ABA2-B8C8E500B491|3||||||RADIODEN|RADIODENSITY||S/H|ABSENT||CAPFUL|NOT DONE|||SLIT LAMP|NA|U|FAMILY MEMBER|ENDOCRINOLOGIST|U|3||39||INDUCTION TREATMENT|1962-04-22|
TRIAL STUDY 134XCP|TR|241CD521-D0BD-40BB-ABA2-B8C8E500B491|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||ML/SEC/1.73M2|UNEQUIVOCAL||/40 HPFS|NOT DONE|||AUTOMATED COUNT|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|Y|4||88||OPEN LABEL TREATMENT|1971-11-19|
TRIAL STUDY 134XCP|TR|241CD521-D0BD-40BB-ABA2-B8C8E500B491|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||FMOL/L|UNCHANGED||STEPS/MIN|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|Y|N|HEALTH CARE PROFESSIONAL|RATER 2|Y|5||7||RUN-IN|1968-12-07|
TRIAL STUDY 134XCP|TR|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||UG/L FEU|FURTHER ENLARGEMENT||MMOL/MOL|NOT DONE|||CONFOCAL MICROSCOPY|NA|U|ADJUDICATOR|OPHTHALMOLOGIST|Y|1||38||CONTINUATION TREATMENT|1964-02-17|
TRIAL STUDY 134XCP|TR|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^9 CFU|PATHOLOGICAL||10^4 CFU/ML|NOT DONE|||PATHOLOGICAL EVALUATION|N|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1969-06-26|
TRIAL STUDY 134XCP|TR|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MG/KG/MIN|FURTHER ENLARGEMENT||PSEC|NOT DONE|||PALM METHOD|N|U|PROXY|NEUROLOGIST 1|N|3||39||OPEN LABEL TREATMENT|1965-09-01|
TRIAL STUDY 134XCP|TR|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||DROP|INCREASED||VG/ML|NOT DONE|||PET/SPECT SCAN|NA|Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|4||88||TREATMENT|1964-09-28|
TRIAL STUDY 134XCP|TR|D37D2206-A2C1-4AC2-93B2-EDB213AF852F|5||||||TUMSTATE|TUMOR STATE||MMOL/G|PATHOLOGICAL||10^3 COPIES/ML|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|U|CHILD|RADIOLOGIST|Y|5||7||WASHOUT|1971-01-02|
TRIAL STUDY 134XCP|TR|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||NMOL/G|ENLARGEMENT FROM NADIR||NEEDLE GAUGE|NOT DONE|||KNEMOMETRY|N|N|CAREGIVER|ONCOLOGIST 1|U|1||38||INDUCTION TREATMENT|1962-04-11|
TRIAL STUDY 134XCP|TR|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/L|INCREASED||U/G/DAY|NOT DONE|||TOTAL BODY RADIOGRAPHY|Y|Y|DOMESTIC PARTNER|OPTOMETRIST|Y|2||58||OPEN LABEL TREATMENT|1970-09-23|
TRIAL STUDY 134XCP|TR|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||BLOCKS|FURTHER ENLARGEMENT||EID 50/ML|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|Y|PROXY|RATER 1|NA|3||39||TREATMENT|1963-02-13|
TRIAL STUDY 134XCP|TR|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||BU/ML|FOCALLY INCREASED||POUCH|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|U|N|PROXY|RADIOLOGIST|N|4||88||WASHOUT|1964-08-06|
TRIAL STUDY 134XCP|TR|FAC78D40-3CBA-4D35-8911-64C0D25C3AE8|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/S/M2|PATHOLOGICAL||NU/CL|NOT DONE|||RAJI CELL RIA|U|NA|PARENT|ADJUDICATOR 3|N|5||7||BLINDED TREATMENT|1961-05-18|
TRIAL STUDY 134XCP|TR|FD609B1C-D1E7-4349-B036-DF0126D96A52|1||||||LESFLIND|LESION FAILURE INDICATOR||U/M2/H|UNCHANGED||ML/M2|NOT DONE|||AUSCULTATION|Y|U|VENDOR|CARDIOLOGIST|U|1||38||TREATMENT|1968-08-25|
TRIAL STUDY 134XCP|TR|FD609B1C-D1E7-4349-B036-DF0126D96A52|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||AMU|UNEQUIVOCAL||VIRTUAL PIXEL|NOT DONE|||HILLMEN COLOR CHART|N|NA|SPOUSE|PHYSIOTHERAPIST|NA|2||58||FOLLOW-UP|1964-12-28|
TRIAL STUDY 134XCP|TR|FD609B1C-D1E7-4349-B036-DF0126D96A52|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ENZYME U/M2|NONPALPABLE||MPL U/ML|NOT DONE|||ELECTRONEUROGRAPHY|Y|N|STUDY SUBJECT|RATER 1|NA|3||39||SCREENING|1970-12-04|
TRIAL STUDY 134XCP|TR|FD609B1C-D1E7-4349-B036-DF0126D96A52|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MIU/L|EQUIVOCAL||KAT|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|U|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|4||88||CONTINUATION TREATMENT|1972-04-09|
TRIAL STUDY 134XCP|TR|FD609B1C-D1E7-4349-B036-DF0126D96A52|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MG/KG|EQUIVOCAL||LOZENGE|NOT DONE|||MAMMOGRAPHY|NA|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|5||7||RUN-IN|1972-05-21|
TRIAL STUDY 134XCP|TR|DEB0593B-E3FD-471C-A800-43058AC5FD86|1||||||VOLUME|VOLUME||UCI/KG|FURTHER ENLARGEMENT||10^5/HPF|NOT DONE|||NEPHELOMETRY|NA|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|1||38||BASELINE|1968-07-04|
TRIAL STUDY 134XCP|TR|DEB0593B-E3FD-471C-A800-43058AC5FD86|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MET*MIN|FOCALLY INCREASED||MAC50|NOT DONE|||TOTAL BODY IRRADIATION|Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2||58||TREATMENT|1971-11-17|
TRIAL STUDY 134XCP|TR|DEB0593B-E3FD-471C-A800-43058AC5FD86|3||||||LDIAM|LONGEST DIAMETER||MHZ|FOCALLY INCREASED||PSI|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|NA|U|PARENT|PEDIATRIC NEUROLOGIST|N|3||39||BLINDED TREATMENT|1966-06-30|
TRIAL STUDY 134XCP|TR|DEB0593B-E3FD-471C-A800-43058AC5FD86|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||GRAIN|DIFFUSELY INCREASED||SFC/10^6 PBMC|NOT DONE|||MICROBIAL CULTURE, LIQUID|U|NA|INVESTIGATOR|ADJUDICATOR 2|N|4||88||SCREENING|1969-10-13|
TRIAL STUDY 134XCP|TR|DEB0593B-E3FD-471C-A800-43058AC5FD86|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MCI/L|DECREASED||BU|NOT DONE|||AUSCULTATION|U|N|STUDY SUBJECT|RATER 1|U|5||7||FOLLOW-UP|1964-05-30|
TRIAL STUDY 134XCP|TR|596BD728-2487-44E4-AFB1-8A4331EEDDF6|1||||||DIAMETER|DIAMETER||ML/S|ENLARGEMENT FROM NADIR||JAR|NOT DONE|||PATHOLOGICAL EVALUATION|N|Y|CAREGIVER|UROLOGIST|N|1||38||OPEN LABEL TREATMENT|1964-11-20|
TRIAL STUDY 134XCP|TR|596BD728-2487-44E4-AFB1-8A4331EEDDF6|2||||||AREA|AREA||NKAT|EQUIVOCAL||10^9 CFU/G|NOT DONE|||X-RAY|NA|U|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1963-01-06|
TRIAL STUDY 134XCP|TR|596BD728-2487-44E4-AFB1-8A4331EEDDF6|3||||||BNLNUM|NUMBER OF BONE LESIONS||U/ANIMAL|NORMAL||10^9 ORGANISMS/G|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|U|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||OBSERVATION|1970-11-19|
TRIAL STUDY 134XCP|TR|596BD728-2487-44E4-AFB1-8A4331EEDDF6|4||||||RADIODEN|RADIODENSITY||ML/MIN/1.73M2|ENLARGEMENT||MMHG*MIN/L|NOT DONE|||DOPPLER ULTRASOUND|NA|NA|INTERVIEWER|READER 1|N|4||88||TREATMENT|1967-04-28|
TRIAL STUDY 134XCP|TR|596BD728-2487-44E4-AFB1-8A4331EEDDF6|5||||||TUMSTATE|TUMOR STATE||ML/MIN|FURTHER ENLARGEMENT||10^3 RNA COPIES/ML|NOT DONE|||ELISA|U|Y|SPOUSE|ONCOLOGIST 2|NA|5||7||FOLLOW-UP|1972-07-24|
TRIAL STUDY 134XCP|TR|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||10^5/HPF|DIFFUSELY INCREASED||MU/L|NOT DONE|||CONTRAST ENHANCED MRI|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|1||38||WASHOUT|1961-01-08|
TRIAL STUDY 134XCP|TR|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|2||||||BNLNUM|NUMBER OF BONE LESIONS||10^6 RNA COPIES/ML|UNCHANGED||COULOMB|NOT DONE|||DUCTOGRAPHY|Y|N|FRIEND|UROLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1971-06-25|
TRIAL STUDY 134XCP|TR|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^6 IU/ML|PATHOLOGICAL||G/CM2|NOT DONE|||IODINE STAIN|U|U|CLINICAL RESEARCH COORDINATOR|RATER 1|NA|3||39||SCREENING|1968-02-13|
TRIAL STUDY 134XCP|TR|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/DAY|NON-PATHOLOGICAL||GMFI|NOT DONE|||CINEANGIOGRAPHY|U|Y|VENDOR|NEUROLOGIST 2|NA|4||88||FOLLOW-UP|1970-07-10|
TRIAL STUDY 134XCP|TR|CAF30D22-3C56-48D4-AB55-46C09A21FDBF|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||CMOL|INCREASED||BQ/MG|NOT DONE|||MYELOPEROXIDASE STAIN|NA|Y|STUDY SUBJECT|OPTOMETRIST|N|5||7||RUN-IN|1962-06-11|
TRIAL STUDY 134XCP|TR|0365EB5F-7364-4B1F-8919-543D8D21B045|1||||||SUMDIAM|SUM OF DIAMETER||MMOL/G|PALPABLE||DAYS|NOT DONE|||SINGLE-MOLECULE ARRAY|N|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST|N|1||38||SCREENING|1961-08-17|
TRIAL STUDY 134XCP|TR|0365EB5F-7364-4B1F-8919-543D8D21B045|2||||||RADIODEN|RADIODENSITY||GBQ/MG|DECREASED||TABLET|NOT DONE|||MICROBIAL CULTURE, SOLID|NA|N|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||TREATMENT|1963-06-16|
TRIAL STUDY 134XCP|TR|0365EB5F-7364-4B1F-8919-543D8D21B045|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||KAT|INCREASED||10^9 ORGANISMS/MG|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|NA|U|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|3||39||INDUCTION TREATMENT|1961-10-17|
TRIAL STUDY 134XCP|TR|0365EB5F-7364-4B1F-8919-543D8D21B045|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BQ|ABSENT||APS U|NOT DONE|||LINE PROBE ASSAY|NA|NA|CHILD|PATHOLOGIST 1|Y|4||88||BASELINE|1973-08-25|
TRIAL STUDY 134XCP|TR|0365EB5F-7364-4B1F-8919-543D8D21B045|5||||||NEWCONF|NEW TUMOR CONFIRMED||10^7 TCID 50/DOSE|FOCALLY INCREASED||GENEQ/ML|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|N|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||CONTINUATION TREATMENT|1962-06-13|
TRIAL STUDY 134XCP|TR|364277A8-875C-4A6F-93C3-C913BB3C97CA|1||||||PALPSTAT|PALPABLE STATE||STEPS/MIN|DECREASED||GPL U|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|U|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1972-12-10|
TRIAL STUDY 134XCP|TR|364277A8-875C-4A6F-93C3-C913BB3C97CA|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||HENRY|PRESENT||MOL|NOT DONE|||ERGOSPIROMETRY|N|NA|PARENT|PATHOLOGIST 2|NA|2||58||OBSERVATION|1960-01-30|
TRIAL STUDY 134XCP|TR|364277A8-875C-4A6F-93C3-C913BB3C97CA|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||FEU|INCREASED||DL|NOT DONE|||TARGETED GENOME SEQUENCING|U|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||RUN-IN|1968-09-23|
TRIAL STUDY 134XCP|TR|364277A8-875C-4A6F-93C3-C913BB3C97CA|4||||||VOLUME|VOLUME||FFU|TUMOR MERGED||BEATS/MIN|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|NA|HEALTH CARE PROFESSIONAL|RATER 2|Y|4||88||BASELINE|1962-07-18|
TRIAL STUDY 134XCP|TR|364277A8-875C-4A6F-93C3-C913BB3C97CA|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||COPIES/UG|NORMAL||MG/L FEU|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|NA|U|HEALTH CARE PROFESSIONAL|READER|NA|5||7||BLINDED TREATMENT|1968-04-13|
TRIAL STUDY 134XCP|TR|B824951F-58EE-4003-A2AD-A91AADBBAC0D|1||||||VOLUME|VOLUME||SHOCK WAVE|DECREASED||CFU/G|NOT DONE|||ACRIDINE ORANGE STAIN|Y|NA|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|1||38||RUN-IN|1972-07-13|
TRIAL STUDY 134XCP|TR|B824951F-58EE-4003-A2AD-A91AADBBAC0D|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||AU/ML|FURTHER ENLARGEMENT||NMOL BCE/NMOL|NOT DONE|||RAJI CELL EIA|U|U|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|2||58||WASHOUT|1961-08-18|
TRIAL STUDY 134XCP|TR|B824951F-58EE-4003-A2AD-A91AADBBAC0D|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MIN/DAY|NORMAL||CIGARETTE|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|U|U|PROXY|PEDIATRIC NEUROLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1967-11-01|
TRIAL STUDY 134XCP|TR|B824951F-58EE-4003-A2AD-A91AADBBAC0D|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||LX|DIFFUSELY INCREASED||UMOL/KG/MIN|NOT DONE|||AUTOREFRACTION|N|U|PROXY|MICROSCOPIST 1|U|4||88||RUN-IN|1965-04-20|
TRIAL STUDY 134XCP|TR|B824951F-58EE-4003-A2AD-A91AADBBAC0D|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||IU/G|ABSENT||NMOL/ML/MIN|NOT DONE|||MAPH|NA|U|CLINICAL RESEARCH COORDINATOR|READER 3|NA|5||7||OBSERVATION|1962-02-09|
TRIAL STUDY 134XCP|TR|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|1||||||SUMDIAM|SUM OF DIAMETER||ML/BREATH|DIFFUSELY INCREASED||GAUSS|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|U|N|INVESTIGATOR|RATER|Y|1||38||LONG-TERM FOLLOW-UP|1962-04-16|
TRIAL STUDY 134XCP|TR|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ML/(MIN*100ML)|DECREASED||PACKET|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|Y|CHILD|READER 3|N|2||58||INDUCTION TREATMENT|1961-12-17|
TRIAL STUDY 134XCP|TR|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/ANIMAL/WK|FURTHER ENLARGEMENT FROM NADIR||10^9/L|NOT DONE|||KNEMOMETRY|U|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|3||39||FOLLOW-UP|1965-02-15|
TRIAL STUDY 134XCP|TR|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|4||||||ORSTATE|ORGAN STATE||ML/M2/DAY|ENLARGEMENT||ML/S/M2|NOT DONE|||IMMUNOPRECIPITATION|Y|NA|SPOUSE|MICROSCOPIST 2|Y|4||88||BLINDED TREATMENT|1965-09-07|
TRIAL STUDY 134XCP|TR|CEB92F29-B105-4F82-B0AC-CDDA2C7D3EE0|5||||||LDIAM|LONGEST DIAMETER||/MS|PATHOLOGICAL||10^11/L|NOT DONE|||MANUAL COUNT|U|NA|CLINICAL RESEARCH ASSOCIATE|RATER|Y|5||7||INDUCTION TREATMENT|1970-01-08|
TRIAL STUDY 134XCP|TR|A108F408-906C-4320-965A-D5D295BC5C31|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ELISA UNIT/ML|FURTHER ENLARGEMENT FROM NADIR||U/KG/MIN|NOT DONE|||SNP ARRAY|NA|NA|CAREGIVER|PATHOLOGIST 2|U|1||38||SCREENING|1960-12-16|
TRIAL STUDY 134XCP|TR|A108F408-906C-4320-965A-D5D295BC5C31|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||L/H/M2|UNCHANGED||10^9/G|NOT DONE|||MUGA|N|N|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|2||58||CONTINUATION TREATMENT|1966-03-08|
TRIAL STUDY 134XCP|TR|A108F408-906C-4320-965A-D5D295BC5C31|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||U/KG/H|ABSENT||TCID 50/DOSE|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|STUDY SUBJECT|RADIOLOGIST|NA|3||39||SCREENING|1962-04-25|
TRIAL STUDY 134XCP|TR|A108F408-906C-4320-965A-D5D295BC5C31|4||||||LESSCIND|LESION SUCCESS INDICATOR||MOSM|NONPALPABLE||/SEC|NOT DONE|||HPLC-FL|Y|NA|DOMESTIC PARTNER|UROLOGIST|N|4||88||RUN-IN|1970-06-16|
TRIAL STUDY 134XCP|TR|A108F408-906C-4320-965A-D5D295BC5C31|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||NG/L|FURTHER ENLARGEMENT FROM NADIR||/WK|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|Y|Y|ADJUDICATOR|ADJUDICATOR 3|NA|5||7||TREATMENT|1967-06-21|
TRIAL STUDY 134XCP|TR|8E627D27-4855-4E1B-B823-1E14368973AF|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||ML/MMHG/MIN/L|NONPALPABLE||IU/ML|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|N|INDEPENDENT ASSESSOR|PATHOLOGIST|U|1||38||INDUCTION TREATMENT|1966-08-06|
TRIAL STUDY 134XCP|TR|8E627D27-4855-4E1B-B823-1E14368973AF|2||||||LESFLIND|LESION FAILURE INDICATOR||ML/KG/DAY|FURTHER ENLARGEMENT FROM NADIR||ML/H|NOT DONE|||RULER MEASUREMENT METHOD|NA|NA|CHILD|PATHOLOGIST 2|N|2||58||RUN-IN|1967-01-06|
TRIAL STUDY 134XCP|TR|8E627D27-4855-4E1B-B823-1E14368973AF|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NSEC|UNEQUIVOCAL||KPA/L/SEC|NOT DONE|||ICP-MS|U|N|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||TREATMENT|1963-10-11|
TRIAL STUDY 134XCP|TR|8E627D27-4855-4E1B-B823-1E14368973AF|4||||||LDIAM|LONGEST DIAMETER||MMOL/MIN/KPA/L|NONPALPABLE||L|NOT DONE|||WESTERGREN|U|N|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1968-11-07|
TRIAL STUDY 134XCP|TR|8E627D27-4855-4E1B-B823-1E14368973AF|5||||||VSLPIND|VESSEL PATENCY INDICATOR||UG/DAY|DECREASED||EJACULATE U|NOT DONE|||PHOTOMETRIC CLOT DETECTION|N|U|SIGNIFICANT OTHER|RATER 1|NA|5||7||INDUCTION TREATMENT|1966-11-07|
TRIAL STUDY 134XCP|TR|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MPL U/ML|FURTHER ENLARGEMENT||UG/ML/H|NOT DONE|||IMMUNORADIOMETRIC ASSAY|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|1||38||CONTINUATION TREATMENT|1960-11-07|
TRIAL STUDY 134XCP|TR|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||G/M2/DAY|FOCALLY INCREASED||KDA|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|NA|PARENT|READER 1|NA|2||58||BLINDED TREATMENT|1962-03-15|
TRIAL STUDY 134XCP|TR|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|3||||||VDIAM|VIABLE DIAMETER||/LSQN|PATHOLOGICAL||10^4/HPF|NOT DONE|||ULTRASOUND|N|U|FRIEND|MICROSCOPIST 3|U|3||39||OPEN LABEL TREATMENT|1964-06-18|
TRIAL STUDY 134XCP|TR|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|4||||||SUMDIAM|SUM OF DIAMETER||MEQ/DL|EQUIVOCAL||U/M2/MIN|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|N|U|CAREGIVER|OPTOMETRIST|U|4||88||LONG-TERM FOLLOW-UP|1969-03-16|
TRIAL STUDY 134XCP|TR|9D1D7F4D-D1F6-4EC8-A3FB-59BB1F596ED2|5||||||VSLPIND|VESSEL PATENCY INDICATOR||CG|PATHOLOGICAL||NG/DL|NOT DONE|||LYMPHANGIOGRAPHY|U|N|VENDOR|PATHOLOGIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1968-06-13|
TRIAL STUDY 134XCP|TR|483D89E1-45FD-41D4-B9E0-22FFB41D323A|1||||||AREA|AREA||KN/CM2|PRESENT||EVENTS|NOT DONE|||TOTAL BODY RADIOGRAPHY|NA|N|CHILD|PHYSIOTHERAPIST|NA|1||38||SCREENING|1962-09-02|
TRIAL STUDY 134XCP|TR|483D89E1-45FD-41D4-B9E0-22FFB41D323A|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||M/SEC|PRESENT||IU/MMOL|NOT DONE|||ORCHIDOMETERY|U|NA|PARENT|PATHOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1971-02-05|
TRIAL STUDY 134XCP|TR|483D89E1-45FD-41D4-B9E0-22FFB41D323A|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||COPIES/UG|ABSENT||ENZYME U/M2|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|U|U|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1970-06-19|
TRIAL STUDY 134XCP|TR|483D89E1-45FD-41D4-B9E0-22FFB41D323A|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||K|DECREASED||SUPPOSITORY|NOT DONE|||MRI WITHOUT CONTRAST|U|U|DOMESTIC PARTNER|READER|N|4||88||OPEN LABEL TREATMENT|1966-02-23|
TRIAL STUDY 134XCP|TR|483D89E1-45FD-41D4-B9E0-22FFB41D323A|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MEQ/DL|ENLARGEMENT FROM NADIR||SEC|NOT DONE|||POLYMERASE CHAIN REACTION|Y|N|GUARDIAN|FORENSIC PATHOLOGIST|NA|5||7||INDUCTION TREATMENT|1967-05-03|
TRIAL STUDY 134XCP|TR|2CCBED9D-5F24-4ED8-B575-8523C820A227|1||||||LNSTATE|LYMPH NODE STATE||AMP|ENLARGEMENT||ML/BEAT|NOT DONE|||WRIGHT STAIN|U|NA|STUDY SUBJECT|ADJUDICATOR 3|Y|1||38||OBSERVATION|1961-06-20|
TRIAL STUDY 134XCP|TR|2CCBED9D-5F24-4ED8-B575-8523C820A227|2||||||VOLUME|VOLUME||MMAL|NONPALPABLE||ML/CM H2O|NOT DONE|||RADIAL IMMUNODIFFUSION|Y|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|2||58||FOLLOW-UP|1970-10-24|
TRIAL STUDY 134XCP|TR|2CCBED9D-5F24-4ED8-B575-8523C820A227|3||||||NEWCONF|NEW TUMOR CONFIRMED||ML/KG/H|PALPABLE||10^6/L|NOT DONE|||MUGA|U|N|PROXY|PATHOLOGIST 2|U|3||39||WASHOUT|1969-08-31|
TRIAL STUDY 134XCP|TR|2CCBED9D-5F24-4ED8-B575-8523C820A227|4||||||LNSTATE|LYMPH NODE STATE||10^6 U|ENLARGEMENT||GENEQ/ML|NOT DONE|||SNELLEN EYE CHART|N|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||CONTINUATION TREATMENT|1967-05-04|
TRIAL STUDY 134XCP|TR|2CCBED9D-5F24-4ED8-B575-8523C820A227|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UU/DL|EQUIVOCAL||10^6 CFU|NOT DONE|||MOUSE PROTECTION ASSAY|Y|U|SIBLING|MICROSCOPIST 1|N|5||7||TREATMENT|1965-04-07|
TRIAL STUDY 134XCP|TR|F4D6A28D-569F-4639-ACE2-10EB517128B2|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||NMOL/G|ENLARGEMENT||AMP|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|NA|N|INTERVIEWER|NEUROLOGIST 1|Y|1||38||FOLLOW-UP|1963-04-10|
TRIAL STUDY 134XCP|TR|F4D6A28D-569F-4639-ACE2-10EB517128B2|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MG/DAY|ENLARGEMENT FROM NADIR||QUANTITY SUFFICIENT|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|2||58||INDUCTION TREATMENT|1973-07-10|
TRIAL STUDY 134XCP|TR|F4D6A28D-569F-4639-ACE2-10EB517128B2|3||||||SUMVOL|SUM OF VOLUME||MG/ANIMAL|NORMAL||U/10^12 RBC|NOT DONE|||INDIA INK STAIN|U|N|DOMESTIC PARTNER|DERMATOLOGIST|Y|3||39||INDUCTION TREATMENT|1966-04-12|
TRIAL STUDY 134XCP|TR|F4D6A28D-569F-4639-ACE2-10EB517128B2|4||||||VOLUME|VOLUME||KG/L|EQUIVOCAL||DPM/0.5 ML|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|Y|Y|INVESTIGATOR|PATHOLOGIST 1|Y|4||88||OBSERVATION|1965-09-18|
TRIAL STUDY 134XCP|TR|F4D6A28D-569F-4639-ACE2-10EB517128B2|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ML/M2|NON-PATHOLOGICAL||KG/L|NOT DONE|||DOPPLER ULTRASOUND|Y|N|STUDY SUBJECT|NEUROLOGIST|Y|5||7||BASELINE|1964-02-01|
TRIAL STUDY 134XCP|TR|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MCI/L|TUMOR MERGED||10^6 CFU/ML|NOT DONE|||KINYOUN STAIN|Y|N|INDEPENDENT ASSESSOR|RADIOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1965-01-23|
TRIAL STUDY 134XCP|TR|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MMAL|FURTHER ENLARGEMENT FROM NADIR||M/SEC2|NOT DONE|||ENZYMATIC COLORIMETRY|N|Y|SIGNIFICANT OTHER|PATHOLOGIST|U|2||58||RUN-IN|1970-09-15|
TRIAL STUDY 134XCP|TR|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|3||||||LPERP|LONGEST PERPENDICULAR||UIU/L|DIFFUSELY INCREASED||/200 HPFS|NOT DONE|||SANGER SEQUENCING|N|Y|INVESTIGATOR|RADIOLOGIST 2|N|3||39||WASHOUT|1971-07-28|
TRIAL STUDY 134XCP|TR|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||DROP|FURTHER ENLARGEMENT||LOG10 ELISA UNIT/DOSE|NOT DONE|||CENTRIFUGATION|Y|U|PROXY|OTOLARYNGOLOGIST|U|4||88||TREATMENT|1961-12-28|
TRIAL STUDY 134XCP|TR|7ABB925B-2CB5-498A-9E20-E1A2BE4E50DA|5||||||VDIAM|VIABLE DIAMETER||%(V/V)|NON-PATHOLOGICAL||PMOL/DL|NOT DONE|||PHOROPTER|Y|N|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1966-02-06|
TRIAL STUDY 134XCP|TR|415EF35E-6D99-48F8-80A1-89A4CDC621B8|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||/7.5 ML|NORMAL||DMOL|NOT DONE|||GEL ELECTROPHORESIS|NA|Y|GUARDIAN|OTOLARYNGOLOGIST|U|1||38||FOLLOW-UP|1968-02-22|
TRIAL STUDY 134XCP|TR|415EF35E-6D99-48F8-80A1-89A4CDC621B8|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UMOL/MIN|NORMAL||MEQ/UL|NOT DONE|||ACRIDINE ORANGE STAIN|U|Y|ADJUDICATOR|RATER 2|NA|2||58||WASHOUT|1971-06-29|
TRIAL STUDY 134XCP|TR|415EF35E-6D99-48F8-80A1-89A4CDC621B8|3||||||LESFLIND|LESION FAILURE INDICATOR||LOG10 TCID 50/DOSE|PALPABLE||CAPSULE|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|Y|N|SPOUSE|UROLOGIST|Y|3||39||SCREENING|1967-06-15|
TRIAL STUDY 134XCP|TR|415EF35E-6D99-48F8-80A1-89A4CDC621B8|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||GRAVITATIONAL UNIT|ENLARGEMENT FROM NADIR||POUCH|NOT DONE|||IMMUNORADIOMETRIC ASSAY|N|U|CLINICAL STUDY SPONSOR|READER|Y|4||88||BLINDED TREATMENT|1962-09-23|
TRIAL STUDY 134XCP|TR|415EF35E-6D99-48F8-80A1-89A4CDC621B8|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||NMOL|PATHOLOGICAL||LOG10 ELISA UNIT/DOSE|NOT DONE|||SISH|Y|N|CHILD|OPTOMETRIST|NA|5||7||OBSERVATION|1961-01-02|
TRIAL STUDY 134XCP|TR|AA0F6192-A377-43C6-8203-BDF7553AEA88|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||L/H/M2|FURTHER ENLARGEMENT FROM NADIR||BU/ML|NOT DONE|||MICRO BROTH DILUTION|Y|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|1||38||TREATMENT|1961-11-20|
TRIAL STUDY 134XCP|TR|AA0F6192-A377-43C6-8203-BDF7553AEA88|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UG/DAY|NORMAL||PMOL/G|NOT DONE|||LC/MS/MS|U|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|2||58||LONG-TERM FOLLOW-UP|1962-06-19|
TRIAL STUDY 134XCP|TR|AA0F6192-A377-43C6-8203-BDF7553AEA88|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||10^9 CFU/ML|EQUIVOCAL||NKAT|NOT DONE|||POLYGRAPHY|NA|NA|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|3||39||BLINDED TREATMENT|1963-03-09|
TRIAL STUDY 134XCP|TR|AA0F6192-A377-43C6-8203-BDF7553AEA88|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MG/ML/MIN|DECREASED||SCOOPFUL|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|U|ADJUDICATOR|ADJUDICATOR 2|Y|4||88||WASHOUT|1971-03-04|
TRIAL STUDY 134XCP|TR|AA0F6192-A377-43C6-8203-BDF7553AEA88|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UMOL/L/MIN|FOCALLY INCREASED||KG/CM2|NOT DONE|||IMMUNOASSAY|NA|U|FAMILY MEMBER|MICROSCOPIST 2|U|5||7||LONG-TERM FOLLOW-UP|1965-03-04|
TRIAL STUDY 134XCP|TR|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|1||||||PALPSTAT|PALPABLE STATE||G/MOL|EQUIVOCAL||NMOL BCE/L|NOT DONE|||IMMUNOPRECIPITATION|U|Y|INTERVIEWER|RATER 1|U|1||38||BASELINE|1962-04-13|
TRIAL STUDY 134XCP|TR|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||10^9 ORGANISMS/MG|UNEQUIVOCAL||BQ/KG|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|U|U|GUARDIAN|MICROSCOPIST 2|U|2||58||TREATMENT|1966-03-30|
TRIAL STUDY 134XCP|TR|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||U/G/DAY|UNCHANGED||MG/ANIMAL|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|Y|SIGNIFICANT OTHER|RADIOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1967-02-23|
TRIAL STUDY 134XCP|TR|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||U|FOCALLY INCREASED||FT3|NOT DONE|||CELL BASED BIOASSAY|U|Y|SPOUSE|ENDOCRINOLOGIST|NA|4||88||BLINDED TREATMENT|1960-02-14|
TRIAL STUDY 134XCP|TR|99DEAF5F-4F2A-4BFC-ABE7-E947C8FB8162|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||FARAD|DECREASED||ML/M2/MIN|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|5||7||RUN-IN|1969-11-29|
TRIAL STUDY 134XCP|TR|A848B1B5-679F-4C45-AD73-6506604C835E|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||DB|NONPALPABLE||BAU/ML|NOT DONE|||EPSILOMETER|U|Y|GUARDIAN|NEUROLOGIST 2|NA|1||38||BASELINE|1965-02-19|
TRIAL STUDY 134XCP|TR|A848B1B5-679F-4C45-AD73-6506604C835E|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^9 ORGANISMS|ENLARGEMENT||DYN|NOT DONE|||HEMAGGLUTINATION ASSAY|Y|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|2||58||BASELINE|1968-01-11|
TRIAL STUDY 134XCP|TR|A848B1B5-679F-4C45-AD73-6506604C835E|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||GY/H|DIFFUSELY INCREASED||10^9 CFU|NOT DONE|||DYNAMOMETRY|Y|NA|SIGNIFICANT OTHER|READER 2|U|3||39||TREATMENT|1966-07-03|
TRIAL STUDY 134XCP|TR|A848B1B5-679F-4C45-AD73-6506604C835E|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^7 CFU|FURTHER ENLARGEMENT FROM NADIR||KEV|NOT DONE|||STRESS ECHOCARDIOGRAPHY|U|N|INTERVIEWER|NEUROLOGIST 2|NA|4||88||BASELINE|1961-06-26|
TRIAL STUDY 134XCP|TR|A848B1B5-679F-4C45-AD73-6506604C835E|5||||||LESSCIND|LESION SUCCESS INDICATOR||IU/ML|DIFFUSELY INCREASED||MCI|NOT DONE|||GRAM STAIN|Y|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|5||7||BLINDED TREATMENT|1966-10-03|
TRIAL STUDY 134XCP|TR|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|1||||||AREA|AREA||MV/SEC|UNEQUIVOCAL||PA|NOT DONE|||MYELOPEROXIDASE STAIN|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|1||38||RUN-IN|1961-01-20|
TRIAL STUDY 134XCP|TR|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UMOL|PRESENT||10^4/HPF|NOT DONE|||DIGITAL PCR|U|Y|FRIEND|PEDIATRIC NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1972-04-04|
TRIAL STUDY 134XCP|TR|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MEQ/ML|ENLARGEMENT FROM NADIR||DEG/MM|NOT DONE|||SPECT SCAN|NA|Y|PROXY|INTERNIST|NA|3||39||FOLLOW-UP|1972-04-08|
TRIAL STUDY 134XCP|TR|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|4||||||SUMVOL|SUM OF VOLUME||TORR|INCREASED||HR/DAY|NOT DONE|||SLOAN LETTER EYE CHART 100%|NA|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|4||88||BLINDED TREATMENT|1966-12-07|
TRIAL STUDY 134XCP|TR|0C1AA66D-A2FC-4F68-B9B6-89F270FD4D47|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MG/DL|NON-PATHOLOGICAL||BQ|NOT DONE|||X-RAY|U|N|PROXY|RATER 1|Y|5||7||RUN-IN|1972-12-05|
TRIAL STUDY 134XCP|TR|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ML/MIN/MMHG|PALPABLE||10^6/EJACULATE U|NOT DONE|||PYROSEQUENCING|Y|Y|SPOUSE|MICROSCOPIST 1|Y|1||38||SCREENING|1963-10-31|
TRIAL STUDY 134XCP|TR|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ML/G/H|FOCALLY INCREASED||UG/KG/DAY|NOT DONE|||FLUORESCEIN STAIN|U|U|CLINICAL STUDY SPONSOR|INTERNIST|Y|2||58||SCREENING|1973-05-22|
TRIAL STUDY 134XCP|TR|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||%(W/W)|NORMAL||RING|NOT DONE|||DARK FIELD MICROSCOPY|NA|N|CHILD|PATHOLOGIST 1|NA|3||39||OBSERVATION|1962-10-13|
TRIAL STUDY 134XCP|TR|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||U/KG/H|ABSENT||UG/L DDU|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|U|PARENT|PEDIATRIC NEUROLOGIST|NA|4||88||SCREENING|1964-03-18|
TRIAL STUDY 134XCP|TR|ABA9682E-D373-48DA-A7BD-68AB1563CFD6|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||UKAT/L|INCREASED||GY|NOT DONE|||MICRODENSITOMETRY|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|5||7||INDUCTION TREATMENT|1962-02-12|
TRIAL STUDY 134XCP|TR|FC155F37-522F-4620-BBFF-4999D37C1379|1||||||LPERP|LONGEST PERPENDICULAR||MG/DOSE|EQUIVOCAL||ML/MIN/MMHG|NOT DONE|||LANDOLT RING|N|N|FRIEND|CLINICAL PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1961-08-30|
TRIAL STUDY 134XCP|TR|FC155F37-522F-4620-BBFF-4999D37C1379|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||CIGARETTE|DECREASED||MBP|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|N|U|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1969-01-09|
TRIAL STUDY 134XCP|TR|FC155F37-522F-4620-BBFF-4999D37C1379|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MG/MIN|EQUIVOCAL||10^7 TCID 50/DOSE|NOT DONE|||CARDIAC THERMODILUTION|U|N|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|3||39||LONG-TERM FOLLOW-UP|1973-06-23|
TRIAL STUDY 134XCP|TR|FC155F37-522F-4620-BBFF-4999D37C1379|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||LOG10 ELISA UNIT/DOSE|UNCHANGED||BEL|NOT DONE|||SURFACE PLASMON RESONANCE|Y|N|DOMESTIC PARTNER|DERMATOLOGIST|NA|4||88||BASELINE|1971-11-10|
TRIAL STUDY 134XCP|TR|FC155F37-522F-4620-BBFF-4999D37C1379|5||||||LNSTATE|LYMPH NODE STATE||DNA COPIES/UG|FURTHER ENLARGEMENT FROM NADIR||MG/CM2|NOT DONE|||MICRO BROTH DILUTION|Y|N|SPOUSE|MICROSCOPIST 3|Y|5||7||BLINDED TREATMENT|1968-06-26|
TRIAL STUDY 134XCP|TR|20F817BC-4C89-4F6C-AA45-36CE786A73A8|1||||||NEWCONF|NEW TUMOR CONFIRMED||PMOL/L/H|NONPALPABLE||ABSORBANCE U/MIN|NOT DONE|||PHOTOMETRIC CLOT DETECTION|Y|U|DOMESTIC PARTNER|ONCOLOGIST 2|N|1||38||SCREENING|1970-11-11|
TRIAL STUDY 134XCP|TR|20F817BC-4C89-4F6C-AA45-36CE786A73A8|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||DEG/S|TUMOR MERGED||/MBP|NOT DONE|||WEBER GREEN STAIN|NA|Y|VENDOR|INTERNIST|U|2||58||SCREENING|1968-05-30|
TRIAL STUDY 134XCP|TR|20F817BC-4C89-4F6C-AA45-36CE786A73A8|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||LOG10 CFU/G|TUMOR MERGED||/200 HPFS|NOT DONE|||SPECT/CT SCAN|Y|Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||FOLLOW-UP|1969-12-16|
TRIAL STUDY 134XCP|TR|20F817BC-4C89-4F6C-AA45-36CE786A73A8|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ML/M2|NON-PATHOLOGICAL||DROP|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|Y|U|VENDOR|ONCOLOGIST|N|4||88||INDUCTION TREATMENT|1968-12-27|
TRIAL STUDY 134XCP|TR|20F817BC-4C89-4F6C-AA45-36CE786A73A8|5||||||TUMSTATE|TUMOR STATE||SCOOPFUL|TUMOR MERGED||GTT|NOT DONE|||POPULATION SEQUENCING|N|NA|SIBLING|ONCOLOGIST 2|NA|5||7||BASELINE|1969-09-13|
TRIAL STUDY 134XCP|TR|99058E64-9873-4CD5-BB31-28C08758A1B5|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||TSP|EQUIVOCAL||G/CAGE/WK|NOT DONE|||PH METER MEASUREMENT METHOD|U|U|CHILD|RADIOLOGIST 1|Y|1||38||RUN-IN|1962-04-12|
TRIAL STUDY 134XCP|TR|99058E64-9873-4CD5-BB31-28C08758A1B5|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||IN|TUMOR MERGED||COULOMB|NOT DONE|||IMPEDANCE CONDUCTIVITY|NA|U|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|2||58||TREATMENT|1962-07-23|
TRIAL STUDY 134XCP|TR|99058E64-9873-4CD5-BB31-28C08758A1B5|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||APL U|UNEQUIVOCAL||10^6/HPF|NOT DONE|||OSCILLOMETRY|Y|NA|SIBLING|NEUROLOGIST 2|N|3||39||INDUCTION TREATMENT|1968-09-21|
TRIAL STUDY 134XCP|TR|99058E64-9873-4CD5-BB31-28C08758A1B5|4||||||LPERP|LONGEST PERPENDICULAR||MMOL/L|UNCHANGED||AFU|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 2|N|4||88||INDUCTION TREATMENT|1964-05-21|
TRIAL STUDY 134XCP|TR|99058E64-9873-4CD5-BB31-28C08758A1B5|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PNU/ML|ENLARGEMENT FROM NADIR||FMOL/G|NOT DONE|||WESTERN BLOT|N|NA|STUDY SUBJECT|ADJUDICATOR 3|Y|5||7||WASHOUT|1963-07-08|
TRIAL STUDY 134XCP|TR|656B6693-1C1C-433B-84E3-77E89F0B543E|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UGEQ/L|ENLARGEMENT FROM NADIR||IU/G HB|NOT DONE|||CENTRIFUGATION|NA|NA|GUARDIAN|RATER 1|Y|1||38||SCREENING|1965-11-25|
TRIAL STUDY 134XCP|TR|656B6693-1C1C-433B-84E3-77E89F0B543E|2||||||TUMSTATE|TUMOR STATE||MKAT|PALPABLE||L/L|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|N|U|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|2||58||FOLLOW-UP|1973-03-05|
TRIAL STUDY 134XCP|TR|656B6693-1C1C-433B-84E3-77E89F0B543E|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MM/H|ABSENT||/40 HPFS|NOT DONE|||MICROSCOPY|Y|N|CAREGIVER|RADIOLOGIST 1|U|3||39||LONG-TERM FOLLOW-UP|1961-05-22|
TRIAL STUDY 134XCP|TR|656B6693-1C1C-433B-84E3-77E89F0B543E|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||U/MG|ABSENT||IU/MMOL|NOT DONE|||HPLC-FL|NA|Y|DOMESTIC PARTNER|HEMATOLOGIST|U|4||88||SCREENING|1969-03-06|
TRIAL STUDY 134XCP|TR|656B6693-1C1C-433B-84E3-77E89F0B543E|5||||||TUMSTATE|TUMOR STATE||V|ABSENT||CI/KG|NOT DONE|||ORCHIDOMETERY|U|N|FAMILY MEMBER|RATER 1|N|5||7||OPEN LABEL TREATMENT|1965-06-20|
TRIAL STUDY 134XCP|TR|43C443F9-AB0F-44BE-B28B-63A60EE09205|1||||||ORSTATE|ORGAN STATE||SYRINGE|DIFFUSELY INCREASED||DMOL|NOT DONE|||NO INFORMATION|Y|N|GUARDIAN|READER|N|1||38||BLINDED TREATMENT|1963-02-01|
TRIAL STUDY 134XCP|TR|43C443F9-AB0F-44BE-B28B-63A60EE09205|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMOL2/L2|TUMOR MERGED||UKAT|NOT DONE|||ETDRS EYE CHART|Y|N|ADJUDICATOR|CLINICAL PATHOLOGIST|N|2||58||TREATMENT|1966-12-15|
TRIAL STUDY 134XCP|TR|43C443F9-AB0F-44BE-B28B-63A60EE09205|3||||||VSLPIND|VESSEL PATENCY INDICATOR||G/G/DAY|DECREASED||MM2|NOT DONE|||CELL BASED BIOASSAY|U|Y|INDEPENDENT ASSESSOR|READER 1|Y|3||39||OBSERVATION|1969-07-26|
TRIAL STUDY 134XCP|TR|43C443F9-AB0F-44BE-B28B-63A60EE09205|4||||||VOLUME|VOLUME||MG2/DL2|PRESENT||IU/KG/H|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|Y|NA|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|4||88||WASHOUT|1967-07-12|
TRIAL STUDY 134XCP|TR|43C443F9-AB0F-44BE-B28B-63A60EE09205|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||PMOL/10^9 CELLS|NON-PATHOLOGICAL||ARBITRARY U|NOT DONE|||SMEAR|U|N|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||SCREENING|1960-03-13|
TRIAL STUDY 134XCP|TR|37FF91B1-CE3C-4587-85CE-F76B880D40E7|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^6/HPF|FOCALLY INCREASED||PPB|NOT DONE|||PET/CT SCAN|N|U|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|1||38||INDUCTION TREATMENT|1963-06-20|
TRIAL STUDY 134XCP|TR|37FF91B1-CE3C-4587-85CE-F76B880D40E7|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UG/KG/MIN|FURTHER ENLARGEMENT FROM NADIR||KDA|NOT DONE|||MUGA|Y|NA|SIBLING|ONCOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1973-05-15|
TRIAL STUDY 134XCP|TR|37FF91B1-CE3C-4587-85CE-F76B880D40E7|3||||||NEWCONF|NEW TUMOR CONFIRMED||DEG/MM|EQUIVOCAL||MIN/DAY|NOT DONE|||LYMPHANGIOGRAPHY|Y|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|3||39||TREATMENT|1973-07-29|
TRIAL STUDY 134XCP|TR|37FF91B1-CE3C-4587-85CE-F76B880D40E7|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||FARAD|NON-PATHOLOGICAL||CM2|NOT DONE|||REFLECTANCE SPECTROSCOPY|N|N|INVESTIGATOR|RATER|U|4||88||INDUCTION TREATMENT|1973-02-23|
TRIAL STUDY 134XCP|TR|37FF91B1-CE3C-4587-85CE-F76B880D40E7|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||NMOL/L|EQUIVOCAL||EIA UNIT|NOT DONE|||ELASTOGRAPHY|NA|NA|PROXY|ADJUDICATOR|NA|5||7||BASELINE|1969-09-08|
TRIAL STUDY 134XCP|TR|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||DEG|DIFFUSELY INCREASED||DYN|NOT DONE|||PET/SPECT SCAN|NA|N|GUARDIAN|RATER 2|N|1||38||LONG-TERM FOLLOW-UP|1967-04-15|
TRIAL STUDY 134XCP|TR|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||WATT|UNEQUIVOCAL||ML/G/MIN|NOT DONE|||COLORIMETRY|Y|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||BASELINE|1969-04-27|
TRIAL STUDY 134XCP|TR|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|3||||||LDIAM|LONGEST DIAMETER||PA|NONPALPABLE||BAU|NOT DONE|||AMSLER GRID|U|NA|PROXY|READER 3|NA|3||39||WASHOUT|1972-08-17|
TRIAL STUDY 134XCP|TR|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|4||||||VDIAM|VIABLE DIAMETER||ML*CMH2O|FURTHER ENLARGEMENT FROM NADIR||UEQ|NOT DONE|||ELECTROCHEMILUMINESCENCE|U|U|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1970-01-19|
TRIAL STUDY 134XCP|TR|9C25B17D-2E57-4EBD-93AF-F4439EB77B03|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||/2000 RBC|FURTHER ENLARGEMENT FROM NADIR||CYCLE/MIN|NOT DONE|||LYMPHANGIOGRAPHY|U|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|N|5||7||FOLLOW-UP|1972-07-19|
TRIAL STUDY 134XCP|TR|49017491-2C28-4F86-BF72-CF83651052F6|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||COPIES/UG|FURTHER ENLARGEMENT FROM NADIR||/7.5 ML|NOT DONE|||LC/MS|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|1||38||FOLLOW-UP|1963-03-15|
TRIAL STUDY 134XCP|TR|49017491-2C28-4F86-BF72-CF83651052F6|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||NU/CL|ENLARGEMENT||DNA COPIES/ML|NOT DONE|||IMPEDANCE CONDUCTIVITY|NA|U|CLINICAL STUDY SPONSOR|READER 2|N|2||58||BASELINE|1965-07-05|
TRIAL STUDY 134XCP|TR|49017491-2C28-4F86-BF72-CF83651052F6|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UG/L/H|DIFFUSELY INCREASED||10^3 DNA COPIES/ML|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|NA|N|SIGNIFICANT OTHER|DERMATOLOGIST|NA|3||39||CONTINUATION TREATMENT|1971-09-04|
TRIAL STUDY 134XCP|TR|49017491-2C28-4F86-BF72-CF83651052F6|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||DNA COPIES/UG|EQUIVOCAL||BAG|NOT DONE|||SPECULAR MICROSCOPY|Y|Y|ADJUDICATION COMMITTEE|HEMATOLOGIST|N|4||88||INDUCTION TREATMENT|1967-05-10|
TRIAL STUDY 134XCP|TR|49017491-2C28-4F86-BF72-CF83651052F6|5||||||BNLNUM|NUMBER OF BONE LESIONS||L/MIN/M2|DECREASED||GENEQ|NOT DONE|||MICRODENSITOMETRY|NA|U|CHILD|PATHOLOGIST|U|5||7||BLINDED TREATMENT|1961-04-10|
TRIAL STUDY 134XCP|TR|DAA65EE6-66ED-4354-935B-1347E1B572A5|1||||||SUMVOL|SUM OF VOLUME||NMOL BCE/NMOL|DIFFUSELY INCREASED||SCM|NOT DONE|||FLUOROSCOPY|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1||38||OBSERVATION|1965-08-23|
TRIAL STUDY 134XCP|TR|DAA65EE6-66ED-4354-935B-1347E1B572A5|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||RAD|PALPABLE||10^9/DOSE|NOT DONE|||IMMUNOBLOT|NA|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|2||58||OBSERVATION|1968-02-19|
TRIAL STUDY 134XCP|TR|DAA65EE6-66ED-4354-935B-1347E1B572A5|3||||||SUMVOL|SUM OF VOLUME||SIEMENS|DIFFUSELY INCREASED||BQ|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|U|U|INVESTIGATOR|RATER|U|3||39||WASHOUT|1970-12-03|
TRIAL STUDY 134XCP|TR|DAA65EE6-66ED-4354-935B-1347E1B572A5|4||||||DIAMETER|DIAMETER||L/KG|NON-PATHOLOGICAL||L/S|NOT DONE|||SINGLE-SLICE SPIRAL CT|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|4||88||BLINDED TREATMENT|1964-03-12|
TRIAL STUDY 134XCP|TR|DAA65EE6-66ED-4354-935B-1347E1B572A5|5||||||SUMVOL|SUM OF VOLUME||NFIU|NONPALPABLE||CGY|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|U|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|5||7||RUN-IN|1967-04-09|
TRIAL STUDY 134XCP|TR|A440A3E5-F87D-4306-9195-3A842F0DDE33|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||NEBULE|EQUIVOCAL||LOG10 ELISA UNIT/DOSE|NOT DONE|||MRS|Y|NA|CHILD|OPHTHALMOLOGIST|N|1||38||WASHOUT|1963-02-07|
TRIAL STUDY 134XCP|TR|A440A3E5-F87D-4306-9195-3A842F0DDE33|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||/2000 RBC|ABSENT||10^3 CFU/G|NOT DONE|||LC-FL|N|N|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|2||58||SCREENING|1960-12-23|
TRIAL STUDY 134XCP|TR|A440A3E5-F87D-4306-9195-3A842F0DDE33|3||||||AREA|AREA||PT_US|PATHOLOGICAL||APPLICATION|NOT DONE|||MOUSE PROTECTION ASSAY|NA|N|SPOUSE|RADIOLOGIST 1|U|3||39||WASHOUT|1967-03-02|
TRIAL STUDY 134XCP|TR|A440A3E5-F87D-4306-9195-3A842F0DDE33|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/4.0 ML|INCREASED||IN2|NOT DONE|||AUSCULTATION|NA|U|CAREGIVER|DERMATOLOGIST|U|4||88||CONTINUATION TREATMENT|1972-08-17|
TRIAL STUDY 134XCP|TR|A440A3E5-F87D-4306-9195-3A842F0DDE33|5||||||LPERP|LONGEST PERPENDICULAR||UG/ANIMAL|ENLARGEMENT FROM NADIR||MET*H|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|U|NA|ADJUDICATION COMMITTEE|MICROSCOPIST|Y|5||7||BLINDED TREATMENT|1968-01-18|
TRIAL STUDY 134XCP|TR|48BBE085-BD68-451A-9700-6A1AB18D84EE|1||||||ORVERLN|ORGAN VERTICAL LENGTH||OHM|PRESENT||RFU|NOT DONE|||HPLC-UV|NA|NA|CAREGIVER|READER|N|1||38||INDUCTION TREATMENT|1964-01-09|
TRIAL STUDY 134XCP|TR|48BBE085-BD68-451A-9700-6A1AB18D84EE|2||||||SUMDIAM|SUM OF DIAMETER||DAYS/MONTH|PALPABLE||U/10^12 RBC|NOT DONE|||SMEAR|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1962-12-30|
TRIAL STUDY 134XCP|TR|48BBE085-BD68-451A-9700-6A1AB18D84EE|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||/MM2|ENLARGEMENT FROM NADIR||M/SEC|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|U|Y|SIGNIFICANT OTHER|RADIOLOGIST|Y|3||39||BASELINE|1966-08-29|
TRIAL STUDY 134XCP|TR|48BBE085-BD68-451A-9700-6A1AB18D84EE|4||||||RADIODEN|RADIODENSITY||NMOL/L/MIN|INCREASED||ML/G/DAY|NOT DONE|||CELLULOSE TAPE|Y|N|INTERVIEWER|RATER 2|U|4||88||BLINDED TREATMENT|1973-01-10|
TRIAL STUDY 134XCP|TR|48BBE085-BD68-451A-9700-6A1AB18D84EE|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||KG/MOL|NORMAL||10^6 COPIES/ML|NOT DONE|||DISK DIFFUSION|NA|U|SIGNIFICANT OTHER|ONCOLOGIST 2|N|5||7||BLINDED TREATMENT|1964-12-10|
TRIAL STUDY 134XCP|TR|F38055A2-11E2-437B-BD6A-662D81521F1D|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||U/M2/DAY|DIFFUSELY INCREASED||KEV|NOT DONE|||IHC|U|N|INTERVIEWER|RATER|Y|1||38||RUN-IN|1963-06-14|
TRIAL STUDY 134XCP|TR|F38055A2-11E2-437B-BD6A-662D81521F1D|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||NEWTON|TUMOR MERGED||PFU/ANIMAL|NOT DONE|||SXA SCAN|N|Y|INVESTIGATOR|OTOLARYNGOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1961-09-29|
TRIAL STUDY 134XCP|TR|F38055A2-11E2-437B-BD6A-662D81521F1D|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||CYLINDER|DECREASED||10^6 ORGANISMS/ML|NOT DONE|||CONTRAST ENHANCED PET SCAN|NA|U|STUDY SUBJECT|NEUROLOGIST|U|3||39||INDUCTION TREATMENT|1967-09-17|
TRIAL STUDY 134XCP|TR|F38055A2-11E2-437B-BD6A-662D81521F1D|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||FT2|TUMOR MERGED||RNA COPIES/ML|NOT DONE|||LYMPHANGIOGRAPHY|Y|NA|INTERVIEWER|MICROSCOPIST 1|Y|4||88||OPEN LABEL TREATMENT|1972-08-23|
TRIAL STUDY 134XCP|TR|F38055A2-11E2-437B-BD6A-662D81521F1D|5||||||BNLNUM|NUMBER OF BONE LESIONS||PUFF|DIFFUSELY INCREASED||MOL/MOL|NOT DONE|||HPLC-FL|N|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||BASELINE|1961-05-10|
TRIAL STUDY 134XCP|TR|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||VG/ML|ENLARGEMENT FROM NADIR||UM|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|N|NA|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||FOLLOW-UP|1965-04-08|
TRIAL STUDY 134XCP|TR|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||TUBERCULIN UNIT|DECREASED||IU/G|NOT DONE|||MICROSCOPY|N|U|DOMESTIC PARTNER|ONCOLOGIST 2|Y|2||58||OPEN LABEL TREATMENT|1971-02-17|
TRIAL STUDY 134XCP|TR|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PG/L|PALPABLE||APS U|NOT DONE|||GC/MS/MS|Y|NA|CLINICAL RESEARCH ASSOCIATE|READER|N|3||39||OPEN LABEL TREATMENT|1962-08-16|
TRIAL STUDY 134XCP|TR|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|4||||||LPERP|LONGEST PERPENDICULAR||MG/KG|INCREASED||ML/G/MIN|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|U|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|4||88||OBSERVATION|1964-08-07|
TRIAL STUDY 134XCP|TR|96CB86AC-5041-4FA3-8CD2-6D390B3269DC|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MU|NON-PATHOLOGICAL||10^4 CFU|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|5||7||SCREENING|1965-10-05|
TRIAL STUDY 134XCP|TR|22B0F097-D571-4E65-9B58-BEF2C3482F05|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||P|NORMAL||FT2|NOT DONE|||SICKLE CELL SOLUBILITY TEST|N|U|INVESTIGATOR|OTOLARYNGOLOGIST|NA|1||38||CONTINUATION TREATMENT|1965-03-30|
TRIAL STUDY 134XCP|TR|22B0F097-D571-4E65-9B58-BEF2C3482F05|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UG/MIN|ENLARGEMENT FROM NADIR||MG/M2/MIN|NOT DONE|||INFRARED SPECTROMETRY|U|U|ADJUDICATOR|ADJUDICATOR 1|N|2||58||LONG-TERM FOLLOW-UP|1961-12-26|
TRIAL STUDY 134XCP|TR|22B0F097-D571-4E65-9B58-BEF2C3482F05|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||10^6 ORGANISMS/G|NON-PATHOLOGICAL||CMH2O*S/ML|NOT DONE|||FLOCCULATION|Y|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1965-12-18|
TRIAL STUDY 134XCP|TR|22B0F097-D571-4E65-9B58-BEF2C3482F05|4||||||TUMSTATE|TUMOR STATE||MDFI|DECREASED||MM3/MM2/YEAR|NOT DONE|||CLINICAL EVALUATION|Y|NA|CHILD|ADJUDICATOR|NA|4||88||INDUCTION TREATMENT|1962-03-25|
TRIAL STUDY 134XCP|TR|22B0F097-D571-4E65-9B58-BEF2C3482F05|5||||||CALCFIND|CALCIFICATION INDICATOR||GPL U/ML|FURTHER ENLARGEMENT FROM NADIR||10^9 ORGANISMS/G|NOT DONE|||MICROBIAL CULTURE|U|NA|FRIEND|RADIOLOGIST|NA|5||7||SCREENING|1971-06-09|
TRIAL STUDY 134XCP|TR|F56B6C70-0513-4032-A0BE-B961F6F2EF30|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||HOURS|PALPABLE||MM3/MM2/YEAR|NOT DONE|||SCANNING ELECTRON MICROSCOPY|U|Y|INVESTIGATOR|HEMATOLOGIST|U|1||38||BASELINE|1965-09-20|
TRIAL STUDY 134XCP|TR|F56B6C70-0513-4032-A0BE-B961F6F2EF30|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||TAMPON|PATHOLOGICAL||HZ|NOT DONE|||FLOW MICROSCOPY|U|N|FAMILY MEMBER|ADJUDICATOR|Y|2||58||CONTINUATION TREATMENT|1960-05-22|
TRIAL STUDY 134XCP|TR|F56B6C70-0513-4032-A0BE-B961F6F2EF30|3||||||DIAMETER|DIAMETER||UG/KG/H|PALPABLE||UG/L/H|NOT DONE|||IHC|NA|Y|PROXY|ADJUDICATOR|U|3||39||FOLLOW-UP|1960-05-25|
TRIAL STUDY 134XCP|TR|F56B6C70-0513-4032-A0BE-B961F6F2EF30|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PACK|UNCHANGED||U/G HB|NOT DONE|||TOTAL BODY RADIOGRAPHY|NA|N|FRIEND|PATHOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1963-06-06|
TRIAL STUDY 134XCP|TR|F56B6C70-0513-4032-A0BE-B961F6F2EF30|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^9 ORGANISMS/ML|ENLARGEMENT||UU/DL|NOT DONE|||RADIOGRAPHY|U|U|DOMESTIC PARTNER|PATHOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1971-08-11|
TRIAL STUDY 134XCP|TR|8E385A66-25C9-417E-9298-FB87A73B661F|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UMOL/KG/MIN|FOCALLY INCREASED||SHOCK WAVE|NOT DONE|||AURAMINE STAIN|Y|N|FRIEND|NEUROLOGIST|NA|1||38||INDUCTION TREATMENT|1960-03-15|
TRIAL STUDY 134XCP|TR|8E385A66-25C9-417E-9298-FB87A73B661F|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||OHM|NON-PATHOLOGICAL||/200 HPFS|NOT DONE|||PELLI-ROBSON EYE CHART|NA|N|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||CONTINUATION TREATMENT|1960-12-27|
TRIAL STUDY 134XCP|TR|8E385A66-25C9-417E-9298-FB87A73B661F|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||CMH2O/ML|UNEQUIVOCAL||MEQ/KG|NOT DONE|||POPULATION SEQUENCING|U|N|PROXY|PHYSIOTHERAPIST|NA|3||39||LONG-TERM FOLLOW-UP|1962-10-01|
TRIAL STUDY 134XCP|TR|8E385A66-25C9-417E-9298-FB87A73B661F|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||/2500 WBC|ENLARGEMENT FROM NADIR||KHZ|NOT DONE|||BALLPOINT PEN TECHNIQUE|Y|Y|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|4||88||SCREENING|1969-05-23|
TRIAL STUDY 134XCP|TR|8E385A66-25C9-417E-9298-FB87A73B661F|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||KEV|FURTHER ENLARGEMENT FROM NADIR||10^3 ORGANISMS|NOT DONE|||FLUORESCEIN STAIN|Y|U|VENDOR|INTERNIST|NA|5||7||RUN-IN|1970-04-23|
TRIAL STUDY 134XCP|TR|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MANSON U/ML|UNEQUIVOCAL||MIN/DAY|NOT DONE|||CISH|Y|NA|SIBLING|READER 3|N|1||38||RUN-IN|1966-10-11|
TRIAL STUDY 134XCP|TR|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||G|DIFFUSELY INCREASED||/2000 RBC|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|2||58||TREATMENT|1968-10-02|
TRIAL STUDY 134XCP|TR|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MG2/DL2|FURTHER ENLARGEMENT FROM NADIR||M/SEC|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|N|Y|PARENT|INTERNIST|Y|3||39||FOLLOW-UP|1972-10-12|
TRIAL STUDY 134XCP|TR|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||DIP|UNEQUIVOCAL||DEG/S|NOT DONE|||PET SCAN|Y|N|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|4||88||SCREENING|1963-04-26|
TRIAL STUDY 134XCP|TR|0471CF8F-4CA2-422C-94F5-7E8A4A5838F3|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||M3|INCREASED||PIXELS/IN|NOT DONE|||JAEGER EYE CHART|Y|N|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|5||7||BASELINE|1967-01-07|
TRIAL STUDY 134XCP|TR|D0AE2069-B430-4771-9A8C-0F5442DFCECE|1||||||NEWCONF|NEW TUMOR CONFIRMED||/MBP|DIFFUSELY INCREASED||MN|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|N|NA|FRIEND|OTOLARYNGOLOGIST|NA|1||38||BLINDED TREATMENT|1964-06-20|
TRIAL STUDY 134XCP|TR|D0AE2069-B430-4771-9A8C-0F5442DFCECE|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UL/ML|EQUIVOCAL||ML/KG/MIN|NOT DONE|||RAJI CELL EIA|Y|Y|ADJUDICATION COMMITTEE|RATER|NA|2||58||INDUCTION TREATMENT|1962-10-28|
TRIAL STUDY 134XCP|TR|D0AE2069-B430-4771-9A8C-0F5442DFCECE|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||CP|NONPALPABLE||NU/CL|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1967-03-25|
TRIAL STUDY 134XCP|TR|D0AE2069-B430-4771-9A8C-0F5442DFCECE|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||RNA COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||10^6 DNA COPIES/ML|NOT DONE|||DIRECT SEQUENCING|NA|Y|CAREGIVER|RADIOLOGIST 2|N|4||88||INDUCTION TREATMENT|1962-03-11|
TRIAL STUDY 134XCP|TR|D0AE2069-B430-4771-9A8C-0F5442DFCECE|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||U/CL|DIFFUSELY INCREASED||10^12 IU/L|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|NA|N|ADJUDICATOR|NEUROLOGIST 2|U|5||7||SCREENING|1972-09-28|
TRIAL STUDY 134XCP|TR|CF214007-AC24-4760-AEDE-F78CDE3D9351|1||||||LMBFLIND|LIMB FAILURE INDICATOR||PG/DL|INCREASED||NSEC|NOT DONE|||MICROBIAL CULTURE, LIQUID|U|U|GUARDIAN|NEUROLOGIST|NA|1||38||TREATMENT|1967-10-22|
TRIAL STUDY 134XCP|TR|CF214007-AC24-4760-AEDE-F78CDE3D9351|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MMOL/MOL|FOCALLY INCREASED||NU/CL|NOT DONE|||HANSEL STAIN|U|N|INVESTIGATOR|RADIOLOGIST 1|NA|2||58||WASHOUT|1967-09-16|
TRIAL STUDY 134XCP|TR|CF214007-AC24-4760-AEDE-F78CDE3D9351|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U/G HB|ENLARGEMENT||10^5/L|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|NA|U|PARENT|MICROSCOPIST|N|3||39||WASHOUT|1965-10-31|
TRIAL STUDY 134XCP|TR|CF214007-AC24-4760-AEDE-F78CDE3D9351|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||HOMEOPATHIC DILUTION|TUMOR MERGED||L/MIN/M2|NOT DONE|||RADIOGRAPHY|U|Y|CHILD|RADIOLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1966-01-13|
TRIAL STUDY 134XCP|TR|CF214007-AC24-4760-AEDE-F78CDE3D9351|5||||||LPERP|LONGEST PERPENDICULAR||/2000 RBC|UNCHANGED||MPL U|NOT DONE|||CONTRAST ENHANCED X-RAY|U|Y|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1961-03-29|
TRIAL STUDY 134XCP|TR|E996BE19-2824-49D3-944F-B777F3D8E746|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||PG|PRESENT||MMHG*MIN/L|NOT DONE|||REFLECTANCE SPECTROSCOPY|U|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|1||38||LONG-TERM FOLLOW-UP|1970-05-23|
TRIAL STUDY 134XCP|TR|E996BE19-2824-49D3-944F-B777F3D8E746|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||PMOL/10^10 CELLS|PRESENT||G/U|NOT DONE|||OPTICAL MAPPING|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER|NA|2||58||WASHOUT|1962-09-03|
TRIAL STUDY 134XCP|TR|E996BE19-2824-49D3-944F-B777F3D8E746|3||||||SUMVOL|SUM OF VOLUME||BQ|PALPABLE||/100 HPFS|NOT DONE|||RYAN BLUE STAIN|Y|Y|VENDOR|READER|NA|3||39||INDUCTION TREATMENT|1968-02-26|
TRIAL STUDY 134XCP|TR|E996BE19-2824-49D3-944F-B777F3D8E746|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ML/M2/H|EQUIVOCAL||NMOL BCE/MMOL|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|NA|U|VENDOR|RATER|N|4||88||BASELINE|1962-05-18|
TRIAL STUDY 134XCP|TR|E996BE19-2824-49D3-944F-B777F3D8E746|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||ANTIBODY UNIT|PRESENT||ARBITRARY U|NOT DONE|||ALCIAN BLUE STAIN|Y|Y|SPOUSE|ADJUDICATOR 2|Y|5||7||FOLLOW-UP|1964-04-13|
TRIAL STUDY 134XCP|TR|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||LOG10 PFU|INCREASED||ML/KG/MIN|NOT DONE|||ENDOSCOPY|N|N|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|1||38||OPEN LABEL TREATMENT|1973-01-08|
TRIAL STUDY 134XCP|TR|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||/200 HPFS|PRESENT||MMHG/SEC|NOT DONE|||LAPAROSCOPY|U|U|CAREGIVER|READER|U|2||58||CONTINUATION TREATMENT|1963-12-16|
TRIAL STUDY 134XCP|TR|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||STEPS/MIN|PATHOLOGICAL||NU/CL|NOT DONE|||ELLA|Y|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|3||39||OBSERVATION|1969-08-14|
TRIAL STUDY 134XCP|TR|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|4||||||LESFLIND|LESION FAILURE INDICATOR||ML/M2/DAY|NON-PATHOLOGICAL||NEEDLE GAUGE|NOT DONE|||MIGET|Y|N|INTERVIEWER|RADIOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1973-05-23|
TRIAL STUDY 134XCP|TR|B2A31803-615A-4B78-9DFD-CD6EB8ABF5AC|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UKAT/10^12 RBC|ENLARGEMENT||ANSON U|NOT DONE|||LYMPHANGIOGRAPHY|U|N|FAMILY MEMBER|ADJUDICATOR|U|5||7||SCREENING|1972-10-07|
TRIAL STUDY 134XCP|TR|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||10^3 CFU/ML|TUMOR MERGED||IU/ML|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|N|INVESTIGATOR|ADJUDICATOR 3|U|1||38||SCREENING|1973-06-07|
TRIAL STUDY 134XCP|TR|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||NMOL BCE/L|DECREASED||PG/L|NOT DONE|||PHASE CONTRAST MICROSCOPY|N|U|CHILD|HEMATOLOGIST|U|2||58||FOLLOW-UP|1964-01-05|
TRIAL STUDY 134XCP|TR|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|3||||||LNSTATE|LYMPH NODE STATE||10^6 ORGANISMS/ML|ENLARGEMENT FROM NADIR||10^6 IU/ML|NOT DONE|||HPLC-UV|NA|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|3||39||CONTINUATION TREATMENT|1965-06-07|
TRIAL STUDY 134XCP|TR|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|4||||||NEWCONF|NEW TUMOR CONFIRMED||OZ EQ|EQUIVOCAL||KG/CM2|NOT DONE|||LIGHT MICROSCOPY|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|4||88||BLINDED TREATMENT|1972-01-02|
TRIAL STUDY 134XCP|TR|21BA7C51-E98D-4C0F-A437-8B4E05E6D6AE|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||UM/DAY|UNEQUIVOCAL||KA_U/DL|NOT DONE|||GC/FID|U|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|5||7||BLINDED TREATMENT|1966-05-21|
TRIAL STUDY 134XCP|TR|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||SBE/ML|ENLARGEMENT FROM NADIR||MMOL/KG|NOT DONE|||SNELLEN EYE CHART|N|Y|INTERVIEWER|CLINICAL PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1962-10-21|
TRIAL STUDY 134XCP|TR|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|2||||||TUMSTATE|TUMOR STATE||GPELISA UNIT/ML|FURTHER ENLARGEMENT FROM NADIR||10^5/L|NOT DONE|||NO INFORMATION|N|Y|STUDY SUBJECT|RADIOLOGIST 2|NA|2||58||BLINDED TREATMENT|1962-11-17|
TRIAL STUDY 134XCP|TR|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|3||||||TUMSTATE|TUMOR STATE||FMOL|EQUIVOCAL||10^7/L|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|Y|SIBLING|RADIOLOGIST|N|3||39||TREATMENT|1963-08-01|
TRIAL STUDY 134XCP|TR|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||ATM|EQUIVOCAL||NMOL BCE/NMOL|NOT DONE|||ELECTROMYOGRAPHY|U|Y|PARENT|PEDIATRIC NEUROLOGIST|U|4||88||RUN-IN|1964-06-09|
TRIAL STUDY 134XCP|TR|3AD9D7F8-CD2F-4B45-AA83-20E7DBE60EA5|5||||||TUMSTATE|TUMOR STATE||NMOL/L/H|PATHOLOGICAL||PIPE|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|NA|N|SIBLING|PHYSIOTHERAPIST|N|5||7||SCREENING|1963-11-02|
TRIAL STUDY 134XCP|TR|1F75D53C-E8AA-45DA-8410-F00266080E80|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||ML/MIN|PALPABLE||UGEQ|NOT DONE|||CLOT DETECTION|N|Y|PARENT|DERMATOLOGIST|Y|1||38||BASELINE|1972-09-07|
TRIAL STUDY 134XCP|TR|1F75D53C-E8AA-45DA-8410-F00266080E80|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||ML/G/DAY|PALPABLE||MM/MIN|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|N|N|SIGNIFICANT OTHER|INTERNIST|N|2||58||INDUCTION TREATMENT|1968-07-22|
TRIAL STUDY 134XCP|TR|1F75D53C-E8AA-45DA-8410-F00266080E80|3||||||RADIODEN|RADIODENSITY||GBQ/MG|NON-PATHOLOGICAL||U.CARR|NOT DONE|||JAEGER EYE CHART|U|U|ADJUDICATOR|ADJUDICATOR 1|U|3||39||OPEN LABEL TREATMENT|1968-07-24|
TRIAL STUDY 134XCP|TR|1F75D53C-E8AA-45DA-8410-F00266080E80|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||ENZYME U/L|PRESENT||TUBERCULIN UNIT/ML|NOT DONE|||MACRO BROTH DILUTION|NA|N|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|4||88||OBSERVATION|1961-03-17|
TRIAL STUDY 134XCP|TR|1F75D53C-E8AA-45DA-8410-F00266080E80|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||LOG10 PFU|UNCHANGED||UG/DL|NOT DONE|||ELASTOGRAPHY|Y|U|ADJUDICATION COMMITTEE|UROLOGIST|U|5||7||TREATMENT|1964-08-16|
TRIAL STUDY 134XCP|TR|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||SBE/ML|NORMAL||CUP EQ|NOT DONE|||U-HPLC/MS/MS|Y|N|SIBLING|ONCOLOGIST 1|U|1||38||WASHOUT|1963-09-01|
TRIAL STUDY 134XCP|TR|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||10^9/DOSE|NONPALPABLE||UEQ|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|N|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|2||58||BLINDED TREATMENT|1962-09-05|
TRIAL STUDY 134XCP|TR|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||NMOL BCE/MMOL|DECREASED||L/H/M2|NOT DONE|||DUKE INCISION METHOD|NA|Y|CLINICAL STUDY SPONSOR|RATER 1|N|3||39||LONG-TERM FOLLOW-UP|1971-03-09|
TRIAL STUDY 134XCP|TR|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||RING|TUMOR MERGED||/200 HPFS|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|U|PROXY|READER|N|4||88||OBSERVATION|1971-02-18|
TRIAL STUDY 134XCP|TR|9CEC9DDD-6ECE-46CB-9C66-C42B46245666|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||CI/MG|ABSENT||G/M2/DAY|NOT DONE|||ORCHIDOMETERY|Y|N|SPOUSE|RATER|N|5||7||LONG-TERM FOLLOW-UP|1965-12-02|
TRIAL STUDY 134XCP|TR|EE14E53E-19A8-4441-BF82-31444CBC8B49|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||VOXEL|ENLARGEMENT||UG/KG/MIN|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|N|U|INVESTIGATOR|ONCOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1972-07-22|
TRIAL STUDY 134XCP|TR|EE14E53E-19A8-4441-BF82-31444CBC8B49|2||||||ORVERLN|ORGAN VERTICAL LENGTH||MMHG/SEC|ENLARGEMENT FROM NADIR||IMPLANT|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|N|U|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|2||58||FOLLOW-UP|1960-02-03|
TRIAL STUDY 134XCP|TR|EE14E53E-19A8-4441-BF82-31444CBC8B49|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||/H|DIFFUSELY INCREASED||BQ/ML|NOT DONE|||THIN SMEAR|Y|Y|INDEPENDENT ASSESSOR|READER 2|NA|3||39||BLINDED TREATMENT|1962-03-03|
TRIAL STUDY 134XCP|TR|EE14E53E-19A8-4441-BF82-31444CBC8B49|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||RATIO|UNEQUIVOCAL||ECL UNIT|NOT DONE|||CHROMOGENIC ASSAY|NA|U|INVESTIGATOR|OPTOMETRIST|Y|4||88||BLINDED TREATMENT|1964-06-23|
TRIAL STUDY 134XCP|TR|EE14E53E-19A8-4441-BF82-31444CBC8B49|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MOL/DAY|TUMOR MERGED||DISK|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|N|N|SPOUSE|ONCOLOGIST 1|NA|5||7||RUN-IN|1972-01-08|
TRIAL STUDY 134XCP|TR|DAF741EF-DCCF-4E18-844B-05640A94C181|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||FRACTION OF 1|FURTHER ENLARGEMENT||/LSQN|NOT DONE|||URANYL ACETATE STAIN|U|Y|VENDOR|RADIOLOGIST 2|U|1||38||WASHOUT|1973-07-28|
TRIAL STUDY 134XCP|TR|DAF741EF-DCCF-4E18-844B-05640A94C181|2||||||AREA|AREA||ML/SEC/1.73M2|NORMAL||CI/G|NOT DONE|||RYAN BLUE STAIN|U|Y|INTERVIEWER|HEMATOLOGIST|N|2||58||CONTINUATION TREATMENT|1969-02-25|
TRIAL STUDY 134XCP|TR|DAF741EF-DCCF-4E18-844B-05640A94C181|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||CI/UL|NORMAL||PMOL/DL|NOT DONE|||THICK SMEAR|N|U|FRIEND|MICROSCOPIST 1|U|3||39||RUN-IN|1964-05-15|
TRIAL STUDY 134XCP|TR|DAF741EF-DCCF-4E18-844B-05640A94C181|4||||||LESSCIND|LESION SUCCESS INDICATOR||CD|NONPALPABLE||/CMH2O|NOT DONE|||LC/MS/MS|Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4||88||INDUCTION TREATMENT|1968-10-27|
TRIAL STUDY 134XCP|TR|DAF741EF-DCCF-4E18-844B-05640A94C181|5||||||ORSTATE|ORGAN STATE||10^5/L|NORMAL||BEL|NOT DONE|||TELLER ACUITY CARDS|Y|U|VENDOR|UROLOGIST|NA|5||7||BLINDED TREATMENT|1961-11-12|
TRIAL STUDY 134XCP|TR|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||/MM|DECREASED||CL|NOT DONE|||MICROBIAL CULTURE, LIQUID|Y|Y|INTERVIEWER|HEMATOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1970-04-23|
TRIAL STUDY 134XCP|TR|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||/MIN|FOCALLY INCREASED||CI/UG|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|NA|GUARDIAN|RADIOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1962-05-12|
TRIAL STUDY 134XCP|TR|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|3||||||NEWCONF|NEW TUMOR CONFIRMED||APL U/ML|ENLARGEMENT||ELISA UNIT/DOSE|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|U|GUARDIAN|RADIOLOGIST 2|NA|3||39||BLINDED TREATMENT|1963-07-26|
TRIAL STUDY 134XCP|TR|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|4||||||LPERP|LONGEST PERPENDICULAR||U/G|TUMOR MERGED||FT|NOT DONE|||ANGIOGRAPHY|N|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|4||88||BLINDED TREATMENT|1972-09-07|
TRIAL STUDY 134XCP|TR|EBABAEE6-8EBE-4E92-9CBA-0AAE56BEAE54|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^5/HPF|UNCHANGED||CYCLE/MIN|NOT DONE|||HPLC-FL|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|5||7||OBSERVATION|1964-04-07|
TRIAL STUDY 134XCP|TR|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||LOG10 CFU/G|DECREASED||TROCHE|NOT DONE|||RYAN BLUE STAIN|U|N|PROXY|OTOLARYNGOLOGIST|N|1||38||CONTINUATION TREATMENT|1968-08-19|
TRIAL STUDY 134XCP|TR|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MSEC|FURTHER ENLARGEMENT FROM NADIR||/CMH2O|NOT DONE|||DXA SCAN|N|Y|FAMILY MEMBER|MICROSCOPIST 2|NA|2||58||TREATMENT|1973-01-04|
TRIAL STUDY 134XCP|TR|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MOSM/KG|FURTHER ENLARGEMENT||PKAT|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|U|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||OBSERVATION|1961-07-11|
TRIAL STUDY 134XCP|TR|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||TUBERCULIN UNIT|ABSENT||MG/ML/DAY|NOT DONE|||RADIOGRAPHY|N|N|STUDY SUBJECT|DERMATOLOGIST|NA|4||88||CONTINUATION TREATMENT|1963-06-14|
TRIAL STUDY 134XCP|TR|9B1490FA-9D19-4E9E-96D6-FA159E2D2B4D|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||NMOL BCE/L|NONPALPABLE||10^6 ORGANISMS/G|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|Y|SIBLING|READER|NA|5||7||OBSERVATION|1963-11-05|
TRIAL STUDY 134XCP|TR|CF3E1636-762F-4821-A44E-455F33F5E4CC|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||10^9 ORGANISMS/MG|ENLARGEMENT||EVENTS|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|NA|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||FOLLOW-UP|1960-08-04|
TRIAL STUDY 134XCP|TR|CF3E1636-762F-4821-A44E-455F33F5E4CC|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||G/M2|UNCHANGED||UG/KG/H|NOT DONE|||KNEMOMETRY|N|N|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||INDUCTION TREATMENT|1970-08-14|
TRIAL STUDY 134XCP|TR|CF3E1636-762F-4821-A44E-455F33F5E4CC|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||CM H2O|DECREASED||WEEKS|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|NA|Y|INDEPENDENT ASSESSOR|INTERNIST|Y|3||39||RUN-IN|1969-01-17|
TRIAL STUDY 134XCP|TR|CF3E1636-762F-4821-A44E-455F33F5E4CC|4||||||LDIAM|LONGEST DIAMETER||HR/DAY|FURTHER ENLARGEMENT||MG/MOL|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|U|U|ADJUDICATOR|MICROSCOPIST 2|NA|4||88||BASELINE|1962-02-14|
TRIAL STUDY 134XCP|TR|CF3E1636-762F-4821-A44E-455F33F5E4CC|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/M2/MIN|UNEQUIVOCAL||AFU|NOT DONE|||EEG|Y|N|CAREGIVER|PATHOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1969-05-01|
TRIAL STUDY 134XCP|TR|3846A0A8-2D38-44C9-A579-84C66315C436|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||RATIO|ENLARGEMENT FROM NADIR||10^9 ORGANISMS|NOT DONE|||DYNAMIC LIGHT SCATTERING|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|1||38||OPEN LABEL TREATMENT|1971-03-15|
TRIAL STUDY 134XCP|TR|3846A0A8-2D38-44C9-A579-84C66315C436|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/G/MIN|ABSENT||LOG EID 50/DOSE|NOT DONE|||AUTOREFRACTION|NA|N|FAMILY MEMBER|PATHOLOGIST|U|2||58||RUN-IN|1962-09-07|
TRIAL STUDY 134XCP|TR|3846A0A8-2D38-44C9-A579-84C66315C436|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||UCI/L|UNEQUIVOCAL||PACK YEAR|NOT DONE|||BETA LACTAMASE|N|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||OBSERVATION|1966-08-14|
TRIAL STUDY 134XCP|TR|3846A0A8-2D38-44C9-A579-84C66315C436|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^4 CFU/ML|FURTHER ENLARGEMENT FROM NADIR||DEG2|NOT DONE|||COLORIMETRY|NA|Y|CHILD|RATER 2|Y|4||88||OBSERVATION|1973-01-23|
TRIAL STUDY 134XCP|TR|3846A0A8-2D38-44C9-A579-84C66315C436|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||NKAT|EQUIVOCAL||DEG|NOT DONE|||FLOCCULATION|N|Y|CHILD|PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1961-05-17|
TRIAL STUDY 134XCP|TR|75B429C2-E173-4F72-8D4A-76F62C97F006|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||POINT|ABSENT||V|NOT DONE|||PERIPHERAL ANGIOGRAPHY|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|1||38||RUN-IN|1973-05-01|
TRIAL STUDY 134XCP|TR|75B429C2-E173-4F72-8D4A-76F62C97F006|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UG/M2/MIN|ABSENT||WAFER|NOT DONE|||LC-FL|NA|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|2||58||INDUCTION TREATMENT|1962-12-09|
TRIAL STUDY 134XCP|TR|75B429C2-E173-4F72-8D4A-76F62C97F006|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||NGEQ/L|ENLARGEMENT FROM NADIR||MG/KG/DAY|NOT DONE|||SINGLE-SLICE SPIRAL CT|U|N|INDEPENDENT ASSESSOR|ADJUDICATOR|U|3||39||LONG-TERM FOLLOW-UP|1968-09-26|
TRIAL STUDY 134XCP|TR|75B429C2-E173-4F72-8D4A-76F62C97F006|4||||||NEWCONF|NEW TUMOR CONFIRMED||BE/ML|NONPALPABLE||BQ|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|N|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|4||88||OBSERVATION|1961-02-02|
TRIAL STUDY 134XCP|TR|75B429C2-E173-4F72-8D4A-76F62C97F006|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/DAY|ENLARGEMENT FROM NADIR||BQ/KG|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|Y|SIBLING|OPHTHALMOLOGIST|NA|5||7||CONTINUATION TREATMENT|1972-03-07|
TRIAL STUDY 134XCP|TR|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|1||||||NEWCONF|NEW TUMOR CONFIRMED||G/KG/DAY|FURTHER ENLARGEMENT FROM NADIR||RFU|NOT DONE|||SPECTROPHOTOMETRY|N|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1972-04-30|
TRIAL STUDY 134XCP|TR|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||LOG10 ELISA UNIT|NORMAL||10^12 IU/L|NOT DONE|||IVY INCISION METHOD|NA|N|PARENT|PATHOLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1963-11-02|
TRIAL STUDY 134XCP|TR|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||TSP|DIFFUSELY INCREASED||SCOOPFUL|NOT DONE|||BETA LACTAMASE|NA|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|3||39||TREATMENT|1970-04-29|
TRIAL STUDY 134XCP|TR|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||DB|DIFFUSELY INCREASED||MPS U|NOT DONE|||HPLC|NA|N|FAMILY MEMBER|MICROSCOPIST 1|N|4||88||OPEN LABEL TREATMENT|1963-11-16|
TRIAL STUDY 134XCP|TR|D0196B36-EE56-4B5E-A60C-5C6E6EAFF381|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||DAGU/ML|FURTHER ENLARGEMENT FROM NADIR||H/WK|NOT DONE|||CINEANGIOGRAPHY|N|Y|CAREGIVER|ADJUDICATOR 3|NA|5||7||LONG-TERM FOLLOW-UP|1971-03-21|
TRIAL STUDY 134XCP|TR|8065F0B9-9183-43E4-998A-D2F096D87998|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||FG|NORMAL||MG/L FEU|NOT DONE|||GC/MS-EI|N|N|FAMILY MEMBER|NEUROLOGIST 2|NA|1||38||TREATMENT|1965-12-16|
TRIAL STUDY 134XCP|TR|8065F0B9-9183-43E4-998A-D2F096D87998|2||||||LESFLIND|LESION FAILURE INDICATOR||MOSM/L|ENLARGEMENT||G/KG/DAY|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|N|SPOUSE|MICROSCOPIST 3|Y|2||58||WASHOUT|1967-08-08|
TRIAL STUDY 134XCP|TR|8065F0B9-9183-43E4-998A-D2F096D87998|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||NG/DAY|UNEQUIVOCAL||10^6 ORGANISMS/ML|NOT DONE|||CINEANGIOGRAPHY|N|U|PROXY|MICROSCOPIST 2|N|3||39||OBSERVATION|1971-11-02|
TRIAL STUDY 134XCP|TR|8065F0B9-9183-43E4-998A-D2F096D87998|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||10^6 COPIES/ML|UNEQUIVOCAL||/HPF|NOT DONE|||DARK FIELD MICROSCOPY|NA|N|CAREGIVER|ADJUDICATOR 1|N|4||88||BASELINE|1967-08-03|
TRIAL STUDY 134XCP|TR|8065F0B9-9183-43E4-998A-D2F096D87998|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MOSM/KG|EQUIVOCAL||PACK|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|NA|INTERVIEWER|RADIOLOGIST|N|5||7||TREATMENT|1962-07-23|
TRIAL STUDY 134XCP|TR|697EB3B7-5AD1-4D1D-BB53-BB0556915957|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||EVENTS|PALPABLE||BOTTLE|NOT DONE|||NO INFORMATION|Y|N|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||SCREENING|1960-05-12|
TRIAL STUDY 134XCP|TR|697EB3B7-5AD1-4D1D-BB53-BB0556915957|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||FARAD|EQUIVOCAL||QUANTITY SUFFICIENT|NOT DONE|||DIGITAL PCR ARRAY|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2||58||BLINDED TREATMENT|1970-07-11|
TRIAL STUDY 134XCP|TR|697EB3B7-5AD1-4D1D-BB53-BB0556915957|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||G/ANIMAL|UNCHANGED||UMOL/DL|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||OPEN LABEL TREATMENT|1965-09-04|
TRIAL STUDY 134XCP|TR|697EB3B7-5AD1-4D1D-BB53-BB0556915957|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6 CFU/ML|ENLARGEMENT FROM NADIR||G/DL|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|NA|Y|STUDY SUBJECT|ADJUDICATOR 3|NA|4||88||OBSERVATION|1962-06-24|
TRIAL STUDY 134XCP|TR|697EB3B7-5AD1-4D1D-BB53-BB0556915957|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MEQ/KG|PALPABLE||H/WK|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|Y|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|NA|5||7||WASHOUT|1970-12-14|
TRIAL STUDY 134XCP|TR|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMOL|NONPALPABLE||AMPULE|NOT DONE|||GC/MS|NA|N|STUDY SUBJECT|MICROSCOPIST|U|1||38||OPEN LABEL TREATMENT|1962-12-01|
TRIAL STUDY 134XCP|TR|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/CM|DECREASED||SFC/10^6 PBMC|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|Y|N|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1964-07-24|
TRIAL STUDY 134XCP|TR|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||G/MOL|TUMOR MERGED||PG/DL|NOT DONE|||MEDIASTINOSCOPY|NA|N|FRIEND|READER 2|NA|3||39||OPEN LABEL TREATMENT|1960-04-11|
TRIAL STUDY 134XCP|TR|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ANTIBODY UNIT|PRESENT||UMOL/L|NOT DONE|||FLOCCULATION, CHARCOAL ENHANCED|NA|Y|INTERVIEWER|ONCOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1965-08-18|
TRIAL STUDY 134XCP|TR|3DC3F05B-BA68-42F0-BC91-003D9FB00A91|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UMOL/H/MMOL|INCREASED||MPA|NOT DONE|||OBSERVATION|U|Y|CAREGIVER|RATER|U|5||7||INDUCTION TREATMENT|1964-08-13|
TRIAL STUDY 134XCP|TR|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^8/L|NONPALPABLE||10^6 RNA COPIES/ML|NOT DONE|||SLIT LAMP|Y|NA|DOMESTIC PARTNER|CARDIOLOGIST|N|1||38||OPEN LABEL TREATMENT|1968-09-26|
TRIAL STUDY 134XCP|TR|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^3 ORGANISMS/ML|ABSENT||BOX|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|2||58||CONTINUATION TREATMENT|1962-09-07|
TRIAL STUDY 134XCP|TR|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UM2|PRESENT||10^3 CFU/ML|NOT DONE|||POPULATION SEQUENCING|N|U|CAREGIVER|READER 2|Y|3||39||CONTINUATION TREATMENT|1964-03-17|
TRIAL STUDY 134XCP|TR|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|4||||||SUMDIAM|SUM OF DIAMETER||PACKAGE|DECREASED||10^3 CFU/ML|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|N|NA|PARENT|ONCOLOGIST 2|N|4||88||SCREENING|1966-04-20|
TRIAL STUDY 134XCP|TR|469A321E-3F7B-4C3E-B5CE-A6A02B8D8A94|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KV|TUMOR MERGED||SIEMENS|NOT DONE|||INFRARED SPECTROMETRY|U|NA|GUARDIAN|MICROSCOPIST 3|U|5||7||SCREENING|1969-11-26|
TRIAL STUDY 134XCP|TR|52EC57AA-56E4-47A8-AADA-36F62653B423|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UG/L/H|FURTHER ENLARGEMENT||ELISA UNIT/DOSE|NOT DONE|||ISHIHARA COLOR PLATES|NA|N|FRIEND|RADIOLOGIST|N|1||38||RUN-IN|1960-05-13|
TRIAL STUDY 134XCP|TR|52EC57AA-56E4-47A8-AADA-36F62653B423|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||U/MG|ENLARGEMENT||MMAL|NOT DONE|||ELECTROGASTROGRAPHY|NA|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|2||58||SCREENING|1960-07-27|
TRIAL STUDY 134XCP|TR|52EC57AA-56E4-47A8-AADA-36F62653B423|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||U/L|PALPABLE||/10^5|NOT DONE|||DROPLET DIGITAL PCR|N|N|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|3||39||OBSERVATION|1971-04-14|
TRIAL STUDY 134XCP|TR|52EC57AA-56E4-47A8-AADA-36F62653B423|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CGY|PALPABLE||ML/MIN/1.73M2|NOT DONE|||REBOUND TONOMETRY|N|U|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|N|4||88||INDUCTION TREATMENT|1969-12-31|
TRIAL STUDY 134XCP|TR|52EC57AA-56E4-47A8-AADA-36F62653B423|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PUFF|PATHOLOGICAL||CMOL/L|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|NA|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|5||7||FOLLOW-UP|1971-08-22|
TRIAL STUDY 134XCP|TR|F09C04A4-4F9E-4033-9115-81C6007DE8B4|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||PIXELS/IN|FURTHER ENLARGEMENT||MG/M2/MIN|NOT DONE|||GC/MS-CI|U|U|CLINICAL RESEARCH ASSOCIATE|RATER 2|U|1||38||FOLLOW-UP|1962-01-18|
TRIAL STUDY 134XCP|TR|F09C04A4-4F9E-4033-9115-81C6007DE8B4|2||||||LESSCIND|LESION SUCCESS INDICATOR||DAMOL/L|NONPALPABLE||BAU|NOT DONE|||FLUOROSCOPY|NA|Y|GUARDIAN|PATHOLOGIST 2|U|2||58||INDUCTION TREATMENT|1969-09-02|
TRIAL STUDY 134XCP|TR|F09C04A4-4F9E-4033-9115-81C6007DE8B4|3||||||LESFLIND|LESION FAILURE INDICATOR||MG/ML/MIN|PATHOLOGICAL||10^6 ORGANISMS|NOT DONE|||GRADIENT DIFFUSION|N|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1969-03-18|
TRIAL STUDY 134XCP|TR|F09C04A4-4F9E-4033-9115-81C6007DE8B4|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MSEC|PRESENT||UU/L|NOT DONE|||IMMUNOFLUORESCENT STAIN|NA|U|SIBLING|RATER 1|NA|4||88||CONTINUATION TREATMENT|1972-04-24|
TRIAL STUDY 134XCP|TR|F09C04A4-4F9E-4033-9115-81C6007DE8B4|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||LOG EID 50/DOSE|FURTHER ENLARGEMENT||KDA|NOT DONE|||TRYPAN BLUE STAIN|NA|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||RUN-IN|1965-08-25|
TRIAL STUDY 134XCP|TR|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||/MBP|FOCALLY INCREASED||10^6/EJACULATE U|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1||38||LONG-TERM FOLLOW-UP|1965-01-11|
TRIAL STUDY 134XCP|TR|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MGEQ|FURTHER ENLARGEMENT FROM NADIR||10^4 CFU|NOT DONE|||ELECTROMYOGRAPHY|Y|U|SPOUSE|NEUROLOGIST|U|2||58||FOLLOW-UP|1963-12-18|
TRIAL STUDY 134XCP|TR|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||OI50|PATHOLOGICAL||DAMOL/L|NOT DONE|||QUANTITATIVE ULTRASOUND|U|NA|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|3||39||BLINDED TREATMENT|1968-11-08|
TRIAL STUDY 134XCP|TR|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UG/KG/H|FURTHER ENLARGEMENT||HOMEOPATHIC DILUTION|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|Y|N|CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|4||88||BLINDED TREATMENT|1966-08-02|
TRIAL STUDY 134XCP|TR|B224E72B-65ED-48A0-AB8E-A6BF0B25D8C3|5||||||AREA|AREA||MG|ENLARGEMENT||FMOL|NOT DONE|||AUTOREFRACTION|U|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|5||7||FOLLOW-UP|1972-06-26|
TRIAL STUDY 134XCP|TR|4779A01C-1219-46AC-B0F7-71C9717A2B45|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MS/MMHG|NON-PATHOLOGICAL||ECL UNIT|NOT DONE|||BALLPOINT PEN TECHNIQUE|U|NA|PARENT|READER 1|Y|1||38||INDUCTION TREATMENT|1961-06-13|
TRIAL STUDY 134XCP|TR|4779A01C-1219-46AC-B0F7-71C9717A2B45|2||||||VOLUME|VOLUME||UG/MIN|PATHOLOGICAL||PATCH|NOT DONE|||CONTRAST ENHANCED MRI|N|N|PARENT|READER 3|NA|2||58||CONTINUATION TREATMENT|1972-06-20|
TRIAL STUDY 134XCP|TR|4779A01C-1219-46AC-B0F7-71C9717A2B45|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MPH|PATHOLOGICAL||FRAMES/S|NOT DONE|||PAP STAIN|N|Y|CHILD|READER|N|3||39||BASELINE|1962-04-04|
TRIAL STUDY 134XCP|TR|4779A01C-1219-46AC-B0F7-71C9717A2B45|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^6/L|DECREASED||BU/ML|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|U|Y|GUARDIAN|READER|N|4||88||WASHOUT|1972-11-05|
TRIAL STUDY 134XCP|TR|4779A01C-1219-46AC-B0F7-71C9717A2B45|5||||||LESFLIND|LESION FAILURE INDICATOR||KV|UNEQUIVOCAL||USP U|NOT DONE|||NUCLEIC ACID SEQUENCING|U|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|5||7||BLINDED TREATMENT|1964-10-28|
TRIAL STUDY 134XCP|TR|5F5C5DED-7547-40D2-9B34-77B37CCD7732|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||LINEAR FT*LB|PRESENT||FFU|NOT DONE|||ELECTROCHEMILUMINESCENCE|Y|U|INVESTIGATOR|ADJUDICATOR 3|Y|1||38||FOLLOW-UP|1972-09-29|
TRIAL STUDY 134XCP|TR|5F5C5DED-7547-40D2-9B34-77B37CCD7732|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||BQ/UG|UNCHANGED||MMOL/KG|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|2||58||LONG-TERM FOLLOW-UP|1960-03-22|
TRIAL STUDY 134XCP|TR|5F5C5DED-7547-40D2-9B34-77B37CCD7732|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^9 ORGANISMS/G|INCREASED||SACHET|NOT DONE|||ANTIBIOTIC AGAR SCREEN|Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1962-12-12|
TRIAL STUDY 134XCP|TR|5F5C5DED-7547-40D2-9B34-77B37CCD7732|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PT_BR|ENLARGEMENT FROM NADIR||MV/SEC|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|U|NA|FRIEND|FORENSIC PATHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1963-02-10|
TRIAL STUDY 134XCP|TR|5F5C5DED-7547-40D2-9B34-77B37CCD7732|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||KAT|PRESENT||NEEDLE GAUGE|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|N|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1960-01-24|
TRIAL STUDY 134XCP|TR|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|1||||||DIAMETER|DIAMETER||PPB|ENLARGEMENT||FOZ_US|NOT DONE|||PHOTOMETRIC CLOT DETECTION|NA|NA|INTERVIEWER|RATER 2|NA|1||38||OBSERVATION|1972-01-31|
TRIAL STUDY 134XCP|TR|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|2||||||CALCFIND|CALCIFICATION INDICATOR||PATCH|FURTHER ENLARGEMENT||UG/M2|NOT DONE|||IMMUNODIFFUSION|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 1|U|2||58||INDUCTION TREATMENT|1969-03-11|
TRIAL STUDY 134XCP|TR|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CFU/ML|UNEQUIVOCAL||MANSON U/ML|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|N|N|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1971-10-08|
TRIAL STUDY 134XCP|TR|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ML/SEC/1.73M2|FOCALLY INCREASED||/WK|NOT DONE|||CLINICAL EVALUATION|Y|U|INVESTIGATOR|PHYSIOTHERAPIST|NA|4||88||INDUCTION TREATMENT|1971-08-11|
TRIAL STUDY 134XCP|TR|9EE4A7A5-2E5A-4BB0-BC6D-87D65BC76857|5||||||SUMVOL|SUM OF VOLUME||10^6 U|EQUIVOCAL||PRESSOR UNITS|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|NA|Y|CAREGIVER|ONCOLOGIST 2|U|5||7||TREATMENT|1965-10-30|
TRIAL STUDY 134XCP|TR|48348DF0-33DA-457F-86C6-797FF7B32857|1||||||CALCFIND|CALCIFICATION INDICATOR||SQU/ML|FOCALLY INCREASED||KG|NOT DONE|||LIQUID SCINTILLATION COUNTING|U|N|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|1||38||OBSERVATION|1973-07-07|
TRIAL STUDY 134XCP|TR|48348DF0-33DA-457F-86C6-797FF7B32857|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||ML/M2|ABSENT||KN/CM2|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|U|FAMILY MEMBER|RADIOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1963-07-16|
TRIAL STUDY 134XCP|TR|48348DF0-33DA-457F-86C6-797FF7B32857|3||||||LDIAM|LONGEST DIAMETER||UMOL/L/H|NON-PATHOLOGICAL||/MBP|NOT DONE|||PALM METHOD|U|N|FAMILY MEMBER|HEMATOLOGIST|U|3||39||FOLLOW-UP|1964-08-16|
TRIAL STUDY 134XCP|TR|48348DF0-33DA-457F-86C6-797FF7B32857|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||NKAT/G HB|PALPABLE||10^3 CFU|NOT DONE|||CENTRIFUGATION|U|Y|VENDOR|RATER 1|NA|4||88||TREATMENT|1972-02-09|
TRIAL STUDY 134XCP|TR|48348DF0-33DA-457F-86C6-797FF7B32857|5||||||SUMVOL|SUM OF VOLUME||KIU|DECREASED||SFC/10^6 PBMC|NOT DONE|||TARGETED GENOME SEQUENCING|N|Y|FAMILY MEMBER|ADJUDICATOR 1|U|5||7||BLINDED TREATMENT|1971-10-29|
TRIAL STUDY 134XCP|TR|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||10^12 IU/L|INCREASED||/2000 RBC|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|1||38||RUN-IN|1970-01-25|
TRIAL STUDY 134XCP|TR|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||RATIO|UNCHANGED||CUP EQ|NOT DONE|||DIFFUSION TENSOR MRI|U|N|PARENT|RATER 1|U|2||58||SCREENING|1968-07-19|
TRIAL STUDY 134XCP|TR|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||AFU|UNEQUIVOCAL||PACKAGE|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|N|PROXY|NEUROLOGIST|U|3||39||BASELINE|1962-11-08|
TRIAL STUDY 134XCP|TR|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|4||||||TUMSTATE|TUMOR STATE||10^4 CFU|EQUIVOCAL||MET|NOT DONE|||RADIATION DOSIMETRY|N|N|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1965-04-22|
TRIAL STUDY 134XCP|TR|B2D1E5B2-17A6-4677-999E-A3F3B24FBBB4|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MIU/L|TUMOR MERGED||STEPS|NOT DONE|||ENZYMATIC COLORIMETRY|Y|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|N|5||7||CONTINUATION TREATMENT|1967-01-21|
TRIAL STUDY 134XCP|TR|396CC122-5F23-418D-A75E-572ADF4FD6C1|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MM/MIN|PATHOLOGICAL||UGEQ/L|NOT DONE|||PYROSEQUENCING|NA|N|SPOUSE|CLINICAL PATHOLOGIST|Y|1||38||TREATMENT|1971-12-27|
TRIAL STUDY 134XCP|TR|396CC122-5F23-418D-A75E-572ADF4FD6C1|2||||||PALPSTAT|PALPABLE STATE||KM/H|FURTHER ENLARGEMENT||10^9/L|NOT DONE|||RAJI CELL RIA|N|NA|INTERVIEWER|RADIOLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1973-03-21|
TRIAL STUDY 134XCP|TR|396CC122-5F23-418D-A75E-572ADF4FD6C1|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MSEC|PATHOLOGICAL||UG/M2|NOT DONE|||PALM METHOD|U|U|ADJUDICATOR|READER|U|3||39||SCREENING|1971-12-09|
TRIAL STUDY 134XCP|TR|396CC122-5F23-418D-A75E-572ADF4FD6C1|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/MMHG|INCREASED||EVENTS|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|N|U|CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|4||88||SCREENING|1970-04-19|
TRIAL STUDY 134XCP|TR|396CC122-5F23-418D-A75E-572ADF4FD6C1|5||||||TUMSTATE|TUMOR STATE||UCI/L|UNCHANGED||L/KG|NOT DONE|||TOTAL BODY IRRADIATION|Y|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|5||7||RUN-IN|1969-10-19|
TRIAL STUDY 134XCP|TR|9CF3CD51-5D5B-40E6-8F13-B314911BE461|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PACKET|PATHOLOGICAL||GLOBULE|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|N|CHILD|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||RUN-IN|1961-04-27|
TRIAL STUDY 134XCP|TR|9CF3CD51-5D5B-40E6-8F13-B314911BE461|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ML/S/M2|UNCHANGED||%(W/V)|NOT DONE|||TEST STRIP|U|N|GUARDIAN|ONCOLOGIST|U|2||58||OBSERVATION|1961-04-04|
TRIAL STUDY 134XCP|TR|9CF3CD51-5D5B-40E6-8F13-B314911BE461|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/G/DAY|ABSENT||MMOL/S|NOT DONE|||CONTRAST ENHANCED CT SCAN|NA|N|PARENT|NEUROLOGIST 2|NA|3||39||FOLLOW-UP|1963-05-19|
TRIAL STUDY 134XCP|TR|9CF3CD51-5D5B-40E6-8F13-B314911BE461|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MG/ML/MIN|PALPABLE||LOZENGE|NOT DONE|||SLIT LAMP PHOTOGRAPHY|NA|Y|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1965-12-08|
TRIAL STUDY 134XCP|TR|9CF3CD51-5D5B-40E6-8F13-B314911BE461|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MOSM|FURTHER ENLARGEMENT||MM/SEC|NOT DONE|||PH METER MEASUREMENT METHOD|Y|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|5||7||INDUCTION TREATMENT|1971-05-07|
TRIAL STUDY 134XCP|TR|CB3B9054-5CDC-418D-8071-7429B1702587|1||||||VSLPIND|VESSEL PATENCY INDICATOR||UG/DOSE|PATHOLOGICAL||10^9 ORGANISMS/G|NOT DONE|||CHROMATOGRAPHY|N|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|1||38||BASELINE|1966-03-07|
TRIAL STUDY 134XCP|TR|CB3B9054-5CDC-418D-8071-7429B1702587|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||TRACE|NORMAL||G/MOL|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|U|GUARDIAN|RADIOLOGIST 2|Y|2||58||WASHOUT|1966-08-06|
TRIAL STUDY 134XCP|TR|CB3B9054-5CDC-418D-8071-7429B1702587|3||||||PALPSTAT|PALPABLE STATE||U/L|PATHOLOGICAL||%(W/W)|NOT DONE|||TONOMETRY|Y|U|PARENT|FORENSIC PATHOLOGIST|U|3||39||OBSERVATION|1972-09-10|
TRIAL STUDY 134XCP|TR|CB3B9054-5CDC-418D-8071-7429B1702587|4||||||AREA|AREA||BAU|PALPABLE||MG/ML/MIN|NOT DONE|||EIA|U|N|GUARDIAN|ADJUDICATOR 1|Y|4||88||FOLLOW-UP|1967-11-23|
TRIAL STUDY 134XCP|TR|CB3B9054-5CDC-418D-8071-7429B1702587|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||G/DAY|NON-PATHOLOGICAL||DPM/100MG|NOT DONE|||POLYSOMNOGRAPHY|N|NA|PROXY|READER|N|5||7||BASELINE|1972-02-02|
TRIAL STUDY 134XCP|TR|1AC4DE34-3486-41FB-A979-8B368912F75A|1||||||SUMVOL|SUM OF VOLUME||DPM/0.5 ML|FURTHER ENLARGEMENT FROM NADIR||MOL/MG|NOT DONE|||GC/MS/MS|NA|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|1||38||WASHOUT|1971-06-23|
TRIAL STUDY 134XCP|TR|1AC4DE34-3486-41FB-A979-8B368912F75A|2||||||ORSTATE|ORGAN STATE||10^6 RNA COPIES/ML|DECREASED||OD UNIT|NOT DONE|||FREEZING POINT DEPRESSION|N|NA|GUARDIAN|ONCOLOGIST 2|Y|2||58||SCREENING|1965-06-27|
TRIAL STUDY 134XCP|TR|1AC4DE34-3486-41FB-A979-8B368912F75A|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MG/ANIMAL|PALPABLE||10^3 DNA COPIES/ML|NOT DONE|||DYNAMIC LIGHT SCATTERING|N|U|SPOUSE|HEMATOLOGIST|N|3||39||INDUCTION TREATMENT|1963-08-24|
TRIAL STUDY 134XCP|TR|1AC4DE34-3486-41FB-A979-8B368912F75A|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||G|UNEQUIVOCAL||DEG/S|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|U|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|4||88||TREATMENT|1970-01-08|
TRIAL STUDY 134XCP|TR|1AC4DE34-3486-41FB-A979-8B368912F75A|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U/M2/H|FOCALLY INCREASED||CM2|NOT DONE|||THIN SMEAR|NA|U|ADJUDICATOR|HEMATOLOGIST|NA|5||7||CONTINUATION TREATMENT|1960-10-26|
TRIAL STUDY 134XCP|TR|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||RAD|UNEQUIVOCAL||U/L|NOT DONE|||PANENDOSCOPY|NA|Y|FRIEND|ONCOLOGIST 1|N|1||38||BASELINE|1969-02-05|
TRIAL STUDY 134XCP|TR|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||/LPF|PRESENT||NMOL BCE/MMOL|NOT DONE|||QUANTITATIVE ULTRASOUND|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|2||58||WASHOUT|1972-01-15|
TRIAL STUDY 134XCP|TR|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||G|ABSENT||BOTTLE|NOT DONE|||LANDOLT RING|Y|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|N|3||39||BLINDED TREATMENT|1967-09-05|
TRIAL STUDY 134XCP|TR|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^3 COPIES/ML|NORMAL||HENRY|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|N|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||TREATMENT|1971-01-05|
TRIAL STUDY 134XCP|TR|FF8E387C-7596-4408-9B7F-5DF85EC62F2E|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||UG|FURTHER ENLARGEMENT||PIXELS/CM|NOT DONE|||THIN SMEAR|Y|U|SIGNIFICANT OTHER|READER 2|N|5||7||RUN-IN|1973-02-28|
TRIAL STUDY 134XCP|TR|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||DISK|UNCHANGED||TORR|NOT DONE|||IRON HEMATOXYLIN STAIN|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|1||38||BASELINE|1973-08-04|
TRIAL STUDY 134XCP|TR|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||KCAL/DAY|ENLARGEMENT FROM NADIR||MOSM|NOT DONE|||MAPH|N|NA|SIGNIFICANT OTHER|ONCOLOGIST|N|2||58||BASELINE|1964-08-29|
TRIAL STUDY 134XCP|TR|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UKAT/L|INCREASED||UG/L|NOT DONE|||MICROSCOPY|N|NA|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|3||39||OBSERVATION|1968-04-03|
TRIAL STUDY 134XCP|TR|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MEQ/MMOL|PRESENT||ML/CAGE/DAY|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|U|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BLINDED TREATMENT|1964-05-05|
TRIAL STUDY 134XCP|TR|2276DCED-0CA7-4F0B-8FBF-5B6D50DE9585|5||||||LMBFLIND|LIMB FAILURE INDICATOR||CMHG|ABSENT||BQ/UG|NOT DONE|||IMMUNOFLUORESCENT STAIN|Y|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|5||7||FOLLOW-UP|1968-07-13|
TRIAL STUDY 134XCP|TR|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BE/ML|ENLARGEMENT||WAFER|NOT DONE|||IMMUNOBLOT|U|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|1||38||OBSERVATION|1967-01-14|
TRIAL STUDY 134XCP|TR|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|2||||||VDIAM|VIABLE DIAMETER||BOTTLE|ENLARGEMENT||G/L|NOT DONE|||PALPATION|N|U|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|2||58||OBSERVATION|1971-04-14|
TRIAL STUDY 134XCP|TR|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|3||||||VDIAM|VIABLE DIAMETER||ANTIBODY UNIT|PALPABLE||L/S/KPA|NOT DONE|||SANGER SEQUENCING|NA|U|STUDY SUBJECT|READER 2|Y|3||39||SCREENING|1960-03-12|
TRIAL STUDY 134XCP|TR|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||C|ENLARGEMENT FROM NADIR||UG/ML/H|NOT DONE|||TOTAL BODY IRRADIATION|NA|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|4||88||OPEN LABEL TREATMENT|1962-10-08|
TRIAL STUDY 134XCP|TR|14CEF8E1-9A4F-4AC4-B452-410E24BC79EF|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MG/H|NORMAL||MMHG*MIN/L|NOT DONE|||AGAR PROPORTION|N|NA|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5||7||FOLLOW-UP|1964-08-06|
TRIAL STUDY 134XCP|TR|0194CD2F-7ABE-4BEE-A6FC-61298880173D|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||BEAM BREAKS|TUMOR MERGED||MM/2H|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|N|U|PARENT|HEMATOLOGIST|N|1||38||FOLLOW-UP|1968-02-07|
TRIAL STUDY 134XCP|TR|0194CD2F-7ABE-4BEE-A6FC-61298880173D|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||CM/S|NONPALPABLE||MCI/L|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|NA|U|FAMILY MEMBER|READER 2|U|2||58||FOLLOW-UP|1971-11-16|
TRIAL STUDY 134XCP|TR|0194CD2F-7ABE-4BEE-A6FC-61298880173D|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CI/MG|TUMOR MERGED||CAN|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|NA|NA|INVESTIGATOR|NEUROLOGIST 1|N|3||39||INDUCTION TREATMENT|1970-08-26|
TRIAL STUDY 134XCP|TR|0194CD2F-7ABE-4BEE-A6FC-61298880173D|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MG/KG|NORMAL||JOULE|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|N|Y|SPOUSE|READER|Y|4||88||RUN-IN|1960-03-23|
TRIAL STUDY 134XCP|TR|0194CD2F-7ABE-4BEE-A6FC-61298880173D|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||L|PRESENT||TBSP|NOT DONE|||NEPHELOMETRY|N|NA|FAMILY MEMBER|PHYSIOTHERAPIST|Y|5||7||CONTINUATION TREATMENT|1961-01-13|
TRIAL STUDY 134XCP|TR|A6E531C7-1BC1-402E-9B2E-03B44313487B|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||LENS|UNCHANGED||L|NOT DONE|||TOLUIDINE BLUE STAIN|Y|Y|GUARDIAN|NEUROLOGIST 2|N|1||38||LONG-TERM FOLLOW-UP|1967-11-01|
TRIAL STUDY 134XCP|TR|A6E531C7-1BC1-402E-9B2E-03B44313487B|2||||||LNSTATE|LYMPH NODE STATE||MM3/MM2/YEAR|DIFFUSELY INCREASED||IU/KG|NOT DONE|||MULTIPLE BREATH WASHOUT|NA|N|FAMILY MEMBER|MICROSCOPIST|NA|2||58||SCREENING|1964-03-19|
TRIAL STUDY 134XCP|TR|A6E531C7-1BC1-402E-9B2E-03B44313487B|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PPTR|UNEQUIVOCAL||/MONTH|NOT DONE|||MICRO BROTH DILUTION|NA|NA|GUARDIAN|NEUROLOGIST 2|NA|3||39||INDUCTION TREATMENT|1962-01-20|
TRIAL STUDY 134XCP|TR|A6E531C7-1BC1-402E-9B2E-03B44313487B|4||||||CALCFIND|CALCIFICATION INDICATOR||OZ EQ|FURTHER ENLARGEMENT FROM NADIR||U/M2|NOT DONE|||MYELOPEROXIDASE STAIN|U|N|CLINICAL RESEARCH COORDINATOR|RATER|Y|4||88||CONTINUATION TREATMENT|1966-05-23|
TRIAL STUDY 134XCP|TR|A6E531C7-1BC1-402E-9B2E-03B44313487B|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MG/H|INCREASED||GPELISA UNIT/ML|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|Y|PARENT|PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1969-02-16|
TRIAL STUDY 134XCP|TR|47C0D833-BEAB-4BF2-B028-891808E729F1|1||||||VDIAM|VIABLE DIAMETER||PMOL/G|FURTHER ENLARGEMENT||TBSP|NOT DONE|||SPIRAL CT|U|N|PROXY|NEUROLOGIST 2|U|1||38||INDUCTION TREATMENT|1970-10-22|
TRIAL STUDY 134XCP|TR|47C0D833-BEAB-4BF2-B028-891808E729F1|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||G/U|EQUIVOCAL||U/ML|NOT DONE|||TEMPLATE INCISION METHOD|N|U|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|2||58||OBSERVATION|1970-05-20|
TRIAL STUDY 134XCP|TR|47C0D833-BEAB-4BF2-B028-891808E729F1|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||VG/KG|DECREASED||MAMP|NOT DONE|||KARYOTYPING|U|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|3||39||RUN-IN|1973-02-11|
TRIAL STUDY 134XCP|TR|47C0D833-BEAB-4BF2-B028-891808E729F1|4||||||VDIAM|VIABLE DIAMETER||L/H|FOCALLY INCREASED||USIEMENS|NOT DONE|||LASER CAPTURE MICRODISSECTION|U|N|STUDY SUBJECT|OPTOMETRIST|NA|4||88||BLINDED TREATMENT|1968-08-09|
TRIAL STUDY 134XCP|TR|47C0D833-BEAB-4BF2-B028-891808E729F1|5||||||VOLUME|VOLUME||KCAL|ABSENT||L|NOT DONE|||CINEANGIOGRAPHY|U|U|ADJUDICATION COMMITTEE|PATHOLOGIST|N|5||7||CONTINUATION TREATMENT|1961-03-25|
TRIAL STUDY 134XCP|TR|BA1773BD-AA89-45FC-B7C6-C5267770B197|1||||||NEWCONF|NEW TUMOR CONFIRMED||10^6/L|ABSENT||UG/DOSE|NOT DONE|||INTRAVASCULAR ULTRASOUND|N|N|FRIEND|PHYSIOTHERAPIST|Y|1||38||WASHOUT|1964-01-04|
TRIAL STUDY 134XCP|TR|BA1773BD-AA89-45FC-B7C6-C5267770B197|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||COPIES/UL|INCREASED||10^3 ORGANISMS|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|NA|CHILD|RADIOLOGIST|Y|2||58||BLINDED TREATMENT|1971-01-14|
TRIAL STUDY 134XCP|TR|BA1773BD-AA89-45FC-B7C6-C5267770B197|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^3 ORGANISMS/G|FURTHER ENLARGEMENT FROM NADIR||CUP|NOT DONE|||PUPILLOMETRY|N|U|CLINICAL RESEARCH ASSOCIATE|RATER|N|3||39||CONTINUATION TREATMENT|1972-08-15|
TRIAL STUDY 134XCP|TR|BA1773BD-AA89-45FC-B7C6-C5267770B197|4||||||ORVERLN|ORGAN VERTICAL LENGTH||CM2|FOCALLY INCREASED||FINGERTIP UNIT|NOT DONE|||HEMAGGLUTINATION ASSAY|NA|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1961-12-27|
TRIAL STUDY 134XCP|TR|BA1773BD-AA89-45FC-B7C6-C5267770B197|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||10^5/L|UNCHANGED||MG/M2/DAY|NOT DONE|||FLUORESCENT SPOT TEST|NA|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||BLINDED TREATMENT|1963-05-10|
TRIAL STUDY 134XCP|TR|03D3DDC6-03FA-469A-B8A4-D504919B68F1|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||NMOL BCE/MMOL|UNCHANGED||PACK YEAR|NOT DONE|||RADIOGRAPHY|NA|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|1||38||TREATMENT|1972-07-23|
TRIAL STUDY 134XCP|TR|03D3DDC6-03FA-469A-B8A4-D504919B68F1|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||TRANSDUCING UNIT|FURTHER ENLARGEMENT||VP/DOSE|NOT DONE|||DYNAMIC LIGHT SCATTERING|N|NA|STUDY SUBJECT|RATER 2|N|2||58||LONG-TERM FOLLOW-UP|1961-07-04|
TRIAL STUDY 134XCP|TR|03D3DDC6-03FA-469A-B8A4-D504919B68F1|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||CPM|PALPABLE||MBQ|NOT DONE|||EEG|N|Y|ADJUDICATOR|RATER 1|Y|3||39||LONG-TERM FOLLOW-UP|1962-10-20|
TRIAL STUDY 134XCP|TR|03D3DDC6-03FA-469A-B8A4-D504919B68F1|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||YEARS|NON-PATHOLOGICAL||UMOL/DL|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|4||88||RUN-IN|1966-12-20|
TRIAL STUDY 134XCP|TR|03D3DDC6-03FA-469A-B8A4-D504919B68F1|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UOSM|FURTHER ENLARGEMENT||/CMH2O|NOT DONE|||NO INFORMATION|N|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|5||7||RUN-IN|1960-01-01|
TRIAL STUDY 134XCP|TR|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||GAUSS|UNEQUIVOCAL||MV|NOT DONE|||PHASE CONTRAST MICROSCOPY|U|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|1||38||FOLLOW-UP|1969-03-10|
TRIAL STUDY 134XCP|TR|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||TSP EQ|ENLARGEMENT FROM NADIR||U/KG|NOT DONE|||PHASE CONTRAST MICROSCOPY|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2||58||FOLLOW-UP|1965-09-20|
TRIAL STUDY 134XCP|TR|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||UMOL/DL|DIFFUSELY INCREASED||HENRY|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|N|U|FRIEND|RADIOLOGIST 1|NA|3||39||LONG-TERM FOLLOW-UP|1964-08-09|
TRIAL STUDY 134XCP|TR|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||LX|EQUIVOCAL||LENS|NOT DONE|||DC SHEATH FLOW|Y|NA|INVESTIGATOR|OPHTHALMOLOGIST|Y|4||88||RUN-IN|1973-01-11|
TRIAL STUDY 134XCP|TR|6AE1E2D2-C023-42DB-A906-39440CB6AAA8|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||TUBE|NORMAL||GPL U/ML|NOT DONE|||ELASTOGRAPHY|U|Y|FRIEND|READER 2|NA|5||7||OBSERVATION|1968-11-22|
TRIAL STUDY 134XCP|TR|1873D4CC-40B7-4303-9F07-8FE0E4595361|1||||||BNLNUM|NUMBER OF BONE LESIONS||S*KPA|FURTHER ENLARGEMENT FROM NADIR||APS U|NOT DONE|||FREEZING POINT DEPRESSION|N|NA|CAREGIVER|NEUROLOGIST 2|N|1||38||FOLLOW-UP|1970-12-03|
TRIAL STUDY 134XCP|TR|1873D4CC-40B7-4303-9F07-8FE0E4595361|2||||||RADIODEN|RADIODENSITY||BAG|PATHOLOGICAL||10^4/L|NOT DONE|||CALIPER MEASUREMENT METHOD|N|N|FRIEND|RADIOLOGIST 2|N|2||58||LONG-TERM FOLLOW-UP|1965-07-09|
TRIAL STUDY 134XCP|TR|1873D4CC-40B7-4303-9F07-8FE0E4595361|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||%(W/V)|NORMAL||NCI|NOT DONE|||OSCILLOMETRY|NA|NA|PROXY|PEDIATRIC NEUROLOGIST|NA|3||39||INDUCTION TREATMENT|1965-03-11|
TRIAL STUDY 134XCP|TR|1873D4CC-40B7-4303-9F07-8FE0E4595361|4||||||PALPSTAT|PALPABLE STATE||GY|FURTHER ENLARGEMENT FROM NADIR||ML/MIN|NOT DONE|||LC/MS|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|4||88||FOLLOW-UP|1972-02-08|
TRIAL STUDY 134XCP|TR|1873D4CC-40B7-4303-9F07-8FE0E4595361|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^6 IU/ML|DIFFUSELY INCREASED||10^6 DNA COPIES/ML|NOT DONE|||AUDIOMETRY|N|NA|GUARDIAN|ADJUDICATOR 2|N|5||7||CONTINUATION TREATMENT|1971-08-06|
TRIAL STUDY 134XCP|TR|23E5569E-B324-4399-AC8A-5EC7C343C1D3|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MOL|DIFFUSELY INCREASED||TSP EQ|NOT DONE|||OLIGO ACGH|NA|NA|STUDY SUBJECT|OTOLARYNGOLOGIST|N|1||38||WASHOUT|1960-05-19|
TRIAL STUDY 134XCP|TR|23E5569E-B324-4399-AC8A-5EC7C343C1D3|2||||||SUMDIAM|SUM OF DIAMETER||DISK|PALPABLE||U/CL|NOT DONE|||HPLC/MS/MS|NA|Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|2||58||OBSERVATION|1971-04-08|
TRIAL STUDY 134XCP|TR|23E5569E-B324-4399-AC8A-5EC7C343C1D3|3||||||TUMSTATE|TUMOR STATE||IN2|PRESENT||/2500 WBC|NOT DONE|||CONTRAST ENHANCED PET SCAN|N|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|3||39||INDUCTION TREATMENT|1966-10-31|
TRIAL STUDY 134XCP|TR|23E5569E-B324-4399-AC8A-5EC7C343C1D3|4||||||LPERP|LONGEST PERPENDICULAR||CMHG|ABSENT||ML/KG/DAY|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|U|N|CAREGIVER|PATHOLOGIST|U|4||88||OPEN LABEL TREATMENT|1966-02-02|
TRIAL STUDY 134XCP|TR|23E5569E-B324-4399-AC8A-5EC7C343C1D3|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||H*%|ENLARGEMENT||ROENTGEN|NOT DONE|||MS/MS|Y|U|PROXY|PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1963-08-23|
TRIAL STUDY 134XCP|TR|B349DD89-C41F-470E-8B54-B3589F0982FE|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^6/HPF|TUMOR MERGED||MEQ|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|NA|U|DOMESTIC PARTNER|NEUROLOGIST 2|Y|1||38||SCREENING|1961-06-25|
TRIAL STUDY 134XCP|TR|B349DD89-C41F-470E-8B54-B3589F0982FE|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||ML/MMHG/MIN/L|UNCHANGED||G/M2/DAY|NOT DONE|||FUNDUS PHOTOGRAPHY|U|Y|FRIEND|MICROSCOPIST 1|NA|2||58||RUN-IN|1965-12-07|
TRIAL STUDY 134XCP|TR|B349DD89-C41F-470E-8B54-B3589F0982FE|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||NU/CL|PALPABLE||MMHG|NOT DONE|||POLYMERASE CHAIN REACTION|NA|NA|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|3||39||BASELINE|1963-06-20|
TRIAL STUDY 134XCP|TR|B349DD89-C41F-470E-8B54-B3589F0982FE|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ATM|EQUIVOCAL||MIN|NOT DONE|||CALIPER MEASUREMENT METHOD|U|U|SPOUSE|ADJUDICATOR|Y|4||88||LONG-TERM FOLLOW-UP|1961-02-19|
TRIAL STUDY 134XCP|TR|B349DD89-C41F-470E-8B54-B3589F0982FE|5||||||LESFLIND|LESION FAILURE INDICATOR||10^7 CFU/ML|DIFFUSELY INCREASED||INHALATION|NOT DONE|||VIRUS PLAQUE ASSAY|Y|N|GUARDIAN|READER|N|5||7||LONG-TERM FOLLOW-UP|1961-07-01|
TRIAL STUDY 134XCP|TR|415D178A-275A-440C-8617-154441A48F8D|1||||||LMBFLIND|LIMB FAILURE INDICATOR||MPH|UNEQUIVOCAL||ANTIBODY UNIT|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|1||38||WASHOUT|1962-12-24|
TRIAL STUDY 134XCP|TR|415D178A-275A-440C-8617-154441A48F8D|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||PG/DL|NONPALPABLE||10^7 CFU/ML|NOT DONE|||POLYGRAPHY|U|Y|VENDOR|UROLOGIST|NA|2||58||BLINDED TREATMENT|1970-12-26|
TRIAL STUDY 134XCP|TR|415D178A-275A-440C-8617-154441A48F8D|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||10^12 IU/L|FURTHER ENLARGEMENT FROM NADIR||COPIES/ML|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|N|INDEPENDENT ASSESSOR|UROLOGIST|Y|3||39||INDUCTION TREATMENT|1965-12-19|
TRIAL STUDY 134XCP|TR|415D178A-275A-440C-8617-154441A48F8D|4||||||LDIAM|LONGEST DIAMETER||MEQ/DAY|DIFFUSELY INCREASED||MG2/DL2|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|U|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|4||88||TREATMENT|1968-05-15|
TRIAL STUDY 134XCP|TR|415D178A-275A-440C-8617-154441A48F8D|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MNFI|INCREASED||U/KG/MIN|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|N|CAREGIVER|RADIOLOGIST 1|N|5||7||FOLLOW-UP|1966-06-06|
TRIAL STUDY 134XCP|TR|C23917E6-6CA5-4314-A59D-A0298483BF53|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||ML/M2/MIN|INCREASED||BQ/L|NOT DONE|||ELECTROPHORESIS|Y|NA|FAMILY MEMBER|NEUROLOGIST 1|NA|1||38||SCREENING|1961-06-02|
TRIAL STUDY 134XCP|TR|C23917E6-6CA5-4314-A59D-A0298483BF53|2||||||LDIAM|LONGEST DIAMETER||M|ABSENT||BEAM BREAKS|NOT DONE|||GC/MS/MS|U|Y|DOMESTIC PARTNER|ADJUDICATOR 2|U|2||58||BLINDED TREATMENT|1961-12-13|
TRIAL STUDY 134XCP|TR|C23917E6-6CA5-4314-A59D-A0298483BF53|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MG/KG/MIN|DECREASED||UGEQ|NOT DONE|||PET/SPECT SCAN|Y|Y|PROXY|CARDIOLOGIST|NA|3||39||FOLLOW-UP|1971-11-23|
TRIAL STUDY 134XCP|TR|C23917E6-6CA5-4314-A59D-A0298483BF53|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MG/M2/H|DIFFUSELY INCREASED||UG/KG/DAY|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 2|Y|4||88||INDUCTION TREATMENT|1966-04-29|
TRIAL STUDY 134XCP|TR|C23917E6-6CA5-4314-A59D-A0298483BF53|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||KM/H|DIFFUSELY INCREASED||UMOL/MG/MIN|NOT DONE|||PALM METHOD|NA|U|HEALTH CARE PROFESSIONAL|RATER 2|NA|5||7||OBSERVATION|1962-05-09|
TRIAL STUDY 134XCP|TR|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||GPL U/ML|NON-PATHOLOGICAL||UEQ|NOT DONE|||PERCUSSION|U|NA|FAMILY MEMBER|READER|NA|1||38||LONG-TERM FOLLOW-UP|1972-03-19|
TRIAL STUDY 134XCP|TR|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|2||||||CALCFIND|CALCIFICATION INDICATOR||UG/KG/H|ENLARGEMENT||NMOL/L/MIN|NOT DONE|||HPLC/MS/MS|N|Y|GUARDIAN|OPTOMETRIST|N|2||58||FOLLOW-UP|1962-09-29|
TRIAL STUDY 134XCP|TR|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|3||||||BNLNUM|NUMBER OF BONE LESIONS||OSM|PALPABLE||ELISA UNIT/DOSE|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|Y|N|CHILD|READER 1|Y|3||39||TREATMENT|1969-03-25|
TRIAL STUDY 134XCP|TR|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|4||||||SUMDIAM|SUM OF DIAMETER||LOG10 CCID 50/DOSE|DIFFUSELY INCREASED||CMH2O/ML|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|Y|NA|CLINICAL STUDY SPONSOR|RATER|NA|4||88||FOLLOW-UP|1966-12-03|
TRIAL STUDY 134XCP|TR|4F449A9E-D7BA-47D4-A4D8-5A39E698F51E|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UGEQ/L|TUMOR MERGED||10^4 CFU/ML|NOT DONE|||DNA MICROARRAY|Y|NA|VENDOR|OPHTHALMOLOGIST|Y|5||7||TREATMENT|1963-04-22|
TRIAL STUDY 134XCP|TR|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||IU/L|PRESENT||CI/L|NOT DONE|||INFRARED SPECTROMETRY|NA|N|ADJUDICATOR|PHYSIOTHERAPIST|NA|1||38||INDUCTION TREATMENT|1962-07-05|
TRIAL STUDY 134XCP|TR|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MEQ/ML|NON-PATHOLOGICAL||MOSM|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|U|ADJUDICATOR|READER 2|N|2||58||WASHOUT|1972-11-11|
TRIAL STUDY 134XCP|TR|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NKAT/L|ENLARGEMENT||UG/KG/MIN|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|3||39||FOLLOW-UP|1968-07-21|
TRIAL STUDY 134XCP|TR|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MG/ML/MIN|ENLARGEMENT FROM NADIR||/LSQN|NOT DONE|||SPIROMETRY|N|U|PROXY|DERMATOLOGIST|U|4||88||CONTINUATION TREATMENT|1966-04-08|
TRIAL STUDY 134XCP|TR|4AB3006A-5B82-4841-800F-D2D6DFCA0DD2|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||GENEQ|FOCALLY INCREASED||NMOL/L|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|Y|NA|PROXY|CARDIOLOGIST|U|5||7||OBSERVATION|1965-12-13|
TRIAL STUDY 134XCP|TR|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||SBE/ML|NONPALPABLE||UG/KG|NOT DONE|||SLIT LAMP PHOTOGRAPHY|U|NA|FRIEND|OTOLARYNGOLOGIST|Y|1||38||BASELINE|1965-12-08|
TRIAL STUDY 134XCP|TR|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||K|PALPABLE||MG/G/H|NOT DONE|||SPIRAL CT|N|N|SIBLING|RATER|N|2||58||BASELINE|1967-02-06|
TRIAL STUDY 134XCP|TR|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|3||||||DIAMETER|DIAMETER||GBQ|ENLARGEMENT FROM NADIR||FOZ_BR|NOT DONE|||OPHTHALMOSCOPY|Y|U|SIBLING|ADJUDICATOR 1|NA|3||39||INDUCTION TREATMENT|1967-11-26|
TRIAL STUDY 134XCP|TR|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||NMOL/ML/MIN|ABSENT||VG/DOSE|NOT DONE|||SEQUENCING|Y|U|STUDY SUBJECT|OPHTHALMOLOGIST|Y|4||88||CONTINUATION TREATMENT|1963-04-27|
TRIAL STUDY 134XCP|TR|95EFAA78-A1BB-40D0-8A6D-B0EF20332820|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||G/ANIMAL/WK|ENLARGEMENT FROM NADIR||UKAT/10^12 RBC|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1963-09-22|
TRIAL STUDY 134XCP|TR|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^3/L|PRESENT||L/MIN|NOT DONE|||CENTRIFUGATION|U|U|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|1||38||BLINDED TREATMENT|1973-03-10|
TRIAL STUDY 134XCP|TR|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|2||||||ORSTATE|ORGAN STATE||MBQ|INCREASED||NKAT|NOT DONE|||SURFACE PLASMON RESONANCE|N|Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|2||58||CONTINUATION TREATMENT|1970-02-07|
TRIAL STUDY 134XCP|TR|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||VIAL|UNCHANGED||MG/ANIMAL|NOT DONE|||DIGITAL PCR|U|U|DOMESTIC PARTNER|RATER 2|U|3||39||SCREENING|1966-09-12|
TRIAL STUDY 134XCP|TR|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|4||||||LDIAM|LONGEST DIAMETER||ML/S|PALPABLE||LINEAR FT*LB|NOT DONE|||AGAR DILUTION|Y|NA|INTERVIEWER|RATER 2|N|4||88||OBSERVATION|1966-02-14|
TRIAL STUDY 134XCP|TR|9E60B53A-37D9-45AE-AC8B-F3B049617CDF|5||||||TUMSTATE|TUMOR STATE||TSP|FOCALLY INCREASED||LOG10 CFU/ML|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|N|SPOUSE|OTOLARYNGOLOGIST|NA|5||7||TREATMENT|1967-07-09|
TRIAL STUDY 134XCP|TR|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|1||||||PALPSTAT|PALPABLE STATE||LINEAR FT*LB|FURTHER ENLARGEMENT||CI|NOT DONE|||SICKLE CELL SOLUBILITY TEST|N|N|PARENT|CLINICAL PATHOLOGIST|N|1||38||OPEN LABEL TREATMENT|1971-08-23|
TRIAL STUDY 134XCP|TR|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||VIRTUAL PIXEL|UNEQUIVOCAL||IU/G HB|NOT DONE|||SMEAR|U|U|CLINICAL STUDY SPONSOR|UROLOGIST|U|2||58||INDUCTION TREATMENT|1966-07-06|
TRIAL STUDY 134XCP|TR|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|3||||||VDIAM|VIABLE DIAMETER||10^6 CFU/ML|FURTHER ENLARGEMENT||P|NOT DONE|||ULTRASOUND|U|N|VENDOR|NEUROLOGIST|U|3||39||RUN-IN|1973-08-26|
TRIAL STUDY 134XCP|TR|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UMOL/H/MMOL|UNEQUIVOCAL||L/L|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|NA|NA|INTERVIEWER|ADJUDICATOR 1|U|4||88||LONG-TERM FOLLOW-UP|1961-10-11|
TRIAL STUDY 134XCP|TR|94DD5640-E6E6-47FA-A91B-D84E330EDCC6|5||||||LMBFLIND|LIMB FAILURE INDICATOR||MNFI|EQUIVOCAL||ML/100G/MIN|NOT DONE|||KINETIC CHROMOGENIC ASSAY|NA|NA|PROXY|ADJUDICATOR 2|U|5||7||SCREENING|1960-09-11|
TRIAL STUDY 134XCP|TR|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||10^3 CFU/G|NON-PATHOLOGICAL||UG/MIN|NOT DONE|||MICRO BROTH DILUTION|U|N|STUDY SUBJECT|PATHOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1966-06-18|
TRIAL STUDY 134XCP|TR|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||SPRAY|ABSENT||10^8/L|NOT DONE|||INFRARED SPECTROMETRY|U|N|CHILD|FORENSIC PATHOLOGIST|N|2||58||TREATMENT|1960-12-08|
TRIAL STUDY 134XCP|TR|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|3||||||RADIODEN|RADIODENSITY||UG/H|FURTHER ENLARGEMENT||UMOL/H/MMOL|NOT DONE|||TRYPAN BLUE STAIN|Y|NA|ADJUDICATION COMMITTEE|DERMATOLOGIST|U|3||39||CONTINUATION TREATMENT|1973-04-28|
TRIAL STUDY 134XCP|TR|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||BU/ML|EQUIVOCAL||GBQ/UG|NOT DONE|||CAPILLARY ELECTROPHORESIS|Y|N|INTERVIEWER|ADJUDICATOR|U|4||88||RUN-IN|1969-12-17|
TRIAL STUDY 134XCP|TR|5F1262FB-AAA2-4F2F-BF2B-F72527AFA115|5||||||LPERP|LONGEST PERPENDICULAR||BAR|ENLARGEMENT||VP/DOSE|NOT DONE|||LINE PROBE ASSAY|Y|N|PROXY|RATER 1|Y|5||7||TREATMENT|1960-05-26|
TRIAL STUDY 134XCP|TR|EDB6B55B-7903-4F89-805C-32F067C2A230|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MMAL|NORMAL||PACKET|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|U|Y|HEALTH CARE PROFESSIONAL|RATER|Y|1||38||TREATMENT|1964-08-19|
TRIAL STUDY 134XCP|TR|EDB6B55B-7903-4F89-805C-32F067C2A230|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||U/DL|PALPABLE||DRUM|NOT DONE|||ALCIAN BLUE STAIN|N|NA|CHILD|RATER 2|N|2||58||WASHOUT|1972-12-22|
TRIAL STUDY 134XCP|TR|EDB6B55B-7903-4F89-805C-32F067C2A230|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||BAR|DIFFUSELY INCREASED||OZ EQ|NOT DONE|||REFRACTOMETRY|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|3||39||FOLLOW-UP|1966-08-28|
TRIAL STUDY 134XCP|TR|EDB6B55B-7903-4F89-805C-32F067C2A230|4||||||LDIAM|LONGEST DIAMETER||MOL/G|UNEQUIVOCAL||CG|NOT DONE|||ANGIOGRAPHY|NA|NA|SPOUSE|OPHTHALMOLOGIST|Y|4||88||RUN-IN|1965-08-18|
TRIAL STUDY 134XCP|TR|EDB6B55B-7903-4F89-805C-32F067C2A230|5||||||SUMVOL|SUM OF VOLUME||UG/G/DAY|UNEQUIVOCAL||MPS U|NOT DONE|||MULTI-SLICE SPIRAL CT|N|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|5||7||BLINDED TREATMENT|1973-08-04|
TRIAL STUDY 134XCP|TR|8F6772DE-E4CA-4706-8754-740D3859ABDF|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||GBQ/UG|INCREASED||UG/M2/H|NOT DONE|||JAEGER EYE CHART|Y|U|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|1||38||SCREENING|1968-09-24|
TRIAL STUDY 134XCP|TR|8F6772DE-E4CA-4706-8754-740D3859ABDF|2||||||DIAMETER|DIAMETER||G/ANIMAL/DAY|NORMAL||FRACTION OF 1|NOT DONE|||TONOMETRY|Y|N|ADJUDICATOR|ONCOLOGIST|Y|2||58||BASELINE|1971-07-10|
TRIAL STUDY 134XCP|TR|8F6772DE-E4CA-4706-8754-740D3859ABDF|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||SCOOPFUL|DECREASED||M2|NOT DONE|||FLUORIMETRY|N|U|PROXY|NEUROLOGIST 1|U|3||39||SCREENING|1965-10-07|
TRIAL STUDY 134XCP|TR|8F6772DE-E4CA-4706-8754-740D3859ABDF|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||G/ANIMAL/WK|UNCHANGED||/VF|NOT DONE|||WESTERGREN|NA|NA|SPOUSE|RATER|Y|4||88||WASHOUT|1969-07-28|
TRIAL STUDY 134XCP|TR|8F6772DE-E4CA-4706-8754-740D3859ABDF|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ECL UNIT|TUMOR MERGED||ML/(MIN*100ML)|NOT DONE|||HILLMEN COLOR CHART|Y|NA|CHILD|RATER 1|N|5||7||LONG-TERM FOLLOW-UP|1962-11-10|
TRIAL STUDY 134XCP|TR|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UMOL/L/MIN|TUMOR MERGED||NG/DAY|NOT DONE|||INTRAVASCULAR ULTRASOUND|N|NA|PROXY|MICROSCOPIST 1|Y|1||38||SCREENING|1967-10-11|
TRIAL STUDY 134XCP|TR|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||QUANTITY SUFFICIENT|FOCALLY INCREASED||IU|NOT DONE|||ENDOSCOPY|N|NA|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-08-16|
TRIAL STUDY 134XCP|TR|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|3||||||BNLNUM|NUMBER OF BONE LESIONS||SQU/ML|INCREASED||CD/M2|NOT DONE|||PALM METHOD|NA|U|SPOUSE|ADJUDICATOR 1|Y|3||39||INDUCTION TREATMENT|1962-01-07|
TRIAL STUDY 134XCP|TR|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|4||||||LMBFLIND|LIMB FAILURE INDICATOR||POUCH|INCREASED||PACKET|NOT DONE|||IMPULSE OSCILLOMETRY|N|N|SIBLING|READER 1|Y|4||88||INDUCTION TREATMENT|1961-03-24|
TRIAL STUDY 134XCP|TR|FE7829C8-7961-4169-B5DD-9DD94B8EF0CD|5||||||BNLNUM|NUMBER OF BONE LESIONS||ANTI-XA IU|FURTHER ENLARGEMENT||UG/MOL|NOT DONE|||ELECTROMYOGRAPHY|N|Y|SIBLING|MICROSCOPIST 1|N|5||7||OPEN LABEL TREATMENT|1966-09-10|
TRIAL STUDY 134XCP|TR|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||LOG10 CCID 50/DOSE|FOCALLY INCREASED||UMOL/DAY|NOT DONE|||CHROMATOGRAPHY|NA|U|INTERVIEWER|MICROSCOPIST 3|NA|1||38||RUN-IN|1961-08-25|
TRIAL STUDY 134XCP|TR|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|2||||||BNLNUM|NUMBER OF BONE LESIONS||IU/G HB|DECREASED||MG2/DL2|NOT DONE|||PLETHYSMOGRAPHY|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|2||58||RUN-IN|1965-11-29|
TRIAL STUDY 134XCP|TR|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|3||||||CALCFIND|CALCIFICATION INDICATOR||CYCLE/MIN|PRESENT||ML/KG/MIN|NOT DONE|||ORCHIDOMETERY|NA|Y|INVESTIGATOR|ADJUDICATOR|U|3||39||BASELINE|1969-06-09|
TRIAL STUDY 134XCP|TR|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|4||||||VSLPIND|VESSEL PATENCY INDICATOR||GAUSS|ENLARGEMENT||RPM|NOT DONE|||ANGIOGRAPHY|NA|NA|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||CONTINUATION TREATMENT|1969-01-01|
TRIAL STUDY 134XCP|TR|D1DEBD72-05CA-4F47-8727-73C44D6A3EFB|5||||||VSLPIND|VESSEL PATENCY INDICATOR||FMOL/L/SEC|INCREASED||PMOL/DL|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|U|Y|PARENT|MICROSCOPIST|N|5||7||LONG-TERM FOLLOW-UP|1970-10-01|
TRIAL STUDY 134XCP|TR|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||PUFF|NONPALPABLE||AMOL|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|U|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1||38||WASHOUT|1961-10-13|
TRIAL STUDY 134XCP|TR|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||/4.0 ML|INCREASED||MG/KG/DAY|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|N|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|2||58||SCREENING|1973-02-16|
TRIAL STUDY 134XCP|TR|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^6 CFU/G|NONPALPABLE||/MM|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|NA|NA|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||BLINDED TREATMENT|1973-04-29|
TRIAL STUDY 134XCP|TR|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UEQ/L|UNEQUIVOCAL||PPB|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|NA|NA|NON-HEALTH CARE PROFESSIONAL|RATER 2|U|4||88||RUN-IN|1960-12-05|
TRIAL STUDY 134XCP|TR|0FF48C06-03EA-47DA-84D1-3FA28D5D39D7|5||||||VOLUME|VOLUME||MMHG/L/MIN|UNCHANGED||%(W/V)|NOT DONE|||SURFACE PLASMON RESONANCE|Y|Y|CHILD|ADJUDICATOR|U|5||7||RUN-IN|1971-04-15|
TRIAL STUDY 134XCP|TR|B3987A78-0D92-419D-A289-039C87C6C202|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/CAGE|UNEQUIVOCAL||HZ/S|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|1||38||INDUCTION TREATMENT|1963-03-09|
TRIAL STUDY 134XCP|TR|B3987A78-0D92-419D-A289-039C87C6C202|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||APPLICATION|EQUIVOCAL||VP/DOSE|NOT DONE|||REVERSE TRANSCRIPTASE PCR|Y|Y|PARENT|MICROSCOPIST|U|2||58||WASHOUT|1973-03-19|
TRIAL STUDY 134XCP|TR|B3987A78-0D92-419D-A289-039C87C6C202|3||||||VSLPIND|VESSEL PATENCY INDICATOR||MIU/L|FOCALLY INCREASED||CS|NOT DONE|||NUCLEIC ACID SEQUENCING|NA|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|3||39||WASHOUT|1971-09-10|
TRIAL STUDY 134XCP|TR|B3987A78-0D92-419D-A289-039C87C6C202|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||FT|EQUIVOCAL||UG/L|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|Y|SIGNIFICANT OTHER|RADIOLOGIST 1|Y|4||88||BASELINE|1960-07-01|
TRIAL STUDY 134XCP|TR|B3987A78-0D92-419D-A289-039C87C6C202|5||||||LESFLIND|LESION FAILURE INDICATOR||MOSM/KG|NON-PATHOLOGICAL||DAYS/WK|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|N|U|SIBLING|READER 3|U|5||7||BASELINE|1968-03-18|
TRIAL STUDY 134XCP|TR|2A0D27D8-EC46-4B40-B1BB-078268E03355|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MNFI|FURTHER ENLARGEMENT||AMOL|NOT DONE|||GIEMSA STAIN|U|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1||38||OBSERVATION|1960-06-24|
TRIAL STUDY 134XCP|TR|2A0D27D8-EC46-4B40-B1BB-078268E03355|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MEQ/L|PALPABLE||MCI/KG|NOT DONE|||DISK DIFFUSION|U|NA|ADJUDICATOR|MICROSCOPIST 2|NA|2||58||OPEN LABEL TREATMENT|1960-02-20|
TRIAL STUDY 134XCP|TR|2A0D27D8-EC46-4B40-B1BB-078268E03355|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||ML/DAY|NON-PATHOLOGICAL||UG/M2/DAY|NOT DONE|||MULTIPLE BREATH WASHOUT|NA|U|INDEPENDENT ASSESSOR|INTERNIST|Y|3||39||RUN-IN|1966-10-16|
TRIAL STUDY 134XCP|TR|2A0D27D8-EC46-4B40-B1BB-078268E03355|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||ML/M2/MIN|NORMAL||10^4 CFU/ML|NOT DONE|||MICRODENSITOMETRY|Y|N|FRIEND|MICROSCOPIST|NA|4||88||WASHOUT|1963-04-30|
TRIAL STUDY 134XCP|TR|2A0D27D8-EC46-4B40-B1BB-078268E03355|5||||||AREA|AREA||APPLICATION|NORMAL||FARAD|NOT DONE|||PHYSICAL EXAMINATION|N|Y|VENDOR|NEUROLOGIST 1|NA|5||7||INDUCTION TREATMENT|1970-03-23|
TRIAL STUDY 134XCP|TR|65EBB2AF-B97A-403A-9FB5-31C1559074C4|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CAPLET|FURTHER ENLARGEMENT FROM NADIR||LOG10 CFU/G|NOT DONE|||HPLC-UV|NA|Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|1||38||FOLLOW-UP|1966-03-13|
TRIAL STUDY 134XCP|TR|65EBB2AF-B97A-403A-9FB5-31C1559074C4|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||AFU|INCREASED||ATM|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|N|Y|FAMILY MEMBER|OPTOMETRIST|NA|2||58||OBSERVATION|1965-01-31|
TRIAL STUDY 134XCP|TR|65EBB2AF-B97A-403A-9FB5-31C1559074C4|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||BQ/G|NONPALPABLE||ML/S|NOT DONE|||CLINICAL EVALUATION|NA|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||INDUCTION TREATMENT|1973-05-14|
TRIAL STUDY 134XCP|TR|65EBB2AF-B97A-403A-9FB5-31C1559074C4|4||||||LDIAM|LONGEST DIAMETER||MV*MIN|PATHOLOGICAL||FOZ_BR|NOT DONE|||ANGIOGRAPHY|N|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|4||88||BASELINE|1966-12-28|
TRIAL STUDY 134XCP|TR|65EBB2AF-B97A-403A-9FB5-31C1559074C4|5||||||VOLUME|VOLUME||ABSORBANCE U/ML|TUMOR MERGED||LOG EID 50/DOSE|NOT DONE|||THIN SMEAR|NA|N|CAREGIVER|OPHTHALMOLOGIST|NA|5||7||BASELINE|1965-04-25|
TRIAL STUDY 134XCP|TR|90892428-99C3-4E7D-B3A8-3C526812EDD2|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||CMOL|PRESENT||EVENTS|NOT DONE|||GC/MS/MS|U|Y|INTERVIEWER|MICROSCOPIST 2|U|1||38||WASHOUT|1967-12-29|
TRIAL STUDY 134XCP|TR|90892428-99C3-4E7D-B3A8-3C526812EDD2|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||KG/L|FURTHER ENLARGEMENT FROM NADIR||AU/ML|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|N|CHILD|READER|U|2||58||BASELINE|1966-08-21|
TRIAL STUDY 134XCP|TR|90892428-99C3-4E7D-B3A8-3C526812EDD2|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||STRIP|TUMOR MERGED||MMOL2/L2|NOT DONE|||MICROBIAL CULTURE, SOLID|N|NA|INDEPENDENT ASSESSOR|NEUROLOGIST|Y|3||39||SCREENING|1969-09-28|
TRIAL STUDY 134XCP|TR|90892428-99C3-4E7D-B3A8-3C526812EDD2|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||LX|NONPALPABLE||SQU/ML|NOT DONE|||ELECTROGASTROGRAPHY|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST|U|4||88||BASELINE|1961-09-13|
TRIAL STUDY 134XCP|TR|90892428-99C3-4E7D-B3A8-3C526812EDD2|5||||||TUMSTATE|TUMOR STATE||ML/BREATH|UNEQUIVOCAL||PSEC|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|Y|Y|INVESTIGATOR|ADJUDICATOR 3|NA|5||7||BASELINE|1966-11-12|
TRIAL STUDY 134XCP|TR|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|1||||||NEWCONF|NEW TUMOR CONFIRMED||AMFI|FURTHER ENLARGEMENT FROM NADIR||BU/ML|NOT DONE|||CELL OF ORIGIN ASSAY|U|Y|GUARDIAN|PATHOLOGIST 2|N|1||38||BLINDED TREATMENT|1971-12-23|
TRIAL STUDY 134XCP|TR|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^3 ORGANISMS|NON-PATHOLOGICAL||10^9 ORGANISMS/G|NOT DONE|||FLUOROSCOPY|U|U|INVESTIGATOR|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1970-07-06|
TRIAL STUDY 134XCP|TR|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|3||||||LDIAM|LONGEST DIAMETER||KN/CM2|DIFFUSELY INCREASED||/WK|NOT DONE|||LC/MS|U|Y|FRIEND|RATER|NA|3||39||BLINDED TREATMENT|1963-12-17|
TRIAL STUDY 134XCP|TR|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||VIRTUAL PIXEL|FOCALLY INCREASED||H*%|NOT DONE|||HPLC/MS/MS|N|U|VENDOR|CARDIOLOGIST|NA|4||88||OBSERVATION|1973-03-03|
TRIAL STUDY 134XCP|TR|4B99A0CB-4DEA-4C46-8B01-FCC0BED015FF|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||%/MIN|DECREASED||MG/KG/MIN|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|U|U|VENDOR|ADJUDICATOR 1|Y|5||7||TREATMENT|1969-06-14|
TRIAL STUDY 134XCP|TR|2B443EEA-B98B-47D9-8D27-801582804AB5|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||/SEC|DECREASED||MM3/MM2/YEAR|NOT DONE|||MAPH|NA|N|VENDOR|MICROSCOPIST 2|U|1||38||LONG-TERM FOLLOW-UP|1961-01-01|
TRIAL STUDY 134XCP|TR|2B443EEA-B98B-47D9-8D27-801582804AB5|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^6/G|TUMOR MERGED||IU/KG/H|NOT DONE|||NUCLEIC ACID SEQUENCING|N|Y|VENDOR|ONCOLOGIST 2|N|2||58||WASHOUT|1973-02-19|
TRIAL STUDY 134XCP|TR|2B443EEA-B98B-47D9-8D27-801582804AB5|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||GBQ|DECREASED||MGEQ|NOT DONE|||ACID FAST STAIN|N|NA|ADJUDICATOR|READER 3|N|3||39||TREATMENT|1970-10-27|
TRIAL STUDY 134XCP|TR|2B443EEA-B98B-47D9-8D27-801582804AB5|4||||||LESSCIND|LESION SUCCESS INDICATOR||KM/H|NONPALPABLE||ML/100G/MIN|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|NA|SPOUSE|OTOLARYNGOLOGIST|N|4||88||FOLLOW-UP|1966-09-03|
TRIAL STUDY 134XCP|TR|2B443EEA-B98B-47D9-8D27-801582804AB5|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||/100 HPFS|ENLARGEMENT||NU/CL|NOT DONE|||SURFACE PLASMON RESONANCE|U|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||FOLLOW-UP|1965-12-25|
TRIAL STUDY 134XCP|TR|0278D57A-30D6-4B7A-A45C-EB973F6686C6|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UG/KG/H|PRESENT||U/G/MIN|NOT DONE|||LAPAROSCOPY|U|NA|CAREGIVER|MICROSCOPIST|U|1||38||TREATMENT|1961-04-28|
TRIAL STUDY 134XCP|TR|0278D57A-30D6-4B7A-A45C-EB973F6686C6|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||TITER|DECREASED||BQ/KG|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|Y|U|ADJUDICATOR|MICROSCOPIST|Y|2||58||CONTINUATION TREATMENT|1964-10-24|
TRIAL STUDY 134XCP|TR|0278D57A-30D6-4B7A-A45C-EB973F6686C6|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||1/(S*KPA)|FURTHER ENLARGEMENT FROM NADIR||/2000 RBC|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|NA|NA|SIBLING|READER 3|NA|3||39||RUN-IN|1972-12-09|
TRIAL STUDY 134XCP|TR|0278D57A-30D6-4B7A-A45C-EB973F6686C6|4||||||VSLPIND|VESSEL PATENCY INDICATOR||PMOL/L/H|NORMAL||ML/100G/MIN|NOT DONE|||MICROBIAL CULTURE|N|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|4||88||OBSERVATION|1968-06-29|
TRIAL STUDY 134XCP|TR|0278D57A-30D6-4B7A-A45C-EB973F6686C6|5||||||RADIODEN|RADIODENSITY||DPM/0.5 ML|ENLARGEMENT||NMOL/L|NOT DONE|||PHOTOGRAPHY|N|NA|ADJUDICATOR|ONCOLOGIST 1|U|5||7||TREATMENT|1967-09-01|
TRIAL STUDY 134XCP|TR|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||APPLICATION|ABSENT||COPIES/UL|NOT DONE|||CT SCAN WITHOUT CONTRAST|Y|NA|CHILD|HEMATOLOGIST|NA|1||38||WASHOUT|1972-03-25|
TRIAL STUDY 134XCP|TR|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||IU/ML|ABSENT||10^4/HPF|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|U|INTERVIEWER|CARDIOLOGIST|Y|2||58||BLINDED TREATMENT|1963-12-03|
TRIAL STUDY 134XCP|TR|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/(MIN*100ML)|PALPABLE||KAT|NOT DONE|||EPSILOMETER|U|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|3||39||FOLLOW-UP|1967-07-30|
TRIAL STUDY 134XCP|TR|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DRINK|EQUIVOCAL||ELISA UNIT/DOSE|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|NA|N|PROXY|OPHTHALMOLOGIST|Y|4||88||BASELINE|1960-09-22|
TRIAL STUDY 134XCP|TR|2FE6BF52-4EA8-4AAE-865C-22BA7CD26BF6|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||KG/CM|TUMOR MERGED||UG/KG/MIN|NOT DONE|||FISH|Y|NA|SPOUSE|UROLOGIST|U|5||7||WASHOUT|1967-10-10|
TRIAL STUDY 134XCP|TR|67D6A191-10C7-4414-BA63-DB7701998DF0|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PIXEL|INCREASED||G/ANIMAL|NOT DONE|||ORCHIDOMETERY|U|N|PROXY|OPHTHALMOLOGIST|NA|1||38||BLINDED TREATMENT|1972-06-25|
TRIAL STUDY 134XCP|TR|67D6A191-10C7-4414-BA63-DB7701998DF0|2||||||AREA|AREA||FOZ_US|DIFFUSELY INCREASED||DPM/100MG|NOT DONE|||ECHOCARDIOGRAPHY|N|NA|ADJUDICATOR|NEUROLOGIST|N|2||58||FOLLOW-UP|1962-01-08|
TRIAL STUDY 134XCP|TR|67D6A191-10C7-4414-BA63-DB7701998DF0|3||||||ORSTATE|ORGAN STATE||FINGERTIP UNIT|PALPABLE||PNU/ML|NOT DONE|||MIGET|U|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|3||39||RUN-IN|1960-09-08|
TRIAL STUDY 134XCP|TR|67D6A191-10C7-4414-BA63-DB7701998DF0|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||GPL U|NONPALPABLE||PSI|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|N|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|NA|4||88||OBSERVATION|1973-02-14|
TRIAL STUDY 134XCP|TR|67D6A191-10C7-4414-BA63-DB7701998DF0|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||FT2|EQUIVOCAL||ML/BEAT|NOT DONE|||FARR ASSAY|NA|Y|CLINICAL RESEARCH COORDINATOR|READER|U|5||7||SCREENING|1964-08-28|
TRIAL STUDY 134XCP|TR|499B5A47-893A-40DE-9B64-60967378C81A|1||||||LPERP|LONGEST PERPENDICULAR||CCID 50/ML|NON-PATHOLOGICAL||MEQ|NOT DONE|||INTERRUPTER TECHNIQUE|Y|NA|CAREGIVER|CARDIOLOGIST|Y|1||38||RUN-IN|1971-09-09|
TRIAL STUDY 134XCP|TR|499B5A47-893A-40DE-9B64-60967378C81A|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MOL|UNEQUIVOCAL||MEQ/ML|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|N|U|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|2||58||OBSERVATION|1963-11-24|
TRIAL STUDY 134XCP|TR|499B5A47-893A-40DE-9B64-60967378C81A|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||AMOL|DIFFUSELY INCREASED||UL/ML|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|3||39||TREATMENT|1972-09-12|
TRIAL STUDY 134XCP|TR|499B5A47-893A-40DE-9B64-60967378C81A|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||GY/H|PALPABLE||SBE/ML|NOT DONE|||EEG|Y|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|4||88||OPEN LABEL TREATMENT|1972-04-08|
TRIAL STUDY 134XCP|TR|499B5A47-893A-40DE-9B64-60967378C81A|5||||||DIAMETER|DIAMETER||MN|PRESENT||MASK|NOT DONE|||HILLMEN COLOR CHART|NA|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||LONG-TERM FOLLOW-UP|1969-04-25|
TRIAL STUDY 134XCP|TR|984103CA-F301-4510-A9DD-4916FA858EA2|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||IU/KG/H|DECREASED||G/M2/DAY|NOT DONE|||SINGLE-SLICE SPIRAL CT|N|N|FAMILY MEMBER|ADJUDICATOR 3|N|1||38||BLINDED TREATMENT|1968-11-20|
TRIAL STUDY 134XCP|TR|984103CA-F301-4510-A9DD-4916FA858EA2|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||ELISA UNIT|ENLARGEMENT||USEC|NOT DONE|||HEMOCYTOMETRY|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|2||58||LONG-TERM FOLLOW-UP|1965-09-15|
TRIAL STUDY 134XCP|TR|984103CA-F301-4510-A9DD-4916FA858EA2|3||||||ORSTATE|ORGAN STATE||H*%|FURTHER ENLARGEMENT FROM NADIR||DPM/0.5 ML|NOT DONE|||NO INFORMATION|U|Y|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|3||39||FOLLOW-UP|1970-07-11|
TRIAL STUDY 134XCP|TR|984103CA-F301-4510-A9DD-4916FA858EA2|4||||||LESSCIND|LESION SUCCESS INDICATOR||UMOL/DAY|EQUIVOCAL||AMOL|NOT DONE|||ENDOSCOPY|NA|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||FOLLOW-UP|1965-06-27|
TRIAL STUDY 134XCP|TR|984103CA-F301-4510-A9DD-4916FA858EA2|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||BLOCKS|PALPABLE||SFC/10^6 PBMC|NOT DONE|||NUCLEAR RADIOLOGY|N|U|INVESTIGATOR|CLINICAL PATHOLOGIST|N|5||7||OBSERVATION|1972-09-21|
TRIAL STUDY 134XCP|TR|50E626B3-9133-4A50-8907-2388DAC22AD1|1||||||VSLPIND|VESSEL PATENCY INDICATOR||UV|NORMAL||YEARS|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|NA|Y|VENDOR|INTERNIST|U|1||38||BASELINE|1969-05-04|
TRIAL STUDY 134XCP|TR|50E626B3-9133-4A50-8907-2388DAC22AD1|2||||||LNSTATE|LYMPH NODE STATE||RATIO|INCREASED||PKAT/L|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|U|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-01-15|
TRIAL STUDY 134XCP|TR|50E626B3-9133-4A50-8907-2388DAC22AD1|3||||||TUMSTATE|TUMOR STATE||MG/MOL|UNCHANGED||MG/M2/H|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|NA|Y|CLINICAL RESEARCH COORDINATOR|READER 1|U|3||39||BASELINE|1973-04-25|
TRIAL STUDY 134XCP|TR|50E626B3-9133-4A50-8907-2388DAC22AD1|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MCI/L|FURTHER ENLARGEMENT FROM NADIR||10^3 CFU|NOT DONE|||RADIATION DOSIMETRY|N|NA|GUARDIAN|RADIOLOGIST|U|4||88||TREATMENT|1962-03-07|
TRIAL STUDY 134XCP|TR|50E626B3-9133-4A50-8907-2388DAC22AD1|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||U/DL|ABSENT||CY/CM|NOT DONE|||GEL ELECTROPHORESIS|N|N|DOMESTIC PARTNER|MICROSCOPIST|Y|5||7||TREATMENT|1960-06-26|
TRIAL STUDY 134XCP|TR|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||RATIO|FOCALLY INCREASED||/7.5 ML|NOT DONE|||KLEIHAUER-BETKE|NA|Y|SPOUSE|HEMATOLOGIST|U|1||38||WASHOUT|1968-03-07|
TRIAL STUDY 134XCP|TR|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||10^6/L|NONPALPABLE||ML/M2/DAY|NOT DONE|||STATIC PERIMETRY|NA|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|2||58||TREATMENT|1963-01-11|
TRIAL STUDY 134XCP|TR|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UKAT/L|FURTHER ENLARGEMENT||10^6 ORGANISMS/MG|NOT DONE|||OSCILLOMETRY|N|NA|CAREGIVER|READER|NA|3||39||BASELINE|1968-07-27|
TRIAL STUDY 134XCP|TR|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|4||||||VSLPIND|VESSEL PATENCY INDICATOR||ML/S|UNCHANGED||LOG10 PFU|NOT DONE|||MICROARRAY|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|4||88||SCREENING|1971-01-20|
TRIAL STUDY 134XCP|TR|C20A4F0A-7E0A-4A53-A47D-ECFB5062FB21|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||TRANSDUCING UNIT/ML|NONPALPABLE||PPTR|NOT DONE|||ECHOCARDIOGRAPHY|U|Y|PARENT|READER 3|U|5||7||TREATMENT|1961-04-27|
TRIAL STUDY 134XCP|TR|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^7 CFU/ML|UNEQUIVOCAL||100 IU/ML|NOT DONE|||FLAME PHOTOMETRY|N|NA|CHILD|HEMATOLOGIST|NA|1||38||CONTINUATION TREATMENT|1965-12-12|
TRIAL STUDY 134XCP|TR|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CAL|DIFFUSELY INCREASED||S^-1(%O2)^-1|NOT DONE|||HPLC-FL|N|Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|2||58||RUN-IN|1960-03-09|
TRIAL STUDY 134XCP|TR|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||/40 HPFS|ENLARGEMENT FROM NADIR||AU/ML|NOT DONE|||FLOW MICROSCOPY|U|N|ADJUDICATION COMMITTEE|PATHOLOGIST 2|NA|3||39||FOLLOW-UP|1963-11-29|
TRIAL STUDY 134XCP|TR|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||TROCHE|ENLARGEMENT||PLUG|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|N|U|FAMILY MEMBER|ONCOLOGIST 2|U|4||88||TREATMENT|1963-10-14|
TRIAL STUDY 134XCP|TR|4D0E7297-DA42-4819-8D28-979D3D3BE1A0|5||||||LMBFLIND|LIMB FAILURE INDICATOR||NMOL/DAY|NONPALPABLE||LOG10 CFU/ML|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|NA|Y|CHILD|OTOLARYNGOLOGIST|N|5||7||BASELINE|1966-08-01|
TRIAL STUDY 134XCP|TR|F8F17A43-A74B-4570-8A06-D7657A4636B4|1||||||VDIAM|VIABLE DIAMETER||DPM/ML|DECREASED||10^9/L|NOT DONE|||SINGLE-SLICE SPIRAL CT|Y|N|FRIEND|MICROSCOPIST|Y|1||38||OBSERVATION|1971-05-08|
TRIAL STUDY 134XCP|TR|F8F17A43-A74B-4570-8A06-D7657A4636B4|2||||||ORSTATE|ORGAN STATE||UG/H|DECREASED||PUFF|NOT DONE|||MICROSCOPY|N|N|INVESTIGATOR|ONCOLOGIST 2|N|2||58||BASELINE|1972-10-10|
TRIAL STUDY 134XCP|TR|F8F17A43-A74B-4570-8A06-D7657A4636B4|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||CI/L|TUMOR MERGED||NKAT/G HB|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|3||39||WASHOUT|1962-02-08|
TRIAL STUDY 134XCP|TR|F8F17A43-A74B-4570-8A06-D7657A4636B4|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/100 HPFS|PATHOLOGICAL||GRAIN|NOT DONE|||ELASTOGRAPHY|NA|U|CLINICAL RESEARCH COORDINATOR|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1960-03-12|
TRIAL STUDY 134XCP|TR|F8F17A43-A74B-4570-8A06-D7657A4636B4|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||% INHIBITION|NONPALPABLE||MET*H|NOT DONE|||BIOPSY|U|U|SIBLING|HEMATOLOGIST|Y|5||7||SCREENING|1970-12-26|
TRIAL STUDY 134XCP|TR|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||U/DL|UNCHANGED||SV|NOT DONE|||IMMUNOPRECIPITATION|U|N|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||RUN-IN|1968-06-16|
TRIAL STUDY 134XCP|TR|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||G/CAGE|EQUIVOCAL||PMOL/L|NOT DONE|||KARYOTYPING|NA|N|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|2||58||OPEN LABEL TREATMENT|1972-08-27|
TRIAL STUDY 134XCP|TR|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||POUCH|EQUIVOCAL||UKAT/10^12 RBC|NOT DONE|||CONTACT SPECULAR MICROSCOPY|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|3||39||RUN-IN|1969-06-27|
TRIAL STUDY 134XCP|TR|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|4||||||LESSCIND|LESION SUCCESS INDICATOR||RING|NONPALPABLE||PACKAGE|NOT DONE|||HPLC-FL|NA|NA|FRIEND|NEUROLOGIST 2|U|4||88||CONTINUATION TREATMENT|1971-11-06|
TRIAL STUDY 134XCP|TR|37EDE304-7A3A-4CC4-BD04-FD36EA27BF74|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/SEC|FURTHER ENLARGEMENT||LOG10 PFU/ML|NOT DONE|||RADIOGRAPHY|NA|NA|FAMILY MEMBER|MICROSCOPIST 2|U|5||7||CONTINUATION TREATMENT|1972-07-17|
TRIAL STUDY 134XCP|TR|1177FD36-AAE8-4139-991A-A8C98B607565|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^6/EJACULATE U|ENLARGEMENT||ML/CM|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|U|1||38||TREATMENT|1970-10-18|
TRIAL STUDY 134XCP|TR|1177FD36-AAE8-4139-991A-A8C98B607565|2||||||TUMSTATE|TUMOR STATE||AMU|DIFFUSELY INCREASED||/MBP|NOT DONE|||CALCOFLUOR WHITE STAIN|NA|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|2||58||FOLLOW-UP|1969-03-05|
TRIAL STUDY 134XCP|TR|1177FD36-AAE8-4139-991A-A8C98B607565|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UMOL/MIN|FOCALLY INCREASED||YD|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|N|U|NON-HEALTH CARE PROFESSIONAL|READER 2|U|3||39||FOLLOW-UP|1973-05-19|
TRIAL STUDY 134XCP|TR|1177FD36-AAE8-4139-991A-A8C98B607565|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||S^-1(%O2)^-1|DIFFUSELY INCREASED||KALLIKREIN INHIBITOR UNIT|NOT DONE|||PET/SPECT SCAN|N|N|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|4||88||OBSERVATION|1962-01-08|
TRIAL STUDY 134XCP|TR|1177FD36-AAE8-4139-991A-A8C98B607565|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||PT_US|PATHOLOGICAL||TRANSDUCING UNIT/ML|NOT DONE|||IMMUNOBLOT|Y|NA|GUARDIAN|FORENSIC PATHOLOGIST|Y|5||7||FOLLOW-UP|1969-02-22|
TRIAL STUDY 134XCP|TR|8C57F469-7CDF-493A-9839-C179D912A8A5|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||NMOL/MOL|FOCALLY INCREASED||FINGERTIP UNIT|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|N|1||38||BLINDED TREATMENT|1973-03-05|
TRIAL STUDY 134XCP|TR|8C57F469-7CDF-493A-9839-C179D912A8A5|2||||||TUMSTATE|TUMOR STATE||/40 HPFS|FURTHER ENLARGEMENT FROM NADIR||MG2/DL2|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|N|NA|INVESTIGATOR|ADJUDICATOR 2|N|2||58||BASELINE|1963-10-31|
TRIAL STUDY 134XCP|TR|8C57F469-7CDF-493A-9839-C179D912A8A5|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/SEC/1.73M2|PRESENT||UMOL/MG/MIN|NOT DONE|||ISHIHARA COLOR PLATES|NA|U|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|3||39||OBSERVATION|1961-12-20|
TRIAL STUDY 134XCP|TR|8C57F469-7CDF-493A-9839-C179D912A8A5|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/100 WBC|ENLARGEMENT FROM NADIR||ML/ANIMAL|NOT DONE|||IMMUNOTURBIDIMETRY|N|U|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|4||88||CONTINUATION TREATMENT|1970-03-22|
TRIAL STUDY 134XCP|TR|8C57F469-7CDF-493A-9839-C179D912A8A5|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||EVENTS|FURTHER ENLARGEMENT||IU/MMOL|NOT DONE|||PERFUSION MRI|N|N|ADJUDICATOR|ONCOLOGIST 2|NA|5||7||OBSERVATION|1969-11-02|
TRIAL STUDY 134XCP|TR|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^12 IU/L|ABSENT||CYLINDER|NOT DONE|||MICROBIAL CONCENTRATION|N|U|ADJUDICATION COMMITTEE|UROLOGIST|N|1||38||OBSERVATION|1967-07-03|
TRIAL STUDY 134XCP|TR|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||L/MIN|EQUIVOCAL||FARAD|NOT DONE|||FLAME PHOTOMETRY|U|NA|STUDY SUBJECT|UROLOGIST|U|2||58||OBSERVATION|1972-05-09|
TRIAL STUDY 134XCP|TR|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|3||||||DIAMETER|DIAMETER||CAPLET|ENLARGEMENT||PMOL/DAY|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|U|U|SPOUSE|PEDIATRIC NEUROLOGIST|U|3||39||TREATMENT|1971-05-18|
TRIAL STUDY 134XCP|TR|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||CAL|ABSENT||DAYS|NOT DONE|||HPLC-UV|N|N|INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|4||88||BLINDED TREATMENT|1963-10-04|
TRIAL STUDY 134XCP|TR|8F3EA8B7-0A0B-45DE-AF82-4DD335C40FE0|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||PFU/ANIMAL|ABSENT||/VF|NOT DONE|||MOUSE PROTECTION ASSAY|U|N|DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|5||7||TREATMENT|1972-08-13|
TRIAL STUDY 134XCP|TR|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|1||||||NEWCONF|NEW TUMOR CONFIRMED||MOL|UNEQUIVOCAL||VIAL|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|NA|INVESTIGATOR|ONCOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1971-09-01|
TRIAL STUDY 134XCP|TR|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||IU/ML|PRESENT||MPH|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|U|DOMESTIC PARTNER|OPTOMETRIST|NA|2||58||FOLLOW-UP|1970-06-11|
TRIAL STUDY 134XCP|TR|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||JDF UNIT|EQUIVOCAL||BREATHS/MIN|NOT DONE|||MICROSCOPY|NA|N|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||FOLLOW-UP|1966-01-26|
TRIAL STUDY 134XCP|TR|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MM/H|PALPABLE||MCI|NOT DONE|||MICROBIAL CULTURE, LIQUID|Y|NA|ADJUDICATOR|INTERNIST|U|4||88||LONG-TERM FOLLOW-UP|1965-12-06|
TRIAL STUDY 134XCP|TR|CAFEA1D3-8DB8-4CDE-89BF-FA604EE2AF9A|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||BQ/MG|FURTHER ENLARGEMENT||G/CM2|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|NA|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|5||7||SCREENING|1961-10-03|
TRIAL STUDY 134XCP|TR|0AE36450-F37E-4F97-A250-79166011FCD7|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||1/(S*KPA)|NON-PATHOLOGICAL||KPA/L/SEC|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|Y|INTERVIEWER|MICROSCOPIST 1|N|1||38||WASHOUT|1967-07-04|
TRIAL STUDY 134XCP|TR|0AE36450-F37E-4F97-A250-79166011FCD7|2||||||NEWCONF|NEW TUMOR CONFIRMED||NMOL/L/H|FOCALLY INCREASED||MG|NOT DONE|||THICK SMEAR|NA|NA|DOMESTIC PARTNER|READER 1|NA|2||58||SCREENING|1973-03-22|
TRIAL STUDY 134XCP|TR|0AE36450-F37E-4F97-A250-79166011FCD7|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||DMOL|NONPALPABLE||GBQ/MG|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|NA|VENDOR|CLINICAL PATHOLOGIST|Y|3||39||FOLLOW-UP|1965-01-20|
TRIAL STUDY 134XCP|TR|0AE36450-F37E-4F97-A250-79166011FCD7|4||||||LESSCIND|LESION SUCCESS INDICATOR||10^3 CFU/ML|FOCALLY INCREASED||ML/KG/MIN|NOT DONE|||NEPHELOMETRY|U|NA|STUDY SUBJECT|ENDOCRINOLOGIST|Y|4||88||RUN-IN|1960-06-27|
TRIAL STUDY 134XCP|TR|0AE36450-F37E-4F97-A250-79166011FCD7|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||CL|UNCHANGED||MU/G|NOT DONE|||HPLC|Y|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||SCREENING|1965-10-28|
TRIAL STUDY 134XCP|TR|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||C|EQUIVOCAL||CAPSULE|NOT DONE|||SLIT LAMP|NA|NA|STUDY SUBJECT|RATER|N|1||38||OBSERVATION|1967-05-19|
TRIAL STUDY 134XCP|TR|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PATCH|DECREASED||PG/L|NOT DONE|||ENZYMATIC COLORIMETRY|Y|N|STUDY SUBJECT|PATHOLOGIST|N|2||58||INDUCTION TREATMENT|1964-01-26|
TRIAL STUDY 134XCP|TR|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|3||||||LPERP|LONGEST PERPENDICULAR||FOZ_US|FURTHER ENLARGEMENT||KDA|NOT DONE|||TWO-COLOR MICROARRAY|Y|N|PROXY|NEUROLOGIST 1|NA|3||39||SCREENING|1970-04-01|
TRIAL STUDY 134XCP|TR|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|4||||||ORVERLN|ORGAN VERTICAL LENGTH||UG/MOL|NORMAL||DPM|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|U|N|SIBLING|PATHOLOGIST 2|Y|4||88||RUN-IN|1962-12-31|
TRIAL STUDY 134XCP|TR|8D5230FF-DE90-48E7-8CE2-F9B0ED562098|5||||||SUMVOL|SUM OF VOLUME||UIU/L|FOCALLY INCREASED||NG/MOL|NOT DONE|||CRYOSCOPY|U|N|SIGNIFICANT OTHER|MICROSCOPIST 3|U|5||7||WASHOUT|1969-08-01|
TRIAL STUDY 134XCP|TR|707FC46F-B8B1-456B-9E09-CABC86EA61D5|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CD|UNEQUIVOCAL||10^3 CFU|NOT DONE|||CLAUSS METHOD|NA|U|FAMILY MEMBER|PATHOLOGIST 1|U|1||38||INDUCTION TREATMENT|1963-10-26|
TRIAL STUDY 134XCP|TR|707FC46F-B8B1-456B-9E09-CABC86EA61D5|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^6 CFU/G|UNEQUIVOCAL||MG/M2|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|NA|STUDY SUBJECT|NEUROLOGIST 2|Y|2||58||OBSERVATION|1964-10-04|
TRIAL STUDY 134XCP|TR|707FC46F-B8B1-456B-9E09-CABC86EA61D5|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DPM/0.5 ML|EQUIVOCAL||GRAVITATIONAL UNIT|NOT DONE|||MODIFIED ACID FAST STAIN|Y|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|N|3||39||RUN-IN|1971-09-21|
TRIAL STUDY 134XCP|TR|707FC46F-B8B1-456B-9E09-CABC86EA61D5|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MILE|FOCALLY INCREASED||COULOMB|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|N|N|CLINICAL RESEARCH COORDINATOR|READER 3|U|4||88||LONG-TERM FOLLOW-UP|1962-09-11|
TRIAL STUDY 134XCP|TR|707FC46F-B8B1-456B-9E09-CABC86EA61D5|5||||||LNSTATE|LYMPH NODE STATE||OI50|DIFFUSELY INCREASED||MKAT|NOT DONE|||APPLANATION TONOMETRY|NA|Y|CAREGIVER|MICROSCOPIST 3|U|5||7||FOLLOW-UP|1962-07-25|
TRIAL STUDY 134XCP|TR|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PFU/ANIMAL|ABSENT||DAGU/ML|NOT DONE|||FLOW MICROSCOPY|N|NA|PROXY|CLINICAL PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1967-03-21|
TRIAL STUDY 134XCP|TR|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|2||||||VDIAM|VIABLE DIAMETER||BP|FURTHER ENLARGEMENT||DRINK|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|NA|INTERVIEWER|NEUROLOGIST 2|NA|2||58||FOLLOW-UP|1960-06-09|
TRIAL STUDY 134XCP|TR|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CP|PATHOLOGICAL||UU/DL|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|NA|N|PROXY|CARDIOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1971-05-25|
TRIAL STUDY 134XCP|TR|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MBQ/UL|PATHOLOGICAL||CI|NOT DONE|||DIGITAL PCR ARRAY|U|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|U|4||88||TREATMENT|1962-01-18|
TRIAL STUDY 134XCP|TR|E9745E48-1B55-49C6-9AB6-5EF7CC950C9F|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||GPS U|ENLARGEMENT||DAYS|NOT DONE|||MICRO BROTH DILUTION|N|NA|FRIEND|ONCOLOGIST 2|N|5||7||OPEN LABEL TREATMENT|1961-11-30|
TRIAL STUDY 134XCP|TR|70196099-5D40-4048-AABF-EB40CE345328|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MG/L|EQUIVOCAL||/WK|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|N|PARENT|ONCOLOGIST 1|N|1||38||TREATMENT|1960-04-29|
TRIAL STUDY 134XCP|TR|70196099-5D40-4048-AABF-EB40CE345328|2||||||LNSTATE|LYMPH NODE STATE||APL U|ENLARGEMENT||UIU/DL|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|NA|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|N|2||58||FOLLOW-UP|1964-07-25|
TRIAL STUDY 134XCP|TR|70196099-5D40-4048-AABF-EB40CE345328|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||TSP|UNEQUIVOCAL||MMHG*MIN/L|NOT DONE|||CLIP|N|NA|SPOUSE|READER 1|Y|3||39||RUN-IN|1966-09-20|
TRIAL STUDY 134XCP|TR|70196099-5D40-4048-AABF-EB40CE345328|4||||||DIAMETER|DIAMETER||U/MMOL|ENLARGEMENT||LENS|NOT DONE|||ELISA|Y|N|SPOUSE|ADJUDICATOR 2|N|4||88||SCREENING|1973-05-06|
TRIAL STUDY 134XCP|TR|70196099-5D40-4048-AABF-EB40CE345328|5||||||LNSTATE|LYMPH NODE STATE||GY/H|FURTHER ENLARGEMENT||MEQ/L|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|Y|NA|CAREGIVER|DERMATOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1967-07-24|
TRIAL STUDY 134XCP|TR|F9D4C544-F217-4676-AC40-F71CC48045AF|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CGY|FURTHER ENLARGEMENT FROM NADIR||MV|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|1||38||BLINDED TREATMENT|1966-06-03|
TRIAL STUDY 134XCP|TR|F9D4C544-F217-4676-AC40-F71CC48045AF|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MEQ/L|PRESENT||MG/G/MIN|NOT DONE|||CISH|U|U|CAREGIVER|DERMATOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1963-10-23|
TRIAL STUDY 134XCP|TR|F9D4C544-F217-4676-AC40-F71CC48045AF|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MILE|PALPABLE||MHZ|NOT DONE|||IMMUNOPRECIPITATION|NA|N|ADJUDICATION COMMITTEE|UROLOGIST|Y|3||39||FOLLOW-UP|1961-10-01|
TRIAL STUDY 134XCP|TR|F9D4C544-F217-4676-AC40-F71CC48045AF|4||||||SUMVOL|SUM OF VOLUME||KDA|ENLARGEMENT||MG|NOT DONE|||RAJI CELL RIA|N|NA|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|NA|4||88||OBSERVATION|1967-12-19|
TRIAL STUDY 134XCP|TR|F9D4C544-F217-4676-AC40-F71CC48045AF|5||||||NEWCONF|NEW TUMOR CONFIRMED||MG/MOL|EQUIVOCAL||OD UNIT|NOT DONE|||SLIT LAMP|Y|U|VENDOR|PEDIATRIC NEUROLOGIST|N|5||7||CONTINUATION TREATMENT|1964-07-30|
TRIAL STUDY 134XCP|TR|E6A42133-B082-4BD7-B840-A60E49E0562B|1||||||VSLPIND|VESSEL PATENCY INDICATOR||10^4/L|FURTHER ENLARGEMENT FROM NADIR||UG/KG/MIN|NOT DONE|||DYNAMIC LIGHT SCATTERING|N|NA|INTERVIEWER|PATHOLOGIST 1|NA|1||38||SCREENING|1971-08-12|
TRIAL STUDY 134XCP|TR|E6A42133-B082-4BD7-B840-A60E49E0562B|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||APL U/ML|PALPABLE||PM|NOT DONE|||LC-FL|NA|NA|VENDOR|ADJUDICATOR 2|N|2||58||WASHOUT|1964-03-28|
TRIAL STUDY 134XCP|TR|E6A42133-B082-4BD7-B840-A60E49E0562B|3||||||LESFLIND|LESION FAILURE INDICATOR||IU/MMOL|FOCALLY INCREASED||CARTRIDGE|NOT DONE|||NO INFORMATION|U|U|SPOUSE|NEUROLOGIST 2|N|3||39||TREATMENT|1963-04-26|
TRIAL STUDY 134XCP|TR|E6A42133-B082-4BD7-B840-A60E49E0562B|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||OD UNIT|ABSENT||PHERESIS UNIT|NOT DONE|||COLORIMETRY|N|NA|PROXY|ONCOLOGIST 2|NA|4||88||RUN-IN|1965-04-09|
TRIAL STUDY 134XCP|TR|E6A42133-B082-4BD7-B840-A60E49E0562B|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MMOL/DAY|DECREASED||SIEMENS|NOT DONE|||CHROMOGENIC ASSAY|Y|Y|CAREGIVER|ONCOLOGIST 2|NA|5||7||OBSERVATION|1969-05-18|
TRIAL STUDY 134XCP|TR|72C9FDBC-AA86-4001-9820-90AAF5422074|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^12 IU/L|FOCALLY INCREASED||IU/G HB|NOT DONE|||FREEZING POINT DEPRESSION|NA|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|1||38||BLINDED TREATMENT|1964-03-05|
TRIAL STUDY 134XCP|TR|72C9FDBC-AA86-4001-9820-90AAF5422074|2||||||LPERP|LONGEST PERPENDICULAR||MOL/L|UNEQUIVOCAL||ELISA UNIT/ML|NOT DONE|||DC SHEATH FLOW|N|Y|CLINICAL STUDY SPONSOR|READER 3|U|2||58||BASELINE|1968-11-29|
TRIAL STUDY 134XCP|TR|72C9FDBC-AA86-4001-9820-90AAF5422074|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||RPM|DECREASED||MG/KG/DAY|NOT DONE|||PET/SPECT SCAN|NA|U|PROXY|CARDIOLOGIST|N|3||39||INDUCTION TREATMENT|1972-02-24|
TRIAL STUDY 134XCP|TR|72C9FDBC-AA86-4001-9820-90AAF5422074|4||||||RADIODEN|RADIODENSITY||TABLET|ABSENT||MG/H|NOT DONE|||CARDIAC THERMODILUTION|N|N|INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|4||88||CONTINUATION TREATMENT|1963-08-17|
TRIAL STUDY 134XCP|TR|72C9FDBC-AA86-4001-9820-90AAF5422074|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||PATCH|FURTHER ENLARGEMENT||MOL|NOT DONE|||PULSE OXIMETRY|Y|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||BLINDED TREATMENT|1971-08-01|
TRIAL STUDY 134XCP|TR|186520B9-8AAD-4063-B48F-16040EF49944|1||||||ORSTATE|ORGAN STATE||DNA COPIES/ML|EQUIVOCAL||TBSP|NOT DONE|||TEMPLATE INCISION METHOD|Y|NA|SPOUSE|INTERNIST|N|1||38||INDUCTION TREATMENT|1972-04-29|
TRIAL STUDY 134XCP|TR|186520B9-8AAD-4063-B48F-16040EF49944|2||||||LDIAM|LONGEST DIAMETER||10^3/HPF|DECREASED||UU/L|NOT DONE|||DIGITAL PCR ARRAY|U|Y|CAREGIVER|ADJUDICATOR 2|Y|2||58||RUN-IN|1961-08-19|
TRIAL STUDY 134XCP|TR|186520B9-8AAD-4063-B48F-16040EF49944|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||TCID 50/DOSE|NONPALPABLE||CYCLE/MIN|NOT DONE|||REFRACTOMETRY|NA|Y|VENDOR|RATER 1|N|3||39||OPEN LABEL TREATMENT|1971-03-11|
TRIAL STUDY 134XCP|TR|186520B9-8AAD-4063-B48F-16040EF49944|4||||||SUMDIAM|SUM OF DIAMETER||COULOMB|ABSENT||DAGU/ML|NOT DONE|||FREEZING POINT DEPRESSION|U|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|4||88||OBSERVATION|1961-05-17|
TRIAL STUDY 134XCP|TR|186520B9-8AAD-4063-B48F-16040EF49944|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||PLUG|FURTHER ENLARGEMENT FROM NADIR||UG/L DDU|NOT DONE|||DIFFUSION WEIGHTED MRI|N|NA|PARENT|ONCOLOGIST|NA|5||7||FOLLOW-UP|1969-01-28|
TRIAL STUDY 134XCP|TR|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BISCUIT|DECREASED||/MM2|NOT DONE|||SEQUENCING|U|U|DOMESTIC PARTNER|RATER 2|N|1||38||BASELINE|1962-10-20|
TRIAL STUDY 134XCP|TR|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|2||||||SUMVOL|SUM OF VOLUME||NG/DAY|UNEQUIVOCAL||DIP|NOT DONE|||SANGER SEQUENCING|Y|N|CAREGIVER|READER 3|U|2||58||SCREENING|1964-11-22|
TRIAL STUDY 134XCP|TR|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PACKET|NONPALPABLE||%/MIN|NOT DONE|||PATHOLOGICAL EVALUATION|N|U|CHILD|RADIOLOGIST 1|Y|3||39||INDUCTION TREATMENT|1973-09-08|
TRIAL STUDY 134XCP|TR|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|4||||||LMBFLIND|LIMB FAILURE INDICATOR||NKAT|DECREASED||LX|NOT DONE|||AUTOREFRACTION|NA|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|4||88||OPEN LABEL TREATMENT|1962-10-07|
TRIAL STUDY 134XCP|TR|31DD3952-685F-4941-A68A-2D0C6FB5ECEF|5||||||PALPSTAT|PALPABLE STATE||M|ENLARGEMENT||WEEKS|NOT DONE|||FLUORESCENT MICROSCOPY|U|N|STUDY SUBJECT|CLINICAL PATHOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1960-05-12|
TRIAL STUDY 134XCP|TR|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||G/CAGE|TUMOR MERGED||MIN|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|NA|STUDY SUBJECT|OPHTHALMOLOGIST|Y|1||38||RUN-IN|1968-06-01|
TRIAL STUDY 134XCP|TR|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||U.CARR|ENLARGEMENT||TSP EQ|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|NA|U|PARENT|RADIOLOGIST 1|U|2||58||SCREENING|1962-09-13|
TRIAL STUDY 134XCP|TR|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|3||||||VDIAM|VIABLE DIAMETER||10^9/G|FOCALLY INCREASED||ML/G/DAY|NOT DONE|||CT SCAN WITHOUT CONTRAST|U|N|INTERVIEWER|ONCOLOGIST 2|U|3||39||WASHOUT|1968-06-09|
TRIAL STUDY 134XCP|TR|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|4||||||BNLNUM|NUMBER OF BONE LESIONS||CYCLE/MIN|NON-PATHOLOGICAL||K|NOT DONE|||RYAN BLUE STAIN|N|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|4||88||SCREENING|1961-04-04|
TRIAL STUDY 134XCP|TR|5292AC86-EB26-4CA7-8DD0-F353948FD4B1|5||||||VOLUME|VOLUME||CI/MG|PALPABLE||TORR|NOT DONE|||IMPULSE OSCILLOMETRY|Y|NA|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|5||7||BASELINE|1966-02-12|
TRIAL STUDY 134XCP|TR|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||U/M2/MIN|NONPALPABLE||NG|NOT DONE|||LC/MS|NA|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|1||38||OPEN LABEL TREATMENT|1971-09-04|
TRIAL STUDY 134XCP|TR|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||AFU|INCREASED||10^6/L|NOT DONE|||PERIODIC ACID SCHIFF STAIN|N|U|SIBLING|RADIOLOGIST|N|2||58||SCREENING|1971-04-15|
TRIAL STUDY 134XCP|TR|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|3||||||TUMSTATE|TUMOR STATE||/MM2|UNCHANGED||KCAL/DAY|NOT DONE|||CALIPER MEASUREMENT METHOD|NA|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||WASHOUT|1963-06-15|
TRIAL STUDY 134XCP|TR|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|4||||||CALCFIND|CALCIFICATION INDICATOR||MM/MIN|UNCHANGED||10^9/DOSE|NOT DONE|||IMMUNOCHROMATOGRAPHY|N|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||OBSERVATION|1969-08-09|
TRIAL STUDY 134XCP|TR|9BC8E789-B7D5-40A9-A4EE-9E88234992CB|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||ENZYME U/L|FURTHER ENLARGEMENT||M3|NOT DONE|||SLIT LAMP|Y|U|DOMESTIC PARTNER|PATHOLOGIST 1|Y|5||7||TREATMENT|1963-11-24|
TRIAL STUDY 134XCP|TR|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CMOL|TUMOR MERGED||OSM|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|NA|Y|ADJUDICATION COMMITTEE|RATER 1|Y|1||38||BLINDED TREATMENT|1963-06-26|
TRIAL STUDY 134XCP|TR|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|2||||||ORVERLN|ORGAN VERTICAL LENGTH||/MONTH|ENLARGEMENT FROM NADIR||UIU/L|NOT DONE|||MECHANICAL CLOT DETECTION|U|N|FAMILY MEMBER|OPHTHALMOLOGIST|Y|2||58||OBSERVATION|1963-05-12|
TRIAL STUDY 134XCP|TR|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||LOG10 TCID 50/DOSE|NOT DONE|||WESTERN BLOT|NA|Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1964-06-15|
TRIAL STUDY 134XCP|TR|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|4||||||TUMSTATE|TUMOR STATE||CI|PATHOLOGICAL||CONTAINER|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|U|U|CHILD|RADIOLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1961-10-17|
TRIAL STUDY 134XCP|TR|90176B5E-72C3-4FAB-AEF3-E75B9BCFE3CE|5||||||TUMSTATE|TUMOR STATE||MMOL/G|DIFFUSELY INCREASED||IMPLANT|NOT DONE|||CLAUSS METHOD|U|NA|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|5||7||INDUCTION TREATMENT|1972-12-14|
TRIAL STUDY 134XCP|TR|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||RAD|NON-PATHOLOGICAL||DPM/0.5 ML|NOT DONE|||REBOUND TONOMETRY|U|NA|CHILD|MICROSCOPIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1963-06-29|
TRIAL STUDY 134XCP|TR|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MESF|TUMOR MERGED||/200 HPFS|NOT DONE|||HILLMEN COLOR CHART|U|U|PARENT|ADJUDICATOR|Y|2||58||LONG-TERM FOLLOW-UP|1969-10-14|
TRIAL STUDY 134XCP|TR|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|3||||||LESFLIND|LESION FAILURE INDICATOR||MBQ/UL|DIFFUSELY INCREASED||C|NOT DONE|||DIGITAL PCR ARRAY|U|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|3||39||OBSERVATION|1962-10-26|
TRIAL STUDY 134XCP|TR|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||HZ|FOCALLY INCREASED||G/CM2|NOT DONE|||CELLULOSE TAPE|NA|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||TREATMENT|1964-12-05|
TRIAL STUDY 134XCP|TR|20B6D4E0-EE72-467E-9A1D-DFAC0137A3BA|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ABSORBANCE U/ML|NONPALPABLE||MG/DL|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|N|DOMESTIC PARTNER|PHYSIOTHERAPIST|N|5||7||SCREENING|1967-12-09|
TRIAL STUDY 134XCP|TR|460486B3-B7C8-4B54-848B-21BA899EAAD6|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||VOXEL|UNEQUIVOCAL||GPELISA UNIT/ML|NOT DONE|||ULTRASOUND|Y|U|GUARDIAN|PHYSIOTHERAPIST|Y|1||38||BLINDED TREATMENT|1967-08-10|
TRIAL STUDY 134XCP|TR|460486B3-B7C8-4B54-848B-21BA899EAAD6|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CYLINDER|EQUIVOCAL||MEQ|NOT DONE|||CT SCAN|N|N|CAREGIVER|RATER 1|NA|2||58||WASHOUT|1968-10-20|
TRIAL STUDY 134XCP|TR|460486B3-B7C8-4B54-848B-21BA899EAAD6|3||||||ORVERLN|ORGAN VERTICAL LENGTH||ML/G/MIN|FURTHER ENLARGEMENT FROM NADIR||UMOL/MG/MIN|NOT DONE|||SCANNING ELECTRON MICROSCOPY|N|U|CLINICAL STUDY SPONSOR|READER 1|Y|3||39||CONTINUATION TREATMENT|1970-06-28|
TRIAL STUDY 134XCP|TR|460486B3-B7C8-4B54-848B-21BA899EAAD6|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MM3/MM2/YEAR|INCREASED||U/MMOL|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|N|SPOUSE|RATER|U|4||88||BASELINE|1962-10-07|
TRIAL STUDY 134XCP|TR|460486B3-B7C8-4B54-848B-21BA899EAAD6|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CAPLET|FOCALLY INCREASED||PMOL/DL|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|NA|N|CHILD|OPHTHALMOLOGIST|N|5||7||BASELINE|1965-03-01|
TRIAL STUDY 134XCP|TR|A068436F-E26E-44C5-8959-0BCBA28832D1|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||BQ|NORMAL||IU/ML|NOT DONE|||FLUORESCEIN STAIN|NA|N|GUARDIAN|RATER 1|Y|1||38||FOLLOW-UP|1968-12-28|
TRIAL STUDY 134XCP|TR|A068436F-E26E-44C5-8959-0BCBA28832D1|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PHERESIS UNIT|NORMAL||GLOBULE|NOT DONE|||OPTICAL DENSITY MEASUREMENT|N|NA|VENDOR|READER|NA|2||58||SCREENING|1960-01-07|
TRIAL STUDY 134XCP|TR|A068436F-E26E-44C5-8959-0BCBA28832D1|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UU/DL|INCREASED||PACKAGE|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|N|FAMILY MEMBER|OPHTHALMOLOGIST|N|3||39||OBSERVATION|1972-12-16|
TRIAL STUDY 134XCP|TR|A068436F-E26E-44C5-8959-0BCBA28832D1|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||ML/(MIN*100ML)|ENLARGEMENT FROM NADIR||CI/UL|NOT DONE|||CLAUSS METHOD|Y|N|INTERVIEWER|INTERNIST|Y|4||88||TREATMENT|1968-05-15|
TRIAL STUDY 134XCP|TR|A068436F-E26E-44C5-8959-0BCBA28832D1|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^4/L|FURTHER ENLARGEMENT FROM NADIR||U/MG|NOT DONE|||SPECT SCAN|NA|NA|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|5||7||RUN-IN|1968-09-18|
TRIAL STUDY 134XCP|TR|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||APL U/ML|DIFFUSELY INCREASED||10^6 U|NOT DONE|||SISH|NA|N|STUDY SUBJECT|ADJUDICATOR|U|1||38||CONTINUATION TREATMENT|1961-07-09|
TRIAL STUDY 134XCP|TR|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||PNU/ML|ENLARGEMENT FROM NADIR||KCAL|NOT DONE|||MICROBIAL CULTURE, SOLID|NA|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2||58||INDUCTION TREATMENT|1970-06-08|
TRIAL STUDY 134XCP|TR|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|3||||||NEWCONF|NEW TUMOR CONFIRMED||APL U/ML|UNCHANGED||G/DAY|NOT DONE|||SPIRAL CT|Y|Y|ADJUDICATION COMMITTEE|RATER|U|3||39||BASELINE|1963-01-18|
TRIAL STUDY 134XCP|TR|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||DAGU|ABSENT||MKAT|NOT DONE|||PEAK FLOWMETRY|NA|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|N|4||88||INDUCTION TREATMENT|1965-02-28|
TRIAL STUDY 134XCP|TR|00B423B2-C33A-4EA2-A5C8-78D3C6531DD5|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MJOULE/CM2|NON-PATHOLOGICAL||GY/MIN|NOT DONE|||MOUSE PROTECTION ASSAY|NA|U|GUARDIAN|UROLOGIST|NA|5||7||CONTINUATION TREATMENT|1960-01-24|
TRIAL STUDY 134XCP|TR|E065D436-92D2-453F-86A7-27F70FE1FD03|1||||||TUMSTATE|TUMOR STATE||INHALATION|UNCHANGED||/H|NOT DONE|||MANUAL COUNT|U|NA|INTERVIEWER|DERMATOLOGIST|U|1||38||RUN-IN|1972-09-25|
TRIAL STUDY 134XCP|TR|E065D436-92D2-453F-86A7-27F70FE1FD03|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||CL|UNEQUIVOCAL||G/ANIMAL/DAY|NOT DONE|||IMMUNOPRECIPITATION|NA|NA|ADJUDICATOR|MICROSCOPIST|Y|2||58||WASHOUT|1971-07-27|
TRIAL STUDY 134XCP|TR|E065D436-92D2-453F-86A7-27F70FE1FD03|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UEQ/L|DECREASED||CS|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|Y|Y|ADJUDICATOR|RATER|Y|3||39||BLINDED TREATMENT|1969-09-03|
TRIAL STUDY 134XCP|TR|E065D436-92D2-453F-86A7-27F70FE1FD03|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LOG10 CFU/G|DECREASED||HOUNSFIELD UNIT|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|NA|NA|PROXY|ADJUDICATOR 3|NA|4||88||CONTINUATION TREATMENT|1972-07-10|
TRIAL STUDY 134XCP|TR|E065D436-92D2-453F-86A7-27F70FE1FD03|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||U/ANIMAL|PALPABLE||PG/L|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|N|PARENT|ONCOLOGIST 1|Y|5||7||OBSERVATION|1964-07-22|
TRIAL STUDY 134XCP|TR|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MET*MIN|FURTHER ENLARGEMENT||PPTH|NOT DONE|||ALCIAN BLUE STAIN|N|U|INTERVIEWER|MICROSCOPIST 3|U|1||38||WASHOUT|1973-02-15|
TRIAL STUDY 134XCP|TR|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|2||||||LMBFLIND|LIMB FAILURE INDICATOR||10^11/L|UNCHANGED||MPH|NOT DONE|||PET/MRI SCAN|Y|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|U|2||58||WASHOUT|1972-12-12|
TRIAL STUDY 134XCP|TR|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|3||||||SUMDIAM|SUM OF DIAMETER||NMOL BCE/NMOL|UNEQUIVOCAL||IN2|NOT DONE|||EEG|Y|U|PROXY|NEUROLOGIST 2|U|3||39||WASHOUT|1969-05-06|
TRIAL STUDY 134XCP|TR|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|4||||||VOLUME|VOLUME||PL|PALPABLE||BQ/UL|NOT DONE|||SCINTIGRAPHY|Y|U|HEALTH CARE PROFESSIONAL|READER 3|NA|4||88||BLINDED TREATMENT|1971-04-03|
TRIAL STUDY 134XCP|TR|E7F5795C-FF55-4DFF-B461-AE4F04BD52F7|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||HOURS|FURTHER ENLARGEMENT||10^6 CFU|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|NA|PROXY|OTOLARYNGOLOGIST|U|5||7||OPEN LABEL TREATMENT|1962-09-10|
TRIAL STUDY 134XCP|TR|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||CD|DIFFUSELY INCREASED||NGEQ/L|NOT DONE|||CARDIAC THERMODILUTION|Y|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||FOLLOW-UP|1970-01-09|
TRIAL STUDY 134XCP|TR|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||LOG10 CCID 50/DOSE|NONPALPABLE||MU/L|NOT DONE|||PHYSICAL EXAMINATION|N|Y|CLINICAL STUDY SPONSOR|HEMATOLOGIST|NA|2||58||WASHOUT|1962-01-09|
TRIAL STUDY 134XCP|TR|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|3||||||NEWCONF|NEW TUMOR CONFIRMED||MG2/DL2|EQUIVOCAL||C|NOT DONE|||ISHIHARA COLOR PLATES|Y|U|STUDY SUBJECT|NEUROLOGIST|N|3||39||RUN-IN|1962-06-28|
TRIAL STUDY 134XCP|TR|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|4||||||LNSTATE|LYMPH NODE STATE||PMOL/10^10 CELLS|NONPALPABLE||CAL|NOT DONE|||MAMMOGRAPHY|N|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|4||88||SCREENING|1971-10-24|
TRIAL STUDY 134XCP|TR|CF5D1305-9DB3-4AA9-A3E1-DFB0BB70E77D|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||VIAL|DIFFUSELY INCREASED||UL/KG/DAY|NOT DONE|||PHOTOMETRIC CLOT DETECTION|NA|NA|PARENT|PATHOLOGIST|NA|5||7||FOLLOW-UP|1973-02-26|
TRIAL STUDY 134XCP|TR|D108D040-7177-4A14-8CA7-748D59DC5F8B|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UIU/L|NORMAL||UEQ/L|NOT DONE|||FORCED OSCILLATION TECHNIQUE|Y|N|CAREGIVER|RATER|N|1||38||LONG-TERM FOLLOW-UP|1968-09-26|
TRIAL STUDY 134XCP|TR|D108D040-7177-4A14-8CA7-748D59DC5F8B|2||||||AREA|AREA||PA|NONPALPABLE||UV*SEC|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|U|Y|FAMILY MEMBER|RATER|NA|2||58||SCREENING|1969-05-21|
TRIAL STUDY 134XCP|TR|D108D040-7177-4A14-8CA7-748D59DC5F8B|3||||||AREA|AREA||GPELISA UNIT/ML|PALPABLE||MG/ML/DAY|NOT DONE|||ALCIAN BLUE STAIN|Y|U|SPOUSE|ONCOLOGIST|Y|3||39||BASELINE|1963-08-17|
TRIAL STUDY 134XCP|TR|D108D040-7177-4A14-8CA7-748D59DC5F8B|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||GENEQ|NON-PATHOLOGICAL||CIGAR|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|Y|U|SIGNIFICANT OTHER|RATER|N|4||88||BASELINE|1963-05-16|
TRIAL STUDY 134XCP|TR|D108D040-7177-4A14-8CA7-748D59DC5F8B|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||BOLUS|TUMOR MERGED||BQ/UG|NOT DONE|||HIGH RESOLUTION CT|Y|Y|FRIEND|NEUROLOGIST 1|Y|5||7||WASHOUT|1960-09-23|
TRIAL STUDY 134XCP|TR|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/200 HPFS|TUMOR MERGED||MV/SEC|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|Y|NA|CHILD|FORENSIC PATHOLOGIST|Y|1||38||SCREENING|1970-11-04|
TRIAL STUDY 134XCP|TR|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|2||||||VDIAM|VIABLE DIAMETER||CAL|PALPABLE||ELISA UNIT|NOT DONE|||CONTRAST ENHANCED X-RAY|N|NA|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1967-03-26|
TRIAL STUDY 134XCP|TR|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||IU/ML|FURTHER ENLARGEMENT||HZ|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|N|Y|SIBLING|ENDOCRINOLOGIST|N|3||39||OBSERVATION|1967-04-28|
TRIAL STUDY 134XCP|TR|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||PMOL/10^10 CELLS|UNEQUIVOCAL||QUANTITY SUFFICIENT|NOT DONE|||DYNAMOMETRY|U|Y|SPOUSE|RADIOLOGIST|Y|4||88||BASELINE|1960-02-08|
TRIAL STUDY 134XCP|TR|6AACC77F-96D3-472F-BDB6-90CC0AF4CAB8|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^6 ORGANISMS/MG|ENLARGEMENT||DL|NOT DONE|||WEBER GREEN STAIN|Y|U|VENDOR|RATER 2|Y|5||7||TREATMENT|1961-01-20|
TRIAL STUDY 134XCP|TR|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UG/L/H|FURTHER ENLARGEMENT FROM NADIR||UMOL/MIN|NOT DONE|||SPECULAR MICROSCOPY|NA|Y|VENDOR|MICROSCOPIST 2|NA|1||38||FOLLOW-UP|1967-09-06|
TRIAL STUDY 134XCP|TR|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MMOL/KG|NON-PATHOLOGICAL||UU/DL|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|N|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1964-12-25|
TRIAL STUDY 134XCP|TR|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|3||||||VSLPIND|VESSEL PATENCY INDICATOR||L/S/KPA|ENLARGEMENT FROM NADIR||KG/M2|NOT DONE|||FISH|NA|U|CHILD|NEUROLOGIST|Y|3||39||RUN-IN|1963-01-11|
TRIAL STUDY 134XCP|TR|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|4||||||BNLNUM|NUMBER OF BONE LESIONS||UEQ|EQUIVOCAL||NMOL/MOL|NOT DONE|||COLORIMETRY|NA|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|4||88||OPEN LABEL TREATMENT|1962-04-27|
TRIAL STUDY 134XCP|TR|F7738305-F17D-4E83-BCD7-5ACAFE10DFD1|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||/40 HPFS|ENLARGEMENT FROM NADIR||MPL U/ML|NOT DONE|||CONTRAST ENHANCED PET SCAN|U|Y|SPOUSE|FORENSIC PATHOLOGIST|NA|5||7||OBSERVATION|1963-06-14|
TRIAL STUDY 134XCP|TR|580CCA66-3D51-4A5C-80E1-361A90369055|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||KEV|NON-PATHOLOGICAL||U/G|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|U|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1||38||WASHOUT|1971-04-26|
TRIAL STUDY 134XCP|TR|580CCA66-3D51-4A5C-80E1-361A90369055|2||||||NEWCONF|NEW TUMOR CONFIRMED||/7.5 ML|ENLARGEMENT||MG/DL|NOT DONE|||COMPLEMENT FIXATION|U|Y|CAREGIVER|UROLOGIST|U|2||58||WASHOUT|1970-11-14|
TRIAL STUDY 134XCP|TR|580CCA66-3D51-4A5C-80E1-361A90369055|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MN|NORMAL||/4.0 ML|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|Y|FRIEND|ONCOLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1963-06-14|
TRIAL STUDY 134XCP|TR|580CCA66-3D51-4A5C-80E1-361A90369055|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||UG/L|UNCHANGED||/CMH2O|NOT DONE|||TWO-COLOR MICROARRAY|U|N|SIGNIFICANT OTHER|ONCOLOGIST|Y|4||88||BLINDED TREATMENT|1960-02-23|
TRIAL STUDY 134XCP|TR|580CCA66-3D51-4A5C-80E1-361A90369055|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KM/H|NORMAL||MOSM/L|NOT DONE|||ALCIAN BLUE STAIN|NA|NA|SPOUSE|READER 2|N|5||7||FOLLOW-UP|1969-02-12|
TRIAL STUDY 134XCP|TR|DAB276EB-3581-4C20-88AC-5A3D267E54D8|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MN|PALPABLE||UM|NOT DONE|||GC/FID|N|N|PROXY|RADIOLOGIST|NA|1||38||TREATMENT|1965-07-12|
TRIAL STUDY 134XCP|TR|DAB276EB-3581-4C20-88AC-5A3D267E54D8|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||GRAVITATIONAL UNIT|PRESENT||MEQ/ML|NOT DONE|||ELASTOGRAPHY|U|N|PROXY|READER|NA|2||58||WASHOUT|1962-01-02|
TRIAL STUDY 134XCP|TR|DAB276EB-3581-4C20-88AC-5A3D267E54D8|3||||||LMBFLIND|LIMB FAILURE INDICATOR||IU/DAY|NORMAL||DYN|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|NA|U|CLINICAL RESEARCH COORDINATOR|RATER|N|3||39||TREATMENT|1969-01-11|
TRIAL STUDY 134XCP|TR|DAB276EB-3581-4C20-88AC-5A3D267E54D8|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ML/(MIN*100ML)|PATHOLOGICAL||MG/KG/DOSE|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|U|INDEPENDENT ASSESSOR|READER 1|U|4||88||RUN-IN|1964-12-06|
TRIAL STUDY 134XCP|TR|DAB276EB-3581-4C20-88AC-5A3D267E54D8|5||||||LESFLIND|LESION FAILURE INDICATOR||PFU/DOSE|ABSENT||PLUG|NOT DONE|||FREEZING POINT DEPRESSION|Y|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|5||7||OPEN LABEL TREATMENT|1967-06-29|
TRIAL STUDY 134XCP|TR|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||/VF|UNEQUIVOCAL||JDF UNIT|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|NA|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|1||38||BASELINE|1964-07-02|
TRIAL STUDY 134XCP|TR|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||NEEDLE GAUGE|NONPALPABLE||DAGU|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|N|U|INTERVIEWER|ADJUDICATOR 3|Y|2||58||CONTINUATION TREATMENT|1966-11-02|
TRIAL STUDY 134XCP|TR|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|3||||||TUMSTATE|TUMOR STATE||PMOL/L/H|UNCHANGED||LOG10 PFU|NOT DONE|||KINETIC CHROMOGENIC ASSAY|Y|N|FRIEND|RATER 1|NA|3||39||WASHOUT|1968-06-12|
TRIAL STUDY 134XCP|TR|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||GPL U/ML|FURTHER ENLARGEMENT||TUBERCULIN UNIT|NOT DONE|||MANUAL COUNT|Y|U|CAREGIVER|MICROSCOPIST 1|NA|4||88||OBSERVATION|1963-03-26|
TRIAL STUDY 134XCP|TR|D251DB10-ACF2-46DD-AC91-43D06F2C1E02|5||||||ORSTATE|ORGAN STATE||UEQ|ENLARGEMENT||RNA COPIES/ML|NOT DONE|||PELLI-ROBSON EYE CHART|N|Y|GUARDIAN|ENDOCRINOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1969-02-22|
TRIAL STUDY 134XCP|TR|5B703A43-A280-4D6A-AC40-FF5187521DB2|1||||||DIAMETER|DIAMETER||ML/M2|UNCHANGED||KPA|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|N|Y|PARENT|HEMATOLOGIST|U|1||38||INDUCTION TREATMENT|1972-04-03|
TRIAL STUDY 134XCP|TR|5B703A43-A280-4D6A-AC40-FF5187521DB2|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MEQ/DAY|DECREASED||GENEQ|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|U|U|STUDY SUBJECT|ONCOLOGIST|U|2||58||TREATMENT|1960-06-16|
TRIAL STUDY 134XCP|TR|5B703A43-A280-4D6A-AC40-FF5187521DB2|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||GPL U|PRESENT||10^9 CFU/G|NOT DONE|||SINGLE-MOLECULE ARRAY|NA|N|PARENT|FORENSIC PATHOLOGIST|U|3||39||SCREENING|1960-09-09|
TRIAL STUDY 134XCP|TR|5B703A43-A280-4D6A-AC40-FF5187521DB2|4||||||LNSTATE|LYMPH NODE STATE||NG/L|ABSENT||MG/KG/H|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|U|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4||88||SCREENING|1962-09-11|
TRIAL STUDY 134XCP|TR|5B703A43-A280-4D6A-AC40-FF5187521DB2|5||||||LNSTATE|LYMPH NODE STATE||NMOL/L|ENLARGEMENT FROM NADIR||MOSM/KG|NOT DONE|||TRANSVAGINAL ULTRASOUND|Y|U|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|5||7||TREATMENT|1967-02-13|
TRIAL STUDY 134XCP|TR|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MMOL|FURTHER ENLARGEMENT||UG/KG/H|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|U|SIGNIFICANT OTHER|RADIOLOGIST 2|Y|1||38||WASHOUT|1971-09-22|
TRIAL STUDY 134XCP|TR|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|2||||||LESFLIND|LESION FAILURE INDICATOR||UG/KG/DAY|FURTHER ENLARGEMENT||IU/G|NOT DONE|||PET SCAN|Y|NA|INVESTIGATOR|PATHOLOGIST|NA|2||58||OBSERVATION|1968-11-18|
TRIAL STUDY 134XCP|TR|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^6 ORGANISMS/MG|NORMAL||BQ/ML|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|U|Y|CAREGIVER|RADIOLOGIST|NA|3||39||FOLLOW-UP|1961-05-29|
TRIAL STUDY 134XCP|TR|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UU/L|UNEQUIVOCAL||MS/MMHG|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|Y|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|4||88||OBSERVATION|1965-06-12|
TRIAL STUDY 134XCP|TR|91862A60-6EB7-40AC-9B43-CCD6E75E86A4|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^3 RNA COPIES/ML|DECREASED||MMOL/S|NOT DONE|||CYSTOSCOPY|N|U|INVESTIGATOR|NEUROLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1960-12-17|
TRIAL STUDY 134XCP|TR|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|1||||||ORVERLN|ORGAN VERTICAL LENGTH||NMOL/KG/DAY|ENLARGEMENT FROM NADIR||MIU/L|NOT DONE|||CONTRAST ENHANCED MRI|N|Y|SIBLING|READER 1|NA|1||38||BLINDED TREATMENT|1971-12-31|
TRIAL STUDY 134XCP|TR|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MMOL/G|PRESENT||PACK YEAR|NOT DONE|||PERIODIC ACID SCHIFF STAIN|U|Y|PARENT|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1968-04-10|
TRIAL STUDY 134XCP|TR|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||BQ/KG|INCREASED||COPIES/UG|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|Y|INTERVIEWER|MICROSCOPIST|N|3||39||SCREENING|1964-07-14|
TRIAL STUDY 134XCP|TR|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|4||||||AREA|AREA||LOG10 COPIES/ML|FOCALLY INCREASED||MOSM/KG|NOT DONE|||PATHOLOGICAL EVALUATION|N|NA|INTERVIEWER|RADIOLOGIST 1|N|4||88||CONTINUATION TREATMENT|1965-02-12|
TRIAL STUDY 134XCP|TR|7C09FD7B-2BC4-4C9F-852B-234A769F73F6|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||LENS|UNEQUIVOCAL||100 IU/ML|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|Y|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|5||7||TREATMENT|1971-10-21|
TRIAL STUDY 134XCP|TR|51F3D3C1-3361-499F-B037-CCE8AB989989|1||||||CALCFIND|CALCIFICATION INDICATOR||NMOL BCE/MMOL|PRESENT||FT2|NOT DONE|||IN SITU HYBRIDIZATION|NA|N|CLINICAL RESEARCH COORDINATOR|READER 3|N|1||38||BASELINE|1969-04-30|
TRIAL STUDY 134XCP|TR|51F3D3C1-3361-499F-B037-CCE8AB989989|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||DNA COPIES/ML|NORMAL||SEC|NOT DONE|||PALM METHOD|Y|Y|INTERVIEWER|RADIOLOGIST|N|2||58||RUN-IN|1968-01-19|
TRIAL STUDY 134XCP|TR|51F3D3C1-3361-499F-B037-CCE8AB989989|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MMOL/KG|NORMAL||UMOL/DAY|NOT DONE|||MIGET|Y|NA|CHILD|FORENSIC PATHOLOGIST|Y|3||39||BASELINE|1965-05-01|
TRIAL STUDY 134XCP|TR|51F3D3C1-3361-499F-B037-CCE8AB989989|4||||||LDIAM|LONGEST DIAMETER||PMOL/DL|NONPALPABLE||NU/CL|NOT DONE|||MICRONEUTRALIZATION ASSAY|U|Y|FAMILY MEMBER|NEUROLOGIST 2|U|4||88||TREATMENT|1963-07-20|
TRIAL STUDY 134XCP|TR|51F3D3C1-3361-499F-B037-CCE8AB989989|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UKAT|FURTHER ENLARGEMENT FROM NADIR||MG/G/MIN|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1963-05-16|
TRIAL STUDY 134XCP|TR|231D401F-CA93-49E0-AC5C-C7F636343D2F|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||/MM2|ENLARGEMENT FROM NADIR||H/WK|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|Y|N|INVESTIGATOR|READER 2|NA|1||38||FOLLOW-UP|1970-05-18|
TRIAL STUDY 134XCP|TR|231D401F-CA93-49E0-AC5C-C7F636343D2F|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||/SEC|DIFFUSELY INCREASED||10^11/L|NOT DONE|||LYMPHANGIOGRAPHY|U|U|ADJUDICATOR|ADJUDICATOR 3|N|2||58||LONG-TERM FOLLOW-UP|1967-02-24|
TRIAL STUDY 134XCP|TR|231D401F-CA93-49E0-AC5C-C7F636343D2F|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||PT_US|FOCALLY INCREASED||PMOL/L/H|NOT DONE|||CLINICAL EVALUATION|U|U|FRIEND|PHYSIOTHERAPIST|Y|3||39||BLINDED TREATMENT|1972-02-15|
TRIAL STUDY 134XCP|TR|231D401F-CA93-49E0-AC5C-C7F636343D2F|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UMOL/DL|PALPABLE||10^4 CFU|NOT DONE|||DIFFUSION TENSOR MRI|U|U|PROXY|OPHTHALMOLOGIST|U|4||88||BASELINE|1962-01-10|
TRIAL STUDY 134XCP|TR|231D401F-CA93-49E0-AC5C-C7F636343D2F|5||||||VSLPIND|VESSEL PATENCY INDICATOR||MG|FURTHER ENLARGEMENT FROM NADIR||PL|NOT DONE|||LAPAROSCOPY|Y|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||TREATMENT|1969-09-24|
TRIAL STUDY 134XCP|TR|2704A3C0-3345-48E5-AC9B-C00EA51AB085|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||TSP|PALPABLE||UG/M2/DAY|NOT DONE|||CYSTOMETRY|Y|NA|SPOUSE|PEDIATRIC NEUROLOGIST|N|1||38||TREATMENT|1964-02-10|
TRIAL STUDY 134XCP|TR|2704A3C0-3345-48E5-AC9B-C00EA51AB085|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MEQ/MMOL|UNCHANGED||ML/KG|NOT DONE|||MECHANICAL CLOT DETECTION|N|NA|DOMESTIC PARTNER|RATER 2|U|2||58||RUN-IN|1966-11-23|
TRIAL STUDY 134XCP|TR|2704A3C0-3345-48E5-AC9B-C00EA51AB085|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MMOL/MIN/KPA|NON-PATHOLOGICAL||M2|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||LONG-TERM FOLLOW-UP|1966-12-24|
TRIAL STUDY 134XCP|TR|2704A3C0-3345-48E5-AC9B-C00EA51AB085|4||||||CALCFIND|CALCIFICATION INDICATOR||TRACE|NORMAL||MMHG*MIN/L|NOT DONE|||MALDI-TOF|NA|Y|ADJUDICATOR|RATER 2|N|4||88||WASHOUT|1963-07-03|
TRIAL STUDY 134XCP|TR|2704A3C0-3345-48E5-AC9B-C00EA51AB085|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UG/KG|NONPALPABLE||MS2|NOT DONE|||LEAD CITRATE STAIN|Y|N|CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|5||7||INDUCTION TREATMENT|1960-10-28|
TRIAL STUDY 134XCP|TR|2F636370-94FE-4BC0-9E16-DDD42D19A985|1||||||LMBFLIND|LIMB FAILURE INDICATOR||FG|FURTHER ENLARGEMENT||BQ/L|NOT DONE|||SNP ARRAY|N|NA|SPOUSE|NEUROLOGIST 2|U|1||38||OBSERVATION|1968-02-01|
TRIAL STUDY 134XCP|TR|2F636370-94FE-4BC0-9E16-DDD42D19A985|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||STEPS/MIN|NON-PATHOLOGICAL||NEEDLE GAUGE|NOT DONE|||PHOTOGRAPHY|N|N|HEALTH CARE PROFESSIONAL|RATER 1|Y|2||58||LONG-TERM FOLLOW-UP|1968-11-18|
TRIAL STUDY 134XCP|TR|2F636370-94FE-4BC0-9E16-DDD42D19A985|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||M/SEC|ABSENT||KDA|NOT DONE|||EPSILOMETER|NA|NA|INDEPENDENT ASSESSOR|READER 3|NA|3||39||OBSERVATION|1966-11-25|
TRIAL STUDY 134XCP|TR|2F636370-94FE-4BC0-9E16-DDD42D19A985|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||/10^4|DIFFUSELY INCREASED||EIA UNIT|NOT DONE|||ALCIAN BLUE STAIN|U|NA|PROXY|DERMATOLOGIST|NA|4||88||FOLLOW-UP|1968-12-19|
TRIAL STUDY 134XCP|TR|2F636370-94FE-4BC0-9E16-DDD42D19A985|5||||||VOLUME|VOLUME||CAPSULE|DECREASED||MNFI|NOT DONE|||MS/MS|N|U|FAMILY MEMBER|ADJUDICATOR|N|5||7||OBSERVATION|1968-08-10|
TRIAL STUDY 134XCP|TR|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|1||||||RADIODEN|RADIODENSITY||MANSON U/ML|ABSENT||UMOL/L/MIN|NOT DONE|||DIRECT SEQUENCING|Y|N|CHILD|READER|Y|1||38||INDUCTION TREATMENT|1972-11-06|
TRIAL STUDY 134XCP|TR|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|2||||||VOLUME|VOLUME||GMFI|NON-PATHOLOGICAL||MG/G/MIN|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|NA|Y|ADJUDICATOR|RATER|Y|2||58||BASELINE|1973-02-25|
TRIAL STUDY 134XCP|TR|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||SFC/10^6 PBMC|PALPABLE||CI/MG|NOT DONE|||FUNDUS PHOTOGRAPHY|N|Y|PROXY|READER 2|N|3||39||WASHOUT|1967-07-19|
TRIAL STUDY 134XCP|TR|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|4||||||AREA|AREA||DRAM|FOCALLY INCREASED||CFU/G|NOT DONE|||KLEIHAUER-BETKE|NA|N|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|4||88||TREATMENT|1972-03-21|
TRIAL STUDY 134XCP|TR|39445F0B-0D22-4B4F-B4AE-C5A90F28F735|5||||||LESFLIND|LESION FAILURE INDICATOR||UCI|INCREASED||ENZYME U|NOT DONE|||RAJI CELL EIA|U|N|INDEPENDENT ASSESSOR|ADJUDICATOR|U|5||7||OPEN LABEL TREATMENT|1970-01-11|
TRIAL STUDY 134XCP|TR|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||GPELISA UNIT/ML|ABSENT||CI/MG|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|NA|U|SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|1||38||WASHOUT|1965-07-11|
TRIAL STUDY 134XCP|TR|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||U/MG|PALPABLE||CI/KG|NOT DONE|||PHASE-CONTRAST MRI|NA|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|2||58||BASELINE|1964-09-03|
TRIAL STUDY 134XCP|TR|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|3||||||BNLNUM|NUMBER OF BONE LESIONS||10^3/HPF|UNCHANGED||100 IU/ML|NOT DONE|||MASS SPECTROMETRY|NA|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1967-10-16|
TRIAL STUDY 134XCP|TR|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||S^-1(%O2)^-1|ENLARGEMENT||UMOL/DL|NOT DONE|||PALM METHOD|NA|Y|DOMESTIC PARTNER|CARDIOLOGIST|Y|4||88||TREATMENT|1972-09-14|
TRIAL STUDY 134XCP|TR|BB7AC683-29D3-4EF7-BA05-A03DE1FB8966|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/M2/MIN|ABSENT||WAFER|NOT DONE|||TRICHROME STAIN|U|U|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|5||7||BASELINE|1971-07-26|
TRIAL STUDY 134XCP|TR|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||%(W/V)|PATHOLOGICAL||CAPFUL|NOT DONE|||MALDI-TOF|U|N|DOMESTIC PARTNER|ADJUDICATOR 3|U|1||38||BLINDED TREATMENT|1965-02-09|
TRIAL STUDY 134XCP|TR|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6 CFU/G|EQUIVOCAL||NG|NOT DONE|||STRESS ECHOCARDIOGRAPHY|NA|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||BASELINE|1970-03-05|
TRIAL STUDY 134XCP|TR|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CYCLE/MIN|NORMAL||PKAT/L|NOT DONE|||IMMUNOTURBIDIMETRY|NA|N|FAMILY MEMBER|NEUROLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1973-07-08|
TRIAL STUDY 134XCP|TR|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||TCID 50/DOSE|ENLARGEMENT FROM NADIR||DNA COPIES/UG|NOT DONE|||GRADIENT DIFFUSION|N|Y|INTERVIEWER|ADJUDICATOR 2|Y|4||88||RUN-IN|1960-10-15|
TRIAL STUDY 134XCP|TR|4BB1CEB1-6D60-48D8-BED0-EFA03F873B50|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MCI/KG|DECREASED||10^8 PFU|NOT DONE|||ELASTOGRAPHY|Y|Y|GUARDIAN|ONCOLOGIST 1|NA|5||7||SCREENING|1962-07-25|
TRIAL STUDY 134XCP|TR|A1FAB383-1757-4832-B888-90C133842EF8|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||IN2|FURTHER ENLARGEMENT FROM NADIR||% INHIBITION|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|Y|INVESTIGATOR|ADJUDICATOR 2|NA|1||38||FOLLOW-UP|1960-03-24|
TRIAL STUDY 134XCP|TR|A1FAB383-1757-4832-B888-90C133842EF8|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/2500 WBC|TUMOR MERGED||CI/UG|NOT DONE|||GC/MS|NA|N|PROXY|DERMATOLOGIST|Y|2||58||INDUCTION TREATMENT|1964-03-16|
TRIAL STUDY 134XCP|TR|A1FAB383-1757-4832-B888-90C133842EF8|3||||||PALPSTAT|PALPABLE STATE||GY/H|ENLARGEMENT FROM NADIR||CL|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|N|CLINICAL RESEARCH ASSOCIATE|READER 3|NA|3||39||OBSERVATION|1969-04-05|
TRIAL STUDY 134XCP|TR|A1FAB383-1757-4832-B888-90C133842EF8|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^5/HPF|FURTHER ENLARGEMENT||MEQ/DAY|NOT DONE|||PHOROPTER|N|U|GUARDIAN|RATER|NA|4||88||SCREENING|1973-08-19|
TRIAL STUDY 134XCP|TR|A1FAB383-1757-4832-B888-90C133842EF8|5||||||LPERP|LONGEST PERPENDICULAR||CIGAR|ENLARGEMENT FROM NADIR||NFIU|NOT DONE|||ELECTROCHEMILUMINESCENCE|NA|Y|CAREGIVER|ADJUDICATOR 2|Y|5||7||FOLLOW-UP|1970-04-05|
TRIAL STUDY 134XCP|TR|72AA1945-E676-4485-BD7F-6B969E314D83|1||||||CALCFIND|CALCIFICATION INDICATOR||UMOL/L/MIN|FOCALLY INCREASED||PPB|NOT DONE|||DUKE INCISION METHOD|Y|Y|GUARDIAN|OTOLARYNGOLOGIST|N|1||38||SCREENING|1963-08-13|
TRIAL STUDY 134XCP|TR|72AA1945-E676-4485-BD7F-6B969E314D83|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||TUBERCULIN UNIT|NON-PATHOLOGICAL||MGEQ|NOT DONE|||CENTRIFUGATION|Y|Y|PARENT|READER 2|U|2||58||WASHOUT|1961-04-04|
TRIAL STUDY 134XCP|TR|72AA1945-E676-4485-BD7F-6B969E314D83|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||HZ|UNEQUIVOCAL||UEQ/L|NOT DONE|||NEPHELOMETRY|U|N|VENDOR|PATHOLOGIST|N|3||39||TREATMENT|1967-07-21|
TRIAL STUDY 134XCP|TR|72AA1945-E676-4485-BD7F-6B969E314D83|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||RFU|UNCHANGED||MET|NOT DONE|||PALPATION|U|Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|4||88||RUN-IN|1962-02-01|
TRIAL STUDY 134XCP|TR|72AA1945-E676-4485-BD7F-6B969E314D83|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||UCI|ENLARGEMENT FROM NADIR||DL|NOT DONE|||IHC|U|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|5||7||LONG-TERM FOLLOW-UP|1968-11-14|
TRIAL STUDY 134XCP|TR|B297C689-0D99-4E36-9F27-F93D4F43E2DD|1||||||DIAMETER|DIAMETER||UMOL/MIN|PALPABLE||STEPS/MIN|NOT DONE|||AUTOMATED COUNT|Y|N|PROXY|READER 3|NA|1||38||RUN-IN|1964-10-10|
TRIAL STUDY 134XCP|TR|B297C689-0D99-4E36-9F27-F93D4F43E2DD|2||||||NEWCONF|NEW TUMOR CONFIRMED||UEQ|NORMAL||LOG10 COPIES/ML|NOT DONE|||TOTAL BODY IRRADIATION|Y|N|FRIEND|PATHOLOGIST 1|Y|2||58||OBSERVATION|1970-10-02|
TRIAL STUDY 134XCP|TR|B297C689-0D99-4E36-9F27-F93D4F43E2DD|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||K|NONPALPABLE||DNA COPIES/ML|NOT DONE|||WHOLE GENOME SEQUENCING|Y|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|3||39||WASHOUT|1973-05-08|
TRIAL STUDY 134XCP|TR|B297C689-0D99-4E36-9F27-F93D4F43E2DD|4||||||VSLPIND|VESSEL PATENCY INDICATOR||ML/(MIN*100ML)|DIFFUSELY INCREASED||MONTHS|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|U|N|ADJUDICATOR|ONCOLOGIST 2|NA|4||88||OBSERVATION|1963-12-29|
TRIAL STUDY 134XCP|TR|B297C689-0D99-4E36-9F27-F93D4F43E2DD|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||ML/M2/MIN|UNCHANGED||MET*MIN|NOT DONE|||MICROARRAY|NA|N|PROXY|ONCOLOGIST|NA|5||7||BASELINE|1972-03-09|
TRIAL STUDY 134XCP|TR|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||PRESSOR UNITS|EQUIVOCAL||ARBITRARY U|NOT DONE|||RADIOGRAPHY|NA|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||CONTINUATION TREATMENT|1972-02-03|
TRIAL STUDY 134XCP|TR|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||RFU|FURTHER ENLARGEMENT FROM NADIR||/7.5 ML|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|N|NA|PROXY|PEDIATRIC NEUROLOGIST|N|2||58||BLINDED TREATMENT|1960-09-11|
TRIAL STUDY 134XCP|TR|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^3/HPF|ENLARGEMENT FROM NADIR||UG/MOL|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|NA|VENDOR|RADIOLOGIST|NA|3||39||INDUCTION TREATMENT|1961-02-15|
TRIAL STUDY 134XCP|TR|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||PACK|FURTHER ENLARGEMENT FROM NADIR||/10^5|NOT DONE|||FARR ASSAY|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|4||88||BASELINE|1966-06-26|
TRIAL STUDY 134XCP|TR|BEED1D48-A50C-4B72-8815-B8CA9F90D01E|5||||||BNLNUM|NUMBER OF BONE LESIONS||VP/DOSE|FURTHER ENLARGEMENT FROM NADIR||10^8 PFU|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|U|CLINICAL RESEARCH COORDINATOR|READER 3|N|5||7||RUN-IN|1966-05-01|
TRIAL STUDY 134XCP|TR|3F18534E-367D-45C8-BB08-C82151A0CF00|1||||||LPERP|LONGEST PERPENDICULAR||BU/ML|FOCALLY INCREASED||KEV|NOT DONE|||MICROSCOPY|Y|U|FRIEND|ADJUDICATOR 3|Y|1||38||OBSERVATION|1965-10-12|
TRIAL STUDY 134XCP|TR|3F18534E-367D-45C8-BB08-C82151A0CF00|2||||||LPERP|LONGEST PERPENDICULAR||NMOL/KG/DAY|PRESENT||P|NOT DONE|||EEG|Y|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|2||58||SCREENING|1967-08-23|
TRIAL STUDY 134XCP|TR|3F18534E-367D-45C8-BB08-C82151A0CF00|3||||||NEWCONF|NEW TUMOR CONFIRMED||MET*MIN|UNEQUIVOCAL||BU|NOT DONE|||CONTRAST ENHANCED X-RAY|N|N|CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|3||39||OPEN LABEL TREATMENT|1963-07-18|
TRIAL STUDY 134XCP|TR|3F18534E-367D-45C8-BB08-C82151A0CF00|4||||||LDIAM|LONGEST DIAMETER||MET|ENLARGEMENT||NKAT/G HB|NOT DONE|||FUNCTIONAL MRI|U|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|4||88||BLINDED TREATMENT|1962-02-21|
TRIAL STUDY 134XCP|TR|3F18534E-367D-45C8-BB08-C82151A0CF00|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||IU/DAY|ABSENT||EJACULATE U|NOT DONE|||AUDIOMETRY|U|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|5||7||TREATMENT|1966-11-15|
TRIAL STUDY 134XCP|TR|81C10FB0-3B47-46D8-B8B7-9C772246CA55|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UG/KG/MIN|EQUIVOCAL||MG/H|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|N|NA|INTERVIEWER|NEUROLOGIST 1|N|1||38||WASHOUT|1961-09-23|
TRIAL STUDY 134XCP|TR|81C10FB0-3B47-46D8-B8B7-9C772246CA55|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||AMOL|UNCHANGED||KEV|NOT DONE|||TEST STRIP|N|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1973-08-30|
TRIAL STUDY 134XCP|TR|81C10FB0-3B47-46D8-B8B7-9C772246CA55|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||U/G/H|NORMAL||%(V/V)|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|Y|DOMESTIC PARTNER|NEUROLOGIST 1|U|3||39||BASELINE|1968-09-29|
TRIAL STUDY 134XCP|TR|81C10FB0-3B47-46D8-B8B7-9C772246CA55|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||/4.0 ML|PALPABLE||STRIP|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|N|U|SIBLING|NEUROLOGIST|U|4||88||WASHOUT|1969-09-11|
TRIAL STUDY 134XCP|TR|81C10FB0-3B47-46D8-B8B7-9C772246CA55|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||U/G/H|ENLARGEMENT||U/10^12 RBC|NOT DONE|||DOUBLE IMMUNODIFFUSION|N|U|DOMESTIC PARTNER|UROLOGIST|NA|5||7||TREATMENT|1969-10-24|
TRIAL STUDY 134XCP|TR|67C99F41-D839-4B8E-9220-6EC161FCD457|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CYCLE/MIN|NONPALPABLE||ML/KG/MIN|NOT DONE|||SPECT/CT SCAN|U|N|PARENT|OPHTHALMOLOGIST|U|1||38||TREATMENT|1961-01-28|
TRIAL STUDY 134XCP|TR|67C99F41-D839-4B8E-9220-6EC161FCD457|2||||||LESFLIND|LESION FAILURE INDICATOR||ML/CAGE|NONPALPABLE||KV|NOT DONE|||CLIP|Y|Y|ADJUDICATOR|ADJUDICATOR 1|N|2||58||WASHOUT|1971-10-11|
TRIAL STUDY 134XCP|TR|67C99F41-D839-4B8E-9220-6EC161FCD457|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ABSORBANCE U|NON-PATHOLOGICAL||10^7 PFU|NOT DONE|||THICK SMEAR|N|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|U|3||39||FOLLOW-UP|1966-10-29|
TRIAL STUDY 134XCP|TR|67C99F41-D839-4B8E-9220-6EC161FCD457|4||||||ORSTATE|ORGAN STATE||TABLET|NORMAL||/200 HPFS|NOT DONE|||MICROBIAL CULTURE, SOLID|N|U|ADJUDICATOR|READER 3|Y|4||88||BASELINE|1972-11-20|
TRIAL STUDY 134XCP|TR|67C99F41-D839-4B8E-9220-6EC161FCD457|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||/100 WBC|EQUIVOCAL||10^9/L|NOT DONE|||FLUOROSCOPY|NA|U|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|5||7||INDUCTION TREATMENT|1972-09-21|
TRIAL STUDY 134XCP|TR|76B9C25F-B418-4979-9E18-4372C8AA700C|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ANTI-XA IU|FURTHER ENLARGEMENT||APL U/ML|NOT DONE|||FLUORESCENT MICROSCOPY|U|NA|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|N|1||38||INDUCTION TREATMENT|1966-11-08|
TRIAL STUDY 134XCP|TR|76B9C25F-B418-4979-9E18-4372C8AA700C|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||LOZENGE|FURTHER ENLARGEMENT FROM NADIR||MV2/HZ|NOT DONE|||CELL OF ORIGIN ASSAY|Y|U|FRIEND|ONCOLOGIST|NA|2||58||CONTINUATION TREATMENT|1973-02-10|
TRIAL STUDY 134XCP|TR|76B9C25F-B418-4979-9E18-4372C8AA700C|3||||||CALCFIND|CALCIFICATION INDICATOR||EID 50/ML|PRESENT||HZ|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|N|GUARDIAN|RADIOLOGIST 1|U|3||39||SCREENING|1960-12-14|
TRIAL STUDY 134XCP|TR|76B9C25F-B418-4979-9E18-4372C8AA700C|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MM/SEC|NON-PATHOLOGICAL||SUPPOSITORY|NOT DONE|||FLUORIMETRY|N|U|PARENT|ENDOCRINOLOGIST|NA|4||88||BASELINE|1971-04-22|
TRIAL STUDY 134XCP|TR|76B9C25F-B418-4979-9E18-4372C8AA700C|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MM/MIN|UNEQUIVOCAL||10^6 ORGANISMS/G|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|U|HEALTH CARE PROFESSIONAL|READER 2|N|5||7||SCREENING|1965-04-27|
TRIAL STUDY 134XCP|TR|9F622B53-71F8-4362-99A5-251993E3A946|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||KIT|ENLARGEMENT FROM NADIR||FMOL|NOT DONE|||CONFOCAL MICROSCOPY|U|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|1||38||OPEN LABEL TREATMENT|1970-07-31|
TRIAL STUDY 134XCP|TR|9F622B53-71F8-4362-99A5-251993E3A946|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MPL U|DECREASED||UMOL/MIN|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1964-05-16|
TRIAL STUDY 134XCP|TR|9F622B53-71F8-4362-99A5-251993E3A946|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||U/M2/DAY|TUMOR MERGED||U/10^12 RBC|NOT DONE|||KINYOUN STAIN|Y|U|INVESTIGATOR|RATER|U|3||39||INDUCTION TREATMENT|1971-10-01|
TRIAL STUDY 134XCP|TR|9F622B53-71F8-4362-99A5-251993E3A946|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||LINEAR FT*LB|ENLARGEMENT FROM NADIR||CM|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|Y|PROXY|ADJUDICATOR 3|N|4||88||OPEN LABEL TREATMENT|1960-12-29|
TRIAL STUDY 134XCP|TR|9F622B53-71F8-4362-99A5-251993E3A946|5||||||VOLUME|VOLUME||GBQ/UG|UNCHANGED||BQ/KG|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|N|STUDY SUBJECT|PATHOLOGIST|U|5||7||BLINDED TREATMENT|1964-04-10|
TRIAL STUDY 134XCP|TR|8F2DC6EB-0264-4112-B379-17896F4266E4|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||%/MIN|INCREASED||UEQ/L|NOT DONE|||LC/MS/MS|NA|Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|Y|1||38||OBSERVATION|1968-06-27|
TRIAL STUDY 134XCP|TR|8F2DC6EB-0264-4112-B379-17896F4266E4|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||V/V|TUMOR MERGED||UMOL|NOT DONE|||NUCLEIC ACID SEQUENCING|U|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||FOLLOW-UP|1972-02-13|
TRIAL STUDY 134XCP|TR|8F2DC6EB-0264-4112-B379-17896F4266E4|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||CIGAR|NORMAL||UG|NOT DONE|||SNP ARRAY|Y|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|3||39||WASHOUT|1973-01-11|
TRIAL STUDY 134XCP|TR|8F2DC6EB-0264-4112-B379-17896F4266E4|4||||||CALCFIND|CALCIFICATION INDICATOR||G/DL|NONPALPABLE||KBQ/UL|NOT DONE|||ELECTRONEUROGRAPHY|U|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||INDUCTION TREATMENT|1970-05-24|
TRIAL STUDY 134XCP|TR|8F2DC6EB-0264-4112-B379-17896F4266E4|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||CCID 50/DOSE|ENLARGEMENT||CYLINDER|NOT DONE|||PET/SPECT SCAN|U|U|FRIEND|PATHOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1961-09-07|
TRIAL STUDY 134XCP|TR|448246D1-5625-4F69-B214-3A8848E86C28|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||PACK|ENLARGEMENT||NFIU|NOT DONE|||CELLULOSE TAPE|Y|NA|FAMILY MEMBER|RADIOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1963-11-11|
TRIAL STUDY 134XCP|TR|448246D1-5625-4F69-B214-3A8848E86C28|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ROENTGEN|ABSENT||PA|NOT DONE|||TRICHROME STAIN|N|N|ADJUDICATION COMMITTEE|NEUROLOGIST 1|NA|2||58||FOLLOW-UP|1961-08-12|
TRIAL STUDY 134XCP|TR|448246D1-5625-4F69-B214-3A8848E86C28|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||ML/ANIMAL/WK|NORMAL||ML/DL|NOT DONE|||FARR ASSAY|Y|NA|PARENT|RATER 2|U|3||39||LONG-TERM FOLLOW-UP|1971-07-08|
TRIAL STUDY 134XCP|TR|448246D1-5625-4F69-B214-3A8848E86C28|4||||||VSLPIND|VESSEL PATENCY INDICATOR||UG/L DDU|NON-PATHOLOGICAL||TITER|NOT DONE|||OLIGO ACGH|N|N|CLINICAL RESEARCH ASSOCIATE|INTERNIST|Y|4||88||OBSERVATION|1962-11-26|
TRIAL STUDY 134XCP|TR|448246D1-5625-4F69-B214-3A8848E86C28|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||WEEKS|PRESENT||PT_US|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|U|STUDY SUBJECT|ONCOLOGIST 2|N|5||7||CONTINUATION TREATMENT|1969-01-01|
TRIAL STUDY 134XCP|TR|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||ML/S|NONPALPABLE||USIEMENS|NOT DONE|||TRIPLE-PHASE MRI SCAN|N|U|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|1||38||BASELINE|1961-08-18|
TRIAL STUDY 134XCP|TR|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML/G/MIN|NON-PATHOLOGICAL||NMOL/ML/MIN|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|N|Y|INTERVIEWER|NEUROLOGIST|Y|2||58||OBSERVATION|1971-01-18|
TRIAL STUDY 134XCP|TR|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||WEEKS|ENLARGEMENT FROM NADIR||EQ|NOT DONE|||NEPHELOMETRY|Y|N|SPOUSE|RATER 2|U|3||39||OBSERVATION|1967-08-01|
TRIAL STUDY 134XCP|TR|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||VIAL|ENLARGEMENT FROM NADIR||TITER|NOT DONE|||PH METER MEASUREMENT METHOD|U|U|CHILD|READER 3|Y|4||88||SCREENING|1960-04-25|
TRIAL STUDY 134XCP|TR|F1D22A3B-8514-4036-BBE5-6765B2F0EBB6|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||G/G|PALPABLE||10^6/L|NOT DONE|||PH METER MEASUREMENT METHOD|NA|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||OBSERVATION|1965-12-14|
TRIAL STUDY 134XCP|TR|27DDBB16-ED11-45B6-987D-FB0D8223B993|1||||||AREA|AREA||AFU|FURTHER ENLARGEMENT FROM NADIR||ML/KG/DAY|NOT DONE|||FLOW MICROSCOPY|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|1||38||INDUCTION TREATMENT|1971-10-07|
TRIAL STUDY 134XCP|TR|27DDBB16-ED11-45B6-987D-FB0D8223B993|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||GMFI|UNEQUIVOCAL||BQ/KG|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|N|NA|CAREGIVER|DERMATOLOGIST|Y|2||58||CONTINUATION TREATMENT|1963-11-30|
TRIAL STUDY 134XCP|TR|27DDBB16-ED11-45B6-987D-FB0D8223B993|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PMOL/DL|NORMAL||VIAL|NOT DONE|||LIGHT MICROSCOPY|NA|U|GUARDIAN|ADJUDICATOR 1|NA|3||39||SCREENING|1960-10-28|
TRIAL STUDY 134XCP|TR|27DDBB16-ED11-45B6-987D-FB0D8223B993|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PPM|ABSENT||MG/G/MIN|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|U|U|INTERVIEWER|RATER|U|4||88||INDUCTION TREATMENT|1960-03-31|
TRIAL STUDY 134XCP|TR|27DDBB16-ED11-45B6-987D-FB0D8223B993|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||LOG10 PFU|PRESENT||GAUSS|NOT DONE|||DNA MICROARRAY|N|Y|SIBLING|NEUROLOGIST|Y|5||7||CONTINUATION TREATMENT|1963-04-18|
TRIAL STUDY 134XCP|TR|5545846C-F90F-4346-A075-05999641B872|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||BQ/G|PATHOLOGICAL||RPM|NOT DONE|||SANGER SEQUENCING|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 2|U|1||38||OBSERVATION|1961-07-08|
TRIAL STUDY 134XCP|TR|5545846C-F90F-4346-A075-05999641B872|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||DRAM|ENLARGEMENT||MIN|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|Y|Y|INTERVIEWER|READER 2|NA|2||58||OPEN LABEL TREATMENT|1969-03-23|
TRIAL STUDY 134XCP|TR|5545846C-F90F-4346-A075-05999641B872|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||IMPLANT|TUMOR MERGED||PFU/ANIMAL|NOT DONE|||PUPILLOMETRY|Y|N|CAREGIVER|RATER|NA|3||39||TREATMENT|1970-03-13|
TRIAL STUDY 134XCP|TR|5545846C-F90F-4346-A075-05999641B872|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PACK|PALPABLE||CARTRIDGE|NOT DONE|||EIA|NA|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||LONG-TERM FOLLOW-UP|1972-12-31|
TRIAL STUDY 134XCP|TR|5545846C-F90F-4346-A075-05999641B872|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||EID 50/ML|UNCHANGED||ML/CM3/MIN|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|U|CAREGIVER|READER 2|U|5||7||TREATMENT|1965-02-05|
TRIAL STUDY 134XCP|TR|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||DPM|PRESENT||IU|NOT DONE|||SNP ARRAY|U|U|INVESTIGATOR|RATER 1|N|1||38||SCREENING|1960-10-29|
TRIAL STUDY 134XCP|TR|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||RNA COPIES/ML|ENLARGEMENT FROM NADIR||LOG10 CCID 50/DOSE|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|Y|NA|PARENT|FORENSIC PATHOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1968-06-10|
TRIAL STUDY 134XCP|TR|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||/10^5|NON-PATHOLOGICAL||STRIP|NOT DONE|||ICC|NA|U|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|3||39||WASHOUT|1964-10-19|
TRIAL STUDY 134XCP|TR|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MG/CM2|FOCALLY INCREASED||MG/G/H|NOT DONE|||KLEIHAUER-BETKE|U|Y|GUARDIAN|READER 3|NA|4||88||RUN-IN|1966-02-22|
TRIAL STUDY 134XCP|TR|F5E96D41-8C4C-45E4-9FB8-C6513C1DE4C1|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||LOG10 ELISA UNIT/DOSE|UNCHANGED||NMOL BCE/MMOL|NOT DONE|||OSCILLOMETRY|U|NA|CAREGIVER|OPTOMETRIST|NA|5||7||SCREENING|1972-08-01|
TRIAL STUDY 134XCP|TR|111541DB-D863-4C68-9E62-B8741A62401C|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||/H|NONPALPABLE||BE/ML|NOT DONE|||U-HPLC/MS/MS|Y|NA|FRIEND|PATHOLOGIST|NA|1||38||FOLLOW-UP|1969-06-18|
TRIAL STUDY 134XCP|TR|111541DB-D863-4C68-9E62-B8741A62401C|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||L/S/KPA|PRESENT||DROP|NOT DONE|||CORONARY ANGIOGRAPHY|N|U|ADJUDICATION COMMITTEE|ONCOLOGIST|U|2||58||FOLLOW-UP|1960-11-24|
TRIAL STUDY 134XCP|TR|111541DB-D863-4C68-9E62-B8741A62401C|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||IU/G HB|DECREASED||VIAL|NOT DONE|||LASER CAPTURE MICRODISSECTION|U|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||WASHOUT|1969-12-10|
TRIAL STUDY 134XCP|TR|111541DB-D863-4C68-9E62-B8741A62401C|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MG/CM2|UNEQUIVOCAL||%/MIN|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|N|U|FRIEND|READER 2|Y|4||88||CONTINUATION TREATMENT|1963-12-25|
TRIAL STUDY 134XCP|TR|111541DB-D863-4C68-9E62-B8741A62401C|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MEQ/UL|FURTHER ENLARGEMENT FROM NADIR||10^6 IU/ML|NOT DONE|||TRIPLE-PHASE MRI SCAN|U|N|GUARDIAN|CARDIOLOGIST|NA|5||7||INDUCTION TREATMENT|1960-09-05|
TRIAL STUDY 134XCP|TR|5095C113-7278-4D41-B860-0DF6B9B98738|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||10^3 CFU|NON-PATHOLOGICAL||SHOCK WAVE|NOT DONE|||MAPH|U|Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||BASELINE|1972-03-21|
TRIAL STUDY 134XCP|TR|5095C113-7278-4D41-B860-0DF6B9B98738|2||||||VSLPIND|VESSEL PATENCY INDICATOR||EU|FOCALLY INCREASED||L/MIN/M2|NOT DONE|||DC SHEATH FLOW|Y|U|FRIEND|READER|NA|2||58||BASELINE|1963-06-12|
TRIAL STUDY 134XCP|TR|5095C113-7278-4D41-B860-0DF6B9B98738|3||||||LPERP|LONGEST PERPENDICULAR||10^6 COPIES/ML|UNEQUIVOCAL||OD UNIT|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|N|Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|3||39||RUN-IN|1965-02-04|
TRIAL STUDY 134XCP|TR|5095C113-7278-4D41-B860-0DF6B9B98738|4||||||CALCFIND|CALCIFICATION INDICATOR||MG/KG/MIN|FURTHER ENLARGEMENT FROM NADIR||%(V/V)|NOT DONE|||TOTAL BODY RADIOGRAPHY|Y|U|NON-HEALTH CARE PROFESSIONAL|READER|N|4||88||WASHOUT|1973-01-13|
TRIAL STUDY 134XCP|TR|5095C113-7278-4D41-B860-0DF6B9B98738|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MM/MIN|PALPABLE||M2|NOT DONE|||GRAM STAIN|N|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|5||7||TREATMENT|1967-04-03|
TRIAL STUDY 134XCP|TR|61319D2E-A512-425F-9301-BAD27B5F5C9B|1||||||LMBFLIND|LIMB FAILURE INDICATOR||GBQ|ENLARGEMENT FROM NADIR||H/WK|NOT DONE|||THICK SMEAR|NA|U|CHILD|PATHOLOGIST|N|1||38||BASELINE|1964-09-06|
TRIAL STUDY 134XCP|TR|61319D2E-A512-425F-9301-BAD27B5F5C9B|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MG|FURTHER ENLARGEMENT FROM NADIR||UM/DAY|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|U|NA|SIGNIFICANT OTHER|PATHOLOGIST 2|U|2||58||RUN-IN|1972-08-26|
TRIAL STUDY 134XCP|TR|61319D2E-A512-425F-9301-BAD27B5F5C9B|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||HZ/S|TUMOR MERGED||L/DAY|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|3||39||BLINDED TREATMENT|1970-06-09|
TRIAL STUDY 134XCP|TR|61319D2E-A512-425F-9301-BAD27B5F5C9B|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MG2/DL2|NONPALPABLE||PG/CELL|NOT DONE|||ETDRS EYE CHART|U|U|GUARDIAN|RADIOLOGIST 1|NA|4||88||SCREENING|1966-05-11|
TRIAL STUDY 134XCP|TR|61319D2E-A512-425F-9301-BAD27B5F5C9B|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||UKAT|TUMOR MERGED||ML/CAGE/DAY|NOT DONE|||HPLC/MS|NA|NA|FRIEND|CARDIOLOGIST|Y|5||7||INDUCTION TREATMENT|1970-12-05|
TRIAL STUDY 134XCP|TR|3B865A8F-949B-4B64-A818-85472EABB8FB|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||G/ANIMAL/WK|ENLARGEMENT||KBQ|NOT DONE|||MRI WITHOUT CONTRAST|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|NA|1||38||SCREENING|1970-07-08|
TRIAL STUDY 134XCP|TR|3B865A8F-949B-4B64-A818-85472EABB8FB|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||NMOL BCE/MMOL|NONPALPABLE||10^5/HPF|NOT DONE|||ISHIHARA COLOR PLATES|NA|Y|INVESTIGATOR|PATHOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1968-04-13|
TRIAL STUDY 134XCP|TR|3B865A8F-949B-4B64-A818-85472EABB8FB|3||||||RADIODEN|RADIODENSITY||/40 HPFS|DECREASED||EJACULATE U|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|N|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|3||39||LONG-TERM FOLLOW-UP|1970-01-17|
TRIAL STUDY 134XCP|TR|3B865A8F-949B-4B64-A818-85472EABB8FB|4||||||PALPSTAT|PALPABLE STATE||ABSORBANCE U|DECREASED||V/SEC|NOT DONE|||CALCULATION|NA|NA|PARENT|CLINICAL PATHOLOGIST|Y|4||88||SCREENING|1972-12-24|
TRIAL STUDY 134XCP|TR|3B865A8F-949B-4B64-A818-85472EABB8FB|5||||||LESSCIND|LESION SUCCESS INDICATOR||G/KG/DAY|ENLARGEMENT FROM NADIR||MM2|NOT DONE|||STATIC PERIMETRY|NA|NA|FAMILY MEMBER|ADJUDICATOR 1|U|5||7||OBSERVATION|1967-08-26|
TRIAL STUDY 134XCP|TR|A6909912-22B9-4EE7-AEDF-F791F243A6B7|1||||||ORVERLN|ORGAN VERTICAL LENGTH||APL U/ML|TUMOR MERGED||MMOL2/L2|NOT DONE|||IMMUNOTURBIDIMETRY|Y|Y|FRIEND|PATHOLOGIST 1|Y|1||38||CONTINUATION TREATMENT|1969-02-15|
TRIAL STUDY 134XCP|TR|A6909912-22B9-4EE7-AEDF-F791F243A6B7|2||||||AREA|AREA||U/KG/MIN|NONPALPABLE||10^3 COPIES/ML|NOT DONE|||DUKE INCISION METHOD|U|N|GUARDIAN|MICROSCOPIST 1|Y|2||58||BLINDED TREATMENT|1960-09-22|
TRIAL STUDY 134XCP|TR|A6909912-22B9-4EE7-AEDF-F791F243A6B7|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||KALLIKREIN INHIBITOR UNIT|NON-PATHOLOGICAL||ML/CAGE/DAY|NOT DONE|||PHOTOGRAPHY|Y|N|SPOUSE|ADJUDICATOR 3|N|3||39||CONTINUATION TREATMENT|1967-07-25|
TRIAL STUDY 134XCP|TR|A6909912-22B9-4EE7-AEDF-F791F243A6B7|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^3/L|PALPABLE||ML/S|NOT DONE|||OPTICAL DENSITY MEASUREMENT|N|Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|4||88||OPEN LABEL TREATMENT|1966-07-06|
TRIAL STUDY 134XCP|TR|A6909912-22B9-4EE7-AEDF-F791F243A6B7|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||IN|UNCHANGED||GAUSS|NOT DONE|||BIOPSY|N|U|INVESTIGATOR|ONCOLOGIST 2|N|5||7||INDUCTION TREATMENT|1973-03-20|
TRIAL STUDY 134XCP|TR|83C8AAD3-B22D-42C6-870A-D069FAC601F3|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||S^-1(%O2)^-1|EQUIVOCAL||MMOL/DAY|NOT DONE|||PALM METHOD|U|U|STUDY SUBJECT|RATER 2|NA|1||38||BASELINE|1968-04-22|
TRIAL STUDY 134XCP|TR|83C8AAD3-B22D-42C6-870A-D069FAC601F3|2||||||LESSCIND|LESION SUCCESS INDICATOR||USIEMENS|TUMOR MERGED||COAT|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|N|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|2||58||TREATMENT|1965-05-22|
TRIAL STUDY 134XCP|TR|83C8AAD3-B22D-42C6-870A-D069FAC601F3|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||IN|ENLARGEMENT||MET*H|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|U|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|3||39||BASELINE|1960-07-28|
TRIAL STUDY 134XCP|TR|83C8AAD3-B22D-42C6-870A-D069FAC601F3|4||||||LESFLIND|LESION FAILURE INDICATOR||ML/ANIMAL/WK|FOCALLY INCREASED||ML/G/DAY|NOT DONE|||HPLC|N|N|STUDY SUBJECT|READER|N|4||88||CONTINUATION TREATMENT|1967-04-01|
TRIAL STUDY 134XCP|TR|83C8AAD3-B22D-42C6-870A-D069FAC601F3|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||PMOL/10^9 CELLS|FURTHER ENLARGEMENT FROM NADIR||/KG|NOT DONE|||PET/SPECT SCAN|N|Y|SIGNIFICANT OTHER|PATHOLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1968-08-04|
TRIAL STUDY 134XCP|TR|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/MIN|ENLARGEMENT FROM NADIR||ML/ANIMAL/DAY|NOT DONE|||RADIAL IMMUNODIFFUSION|U|U|GUARDIAN|READER 2|N|1||38||BLINDED TREATMENT|1965-09-24|
TRIAL STUDY 134XCP|TR|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||%/S|NON-PATHOLOGICAL||IU/KG|NOT DONE|||MAMMOGRAPHY|NA|U|PROXY|RATER|N|2||58||INDUCTION TREATMENT|1962-09-30|
TRIAL STUDY 134XCP|TR|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MET|INCREASED||L/H/M2|NOT DONE|||MULTI-SLICE SPIRAL CT|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|3||39||WASHOUT|1964-09-24|
TRIAL STUDY 134XCP|TR|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||HZ|ENLARGEMENT FROM NADIR||MEQ/ML|NOT DONE|||FLUORIMETRY|Y|U|SIBLING|READER 2|Y|4||88||BASELINE|1973-02-07|
TRIAL STUDY 134XCP|TR|4EE77C34-2BA7-482D-81DE-49BBA9AEE4E5|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CUP|FURTHER ENLARGEMENT FROM NADIR||LOG10 IU/ML|NOT DONE|||AUDIOMETRY|N|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|5||7||INDUCTION TREATMENT|1963-02-01|
TRIAL STUDY 134XCP|TR|937BF41A-157D-45F6-9797-2C5D19D100E6|1||||||LDIAM|LONGEST DIAMETER||MDFI|PRESENT||LOG10 TCID 50/DOSE|NOT DONE|||WHOLE GENOME SEQUENCING|NA|U|VENDOR|MICROSCOPIST 2|U|1||38||TREATMENT|1971-08-31|
TRIAL STUDY 134XCP|TR|937BF41A-157D-45F6-9797-2C5D19D100E6|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||CCID 50/ML|UNEQUIVOCAL||PRESSOR UNITS|NOT DONE|||PET/MRI SCAN|NA|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST|N|2||58||RUN-IN|1971-04-08|
TRIAL STUDY 134XCP|TR|937BF41A-157D-45F6-9797-2C5D19D100E6|3||||||SUMDIAM|SUM OF DIAMETER||DAMOL/L|INCREASED||10^6 ORGANISMS|NOT DONE|||TWO-COLOR MICROARRAY|Y|N|ADJUDICATOR|ADJUDICATOR 2|Y|3||39||INDUCTION TREATMENT|1961-10-09|
TRIAL STUDY 134XCP|TR|937BF41A-157D-45F6-9797-2C5D19D100E6|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||DPM|ENLARGEMENT||MCI|NOT DONE|||EIA|N|U|INVESTIGATOR|OPTOMETRIST|N|4||88||CONTINUATION TREATMENT|1972-09-13|
TRIAL STUDY 134XCP|TR|937BF41A-157D-45F6-9797-2C5D19D100E6|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||U/G/H|FURTHER ENLARGEMENT||MMU/ML|NOT DONE|||PHYSICAL EXAMINATION|NA|Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|5||7||INDUCTION TREATMENT|1971-10-27|
TRIAL STUDY 134XCP|TR|1BA56D89-E536-491E-AD6A-190A07331BEA|1||||||SUMDIAM|SUM OF DIAMETER||CS|PRESENT||10^9 ORGANISMS/ML|NOT DONE|||LYMPHANGIOGRAPHY|U|NA|STUDY SUBJECT|HEMATOLOGIST|Y|1||38||RUN-IN|1963-02-09|
TRIAL STUDY 134XCP|TR|1BA56D89-E536-491E-AD6A-190A07331BEA|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||RAD|NONPALPABLE||STRIP|NOT DONE|||SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|N|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|2||58||FOLLOW-UP|1971-04-25|
TRIAL STUDY 134XCP|TR|1BA56D89-E536-491E-AD6A-190A07331BEA|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||RPM|EQUIVOCAL||10^10/L|NOT DONE|||DUKE INCISION METHOD|Y|N|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|3||39||SCREENING|1961-03-26|
TRIAL STUDY 134XCP|TR|1BA56D89-E536-491E-AD6A-190A07331BEA|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||/SEC|NONPALPABLE||INHALATION|NOT DONE|||RAJI CELL RIA|Y|Y|SIGNIFICANT OTHER|READER 3|U|4||88||CONTINUATION TREATMENT|1967-06-26|
TRIAL STUDY 134XCP|TR|1BA56D89-E536-491E-AD6A-190A07331BEA|5||||||SUMDIAM|SUM OF DIAMETER||UG|ABSENT||GY/MIN|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|NA|5||7||FOLLOW-UP|1962-04-15|
TRIAL STUDY 134XCP|TR|BE208D93-7322-427F-A8E5-1DBE5040BE8F|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||/HPF|UNCHANGED||KG/CM2|NOT DONE|||MRI WITHOUT CONTRAST|NA|N|FRIEND|ADJUDICATOR 3|U|1||38||LONG-TERM FOLLOW-UP|1967-08-10|
TRIAL STUDY 134XCP|TR|BE208D93-7322-427F-A8E5-1DBE5040BE8F|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MG/ML/MIN|TUMOR MERGED||NSEC|NOT DONE|||RYAN BLUE STAIN|NA|U|DOMESTIC PARTNER|OPTOMETRIST|N|2||58||FOLLOW-UP|1967-06-04|
TRIAL STUDY 134XCP|TR|BE208D93-7322-427F-A8E5-1DBE5040BE8F|3||||||LPERP|LONGEST PERPENDICULAR||UM2|DIFFUSELY INCREASED||G/ANIMAL/DAY|NOT DONE|||SPECULAR MICROSCOPY|U|U|SIGNIFICANT OTHER|INTERNIST|N|3||39||LONG-TERM FOLLOW-UP|1970-11-08|
TRIAL STUDY 134XCP|TR|BE208D93-7322-427F-A8E5-1DBE5040BE8F|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||BLOCKS|INCREASED||AMFI|NOT DONE|||MICROSCOPY|NA|U|SIBLING|NEUROLOGIST 2|NA|4||88||FOLLOW-UP|1970-11-22|
TRIAL STUDY 134XCP|TR|BE208D93-7322-427F-A8E5-1DBE5040BE8F|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PMOL/10^10 CELLS|NONPALPABLE||RNA COPIES/ML|NOT DONE|||MRI|U|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5||7||INDUCTION TREATMENT|1960-06-10|
TRIAL STUDY 134XCP|TR|A58C5E7B-21EC-4F59-BB74-3264AC945F61|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MMHG|PRESENT||PACK|NOT DONE|||PET/SPECT SCAN|N|U|CLINICAL STUDY SPONSOR|UROLOGIST|Y|1||38||FOLLOW-UP|1968-11-09|
TRIAL STUDY 134XCP|TR|A58C5E7B-21EC-4F59-BB74-3264AC945F61|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ELISA UNIT/ML|INCREASED||SFC/10^6 PBMC|NOT DONE|||SPIRAL CT|Y|NA|DOMESTIC PARTNER|HEMATOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1963-12-28|
TRIAL STUDY 134XCP|TR|A58C5E7B-21EC-4F59-BB74-3264AC945F61|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ML/BREATH|FURTHER ENLARGEMENT FROM NADIR||CM H2O|NOT DONE|||PELLI-ROBSON EYE CHART|NA|Y|GUARDIAN|PATHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1961-01-16|
TRIAL STUDY 134XCP|TR|A58C5E7B-21EC-4F59-BB74-3264AC945F61|4||||||AREA|AREA||10^7 PFU|PATHOLOGICAL||UL/ML|NOT DONE|||MICROBIAL CULTURE, LIQUID|Y|N|CLINICAL STUDY SPONSOR|READER|N|4||88||OPEN LABEL TREATMENT|1960-02-01|
TRIAL STUDY 134XCP|TR|A58C5E7B-21EC-4F59-BB74-3264AC945F61|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||V|DIFFUSELY INCREASED||KG/M2|NOT DONE|||WHOLE GENOME SEQUENCING|NA|N|PROXY|ADJUDICATOR 2|NA|5||7||SCREENING|1965-02-17|
TRIAL STUDY 134XCP|TR|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|1||||||ORSTATE|ORGAN STATE||PG/DL|ENLARGEMENT FROM NADIR||MG/KG/MIN|NOT DONE|||HEMOCYTOMETRY|NA|N|CHILD|CARDIOLOGIST|U|1||38||BLINDED TREATMENT|1960-02-07|
TRIAL STUDY 134XCP|TR|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||UMOL|NORMAL||MS2|NOT DONE|||PHOTOGRAPHY|U|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1971-05-07|
TRIAL STUDY 134XCP|TR|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|3||||||LDIAM|LONGEST DIAMETER||TRANSDUCING UNIT/ML|NONPALPABLE||NEEDLE GAUGE|NOT DONE|||OPHTHALMOSCOPY|Y|U|CAREGIVER|ADJUDICATOR 3|U|3||39||BASELINE|1961-08-23|
TRIAL STUDY 134XCP|TR|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||TROCHE|INCREASED||LOG10 CCID 50/DOSE|NOT DONE|||SANGER SEQUENCING|Y|NA|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|4||88||FOLLOW-UP|1965-12-02|
TRIAL STUDY 134XCP|TR|470EB5DB-57D1-4D39-8C30-1444C88DB4E2|5||||||LNSTATE|LYMPH NODE STATE||IU/MMOL|ENLARGEMENT||LINEAR FT*LB|NOT DONE|||ELECTRONEUROGRAPHY|N|NA|VENDOR|CLINICAL PATHOLOGIST|Y|5||7||WASHOUT|1968-07-06|
TRIAL STUDY 134XCP|TR|434B4F6A-C436-4F92-8FA5-9C2F1964098A|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||DIP|PALPABLE||MG/M2|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|NA|CHILD|RADIOLOGIST 2|N|1||38||INDUCTION TREATMENT|1967-08-15|
TRIAL STUDY 134XCP|TR|434B4F6A-C436-4F92-8FA5-9C2F1964098A|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U/KG/H|FURTHER ENLARGEMENT FROM NADIR||PG/CELL|NOT DONE|||TOTAL BODY RADIOGRAPHY|N|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|U|2||58||BASELINE|1971-02-02|
TRIAL STUDY 134XCP|TR|434B4F6A-C436-4F92-8FA5-9C2F1964098A|3||||||LESFLIND|LESION FAILURE INDICATOR||EJACULATE U|INCREASED||UIU/DL|NOT DONE|||KINYOUN STAIN|NA|U|VENDOR|PEDIATRIC NEUROLOGIST|U|3||39||SCREENING|1972-03-12|
TRIAL STUDY 134XCP|TR|434B4F6A-C436-4F92-8FA5-9C2F1964098A|4||||||LMBFLIND|LIMB FAILURE INDICATOR||MMU/ML|NORMAL||KIT|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|N|N|FAMILY MEMBER|HEMATOLOGIST|U|4||88||OPEN LABEL TREATMENT|1961-05-08|
TRIAL STUDY 134XCP|TR|434B4F6A-C436-4F92-8FA5-9C2F1964098A|5||||||LDIAM|LONGEST DIAMETER||FFU|ABSENT||CD*S/M2|NOT DONE|||CLOT DETECTION|NA|NA|SIBLING|NEUROLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1968-05-18|
TRIAL STUDY 134XCP|TR|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|1||||||VSLPIND|VESSEL PATENCY INDICATOR||IMPLANT|NON-PATHOLOGICAL||UMOL/DL|NOT DONE|||PLETHYSMOGRAPHY|NA|U|INDEPENDENT ASSESSOR|INTERNIST|Y|1||38||LONG-TERM FOLLOW-UP|1962-08-29|
TRIAL STUDY 134XCP|TR|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||COPIES/ML|NONPALPABLE||FG|NOT DONE|||LC-FL|Y|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|2||58||RUN-IN|1964-08-04|
TRIAL STUDY 134XCP|TR|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MPH|FOCALLY INCREASED||EP U|NOT DONE|||PET SCAN|U|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|N|3||39||OBSERVATION|1965-12-01|
TRIAL STUDY 134XCP|TR|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^7 CFU|ENLARGEMENT||CGY|NOT DONE|||SNELLEN EYE CHART|N|NA|STUDY SUBJECT|ONCOLOGIST 2|N|4||88||TREATMENT|1973-04-17|
TRIAL STUDY 134XCP|TR|F50D12BE-0D22-4347-BE0B-A61EF6CC1FC7|5||||||PALPSTAT|PALPABLE STATE||F|NON-PATHOLOGICAL||RAD|NOT DONE|||POTENTIOMETRY|Y|Y|GUARDIAN|MICROSCOPIST 2|Y|5||7||WASHOUT|1972-03-02|
TRIAL STUDY 134XCP|TR|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||NMOL BCE/NMOL|UNCHANGED||UMOL/L|NOT DONE|||IMMUNOBLOT|N|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||INDUCTION TREATMENT|1966-07-07|
TRIAL STUDY 134XCP|TR|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||GAUSS|PATHOLOGICAL||UL/DOSE|NOT DONE|||POLYMERASE CHAIN REACTION|U|N|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1961-07-20|
TRIAL STUDY 134XCP|TR|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PMOL/DAY|ENLARGEMENT||MET*MIN|NOT DONE|||CINEANGIOGRAPHY|U|Y|SPOUSE|DERMATOLOGIST|NA|3||39||BASELINE|1964-08-01|
TRIAL STUDY 134XCP|TR|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MCI|DECREASED||LOZENGE|NOT DONE|||MICRONEUTRALIZATION ASSAY|U|NA|FRIEND|ONCOLOGIST 2|U|4||88||BASELINE|1961-11-09|
TRIAL STUDY 134XCP|TR|EAEE4DF4-21F6-41EA-9CA0-CC49C9B323EB|5||||||VSLPIND|VESSEL PATENCY INDICATOR||CI/ML|NONPALPABLE||10^7/L|NOT DONE|||FLUORIMETRY|NA|N|STUDY SUBJECT|RADIOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1969-01-08|
TRIAL STUDY 134XCP|TR|73C4A4D7-2177-47F3-818A-C0774F5E4A08|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PA|FOCALLY INCREASED||VG/ML|NOT DONE|||PAP STAIN|NA|Y|STUDY SUBJECT|READER 1|NA|1||38||BLINDED TREATMENT|1961-01-06|
TRIAL STUDY 134XCP|TR|73C4A4D7-2177-47F3-818A-C0774F5E4A08|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||10^3 RNA COPIES/ML|ENLARGEMENT||G/M2/DAY|NOT DONE|||PHYSICAL EXAMINATION|NA|NA|ADJUDICATOR|ONCOLOGIST 2|Y|2||58||WASHOUT|1973-03-02|
TRIAL STUDY 134XCP|TR|73C4A4D7-2177-47F3-818A-C0774F5E4A08|3||||||VSLPIND|VESSEL PATENCY INDICATOR||MDFI|FURTHER ENLARGEMENT||MEQ/ML|NOT DONE|||OPHTHALMOSCOPY|N|N|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|3||39||INDUCTION TREATMENT|1967-02-27|
TRIAL STUDY 134XCP|TR|73C4A4D7-2177-47F3-818A-C0774F5E4A08|4||||||CALCFIND|CALCIFICATION INDICATOR||MEQ/L|PATHOLOGICAL||MIN*MG/ML|NOT DONE|||SLOAN LETTER EYE CHART 100%|Y|N|FRIEND|OPHTHALMOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1972-11-06|
TRIAL STUDY 134XCP|TR|73C4A4D7-2177-47F3-818A-C0774F5E4A08|5||||||LDIAM|LONGEST DIAMETER||GENEQ/ML|DIFFUSELY INCREASED||100 IU/ML|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|U|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5||7||RUN-IN|1964-09-19|
TRIAL STUDY 134XCP|TR|4E3929B3-63F2-4E89-8EB4-60991E7284E1|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UG/M2/MIN|FURTHER ENLARGEMENT FROM NADIR||FIU|NOT DONE|||PHOROPTER|U|U|INVESTIGATOR|UROLOGIST|U|1||38||TREATMENT|1960-06-03|
TRIAL STUDY 134XCP|TR|4E3929B3-63F2-4E89-8EB4-60991E7284E1|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UM/S|PALPABLE||CD/M2|NOT DONE|||PET/MRI SCAN|N|U|FRIEND|MICROSCOPIST 2|Y|2||58||TREATMENT|1963-07-08|
TRIAL STUDY 134XCP|TR|4E3929B3-63F2-4E89-8EB4-60991E7284E1|3||||||SUMVOL|SUM OF VOLUME||PHERESIS UNIT|INCREASED||CYLINDER|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|Y|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|3||39||BLINDED TREATMENT|1962-09-20|
TRIAL STUDY 134XCP|TR|4E3929B3-63F2-4E89-8EB4-60991E7284E1|4||||||RADIODEN|RADIODENSITY||MOL/ML|NONPALPABLE||ABSORBANCE U|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|4||88||CONTINUATION TREATMENT|1964-11-26|
TRIAL STUDY 134XCP|TR|4E3929B3-63F2-4E89-8EB4-60991E7284E1|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MIU/L|PALPABLE||U/M2/DAY|NOT DONE|||FLOCCULATION|N|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|5||7||OBSERVATION|1964-02-12|
TRIAL STUDY 134XCP|TR|F26E2F67-3F90-448C-92BB-AD60E71D5664|1||||||ORVERLN|ORGAN VERTICAL LENGTH||V|PATHOLOGICAL||LOG10 COPIES/ML|NOT DONE|||FLOW MICROSCOPY|Y|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|1||38||LONG-TERM FOLLOW-UP|1971-03-04|
TRIAL STUDY 134XCP|TR|F26E2F67-3F90-448C-92BB-AD60E71D5664|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||U/G/DAY|NON-PATHOLOGICAL||UG/MOL|NOT DONE|||CELL OF ORIGIN ASSAY|U|Y|CHILD|FORENSIC PATHOLOGIST|NA|2||58||BASELINE|1966-10-31|
TRIAL STUDY 134XCP|TR|F26E2F67-3F90-448C-92BB-AD60E71D5664|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||/WK|PRESENT||TUBERCULIN UNIT/ML|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|N|Y|INVESTIGATOR|DERMATOLOGIST|NA|3||39||SCREENING|1963-10-19|
TRIAL STUDY 134XCP|TR|F26E2F67-3F90-448C-92BB-AD60E71D5664|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||UG|PATHOLOGICAL||MU/L|NOT DONE|||HPLC-UV|N|Y|CHILD|OPTOMETRIST|N|4||88||OBSERVATION|1967-06-20|
TRIAL STUDY 134XCP|TR|F26E2F67-3F90-448C-92BB-AD60E71D5664|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^3/HPF|FOCALLY INCREASED||MOL|NOT DONE|||KINYOUN STAIN|U|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|5||7||TREATMENT|1966-03-23|
TRIAL STUDY 134XCP|TR|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^3 CFU/G|PATHOLOGICAL||CARTRIDGE|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|N|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|1||38||CONTINUATION TREATMENT|1965-12-22|
TRIAL STUDY 134XCP|TR|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|2||||||AREA|AREA||PG|FOCALLY INCREASED||KBQ/UL|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|N|NA|SIBLING|RADIOLOGIST|U|2||58||OBSERVATION|1968-05-05|
TRIAL STUDY 134XCP|TR|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||SHOCK WAVE|DIFFUSELY INCREASED||CARTRIDGE|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|NA|Y|GUARDIAN|ADJUDICATOR 3|Y|3||39||TREATMENT|1967-04-01|
TRIAL STUDY 134XCP|TR|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||U/G/H|UNCHANGED||/7.5 ML|NOT DONE|||PH METER MEASUREMENT METHOD|N|N|ADJUDICATION COMMITTEE|ADJUDICATOR|U|4||88||TREATMENT|1966-12-28|
TRIAL STUDY 134XCP|TR|3D3F1B3A-DDC4-43C1-A4C1-AA775C3AC980|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||KG/M2|ABSENT||BQ/UL|NOT DONE|||MIGET|NA|N|VENDOR|ADJUDICATOR 2|NA|5||7||INDUCTION TREATMENT|1967-03-21|
TRIAL STUDY 134XCP|TR|F2F1151C-F987-49CE-BC16-719DD339DBE7|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^11/L|EQUIVOCAL||DIP|NOT DONE|||CT SCAN WITHOUT CONTRAST|NA|NA|CAREGIVER|PATHOLOGIST 2|U|1||38||SCREENING|1962-02-16|
TRIAL STUDY 134XCP|TR|F2F1151C-F987-49CE-BC16-719DD339DBE7|2||||||LNSTATE|LYMPH NODE STATE||FT3|EQUIVOCAL||M3|NOT DONE|||GC/MS|U|NA|STUDY SUBJECT|PHYSIOTHERAPIST|NA|2||58||SCREENING|1968-11-21|
TRIAL STUDY 134XCP|TR|F2F1151C-F987-49CE-BC16-719DD339DBE7|3||||||LDIAM|LONGEST DIAMETER||/MONTH|FURTHER ENLARGEMENT||SPRAY|NOT DONE|||PET/MRI SCAN|U|U|PROXY|HEMATOLOGIST|NA|3||39||OBSERVATION|1963-09-15|
TRIAL STUDY 134XCP|TR|F2F1151C-F987-49CE-BC16-719DD339DBE7|4||||||VDIAM|VIABLE DIAMETER||LOG10 CFU/G|NORMAL||10^9 CFU|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|Y|U|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BLINDED TREATMENT|1965-07-22|
TRIAL STUDY 134XCP|TR|F2F1151C-F987-49CE-BC16-719DD339DBE7|5||||||ORVERLN|ORGAN VERTICAL LENGTH||CS|INCREASED||/100 HPFS|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|N|N|GUARDIAN|OPHTHALMOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1962-12-12|
TRIAL STUDY 134XCP|TR|F88FCFA6-90D7-4033-86DF-223A63A6152D|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U.CARR|FURTHER ENLARGEMENT||CARTRIDGE|NOT DONE|||PAP STAIN|N|U|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|1||38||OPEN LABEL TREATMENT|1968-10-29|
TRIAL STUDY 134XCP|TR|F88FCFA6-90D7-4033-86DF-223A63A6152D|2||||||BNLNUM|NUMBER OF BONE LESIONS||CMH2O*S/ML|UNCHANGED||UG/ML/H|NOT DONE|||GC/MS/MS|Y|NA|CLINICAL RESEARCH COORDINATOR|READER 2|NA|2||58||FOLLOW-UP|1965-06-01|
TRIAL STUDY 134XCP|TR|F88FCFA6-90D7-4033-86DF-223A63A6152D|3||||||NEWCONF|NEW TUMOR CONFIRMED||PKAT|FURTHER ENLARGEMENT FROM NADIR||DEG/MM|NOT DONE|||CARDIAC THERMODILUTION|U|Y|PARENT|RADIOLOGIST 2|Y|3||39||CONTINUATION TREATMENT|1964-04-14|
TRIAL STUDY 134XCP|TR|F88FCFA6-90D7-4033-86DF-223A63A6152D|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||NCI|TUMOR MERGED||RNA COPIES/ML|NOT DONE|||MICROBIAL CULTURE, SOLID|NA|N|FRIEND|PEDIATRIC NEUROLOGIST|U|4||88||BASELINE|1968-11-24|
TRIAL STUDY 134XCP|TR|F88FCFA6-90D7-4033-86DF-223A63A6152D|5||||||LNSTATE|LYMPH NODE STATE||MMOL/DAY|EQUIVOCAL||PPB|NOT DONE|||DIRECT SEQUENCING|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|5||7||BLINDED TREATMENT|1964-05-14|
TRIAL STUDY 134XCP|TR|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MEQ/UL|NON-PATHOLOGICAL||ML/H|NOT DONE|||JAEGER EYE CHART|U|U|DOMESTIC PARTNER|ONCOLOGIST 2|U|1||38||INDUCTION TREATMENT|1962-05-26|
TRIAL STUDY 134XCP|TR|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^12 IU/L|DIFFUSELY INCREASED||NEEDLE GAUGE|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|Y|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|2||58||INDUCTION TREATMENT|1970-04-20|
TRIAL STUDY 134XCP|TR|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||%(W/W)|UNEQUIVOCAL||KAT|NOT DONE|||RYAN BLUE STAIN|N|U|NON-HEALTH CARE PROFESSIONAL|RATER|U|3||39||OBSERVATION|1968-02-25|
TRIAL STUDY 134XCP|TR|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||FEU|NON-PATHOLOGICAL||SBE/ML|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|N|NA|CHILD|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BASELINE|1962-05-27|
TRIAL STUDY 134XCP|TR|F8D7D2AA-6125-450D-B71D-6109FFA1AC3E|5||||||ORSTATE|ORGAN STATE||BREATHS/30S|DIFFUSELY INCREASED||NG/MOL|NOT DONE|||PHOTOMETRY|Y|U|SIBLING|ADJUDICATOR|N|5||7||OBSERVATION|1971-07-09|
TRIAL STUDY 134XCP|TR|7D35B2F5-7334-448B-B4E1-14671B850B6A|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||L/S/KPA|UNEQUIVOCAL||BOX|NOT DONE|||DIFFUSION WEIGHTED MRI|NA|NA|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1962-09-12|
TRIAL STUDY 134XCP|TR|7D35B2F5-7334-448B-B4E1-14671B850B6A|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LINEAR FT*LB|ABSENT||PACKET|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|U|U|CHILD|READER 2|N|2||58||BLINDED TREATMENT|1969-12-07|
TRIAL STUDY 134XCP|TR|7D35B2F5-7334-448B-B4E1-14671B850B6A|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UMOL/MG/MIN|ENLARGEMENT||U/M2/H|NOT DONE|||HEMOCYTOMETRY|Y|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3||39||TREATMENT|1964-09-26|
TRIAL STUDY 134XCP|TR|7D35B2F5-7334-448B-B4E1-14671B850B6A|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||BQ/G|NORMAL||TBSP|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|N|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|4||88||BASELINE|1973-08-29|
TRIAL STUDY 134XCP|TR|7D35B2F5-7334-448B-B4E1-14671B850B6A|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UMOL/MOL|PATHOLOGICAL||COPIES/ML|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|N|Y|PARENT|FORENSIC PATHOLOGIST|N|5||7||WASHOUT|1971-11-30|
TRIAL STUDY 134XCP|TR|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|1||||||ORSTATE|ORGAN STATE||KM|TUMOR MERGED||FOZ_BR|NOT DONE|||CELL BASED BIOASSAY|Y|NA|GUARDIAN|PATHOLOGIST 2|NA|1||38||BASELINE|1968-02-08|
TRIAL STUDY 134XCP|TR|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||NG/DAY|ABSENT||CYCLE/MIN|NOT DONE|||CALCOFLUOR WHITE STAIN|N|NA|CAREGIVER|MICROSCOPIST|U|2||58||CONTINUATION TREATMENT|1968-03-18|
TRIAL STUDY 134XCP|TR|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||LOG10 TCID 50/ML|DIFFUSELY INCREASED||NKAT|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|Y|SPOUSE|PHYSIOTHERAPIST|Y|3||39||BASELINE|1971-10-15|
TRIAL STUDY 134XCP|TR|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||TRANSDUCING UNIT|DECREASED||MG/M2/DAY|NOT DONE|||MRI WITHOUT CONTRAST|NA|Y|INVESTIGATOR|PATHOLOGIST 2|NA|4||88||INDUCTION TREATMENT|1973-01-10|
TRIAL STUDY 134XCP|TR|8FDF7A91-BB16-4A4D-8D35-F1B1B40719E9|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||TCID 50/DOSE|FURTHER ENLARGEMENT FROM NADIR||U/KG/H|NOT DONE|||GC/MS-EI|N|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|5||7||BLINDED TREATMENT|1963-02-07|
TRIAL STUDY 134XCP|TR|B09D371C-2E5C-4F84-986E-5A603C0C4A28|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||NEBULE|PALPABLE||GPL U|NOT DONE|||PET/CT SCAN|U|NA|DOMESTIC PARTNER|ADJUDICATOR|U|1||38||SCREENING|1961-05-05|
TRIAL STUDY 134XCP|TR|B09D371C-2E5C-4F84-986E-5A603C0C4A28|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||SIEMENS|ABSENT||TESLA|NOT DONE|||HPLC-FL|U|NA|PARENT|MICROSCOPIST|NA|2||58||TREATMENT|1967-05-08|
TRIAL STUDY 134XCP|TR|B09D371C-2E5C-4F84-986E-5A603C0C4A28|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||U/CL|UNEQUIVOCAL||MG/ML/MIN|NOT DONE|||MUGA|NA|N|SPOUSE|ADJUDICATOR 3|NA|3||39||BASELINE|1968-01-22|
TRIAL STUDY 134XCP|TR|B09D371C-2E5C-4F84-986E-5A603C0C4A28|4||||||SUMDIAM|SUM OF DIAMETER||G/CAGE|EQUIVOCAL||UV|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|Y|NA|STUDY SUBJECT|READER 1|NA|4||88||OPEN LABEL TREATMENT|1962-08-16|
TRIAL STUDY 134XCP|TR|B09D371C-2E5C-4F84-986E-5A603C0C4A28|5||||||LMBFLIND|LIMB FAILURE INDICATOR||MU|PRESENT||MG/G/H|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|NA|NA|DOMESTIC PARTNER|RADIOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1961-11-07|
TRIAL STUDY 134XCP|TR|11CB653E-F113-4639-B15C-B236A2F65F47|1||||||ORSTATE|ORGAN STATE||G/DAY|DECREASED||UIU/L|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|Y|U|PARENT|READER 2|N|1||38||OBSERVATION|1973-06-10|
TRIAL STUDY 134XCP|TR|11CB653E-F113-4639-B15C-B236A2F65F47|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||IU/ML|DIFFUSELY INCREASED||CONTAINER|NOT DONE|||CLIP|U|NA|CAREGIVER|UROLOGIST|Y|2||58||TREATMENT|1968-07-21|
TRIAL STUDY 134XCP|TR|11CB653E-F113-4639-B15C-B236A2F65F47|3||||||ORSTATE|ORGAN STATE||CMOL/L|INCREASED||10^9/G|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST|N|3||39||OPEN LABEL TREATMENT|1966-05-24|
TRIAL STUDY 134XCP|TR|11CB653E-F113-4639-B15C-B236A2F65F47|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||BAR|NONPALPABLE||APL U/ML|NOT DONE|||FLUORESCENT IMMUNOASSAY|U|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|N|4||88||WASHOUT|1964-10-13|
TRIAL STUDY 134XCP|TR|11CB653E-F113-4639-B15C-B236A2F65F47|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||UG/MOL|NORMAL||LINEAR FT*LB|NOT DONE|||FLOCCULATION, CHARCOAL ENHANCED|N|N|SPOUSE|MICROSCOPIST 3|NA|5||7||INDUCTION TREATMENT|1960-01-19|
TRIAL STUDY 134XCP|TR|2AB992E7-55B7-4327-987C-47FD605B7D78|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PACK YEAR|PALPABLE||U/M2/H|NOT DONE|||MALDI-TOF|U|U|ADJUDICATION COMMITTEE|READER 3|Y|1||38||LONG-TERM FOLLOW-UP|1963-10-28|
TRIAL STUDY 134XCP|TR|2AB992E7-55B7-4327-987C-47FD605B7D78|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||UV|PATHOLOGICAL||10^4 CFU/ML|NOT DONE|||HPLC-FL|N|U|PARENT|READER 3|NA|2||58||LONG-TERM FOLLOW-UP|1965-05-09|
TRIAL STUDY 134XCP|TR|2AB992E7-55B7-4327-987C-47FD605B7D78|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PFU/ML|INCREASED||M/SEC|NOT DONE|||TEMPLATE INCISION METHOD|N|NA|PROXY|RATER 2|NA|3||39||INDUCTION TREATMENT|1969-11-30|
TRIAL STUDY 134XCP|TR|2AB992E7-55B7-4327-987C-47FD605B7D78|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||LOG10 PFU/ML|ENLARGEMENT FROM NADIR||BAR|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|NA|N|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|4||88||BASELINE|1967-01-24|
TRIAL STUDY 134XCP|TR|2AB992E7-55B7-4327-987C-47FD605B7D78|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^3 RNA COPIES/ML|NORMAL||IU/L|NOT DONE|||SPECT/CT SCAN|N|Y|ADJUDICATION COMMITTEE|PATHOLOGIST|U|5||7||WASHOUT|1973-05-26|
TRIAL STUDY 134XCP|TR|6AF1B0B0-9923-459A-8629-5E628400AD00|1||||||SUMVOL|SUM OF VOLUME||ABSORBANCE U|TUMOR MERGED||POINT|NOT DONE|||HPLC/MS/MS|U|U|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|1||38||OBSERVATION|1968-06-24|
TRIAL STUDY 134XCP|TR|6AF1B0B0-9923-459A-8629-5E628400AD00|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||DPM/MG|DECREASED||UG/ANIMAL|NOT DONE|||RADIOGRAPHY|Y|NA|STUDY SUBJECT|MICROSCOPIST 3|N|2||58||LONG-TERM FOLLOW-UP|1963-07-28|
TRIAL STUDY 134XCP|TR|6AF1B0B0-9923-459A-8629-5E628400AD00|3||||||NEWCONF|NEW TUMOR CONFIRMED||P|NORMAL||AMFI|NOT DONE|||WEBER GREEN STAIN|N|Y|INVESTIGATOR|RADIOLOGIST 1|U|3||39||TREATMENT|1971-08-26|
TRIAL STUDY 134XCP|TR|6AF1B0B0-9923-459A-8629-5E628400AD00|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CI/MG|ENLARGEMENT||MG/KG/MIN|NOT DONE|||TRICHROME STAIN|Y|Y|CHILD|ONCOLOGIST 2|NA|4||88||OPEN LABEL TREATMENT|1960-04-18|
TRIAL STUDY 134XCP|TR|6AF1B0B0-9923-459A-8629-5E628400AD00|5||||||LESSCIND|LESION SUCCESS INDICATOR||GBQ/UG|FURTHER ENLARGEMENT||VIAL|NOT DONE|||MICROBIAL CULTURE, SOLID|U|U|CLINICAL STUDY SPONSOR|RADIOLOGIST|Y|5||7||SCREENING|1966-03-10|
TRIAL STUDY 134XCP|TR|E1305E4E-DF64-4FD1-B0B2-131459AB629D|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ABSORBANCE U/ML|ENLARGEMENT||ANSON U|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|U|CLINICAL STUDY SPONSOR|READER 1|NA|1||38||CONTINUATION TREATMENT|1963-04-22|
TRIAL STUDY 134XCP|TR|E1305E4E-DF64-4FD1-B0B2-131459AB629D|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||/100 WBC|PALPABLE||COPIES/UG|NOT DONE|||MECHANICAL CLOT DETECTION|U|U|FAMILY MEMBER|MICROSCOPIST 1|N|2||58||SCREENING|1964-07-05|
TRIAL STUDY 134XCP|TR|E1305E4E-DF64-4FD1-B0B2-131459AB629D|3||||||BNLNUM|NUMBER OF BONE LESIONS||ML/DL|PATHOLOGICAL||/MIN|NOT DONE|||SEQUENCING|NA|U|SPOUSE|RADIOLOGIST|NA|3||39||SCREENING|1962-02-02|
TRIAL STUDY 134XCP|TR|E1305E4E-DF64-4FD1-B0B2-131459AB629D|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||U.CARR|FOCALLY INCREASED||UG/G/DAY|NOT DONE|||CYSTOSCOPY|U|U|NON-HEALTH CARE PROFESSIONAL|RATER 2|N|4||88||OBSERVATION|1965-06-29|
TRIAL STUDY 134XCP|TR|E1305E4E-DF64-4FD1-B0B2-131459AB629D|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ML/SEC/1.73M2|INCREASED||PKAT|NOT DONE|||HILLMEN COLOR CHART|Y|U|SPOUSE|OTOLARYNGOLOGIST|N|5||7||BASELINE|1961-09-11|
TRIAL STUDY 134XCP|TR|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MM2|DIFFUSELY INCREASED||KPA/L/SEC|NOT DONE|||ELASTOGRAPHY|U|Y|FAMILY MEMBER|ONCOLOGIST 1|Y|1||38||RUN-IN|1964-11-16|
TRIAL STUDY 134XCP|TR|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||/SEC|ENLARGEMENT||IU/MG|NOT DONE|||ETDRS EYE CHART|NA|Y|DOMESTIC PARTNER|OPTOMETRIST|Y|2||58||LONG-TERM FOLLOW-UP|1964-09-24|
TRIAL STUDY 134XCP|TR|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||NSEC|UNCHANGED||UG/G/MIN|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|N|INVESTIGATOR|UROLOGIST|N|3||39||INDUCTION TREATMENT|1966-01-14|
TRIAL STUDY 134XCP|TR|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|4||||||SUMDIAM|SUM OF DIAMETER||ML/BEAT|EQUIVOCAL||PG|NOT DONE|||AUTOREFRACTION|NA|NA|NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4||88||SCREENING|1967-07-02|
TRIAL STUDY 134XCP|TR|9FEA7E3E-BEB9-4FD6-930D-5D724262B066|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||POINT|NON-PATHOLOGICAL||CARTRIDGE|NOT DONE|||MICROBIAL CULTURE, SOLID|Y|N|PARENT|CLINICAL PATHOLOGIST|Y|5||7||SCREENING|1964-07-02|
TRIAL STUDY 134XCP|TR|0FD7F837-3D76-4A1C-B414-373B55A39506|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NKAT/G HB|INCREASED||SFC/10^6 PBMC|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|NA|N|INDEPENDENT ASSESSOR|HEMATOLOGIST|N|1||38||FOLLOW-UP|1967-04-11|
TRIAL STUDY 134XCP|TR|0FD7F837-3D76-4A1C-B414-373B55A39506|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PFU|PALPABLE||U/MMOL|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|N|U|SIBLING|READER|Y|2||58||SCREENING|1960-06-06|
TRIAL STUDY 134XCP|TR|0FD7F837-3D76-4A1C-B414-373B55A39506|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||TBSP|FOCALLY INCREASED||PMOL|NOT DONE|||MALDI-TOF|U|NA|FRIEND|OPTOMETRIST|N|3||39||SCREENING|1967-04-19|
TRIAL STUDY 134XCP|TR|0FD7F837-3D76-4A1C-B414-373B55A39506|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UMOL/MIN|UNCHANGED||OI50|NOT DONE|||PET SCAN|N|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|4||88||INDUCTION TREATMENT|1968-10-24|
TRIAL STUDY 134XCP|TR|0FD7F837-3D76-4A1C-B414-373B55A39506|5||||||ORVERLN|ORGAN VERTICAL LENGTH||WEBER|DECREASED||BQ/ML|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|N|NA|DOMESTIC PARTNER|ADJUDICATOR 2|U|5||7||OBSERVATION|1960-07-02|
TRIAL STUDY 134XCP|TR|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|1||||||ORVERLN|ORGAN VERTICAL LENGTH||VP/DOSE|ABSENT||UG/CM2|NOT DONE|||MULTIPLE BREATH WASHOUT|U|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1969-01-23|
TRIAL STUDY 134XCP|TR|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|2||||||TUMSTATE|TUMOR STATE||10^3 CFU/ML|PRESENT||NMOL BCE/MMOL|NOT DONE|||PERCUSSION|NA|Y|CAREGIVER|READER|U|2||58||BLINDED TREATMENT|1961-11-19|
TRIAL STUDY 134XCP|TR|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||10^6 U|FURTHER ENLARGEMENT||MG/M2/H|NOT DONE|||MICROBIAL CULTURE|NA|NA|PARENT|RADIOLOGIST|N|3||39||SCREENING|1964-06-27|
TRIAL STUDY 134XCP|TR|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CM H2O|FURTHER ENLARGEMENT FROM NADIR||DL|NOT DONE|||KINYOUN STAIN|Y|NA|INTERVIEWER|READER 3|N|4||88||LONG-TERM FOLLOW-UP|1962-12-08|
TRIAL STUDY 134XCP|TR|B9FE22A2-67DF-44AC-BBC6-B911BB5957AA|5||||||ORVERLN|ORGAN VERTICAL LENGTH||DEG/S|DECREASED||PRESSOR UNITS|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||BLINDED TREATMENT|1961-11-07|
TRIAL STUDY 134XCP|TR|92FB0125-67D2-41CC-9116-8C949F15614A|1||||||TUMSTATE|TUMOR STATE||DRINK|UNCHANGED||MNFI|NOT DONE|||MRI WITHOUT CONTRAST|Y|U|INTERVIEWER|NEUROLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1962-12-23|
TRIAL STUDY 134XCP|TR|92FB0125-67D2-41CC-9116-8C949F15614A|2||||||SUMDIAM|SUM OF DIAMETER||PPTR|ENLARGEMENT||TESLA|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|U|N|INTERVIEWER|INTERNIST|NA|2||58||RUN-IN|1960-12-15|
TRIAL STUDY 134XCP|TR|92FB0125-67D2-41CC-9116-8C949F15614A|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||KALLIKREIN INHIBITOR UNIT|UNCHANGED||10^3/L|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|NA|N|CHILD|PATHOLOGIST 2|N|3||39||INDUCTION TREATMENT|1972-10-23|
TRIAL STUDY 134XCP|TR|92FB0125-67D2-41CC-9116-8C949F15614A|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||TABLET|FURTHER ENLARGEMENT FROM NADIR||10^4/L|NOT DONE|||SLOAN LETTER EYE CHART 100%|Y|N|CLINICAL RESEARCH COORDINATOR|RATER 1|U|4||88||OBSERVATION|1972-09-02|
TRIAL STUDY 134XCP|TR|92FB0125-67D2-41CC-9116-8C949F15614A|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MMHG|FURTHER ENLARGEMENT||COPIES/ML|NOT DONE|||CT SCAN|U|U|GUARDIAN|RADIOLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1961-11-22|
TRIAL STUDY 134XCP|TR|7042617F-0C29-4928-B3ED-9549A53BC195|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||ML/G/DAY|NONPALPABLE||/CMH2O|NOT DONE|||REBOUND TONOMETRY|N|Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|1||38||WASHOUT|1967-04-06|
TRIAL STUDY 134XCP|TR|7042617F-0C29-4928-B3ED-9549A53BC195|2||||||LPERP|LONGEST PERPENDICULAR||FFU|ENLARGEMENT FROM NADIR||MM3/MM2/YEAR|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|U|N|INVESTIGATOR|ADJUDICATOR 3|N|2||58||OBSERVATION|1960-12-21|
TRIAL STUDY 134XCP|TR|7042617F-0C29-4928-B3ED-9549A53BC195|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MAC50|PALPABLE||MMOL/MIN/KPA/L|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|U|U|CLINICAL STUDY SPONSOR|READER 2|Y|3||39||TREATMENT|1972-12-19|
TRIAL STUDY 134XCP|TR|7042617F-0C29-4928-B3ED-9549A53BC195|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||NU/CL|FOCALLY INCREASED||UMOL/MOL|NOT DONE|||BETA LACTAMASE|Y|U|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|4||88||WASHOUT|1961-07-05|
TRIAL STUDY 134XCP|TR|7042617F-0C29-4928-B3ED-9549A53BC195|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MMOL/KG|DIFFUSELY INCREASED||PMOL|NOT DONE|||FLUORESCENT SPOT TEST|NA|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|5||7||FOLLOW-UP|1965-07-07|
TRIAL STUDY 134XCP|TR|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|1||||||PALPSTAT|PALPABLE STATE||NKAT/L|UNCHANGED||KCAL/DAY|NOT DONE|||LYMPHANGIOGRAPHY|N|U|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||OBSERVATION|1968-05-28|
TRIAL STUDY 134XCP|TR|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||USEC|TUMOR MERGED||ML/M2/H|NOT DONE|||DNA MICROARRAY|Y|U|INVESTIGATOR|RADIOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1969-08-19|
TRIAL STUDY 134XCP|TR|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||/200 HPFS|DIFFUSELY INCREASED||UV2|NOT DONE|||IMMUNOPRECIPITATION|N|N|CLINICAL RESEARCH COORDINATOR|READER 2|U|3||39||OBSERVATION|1960-07-12|
TRIAL STUDY 134XCP|TR|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|4||||||ORSTATE|ORGAN STATE||10^9/DOSE|EQUIVOCAL||10^6 COPIES/ML|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|NA|NA|PARENT|CARDIOLOGIST|Y|4||88||TREATMENT|1973-04-15|
TRIAL STUDY 134XCP|TR|C6707A8F-FA0D-4A20-BDF3-62F12465EEDD|5||||||PALPSTAT|PALPABLE STATE||ENZYME U/M2|ABSENT||CD*S/M2|NOT DONE|||SPECT SCAN|NA|U|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||SCREENING|1962-01-30|
TRIAL STUDY 134XCP|TR|6633CC54-D711-4780-A833-A71756D8B234|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||NMOL/L/H|FOCALLY INCREASED||10^3 ORGANISMS/ML|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|Y|CHILD|NEUROLOGIST 1|U|1||38||FOLLOW-UP|1962-08-17|
TRIAL STUDY 134XCP|TR|6633CC54-D711-4780-A833-A71756D8B234|2||||||RADIODEN|RADIODENSITY||PUFF|NORMAL||NM|NOT DONE|||BALLPOINT PEN TECHNIQUE|Y|N|PROXY|MICROSCOPIST 3|NA|2||58||BLINDED TREATMENT|1960-11-22|
TRIAL STUDY 134XCP|TR|6633CC54-D711-4780-A833-A71756D8B234|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||APL U/ML|ENLARGEMENT FROM NADIR||PRESSOR UNITS|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|NA|N|VENDOR|MICROSCOPIST 2|NA|3||39||SCREENING|1969-07-18|
TRIAL STUDY 134XCP|TR|6633CC54-D711-4780-A833-A71756D8B234|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||U/G/MIN|ENLARGEMENT||MASK|NOT DONE|||KLEIHAUER-BETKE|U|N|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|4||88||WASHOUT|1970-05-22|
TRIAL STUDY 134XCP|TR|6633CC54-D711-4780-A833-A71756D8B234|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||/VF|ABSENT||ATM|NOT DONE|||HEMOCYTOMETRY|NA|U|CAREGIVER|ADJUDICATOR 2|NA|5||7||FOLLOW-UP|1971-06-29|
TRIAL STUDY 134XCP|TR|84C642FE-6D84-4525-AB1C-15FAF740D63B|1||||||CALCFIND|CALCIFICATION INDICATOR||MMOL/G|FOCALLY INCREASED||EID 50/DOSE|NOT DONE|||SLIT LAMP|N|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||TREATMENT|1963-10-31|
TRIAL STUDY 134XCP|TR|84C642FE-6D84-4525-AB1C-15FAF740D63B|2||||||LESSCIND|LESION SUCCESS INDICATOR||LM|TUMOR MERGED||PHERESIS UNIT|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|U|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|2||58||BASELINE|1972-04-13|
TRIAL STUDY 134XCP|TR|84C642FE-6D84-4525-AB1C-15FAF740D63B|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ML/H|ENLARGEMENT FROM NADIR||10^3 ORGANISMS/G|NOT DONE|||MULTIPLE BREATH WASHOUT|Y|NA|STUDY SUBJECT|NEUROLOGIST|N|3||39||CONTINUATION TREATMENT|1962-03-29|
TRIAL STUDY 134XCP|TR|84C642FE-6D84-4525-AB1C-15FAF740D63B|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||BQ/UL|EQUIVOCAL||DRUM|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|N|Y|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||SCREENING|1973-01-16|
TRIAL STUDY 134XCP|TR|84C642FE-6D84-4525-AB1C-15FAF740D63B|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||/10^3|NORMAL||MHZ|NOT DONE|||MACRO BROTH DILUTION|U|NA|VENDOR|PEDIATRIC NEUROLOGIST|Y|5||7||TREATMENT|1967-05-10|
TRIAL STUDY 134XCP|TR|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|1||||||LESSCIND|LESION SUCCESS INDICATOR||10^6/HPF|PATHOLOGICAL||MG/MIN|NOT DONE|||CLAUSS METHOD|Y|U|PROXY|READER 1|Y|1||38||OPEN LABEL TREATMENT|1967-03-04|
TRIAL STUDY 134XCP|TR|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||CFU/G|DIFFUSELY INCREASED||NMOL/L/MIN|NOT DONE|||TOLUIDINE BLUE STAIN|NA|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|2||58||WASHOUT|1965-10-19|
TRIAL STUDY 134XCP|TR|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/4.0 ML|PRESENT||L/DAY|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|NA|FRIEND|RADIOLOGIST 1|N|3||39||RUN-IN|1969-10-01|
TRIAL STUDY 134XCP|TR|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^6/L|FURTHER ENLARGEMENT FROM NADIR||MN|NOT DONE|||DIRECT SEQUENCING|Y|Y|STUDY SUBJECT|PATHOLOGIST|NA|4||88||RUN-IN|1968-04-05|
TRIAL STUDY 134XCP|TR|1445FD45-1E9D-41C0-B81C-37E2FD2F20D7|5||||||VSLPIND|VESSEL PATENCY INDICATOR||CPM|ENLARGEMENT||GBQ/UG|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|N|U|INTERVIEWER|UROLOGIST|U|5||7||BASELINE|1962-07-01|
TRIAL STUDY 134XCP|TR|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^12/L|UNCHANGED||%(W/W)|NOT DONE|||MRS|Y|Y|VENDOR|MICROSCOPIST 1|NA|1||38||BLINDED TREATMENT|1973-04-10|
TRIAL STUDY 134XCP|TR|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UG/L DDU|DIFFUSELY INCREASED||IU/L|NOT DONE|||SNP ARRAY|NA|N|SPOUSE|READER 2|Y|2||58||RUN-IN|1968-05-18|
TRIAL STUDY 134XCP|TR|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KG|UNCHANGED||GBQ/G|NOT DONE|||MICROBIAL CONCENTRATION|U|Y|PARENT|MICROSCOPIST 2|NA|3||39||FOLLOW-UP|1968-06-13|
TRIAL STUDY 134XCP|TR|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|4||||||VSLPIND|VESSEL PATENCY INDICATOR||U/10^12 RBC|ENLARGEMENT||MG2/DL2|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|U|Y|CAREGIVER|ADJUDICATOR 3|U|4||88||TREATMENT|1970-11-01|
TRIAL STUDY 134XCP|TR|AAF75D2D-0DF1-4A15-B7FC-1EEE65FFAC62|5||||||VDIAM|VIABLE DIAMETER||INHALATION|NON-PATHOLOGICAL||MMHG/L/MIN|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|N|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|5||7||BASELINE|1966-10-13|
TRIAL STUDY 134XCP|TR|A0757669-2DF6-4E78-A021-9C777BEF5697|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CM H2O|INCREASED||MM2|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|NA|STUDY SUBJECT|MICROSCOPIST 3|U|1||38||FOLLOW-UP|1961-12-25|
TRIAL STUDY 134XCP|TR|A0757669-2DF6-4E78-A021-9C777BEF5697|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MG/MIN|PRESENT||BEATS/MIN|NOT DONE|||DROPLET DIGITAL PCR|N|N|SPOUSE|UROLOGIST|NA|2||58||TREATMENT|1964-01-22|
TRIAL STUDY 134XCP|TR|A0757669-2DF6-4E78-A021-9C777BEF5697|3||||||CALCFIND|CALCIFICATION INDICATOR||SYRINGE|UNCHANGED||ML/100G/MIN|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|NA|U|FAMILY MEMBER|RATER 1|N|3||39||CONTINUATION TREATMENT|1963-04-29|
TRIAL STUDY 134XCP|TR|A0757669-2DF6-4E78-A021-9C777BEF5697|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||ML/100G/MIN|PALPABLE||GBQ/UG|NOT DONE|||FREEZING POINT DEPRESSION|N|NA|SIGNIFICANT OTHER|MICROSCOPIST|NA|4||88||RUN-IN|1960-06-29|
TRIAL STUDY 134XCP|TR|A0757669-2DF6-4E78-A021-9C777BEF5697|5||||||PALPSTAT|PALPABLE STATE||CM|EQUIVOCAL||COPIES/ML|NOT DONE|||EIA|N|Y|VENDOR|PATHOLOGIST 1|Y|5||7||BLINDED TREATMENT|1968-10-05|
TRIAL STUDY 134XCP|TR|DAF7255A-888D-43D3-97B8-5E432938747F|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||FFU|EQUIVOCAL||HZ|NOT DONE|||HPLC/IEX|U|U|GUARDIAN|READER 2|NA|1||38||OBSERVATION|1964-03-08|
TRIAL STUDY 134XCP|TR|DAF7255A-888D-43D3-97B8-5E432938747F|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||H*%|PRESENT||10^6/G|NOT DONE|||SEQUENCING|U|U|ADJUDICATION COMMITTEE|ONCOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1964-06-20|
TRIAL STUDY 134XCP|TR|DAF7255A-888D-43D3-97B8-5E432938747F|3||||||TUMSTATE|TUMOR STATE||PUFF|EQUIVOCAL||SFC/10^6 PBMC|NOT DONE|||LANDOLT RING|NA|NA|ADJUDICATION COMMITTEE|READER 2|Y|3||39||BLINDED TREATMENT|1967-09-26|
TRIAL STUDY 134XCP|TR|DAF7255A-888D-43D3-97B8-5E432938747F|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^9 ORGANISMS|UNEQUIVOCAL||MMHG*MIN/L|NOT DONE|||IMPULSE OSCILLOMETRY|N|NA|ADJUDICATOR|NEUROLOGIST 2|N|4||88||OBSERVATION|1963-04-23|
TRIAL STUDY 134XCP|TR|DAF7255A-888D-43D3-97B8-5E432938747F|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||UMOL/MOL|ENLARGEMENT||APL U|NOT DONE|||FLOCCULATION|N|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||CONTINUATION TREATMENT|1970-11-04|
TRIAL STUDY 134XCP|TR|51989FEC-B63E-4F58-B748-2FF5E73E5D14|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PMOL/DAY|DECREASED||CYLINDER|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|U|U|VENDOR|HEMATOLOGIST|Y|1||38||FOLLOW-UP|1969-11-16|
TRIAL STUDY 134XCP|TR|51989FEC-B63E-4F58-B748-2FF5E73E5D14|2||||||CALCFIND|CALCIFICATION INDICATOR||U/M2/DAY|DIFFUSELY INCREASED||DPM/MG|NOT DONE|||VIRUS PLAQUE ASSAY|U|N|DOMESTIC PARTNER|NEUROLOGIST 2|N|2||58||RUN-IN|1969-06-12|
TRIAL STUDY 134XCP|TR|51989FEC-B63E-4F58-B748-2FF5E73E5D14|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ML/BREATH|FURTHER ENLARGEMENT||/H|NOT DONE|||TRICHROME STAIN|U|N|SPOUSE|NEUROLOGIST 1|U|3||39||RUN-IN|1968-09-26|
TRIAL STUDY 134XCP|TR|51989FEC-B63E-4F58-B748-2FF5E73E5D14|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ENZYME U|FURTHER ENLARGEMENT FROM NADIR||PT_US|NOT DONE|||PHOTOGRAPHY|N|Y|VENDOR|ENDOCRINOLOGIST|N|4||88||OPEN LABEL TREATMENT|1968-05-19|
TRIAL STUDY 134XCP|TR|51989FEC-B63E-4F58-B748-2FF5E73E5D14|5||||||SUMDIAM|SUM OF DIAMETER||VG/ML|FURTHER ENLARGEMENT FROM NADIR||CAL|NOT DONE|||FLOW MICROSCOPY|NA|NA|SPOUSE|MICROSCOPIST 1|U|5||7||WASHOUT|1964-01-15|
TRIAL STUDY 134XCP|TR|776299DC-1CD5-448F-82C2-C1659CEE689D|1||||||VSLPIND|VESSEL PATENCY INDICATOR||/7.5 ML|ENLARGEMENT||PFU/DOSE|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|U|U|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1||38||OPEN LABEL TREATMENT|1966-06-13|
TRIAL STUDY 134XCP|TR|776299DC-1CD5-448F-82C2-C1659CEE689D|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||GPELISA UNIT/ML|UNEQUIVOCAL||BEATS/MIN|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|Y|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|2||58||BASELINE|1962-05-17|
TRIAL STUDY 134XCP|TR|776299DC-1CD5-448F-82C2-C1659CEE689D|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UMOL/DL|NONPALPABLE||AG|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|NA|HEALTH CARE PROFESSIONAL|READER 3|NA|3||39||SCREENING|1971-09-03|
TRIAL STUDY 134XCP|TR|776299DC-1CD5-448F-82C2-C1659CEE689D|4||||||BNLNUM|NUMBER OF BONE LESIONS||DRAM|NONPALPABLE||AMU|NOT DONE|||HPLC/IEX|N|Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||RUN-IN|1972-11-25|
TRIAL STUDY 134XCP|TR|776299DC-1CD5-448F-82C2-C1659CEE689D|5||||||LPERP|LONGEST PERPENDICULAR||MG/DL|FURTHER ENLARGEMENT||L/S/KPA|NOT DONE|||FUNCTIONAL MRI|N|N|INTERVIEWER|INTERNIST|N|5||7||WASHOUT|1961-02-09|
TRIAL STUDY 134XCP|TR|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|1||||||LESFLIND|LESION FAILURE INDICATOR||ARBITRARY U|PRESENT||BAR|NOT DONE|||FLUORIMETRY|N|NA|PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1971-03-29|
TRIAL STUDY 134XCP|TR|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||FT3|UNCHANGED||PMOL|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|SPOUSE|MICROSCOPIST 2|NA|2||58||SCREENING|1973-07-30|
TRIAL STUDY 134XCP|TR|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||CY/CM|INCREASED||L/MIN/M2|NOT DONE|||PELLI-ROBSON EYE CHART|Y|Y|STUDY SUBJECT|ADJUDICATOR|Y|3||39||BASELINE|1963-08-21|
TRIAL STUDY 134XCP|TR|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ABSORBANCE U/ML|ENLARGEMENT||GBQ|NOT DONE|||LINE PROBE ASSAY|NA|NA|INVESTIGATOR|NEUROLOGIST 2|U|4||88||RUN-IN|1968-12-23|
TRIAL STUDY 134XCP|TR|1E9755DC-A5EA-4DAF-A95E-47D8FA3765D7|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MG|ENLARGEMENT||GMFI|NOT DONE|||MICROBIAL CONCENTRATION|Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|5||7||LONG-TERM FOLLOW-UP|1969-12-10|
TRIAL STUDY 134XCP|TR|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|1||||||SUMVOL|SUM OF VOLUME||BAU/ML|ABSENT||CM|NOT DONE|||PET SCAN|N|Y|INVESTIGATOR|RADIOLOGIST|NA|1||38||BLINDED TREATMENT|1971-02-06|
TRIAL STUDY 134XCP|TR|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||VP/DOSE|ABSENT||10^3 DNA COPIES/ML|NOT DONE|||ACRIDINE ORANGE STAIN|N|NA|GUARDIAN|RADIOLOGIST|N|2||58||INDUCTION TREATMENT|1961-11-08|
TRIAL STUDY 134XCP|TR|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||BQ/G|TUMOR MERGED||COPIES/ML|NOT DONE|||PELLI-ROBSON EYE CHART|N|NA|PROXY|READER 2|N|3||39||WASHOUT|1971-05-27|
TRIAL STUDY 134XCP|TR|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UU/L|DIFFUSELY INCREASED||G/M2/DAY|NOT DONE|||INFRARED SPECTROMETRY|NA|Y|PARENT|ONCOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1961-01-16|
TRIAL STUDY 134XCP|TR|2844C9EF-3DEE-4C8E-A89C-0206F4073CB1|5||||||LDIAM|LONGEST DIAMETER||DAYS|NONPALPABLE||MEQ|NOT DONE|||LEAD CITRATE STAIN|U|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|5||7||INDUCTION TREATMENT|1965-03-01|
TRIAL STUDY 134XCP|TR|054D4740-C675-4904-B912-B00A0B089F12|1||||||DIAMETER|DIAMETER||MBQ/UL|ABSENT||M2|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 3|Y|1||38||INDUCTION TREATMENT|1971-10-29|
TRIAL STUDY 134XCP|TR|054D4740-C675-4904-B912-B00A0B089F12|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||OZ|PALPABLE||ML/KG/DAY|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|N|Y|PARENT|MICROSCOPIST 2|U|2||58||RUN-IN|1963-04-29|
TRIAL STUDY 134XCP|TR|054D4740-C675-4904-B912-B00A0B089F12|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MIN|DIFFUSELY INCREASED||10^8/L|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|3||39||OBSERVATION|1964-07-21|
TRIAL STUDY 134XCP|TR|054D4740-C675-4904-B912-B00A0B089F12|4||||||LESFLIND|LESION FAILURE INDICATOR||BU|FURTHER ENLARGEMENT||AMU|NOT DONE|||REFLECTANCE SPECTROSCOPY|N|Y|INVESTIGATOR|READER|N|4||88||BASELINE|1962-07-17|
TRIAL STUDY 134XCP|TR|054D4740-C675-4904-B912-B00A0B089F12|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MG/M2|FOCALLY INCREASED||TSP EQ|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|U|SIGNIFICANT OTHER|UROLOGIST|U|5||7||BASELINE|1970-05-26|
TRIAL STUDY 134XCP|TR|9548556E-EECF-4460-A7DD-D93F853E9EA8|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||L/L|NONPALPABLE||10^6/HPF|NOT DONE|||CORONARY ANGIOGRAPHY|Y|N|GUARDIAN|READER 2|U|1||38||WASHOUT|1962-12-01|
TRIAL STUDY 134XCP|TR|9548556E-EECF-4460-A7DD-D93F853E9EA8|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||RFU|NONPALPABLE||MG/M2|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|Y|HEALTH CARE PROFESSIONAL|READER 1|Y|2||58||SCREENING|1972-02-12|
TRIAL STUDY 134XCP|TR|9548556E-EECF-4460-A7DD-D93F853E9EA8|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||PACK|NONPALPABLE||CM/S|NOT DONE|||SPECT SCAN|N|NA|INDEPENDENT ASSESSOR|READER 2|Y|3||39||TREATMENT|1972-07-17|
TRIAL STUDY 134XCP|TR|9548556E-EECF-4460-A7DD-D93F853E9EA8|4||||||BNLNUM|NUMBER OF BONE LESIONS||MMHG*MIN/L|EQUIVOCAL||MGEQ|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|U|VENDOR|MICROSCOPIST 1|Y|4||88||SCREENING|1962-06-18|
TRIAL STUDY 134XCP|TR|9548556E-EECF-4460-A7DD-D93F853E9EA8|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||UG/DOSE|PALPABLE||/4.0 ML|NOT DONE|||CONFOCAL MICROSCOPY|Y|N|INTERVIEWER|ONCOLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1964-08-26|
TRIAL STUDY 134XCP|TR|0BCF6152-3718-402C-9333-A3EFBB3086FF|1||||||VDIAM|VIABLE DIAMETER||PMOL/DL|PRESENT||CM|NOT DONE|||CHROMOGENIC ASSAY|Y|N|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|1||38||WASHOUT|1967-02-12|
TRIAL STUDY 134XCP|TR|0BCF6152-3718-402C-9333-A3EFBB3086FF|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MET|UNEQUIVOCAL||CMH2O*S/ML|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|U|SPOUSE|RADIOLOGIST|U|2||58||WASHOUT|1966-12-25|
TRIAL STUDY 134XCP|TR|0BCF6152-3718-402C-9333-A3EFBB3086FF|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||L/S|ENLARGEMENT FROM NADIR||JDF UNIT|NOT DONE|||IRON HEMATOXYLIN STAIN|Y|Y|ADJUDICATOR|RADIOLOGIST|Y|3||39||WASHOUT|1963-04-12|
TRIAL STUDY 134XCP|TR|0BCF6152-3718-402C-9333-A3EFBB3086FF|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CIGAR|ABSENT||10^6 ORGANISMS|NOT DONE|||NEXT GENERATION SEQUENCING|N|NA|CHILD|UROLOGIST|Y|4||88||TREATMENT|1965-10-12|
TRIAL STUDY 134XCP|TR|0BCF6152-3718-402C-9333-A3EFBB3086FF|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||IMPLANT|FURTHER ENLARGEMENT||TAMPON|NOT DONE|||HIGH RESOLUTION CT|NA|NA|PROXY|PATHOLOGIST|U|5||7||BASELINE|1967-11-23|
TRIAL STUDY 134XCP|TR|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||DAYS/WK|PALPABLE||U/KG|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|NA|Y|FAMILY MEMBER|RATER|Y|1||38||CONTINUATION TREATMENT|1968-05-08|
TRIAL STUDY 134XCP|TR|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||FMOL/G|NON-PATHOLOGICAL||CS|NOT DONE|||URANYL ACETATE STAIN|NA|N|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|N|2||58||BASELINE|1961-08-07|
TRIAL STUDY 134XCP|TR|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||PFU/DOSE|INCREASED||ML/MIN/MMHG|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||TREATMENT|1965-09-17|
TRIAL STUDY 134XCP|TR|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|4||||||NEWCONF|NEW TUMOR CONFIRMED||MSEC|NON-PATHOLOGICAL||CPM|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|NA|Y|ADJUDICATOR|MICROSCOPIST 3|U|4||88||INDUCTION TREATMENT|1962-02-26|
TRIAL STUDY 134XCP|TR|3EC28B44-0649-4C7F-8840-E0E9FC404DA7|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PPM|PALPABLE||UG|NOT DONE|||CALIPER MEASUREMENT METHOD|Y|N|SIGNIFICANT OTHER|READER 1|NA|5||7||SCREENING|1967-10-05|
TRIAL STUDY 134XCP|TR|EED12AC0-1CBD-4D42-8786-91834AB33A46|1||||||VDIAM|VIABLE DIAMETER||MBQ/UL|NONPALPABLE||ML*CMH2O|NOT DONE|||PERFUSION MRI|Y|NA|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||CONTINUATION TREATMENT|1966-06-23|
TRIAL STUDY 134XCP|TR|EED12AC0-1CBD-4D42-8786-91834AB33A46|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MMOL/MOL|FURTHER ENLARGEMENT FROM NADIR||NMOL/L|NOT DONE|||DIFFUSION WEIGHTED MRI|N|N|ADJUDICATION COMMITTEE|INTERNIST|NA|2||58||BASELINE|1972-09-03|
TRIAL STUDY 134XCP|TR|EED12AC0-1CBD-4D42-8786-91834AB33A46|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||IU/MG|NON-PATHOLOGICAL||FG|NOT DONE|||DROPLET DIGITAL PCR|NA|Y|GUARDIAN|ENDOCRINOLOGIST|U|3||39||INDUCTION TREATMENT|1967-08-21|
TRIAL STUDY 134XCP|TR|EED12AC0-1CBD-4D42-8786-91834AB33A46|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||FRAMES/S|PRESENT||MET*H|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|U|N|INTERVIEWER|RADIOLOGIST 1|NA|4||88||RUN-IN|1972-06-02|
TRIAL STUDY 134XCP|TR|EED12AC0-1CBD-4D42-8786-91834AB33A46|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MV2/HZ|TUMOR MERGED||MEQ/UG|NOT DONE|||TELLER ACUITY CARDS|U|Y|FRIEND|ONCOLOGIST|U|5||7||TREATMENT|1967-09-24|
TRIAL STUDY 134XCP|TR|F30DC3E9-E919-4920-87FE-103CD85D89FA|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||TUBERCULIN UNIT/ML|ENLARGEMENT FROM NADIR||UL/KG/DAY|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|N|Y|SIBLING|ADJUDICATOR 1|Y|1||38||BLINDED TREATMENT|1962-05-20|
TRIAL STUDY 134XCP|TR|F30DC3E9-E919-4920-87FE-103CD85D89FA|2||||||LESSCIND|LESION SUCCESS INDICATOR||DISK|PRESENT||UG|NOT DONE|||DIPSTICK|N|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|2||58||LONG-TERM FOLLOW-UP|1972-10-15|
TRIAL STUDY 134XCP|TR|F30DC3E9-E919-4920-87FE-103CD85D89FA|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/DL|DIFFUSELY INCREASED||UU/L|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|N|SIBLING|CLINICAL PATHOLOGIST|NA|3||39||BASELINE|1972-01-16|
TRIAL STUDY 134XCP|TR|F30DC3E9-E919-4920-87FE-103CD85D89FA|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PHERESIS UNIT|ENLARGEMENT FROM NADIR||DAMOL/L|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|N|NA|ADJUDICATOR|HEMATOLOGIST|Y|4||88||OBSERVATION|1973-07-27|
TRIAL STUDY 134XCP|TR|F30DC3E9-E919-4920-87FE-103CD85D89FA|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/M2/MIN|INCREASED||IU/MG|NOT DONE|||LC/MS|N|N|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||FOLLOW-UP|1968-04-19|
TRIAL STUDY 134XCP|TR|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|1||||||BNLNUM|NUMBER OF BONE LESIONS||MPL U/ML|UNCHANGED||MMHG|NOT DONE|||CALCULATION|N|N|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||TREATMENT|1966-01-06|
TRIAL STUDY 134XCP|TR|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|2||||||SUMDIAM|SUM OF DIAMETER||CI/UL|DECREASED||UG/MOL|NOT DONE|||KLEIHAUER-BETKE|Y|Y|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1969-04-04|
TRIAL STUDY 134XCP|TR|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||LX|FURTHER ENLARGEMENT FROM NADIR||USEC|NOT DONE|||CLOT DETECTION|NA|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|3||39||RUN-IN|1960-06-09|
TRIAL STUDY 134XCP|TR|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|4||||||CALCFIND|CALCIFICATION INDICATOR||TSP|UNCHANGED||MM/H|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|U|Y|PROXY|ONCOLOGIST 2|Y|4||88||RUN-IN|1973-02-14|
TRIAL STUDY 134XCP|TR|EBECDED4-D06C-49D4-95F2-C6E9CDBA802B|5||||||LPERP|LONGEST PERPENDICULAR||MOL/DAY|EQUIVOCAL||KBQ/UL|NOT DONE|||PEAK FLOWMETRY|N|NA|DOMESTIC PARTNER|READER|U|5||7||FOLLOW-UP|1965-03-27|
TRIAL STUDY 134XCP|TR|729D254F-628C-4D35-8906-A1344833A610|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||IU/MMOL|INCREASED||MMHG*MIN/L|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|U|Y|PROXY|NEUROLOGIST 2|NA|1||38||WASHOUT|1963-02-24|
TRIAL STUDY 134XCP|TR|729D254F-628C-4D35-8906-A1344833A610|2||||||SUMVOL|SUM OF VOLUME||/2000 RBC|DECREASED||BAR|NOT DONE|||MAPH|Y|N|STUDY SUBJECT|CLINICAL PATHOLOGIST|N|2||58||BASELINE|1969-02-21|
TRIAL STUDY 134XCP|TR|729D254F-628C-4D35-8906-A1344833A610|3||||||ORVERLN|ORGAN VERTICAL LENGTH||PACKET|NORMAL||ABSORBANCE U|NOT DONE|||CONGO RED STAIN|NA|NA|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1973-05-08|
TRIAL STUDY 134XCP|TR|729D254F-628C-4D35-8906-A1344833A610|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MBQ|PALPABLE||G/KG|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|N|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||SCREENING|1972-11-19|
TRIAL STUDY 134XCP|TR|729D254F-628C-4D35-8906-A1344833A610|5||||||LDIAM|LONGEST DIAMETER||CMHG|TUMOR MERGED||UL/ML|NOT DONE|||KNEMOMETRY|U|N|VENDOR|RADIOLOGIST|N|5||7||INDUCTION TREATMENT|1968-06-08|
TRIAL STUDY 134XCP|TR|A78936A2-B8B1-4D07-8679-E324F6447EFF|1||||||LESSCIND|LESION SUCCESS INDICATOR||OSM|DIFFUSELY INCREASED||LX|NOT DONE|||DIGITAL PCR ARRAY|Y|Y|GUARDIAN|PEDIATRIC NEUROLOGIST|NA|1||38||OBSERVATION|1972-12-13|
TRIAL STUDY 134XCP|TR|A78936A2-B8B1-4D07-8679-E324F6447EFF|2||||||VOLUME|VOLUME||PPM|UNCHANGED||G/M2|NOT DONE|||EPSILOMETER|NA|N|ADJUDICATION COMMITTEE|ONCOLOGIST|NA|2||58||SCREENING|1973-04-07|
TRIAL STUDY 134XCP|TR|A78936A2-B8B1-4D07-8679-E324F6447EFF|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||VP/DOSE|UNEQUIVOCAL||MG/H|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|Y|PARENT|MICROSCOPIST 3|Y|3||39||OPEN LABEL TREATMENT|1964-02-06|
TRIAL STUDY 134XCP|TR|A78936A2-B8B1-4D07-8679-E324F6447EFF|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||KCAL|INCREASED||RNA COPIES/ML|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|NA|Y|SIGNIFICANT OTHER|PATHOLOGIST|N|4||88||TREATMENT|1961-03-13|
TRIAL STUDY 134XCP|TR|A78936A2-B8B1-4D07-8679-E324F6447EFF|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||KUSP|ENLARGEMENT||MEQ/DL|NOT DONE|||CHROMATOGRAPHY|NA|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|U|5||7||TREATMENT|1960-06-18|
TRIAL STUDY 134XCP|TR|239B331A-08CD-41D9-BBB8-CE229480FC12|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||%/S|INCREASED||UG/M2/H|NOT DONE|||FORCED OSCILLATION TECHNIQUE|U|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|1||38||RUN-IN|1968-01-22|
TRIAL STUDY 134XCP|TR|239B331A-08CD-41D9-BBB8-CE229480FC12|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UG/DL|FURTHER ENLARGEMENT FROM NADIR||DAMOL/L|NOT DONE|||GIEMSA STAIN|U|NA|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1969-09-17|
TRIAL STUDY 134XCP|TR|239B331A-08CD-41D9-BBB8-CE229480FC12|3||||||LDIAM|LONGEST DIAMETER||CS|ABSENT||PG|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|Y|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1962-01-27|
TRIAL STUDY 134XCP|TR|239B331A-08CD-41D9-BBB8-CE229480FC12|4||||||DIAMETER|DIAMETER||MNFI|UNCHANGED||/MIN|NOT DONE|||PHYSICAL EXAMINATION|N|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1965-07-31|
TRIAL STUDY 134XCP|TR|239B331A-08CD-41D9-BBB8-CE229480FC12|5||||||NEWCONF|NEW TUMOR CONFIRMED||AG|PATHOLOGICAL||CYLINDER|NOT DONE|||PULMONARY ANGIOGRAPHY|Y|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|5||7||WASHOUT|1961-01-20|
TRIAL STUDY 134XCP|TR|958D39CD-D511-40C8-A0A6-8A138225470B|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MG/M2/DAY|FURTHER ENLARGEMENT FROM NADIR||DAMOL/L|NOT DONE|||CLIP|NA|U|FAMILY MEMBER|RADIOLOGIST|N|1||38||BASELINE|1968-09-03|
TRIAL STUDY 134XCP|TR|958D39CD-D511-40C8-A0A6-8A138225470B|2||||||BNLNUM|NUMBER OF BONE LESIONS||DIP|NORMAL||G/CAGE/DAY|NOT DONE|||SPIROMETRY|U|NA|PROXY|HEMATOLOGIST|U|2||58||WASHOUT|1973-07-29|
TRIAL STUDY 134XCP|TR|958D39CD-D511-40C8-A0A6-8A138225470B|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||FARAD|ABSENT||MANSON U/ML|NOT DONE|||LC/MS/MS|NA|Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|3||39||FOLLOW-UP|1963-06-16|
TRIAL STUDY 134XCP|TR|958D39CD-D511-40C8-A0A6-8A138225470B|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||BQ/KG|PALPABLE||KIU|NOT DONE|||ISHIHARA COLOR PLATES|U|Y|PROXY|ADJUDICATOR 1|N|4||88||FOLLOW-UP|1963-05-06|
TRIAL STUDY 134XCP|TR|958D39CD-D511-40C8-A0A6-8A138225470B|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||TSP|TUMOR MERGED||U/M2|NOT DONE|||ELISA|U|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|5||7||BASELINE|1963-01-12|
TRIAL STUDY 134XCP|TR|5DA21FE5-E5B9-4461-9509-94AA264B59A8|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^6 DNA COPIES/ML|PRESENT||SPRAY|NOT DONE|||CYSTOMETRY|N|N|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|1||38||RUN-IN|1960-07-07|
TRIAL STUDY 134XCP|TR|5DA21FE5-E5B9-4461-9509-94AA264B59A8|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/10^5|PATHOLOGICAL||/MM|NOT DONE|||LC-FL|U|NA|VENDOR|CARDIOLOGIST|N|2||58||BASELINE|1963-12-31|
TRIAL STUDY 134XCP|TR|5DA21FE5-E5B9-4461-9509-94AA264B59A8|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MG/DOSE|PALPABLE||L/H|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|Y|CAREGIVER|READER|Y|3||39||WASHOUT|1972-02-12|
TRIAL STUDY 134XCP|TR|5DA21FE5-E5B9-4461-9509-94AA264B59A8|4||||||DIAMETER|DIAMETER||ABSORBANCE U/ML|TUMOR MERGED||MMHG|NOT DONE|||POLYSOMNOGRAPHY|U|N|STUDY SUBJECT|ENDOCRINOLOGIST|NA|4||88||BLINDED TREATMENT|1967-05-30|
TRIAL STUDY 134XCP|TR|5DA21FE5-E5B9-4461-9509-94AA264B59A8|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||PNU/ML|NON-PATHOLOGICAL||BQ/UG|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|N|U|DOMESTIC PARTNER|ADJUDICATOR 1|Y|5||7||INDUCTION TREATMENT|1961-07-27|
TRIAL STUDY 134XCP|TR|B125DCB9-1705-430B-9982-A20E7C4CA6A8|1||||||VOLUME|VOLUME||MG2/DL2|FURTHER ENLARGEMENT||10^4 CFU|NOT DONE|||NUCLEIC ACID SEQUENCING|U|NA|SIGNIFICANT OTHER|RADIOLOGIST|NA|1||38||RUN-IN|1969-03-05|
TRIAL STUDY 134XCP|TR|B125DCB9-1705-430B-9982-A20E7C4CA6A8|2||||||VDIAM|VIABLE DIAMETER||NMOL BCE/L|ENLARGEMENT FROM NADIR||AMOL|NOT DONE|||PHASE-CONTRAST MRI|U|U|HEALTH CARE PROFESSIONAL|READER 1|Y|2||58||OPEN LABEL TREATMENT|1965-01-21|
TRIAL STUDY 134XCP|TR|B125DCB9-1705-430B-9982-A20E7C4CA6A8|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^6/EJACULATE U|EQUIVOCAL||BAU/ML|NOT DONE|||INTERRUPTER TECHNIQUE|U|NA|SIBLING|MICROSCOPIST 2|Y|3||39||RUN-IN|1964-04-03|
TRIAL STUDY 134XCP|TR|B125DCB9-1705-430B-9982-A20E7C4CA6A8|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||KG/CM|NONPALPABLE||CMHG|NOT DONE|||MUGA|NA|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|U|4||88||RUN-IN|1969-11-21|
TRIAL STUDY 134XCP|TR|B125DCB9-1705-430B-9982-A20E7C4CA6A8|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MOL/DAY|DIFFUSELY INCREASED||BEAM BREAKS|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|Y|N|SPOUSE|NEUROLOGIST 2|U|5||7||OBSERVATION|1965-01-22|
TRIAL STUDY 134XCP|TR|95C72325-301E-40D4-AA2D-49B80067FE23|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UL/ML|FOCALLY INCREASED||MMHG*MIN/L|NOT DONE|||KNEMOMETRY|Y|U|CHILD|RATER 2|Y|1||38||CONTINUATION TREATMENT|1963-10-09|
TRIAL STUDY 134XCP|TR|95C72325-301E-40D4-AA2D-49B80067FE23|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||GENEQ/ML|PRESENT||CD/M2|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|N|NA|INTERVIEWER|RADIOLOGIST|U|2||58||OBSERVATION|1960-07-17|
TRIAL STUDY 134XCP|TR|95C72325-301E-40D4-AA2D-49B80067FE23|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||L/H/M2|UNCHANGED||BEATS/MIN|NOT DONE|||DYNAMIC LIGHT SCATTERING|Y|NA|SPOUSE|OPTOMETRIST|U|3||39||WASHOUT|1972-09-10|
TRIAL STUDY 134XCP|TR|95C72325-301E-40D4-AA2D-49B80067FE23|4||||||BNLNUM|NUMBER OF BONE LESIONS||DROP|FOCALLY INCREASED||ML/BEAT|NOT DONE|||POPULATION SEQUENCING|U|NA|FRIEND|MICROSCOPIST|N|4||88||TREATMENT|1972-03-16|
TRIAL STUDY 134XCP|TR|95C72325-301E-40D4-AA2D-49B80067FE23|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||CS|ABSENT||MG/M2|NOT DONE|||SLIT LAMP PHOTOGRAPHY|Y|Y|ADJUDICATOR|PATHOLOGIST 1|N|5||7||INDUCTION TREATMENT|1960-09-04|
TRIAL STUDY 134XCP|TR|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UL/KG/DAY|EQUIVOCAL||L|NOT DONE|||MANUAL CLOT DETECTION|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|1||38||INDUCTION TREATMENT|1961-01-23|
TRIAL STUDY 134XCP|TR|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||DPM/100MG|DECREASED||ATM|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|2||58||CONTINUATION TREATMENT|1961-06-05|
TRIAL STUDY 134XCP|TR|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UG/KG|UNEQUIVOCAL||COPIES/UL|NOT DONE|||MANUAL COUNT|U|U|INTERVIEWER|ENDOCRINOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1964-11-16|
TRIAL STUDY 134XCP|TR|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|4||||||VSLPIND|VESSEL PATENCY INDICATOR||EIA UNIT|DECREASED||HPA|NOT DONE|||PULMONARY ANGIOGRAPHY|N|NA|VENDOR|OTOLARYNGOLOGIST|N|4||88||BLINDED TREATMENT|1961-07-24|
TRIAL STUDY 134XCP|TR|7FFBD039-64CD-4D6F-85EC-83F0D11C57E5|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||/40 HPFS|EQUIVOCAL||IU/G|NOT DONE|||ENDPOINT DILUTION ASSAY|U|NA|INTERVIEWER|ONCOLOGIST|U|5||7||OPEN LABEL TREATMENT|1962-11-12|
TRIAL STUDY 134XCP|TR|7DF25CA4-0846-4180-9356-F53C704F0233|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NGEQ/L|DIFFUSELY INCREASED||ML/CM H2O|NOT DONE|||DNA MICROARRAY|N|U|STUDY SUBJECT|OTOLARYNGOLOGIST|Y|1||38||OBSERVATION|1962-08-23|
TRIAL STUDY 134XCP|TR|7DF25CA4-0846-4180-9356-F53C704F0233|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ML/DOSE|FURTHER ENLARGEMENT||ELISA UNIT|NOT DONE|||DYNAMIC LIGHT SCATTERING|U|Y|VENDOR|PATHOLOGIST|U|2||58||INDUCTION TREATMENT|1972-01-09|
TRIAL STUDY 134XCP|TR|7DF25CA4-0846-4180-9356-F53C704F0233|3||||||CALCFIND|CALCIFICATION INDICATOR||UG/M2/H|INCREASED||VP/DOSE|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|U|U|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|3||39||INDUCTION TREATMENT|1970-10-07|
TRIAL STUDY 134XCP|TR|7DF25CA4-0846-4180-9356-F53C704F0233|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||% INHIBITION|PALPABLE||PNU/ML|NOT DONE|||SISH|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|4||88||LONG-TERM FOLLOW-UP|1966-12-11|
TRIAL STUDY 134XCP|TR|7DF25CA4-0846-4180-9356-F53C704F0233|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||CM/MIN|DIFFUSELY INCREASED||/LSQN|NOT DONE|||FARR ASSAY|NA|U|CAREGIVER|RADIOLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1970-07-15|
TRIAL STUDY 134XCP|TR|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^6 DNA COPIES/ML|FURTHER ENLARGEMENT||CARTRIDGE|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|U|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST|U|1||38||FOLLOW-UP|1972-03-28|
TRIAL STUDY 134XCP|TR|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MV*MIN|FURTHER ENLARGEMENT||SUPPOSITORY|NOT DONE|||CISH|N|Y|PARENT|CLINICAL PATHOLOGIST|Y|2||58||TREATMENT|1969-01-29|
TRIAL STUDY 134XCP|TR|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|3||||||LMBFLIND|LIMB FAILURE INDICATOR||MANSON U/ML|TUMOR MERGED||ML/KG/DAY|NOT DONE|||HANSEL STAIN|Y|NA|SPOUSE|ENDOCRINOLOGIST|U|3||39||RUN-IN|1971-07-30|
TRIAL STUDY 134XCP|TR|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|4||||||CALCFIND|CALCIFICATION INDICATOR||AMPULE|FURTHER ENLARGEMENT FROM NADIR||CL|NOT DONE|||BIOPSY|N|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|4||88||RUN-IN|1968-01-26|
TRIAL STUDY 134XCP|TR|92FB74AC-D410-4E35-AD9E-5F5A350B26C5|5||||||SUMVOL|SUM OF VOLUME||DNA COPIES/ML|DECREASED||KAT|NOT DONE|||ELECTROMYOGRAPHY|U|Y|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-06-19|
TRIAL STUDY 134XCP|TR|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||SUPPOSITORY|EQUIVOCAL||MM|NOT DONE|||PHASE CONTRAST MICROSCOPY|NA|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||TREATMENT|1964-01-11|
TRIAL STUDY 134XCP|TR|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^9 ORGANISMS/G|UNEQUIVOCAL||ELISA UNIT/ML|NOT DONE|||WESTERGREN|NA|U|ADJUDICATOR|NEUROLOGIST|NA|2||58||RUN-IN|1967-05-22|
TRIAL STUDY 134XCP|TR|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||UMOL/MOL|UNEQUIVOCAL||BISCUIT|NOT DONE|||MRI|N|NA|ADJUDICATION COMMITTEE|READER 3|N|3||39||WASHOUT|1964-11-29|
TRIAL STUDY 134XCP|TR|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|4||||||BNLNUM|NUMBER OF BONE LESIONS||BU|UNEQUIVOCAL||L/H/M2|NOT DONE|||TEST STRIP|Y|Y|PROXY|ADJUDICATOR 3|Y|4||88||INDUCTION TREATMENT|1969-11-27|
TRIAL STUDY 134XCP|TR|5ABEF81B-9399-4A5D-B57B-2CD0DE531EF6|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||IU/KG|TUMOR MERGED||10^9 ORGANISMS/G|NOT DONE|||HPLC|N|N|STUDY SUBJECT|ENDOCRINOLOGIST|U|5||7||SCREENING|1961-01-11|
TRIAL STUDY 134XCP|TR|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ABSORBANCE U/ML|ENLARGEMENT FROM NADIR||LINEAR FT*LB|NOT DONE|||MICRO BROTH DILUTION|N|Y|FRIEND|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1969-02-24|
TRIAL STUDY 134XCP|TR|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/MIN|NORMAL||PL|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|NA|FRIEND|PHYSIOTHERAPIST|U|2||58||BLINDED TREATMENT|1962-04-18|
TRIAL STUDY 134XCP|TR|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||DNA COPIES/UG|PRESENT||MM/SEC|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|Y|FAMILY MEMBER|PATHOLOGIST|NA|3||39||SCREENING|1965-11-15|
TRIAL STUDY 134XCP|TR|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||L/KG|DECREASED||/WK|NOT DONE|||ENZYMATIC COLORIMETRY|N|U|VENDOR|PATHOLOGIST|Y|4||88||FOLLOW-UP|1973-02-19|
TRIAL STUDY 134XCP|TR|895AAD86-9D50-41E1-AD1B-95CD9A7911C6|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||UG/H|NORMAL||UG/L|NOT DONE|||PHASE-CONTRAST MRI|NA|NA|VENDOR|OPHTHALMOLOGIST|Y|5||7||TREATMENT|1967-09-12|
TRIAL STUDY 134XCP|TR|2C15756E-1096-403B-989D-D2C3D31396A9|1||||||LDIAM|LONGEST DIAMETER||OSM|PALPABLE||LOZENGE|NOT DONE|||GRAM STAIN|N|N|PROXY|OPHTHALMOLOGIST|NA|1||38||TREATMENT|1960-03-31|
TRIAL STUDY 134XCP|TR|2C15756E-1096-403B-989D-D2C3D31396A9|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/CM3/MIN|NONPALPABLE||MS/MMHG|NOT DONE|||AUSCULTATION|Y|Y|STUDY SUBJECT|ADJUDICATOR 2|N|2||58||OBSERVATION|1973-03-07|
TRIAL STUDY 134XCP|TR|2C15756E-1096-403B-989D-D2C3D31396A9|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||BQ/L|NORMAL||NKAT/L|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|N|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|3||39||WASHOUT|1960-07-17|
TRIAL STUDY 134XCP|TR|2C15756E-1096-403B-989D-D2C3D31396A9|4||||||NEWCONF|NEW TUMOR CONFIRMED||UMOL/L|UNEQUIVOCAL||MCI/KG|NOT DONE|||CYSTOSCOPY|N|N|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|4||88||CONTINUATION TREATMENT|1961-05-30|
TRIAL STUDY 134XCP|TR|2C15756E-1096-403B-989D-D2C3D31396A9|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UG/M2/MIN|INCREASED||PPB|NOT DONE|||MICROBIAL CONCENTRATION|U|Y|VENDOR|MICROSCOPIST|N|5||7||CONTINUATION TREATMENT|1965-10-25|
TRIAL STUDY 134XCP|TR|CD103276-37FC-4E40-A0C8-8D1300D21AE1|1||||||ORSTATE|ORGAN STATE||10^9/L|NORMAL||KEV|NOT DONE|||MRI|N|Y|FRIEND|DERMATOLOGIST|NA|1||38||OPEN LABEL TREATMENT|1973-04-23|
TRIAL STUDY 134XCP|TR|CD103276-37FC-4E40-A0C8-8D1300D21AE1|2||||||RADIODEN|RADIODENSITY||MESF|PRESENT||MEQ/UL|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|NA|NA|DOMESTIC PARTNER|ADJUDICATOR 2|N|2||58||TREATMENT|1967-05-26|
TRIAL STUDY 134XCP|TR|CD103276-37FC-4E40-A0C8-8D1300D21AE1|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BE/ML|INCREASED||10^9 CFU/ML|NOT DONE|||HILLMEN COLOR CHART|NA|Y|ADJUDICATION COMMITTEE|RATER|U|3||39||SCREENING|1960-11-26|
TRIAL STUDY 134XCP|TR|CD103276-37FC-4E40-A0C8-8D1300D21AE1|4||||||BNLNUM|NUMBER OF BONE LESIONS||UG/DOSE|UNEQUIVOCAL||PNU/ML|NOT DONE|||TWO-COLOR MICROARRAY|Y|U|CLINICAL RESEARCH COORDINATOR|RATER 2|N|4||88||CONTINUATION TREATMENT|1972-06-27|
TRIAL STUDY 134XCP|TR|CD103276-37FC-4E40-A0C8-8D1300D21AE1|5||||||ORVERLN|ORGAN VERTICAL LENGTH||ABSORBANCE U/ML|EQUIVOCAL||BQ|NOT DONE|||TRYPAN BLUE STAIN|Y|NA|ADJUDICATOR|ONCOLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1966-02-19|
TRIAL STUDY 134XCP|TR|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||GTT|ENLARGEMENT FROM NADIR||ELISA UNIT/DOSE|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|N|GUARDIAN|CARDIOLOGIST|Y|1||38||BLINDED TREATMENT|1968-10-04|
TRIAL STUDY 134XCP|TR|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MPH|UNCHANGED||10^6/L|NOT DONE|||MAMMOGRAPHY|U|NA|PROXY|ADJUDICATOR 3|U|2||58||CONTINUATION TREATMENT|1968-11-29|
TRIAL STUDY 134XCP|TR|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|3||||||ORVERLN|ORGAN VERTICAL LENGTH||MAC50|FURTHER ENLARGEMENT FROM NADIR||LOG10 TCID 50/ML|NOT DONE|||FREEZING POINT DEPRESSION|N|Y|PROXY|HEMATOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1969-06-25|
TRIAL STUDY 134XCP|TR|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||CM/S|UNCHANGED||MG/KG/WEEK|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|N|U|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1970-11-30|
TRIAL STUDY 134XCP|TR|B9868C79-E6CC-4588-B5FA-3C9457D3C9C9|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||PMOL/DAY|NONPALPABLE||AFU|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|NA|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|5||7||INDUCTION TREATMENT|1960-01-20|
TRIAL STUDY 134XCP|TR|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||OI50|DECREASED||M/SEC2|NOT DONE|||FLAME PHOTOMETRY|Y|U|DOMESTIC PARTNER|ONCOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1971-11-30|
TRIAL STUDY 134XCP|TR|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MCI/L|NONPALPABLE||TSP|NOT DONE|||OBSERVATION|Y|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|N|2||58||BLINDED TREATMENT|1965-06-10|
TRIAL STUDY 134XCP|TR|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||NG/DL|FURTHER ENLARGEMENT FROM NADIR||UG/ML/H|NOT DONE|||FLOCCULATION|U|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|3||39||OPEN LABEL TREATMENT|1971-07-14|
TRIAL STUDY 134XCP|TR|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|4||||||ORVERLN|ORGAN VERTICAL LENGTH||MDFI|ABSENT||NMOL|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|N|VENDOR|ADJUDICATOR 1|N|4||88||BLINDED TREATMENT|1972-08-28|
TRIAL STUDY 134XCP|TR|EBF85B6C-B5DE-4E96-A9F8-96E24920545A|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^6/EJACULATE U|UNCHANGED||UL/DOSE|NOT DONE|||X-RAY|NA|Y|CAREGIVER|READER 1|U|5||7||TREATMENT|1971-01-21|
TRIAL STUDY 134XCP|TR|7B583F10-E460-4B25-8A6B-530A154442CD|1||||||VOLUME|VOLUME||UMOL/L/MIN|ABSENT||U/M2|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|Y|SIBLING|NEUROLOGIST 2|N|1||38||OPEN LABEL TREATMENT|1965-07-30|
TRIAL STUDY 134XCP|TR|7B583F10-E460-4B25-8A6B-530A154442CD|2||||||ORSTATE|ORGAN STATE||L/KG|PRESENT||MS/MMHG|NOT DONE|||PET/SPECT SCAN|N|Y|VENDOR|PATHOLOGIST 1|U|2||58||OPEN LABEL TREATMENT|1962-06-21|
TRIAL STUDY 134XCP|TR|7B583F10-E460-4B25-8A6B-530A154442CD|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||C|DECREASED||U/G HB|NOT DONE|||AMSLER GRID|U|N|FRIEND|CARDIOLOGIST|U|3||39||OBSERVATION|1962-12-30|
TRIAL STUDY 134XCP|TR|7B583F10-E460-4B25-8A6B-530A154442CD|4||||||ORSTATE|ORGAN STATE||MEQ/ML|PALPABLE||MPL U/ML|NOT DONE|||PET/SPECT SCAN|N|Y|HEALTH CARE PROFESSIONAL|READER|U|4||88||OBSERVATION|1960-03-22|
TRIAL STUDY 134XCP|TR|7B583F10-E460-4B25-8A6B-530A154442CD|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MAC50|TUMOR MERGED||BU/ML|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|Y|Y|CAREGIVER|MICROSCOPIST 1|U|5||7||TREATMENT|1960-11-23|
TRIAL STUDY 134XCP|TR|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|1||||||CALCFIND|CALCIFICATION INDICATOR||MPL U/ML|ABSENT||UMOL/DAY|NOT DONE|||POLYMERASE CHAIN REACTION|Y|NA|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|1||38||TREATMENT|1967-02-28|
TRIAL STUDY 134XCP|TR|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|2||||||TUMSTATE|TUMOR STATE||CAN|FURTHER ENLARGEMENT FROM NADIR||APS U|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|NA|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|U|2||58||BLINDED TREATMENT|1964-12-03|
TRIAL STUDY 134XCP|TR|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ML/M2/H|EQUIVOCAL||MIU/L|NOT DONE|||LISSAMINE GREEN STAIN|NA|NA|ADJUDICATOR|OPTOMETRIST|NA|3||39||RUN-IN|1973-05-12|
TRIAL STUDY 134XCP|TR|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|4||||||LESFLIND|LESION FAILURE INDICATOR||SCOOPFUL|PATHOLOGICAL||MAC50|NOT DONE|||ISHIHARA COLOR PLATES|Y|Y|VENDOR|MICROSCOPIST|NA|4||88||BASELINE|1972-08-16|
TRIAL STUDY 134XCP|TR|85FCA6B5-F6DC-4ED6-BBFD-92DB6DC4FEC6|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||GPL U|PRESENT||MOSM|NOT DONE|||RULER MEASUREMENT METHOD|N|N|SPOUSE|READER 2|Y|5||7||WASHOUT|1965-12-25|
TRIAL STUDY 134XCP|TR|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|1||||||BNLNUM|NUMBER OF BONE LESIONS||MMOL/MOL|ABSENT||U/KG/MIN|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|U|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|1||38||TREATMENT|1973-08-17|
TRIAL STUDY 134XCP|TR|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||HOURS|NON-PATHOLOGICAL||VIRTUAL PIXEL|NOT DONE|||MRI|U|NA|SIGNIFICANT OTHER|RATER 1|NA|2||58||BLINDED TREATMENT|1969-03-09|
TRIAL STUDY 134XCP|TR|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MEQ/UG|TUMOR MERGED||AU/ML|NOT DONE|||AMSLER GRID|U|NA|INVESTIGATOR|MICROSCOPIST 1|U|3||39||FOLLOW-UP|1968-10-02|
TRIAL STUDY 134XCP|TR|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|4||||||BNLNUM|NUMBER OF BONE LESIONS||IU/KG|UNEQUIVOCAL||MPH|NOT DONE|||APPLANATION TONOMETRY|Y|N|PROXY|INTERNIST|U|4||88||OPEN LABEL TREATMENT|1960-06-26|
TRIAL STUDY 134XCP|TR|E8D7AE54-09E7-429B-BD5B-318A1A4923CA|5||||||BNLNUM|NUMBER OF BONE LESIONS||ML/BEAT|FURTHER ENLARGEMENT||MOSM/KG|NOT DONE|||OBSERVATION|N|N|FRIEND|READER 3|N|5||7||WASHOUT|1964-07-29|
TRIAL STUDY 134XCP|TR|51FE575E-2161-414B-B772-9F1888E7C5CC|1||||||VSLPIND|VESSEL PATENCY INDICATOR||BLOCKS|NONPALPABLE||DAGU/ML|NOT DONE|||GEL ELECTROPHORESIS|Y|Y|NON-HEALTH CARE PROFESSIONAL|RATER|NA|1||38||SCREENING|1963-09-27|
TRIAL STUDY 134XCP|TR|51FE575E-2161-414B-B772-9F1888E7C5CC|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MOL/ML|FURTHER ENLARGEMENT FROM NADIR||UG/DAY|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|U|N|SIBLING|READER|U|2||58||BASELINE|1971-01-07|
TRIAL STUDY 134XCP|TR|51FE575E-2161-414B-B772-9F1888E7C5CC|3||||||AREA|AREA||10^6 CFU|DIFFUSELY INCREASED||10^6/EJACULATE U|NOT DONE|||IMMUNO-PET SCAN|NA|U|HEALTH CARE PROFESSIONAL|READER|NA|3||39||TREATMENT|1962-11-04|
TRIAL STUDY 134XCP|TR|51FE575E-2161-414B-B772-9F1888E7C5CC|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||KBQ/UL|PALPABLE||UV*SEC|NOT DONE|||DIRECT SEQUENCING|NA|N|INTERVIEWER|READER 2|NA|4||88||BASELINE|1965-08-20|
TRIAL STUDY 134XCP|TR|51FE575E-2161-414B-B772-9F1888E7C5CC|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||G/ANIMAL|UNEQUIVOCAL||SPRAY|NOT DONE|||NUCLEIC ACID SEQUENCING|Y|NA|FAMILY MEMBER|MICROSCOPIST 2|U|5||7||OBSERVATION|1972-08-19|
TRIAL STUDY 134XCP|TR|991C72FC-777F-4CED-824B-A4DECA57BE99|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||/LPF|ENLARGEMENT FROM NADIR||POUCH|NOT DONE|||PELLI-ROBSON EYE CHART|Y|Y|FAMILY MEMBER|NEUROLOGIST 1|N|1||38||CONTINUATION TREATMENT|1962-07-08|
TRIAL STUDY 134XCP|TR|991C72FC-777F-4CED-824B-A4DECA57BE99|2||||||ORVERLN|ORGAN VERTICAL LENGTH||H*%|UNEQUIVOCAL||LM|NOT DONE|||MAMMOGRAPHY|N|Y|CHILD|RATER 2|NA|2||58||CONTINUATION TREATMENT|1965-08-15|
TRIAL STUDY 134XCP|TR|991C72FC-777F-4CED-824B-A4DECA57BE99|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||GPL U|FURTHER ENLARGEMENT||MU/L|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|U|NA|INVESTIGATOR|READER 1|NA|3||39||OBSERVATION|1961-03-12|
TRIAL STUDY 134XCP|TR|991C72FC-777F-4CED-824B-A4DECA57BE99|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MOL/MOL|ENLARGEMENT FROM NADIR||10^7 PFU|NOT DONE|||OPTICAL MAPPING|N|N|PROXY|READER 2|N|4||88||WASHOUT|1967-07-14|
TRIAL STUDY 134XCP|TR|991C72FC-777F-4CED-824B-A4DECA57BE99|5||||||AREA|AREA||PPTR|UNEQUIVOCAL||10^3 COPIES/ML|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|NA|NA|CLINICAL STUDY SPONSOR|RATER 1|N|5||7||WASHOUT|1962-10-21|
TRIAL STUDY 134XCP|TR|FFECA538-8D16-421C-ACA2-4A769BC15D7D|1||||||VSLPIND|VESSEL PATENCY INDICATOR||MAMP|NONPALPABLE||UG|NOT DONE|||SPIRAL CT|NA|N|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|1||38||RUN-IN|1971-12-08|
TRIAL STUDY 134XCP|TR|FFECA538-8D16-421C-ACA2-4A769BC15D7D|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UG/KG|PALPABLE||BOWL|NOT DONE|||CT SCAN WITHOUT CONTRAST|U|N|SIGNIFICANT OTHER|UROLOGIST|N|2||58||RUN-IN|1963-01-04|
TRIAL STUDY 134XCP|TR|FFECA538-8D16-421C-ACA2-4A769BC15D7D|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KG/MOL|TUMOR MERGED||FT|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|U|NA|INTERVIEWER|MICROSCOPIST 1|N|3||39||BLINDED TREATMENT|1970-10-17|
TRIAL STUDY 134XCP|TR|FFECA538-8D16-421C-ACA2-4A769BC15D7D|4||||||VOLUME|VOLUME||1/(S*KPA)|DECREASED||MMHG/L/MIN|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|N|U|ADJUDICATOR|NEUROLOGIST|U|4||88||RUN-IN|1964-01-15|
TRIAL STUDY 134XCP|TR|FFECA538-8D16-421C-ACA2-4A769BC15D7D|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||DMOL|PATHOLOGICAL||BAR|NOT DONE|||IMMUNORADIOMETRIC ASSAY|NA|U|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|5||7||TREATMENT|1971-05-14|
TRIAL STUDY 134XCP|TR|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||/5X10^4 WBC|INCREASED||U/DL|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|Y|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|U|1||38||CONTINUATION TREATMENT|1965-05-09|
TRIAL STUDY 134XCP|TR|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||NMOL/DAY|FURTHER ENLARGEMENT||GY|NOT DONE|||WRIGHT-GIEMSA STAIN|U|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|2||58||TREATMENT|1967-09-29|
TRIAL STUDY 134XCP|TR|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^7/L|EQUIVOCAL||KA_U/DL|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|U|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|3||39||FOLLOW-UP|1965-02-25|
TRIAL STUDY 134XCP|TR|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||RATIO|UNEQUIVOCAL||BEAM BREAKS|NOT DONE|||GC/FID|N|Y|FRIEND|ENDOCRINOLOGIST|U|4||88||OBSERVATION|1972-04-09|
TRIAL STUDY 134XCP|TR|72FB03F9-3FF5-4039-98AE-8FC966A6E01E|5||||||DIAMETER|DIAMETER||LOG10 TCID 50/UL|NONPALPABLE||GBQ|NOT DONE|||NO INFORMATION|U|N|PROXY|RADIOLOGIST 1|U|5||7||INDUCTION TREATMENT|1973-07-07|
TRIAL STUDY 134XCP|TR|54507F00-0C16-4F35-A762-104B47390283|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||U/G/MIN|NORMAL||ML/M2/H|NOT DONE|||RADIATION DOSIMETRY|N|NA|STUDY SUBJECT|ADJUDICATOR 3|Y|1||38||SCREENING|1972-08-31|
TRIAL STUDY 134XCP|TR|54507F00-0C16-4F35-A762-104B47390283|2||||||VSLPIND|VESSEL PATENCY INDICATOR||CI/G|FURTHER ENLARGEMENT FROM NADIR||IU/KG|NOT DONE|||ERGOSPIROMETRY|NA|NA|PARENT|NEUROLOGIST 2|U|2||58||SCREENING|1972-02-28|
TRIAL STUDY 134XCP|TR|54507F00-0C16-4F35-A762-104B47390283|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MV/SEC|INCREASED||MG2/DL2|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|N|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|Y|3||39||INDUCTION TREATMENT|1960-10-15|
TRIAL STUDY 134XCP|TR|54507F00-0C16-4F35-A762-104B47390283|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||FRAMES/S|PRESENT||M/SEC|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|N|Y|STUDY SUBJECT|RATER 1|NA|4||88||BLINDED TREATMENT|1963-10-17|
TRIAL STUDY 134XCP|TR|54507F00-0C16-4F35-A762-104B47390283|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||/WK|NORMAL||UG/L/H|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|N|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|5||7||BLINDED TREATMENT|1966-01-10|
TRIAL STUDY 134XCP|TR|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MM/2H|PALPABLE||U/ANIMAL|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|Y|Y|FAMILY MEMBER|ONCOLOGIST|Y|1||38||TREATMENT|1961-11-30|
TRIAL STUDY 134XCP|TR|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|2||||||AREA|AREA||S*KPA|ENLARGEMENT FROM NADIR||RING|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|NA|U|INTERVIEWER|UROLOGIST|Y|2||58||OBSERVATION|1964-02-01|
TRIAL STUDY 134XCP|TR|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||G/DAY|DECREASED||KV|NOT DONE|||ROMANOWSKY STAIN|N|N|SIBLING|DERMATOLOGIST|NA|3||39||CONTINUATION TREATMENT|1960-04-06|
TRIAL STUDY 134XCP|TR|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||HENRY|DECREASED||ANSON U|NOT DONE|||IODINE STAIN|N|N|STUDY SUBJECT|RADIOLOGIST|U|4||88||TREATMENT|1966-05-10|
TRIAL STUDY 134XCP|TR|2CFF24EC-FBE1-4A45-9FCE-9DAAD35D9566|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||G/KG/DAY|PATHOLOGICAL||NCI|NOT DONE|||POLYGRAPHY|U|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|5||7||FOLLOW-UP|1960-03-19|
TRIAL STUDY 134XCP|TR|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/DAY|FURTHER ENLARGEMENT||RING|NOT DONE|||HANSEL STAIN|U|N|PARENT|ONCOLOGIST 2|U|1||38||SCREENING|1965-09-03|
TRIAL STUDY 134XCP|TR|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|2||||||PALPSTAT|PALPABLE STATE||KG/M2|NORMAL||MOSM/L|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|NA|U|VENDOR|MICROSCOPIST 1|NA|2||58||OPEN LABEL TREATMENT|1963-10-13|
TRIAL STUDY 134XCP|TR|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|3||||||LNSTATE|LYMPH NODE STATE||GRAIN|PRESENT||MG/M2/DAY|NOT DONE|||NO INFORMATION|N|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|3||39||BLINDED TREATMENT|1960-02-18|
TRIAL STUDY 134XCP|TR|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MM/H|EQUIVOCAL||CM2|NOT DONE|||ELECTROMYOGRAPHY|U|Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BLINDED TREATMENT|1965-04-04|
TRIAL STUDY 134XCP|TR|C16428B9-880B-47B9-BF1D-2CF87DE8ECE1|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||BQ/KG|NON-PATHOLOGICAL||MM/H|NOT DONE|||DC SHEATH FLOW|U|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|5||7||BASELINE|1964-12-07|
TRIAL STUDY 134XCP|TR|CF8F9036-3380-4A0B-B17A-7EF814B02700|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PG/L|NORMAL||G|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|SPOUSE|READER 2|N|1||38||TREATMENT|1969-04-17|
TRIAL STUDY 134XCP|TR|CF8F9036-3380-4A0B-B17A-7EF814B02700|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||PMOL/L|NONPALPABLE||IU/L|NOT DONE|||MICROBIAL CULTURE, LIQUID|N|U|CHILD|MICROSCOPIST 1|U|2||58||BLINDED TREATMENT|1966-02-07|
TRIAL STUDY 134XCP|TR|CF8F9036-3380-4A0B-B17A-7EF814B02700|3||||||PALPSTAT|PALPABLE STATE||MG/G/H|ENLARGEMENT||U/G|NOT DONE|||SCINTIGRAPHY|Y|NA|CAREGIVER|RATER 2|Y|3||39||LONG-TERM FOLLOW-UP|1972-01-14|
TRIAL STUDY 134XCP|TR|CF8F9036-3380-4A0B-B17A-7EF814B02700|4||||||AREA|AREA||DROP|DIFFUSELY INCREASED||10^3/HPF|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|NA|N|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|4||88||WASHOUT|1965-10-07|
TRIAL STUDY 134XCP|TR|CF8F9036-3380-4A0B-B17A-7EF814B02700|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^6 U|NONPALPABLE||10^4 CFU/ML|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|NA|SPOUSE|INTERNIST|U|5||7||BASELINE|1967-05-17|
TRIAL STUDY 134XCP|TR|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|1||||||LESFLIND|LESION FAILURE INDICATOR||DPM/ML|INCREASED||10^3/HPF|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|U|U|SIBLING|CARDIOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1968-05-30|
TRIAL STUDY 134XCP|TR|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||%/S|ENLARGEMENT||MCI|NOT DONE|||GC/MS-EI|U|U|SPOUSE|ADJUDICATOR 2|N|2||58||RUN-IN|1970-08-18|
TRIAL STUDY 134XCP|TR|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|3||||||LESFLIND|LESION FAILURE INDICATOR||MM3/MM2/YEAR|DIFFUSELY INCREASED||SYRINGE|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|FRIEND|ONCOLOGIST|Y|3||39||OBSERVATION|1972-08-28|
TRIAL STUDY 134XCP|TR|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MOL|ABSENT||FFU|NOT DONE|||CONFOCAL MICROSCOPY|U|U|FRIEND|READER 1|U|4||88||FOLLOW-UP|1971-09-02|
TRIAL STUDY 134XCP|TR|0DE06EA9-D4D1-4E52-8FF6-29B334E9BB8D|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ABSORBANCE U/ML|PALPABLE||GY/MIN|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|NA|NA|CHILD|ADJUDICATOR|NA|5||7||OBSERVATION|1960-10-06|
TRIAL STUDY 134XCP|TR|58360390-F6AB-41D7-9A0D-1039E795403E|1||||||VDIAM|VIABLE DIAMETER||/2000 RBC|EQUIVOCAL||/MIN|NOT DONE|||MYELOPEROXIDASE STAIN|N|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1||38||FOLLOW-UP|1963-12-10|
TRIAL STUDY 134XCP|TR|58360390-F6AB-41D7-9A0D-1039E795403E|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||IN2|NONPALPABLE||MEQ/ML|NOT DONE|||CONGO RED STAIN|NA|U|FRIEND|NEUROLOGIST 2|NA|2||58||FOLLOW-UP|1965-10-02|
TRIAL STUDY 134XCP|TR|58360390-F6AB-41D7-9A0D-1039E795403E|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||OZ|ENLARGEMENT FROM NADIR||WEEKS|NOT DONE|||TOTAL BODY RADIOGRAPHY|U|N|SIBLING|INTERNIST|Y|3||39||SCREENING|1966-12-06|
TRIAL STUDY 134XCP|TR|58360390-F6AB-41D7-9A0D-1039E795403E|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||COPIES/UG|ENLARGEMENT FROM NADIR||BU|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|N|Y|FRIEND|NEUROLOGIST|U|4||88||BASELINE|1966-05-12|
TRIAL STUDY 134XCP|TR|58360390-F6AB-41D7-9A0D-1039E795403E|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||L/L|DECREASED||MPL U/ML|NOT DONE|||HIGH RESOLUTION CT|NA|N|DOMESTIC PARTNER|ONCOLOGIST 2|Y|5||7||BASELINE|1966-12-29|
TRIAL STUDY 134XCP|TR|61B02780-0C99-47F8-93B2-CA839876604E|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MOSM/L|FOCALLY INCREASED||DAYS|NOT DONE|||IMPULSE OSCILLOMETRY|U|Y|FAMILY MEMBER|ENDOCRINOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1964-05-21|
TRIAL STUDY 134XCP|TR|61B02780-0C99-47F8-93B2-CA839876604E|2||||||VDIAM|VIABLE DIAMETER||UG/L/H|PRESENT||KM/H|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|NA|N|CHILD|UROLOGIST|U|2||58||FOLLOW-UP|1961-12-03|
TRIAL STUDY 134XCP|TR|61B02780-0C99-47F8-93B2-CA839876604E|3||||||CALCFIND|CALCIFICATION INDICATOR||NM|DECREASED||OSM|NOT DONE|||HANSEL STAIN|N|N|CAREGIVER|MICROSCOPIST 1|N|3||39||INDUCTION TREATMENT|1971-01-21|
TRIAL STUDY 134XCP|TR|61B02780-0C99-47F8-93B2-CA839876604E|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PIPE|UNEQUIVOCAL||MG/ML/MIN|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|N|Y|SIGNIFICANT OTHER|ADJUDICATOR|U|4||88||TREATMENT|1966-12-09|
TRIAL STUDY 134XCP|TR|61B02780-0C99-47F8-93B2-CA839876604E|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||PMOL/DAY|PATHOLOGICAL||10^6 IU/ML|NOT DONE|||CYSTOSCOPY|U|NA|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|5||7||TREATMENT|1971-09-13|
TRIAL STUDY 134XCP|TR|1381458A-D702-467D-ADCA-984EE7BD894D|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||FG|PRESENT||UCI/L|NOT DONE|||FLUORESCEIN STAIN|Y|Y|ADJUDICATOR|ADJUDICATOR 3|N|1||38||LONG-TERM FOLLOW-UP|1960-11-11|
TRIAL STUDY 134XCP|TR|1381458A-D702-467D-ADCA-984EE7BD894D|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||AMFI|NORMAL||F|NOT DONE|||GIEMSA STAIN|N|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|2||58||BASELINE|1965-01-12|
TRIAL STUDY 134XCP|TR|1381458A-D702-467D-ADCA-984EE7BD894D|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||FT3|FURTHER ENLARGEMENT FROM NADIR||LOG10 IU/ML|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|N|PARENT|OPHTHALMOLOGIST|U|3||39||FOLLOW-UP|1968-10-29|
TRIAL STUDY 134XCP|TR|1381458A-D702-467D-ADCA-984EE7BD894D|4||||||VDIAM|VIABLE DIAMETER||NEEDLE GAUGE|FOCALLY INCREASED||PPM|NOT DONE|||CARDIAC THERMODILUTION|NA|Y|INDEPENDENT ASSESSOR|READER 1|N|4||88||TREATMENT|1965-10-31|
TRIAL STUDY 134XCP|TR|1381458A-D702-467D-ADCA-984EE7BD894D|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||DPM/MG|DECREASED||UCI/L|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|N|Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|5||7||RUN-IN|1962-05-01|
TRIAL STUDY 134XCP|TR|04211DA3-CFD5-4750-9D61-C91FF7BC338A|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||PIXEL|UNCHANGED||MG/MIN|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|N|DOMESTIC PARTNER|ADJUDICATOR 3|Y|1||38||RUN-IN|1970-06-09|
TRIAL STUDY 134XCP|TR|04211DA3-CFD5-4750-9D61-C91FF7BC338A|2||||||CALCFIND|CALCIFICATION INDICATOR||10^6 COPIES/ML|PATHOLOGICAL||IU|NOT DONE|||INDIA INK STAIN|N|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|2||58||OBSERVATION|1973-07-20|
TRIAL STUDY 134XCP|TR|04211DA3-CFD5-4750-9D61-C91FF7BC338A|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MG/H|TUMOR MERGED||YD|NOT DONE|||PHOROPTER|NA|N|CHILD|ADJUDICATOR 2|Y|3||39||SCREENING|1967-02-04|
TRIAL STUDY 134XCP|TR|04211DA3-CFD5-4750-9D61-C91FF7BC338A|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||COPIES/ML|TUMOR MERGED||IU/G|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|N|N|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|4||88||FOLLOW-UP|1973-01-29|
TRIAL STUDY 134XCP|TR|04211DA3-CFD5-4750-9D61-C91FF7BC338A|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||10^12 IU/L|PRESENT||PL|NOT DONE|||OBSERVATION|NA|Y|FAMILY MEMBER|ADJUDICATOR|Y|5||7||INDUCTION TREATMENT|1973-07-10|
TRIAL STUDY 134XCP|TR|EF707A48-6FAD-47C0-913A-5CBCACA539E0|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||BQ/KG|NON-PATHOLOGICAL||CI/ML|NOT DONE|||CONTRAST ENHANCED MRI|U|Y|SPOUSE|NEUROLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1963-02-27|
TRIAL STUDY 134XCP|TR|EF707A48-6FAD-47C0-913A-5CBCACA539E0|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^3/L|PRESENT||CM/MIN|NOT DONE|||REVERSE TRANSCRIPTASE PCR|NA|U|ADJUDICATOR|ADJUDICATOR 3|Y|2||58||INDUCTION TREATMENT|1963-12-04|
TRIAL STUDY 134XCP|TR|EF707A48-6FAD-47C0-913A-5CBCACA539E0|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KCAL/DAY|TUMOR MERGED||UG/L|NOT DONE|||GRAM STAIN|N|NA|INTERVIEWER|ADJUDICATOR 2|N|3||39||FOLLOW-UP|1970-09-19|
TRIAL STUDY 134XCP|TR|EF707A48-6FAD-47C0-913A-5CBCACA539E0|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||STEPS|UNEQUIVOCAL||COPIES/ML|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|U|U|FRIEND|DERMATOLOGIST|NA|4||88||TREATMENT|1960-05-26|
TRIAL STUDY 134XCP|TR|EF707A48-6FAD-47C0-913A-5CBCACA539E0|5||||||LESFLIND|LESION FAILURE INDICATOR||U/KG/H|ENLARGEMENT||MJOULE/CM2|NOT DONE|||HEMAGGLUTINATION ASSAY|U|Y|CLINICAL STUDY SPONSOR|READER 3|N|5||7||CONTINUATION TREATMENT|1967-01-26|
TRIAL STUDY 134XCP|TR|C896767E-2418-4226-A8AE-D875DA40F9FB|1||||||PALPSTAT|PALPABLE STATE||G/L|DIFFUSELY INCREASED||HEP|NOT DONE|||TARGETED GENOME SEQUENCING|NA|Y|PARENT|ONCOLOGIST|N|1||38||OBSERVATION|1960-11-26|
TRIAL STUDY 134XCP|TR|C896767E-2418-4226-A8AE-D875DA40F9FB|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MMOL/G|TUMOR MERGED||MIN*MG/ML|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|NA|SIGNIFICANT OTHER|INTERNIST|Y|2||58||WASHOUT|1960-08-17|
TRIAL STUDY 134XCP|TR|C896767E-2418-4226-A8AE-D875DA40F9FB|3||||||DIAMETER|DIAMETER||UV|ENLARGEMENT||NG/DAY|NOT DONE|||SICKLE CELL SOLUBILITY TEST|N|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|3||39||BASELINE|1968-03-30|
TRIAL STUDY 134XCP|TR|C896767E-2418-4226-A8AE-D875DA40F9FB|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UKAT|ABSENT||/MIN|NOT DONE|||CELLULAR PROLIFERATION ASSAY|Y|NA|FRIEND|READER 3|NA|4||88||WASHOUT|1965-05-29|
TRIAL STUDY 134XCP|TR|C896767E-2418-4226-A8AE-D875DA40F9FB|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||KG|ABSENT||FIU|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||RUN-IN|1970-02-02|
TRIAL STUDY 134XCP|TR|666BC019-B828-4DB4-BD2F-973BA689C9E7|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ML/BREATH|DIFFUSELY INCREASED||KDA|NOT DONE|||DXA SCAN|N|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|1||38||OBSERVATION|1970-09-28|
TRIAL STUDY 134XCP|TR|666BC019-B828-4DB4-BD2F-973BA689C9E7|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MU/L|INCREASED||10^5/HPF|NOT DONE|||WEBER GREEN STAIN|N|Y|CAREGIVER|FORENSIC PATHOLOGIST|N|2||58||INDUCTION TREATMENT|1972-03-20|
TRIAL STUDY 134XCP|TR|666BC019-B828-4DB4-BD2F-973BA689C9E7|3||||||LMBFLIND|LIMB FAILURE INDICATOR||CI/UG|DIFFUSELY INCREASED||PG/CELL|NOT DONE|||MANUAL COUNT|N|Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3||39||OPEN LABEL TREATMENT|1972-01-04|
TRIAL STUDY 134XCP|TR|666BC019-B828-4DB4-BD2F-973BA689C9E7|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||BOX|ENLARGEMENT FROM NADIR||U/10^12 RBC|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|N|N|STUDY SUBJECT|ADJUDICATOR|NA|4||88||FOLLOW-UP|1971-06-21|
TRIAL STUDY 134XCP|TR|666BC019-B828-4DB4-BD2F-973BA689C9E7|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||LOG10 CFU/ML|ENLARGEMENT||KCAL/DAY|NOT DONE|||NO INFORMATION|N|N|STUDY SUBJECT|ONCOLOGIST 1|U|5||7||LONG-TERM FOLLOW-UP|1960-08-09|
TRIAL STUDY 134XCP|TR|91282D87-4943-4527-8F33-27A5C153951C|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||OI50|ENLARGEMENT FROM NADIR||KA_U/DL|NOT DONE|||AUDIOMETRY|N|NA|INTERVIEWER|ONCOLOGIST 2|NA|1||38||TREATMENT|1970-02-11|
TRIAL STUDY 134XCP|TR|91282D87-4943-4527-8F33-27A5C153951C|2||||||LESFLIND|LESION FAILURE INDICATOR||KPA|TUMOR MERGED||ML/ANIMAL/DAY|NOT DONE|||FLUOROSCOPY|Y|Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||LONG-TERM FOLLOW-UP|1966-06-18|
TRIAL STUDY 134XCP|TR|91282D87-4943-4527-8F33-27A5C153951C|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^8 PFU|TUMOR MERGED||EID 50/DOSE|NOT DONE|||SMEAR|U|N|CAREGIVER|ADJUDICATOR|N|3||39||BASELINE|1965-05-23|
TRIAL STUDY 134XCP|TR|91282D87-4943-4527-8F33-27A5C153951C|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||NG/DAY|NONPALPABLE||COULOMB|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|U|Y|SIBLING|READER 2|NA|4||88||INDUCTION TREATMENT|1971-06-30|
TRIAL STUDY 134XCP|TR|91282D87-4943-4527-8F33-27A5C153951C|5||||||BNLNUM|NUMBER OF BONE LESIONS||UG/L/H|PRESENT||FFU|NOT DONE|||DYNAMOMETRY|U|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1960-10-13|
TRIAL STUDY 134XCP|TR|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||LENS|ENLARGEMENT FROM NADIR||UMOL/MIN|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|1||38||FOLLOW-UP|1966-04-22|
TRIAL STUDY 134XCP|TR|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||ML|FURTHER ENLARGEMENT FROM NADIR||ML/G/DAY|NOT DONE|||ENDPOINT DILUTION ASSAY|NA|NA|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|2||58||BASELINE|1966-07-09|
TRIAL STUDY 134XCP|TR|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|3||||||LESFLIND|LESION FAILURE INDICATOR||10^6 DNA COPIES/ML|FURTHER ENLARGEMENT||UMOL/DL|NOT DONE|||CLINICAL EVALUATION|NA|N|CAREGIVER|OPHTHALMOLOGIST|Y|3||39||BASELINE|1971-05-22|
TRIAL STUDY 134XCP|TR|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|4||||||ORSTATE|ORGAN STATE||/KG|FOCALLY INCREASED||ML/S|NOT DONE|||MAPH|NA|Y|INVESTIGATOR|ENDOCRINOLOGIST|N|4||88||BASELINE|1961-05-14|
TRIAL STUDY 134XCP|TR|1A56C9D3-ADEE-42C0-BF43-CE42F70E9A6A|5||||||TUMSTATE|TUMOR STATE||PPM|DECREASED||CPM|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|N|NA|ADJUDICATION COMMITTEE|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1967-01-25|
TRIAL STUDY 134XCP|TR|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|1||||||DIAMETER|DIAMETER||UG/KG|FOCALLY INCREASED||TROCHE|NOT DONE|||PEAK FLOWMETRY|NA|U|GUARDIAN|RATER 1|Y|1||38||SCREENING|1961-09-11|
TRIAL STUDY 134XCP|TR|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||TESLA|UNEQUIVOCAL||MG/KG/DOSE|NOT DONE|||RYAN BLUE STAIN|NA|U|STUDY SUBJECT|OTOLARYNGOLOGIST|NA|2||58||WASHOUT|1961-06-03|
TRIAL STUDY 134XCP|TR|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MG/KG/H|UNCHANGED||LOG10 ELISA UNIT/DOSE|NOT DONE|||PULMONARY ANGIOGRAPHY|Y|U|SIGNIFICANT OTHER|RADIOLOGIST 1|N|3||39||RUN-IN|1967-03-30|
TRIAL STUDY 134XCP|TR|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|4||||||SUMVOL|SUM OF VOLUME||DPM/100MG|FURTHER ENLARGEMENT FROM NADIR||/10^5|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|U|PROXY|INTERNIST|NA|4||88||CONTINUATION TREATMENT|1966-05-14|
TRIAL STUDY 134XCP|TR|0D0EC1C5-B2B7-4D1C-9986-5F9915B81DE2|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MEQ/MMOL|PALPABLE||CP|NOT DONE|||AGAR DILUTION|N|U|ADJUDICATOR|ONCOLOGIST 2|Y|5||7||SCREENING|1972-07-12|
TRIAL STUDY 134XCP|TR|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||DRUM|ENLARGEMENT||UEQ/L|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|NA|GUARDIAN|READER|Y|1||38||FOLLOW-UP|1968-01-01|
TRIAL STUDY 134XCP|TR|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||LOG10 CFU/G|NORMAL||ROENTGEN|NOT DONE|||MICRONEUTRALIZATION ASSAY|N|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|2||58||CONTINUATION TREATMENT|1966-07-22|
TRIAL STUDY 134XCP|TR|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||ML/DL|PRESENT||G|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|NA|U|INVESTIGATOR|NEUROLOGIST|NA|3||39||SCREENING|1972-08-06|
TRIAL STUDY 134XCP|TR|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||IU|NONPALPABLE||LOG10 CFU/ML|NOT DONE|||DUCTOGRAPHY|NA|U|VENDOR|ONCOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1961-05-23|
TRIAL STUDY 134XCP|TR|5A3D2F32-F73C-4ADF-988C-8AB33B0754B1|5||||||LESSCIND|LESION SUCCESS INDICATOR||MEQ/KG|PRESENT||MG/M2|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|N|Y|ADJUDICATOR|RATER 2|U|5||7||SCREENING|1967-04-07|
TRIAL STUDY 134XCP|TR|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ABSORBANCE U/MIN|DIFFUSELY INCREASED||U/G|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|N|STUDY SUBJECT|CARDIOLOGIST|N|1||38||OBSERVATION|1970-07-29|
TRIAL STUDY 134XCP|TR|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||BQ/G|EQUIVOCAL||MMOL/MIN/KPA/L|NOT DONE|||MUGA|Y|U|INTERVIEWER|INTERNIST|N|2||58||BASELINE|1970-11-24|
TRIAL STUDY 134XCP|TR|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|3||||||LDIAM|LONGEST DIAMETER||BOLUS|EQUIVOCAL||GPS U|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|Y|N|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|3||39||TREATMENT|1960-10-26|
TRIAL STUDY 134XCP|TR|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|4||||||VSLPIND|VESSEL PATENCY INDICATOR||NEWTON|INCREASED||HZ|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|U|ADJUDICATOR|MICROSCOPIST 2|N|4||88||BLINDED TREATMENT|1965-05-20|
TRIAL STUDY 134XCP|TR|9D32C2B3-CC4A-4C8C-9D91-6726F4D280C6|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||KPA|DIFFUSELY INCREASED||DL|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|U|N|DOMESTIC PARTNER|ADJUDICATOR 2|N|5||7||RUN-IN|1971-08-09|
TRIAL STUDY 134XCP|TR|0320460C-3770-486A-85EB-ECD133AE6EFA|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||ENZYME U|ABSENT||VIAL|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|N|Y|STUDY SUBJECT|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1970-03-01|
TRIAL STUDY 134XCP|TR|0320460C-3770-486A-85EB-ECD133AE6EFA|2||||||CALCFIND|CALCIFICATION INDICATOR||AG|PATHOLOGICAL||MONTHS|NOT DONE|||GC/MS-EI|NA|N|SIGNIFICANT OTHER|RADIOLOGIST 2|N|2||58||INDUCTION TREATMENT|1969-12-05|
TRIAL STUDY 134XCP|TR|0320460C-3770-486A-85EB-ECD133AE6EFA|3||||||LNSTATE|LYMPH NODE STATE||ML/S/M2|NON-PATHOLOGICAL||10^4 CFU|NOT DONE|||ENZYMATIC COLORIMETRY|U|NA|CAREGIVER|OPHTHALMOLOGIST|N|3||39||BASELINE|1968-12-14|
TRIAL STUDY 134XCP|TR|0320460C-3770-486A-85EB-ECD133AE6EFA|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||U/G|EQUIVOCAL||CM/S|NOT DONE|||HPLC/MS/MS|NA|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|4||88||BASELINE|1973-07-03|
TRIAL STUDY 134XCP|TR|0320460C-3770-486A-85EB-ECD133AE6EFA|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||INHALATION|NON-PATHOLOGICAL||CM H2O|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|NA|N|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|5||7||CONTINUATION TREATMENT|1967-02-22|
TRIAL STUDY 134XCP|TR|810B0B08-9236-41EC-8879-924661FA224E|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||/100 HPFS|NON-PATHOLOGICAL||MM3/MM2/YEAR|NOT DONE|||RIA|Y|Y|CHILD|MICROSCOPIST|NA|1||38||FOLLOW-UP|1965-07-03|
TRIAL STUDY 134XCP|TR|810B0B08-9236-41EC-8879-924661FA224E|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||C|EQUIVOCAL||LOG10 CFU/ML|NOT DONE|||SPECT SCAN|U|NA|FRIEND|RADIOLOGIST 2|U|2||58||SCREENING|1964-04-26|
TRIAL STUDY 134XCP|TR|810B0B08-9236-41EC-8879-924661FA224E|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||LM|UNCHANGED||ML/MMHG/MIN/L|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|3||39||BLINDED TREATMENT|1961-03-19|
TRIAL STUDY 134XCP|TR|810B0B08-9236-41EC-8879-924661FA224E|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||G/L|UNCHANGED||UG/L/H|NOT DONE|||MICRODENSITOMETRY|Y|NA|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||WASHOUT|1968-10-17|
TRIAL STUDY 134XCP|TR|810B0B08-9236-41EC-8879-924661FA224E|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||KALLIKREIN INHIBITOR UNIT|NORMAL||LOG10 ELISA UNIT/DOSE|NOT DONE|||FUNDUS PHOTOGRAPHY|U|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|5||7||RUN-IN|1965-11-13|
TRIAL STUDY 134XCP|TR|BA3B0D91-DC95-4916-8ACA-71451447BE81|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MMOL/S|DIFFUSELY INCREASED||OSM|NOT DONE|||PHASE-CONTRAST MRI|NA|U|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|1||38||BLINDED TREATMENT|1963-09-12|
TRIAL STUDY 134XCP|TR|BA3B0D91-DC95-4916-8ACA-71451447BE81|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||DRUM|PALPABLE||GPS U|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|NA|FAMILY MEMBER|DERMATOLOGIST|Y|2||58||BLINDED TREATMENT|1966-09-19|
TRIAL STUDY 134XCP|TR|BA3B0D91-DC95-4916-8ACA-71451447BE81|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||CONTAINER|UNCHANGED||DNA COPIES/ML|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|U|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||BASELINE|1966-06-10|
TRIAL STUDY 134XCP|TR|BA3B0D91-DC95-4916-8ACA-71451447BE81|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||TRANSDUCING UNIT|PALPABLE||IN2|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|Y|PARENT|PATHOLOGIST|Y|4||88||BASELINE|1961-09-03|
TRIAL STUDY 134XCP|TR|BA3B0D91-DC95-4916-8ACA-71451447BE81|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||/LSQN|ENLARGEMENT||MOL/ML|NOT DONE|||SMEAR|U|N|GUARDIAN|READER 1|U|5||7||BLINDED TREATMENT|1973-03-04|
TRIAL STUDY 134XCP|TR|DE385129-5FB9-43C3-9FB1-005886674C9B|1||||||LPERP|LONGEST PERPENDICULAR||FMOL/G|NON-PATHOLOGICAL||IU/KG/H|NOT DONE|||ENDPOINT DILUTION ASSAY|NA|NA|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1964-03-21|
TRIAL STUDY 134XCP|TR|DE385129-5FB9-43C3-9FB1-005886674C9B|2||||||LNSTATE|LYMPH NODE STATE||MMHG/L/MIN|TUMOR MERGED||H/WK|NOT DONE|||TEMPLATE INCISION METHOD|NA|U|PROXY|OPTOMETRIST|N|2||58||RUN-IN|1962-04-18|
TRIAL STUDY 134XCP|TR|DE385129-5FB9-43C3-9FB1-005886674C9B|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||EQ|FOCALLY INCREASED||CYCLE/MIN|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|NA|FRIEND|READER 2|Y|3||39||INDUCTION TREATMENT|1966-02-25|
TRIAL STUDY 134XCP|TR|DE385129-5FB9-43C3-9FB1-005886674C9B|4||||||SUMVOL|SUM OF VOLUME||PNU/ML|UNCHANGED||SV|NOT DONE|||FLUORESCENT MICROSCOPY|U|NA|DOMESTIC PARTNER|NEUROLOGIST 1|N|4||88||RUN-IN|1966-05-16|
TRIAL STUDY 134XCP|TR|DE385129-5FB9-43C3-9FB1-005886674C9B|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML/ANIMAL/WK|FURTHER ENLARGEMENT||10^7 TCID 50/DOSE|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|U|NA|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|5||7||LONG-TERM FOLLOW-UP|1967-12-27|
TRIAL STUDY 134XCP|TR|8AE8077F-A13C-4593-B012-213A5EBE0A1D|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||ML/H|NORMAL||MMOL/G|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|N|NA|VENDOR|MICROSCOPIST|NA|1||38||CONTINUATION TREATMENT|1962-07-08|
TRIAL STUDY 134XCP|TR|8AE8077F-A13C-4593-B012-213A5EBE0A1D|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||L/S/KPA|FURTHER ENLARGEMENT||L/MIN/M2|NOT DONE|||TELLER ACUITY CARDS|U|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|2||58||FOLLOW-UP|1970-01-29|
TRIAL STUDY 134XCP|TR|8AE8077F-A13C-4593-B012-213A5EBE0A1D|3||||||LESFLIND|LESION FAILURE INDICATOR||DMOL|ENLARGEMENT||DAGU|NOT DONE|||MICROBIAL CULTURE, LIQUID|N|U|INVESTIGATOR|RADIOLOGIST 2|U|3||39||BLINDED TREATMENT|1970-02-17|
TRIAL STUDY 134XCP|TR|8AE8077F-A13C-4593-B012-213A5EBE0A1D|4||||||SUMDIAM|SUM OF DIAMETER||EID 50/DOSE|UNEQUIVOCAL||MPS U|NOT DONE|||RADIATION DOSIMETRY|N|U|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|4||88||OBSERVATION|1973-04-26|
TRIAL STUDY 134XCP|TR|8AE8077F-A13C-4593-B012-213A5EBE0A1D|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^9 CFU|DIFFUSELY INCREASED||DAMOL/L|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|N|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|N|5||7||WASHOUT|1963-02-10|
TRIAL STUDY 134XCP|TR|72FCE18B-B3D6-45AC-993F-9883E4D11313|1||||||LESSCIND|LESION SUCCESS INDICATOR||DNA COPIES/UG|UNEQUIVOCAL||G/ANIMAL/DAY|NOT DONE|||MICRONEUTRALIZATION ASSAY|U|NA|PROXY|ONCOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1964-07-28|
TRIAL STUDY 134XCP|TR|72FCE18B-B3D6-45AC-993F-9883E4D11313|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ML/M2|INCREASED||BOLUS|NOT DONE|||IMPULSE OSCILLOMETRY|NA|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|2||58||TREATMENT|1960-11-03|
TRIAL STUDY 134XCP|TR|72FCE18B-B3D6-45AC-993F-9883E4D11313|3||||||DIAMETER|DIAMETER||PMOL/DL|FURTHER ENLARGEMENT||SIEMENS|NOT DONE|||CLIP|NA|Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|3||39||INDUCTION TREATMENT|1966-10-24|
TRIAL STUDY 134XCP|TR|72FCE18B-B3D6-45AC-993F-9883E4D11313|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||AFU|FOCALLY INCREASED||GENEQ/ML|NOT DONE|||INTERRUPTER TECHNIQUE|U|N|STUDY SUBJECT|UROLOGIST|U|4||88||BLINDED TREATMENT|1973-08-22|
TRIAL STUDY 134XCP|TR|72FCE18B-B3D6-45AC-993F-9883E4D11313|5||||||BNLNUM|NUMBER OF BONE LESIONS||UM/S|UNCHANGED||RING|NOT DONE|||FLUORESCEIN STAIN|NA|U|PROXY|ADJUDICATOR 2|NA|5||7||LONG-TERM FOLLOW-UP|1973-05-11|
TRIAL STUDY 134XCP|TR|1123F894-0821-41DF-9C28-ED6BC4A7098C|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||LOG10 IU/ML|DIFFUSELY INCREASED||MG/ML/DAY|NOT DONE|||AUTOMATED COUNT|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|U|1||38||BLINDED TREATMENT|1970-04-25|
TRIAL STUDY 134XCP|TR|1123F894-0821-41DF-9C28-ED6BC4A7098C|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NSEC|PALPABLE||10^6 U|NOT DONE|||DNA MICROARRAY|NA|N|PROXY|MICROSCOPIST 2|Y|2||58||CONTINUATION TREATMENT|1962-10-17|
TRIAL STUDY 134XCP|TR|1123F894-0821-41DF-9C28-ED6BC4A7098C|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||BQ/ML|NORMAL||MET*H|NOT DONE|||PERIODIC ACID SCHIFF STAIN|N|NA|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|3||39||OBSERVATION|1972-05-15|
TRIAL STUDY 134XCP|TR|1123F894-0821-41DF-9C28-ED6BC4A7098C|4||||||LPERP|LONGEST PERPENDICULAR||PACKET|ABSENT||MMOL/L|NOT DONE|||ELASTOGRAPHY|NA|NA|PROXY|MICROSCOPIST|Y|4||88||INDUCTION TREATMENT|1970-07-14|
TRIAL STUDY 134XCP|TR|1123F894-0821-41DF-9C28-ED6BC4A7098C|5||||||LDIAM|LONGEST DIAMETER||PRESSOR UNITS|PATHOLOGICAL||BOX|NOT DONE|||ELLA|N|N|HEALTH CARE PROFESSIONAL|READER 3|Y|5||7||INDUCTION TREATMENT|1963-12-19|
TRIAL STUDY 134XCP|TR|42DD827A-E788-4E61-8E9F-421136A16166|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MM2|FOCALLY INCREASED||MIN*MG/ML|NOT DONE|||ERGOSPIROMETRY|Y|U|CAREGIVER|ENDOCRINOLOGIST|N|1||38||FOLLOW-UP|1972-05-08|
TRIAL STUDY 134XCP|TR|42DD827A-E788-4E61-8E9F-421136A16166|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||COULOMB|NORMAL||HEP|NOT DONE|||PET/MRI SCAN|Y|U|FRIEND|MICROSCOPIST 3|N|2||58||RUN-IN|1970-07-27|
TRIAL STUDY 134XCP|TR|42DD827A-E788-4E61-8E9F-421136A16166|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||EQ|PALPABLE||H*%|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|U|N|INVESTIGATOR|RATER|Y|3||39||RUN-IN|1972-11-01|
TRIAL STUDY 134XCP|TR|42DD827A-E788-4E61-8E9F-421136A16166|4||||||AREA|AREA||VG/DOSE|PALPABLE||MEQ/UG|NOT DONE|||HEMAGGLUTINATION ASSAY|Y|Y|INDEPENDENT ASSESSOR|READER 2|NA|4||88||CONTINUATION TREATMENT|1966-06-11|
TRIAL STUDY 134XCP|TR|42DD827A-E788-4E61-8E9F-421136A16166|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||U/G/H|PRESENT||LOG10 TCID 50/DOSE|NOT DONE|||X-RAY|Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|Y|5||7||BASELINE|1972-06-14|
TRIAL STUDY 134XCP|TR|CC1E2338-4454-4CBA-8848-0B994C459F05|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||STRIP|FOCALLY INCREASED||PIXEL|NOT DONE|||ICP-MS|Y|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|1||38||LONG-TERM FOLLOW-UP|1964-09-10|
TRIAL STUDY 134XCP|TR|CC1E2338-4454-4CBA-8848-0B994C459F05|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||10^3 RNA COPIES/ML|NON-PATHOLOGICAL||MOL/ML|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|N|N|INVESTIGATOR|READER 3|U|2||58||CONTINUATION TREATMENT|1964-11-10|
TRIAL STUDY 134XCP|TR|CC1E2338-4454-4CBA-8848-0B994C459F05|3||||||LNSTATE|LYMPH NODE STATE||ML/KG/MIN|FURTHER ENLARGEMENT FROM NADIR||ML/CM H2O|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|Y|Y|VENDOR|PEDIATRIC NEUROLOGIST|NA|3||39||CONTINUATION TREATMENT|1966-09-27|
TRIAL STUDY 134XCP|TR|CC1E2338-4454-4CBA-8848-0B994C459F05|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||GRAVITATIONAL UNIT|PATHOLOGICAL||KALLIKREIN INHIBITOR UNIT|NOT DONE|||TEST STRIP|Y|NA|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|4||88||BASELINE|1970-06-26|
TRIAL STUDY 134XCP|TR|CC1E2338-4454-4CBA-8848-0B994C459F05|5||||||LDIAM|LONGEST DIAMETER||MOSM|NORMAL||CUP EQ|NOT DONE|||LEAD CITRATE STAIN|N|U|ADJUDICATOR|ADJUDICATOR 2|NA|5||7||SCREENING|1962-02-01|
TRIAL STUDY 134XCP|TR|ED04E60D-256A-4DB9-9290-4EFD0602A130|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^3/L|NON-PATHOLOGICAL||SHOCK WAVE|NOT DONE|||HIGH RESOLUTION CT|U|N|INDEPENDENT ASSESSOR|READER 3|Y|1||38||WASHOUT|1970-06-12|
TRIAL STUDY 134XCP|TR|ED04E60D-256A-4DB9-9290-4EFD0602A130|2||||||ORSTATE|ORGAN STATE||GMFI|UNEQUIVOCAL||CD|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|U|NA|CAREGIVER|RADIOLOGIST|NA|2||58||BLINDED TREATMENT|1966-09-03|
TRIAL STUDY 134XCP|TR|ED04E60D-256A-4DB9-9290-4EFD0602A130|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||/KG|FURTHER ENLARGEMENT||DEG/S|NOT DONE|||IN SITU HYBRIDIZATION|N|U|CHILD|CLINICAL PATHOLOGIST|NA|3||39||BASELINE|1960-11-11|
TRIAL STUDY 134XCP|TR|ED04E60D-256A-4DB9-9290-4EFD0602A130|4||||||ORSTATE|ORGAN STATE||V/V|DIFFUSELY INCREASED||TSP EQ|NOT DONE|||FARR ASSAY|U|N|INVESTIGATOR|NEUROLOGIST|U|4||88||INDUCTION TREATMENT|1961-09-23|
TRIAL STUDY 134XCP|TR|ED04E60D-256A-4DB9-9290-4EFD0602A130|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^3 RNA COPIES/ML|UNEQUIVOCAL||G/ANIMAL/DAY|NOT DONE|||MULTI-SLICE SPIRAL CT|NA|NA|INDEPENDENT ASSESSOR|DERMATOLOGIST|N|5||7||INDUCTION TREATMENT|1970-03-04|
TRIAL STUDY 134XCP|TR|C70F82F6-3280-429D-9657-CDFBA6B7F626|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||C|FOCALLY INCREASED||PT_BR|NOT DONE|||U-HPLC/MS/MS|Y|NA|CHILD|ONCOLOGIST 1|NA|1||38||RUN-IN|1961-09-20|
TRIAL STUDY 134XCP|TR|C70F82F6-3280-429D-9657-CDFBA6B7F626|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||CGY|NONPALPABLE||L/KG|NOT DONE|||HPLC/IEX|NA|NA|CAREGIVER|NEUROLOGIST|N|2||58||FOLLOW-UP|1963-07-22|
TRIAL STUDY 134XCP|TR|C70F82F6-3280-429D-9657-CDFBA6B7F626|3||||||LESSCIND|LESION SUCCESS INDICATOR||PMOL/DAY|PATHOLOGICAL||MU/L|NOT DONE|||STRESS ECHOCARDIOGRAPHY|U|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|Y|3||39||INDUCTION TREATMENT|1965-08-20|
TRIAL STUDY 134XCP|TR|C70F82F6-3280-429D-9657-CDFBA6B7F626|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||VG/KG|FOCALLY INCREASED||L/DAY|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|U|U|SIGNIFICANT OTHER|INTERNIST|N|4||88||FOLLOW-UP|1961-07-20|
TRIAL STUDY 134XCP|TR|C70F82F6-3280-429D-9657-CDFBA6B7F626|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||CONTAINER|NORMAL||GRAIN|NOT DONE|||DYNAMIC LIGHT SCATTERING|Y|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5||7||TREATMENT|1964-01-29|
TRIAL STUDY 134XCP|TR|D735D137-2C27-4F27-BA18-9A0F7FF0B145|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^8 PFU|TUMOR MERGED||F|NOT DONE|||RYAN BLUE STAIN|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|1||38||SCREENING|1967-12-23|
TRIAL STUDY 134XCP|TR|D735D137-2C27-4F27-BA18-9A0F7FF0B145|2||||||LNSTATE|LYMPH NODE STATE||GENEQ/ML|INCREASED||GY|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|U|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||SCREENING|1969-02-20|
TRIAL STUDY 134XCP|TR|D735D137-2C27-4F27-BA18-9A0F7FF0B145|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||BOX|PRESENT||NCI|NOT DONE|||LANDOLT RING|U|U|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|3||39||BLINDED TREATMENT|1973-01-20|
TRIAL STUDY 134XCP|TR|D735D137-2C27-4F27-BA18-9A0F7FF0B145|4||||||SUMDIAM|SUM OF DIAMETER||MMHG*MIN/L|FURTHER ENLARGEMENT FROM NADIR||S/H|NOT DONE|||ISHIHARA COLOR PLATES|Y|NA|FRIEND|ADJUDICATOR 2|U|4||88||RUN-IN|1963-01-25|
TRIAL STUDY 134XCP|TR|D735D137-2C27-4F27-BA18-9A0F7FF0B145|5||||||LDIAM|LONGEST DIAMETER||PIXEL|PRESENT||/HPF|NOT DONE|||COULOMETRIC TITRATION|N|NA|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|N|5||7||TREATMENT|1962-02-01|
TRIAL STUDY 134XCP|TR|B00194E0-0E85-46DD-86C3-CD9048535986|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MG/KG/DAY|ABSENT||UL|NOT DONE|||HANSEL STAIN|Y|N|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1||38||INDUCTION TREATMENT|1967-04-13|
TRIAL STUDY 134XCP|TR|B00194E0-0E85-46DD-86C3-CD9048535986|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MG/KG/MIN|INCREASED||MG/ANIMAL|NOT DONE|||OPHTHALMOSCOPY|Y|N|VENDOR|OPTOMETRIST|U|2||58||BASELINE|1968-06-02|
TRIAL STUDY 134XCP|TR|B00194E0-0E85-46DD-86C3-CD9048535986|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||IU/DL|NONPALPABLE||M3|NOT DONE|||CELLULOSE TAPE|U|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||OPEN LABEL TREATMENT|1972-07-14|
TRIAL STUDY 134XCP|TR|B00194E0-0E85-46DD-86C3-CD9048535986|4||||||LMBFLIND|LIMB FAILURE INDICATOR||LOG10 ELISA UNIT/DOSE|INCREASED||DPM/ML|NOT DONE|||ETDRS EYE CHART|Y|N|ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|4||88||LONG-TERM FOLLOW-UP|1969-04-29|
TRIAL STUDY 134XCP|TR|B00194E0-0E85-46DD-86C3-CD9048535986|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CI/ML|ABSENT||OD UNIT|NOT DONE|||IMMUNOFLUORESCENT STAIN|Y|NA|ADJUDICATOR|INTERNIST|NA|5||7||BLINDED TREATMENT|1960-11-21|
TRIAL STUDY 134XCP|TR|B4F372E9-C461-414A-95B4-93CA0221D396|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/ANIMAL/WK|PATHOLOGICAL||10^8/L|NOT DONE|||SLIT LAMP|N|N|SPOUSE|PATHOLOGIST 2|U|1||38||BLINDED TREATMENT|1961-08-01|
TRIAL STUDY 134XCP|TR|B4F372E9-C461-414A-95B4-93CA0221D396|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^6/HPF|PATHOLOGICAL||HR/DAY|NOT DONE|||HIGH RESOLUTION CT|NA|NA|PROXY|PATHOLOGIST|N|2||58||TREATMENT|1964-06-12|
TRIAL STUDY 134XCP|TR|B4F372E9-C461-414A-95B4-93CA0221D396|3||||||BNLNUM|NUMBER OF BONE LESIONS||ENZYME U/G HB|ENLARGEMENT||BQ/UG|NOT DONE|||PET/SPECT SCAN|N|N|PROXY|NEUROLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1963-09-05|
TRIAL STUDY 134XCP|TR|B4F372E9-C461-414A-95B4-93CA0221D396|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||HOURS|INCREASED||KM|NOT DONE|||BAC ACGH|Y|Y|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||OPEN LABEL TREATMENT|1964-05-21|
TRIAL STUDY 134XCP|TR|B4F372E9-C461-414A-95B4-93CA0221D396|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/MIN/1.73M2|DECREASED||COPIES/ML|NOT DONE|||DNA MICROARRAY|U|N|DOMESTIC PARTNER|ADJUDICATOR|U|5||7||LONG-TERM FOLLOW-UP|1969-07-11|
TRIAL STUDY 134XCP|TR|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|1||||||CALCFIND|CALCIFICATION INDICATOR||/HPF|ENLARGEMENT FROM NADIR||NMOL/DAY|NOT DONE|||HANSEL STAIN|NA|N|VENDOR|UROLOGIST|NA|1||38||OBSERVATION|1969-05-16|
TRIAL STUDY 134XCP|TR|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||AMOL|PRESENT||CPM|NOT DONE|||IVY INCISION METHOD|Y|U|INVESTIGATOR|NEUROLOGIST 2|U|2||58||BLINDED TREATMENT|1965-05-04|
TRIAL STUDY 134XCP|TR|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||KIU|PRESENT||MG/ML/MIN|NOT DONE|||CT SCAN WITHOUT CONTRAST|U|U|CHILD|READER 2|Y|3||39||TREATMENT|1961-07-04|
TRIAL STUDY 134XCP|TR|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MPL U/ML|PATHOLOGICAL||CGY|NOT DONE|||DIFFUSION WEIGHTED MRI|U|U|FAMILY MEMBER|UROLOGIST|NA|4||88||CONTINUATION TREATMENT|1972-03-30|
TRIAL STUDY 134XCP|TR|54C204AA-3DEF-4CB6-A0B6-3AA4090C02D7|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||PL|NORMAL||KIT|NOT DONE|||IMMUNODIFFUSION|NA|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|5||7||OBSERVATION|1967-03-28|
TRIAL STUDY 134XCP|TR|E43169E4-8B57-47D7-9C91-D42E40DD579B|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CM/S|NORMAL||10^10/L|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|N|Y|GUARDIAN|MICROSCOPIST 2|NA|1||38||CONTINUATION TREATMENT|1972-10-21|
TRIAL STUDY 134XCP|TR|E43169E4-8B57-47D7-9C91-D42E40DD579B|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MKAT|DIFFUSELY INCREASED||LB|NOT DONE|||PELLI-ROBSON EYE CHART|Y|U|FAMILY MEMBER|ONCOLOGIST 2|U|2||58||OPEN LABEL TREATMENT|1960-07-31|
TRIAL STUDY 134XCP|TR|E43169E4-8B57-47D7-9C91-D42E40DD579B|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||VP/DOSE|FURTHER ENLARGEMENT||ML/CM|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|Y|SPOUSE|MICROSCOPIST 1|U|3||39||WASHOUT|1961-10-21|
TRIAL STUDY 134XCP|TR|E43169E4-8B57-47D7-9C91-D42E40DD579B|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||FL|EQUIVOCAL||10^4/HPF|NOT DONE|||ECHOCARDIOGRAPHY|N|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1973-06-08|
TRIAL STUDY 134XCP|TR|E43169E4-8B57-47D7-9C91-D42E40DD579B|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||CM H2O|FOCALLY INCREASED||KUSP|NOT DONE|||CHROMOGENIC ASSAY|Y|U|SPOUSE|PHYSIOTHERAPIST|Y|5||7||CONTINUATION TREATMENT|1969-09-19|
TRIAL STUDY 134XCP|TR|066393EE-D112-41DD-AF8F-65EF57A4415B|1||||||VDIAM|VIABLE DIAMETER||MG/G/MIN|NORMAL||GY/MIN|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|Y|ADJUDICATOR|MICROSCOPIST|U|1||38||BLINDED TREATMENT|1966-01-26|
TRIAL STUDY 134XCP|TR|066393EE-D112-41DD-AF8F-65EF57A4415B|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||AFU|ENLARGEMENT||%|NOT DONE|||FLUORESCENT MICROSCOPY|NA|U|STUDY SUBJECT|ADJUDICATOR 3|NA|2||58||SCREENING|1960-01-22|
TRIAL STUDY 134XCP|TR|066393EE-D112-41DD-AF8F-65EF57A4415B|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||EID 50/DOSE|NON-PATHOLOGICAL||10^4/L|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|Y|N|VENDOR|RATER 1|U|3||39||FOLLOW-UP|1964-08-10|
TRIAL STUDY 134XCP|TR|066393EE-D112-41DD-AF8F-65EF57A4415B|4||||||PALPSTAT|PALPABLE STATE||EVENTS|ENLARGEMENT||UG/L|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|Y|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|4||88||OPEN LABEL TREATMENT|1967-11-28|
TRIAL STUDY 134XCP|TR|066393EE-D112-41DD-AF8F-65EF57A4415B|5||||||CALCFIND|CALCIFICATION INDICATOR||/CMH2O|PRESENT||UM|NOT DONE|||FLUORESCENT MICROSCOPY|U|U|DOMESTIC PARTNER|ADJUDICATOR 3|U|5||7||BASELINE|1964-12-30|
TRIAL STUDY 134XCP|TR|573C9228-D341-491C-9D66-0D0435E2C631|1||||||PALPSTAT|PALPABLE STATE||MG/H|ENLARGEMENT FROM NADIR||BQ/MG|NOT DONE|||CLAUSS METHOD|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR|Y|1||38||BASELINE|1968-08-22|
TRIAL STUDY 134XCP|TR|573C9228-D341-491C-9D66-0D0435E2C631|2||||||SUMDIAM|SUM OF DIAMETER||P|UNEQUIVOCAL||IU/DAY|NOT DONE|||JAFFE REACTION|U|N|FAMILY MEMBER|PHYSIOTHERAPIST|Y|2||58||LONG-TERM FOLLOW-UP|1970-05-22|
TRIAL STUDY 134XCP|TR|573C9228-D341-491C-9D66-0D0435E2C631|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UL/KG/DAY|NORMAL||U/MG|NOT DONE|||RAJI CELL RIA|Y|N|GUARDIAN|ONCOLOGIST 2|Y|3||39||LONG-TERM FOLLOW-UP|1966-07-29|
TRIAL STUDY 134XCP|TR|573C9228-D341-491C-9D66-0D0435E2C631|4||||||TUMSTATE|TUMOR STATE||UG/M2/H|INCREASED||FT3|NOT DONE|||ACID FAST STAIN|NA|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|4||88||INDUCTION TREATMENT|1973-03-05|
TRIAL STUDY 134XCP|TR|573C9228-D341-491C-9D66-0D0435E2C631|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||PACK|ENLARGEMENT||%(W/W)|NOT DONE|||RAJI CELL RIA|NA|U|CHILD|RADIOLOGIST 1|U|5||7||TREATMENT|1967-11-25|
TRIAL STUDY 134XCP|TR|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||APL U/ML|PATHOLOGICAL||MMU/ML|NOT DONE|||PHYSICAL EXAMINATION|U|NA|FRIEND|PATHOLOGIST 1|Y|1||38||INDUCTION TREATMENT|1970-05-03|
TRIAL STUDY 134XCP|TR|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||NMOL/DAY|ENLARGEMENT FROM NADIR||NEWTON|NOT DONE|||MICRODENSITOMETRY|NA|N|INVESTIGATOR|ADJUDICATOR|N|2||58||BASELINE|1972-05-04|
TRIAL STUDY 134XCP|TR|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||SHOCK WAVE|NON-PATHOLOGICAL||MEQ/L|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|3||39||OBSERVATION|1966-08-12|
TRIAL STUDY 134XCP|TR|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||ROENTGEN|FURTHER ENLARGEMENT FROM NADIR||V|NOT DONE|||PAP STAIN|U|U|PARENT|ONCOLOGIST 2|U|4||88||SCREENING|1962-06-29|
TRIAL STUDY 134XCP|TR|7BEDACC1-33A3-4A05-BE16-5D00D7A6BE36|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MMOL/DAY|FOCALLY INCREASED||OI50|NOT DONE|||JAFFE REACTION|U|NA|SPOUSE|MICROSCOPIST 3|N|5||7||LONG-TERM FOLLOW-UP|1969-05-04|
TRIAL STUDY 134XCP|TR|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|1||||||AREA|AREA||IN2|PATHOLOGICAL||LOG10 PFU|NOT DONE|||RADIAL IMMUNODIFFUSION|U|N|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1||38||BLINDED TREATMENT|1972-06-14|
TRIAL STUDY 134XCP|TR|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||DNA COPIES/ML|NORMAL||UM|NOT DONE|||ISHIHARA COLOR PLATES|U|U|CHILD|NEUROLOGIST|U|2||58||TREATMENT|1966-08-16|
TRIAL STUDY 134XCP|TR|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||NMOL BCE/L|FURTHER ENLARGEMENT FROM NADIR||L/MIN|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|U|NA|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1971-05-24|
TRIAL STUDY 134XCP|TR|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||G/CM2|FURTHER ENLARGEMENT||PNU/ML|NOT DONE|||MYELOPEROXIDASE STAIN|Y|NA|SIBLING|ONCOLOGIST 1|U|4||88||BLINDED TREATMENT|1965-01-29|
TRIAL STUDY 134XCP|TR|9AFEAA8A-AF9C-4C16-ACFA-1E37D258F5FF|5||||||ORSTATE|ORGAN STATE||MMOL/S|ENLARGEMENT||PFU/ML|NOT DONE|||GEL ELECTROPHORESIS|N|N|INVESTIGATOR|READER|NA|5||7||LONG-TERM FOLLOW-UP|1961-10-02|
TRIAL STUDY 134XCP|TR|61C75130-5C1A-4B8D-804C-92D3288B55D2|1||||||LESFLIND|LESION FAILURE INDICATOR||RNA COPIES/ML|INCREASED||PPTR|NOT DONE|||OBSERVATION|NA|N|FAMILY MEMBER|ADJUDICATOR 1|U|1||38||LONG-TERM FOLLOW-UP|1967-04-21|
TRIAL STUDY 134XCP|TR|61C75130-5C1A-4B8D-804C-92D3288B55D2|2||||||LESFLIND|LESION FAILURE INDICATOR||MM/SEC|ABSENT||DAGU/ML|NOT DONE|||DISK DIFFUSION|U|NA|VENDOR|FORENSIC PATHOLOGIST|U|2||58||RUN-IN|1968-03-22|
TRIAL STUDY 134XCP|TR|61C75130-5C1A-4B8D-804C-92D3288B55D2|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ENZYME U/L|FOCALLY INCREASED||TUBE|NOT DONE|||ULTRASOUND|N|U|STUDY SUBJECT|RADIOLOGIST 1|Y|3||39||BLINDED TREATMENT|1969-06-07|
TRIAL STUDY 134XCP|TR|61C75130-5C1A-4B8D-804C-92D3288B55D2|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||10^7 TCID 50/DOSE|NONPALPABLE||10^9/DOSE|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|NA|U|CAREGIVER|MICROSCOPIST 1|U|4||88||CONTINUATION TREATMENT|1961-08-10|
TRIAL STUDY 134XCP|TR|61C75130-5C1A-4B8D-804C-92D3288B55D2|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||%(V/V)|UNEQUIVOCAL||10^6 ORGANISMS/MG|NOT DONE|||SEQUENCING|NA|U|CHILD|RATER 1|U|5||7||CONTINUATION TREATMENT|1973-03-24|
TRIAL STUDY 134XCP|TR|90AFB57A-125C-4C08-AE92-061F66FC2DAC|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||USEC|INCREASED||MDFI|NOT DONE|||DIFFUSION TENSOR MRI|U|NA|CAREGIVER|READER 1|NA|1||38||TREATMENT|1968-11-16|
TRIAL STUDY 134XCP|TR|90AFB57A-125C-4C08-AE92-061F66FC2DAC|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/M2/H|FURTHER ENLARGEMENT||%|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|N|NA|VENDOR|OPTOMETRIST|NA|2||58||FOLLOW-UP|1972-04-14|
TRIAL STUDY 134XCP|TR|90AFB57A-125C-4C08-AE92-061F66FC2DAC|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UMOL/KG/MIN|UNCHANGED||MPS U|NOT DONE|||IMPULSE OSCILLOMETRY|N|U|VENDOR|ADJUDICATOR 1|Y|3||39||TREATMENT|1966-09-21|
TRIAL STUDY 134XCP|TR|90AFB57A-125C-4C08-AE92-061F66FC2DAC|4||||||CALCFIND|CALCIFICATION INDICATOR||NGEQ/L|NON-PATHOLOGICAL||10^6 U|NOT DONE|||AUSCULTATION|U|Y|CHILD|OPHTHALMOLOGIST|N|4||88||WASHOUT|1963-02-22|
TRIAL STUDY 134XCP|TR|90AFB57A-125C-4C08-AE92-061F66FC2DAC|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||M/SEC2|EQUIVOCAL||ABSORBANCE U/ML|NOT DONE|||SINGLE-SLICE SPIRAL CT|U|Y|FAMILY MEMBER|ADJUDICATOR 1|Y|5||7||RUN-IN|1972-10-13|
TRIAL STUDY 134XCP|TR|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MET|NON-PATHOLOGICAL||UIU/L|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|NA|NA|VENDOR|HEMATOLOGIST|U|1||38||FOLLOW-UP|1964-10-31|
TRIAL STUDY 134XCP|TR|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PKAT/L|FURTHER ENLARGEMENT||/100 WBC|NOT DONE|||JAFFE REACTION|N|U|PARENT|RADIOLOGIST 2|NA|2||58||WASHOUT|1964-10-01|
TRIAL STUDY 134XCP|TR|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|3||||||SUMVOL|SUM OF VOLUME||DRINK|FOCALLY INCREASED||GPL U|NOT DONE|||IMMUNOPRECIPITATION|N|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|Y|3||39||CONTINUATION TREATMENT|1964-03-23|
TRIAL STUDY 134XCP|TR|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||IU/MMOL|NON-PATHOLOGICAL||U/G|NOT DONE|||HPLC/MS|Y|Y|FRIEND|RATER|NA|4||88||CONTINUATION TREATMENT|1972-08-26|
TRIAL STUDY 134XCP|TR|B980E6D5-3883-4A1C-A7BA-FC4BA768B3E4|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/MMOL|PATHOLOGICAL||NEWTON|NOT DONE|||GC/MS-CI|Y|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1969-12-24|
TRIAL STUDY 134XCP|TR|01A42FAE-1EE2-4203-A62E-E368F31434F7|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||VG/ML|UNEQUIVOCAL||MEQ/DL|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1965-09-10|
TRIAL STUDY 134XCP|TR|01A42FAE-1EE2-4203-A62E-E368F31434F7|2||||||NEWCONF|NEW TUMOR CONFIRMED||CGY|FOCALLY INCREASED||DYN|NOT DONE|||DARK FIELD MICROSCOPY|Y|N|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||CONTINUATION TREATMENT|1962-03-12|
TRIAL STUDY 134XCP|TR|01A42FAE-1EE2-4203-A62E-E368F31434F7|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||/KG|INCREASED||PATCH|NOT DONE|||LYMPHANGIOGRAPHY|N|NA|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|3||39||OBSERVATION|1960-12-07|
TRIAL STUDY 134XCP|TR|01A42FAE-1EE2-4203-A62E-E368F31434F7|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||FT2|UNCHANGED||ML/MMHG/MIN/L|NOT DONE|||MRI WITHOUT CONTRAST|Y|NA|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|4||88||SCREENING|1962-01-09|
TRIAL STUDY 134XCP|TR|01A42FAE-1EE2-4203-A62E-E368F31434F7|5||||||ORSTATE|ORGAN STATE||ML/M2/MIN|DECREASED||FT|NOT DONE|||PET/MRI SCAN|N|U|CHILD|RATER|NA|5||7||OBSERVATION|1969-01-21|
TRIAL STUDY 134XCP|TR|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^3 CFU/ML|FURTHER ENLARGEMENT||USIEMENS|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|U|U|GUARDIAN|PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1972-08-04|
TRIAL STUDY 134XCP|TR|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^6 DNA COPIES/ML|PRESENT||ML*CMH2O|NOT DONE|||MICROBIAL CONCENTRATION|Y|NA|SPOUSE|CARDIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1971-09-10|
TRIAL STUDY 134XCP|TR|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^6 U|UNCHANGED||INHALATION|NOT DONE|||LYMPHANGIOGRAPHY|Y|NA|VENDOR|INTERNIST|N|3||39||OPEN LABEL TREATMENT|1968-03-08|
TRIAL STUDY 134XCP|TR|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||BEL|FURTHER ENLARGEMENT FROM NADIR||ARBITRARY U|NOT DONE|||EPSILOMETER|N|U|GUARDIAN|ENDOCRINOLOGIST|Y|4||88||INDUCTION TREATMENT|1964-11-07|
TRIAL STUDY 134XCP|TR|4764675D-2F2B-4CE1-AF43-E2A28A30FB74|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||%/MIN|UNEQUIVOCAL||PA|NOT DONE|||RYAN BLUE STAIN|N|Y|INTERVIEWER|MICROSCOPIST 1|Y|5||7||BLINDED TREATMENT|1970-11-13|
TRIAL STUDY 134XCP|TR|92232C8B-0D28-4E2A-AA56-BA938429CCBF|1||||||PALPSTAT|PALPABLE STATE||KBQ|EQUIVOCAL||MG/KG/DOSE|NOT DONE|||TWO-COLOR MICROARRAY|U|Y|INVESTIGATOR|MICROSCOPIST 3|N|1||38||RUN-IN|1962-01-07|
TRIAL STUDY 134XCP|TR|92232C8B-0D28-4E2A-AA56-BA938429CCBF|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/G/MIN|FURTHER ENLARGEMENT FROM NADIR||10^7 PFU|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|NA|DOMESTIC PARTNER|ADJUDICATOR 3|N|2||58||SCREENING|1964-12-30|
TRIAL STUDY 134XCP|TR|92232C8B-0D28-4E2A-AA56-BA938429CCBF|3||||||LESFLIND|LESION FAILURE INDICATOR||CIGARETTE|DECREASED||POUCH|NOT DONE|||WESTERGREN|U|N|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|3||39||RUN-IN|1960-04-12|
TRIAL STUDY 134XCP|TR|92232C8B-0D28-4E2A-AA56-BA938429CCBF|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML*CMH2O|EQUIVOCAL||KDA|NOT DONE|||PET/MRI SCAN|NA|NA|CHILD|NEUROLOGIST 2|N|4||88||BASELINE|1962-03-04|
TRIAL STUDY 134XCP|TR|92232C8B-0D28-4E2A-AA56-BA938429CCBF|5||||||TUMSTATE|TUMOR STATE||MM2|UNEQUIVOCAL||MET|NOT DONE|||MICROBIAL CONCENTRATION|NA|NA|VENDOR|INTERNIST|NA|5||7||RUN-IN|1968-02-28|
TRIAL STUDY 134XCP|TR|F4F12AAA-E825-45D7-B414-A06F2D20381A|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||EJACULATE U|UNCHANGED||10^6 IU/ML|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|U|VENDOR|ADJUDICATOR 1|Y|1||38||SCREENING|1965-10-17|
TRIAL STUDY 134XCP|TR|F4F12AAA-E825-45D7-B414-A06F2D20381A|2||||||LESFLIND|LESION FAILURE INDICATOR||UG/M2|ENLARGEMENT||KIT|NOT DONE|||DUCTOGRAPHY|U|N|INTERVIEWER|OTOLARYNGOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1966-05-06|
TRIAL STUDY 134XCP|TR|F4F12AAA-E825-45D7-B414-A06F2D20381A|3||||||VDIAM|VIABLE DIAMETER||UMOL/DAY|NON-PATHOLOGICAL||EID 50/DOSE|NOT DONE|||ELECTROMYOGRAPHY|NA|NA|PROXY|INTERNIST|U|3||39||TREATMENT|1967-06-12|
TRIAL STUDY 134XCP|TR|F4F12AAA-E825-45D7-B414-A06F2D20381A|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MG/G/MIN|ENLARGEMENT||MMHG/L/MIN|NOT DONE|||POLYMERASE CHAIN REACTION|Y|Y|STUDY SUBJECT|HEMATOLOGIST|NA|4||88||RUN-IN|1964-10-17|
TRIAL STUDY 134XCP|TR|F4F12AAA-E825-45D7-B414-A06F2D20381A|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PSEC|FOCALLY INCREASED||CUP|NOT DONE|||MS/MS|Y|U|ADJUDICATOR|HEMATOLOGIST|U|5||7||OPEN LABEL TREATMENT|1972-03-17|
TRIAL STUDY 134XCP|TR|6CF611F2-686E-4AE9-B491-32157710F46D|1||||||AREA|AREA||CI/ML|INCREASED||PMOL/G|NOT DONE|||IHC|Y|Y|CAREGIVER|OPTOMETRIST|N|1||38||FOLLOW-UP|1967-01-10|
TRIAL STUDY 134XCP|TR|6CF611F2-686E-4AE9-B491-32157710F46D|2||||||RADIODEN|RADIODENSITY||DIOPTER|ENLARGEMENT||RFU|NOT DONE|||MOUSE PROTECTION ASSAY|NA|NA|SPOUSE|INTERNIST|N|2||58||WASHOUT|1962-01-03|
TRIAL STUDY 134XCP|TR|6CF611F2-686E-4AE9-B491-32157710F46D|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PMOL/L/H|ENLARGEMENT||MMOL/G|NOT DONE|||PALPATION|NA|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|3||39||OPEN LABEL TREATMENT|1968-07-23|
TRIAL STUDY 134XCP|TR|6CF611F2-686E-4AE9-B491-32157710F46D|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||LOG10 CCID 50/DOSE|FURTHER ENLARGEMENT FROM NADIR||L/MIN|NOT DONE|||ANTIMICROBIAL COMBINATION TESTING|U|Y|FAMILY MEMBER|ADJUDICATOR 3|N|4||88||RUN-IN|1965-12-27|
TRIAL STUDY 134XCP|TR|6CF611F2-686E-4AE9-B491-32157710F46D|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KIU|NON-PATHOLOGICAL||BQ|NOT DONE|||TEST STRIP|Y|U|FRIEND|READER 2|U|5||7||RUN-IN|1962-05-13|
TRIAL STUDY 134XCP|TR|417DBC64-7BF9-4EB8-A14B-C5F63541F826|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||BAG|NONPALPABLE||EU|NOT DONE|||MICRO BROTH DILUTION|U|NA|CHILD|CARDIOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1969-03-03|
TRIAL STUDY 134XCP|TR|417DBC64-7BF9-4EB8-A14B-C5F63541F826|2||||||VOLUME|VOLUME||HEP|EQUIVOCAL||CM/MIN|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|N|SIBLING|RADIOLOGIST|U|2||58||BASELINE|1969-03-13|
TRIAL STUDY 134XCP|TR|417DBC64-7BF9-4EB8-A14B-C5F63541F826|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||IN|ABSENT||MG/KG/WEEK|NOT DONE|||HPLC-UV|N|N|SPOUSE|CLINICAL PATHOLOGIST|Y|3||39||SCREENING|1966-02-17|
TRIAL STUDY 134XCP|TR|417DBC64-7BF9-4EB8-A14B-C5F63541F826|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MU/G|NONPALPABLE||FOZ_US|NOT DONE|||LC/MS|NA|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|4||88||RUN-IN|1972-04-22|
TRIAL STUDY 134XCP|TR|417DBC64-7BF9-4EB8-A14B-C5F63541F826|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||DISK|ABSENT||M/SEC2|NOT DONE|||PH METER MEASUREMENT METHOD|U|U|CAREGIVER|RADIOLOGIST|U|5||7||SCREENING|1970-02-10|
TRIAL STUDY 134XCP|TR|C3EF644E-25DC-4E0D-9073-735AED77EFAF|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||DMOL|ABSENT||TCID 50/DOSE|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|NA|CAREGIVER|INTERNIST|U|1||38||TREATMENT|1960-06-01|
TRIAL STUDY 134XCP|TR|C3EF644E-25DC-4E0D-9073-735AED77EFAF|2||||||ORVERLN|ORGAN VERTICAL LENGTH||NGEQ/L|INCREASED||10^3 RNA COPIES/ML|NOT DONE|||THICK SMEAR|U|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|2||58||OPEN LABEL TREATMENT|1963-04-06|
TRIAL STUDY 134XCP|TR|C3EF644E-25DC-4E0D-9073-735AED77EFAF|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||GENEQ/ML|FOCALLY INCREASED||AG|NOT DONE|||RAJI CELL EIA|NA|Y|SIBLING|DERMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1970-01-26|
TRIAL STUDY 134XCP|TR|C3EF644E-25DC-4E0D-9073-735AED77EFAF|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MU|DIFFUSELY INCREASED||UG/L/H|NOT DONE|||BIOPSY|NA|U|SPOUSE|ONCOLOGIST|N|4||88||WASHOUT|1964-11-20|
TRIAL STUDY 134XCP|TR|C3EF644E-25DC-4E0D-9073-735AED77EFAF|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||ML/G/H|FURTHER ENLARGEMENT FROM NADIR||MET*H|NOT DONE|||TRIPLE-PHASE MRI SCAN|NA|NA|STUDY SUBJECT|NEUROLOGIST|N|5||7||OBSERVATION|1970-06-26|
TRIAL STUDY 134XCP|TR|CAE5F41C-0560-4782-BA27-E314BF7E66B6|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||IU/G HB|NORMAL||ML/MIN/MMHG|NOT DONE|||ENZYMATIC COLORIMETRY|Y|NA|PROXY|ADJUDICATOR 2|Y|1||38||LONG-TERM FOLLOW-UP|1963-01-30|
TRIAL STUDY 134XCP|TR|CAE5F41C-0560-4782-BA27-E314BF7E66B6|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||CM|ENLARGEMENT||MOSM/KG|NOT DONE|||FLUOROSCOPY|NA|Y|INVESTIGATOR|ONCOLOGIST 1|NA|2||58||CONTINUATION TREATMENT|1971-08-28|
TRIAL STUDY 134XCP|TR|CAE5F41C-0560-4782-BA27-E314BF7E66B6|3||||||ORVERLN|ORGAN VERTICAL LENGTH||KG/MOL|PALPABLE||ML/MMHG/MIN/L|NOT DONE|||LINE PROBE ASSAY|N|N|ADJUDICATOR|DERMATOLOGIST|N|3||39||WASHOUT|1963-03-05|
TRIAL STUDY 134XCP|TR|CAE5F41C-0560-4782-BA27-E314BF7E66B6|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MG/MIN|PALPABLE||/LPF|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|U|HEALTH CARE PROFESSIONAL|RATER 1|NA|4||88||BLINDED TREATMENT|1967-10-23|
TRIAL STUDY 134XCP|TR|CAE5F41C-0560-4782-BA27-E314BF7E66B6|5||||||LESSCIND|LESION SUCCESS INDICATOR||MBQ/UL|EQUIVOCAL||10^6/EJACULATE U|NOT DONE|||PHOTOGRAPHY|N|U|SPOUSE|MICROSCOPIST 1|Y|5||7||SCREENING|1962-08-30|
TRIAL STUDY 134XCP|TR|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|1||||||BNLNUM|NUMBER OF BONE LESIONS||DAGU/ML|DECREASED||DNA COPIES/ML|NOT DONE|||NEPHELOMETRY|N|NA|GUARDIAN|READER|NA|1||38||OPEN LABEL TREATMENT|1961-11-05|
TRIAL STUDY 134XCP|TR|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|2||||||ORVERLN|ORGAN VERTICAL LENGTH||10^3 CFU|ENLARGEMENT FROM NADIR||MHZ|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|NA|CHILD|MICROSCOPIST 3|NA|2||58||BLINDED TREATMENT|1968-01-17|
TRIAL STUDY 134XCP|TR|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UG/M2/MIN|ENLARGEMENT FROM NADIR||U/KG/DAY|NOT DONE|||STRESS ECHOCARDIOGRAPHY|N|NA|PARENT|ADJUDICATOR 3|N|3||39||TREATMENT|1965-05-07|
TRIAL STUDY 134XCP|TR|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|4||||||PALPSTAT|PALPABLE STATE||APS U|NONPALPABLE||10^6 COPIES/ML|NOT DONE|||STRESS ECHOCARDIOGRAPHY|N|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|4||88||WASHOUT|1967-12-21|
TRIAL STUDY 134XCP|TR|08CEB6E7-DE68-4F9D-902C-08F6D069EF05|5||||||LMBFLIND|LIMB FAILURE INDICATOR||CD/M2|INCREASED||HEP|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|Y|N|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5||7||SCREENING|1969-08-11|
TRIAL STUDY 134XCP|TR|F34E7DCC-8637-463D-88E6-28AEBF495E9B|1||||||TUMSTATE|TUMOR STATE||10^9 ORGANISMS/MG|ABSENT||ML/G/DAY|NOT DONE|||ELECTROMYOGRAPHY|Y|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1961-08-08|
TRIAL STUDY 134XCP|TR|F34E7DCC-8637-463D-88E6-28AEBF495E9B|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^6 U|DECREASED||ML/DOSE|NOT DONE|||MRI WITHOUT CONTRAST|Y|N|PARENT|UROLOGIST|N|2||58||OPEN LABEL TREATMENT|1967-02-12|
TRIAL STUDY 134XCP|TR|F34E7DCC-8637-463D-88E6-28AEBF495E9B|3||||||LNSTATE|LYMPH NODE STATE||DMOL|PATHOLOGICAL||MGEQ|NOT DONE|||CELL OF ORIGIN ASSAY|Y|U|FRIEND|PHYSIOTHERAPIST|N|3||39||BASELINE|1971-08-21|
TRIAL STUDY 134XCP|TR|F34E7DCC-8637-463D-88E6-28AEBF495E9B|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||NG|ENLARGEMENT||MG/G/H|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y|U|FRIEND|RADIOLOGIST 2|NA|4||88||OBSERVATION|1971-10-28|
TRIAL STUDY 134XCP|TR|F34E7DCC-8637-463D-88E6-28AEBF495E9B|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||EVENTS|PATHOLOGICAL||LOG10 TCID 50/ML|NOT DONE|||TURBIDIMETRY|Y|NA|INTERVIEWER|ADJUDICATOR 1|Y|5||7||OPEN LABEL TREATMENT|1963-06-02|
TRIAL STUDY 134XCP|TR|69530FE0-6896-4585-8B20-29AE90DB91F5|1||||||PALPSTAT|PALPABLE STATE||MPH|FOCALLY INCREASED||PIXELS/IN|NOT DONE|||MALDI|NA|Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|1||38||INDUCTION TREATMENT|1972-07-01|
TRIAL STUDY 134XCP|TR|69530FE0-6896-4585-8B20-29AE90DB91F5|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||PMOL/DAY|PALPABLE||WAFER|NOT DONE|||DISK DIFFUSION|N|U|INVESTIGATOR|DERMATOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1966-01-24|
TRIAL STUDY 134XCP|TR|69530FE0-6896-4585-8B20-29AE90DB91F5|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||GY/H|NON-PATHOLOGICAL||NM|NOT DONE|||RADIOGRAPHY|Y|Y|SIGNIFICANT OTHER|RADIOLOGIST|NA|3||39||RUN-IN|1969-12-23|
TRIAL STUDY 134XCP|TR|69530FE0-6896-4585-8B20-29AE90DB91F5|4||||||DIAMETER|DIAMETER||MIN|TUMOR MERGED||KA_U/DL|NOT DONE|||DIRECT SEQUENCING|Y|NA|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|Y|4||88||OBSERVATION|1961-03-25|
TRIAL STUDY 134XCP|TR|69530FE0-6896-4585-8B20-29AE90DB91F5|5||||||LESFLIND|LESION FAILURE INDICATOR||C|DIFFUSELY INCREASED||MCI/KG|NOT DONE|||PALPATION|NA|U|INVESTIGATOR|DERMATOLOGIST|U|5||7||BLINDED TREATMENT|1972-02-14|
TRIAL STUDY 134XCP|TR|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PMOL/10^9 CELLS|DECREASED||ML/M2|NOT DONE|||RAJI CELL RIA|NA|U|NON-HEALTH CARE PROFESSIONAL|READER 1|N|1||38||OBSERVATION|1963-08-08|
TRIAL STUDY 134XCP|TR|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||BU|PATHOLOGICAL||IU/DAY|NOT DONE|||WHOLE GENOME SEQUENCING|NA|U|INTERVIEWER|RADIOLOGIST|Y|2||58||TREATMENT|1963-03-04|
TRIAL STUDY 134XCP|TR|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|3||||||BNLNUM|NUMBER OF BONE LESIONS||L/H/M2|UNCHANGED||BE/ML|NOT DONE|||BIOPSY|NA|NA|CHILD|OTOLARYNGOLOGIST|N|3||39||TREATMENT|1969-04-16|
TRIAL STUDY 134XCP|TR|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||10^6 CFU/ML|FURTHER ENLARGEMENT||AMFI|NOT DONE|||HIGH RESOLUTION CT|N|Y|SPOUSE|OTOLARYNGOLOGIST|NA|4||88||FOLLOW-UP|1964-05-26|
TRIAL STUDY 134XCP|TR|64FA868A-1774-484C-BA89-4A2ACEF3A8A6|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MEQ/MMOL|UNEQUIVOCAL||ANTIBODY UNIT|NOT DONE|||DIPSTICK|U|U|SIGNIFICANT OTHER|RATER|Y|5||7||LONG-TERM FOLLOW-UP|1962-05-08|
TRIAL STUDY 134XCP|TR|F1EF928C-B819-4620-8991-ABDC4E182217|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UG/MOL|INCREASED||BQ|NOT DONE|||GRADIENT DIFFUSION|U|Y|GUARDIAN|READER 2|U|1||38||RUN-IN|1963-09-07|
TRIAL STUDY 134XCP|TR|F1EF928C-B819-4620-8991-ABDC4E182217|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||CP|PRESENT||PELLET|NOT DONE|||POTENTIOMETRY|N|NA|SPOUSE|MICROSCOPIST 1|N|2||58||LONG-TERM FOLLOW-UP|1964-03-23|
TRIAL STUDY 134XCP|TR|F1EF928C-B819-4620-8991-ABDC4E182217|3||||||DIAMETER|DIAMETER||GPELISA UNIT/ML|UNCHANGED||10^6/L|NOT DONE|||CALCOFLUOR WHITE STAIN|NA|Y|CHILD|RATER 2|NA|3||39||SCREENING|1966-12-29|
TRIAL STUDY 134XCP|TR|F1EF928C-B819-4620-8991-ABDC4E182217|4||||||RADIODEN|RADIODENSITY||TSP EQ|UNEQUIVOCAL||POUCH|NOT DONE|||CHROMOGENIC ASSAY|U|NA|INVESTIGATOR|RATER 1|Y|4||88||FOLLOW-UP|1964-09-04|
TRIAL STUDY 134XCP|TR|F1EF928C-B819-4620-8991-ABDC4E182217|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||FOZ_BR|PRESENT||MEQ/ML|NOT DONE|||MRI WITHOUT CONTRAST|NA|N|ADJUDICATOR|UROLOGIST|Y|5||7||SCREENING|1960-04-03|
TRIAL STUDY 134XCP|TR|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||ECL UNIT|ENLARGEMENT||PPTR|NOT DONE|||CLINICAL EVALUATION|NA|U|ADJUDICATION COMMITTEE|READER 3|NA|1||38||BASELINE|1968-02-29|
TRIAL STUDY 134XCP|TR|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||FMOL|DIFFUSELY INCREASED||KAT|NOT DONE|||MYELOPEROXIDASE STAIN|N|N|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|2||58||INDUCTION TREATMENT|1968-01-31|
TRIAL STUDY 134XCP|TR|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|3||||||VSLPIND|VESSEL PATENCY INDICATOR||GTT|FURTHER ENLARGEMENT||LOG10 TCID 50/UL|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|NA|NA|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|3||39||SCREENING|1962-06-23|
TRIAL STUDY 134XCP|TR|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U/MMOL|EQUIVOCAL||10^6 CFU/G|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|4||88||FOLLOW-UP|1972-01-23|
TRIAL STUDY 134XCP|TR|3AE9E2AF-41FA-4B19-8885-C7E9B4CAD2AC|5||||||DIAMETER|DIAMETER||MV*MIN|PATHOLOGICAL||PMOL/L/H|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|U|Y|INTERVIEWER|PATHOLOGIST 2|N|5||7||FOLLOW-UP|1973-05-18|
TRIAL STUDY 134XCP|TR|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UG/L|FOCALLY INCREASED||VG/KG|NOT DONE|||AUSCULTATION|NA|N|PARENT|INTERNIST|Y|1||38||OPEN LABEL TREATMENT|1964-09-24|
TRIAL STUDY 134XCP|TR|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||HOMEOPATHIC DILUTION|PALPABLE||LM|NOT DONE|||FLOCCULATION|U|NA|INDEPENDENT ASSESSOR|INTERNIST|N|2||58||LONG-TERM FOLLOW-UP|1968-07-13|
TRIAL STUDY 134XCP|TR|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6 ORGANISMS/MG|FOCALLY INCREASED||MS/MMHG|NOT DONE|||APPLANATION TONOMETRY|Y|NA|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1969-09-22|
TRIAL STUDY 134XCP|TR|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MM/H|PALPABLE||ML/CM H2O|NOT DONE|||ANGIOGRAPHY|NA|NA|CHILD|ADJUDICATOR 2|NA|4||88||WASHOUT|1961-12-10|
TRIAL STUDY 134XCP|TR|41EF9E3A-3B71-4D35-B25F-29E6E3FC3BB1|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UGEQ|TUMOR MERGED||PFU/DOSE|NOT DONE|||ACID FAST STAIN|NA|N|SIBLING|CLINICAL PATHOLOGIST|U|5||7||BLINDED TREATMENT|1968-01-05|
TRIAL STUDY 134XCP|TR|27D5690D-BCB3-4FEC-988C-666C29D5239A|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||AFU|TUMOR MERGED||ML/100G/MIN|NOT DONE|||REFRACTOMETRY|U|N|ADJUDICATOR|MICROSCOPIST|Y|1||38||LONG-TERM FOLLOW-UP|1972-02-17|
TRIAL STUDY 134XCP|TR|27D5690D-BCB3-4FEC-988C-666C29D5239A|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||/MONTH|NON-PATHOLOGICAL||YD|NOT DONE|||CALCULATION|Y|NA|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|2||58||WASHOUT|1966-08-03|
TRIAL STUDY 134XCP|TR|27D5690D-BCB3-4FEC-988C-666C29D5239A|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PPM|UNEQUIVOCAL||NG/MOL|NOT DONE|||OPTICAL MAPPING|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|3||39||SCREENING|1966-03-16|
TRIAL STUDY 134XCP|TR|27D5690D-BCB3-4FEC-988C-666C29D5239A|4||||||NEWCONF|NEW TUMOR CONFIRMED||BOTTLE|PATHOLOGICAL||YEARS|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|NA|Y|INVESTIGATOR|CARDIOLOGIST|U|4||88||OPEN LABEL TREATMENT|1970-04-18|
TRIAL STUDY 134XCP|TR|27D5690D-BCB3-4FEC-988C-666C29D5239A|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||GRAVITATIONAL UNIT|FURTHER ENLARGEMENT||IU/KG/H|NOT DONE|||TURBIDIMETRY|U|Y|ADJUDICATION COMMITTEE|INTERNIST|Y|5||7||TREATMENT|1962-12-04|
TRIAL STUDY 134XCP|TR|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NMOL BCE/NMOL|NONPALPABLE||PM|NOT DONE|||TRANSVAGINAL ULTRASOUND|NA|N|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1||38||OBSERVATION|1968-11-14|
TRIAL STUDY 134XCP|TR|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||G/DAY|ABSENT||LB|NOT DONE|||ACID FAST STAIN|Y|N|CAREGIVER|CARDIOLOGIST|N|2||58||SCREENING|1967-10-19|
TRIAL STUDY 134XCP|TR|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||CIGAR|UNEQUIVOCAL||10^3 CFU/G|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|Y|U|STUDY SUBJECT|MICROSCOPIST|NA|3||39||OPEN LABEL TREATMENT|1964-02-22|
TRIAL STUDY 134XCP|TR|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|4||||||ORSTATE|ORGAN STATE||/LPF|NONPALPABLE||PACK YEAR|NOT DONE|||HILLMEN COLOR CHART|NA|N|FAMILY MEMBER|INTERNIST|N|4||88||BASELINE|1965-08-09|
TRIAL STUDY 134XCP|TR|7639ABA6-8AC8-4066-BF07-AEC230A2BF69|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LX|PRESENT||/LPF|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|U|Y|PROXY|RATER 1|U|5||7||BASELINE|1963-09-30|
TRIAL STUDY 134XCP|TR|8E25F21F-A565-40CB-B0D7-6CC496171293|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||USEC|UNEQUIVOCAL||PMOL/10^9 CELLS|NOT DONE|||GRADIENT DIFFUSION|N|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|N|1||38||TREATMENT|1966-08-14|
TRIAL STUDY 134XCP|TR|8E25F21F-A565-40CB-B0D7-6CC496171293|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||OSM|DECREASED||CI/KG|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|U|NA|FAMILY MEMBER|HEMATOLOGIST|U|2||58||RUN-IN|1971-12-26|
TRIAL STUDY 134XCP|TR|8E25F21F-A565-40CB-B0D7-6CC496171293|3||||||BNLNUM|NUMBER OF BONE LESIONS||MANSON U/ML|UNEQUIVOCAL||MM|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|U|N|PROXY|RATER 2|Y|3||39||RUN-IN|1965-11-17|
TRIAL STUDY 134XCP|TR|8E25F21F-A565-40CB-B0D7-6CC496171293|4||||||ORVERLN|ORGAN VERTICAL LENGTH||LOG10 PFU|ABSENT||LM|NOT DONE|||CYSTOSCOPY|N|NA|SIBLING|ADJUDICATOR 2|N|4||88||TREATMENT|1964-02-09|
TRIAL STUDY 134XCP|TR|8E25F21F-A565-40CB-B0D7-6CC496171293|5||||||LESFLIND|LESION FAILURE INDICATOR||MG/KG/H|ENLARGEMENT||/500 WBC|NOT DONE|||FISH|Y|U|CAREGIVER|CLINICAL PATHOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1968-01-26|
TRIAL STUDY 134XCP|TR|8CDD2247-485D-495C-9186-FF4CA3FFC32E|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MMHG|UNCHANGED||G/ANIMAL|NOT DONE|||FLOW MICROSCOPY|N|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|1||38||OPEN LABEL TREATMENT|1971-01-26|
TRIAL STUDY 134XCP|TR|8CDD2247-485D-495C-9186-FF4CA3FFC32E|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||KG/M2|TUMOR MERGED||KPA|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|N|U|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|2||58||TREATMENT|1963-03-16|
TRIAL STUDY 134XCP|TR|8CDD2247-485D-495C-9186-FF4CA3FFC32E|3||||||BNLNUM|NUMBER OF BONE LESIONS||U/M2/MIN|ENLARGEMENT FROM NADIR||BE/ML|NOT DONE|||CONFOCAL MICROSCOPY|N|Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|3||39||WASHOUT|1963-09-16|
TRIAL STUDY 134XCP|TR|8CDD2247-485D-495C-9186-FF4CA3FFC32E|4||||||BNLNUM|NUMBER OF BONE LESIONS||PMOL/G|ABSENT||CONTAINER|NOT DONE|||PERIODIC ACID SCHIFF STAIN|U|Y|STUDY SUBJECT|ADJUDICATOR 2|NA|4||88||TREATMENT|1967-03-23|
TRIAL STUDY 134XCP|TR|8CDD2247-485D-495C-9186-FF4CA3FFC32E|5||||||LDIAM|LONGEST DIAMETER||G/G/DAY|NORMAL||PM|NOT DONE|||CLAUSS METHOD|Y|Y|PARENT|FORENSIC PATHOLOGIST|U|5||7||CONTINUATION TREATMENT|1969-06-06|
TRIAL STUDY 134XCP|TR|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PFU|UNCHANGED||/7.5 ML|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|1||38||RUN-IN|1964-09-11|
TRIAL STUDY 134XCP|TR|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||GPL U|FURTHER ENLARGEMENT||BEL|NOT DONE|||HPLC/MS/MS|NA|Y|STUDY SUBJECT|MICROSCOPIST 1|NA|2||58||WASHOUT|1971-11-01|
TRIAL STUDY 134XCP|TR|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^9 ORGANISMS|ENLARGEMENT FROM NADIR||SHOCK WAVE|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|NA|N|STUDY SUBJECT|RADIOLOGIST|N|3||39||FOLLOW-UP|1972-10-22|
TRIAL STUDY 134XCP|TR|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|4||||||LPERP|LONGEST PERPENDICULAR||ELISA UNIT/DOSE|NONPALPABLE||EQ|NOT DONE|||TOLUIDINE BLUE STAIN|U|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4||88||TREATMENT|1965-10-15|
TRIAL STUDY 134XCP|TR|E50F5B98-1DC4-41A8-8D68-A4E98D9E6B13|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||NKAT/G HB|TUMOR MERGED||10^3 ORGANISMS|NOT DONE|||ELECTROPHORESIS|U|U|INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|5||7||OPEN LABEL TREATMENT|1961-10-17|
TRIAL STUDY 134XCP|TR|C004A8EB-220F-4FC5-A150-B5159DCA84D9|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||G/L|DIFFUSELY INCREASED||BE/ML|NOT DONE|||BAC ACGH|U|N|INVESTIGATOR|CARDIOLOGIST|Y|1||38||BLINDED TREATMENT|1961-06-05|
TRIAL STUDY 134XCP|TR|C004A8EB-220F-4FC5-A150-B5159DCA84D9|2||||||SUMVOL|SUM OF VOLUME||L/H|ABSENT||L/L|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|U|FAMILY MEMBER|RATER 2|U|2||58||CONTINUATION TREATMENT|1971-07-24|
TRIAL STUDY 134XCP|TR|C004A8EB-220F-4FC5-A150-B5159DCA84D9|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||OZ|INCREASED||AFU|NOT DONE|||HEMAGGLUTINATION ASSAY|U|U|VENDOR|ADJUDICATOR 2|NA|3||39||BLINDED TREATMENT|1970-03-02|
TRIAL STUDY 134XCP|TR|C004A8EB-220F-4FC5-A150-B5159DCA84D9|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||TITER|NONPALPABLE||GBQ|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|NA|NA|FAMILY MEMBER|HEMATOLOGIST|NA|4||88||FOLLOW-UP|1965-10-16|
TRIAL STUDY 134XCP|TR|C004A8EB-220F-4FC5-A150-B5159DCA84D9|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||TUBERCULIN UNIT/ML|PALPABLE||NG/DAY|NOT DONE|||IN SITU HYBRIDIZATION|U|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|5||7||SCREENING|1973-05-17|
TRIAL STUDY 134XCP|TR|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|1||||||VOLUME|VOLUME||MIN|PATHOLOGICAL||UG/KG/MIN|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|NA|NA|STUDY SUBJECT|RADIOLOGIST|Y|1||38||OBSERVATION|1970-03-28|
TRIAL STUDY 134XCP|TR|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|2||||||LESSCIND|LESION SUCCESS INDICATOR||BEAM BREAKS|NON-PATHOLOGICAL||CI/UG|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|N|N|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|2||58||TREATMENT|1964-09-20|
TRIAL STUDY 134XCP|TR|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||CM/S|ENLARGEMENT||PSI|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|NA|SPOUSE|READER|N|3||39||SCREENING|1972-11-22|
TRIAL STUDY 134XCP|TR|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||SIEMENS|FURTHER ENLARGEMENT FROM NADIR||10^9 CFU/ML|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|Y|SPOUSE|ADJUDICATOR 2|N|4||88||SCREENING|1963-01-01|
TRIAL STUDY 134XCP|TR|5F3947A1-23B5-45DD-AFF6-A9285C85CD3E|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||M/SEC|ENLARGEMENT||G/M2/DAY|NOT DONE|||FLOW CYTOMETRY|U|N|CAREGIVER|MICROSCOPIST|N|5||7||OPEN LABEL TREATMENT|1963-08-03|
TRIAL STUDY 134XCP|TR|AE127EDD-D708-4B1A-95F7-176A541A9584|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||KV|PRESENT||AFU|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|U|HEALTH CARE PROFESSIONAL|INTERNIST|Y|1||38||SCREENING|1972-12-30|
TRIAL STUDY 134XCP|TR|AE127EDD-D708-4B1A-95F7-176A541A9584|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||UGEQ|ABSENT||APL U|NOT DONE|||MICROARRAY|U|NA|SIGNIFICANT OTHER|NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1969-06-12|
TRIAL STUDY 134XCP|TR|AE127EDD-D708-4B1A-95F7-176A541A9584|3||||||PALPSTAT|PALPABLE STATE||PA|PATHOLOGICAL||FT3|NOT DONE|||MACRO BROTH DILUTION|N|U|SPOUSE|PATHOLOGIST 1|N|3||39||TREATMENT|1970-12-22|
TRIAL STUDY 134XCP|TR|AE127EDD-D708-4B1A-95F7-176A541A9584|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MM/SEC|INCREASED||MDFI|NOT DONE|||FLOCCULATION|U|U|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|4||88||SCREENING|1966-05-15|
TRIAL STUDY 134XCP|TR|AE127EDD-D708-4B1A-95F7-176A541A9584|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MMOL|PRESENT||RATIO|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|U|INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|5||7||BASELINE|1962-09-18|
TRIAL STUDY 134XCP|TR|F642D4A0-A67F-4A10-BB21-E4644E963D45|1||||||VSLPIND|VESSEL PATENCY INDICATOR||MU/L|ENLARGEMENT FROM NADIR||ML/BREATH|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|NA|STUDY SUBJECT|ADJUDICATOR 1|Y|1||38||BLINDED TREATMENT|1972-04-17|
TRIAL STUDY 134XCP|TR|F642D4A0-A67F-4A10-BB21-E4644E963D45|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||KG/CM2|NONPALPABLE||UG/L FEU|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|U|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|U|2||58||TREATMENT|1961-05-31|
TRIAL STUDY 134XCP|TR|F642D4A0-A67F-4A10-BB21-E4644E963D45|3||||||NEWCONF|NEW TUMOR CONFIRMED||GMFI|ABSENT||/DAY|NOT DONE|||IMMUNOASSAY|U|NA|GUARDIAN|MICROSCOPIST|U|3||39||OBSERVATION|1966-09-22|
TRIAL STUDY 134XCP|TR|F642D4A0-A67F-4A10-BB21-E4644E963D45|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ML/CAGE|FURTHER ENLARGEMENT||MAMP|NOT DONE|||OPTICAL MAPPING|Y|Y|ADJUDICATOR|READER 2|N|4||88||RUN-IN|1971-01-07|
TRIAL STUDY 134XCP|TR|F642D4A0-A67F-4A10-BB21-E4644E963D45|5||||||DIAMETER|DIAMETER||IU/G|NON-PATHOLOGICAL||PPB|NOT DONE|||CLINICAL EVALUATION|N|N|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|5||7||INDUCTION TREATMENT|1963-04-19|
TRIAL STUDY 134XCP|TR|933A6DFF-D519-46F4-AB52-78E6A898E4A1|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||INHALATION|INCREASED||TSP EQ|NOT DONE|||PET/MRI SCAN|NA|Y|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|1||38||TREATMENT|1960-01-18|
TRIAL STUDY 134XCP|TR|933A6DFF-D519-46F4-AB52-78E6A898E4A1|2||||||BNLNUM|NUMBER OF BONE LESIONS||TUBERCULIN UNIT/ML|NORMAL||CI/MG|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|U|U|SIBLING|RADIOLOGIST 1|NA|2||58||WASHOUT|1961-06-14|
TRIAL STUDY 134XCP|TR|933A6DFF-D519-46F4-AB52-78E6A898E4A1|3||||||LDIAM|LONGEST DIAMETER||FEU|DECREASED||/VF|NOT DONE|||ENZYMATIC COLORIMETRY|U|U|PARENT|DERMATOLOGIST|U|3||39||OBSERVATION|1964-03-03|
TRIAL STUDY 134XCP|TR|933A6DFF-D519-46F4-AB52-78E6A898E4A1|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||G/DAY|ENLARGEMENT FROM NADIR||10^3 ORGANISMS|NOT DONE|||PHOTOMETRY|N|NA|FRIEND|FORENSIC PATHOLOGIST|NA|4||88||BLINDED TREATMENT|1969-11-17|
TRIAL STUDY 134XCP|TR|933A6DFF-D519-46F4-AB52-78E6A898E4A1|5||||||LNSTATE|LYMPH NODE STATE||MEQ/MMOL|NONPALPABLE||NMOL BCE/L|NOT DONE|||FLUORESCENT SPOT TEST|N|Y|NON-HEALTH CARE PROFESSIONAL|READER|U|5||7||INDUCTION TREATMENT|1971-05-20|
TRIAL STUDY 134XCP|TR|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MM3/MM2/YEAR|NON-PATHOLOGICAL||ROENTGEN|NOT DONE|||ELECTROMYOGRAPHY|Y|NA|INTERVIEWER|CARDIOLOGIST|N|1||38||INDUCTION TREATMENT|1962-08-04|
TRIAL STUDY 134XCP|TR|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|2||||||SUMVOL|SUM OF VOLUME||/SEC|UNCHANGED||CIGAR|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|NA|STUDY SUBJECT|PATHOLOGIST 1|Y|2||58||BLINDED TREATMENT|1970-01-06|
TRIAL STUDY 134XCP|TR|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||ELISA UNIT|TUMOR MERGED||STEPS|NOT DONE|||LC/MS|Y|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|3||39||FOLLOW-UP|1970-03-05|
TRIAL STUDY 134XCP|TR|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||PIPE|NON-PATHOLOGICAL||CMOL/L|NOT DONE|||MECHANICAL CLOT DETECTION|NA|U|ADJUDICATOR|READER 2|N|4||88||OBSERVATION|1971-02-09|
TRIAL STUDY 134XCP|TR|CF880C64-8AA1-4A19-B8A3-821F3EDF83FD|5||||||BNLNUM|NUMBER OF BONE LESIONS||10^3 CFU/ML|PALPABLE||UIU/DL|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|5||7||BASELINE|1964-09-16|
TRIAL STUDY 134XCP|TR|38E177D4-1A58-4E78-90B7-85F76BF66826|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||SV|FOCALLY INCREASED||U/M2|NOT DONE|||TOLUIDINE BLUE STAIN|U|U|VENDOR|CLINICAL PATHOLOGIST|Y|1||38||TREATMENT|1962-09-05|
TRIAL STUDY 134XCP|TR|38E177D4-1A58-4E78-90B7-85F76BF66826|2||||||LPERP|LONGEST PERPENDICULAR||GRAVITATIONAL UNIT|FOCALLY INCREASED||MG/KG/DAY|NOT DONE|||SPIRAL CT|NA|U|SIBLING|UROLOGIST|Y|2||58||WASHOUT|1961-03-01|
TRIAL STUDY 134XCP|TR|38E177D4-1A58-4E78-90B7-85F76BF66826|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||APL U/ML|ABSENT||KCAL/DAY|NOT DONE|||NUCLEAR RADIOLOGY|NA|N|PROXY|ENDOCRINOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1973-01-07|
TRIAL STUDY 134XCP|TR|38E177D4-1A58-4E78-90B7-85F76BF66826|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||AG|PALPABLE||MEQ/UG|NOT DONE|||PHOTOGRAPHY|U|Y|INVESTIGATOR|INTERNIST|Y|4||88||LONG-TERM FOLLOW-UP|1968-12-21|
TRIAL STUDY 134XCP|TR|38E177D4-1A58-4E78-90B7-85F76BF66826|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UKAT/L|EQUIVOCAL||FRAMES/S|NOT DONE|||LEAD CITRATE STAIN|U|N|FRIEND|PHYSIOTHERAPIST|N|5||7||SCREENING|1965-06-06|
TRIAL STUDY 134XCP|TR|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|1||||||VOLUME|VOLUME||/WK|PALPABLE||MEQ/UL|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|NA|Y|PARENT|UROLOGIST|NA|1||38||BLINDED TREATMENT|1965-03-03|
TRIAL STUDY 134XCP|TR|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UIU/L|TUMOR MERGED||MJOULE/CM2|NOT DONE|||FLOW MICROSCOPY|Y|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||BLINDED TREATMENT|1964-01-22|
TRIAL STUDY 134XCP|TR|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^9 ORGANISMS/ML|EQUIVOCAL||MMOL/MOL|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|NA|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|3||39||RUN-IN|1964-11-14|
TRIAL STUDY 134XCP|TR|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||VIAL|DECREASED||APL U/ML|NOT DONE|||REBOUND TONOMETRY|NA|Y|SIBLING|READER 2|U|4||88||OPEN LABEL TREATMENT|1969-11-30|
TRIAL STUDY 134XCP|TR|43EFF4FE-66EE-45FD-8CA1-CDE9404CA2D9|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||/H|DIFFUSELY INCREASED||MMHG/L/MIN|NOT DONE|||IMMUNO-PET SCAN|Y|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||SCREENING|1970-04-01|
TRIAL STUDY 134XCP|TR|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|1||||||VSLPIND|VESSEL PATENCY INDICATOR||MBQ|PRESENT||CUP EQ|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|NA|NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|1||38||WASHOUT|1972-11-17|
TRIAL STUDY 134XCP|TR|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||MDFI|PATHOLOGICAL||MOL/G|NOT DONE|||URANYL ACETATE STAIN|U|Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|2||58||TREATMENT|1963-09-06|
TRIAL STUDY 134XCP|TR|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||/MM|NON-PATHOLOGICAL||MG/MOL|NOT DONE|||LEAD CITRATE STAIN|U|Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||INDUCTION TREATMENT|1966-10-04|
TRIAL STUDY 134XCP|TR|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||%|TUMOR MERGED||RING|NOT DONE|||MYELOPEROXIDASE STAIN|NA|N|GUARDIAN|RATER 1|NA|4||88||CONTINUATION TREATMENT|1970-11-01|
TRIAL STUDY 134XCP|TR|2FC40644-58C4-44B4-AF2A-D1D2EB66980B|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||HOURS|DECREASED||ML/ANIMAL/WK|NOT DONE|||AUTOREFRACTION|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 3|N|5||7||FOLLOW-UP|1965-10-09|
TRIAL STUDY 134XCP|TR|50CFC814-7135-4356-BAC2-3F975B9F6AE3|1||||||DIAMETER|DIAMETER||LOG10 ELISA UNIT/DOSE|PALPABLE||LOZENGE|NOT DONE|||APPLANATION TONOMETRY|U|U|VENDOR|RATER 2|Y|1||38||OPEN LABEL TREATMENT|1966-09-13|
TRIAL STUDY 134XCP|TR|50CFC814-7135-4356-BAC2-3F975B9F6AE3|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||TUBE|DECREASED||MCI/KG|NOT DONE|||CISH|Y|NA|HEALTH CARE PROFESSIONAL|RATER|N|2||58||LONG-TERM FOLLOW-UP|1963-06-07|
TRIAL STUDY 134XCP|TR|50CFC814-7135-4356-BAC2-3F975B9F6AE3|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||KM/H|FOCALLY INCREASED||UG/G/H|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|NA|N|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|3||39||RUN-IN|1972-02-16|
TRIAL STUDY 134XCP|TR|50CFC814-7135-4356-BAC2-3F975B9F6AE3|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||V/V|FOCALLY INCREASED||10^9 ORGANISMS/G|NOT DONE|||EEG|Y|Y|FAMILY MEMBER|READER 3|NA|4||88||BLINDED TREATMENT|1963-04-27|
TRIAL STUDY 134XCP|TR|50CFC814-7135-4356-BAC2-3F975B9F6AE3|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UKAT/10^12 RBC|UNEQUIVOCAL||FRAMES/S|NOT DONE|||OPTICAL MAPPING|Y|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|5||7||BASELINE|1971-04-05|
TRIAL STUDY 134XCP|TR|8A639816-D878-4FD7-AF28-CF9EA2236462|1||||||VSLPIND|VESSEL PATENCY INDICATOR||VIRTUAL PIXEL|NORMAL||/HPF|NOT DONE|||HPLC-FL|NA|U|INVESTIGATOR|FORENSIC PATHOLOGIST|N|1||38||INDUCTION TREATMENT|1967-02-25|
TRIAL STUDY 134XCP|TR|8A639816-D878-4FD7-AF28-CF9EA2236462|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6/G|PALPABLE||PMOL/DAY|NOT DONE|||REVERSE TRANSCRIPTASE PCR|U|U|FAMILY MEMBER|OPHTHALMOLOGIST|U|2||58||RUN-IN|1967-09-06|
TRIAL STUDY 134XCP|TR|8A639816-D878-4FD7-AF28-CF9EA2236462|3||||||DIAMETER|DIAMETER||QUANTITY SUFFICIENT|INCREASED||UMOL/L/H|NOT DONE|||AUDIOMETRY|U|N|INVESTIGATOR|OPTOMETRIST|Y|3||39||TREATMENT|1966-01-03|
TRIAL STUDY 134XCP|TR|8A639816-D878-4FD7-AF28-CF9EA2236462|4||||||LMBFLIND|LIMB FAILURE INDICATOR||CI/UG|NON-PATHOLOGICAL||PELLET|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|U|NA|SPOUSE|HEMATOLOGIST|Y|4||88||RUN-IN|1970-06-03|
TRIAL STUDY 134XCP|TR|8A639816-D878-4FD7-AF28-CF9EA2236462|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||NMOL BCE/L|ABSENT||10^6 IU|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|U|SPOUSE|PHYSIOTHERAPIST|U|5||7||TREATMENT|1960-08-13|
TRIAL STUDY 134XCP|TR|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||BREATHS/30S|FOCALLY INCREASED||MG/KG/MIN|NOT DONE|||JAEGER EYE CHART|U|N|FAMILY MEMBER|MICROSCOPIST 1|NA|1||38||RUN-IN|1972-03-23|
TRIAL STUDY 134XCP|TR|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||IU/ML|PALPABLE||NCI|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|NA|ADJUDICATOR|CARDIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1972-02-24|
TRIAL STUDY 134XCP|TR|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||/MS|FOCALLY INCREASED||GAUSS|NOT DONE|||MRI WITHOUT CONTRAST|NA|N|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|3||39||OPEN LABEL TREATMENT|1960-07-13|
TRIAL STUDY 134XCP|TR|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|4||||||LMBFLIND|LIMB FAILURE INDICATOR||MV/SEC|NORMAL||UEQ/L|NOT DONE|||MASS SPECTROMETRY|N|N|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|4||88||FOLLOW-UP|1970-12-21|
TRIAL STUDY 134XCP|TR|AB5AD6EB-8F8D-45B6-9FAB-9B6B43614A19|5||||||VOLUME|VOLUME||BAU|ABSENT||BQ/ML|NOT DONE|||FLUORESCEIN STAIN|U|U|PROXY|RATER 1|U|5||7||BLINDED TREATMENT|1963-07-25|
TRIAL STUDY 134XCP|TR|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||PFU/ANIMAL|ENLARGEMENT||10^3 DNA COPIES/ML|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|U|CAREGIVER|READER 3|U|1||38||LONG-TERM FOLLOW-UP|1961-04-17|
TRIAL STUDY 134XCP|TR|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||UG/L DDU|NORMAL||ML/H|NOT DONE|||POLYGRAPHY|U|NA|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||BASELINE|1971-03-05|
TRIAL STUDY 134XCP|TR|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|3||||||AREA|AREA||10^11/L|ABSENT||OZ|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|N|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1971-01-15|
TRIAL STUDY 134XCP|TR|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|4||||||SUMVOL|SUM OF VOLUME||ANTI-XA IU|NON-PATHOLOGICAL||MAC50|NOT DONE|||CLINICAL EVALUATION|NA|NA|CAREGIVER|READER 2|NA|4||88||BLINDED TREATMENT|1963-05-15|
TRIAL STUDY 134XCP|TR|B48ADEF8-4C6D-4DFC-8623-8C677DF57BB3|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||L/H/M2|DECREASED||MET|NOT DONE|||KINETIC CHROMOGENIC ASSAY|Y|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|5||7||LONG-TERM FOLLOW-UP|1967-01-05|
TRIAL STUDY 134XCP|TR|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|1||||||ORSTATE|ORGAN STATE||CI/ML|PATHOLOGICAL||MCI/KG|NOT DONE|||FLUOROSCOPY|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|1||38||WASHOUT|1963-02-26|
TRIAL STUDY 134XCP|TR|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/ANIMAL|PATHOLOGICAL||UG/L|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|NA|N|FRIEND|ADJUDICATOR|U|2||58||OPEN LABEL TREATMENT|1972-06-04|
TRIAL STUDY 134XCP|TR|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MG/M2|ENLARGEMENT FROM NADIR||DPM/ML|NOT DONE|||RAJI CELL EIA|U|N|PARENT|OPHTHALMOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1973-06-08|
TRIAL STUDY 134XCP|TR|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|4||||||NEWCONF|NEW TUMOR CONFIRMED||UG/KG/H|ABSENT||G/ANIMAL|NOT DONE|||MAPH|Y|U|CAREGIVER|NEUROLOGIST 2|NA|4||88||OPEN LABEL TREATMENT|1971-09-10|
TRIAL STUDY 134XCP|TR|3BF3C4EE-9526-4E22-956C-E72A1D9D9790|5||||||TUMSTATE|TUMOR STATE||G/DAY|ENLARGEMENT FROM NADIR||F|NOT DONE|||MYELOPEROXIDASE STAIN|Y|N|CAREGIVER|RADIOLOGIST 2|N|5||7||TREATMENT|1965-04-20|
TRIAL STUDY 134XCP|TR|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||IN|NONPALPABLE||APPLICATION|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1972-08-23|
TRIAL STUDY 134XCP|TR|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||LOG10 CFU/ML|EQUIVOCAL||TRANSDUCING UNIT|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|NA|U|INDEPENDENT ASSESSOR|RATER 2|U|2||58||RUN-IN|1972-08-29|
TRIAL STUDY 134XCP|TR|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||/SEC|INCREASED||/100 WBC|NOT DONE|||ICC|Y|Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3||39||OBSERVATION|1964-07-17|
TRIAL STUDY 134XCP|TR|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|4||||||NEWCONF|NEW TUMOR CONFIRMED||MBP|NON-PATHOLOGICAL||/4.0 ML|NOT DONE|||ROMANOWSKY STAIN|U|U|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|NA|4||88||BLINDED TREATMENT|1960-10-22|
TRIAL STUDY 134XCP|TR|0E9EBFA5-BA5B-4578-945F-4A3F5192BB43|5||||||VOLUME|VOLUME||%/S|PALPABLE||BAU/ML|NOT DONE|||MEDIASTINOSCOPY|NA|U|FRIEND|PATHOLOGIST 1|U|5||7||OPEN LABEL TREATMENT|1969-03-11|
TRIAL STUDY 134XCP|TR|30419F44-B519-488C-A505-F23D88A46024|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MMOL/MOL|PALPABLE||RNA COPIES/ML|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|1||38||TREATMENT|1961-08-23|
TRIAL STUDY 134XCP|TR|30419F44-B519-488C-A505-F23D88A46024|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||OZ|FURTHER ENLARGEMENT FROM NADIR||BU/ML|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|Y|N|GUARDIAN|MICROSCOPIST 2|N|2||58||WASHOUT|1969-03-12|
TRIAL STUDY 134XCP|TR|30419F44-B519-488C-A505-F23D88A46024|3||||||VSLPIND|VESSEL PATENCY INDICATOR||PIXELS/IN|NONPALPABLE||NG/L|NOT DONE|||PERIPHERAL ANGIOGRAPHY|U|Y|SIGNIFICANT OTHER|READER|N|3||39||SCREENING|1972-11-13|
TRIAL STUDY 134XCP|TR|30419F44-B519-488C-A505-F23D88A46024|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||APPLICATION|PALPABLE||IU/ML|NOT DONE|||PATHOLOGICAL EVALUATION|N|N|STUDY SUBJECT|HEMATOLOGIST|Y|4||88||CONTINUATION TREATMENT|1960-09-29|
TRIAL STUDY 134XCP|TR|30419F44-B519-488C-A505-F23D88A46024|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||10^6 CFU/G|UNCHANGED||UG/M2/DAY|NOT DONE|||ANGIOGRAPHY|NA|NA|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|5||7||FOLLOW-UP|1971-11-26|
TRIAL STUDY 134XCP|TR|2AF06F66-5E51-4AC9-AF62-A34329724F7D|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MJOULE/CM2|UNEQUIVOCAL||RATIO|NOT DONE|||GIEMSA STAIN|U|U|GUARDIAN|READER 1|N|1||38||FOLLOW-UP|1966-01-16|
TRIAL STUDY 134XCP|TR|2AF06F66-5E51-4AC9-AF62-A34329724F7D|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||VP/DOSE|PATHOLOGICAL||MONTHS|NOT DONE|||PYROSEQUENCING|NA|Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|2||58||TREATMENT|1967-04-22|
TRIAL STUDY 134XCP|TR|2AF06F66-5E51-4AC9-AF62-A34329724F7D|3||||||LESSCIND|LESION SUCCESS INDICATOR||UG/MOL|FURTHER ENLARGEMENT||JDF UNIT|NOT DONE|||IMMUNOBLOT|Y|N|CLINICAL RESEARCH COORDINATOR|READER 3|U|3||39||OBSERVATION|1970-05-01|
TRIAL STUDY 134XCP|TR|2AF06F66-5E51-4AC9-AF62-A34329724F7D|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MPL U|DECREASED||/MONTH|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|N|U|SPOUSE|ADJUDICATOR|N|4||88||INDUCTION TREATMENT|1972-05-15|
TRIAL STUDY 134XCP|TR|2AF06F66-5E51-4AC9-AF62-A34329724F7D|5||||||NEWCONF|NEW TUMOR CONFIRMED||BLOCKS|FOCALLY INCREASED||UG/CM2|NOT DONE|||MS/MS|NA|Y|VENDOR|RATER 2|U|5||7||INDUCTION TREATMENT|1964-08-17|
TRIAL STUDY 134XCP|TR|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MANSON U/ML|FOCALLY INCREASED||FIU|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|Y|FAMILY MEMBER|DERMATOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1966-04-17|
TRIAL STUDY 134XCP|TR|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||U/G/DAY|PALPABLE||OD UNIT|NOT DONE|||CHROMOGENIC ASSAY|Y|Y|FRIEND|PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1960-06-11|
TRIAL STUDY 134XCP|TR|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||U/G/DAY|FOCALLY INCREASED||/4.0 ML|NOT DONE|||PET SCAN|N|U|INVESTIGATOR|READER 2|Y|3||39||SCREENING|1968-08-19|
TRIAL STUDY 134XCP|TR|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MPL U|NON-PATHOLOGICAL||ANTI-XA IU/ML|NOT DONE|||POLYMERASE CHAIN REACTION|Y|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1968-06-22|
TRIAL STUDY 134XCP|TR|DAE5B7A9-FB1D-4743-B6A5-C05FFC9AF829|5||||||SUMDIAM|SUM OF DIAMETER||PHERESIS UNIT|FOCALLY INCREASED||10^8 PFU|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y|U|ADJUDICATOR|PATHOLOGIST 2|NA|5||7||BLINDED TREATMENT|1969-03-01|
TRIAL STUDY 134XCP|TR|94F4C997-3114-4444-BF89-E762226AAC89|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||TRANSDUCING UNIT|NON-PATHOLOGICAL||10^4/L|NOT DONE|||DIFFUSION TENSOR MRI|NA|U|PARENT|DERMATOLOGIST|Y|1||38||TREATMENT|1969-10-02|
TRIAL STUDY 134XCP|TR|94F4C997-3114-4444-BF89-E762226AAC89|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||GBQ|INCREASED||AMU|NOT DONE|||FLUORESCEIN STAIN|Y|N|VENDOR|NEUROLOGIST|U|2||58||BASELINE|1960-02-14|
TRIAL STUDY 134XCP|TR|94F4C997-3114-4444-BF89-E762226AAC89|3||||||LMBFLIND|LIMB FAILURE INDICATOR||PG/CELL|NORMAL||PPB|NOT DONE|||CONGO RED STAIN|U|NA|CLINICAL RESEARCH ASSOCIATE|READER 3|Y|3||39||RUN-IN|1969-01-21|
TRIAL STUDY 134XCP|TR|94F4C997-3114-4444-BF89-E762226AAC89|4||||||SUMVOL|SUM OF VOLUME||LOG10 TCID 50/ML|DECREASED||FG|NOT DONE|||AGAR PROPORTION|NA|Y|GUARDIAN|DERMATOLOGIST|Y|4||88||OBSERVATION|1969-09-20|
TRIAL STUDY 134XCP|TR|94F4C997-3114-4444-BF89-E762226AAC89|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||NFIU|DECREASED||M|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|NA|NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|5||7||TREATMENT|1966-11-09|
TRIAL STUDY 134XCP|TR|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|1||||||VOLUME|VOLUME||DROP|NON-PATHOLOGICAL||DMOL|NOT DONE|||PAP STAIN|U|NA|CHILD|ADJUDICATOR 2|NA|1||38||LONG-TERM FOLLOW-UP|1962-03-20|
TRIAL STUDY 134XCP|TR|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||%(W/V)|INCREASED||MMOL2/L2|NOT DONE|||PYROSEQUENCING|NA|Y|INVESTIGATOR|RATER 2|U|2||58||OBSERVATION|1970-09-15|
TRIAL STUDY 134XCP|TR|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|3||||||RADIODEN|RADIODENSITY||RNA COPIES/ML|NONPALPABLE||PIXELS/IN|NOT DONE|||PERFUSION MRI|U|U|CAREGIVER|READER 2|U|3||39||FOLLOW-UP|1966-06-22|
TRIAL STUDY 134XCP|TR|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||BAU|UNCHANGED||%(W/W)|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|NA|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||BLINDED TREATMENT|1965-07-11|
TRIAL STUDY 134XCP|TR|5EBDAAC2-9202-4BE7-BD9A-7CCBBC963DB7|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MV2/HZ|NON-PATHOLOGICAL||PG/DL|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|U|ADJUDICATOR|RADIOLOGIST 2|NA|5||7||TREATMENT|1965-01-29|
TRIAL STUDY 134XCP|TR|D20DE6F0-DA30-4453-8F80-61093BF046A6|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UG/KG/H|NORMAL||10^8 PFU|NOT DONE|||PALM METHOD|Y|N|VENDOR|MICROSCOPIST|U|1||38||CONTINUATION TREATMENT|1967-05-04|
TRIAL STUDY 134XCP|TR|D20DE6F0-DA30-4453-8F80-61093BF046A6|2||||||RADIODEN|RADIODENSITY||RING|PALPABLE||BQ/MG|NOT DONE|||POLYMERASE CHAIN REACTION|NA|U|DOMESTIC PARTNER|ADJUDICATOR 2|NA|2||58||INDUCTION TREATMENT|1972-10-12|
TRIAL STUDY 134XCP|TR|D20DE6F0-DA30-4453-8F80-61093BF046A6|3||||||DIAMETER|DIAMETER||BEAM BREAKS|ENLARGEMENT FROM NADIR||CCID 50/ML|NOT DONE|||MUGA|N|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|3||39||BLINDED TREATMENT|1968-04-06|
TRIAL STUDY 134XCP|TR|D20DE6F0-DA30-4453-8F80-61093BF046A6|4||||||RADIODEN|RADIODENSITY||F|UNCHANGED||/200 HPFS|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|Y|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|4||88||OBSERVATION|1964-06-03|
TRIAL STUDY 134XCP|TR|D20DE6F0-DA30-4453-8F80-61093BF046A6|5||||||LESFLIND|LESION FAILURE INDICATOR||HOUNSFIELD UNIT|NORMAL||MMOL/G|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|NA|NA|HEALTH CARE PROFESSIONAL|RATER 2|NA|5||7||CONTINUATION TREATMENT|1968-10-13|
TRIAL STUDY 134XCP|TR|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MG/M2|NONPALPABLE||IU/MG|NOT DONE|||ERGOSPIROMETRY|Y|U|SIGNIFICANT OTHER|ONCOLOGIST|NA|1||38||BASELINE|1969-01-13|
TRIAL STUDY 134XCP|TR|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||S/H|INCREASED||MG/ML/MIN|NOT DONE|||CISH|NA|NA|ADJUDICATION COMMITTEE|READER 1|NA|2||58||FOLLOW-UP|1969-04-28|
TRIAL STUDY 134XCP|TR|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||10^6 IU/ML|UNEQUIVOCAL||MMU/ML|NOT DONE|||ELLA|NA|NA|INVESTIGATOR|CLINICAL PATHOLOGIST|Y|3||39||CONTINUATION TREATMENT|1968-07-20|
TRIAL STUDY 134XCP|TR|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|4||||||LESFLIND|LESION FAILURE INDICATOR||ML/MMHG/MIN/L|UNEQUIVOCAL||%/S|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|NA|PARENT|OPTOMETRIST|NA|4||88||OPEN LABEL TREATMENT|1966-03-11|
TRIAL STUDY 134XCP|TR|9F6968CB-46E4-4DF7-B07D-33355B18A5F3|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MIN|EQUIVOCAL||TAMPON|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|Y|Y|GUARDIAN|ONCOLOGIST|NA|5||7||OBSERVATION|1962-05-08|
TRIAL STUDY 134XCP|TR|F20939CF-C668-4514-A2CF-63723560FA46|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||USP U|UNCHANGED||% INHIBITION|NOT DONE|||IMPEDANCE CONDUCTIVITY|Y|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||TREATMENT|1965-12-04|
TRIAL STUDY 134XCP|TR|F20939CF-C668-4514-A2CF-63723560FA46|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||JOULE|ABSENT||MEQ/DL|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|Y|NA|CHILD|MICROSCOPIST 3|U|2||58||RUN-IN|1962-07-23|
TRIAL STUDY 134XCP|TR|F20939CF-C668-4514-A2CF-63723560FA46|3||||||LNSTATE|LYMPH NODE STATE||MEQ/KG|DIFFUSELY INCREASED||10^3 ORGANISMS/G|NOT DONE|||RAJI CELL RIA|U|Y|DOMESTIC PARTNER|CARDIOLOGIST|NA|3||39||INDUCTION TREATMENT|1970-02-16|
TRIAL STUDY 134XCP|TR|F20939CF-C668-4514-A2CF-63723560FA46|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||CI/UL|INCREASED||NKAT|NOT DONE|||MICROBIAL CULTURE|NA|NA|SIBLING|UROLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1972-12-21|
TRIAL STUDY 134XCP|TR|F20939CF-C668-4514-A2CF-63723560FA46|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||FMOL/G|UNEQUIVOCAL||/WK|NOT DONE|||FLOW MICROSCOPY|N|N|INVESTIGATOR|READER 1|N|5||7||RUN-IN|1967-05-03|
TRIAL STUDY 134XCP|TR|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|1||||||SUMDIAM|SUM OF DIAMETER||MMOL/L|NORMAL||COULOMB|NOT DONE|||SANGER SEQUENCING|N|NA|GUARDIAN|RADIOLOGIST 2|U|1||38||CONTINUATION TREATMENT|1962-01-26|
TRIAL STUDY 134XCP|TR|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PFU|INCREASED||10^9 CFU/ML|NOT DONE|||ACRIDINE ORANGE STAIN|NA|U|INTERVIEWER|MICROSCOPIST 3|NA|2||58||INDUCTION TREATMENT|1966-03-27|
TRIAL STUDY 134XCP|TR|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|3||||||VDIAM|VIABLE DIAMETER||10^9 CFU/G|PATHOLOGICAL||DPM/MG|NOT DONE|||RIA|Y|U|ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|3||39||WASHOUT|1973-09-08|
TRIAL STUDY 134XCP|TR|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||EID 50/DOSE|UNEQUIVOCAL||UV2|NOT DONE|||POLYMERASE CHAIN REACTION|N|NA|SIBLING|RATER|U|4||88||BLINDED TREATMENT|1960-05-10|
TRIAL STUDY 134XCP|TR|CECB0ED0-5ADE-46DC-B56B-6AC63A89D791|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MNFI|UNCHANGED||ML/ANIMAL/WK|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|U|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|5||7||FOLLOW-UP|1966-02-15|
TRIAL STUDY 134XCP|TR|9A60A414-54A0-4A7F-84EE-FCB8246D2477|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||GBQ/MG|NORMAL||FMOL/L|NOT DONE|||MRI WITHOUT CONTRAST|U|U|SPOUSE|ADJUDICATOR 1|N|1||38||SCREENING|1968-02-12|
TRIAL STUDY 134XCP|TR|9A60A414-54A0-4A7F-84EE-FCB8246D2477|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||ML/100G/MIN|UNCHANGED||PMOL/DAY|NOT DONE|||CLOT DETECTION|U|NA|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|Y|2||58||BLINDED TREATMENT|1966-05-18|
TRIAL STUDY 134XCP|TR|9A60A414-54A0-4A7F-84EE-FCB8246D2477|3||||||AREA|AREA||ABSORBANCE U/ML|FOCALLY INCREASED||NEBULE|NOT DONE|||RYAN BLUE STAIN|U|U|INTERVIEWER|ENDOCRINOLOGIST|U|3||39||INDUCTION TREATMENT|1968-10-18|
TRIAL STUDY 134XCP|TR|9A60A414-54A0-4A7F-84EE-FCB8246D2477|4||||||TUMSTATE|TUMOR STATE||MU/G|NON-PATHOLOGICAL||UG/ML/H|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|4||88||BASELINE|1961-01-27|
TRIAL STUDY 134XCP|TR|9A60A414-54A0-4A7F-84EE-FCB8246D2477|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^4 CFU|FOCALLY INCREASED||MMOL|NOT DONE|||ELASTOGRAPHY|NA|NA|HEALTH CARE PROFESSIONAL|RATER 2|NA|5||7||INDUCTION TREATMENT|1966-01-29|
TRIAL STUDY 134XCP|TR|8D546F1C-E719-4C03-A66A-9916EFF2A144|1||||||VDIAM|VIABLE DIAMETER||GPL U|FOCALLY INCREASED||L/MIN/M2|NOT DONE|||HPLC-UV|N|Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|1||38||SCREENING|1964-07-24|
TRIAL STUDY 134XCP|TR|8D546F1C-E719-4C03-A66A-9916EFF2A144|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||10^6 DNA COPIES/ML|TUMOR MERGED||IU/MMOL|NOT DONE|||DIFFUSION WEIGHTED MRI|U|U|CLINICAL STUDY SPONSOR|READER 2|U|2||58||LONG-TERM FOLLOW-UP|1971-11-12|
TRIAL STUDY 134XCP|TR|8D546F1C-E719-4C03-A66A-9916EFF2A144|3||||||PALPSTAT|PALPABLE STATE||STRIP|UNCHANGED||ML/H|NOT DONE|||OSCILLOMETRY|Y|N|HEALTH CARE PROFESSIONAL|INTERNIST|U|3||39||BLINDED TREATMENT|1965-12-26|
TRIAL STUDY 134XCP|TR|8D546F1C-E719-4C03-A66A-9916EFF2A144|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||WEBER|PRESENT||10^8/L|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|U|U|INDEPENDENT ASSESSOR|OPTOMETRIST|NA|4||88||OPEN LABEL TREATMENT|1968-08-24|
TRIAL STUDY 134XCP|TR|8D546F1C-E719-4C03-A66A-9916EFF2A144|5||||||TUMSTATE|TUMOR STATE||DAYS/MONTH|EQUIVOCAL||POUCH|NOT DONE|||REBOUND TONOMETRY|Y|N|HEALTH CARE PROFESSIONAL|INTERNIST|N|5||7||SCREENING|1971-04-19|
TRIAL STUDY 134XCP|TR|B998085D-F227-46C8-B2D8-37E97BA799D2|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||/CMH2O|FURTHER ENLARGEMENT FROM NADIR||L/S/KPA|NOT DONE|||SPECT SCAN|U|Y|INDEPENDENT ASSESSOR|READER 3|NA|1||38||BASELINE|1961-01-24|
TRIAL STUDY 134XCP|TR|B998085D-F227-46C8-B2D8-37E97BA799D2|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ROENTGEN|PRESENT||ML/ANIMAL/DAY|NOT DONE|||SPECT SCAN|NA|NA|PARENT|READER|Y|2||58||TREATMENT|1967-04-21|
TRIAL STUDY 134XCP|TR|B998085D-F227-46C8-B2D8-37E97BA799D2|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||DYN|EQUIVOCAL||IU/MMOL|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|N|STUDY SUBJECT|ONCOLOGIST 2|NA|3||39||FOLLOW-UP|1969-11-23|
TRIAL STUDY 134XCP|TR|B998085D-F227-46C8-B2D8-37E97BA799D2|4||||||LESSCIND|LESION SUCCESS INDICATOR||YEARS|NONPALPABLE||U/M2/MIN|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|U|U|VENDOR|ONCOLOGIST 2|NA|4||88||BLINDED TREATMENT|1963-02-12|
TRIAL STUDY 134XCP|TR|B998085D-F227-46C8-B2D8-37E97BA799D2|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||GPELISA UNIT/ML|PALPABLE||CPM|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|N|5||7||BLINDED TREATMENT|1964-05-28|
TRIAL STUDY 134XCP|TR|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|1||||||VSLPIND|VESSEL PATENCY INDICATOR||/MS|FURTHER ENLARGEMENT||PUFF|NOT DONE|||DIGITAL PCR ARRAY|Y|N|HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|1||38||BASELINE|1961-04-07|
TRIAL STUDY 134XCP|TR|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||SUPPOSITORY|PATHOLOGICAL||/MONTH|NOT DONE|||RAJI CELL RIA|Y|U|CLINICAL STUDY SPONSOR|INTERNIST|N|2||58||OPEN LABEL TREATMENT|1972-01-14|
TRIAL STUDY 134XCP|TR|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MV2/HZ|PATHOLOGICAL||CI|NOT DONE|||KINYOUN STAIN|U|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|3||39||CONTINUATION TREATMENT|1960-05-05|
TRIAL STUDY 134XCP|TR|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^9 ORGANISMS/ML|ABSENT||FOZ_BR|NOT DONE|||ICP-MS|N|NA|GUARDIAN|MICROSCOPIST 3|Y|4||88||OPEN LABEL TREATMENT|1964-04-06|
TRIAL STUDY 134XCP|TR|DDAF2BC7-9329-4528-B1D5-00C8E0D284D9|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UG/KG/MIN|DIFFUSELY INCREASED||MET*MIN|NOT DONE|||COULOMETRIC TITRATION|NA|NA|DOMESTIC PARTNER|PATHOLOGIST 2|Y|5||7||OBSERVATION|1966-07-28|
TRIAL STUDY 134XCP|TR|537CE647-EA58-430C-B37B-F56BF20B5AF0|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||EID 50/ML|PRESENT||10^10/L|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|NA|NA|FRIEND|RADIOLOGIST 2|N|1||38||WASHOUT|1965-02-14|
TRIAL STUDY 134XCP|TR|537CE647-EA58-430C-B37B-F56BF20B5AF0|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PSEC|PALPABLE||NFIU|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|N|U|PROXY|DERMATOLOGIST|U|2||58||BLINDED TREATMENT|1960-05-27|
TRIAL STUDY 134XCP|TR|537CE647-EA58-430C-B37B-F56BF20B5AF0|3||||||NEWCONF|NEW TUMOR CONFIRMED||GPELISA UNIT/ML|INCREASED||ML/KG/DAY|NOT DONE|||KLEIHAUER-BETKE|Y|N|SIGNIFICANT OTHER|MICROSCOPIST 2|Y|3||39||TREATMENT|1960-11-25|
TRIAL STUDY 134XCP|TR|537CE647-EA58-430C-B37B-F56BF20B5AF0|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MOSM/L|PRESENT||LB|NOT DONE|||PET/MRI SCAN|Y|U|GUARDIAN|PHYSIOTHERAPIST|NA|4||88||SCREENING|1970-10-17|
TRIAL STUDY 134XCP|TR|537CE647-EA58-430C-B37B-F56BF20B5AF0|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||/MM2|PRESENT||ENZYME U/L|NOT DONE|||TOTAL BODY RADIOGRAPHY|U|Y|ADJUDICATOR|CARDIOLOGIST|N|5||7||BASELINE|1962-07-17|
TRIAL STUDY 134XCP|TR|3464201C-9704-40B6-B3B3-2BADE02BD58F|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MOL/MOL|ENLARGEMENT FROM NADIR||NU/CL|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|N|FRIEND|RADIOLOGIST 1|U|1||38||OBSERVATION|1969-04-13|
TRIAL STUDY 134XCP|TR|3464201C-9704-40B6-B3B3-2BADE02BD58F|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/MMHG/MIN/L|UNCHANGED||BQ/MG|NOT DONE|||WESTERN BLOT|NA|Y|SIBLING|MICROSCOPIST|NA|2||58||OPEN LABEL TREATMENT|1965-03-05|
TRIAL STUDY 134XCP|TR|3464201C-9704-40B6-B3B3-2BADE02BD58F|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||KIU|INCREASED||H*%|NOT DONE|||OBSERVATION|N|N|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||INDUCTION TREATMENT|1960-08-06|
TRIAL STUDY 134XCP|TR|3464201C-9704-40B6-B3B3-2BADE02BD58F|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ELISA UNIT/DOSE|TUMOR MERGED||UV*SEC|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|N|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|4||88||BLINDED TREATMENT|1962-10-16|
TRIAL STUDY 134XCP|TR|3464201C-9704-40B6-B3B3-2BADE02BD58F|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MG/KG/WEEK|TUMOR MERGED||NSEC|NOT DONE|||TRIPLE-PHASE MRI SCAN|NA|U|FAMILY MEMBER|PHYSIOTHERAPIST|NA|5||7||LONG-TERM FOLLOW-UP|1966-12-10|
TRIAL STUDY 134XCP|TR|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|1||||||LESFLIND|LESION FAILURE INDICATOR||DDU|PATHOLOGICAL||BREATHS/30S|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|Y|N|SIBLING|RADIOLOGIST 1|Y|1||38||OBSERVATION|1967-05-25|
TRIAL STUDY 134XCP|TR|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||G/M2|NON-PATHOLOGICAL||LX|NOT DONE|||KNEMOMETRY|NA|Y|INVESTIGATOR|CLINICAL PATHOLOGIST|N|2||58||RUN-IN|1964-06-25|
TRIAL STUDY 134XCP|TR|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MOL/DAY|ENLARGEMENT FROM NADIR||G/L|NOT DONE|||PERCUSSION|NA|N|STUDY SUBJECT|FORENSIC PATHOLOGIST|U|3||39||SCREENING|1966-07-21|
TRIAL STUDY 134XCP|TR|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||HOUNSFIELD UNIT|FURTHER ENLARGEMENT FROM NADIR||FL|NOT DONE|||IHC|N|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||BASELINE|1965-02-25|
TRIAL STUDY 134XCP|TR|1CB9F8AF-8CC3-44B2-8B93-24CADF4225C7|5||||||DIAMETER|DIAMETER||DDU|DECREASED||KUSP|NOT DONE|||AGAR PROPORTION|NA|U|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||TREATMENT|1962-03-01|
TRIAL STUDY 134XCP|TR|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|1||||||LESSCIND|LESION SUCCESS INDICATOR||APL U/ML|NORMAL||JDF UNIT|NOT DONE|||CT SCAN|NA|N|SIGNIFICANT OTHER|ONCOLOGIST 1|NA|1||38||BASELINE|1963-02-03|
TRIAL STUDY 134XCP|TR|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|2||||||LNSTATE|LYMPH NODE STATE||/DAY|FOCALLY INCREASED||KPA|NOT DONE|||SLOAN LETTER EYE CHART 100%|U|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|2||58||WASHOUT|1960-09-20|
TRIAL STUDY 134XCP|TR|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|3||||||CALCFIND|CALCIFICATION INDICATOR||ML/SEC/1.73M2|NORMAL||APPLICATION|NOT DONE|||PAP STAIN|N|NA|CHILD|CLINICAL PATHOLOGIST|Y|3||39||SCREENING|1963-07-04|
TRIAL STUDY 134XCP|TR|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|4||||||PALPSTAT|PALPABLE STATE||MEQ/MMOL|TUMOR MERGED||KN/CM2|NOT DONE|||PET SCAN|Y|NA|INTERVIEWER|ADJUDICATOR|Y|4||88||CONTINUATION TREATMENT|1969-09-27|
TRIAL STUDY 134XCP|TR|7E66F52C-0967-4F56-9E1D-C3C3DC7F76FB|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||GTT|FOCALLY INCREASED||PM|NOT DONE|||MASS SPECTROMETRY|U|NA|DOMESTIC PARTNER|RADIOLOGIST|N|5||7||FOLLOW-UP|1973-01-23|
TRIAL STUDY 134XCP|TR|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||BOLUS|TUMOR MERGED||GY|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|NA|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|1||38||FOLLOW-UP|1967-10-15|
TRIAL STUDY 134XCP|TR|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|2||||||ORSTATE|ORGAN STATE||DB|UNCHANGED||CL|NOT DONE|||MANUAL COUNT|N|Y|PROXY|PATHOLOGIST 2|Y|2||58||SCREENING|1963-01-19|
TRIAL STUDY 134XCP|TR|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||DIOPTER|TUMOR MERGED||PKAT/L|NOT DONE|||IMMUNOTURBIDIMETRY|NA|Y|PROXY|ADJUDICATOR 1|Y|3||39||BLINDED TREATMENT|1966-11-29|
TRIAL STUDY 134XCP|TR|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||SV|NORMAL||/100 WBC|NOT DONE|||TONOMETRY|N|NA|FRIEND|MICROSCOPIST|Y|4||88||BASELINE|1966-03-27|
TRIAL STUDY 134XCP|TR|916EA783-F2CD-4C42-BA37-EF0F86C2F5DD|5||||||LESSCIND|LESION SUCCESS INDICATOR||HOURS|NORMAL||UG/DL|NOT DONE|||PET SCAN|U|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|5||7||CONTINUATION TREATMENT|1965-08-27|
TRIAL STUDY 134XCP|TR|11A6144A-895B-4143-85D2-69952C6D452C|1||||||BNLNUM|NUMBER OF BONE LESIONS||MIN/DAY|UNEQUIVOCAL||GPELISA UNIT/ML|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|1||38||TREATMENT|1972-09-29|
TRIAL STUDY 134XCP|TR|11A6144A-895B-4143-85D2-69952C6D452C|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||LOG10 CFU/ML|PALPABLE||UMOL/L/H|NOT DONE|||PANENDOSCOPY|NA|N|INTERVIEWER|MICROSCOPIST 3|U|2||58||TREATMENT|1964-07-26|
TRIAL STUDY 134XCP|TR|11A6144A-895B-4143-85D2-69952C6D452C|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MG/M2/DAY|PATHOLOGICAL||10^6 ORGANISMS/G|NOT DONE|||CLINICAL EVALUATION|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|3||39||LONG-TERM FOLLOW-UP|1964-07-06|
TRIAL STUDY 134XCP|TR|11A6144A-895B-4143-85D2-69952C6D452C|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||/MM2|NON-PATHOLOGICAL||L/H|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|Y|NA|GUARDIAN|RATER 2|N|4||88||LONG-TERM FOLLOW-UP|1961-03-16|
TRIAL STUDY 134XCP|TR|11A6144A-895B-4143-85D2-69952C6D452C|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||EJACULATE U|ENLARGEMENT FROM NADIR||IU/KG|NOT DONE|||SLIT LAMP PHOTOGRAPHY|U|NA|SIBLING|READER 1|N|5||7||WASHOUT|1971-03-25|
TRIAL STUDY 134XCP|TR|8958D35E-F685-4542-AE01-625133F1EF7D|1||||||LDIAM|LONGEST DIAMETER||COPIES/UL|PALPABLE||/KG|NOT DONE|||HEMOCYTOMETRY|N|N|SIGNIFICANT OTHER|MICROSCOPIST 3|NA|1||38||BLINDED TREATMENT|1965-02-16|
TRIAL STUDY 134XCP|TR|8958D35E-F685-4542-AE01-625133F1EF7D|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||/200 HPFS|EQUIVOCAL||10^3 ORGANISMS/ML|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|Y|NA|SIBLING|NEUROLOGIST|Y|2||58||WASHOUT|1970-04-03|
TRIAL STUDY 134XCP|TR|8958D35E-F685-4542-AE01-625133F1EF7D|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||%/S|ENLARGEMENT FROM NADIR||G/KG/DAY|NOT DONE|||NO INFORMATION|U|U|VENDOR|MICROSCOPIST|Y|3||39||WASHOUT|1965-08-09|
TRIAL STUDY 134XCP|TR|8958D35E-F685-4542-AE01-625133F1EF7D|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||ML/M2|ABSENT||UCI/L|NOT DONE|||IMMUNOTURBIDIMETRY|Y|N|INVESTIGATOR|UROLOGIST|Y|4||88||BASELINE|1966-01-07|
TRIAL STUDY 134XCP|TR|8958D35E-F685-4542-AE01-625133F1EF7D|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||%(V/V)|FURTHER ENLARGEMENT FROM NADIR||M3|NOT DONE|||PET/SPECT SCAN|N|Y|PROXY|CARDIOLOGIST|Y|5||7||INDUCTION TREATMENT|1960-09-15|
TRIAL STUDY 134XCP|TR|00982640-C826-4CD4-B927-A311227E63CC|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CL|DECREASED||UU/L|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|Y|SPOUSE|PEDIATRIC NEUROLOGIST|N|1||38||INDUCTION TREATMENT|1966-02-09|
TRIAL STUDY 134XCP|TR|00982640-C826-4CD4-B927-A311227E63CC|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MSEC|ENLARGEMENT FROM NADIR||ML/BREATH|NOT DONE|||AGAR DILUTION|NA|NA|SIBLING|RADIOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1964-10-25|
TRIAL STUDY 134XCP|TR|00982640-C826-4CD4-B927-A311227E63CC|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MOSM|PRESENT||BQ/G|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|N|U|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|3||39||SCREENING|1970-08-22|
TRIAL STUDY 134XCP|TR|00982640-C826-4CD4-B927-A311227E63CC|4||||||ORSTATE|ORGAN STATE||/100 WBC|NON-PATHOLOGICAL||YEARS|NOT DONE|||CENTRIFUGATION|NA|N|SPOUSE|NEUROLOGIST|U|4||88||OPEN LABEL TREATMENT|1969-09-05|
TRIAL STUDY 134XCP|TR|00982640-C826-4CD4-B927-A311227E63CC|5||||||AREA|AREA||BEL|DIFFUSELY INCREASED||MG/ANIMAL|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|U|U|SIGNIFICANT OTHER|NEUROLOGIST|N|5||7||OBSERVATION|1963-09-21|
TRIAL STUDY 134XCP|TR|C213CAA8-2FAC-402C-A19E-11A60708A71A|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||PRESSOR UNITS|ENLARGEMENT||UKAT|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|Y|Y|FRIEND|READER 2|Y|1||38||CONTINUATION TREATMENT|1963-11-29|
TRIAL STUDY 134XCP|TR|C213CAA8-2FAC-402C-A19E-11A60708A71A|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||ANTI-XA IU/ML|EQUIVOCAL||U/L|NOT DONE|||FREEZING POINT DEPRESSION|U|NA|INVESTIGATOR|NEUROLOGIST 2|U|2||58||FOLLOW-UP|1964-12-15|
TRIAL STUDY 134XCP|TR|C213CAA8-2FAC-402C-A19E-11A60708A71A|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||NGEQ/L|TUMOR MERGED||AMOL|NOT DONE|||ERGOSPIROMETRY|Y|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|3||39||FOLLOW-UP|1961-05-22|
TRIAL STUDY 134XCP|TR|C213CAA8-2FAC-402C-A19E-11A60708A71A|4||||||VSLPIND|VESSEL PATENCY INDICATOR||U/DL|NON-PATHOLOGICAL||BAU|NOT DONE|||SLIT LAMP PHOTOGRAPHY|NA|U|CLINICAL STUDY SPONSOR|PATHOLOGIST|U|4||88||SCREENING|1963-10-18|
TRIAL STUDY 134XCP|TR|C213CAA8-2FAC-402C-A19E-11A60708A71A|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||FMOL/G|ABSENT||10^7 PFU|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|NA|NA|ADJUDICATION COMMITTEE|READER 2|N|5||7||FOLLOW-UP|1972-04-12|
TRIAL STUDY 134XCP|TR|F0559682-CD36-4ED0-8082-A54D40305512|1||||||AREA|AREA||PFU|INCREASED||U/KG|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|U|U|FAMILY MEMBER|READER 2|U|1||38||SCREENING|1964-09-24|
TRIAL STUDY 134XCP|TR|F0559682-CD36-4ED0-8082-A54D40305512|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||WATT|NORMAL||KA_U/DL|NOT DONE|||OPTICAL DENSITY MEASUREMENT|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 1|N|2||58||LONG-TERM FOLLOW-UP|1965-01-04|
TRIAL STUDY 134XCP|TR|F0559682-CD36-4ED0-8082-A54D40305512|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MG/CM2|FOCALLY INCREASED||M2|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|NA|NA|CLINICAL RESEARCH COORDINATOR|READER|U|3||39||OBSERVATION|1972-04-17|
TRIAL STUDY 134XCP|TR|F0559682-CD36-4ED0-8082-A54D40305512|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||UMOL/MIN|EQUIVOCAL||/MONTH|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|4||88||CONTINUATION TREATMENT|1964-07-09|
TRIAL STUDY 134XCP|TR|F0559682-CD36-4ED0-8082-A54D40305512|5||||||AREA|AREA||CAL|NONPALPABLE||UU/DL|NOT DONE|||CLIP SEQUENCING|Y|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1965-03-03|
TRIAL STUDY 134XCP|TR|C004A4D5-DBD0-4967-9597-8C1653AB8298|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^3 ORGANISMS|ENLARGEMENT||MBP|NOT DONE|||REBOUND TONOMETRY|U|U|SPOUSE|RATER 1|U|1||38||TREATMENT|1973-05-17|
TRIAL STUDY 134XCP|TR|C004A4D5-DBD0-4967-9597-8C1653AB8298|2||||||PALPSTAT|PALPABLE STATE||PKAT|PATHOLOGICAL||CI/L|NOT DONE|||NUCLEAR RADIOLOGY|Y|U|ADJUDICATOR|NEUROLOGIST 1|N|2||58||RUN-IN|1971-11-23|
TRIAL STUDY 134XCP|TR|C004A4D5-DBD0-4967-9597-8C1653AB8298|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MG/M2/MIN|TUMOR MERGED||MOL|NOT DONE|||LANDOLT RING|N|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|N|3||39||BASELINE|1965-08-20|
TRIAL STUDY 134XCP|TR|C004A4D5-DBD0-4967-9597-8C1653AB8298|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||CI/L|FOCALLY INCREASED||UCI|NOT DONE|||EPSILOMETER|Y|U|SIGNIFICANT OTHER|RATER 1|U|4||88||RUN-IN|1962-02-21|
TRIAL STUDY 134XCP|TR|C004A4D5-DBD0-4967-9597-8C1653AB8298|5||||||LDIAM|LONGEST DIAMETER||DAGU|TUMOR MERGED||CD/M2|NOT DONE|||PERIPHERAL ANGIOGRAPHY|N|U|ADJUDICATION COMMITTEE|RATER|N|5||7||LONG-TERM FOLLOW-UP|1971-03-27|
TRIAL STUDY 134XCP|TR|ABB838A1-2387-471E-8F50-1F48205BC8EE|1||||||LPERP|LONGEST PERPENDICULAR||G/CAGE/WK|PATHOLOGICAL||BAG|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y|U|ADJUDICATION COMMITTEE|READER 1|N|1||38||OBSERVATION|1960-01-01|
TRIAL STUDY 134XCP|TR|ABB838A1-2387-471E-8F50-1F48205BC8EE|2||||||ORVERLN|ORGAN VERTICAL LENGTH||GBQ/MG|PATHOLOGICAL||/100 HPFS|NOT DONE|||WRIGHT STAIN|Y|N|FRIEND|OPTOMETRIST|Y|2||58||OPEN LABEL TREATMENT|1973-03-08|
TRIAL STUDY 134XCP|TR|ABB838A1-2387-471E-8F50-1F48205BC8EE|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||LOG10 PFU/ML|DIFFUSELY INCREASED||10^6 IU|NOT DONE|||JAEGER EYE CHART|U|N|PARENT|ADJUDICATOR|U|3||39||TREATMENT|1963-10-25|
TRIAL STUDY 134XCP|TR|ABB838A1-2387-471E-8F50-1F48205BC8EE|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||HZ/S|PRESENT||ENZYME U/M2|NOT DONE|||TWO-COLOR MICROARRAY|NA|N|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|4||88||RUN-IN|1963-12-03|
TRIAL STUDY 134XCP|TR|ABB838A1-2387-471E-8F50-1F48205BC8EE|5||||||VOLUME|VOLUME||10^6 ORGANISMS/G|INCREASED||CAPLET|NOT DONE|||MYELOPEROXIDASE STAIN|U|Y|SIGNIFICANT OTHER|MICROSCOPIST 1|N|5||7||FOLLOW-UP|1960-06-18|
TRIAL STUDY 134XCP|TR|88126417-8564-4659-AA60-63642067113D|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||G/CM2|FURTHER ENLARGEMENT FROM NADIR||V/V|NOT DONE|||CENTRIFUGATION|N|NA|STUDY SUBJECT|RADIOLOGIST 2|N|1||38||OPEN LABEL TREATMENT|1968-12-24|
TRIAL STUDY 134XCP|TR|88126417-8564-4659-AA60-63642067113D|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||TRANSDUCING UNIT/ML|PALPABLE||CI/G|NOT DONE|||FLOCCULATION|NA|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|2||58||WASHOUT|1962-02-12|
TRIAL STUDY 134XCP|TR|88126417-8564-4659-AA60-63642067113D|3||||||LESSCIND|LESION SUCCESS INDICATOR||UIU/L|EQUIVOCAL||U/ANIMAL|NOT DONE|||ANGIOGRAPHY|U|NA|CAREGIVER|DERMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1968-10-28|
TRIAL STUDY 134XCP|TR|88126417-8564-4659-AA60-63642067113D|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U/ML|PALPABLE||CUP|NOT DONE|||PET/MRI SCAN|Y|NA|GUARDIAN|ADJUDICATOR 3|NA|4||88||SCREENING|1962-12-17|
TRIAL STUDY 134XCP|TR|88126417-8564-4659-AA60-63642067113D|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||TORR|NONPALPABLE||ML/(MIN*100ML)|NOT DONE|||MACRO BROTH DILUTION|NA|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OBSERVATION|1968-07-01|
TRIAL STUDY 134XCP|TR|6ADA444E-F1B4-4E59-9F2D-26DC78845397|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^4 CFU|NONPALPABLE||10^7/L|NOT DONE|||MICROBIAL CULTURE, SOLID|N|N|PARENT|INTERNIST|N|1||38||RUN-IN|1967-09-12|
TRIAL STUDY 134XCP|TR|6ADA444E-F1B4-4E59-9F2D-26DC78845397|2||||||LNSTATE|LYMPH NODE STATE||U/G HB|NONPALPABLE||MEQ/UL|NOT DONE|||CYSTOMETRY|U|NA|INVESTIGATOR|MICROSCOPIST 2|Y|2||58||RUN-IN|1966-04-25|
TRIAL STUDY 134XCP|TR|6ADA444E-F1B4-4E59-9F2D-26DC78845397|3||||||DIAMETER|DIAMETER||/10^3|NORMAL||UG/M2|NOT DONE|||NUCLEAR RADIOLOGY|NA|N|FRIEND|MICROSCOPIST|Y|3||39||WASHOUT|1964-06-28|
TRIAL STUDY 134XCP|TR|6ADA444E-F1B4-4E59-9F2D-26DC78845397|4||||||LESSCIND|LESION SUCCESS INDICATOR||10^3 RNA COPIES/ML|ABSENT||NMOL/MOL|NOT DONE|||ORCHIDOMETERY|N|U|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||WASHOUT|1970-11-21|
TRIAL STUDY 134XCP|TR|6ADA444E-F1B4-4E59-9F2D-26DC78845397|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||GBQ|ENLARGEMENT FROM NADIR||TBSP|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|5||7||WASHOUT|1967-01-16|
TRIAL STUDY 134XCP|TR|85060A90-92F7-4440-AD1C-62A70C2FD5CB|1||||||LESSCIND|LESION SUCCESS INDICATOR||UMOL/MIN|FURTHER ENLARGEMENT FROM NADIR||10^6/G|NOT DONE|||GIEMSA STAIN|NA|NA|HEALTH CARE PROFESSIONAL|RATER 1|N|1||38||RUN-IN|1963-04-03|
TRIAL STUDY 134XCP|TR|85060A90-92F7-4440-AD1C-62A70C2FD5CB|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||ANTIBODY UNIT|FURTHER ENLARGEMENT FROM NADIR||10^4 CFU/ML|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|N|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|2||58||RUN-IN|1968-03-05|
TRIAL STUDY 134XCP|TR|85060A90-92F7-4440-AD1C-62A70C2FD5CB|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||KV|ENLARGEMENT FROM NADIR||BOLUS|NOT DONE|||INTRAVASCULAR ULTRASOUND|NA|N|STUDY SUBJECT|MICROSCOPIST|U|3||39||WASHOUT|1971-08-24|
TRIAL STUDY 134XCP|TR|85060A90-92F7-4440-AD1C-62A70C2FD5CB|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||NU/CL|ABSENT||NMOL/KG/DAY|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|NA|NA|CHILD|OTOLARYNGOLOGIST|N|4||88||OBSERVATION|1960-12-28|
TRIAL STUDY 134XCP|TR|85060A90-92F7-4440-AD1C-62A70C2FD5CB|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||INHALATION|ABSENT||MG/L FEU|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|N|Y|CHILD|NEUROLOGIST 1|NA|5||7||FOLLOW-UP|1970-06-30|
TRIAL STUDY 134XCP|TR|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|1||||||VSLPIND|VESSEL PATENCY INDICATOR||TUBE|DECREASED||% INHIBITION|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|N|NA|CAREGIVER|ENDOCRINOLOGIST|NA|1||38||RUN-IN|1969-01-22|
TRIAL STUDY 134XCP|TR|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||UCI/KG|FURTHER ENLARGEMENT||MILE|NOT DONE|||TONOMETRY|N|U|STUDY SUBJECT|PATHOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1968-10-30|
TRIAL STUDY 134XCP|TR|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BU|EQUIVOCAL||UG/MIN|NOT DONE|||MS/MS|U|NA|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|3||39||SCREENING|1971-03-15|
TRIAL STUDY 134XCP|TR|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MG/DL|DECREASED||MMOL/G|NOT DONE|||SNELLEN EYE CHART|U|NA|ADJUDICATOR|CLINICAL PATHOLOGIST|Y|4||88||RUN-IN|1961-05-07|
TRIAL STUDY 134XCP|TR|719D483D-67B4-49DE-A86A-CBE7D4CBB8D0|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||PMOL/10^9 CELLS|DIFFUSELY INCREASED||ENZYME U|NOT DONE|||REFLECTANCE SPECTROSCOPY|N|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|5||7||BLINDED TREATMENT|1960-06-27|
TRIAL STUDY 134XCP|TR|170052E6-031C-48EF-9CE4-CA84ED6B77FF|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PMOL/10^9 CELLS|ENLARGEMENT FROM NADIR||MV/SEC|NOT DONE|||POLYMERASE CHAIN REACTION|N|N|CHILD|OTOLARYNGOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1966-06-21|
TRIAL STUDY 134XCP|TR|170052E6-031C-48EF-9CE4-CA84ED6B77FF|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ROENTGEN|ENLARGEMENT||U.CARR|NOT DONE|||WRIGHT-GIEMSA STAIN|Y|Y|STUDY SUBJECT|ONCOLOGIST 1|Y|2||58||FOLLOW-UP|1962-05-08|
TRIAL STUDY 134XCP|TR|170052E6-031C-48EF-9CE4-CA84ED6B77FF|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MEQ/UG|ABSENT||ECL UNIT|NOT DONE|||MAMMOGRAPHY|Y|NA|GUARDIAN|MICROSCOPIST 1|N|3||39||SCREENING|1968-05-24|
TRIAL STUDY 134XCP|TR|170052E6-031C-48EF-9CE4-CA84ED6B77FF|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MG/ML/DAY|NONPALPABLE||NKAT/G HB|NOT DONE|||DIFFUSION TENSOR MRI|N|Y|INVESTIGATOR|UROLOGIST|NA|4||88||RUN-IN|1969-12-16|
TRIAL STUDY 134XCP|TR|170052E6-031C-48EF-9CE4-CA84ED6B77FF|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MAC50|ENLARGEMENT||10^6/EJACULATE U|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|NA|Y|PROXY|PHYSIOTHERAPIST|Y|5||7||WASHOUT|1968-12-09|
TRIAL STUDY 134XCP|TR|D3F628DE-8358-4C2C-B474-763E48719E5E|1||||||VOLUME|VOLUME||/SEC|ABSENT||DPM|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|NA|STUDY SUBJECT|CLINICAL PATHOLOGIST|Y|1||38||OBSERVATION|1963-04-27|
TRIAL STUDY 134XCP|TR|D3F628DE-8358-4C2C-B474-763E48719E5E|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MG/M2/H|PALPABLE||BREATHS/30S|NOT DONE|||HIGH RESOLUTION CT|Y|U|NON-HEALTH CARE PROFESSIONAL|READER 1|NA|2||58||INDUCTION TREATMENT|1960-04-30|
TRIAL STUDY 134XCP|TR|D3F628DE-8358-4C2C-B474-763E48719E5E|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||KPA/L/SEC|UNCHANGED||G/DL|NOT DONE|||MRI|N|Y|CHILD|DERMATOLOGIST|NA|3||39||CONTINUATION TREATMENT|1961-06-09|
TRIAL STUDY 134XCP|TR|D3F628DE-8358-4C2C-B474-763E48719E5E|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PFU|DECREASED||% INHIBITION|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|N|N|CLINICAL STUDY SPONSOR|RADIOLOGIST|Y|4||88||INDUCTION TREATMENT|1966-04-04|
TRIAL STUDY 134XCP|TR|D3F628DE-8358-4C2C-B474-763E48719E5E|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||IU/G HB|PATHOLOGICAL||MEQ/UL|NOT DONE|||STRESS ECHOCARDIOGRAPHY|NA|U|FRIEND|RADIOLOGIST 1|NA|5||7||TREATMENT|1964-02-20|
TRIAL STUDY 134XCP|TR|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MET|UNCHANGED||NG|NOT DONE|||GC/MS-CI|N|N|SIGNIFICANT OTHER|RATER|NA|1||38||TREATMENT|1960-10-31|
TRIAL STUDY 134XCP|TR|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MONTHS|PRESENT||CAN|NOT DONE|||FORCED OSCILLATION TECHNIQUE|NA|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|2||58||INDUCTION TREATMENT|1961-09-06|
TRIAL STUDY 134XCP|TR|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|3||||||LDIAM|LONGEST DIAMETER||PMOL|EQUIVOCAL||G/MOL|NOT DONE|||GIEMSA STAIN|Y|U|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|3||39||CONTINUATION TREATMENT|1964-03-12|
TRIAL STUDY 134XCP|TR|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|4||||||BNLNUM|NUMBER OF BONE LESIONS||WAFER|ENLARGEMENT FROM NADIR||NFIU|NOT DONE|||HPLC|N|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||BLINDED TREATMENT|1966-04-21|
TRIAL STUDY 134XCP|TR|33137C67-0DA6-49EB-AF5D-6B6AFB44738F|5||||||LESFLIND|LESION FAILURE INDICATOR||DROP|PALPABLE||/200 HPFS|NOT DONE|||DUCTOGRAPHY|N|U|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||CONTINUATION TREATMENT|1965-07-03|
TRIAL STUDY 134XCP|TR|4395486D-C521-4478-9442-68CF0344C6FB|1||||||ORVERLN|ORGAN VERTICAL LENGTH||GY|NON-PATHOLOGICAL||ML/MMHG|NOT DONE|||KINETIC CHROMOGENIC ASSAY|U|N|ADJUDICATOR|PATHOLOGIST 2|U|1||38||TREATMENT|1969-05-20|
TRIAL STUDY 134XCP|TR|4395486D-C521-4478-9442-68CF0344C6FB|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||PG/CELL|NORMAL||AMPULE|NOT DONE|||ECHOCARDIOGRAPHY|NA|U|SPOUSE|NEUROLOGIST 2|Y|2||58||BLINDED TREATMENT|1972-01-26|
TRIAL STUDY 134XCP|TR|4395486D-C521-4478-9442-68CF0344C6FB|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||1/(S*KPA)|ENLARGEMENT||MV|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|Y|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|3||39||FOLLOW-UP|1972-04-22|
TRIAL STUDY 134XCP|TR|4395486D-C521-4478-9442-68CF0344C6FB|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MM/2H|NORMAL||10^6/L|NOT DONE|||REBOUND TONOMETRY|Y|U|FAMILY MEMBER|OTOLARYNGOLOGIST|Y|4||88||INDUCTION TREATMENT|1964-08-08|
TRIAL STUDY 134XCP|TR|4395486D-C521-4478-9442-68CF0344C6FB|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||HEP|NONPALPABLE||NU/CL|NOT DONE|||GC/MS-CI|N|U|FAMILY MEMBER|CARDIOLOGIST|N|5||7||RUN-IN|1962-01-08|
TRIAL STUDY 134XCP|TR|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|1||||||LNSTATE|LYMPH NODE STATE||ENZYME U/M2|DIFFUSELY INCREASED||MG/G/MIN|NOT DONE|||MODIFIED ACID FAST STAIN|Y|N|ADJUDICATOR|ADJUDICATOR|NA|1||38||FOLLOW-UP|1964-06-01|
TRIAL STUDY 134XCP|TR|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||FT|PRESENT||10^3 DNA COPIES/ML|NOT DONE|||ALCIAN BLUE STAIN|N|N|SIGNIFICANT OTHER|HEMATOLOGIST|N|2||58||SCREENING|1972-05-07|
TRIAL STUDY 134XCP|TR|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||CYLINDER|NON-PATHOLOGICAL||CI/UL|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|3||39||BLINDED TREATMENT|1962-07-21|
TRIAL STUDY 134XCP|TR|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||FMOL/L|TUMOR MERGED||PMOL/DL|NOT DONE|||WESTERN BLOT|U|Y|INTERVIEWER|MICROSCOPIST 1|N|4||88||CONTINUATION TREATMENT|1973-06-14|
TRIAL STUDY 134XCP|TR|4818BCD8-8B7B-46B1-86C5-F5D2067FD317|5||||||VDIAM|VIABLE DIAMETER||/2000 RBC|EQUIVOCAL||ML/SEC/1.73M2|NOT DONE|||WESTERN BLOT|N|U|HEALTH CARE PROFESSIONAL|RATER|NA|5||7||BASELINE|1971-12-14|
TRIAL STUDY 134XCP|TR|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|1||||||VDIAM|VIABLE DIAMETER||LOG10 PFU|EQUIVOCAL||MBP|NOT DONE|||LISSAMINE GREEN STAIN|Y|NA|CAREGIVER|NEUROLOGIST 2|Y|1||38||BLINDED TREATMENT|1970-06-19|
TRIAL STUDY 134XCP|TR|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||H/WK|ENLARGEMENT FROM NADIR||CP|NOT DONE|||GC/MS-CI|N|N|CLINICAL STUDY SPONSOR|READER|U|2||58||FOLLOW-UP|1971-04-06|
TRIAL STUDY 134XCP|TR|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||POINT|UNCHANGED||GENEQ/ML|NOT DONE|||DIRECT SEQUENCING|NA|N|SPOUSE|RATER 2|NA|3||39||FOLLOW-UP|1960-11-01|
TRIAL STUDY 134XCP|TR|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UG/KG/H|NORMAL||MEQ/ML|NOT DONE|||PHOTOGRAPHY|U|NA|CLINICAL STUDY SPONSOR|RATER 1|Y|4||88||TREATMENT|1970-03-27|
TRIAL STUDY 134XCP|TR|2E2BF203-2C02-4D9A-AA64-7AE7968282A1|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||BU/ML|NONPALPABLE||CYLINDER|NOT DONE|||FLUORESCENT IMMUNOASSAY|Y|Y|SPOUSE|NEUROLOGIST|U|5||7||SCREENING|1970-04-30|
TRIAL STUDY 134XCP|TR|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||FIU|UNEQUIVOCAL||PKAT|NOT DONE|||THICK SMEAR|U|N|INDEPENDENT ASSESSOR|RATER 1|N|1||38||FOLLOW-UP|1972-10-31|
TRIAL STUDY 134XCP|TR|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|2||||||DIAMETER|DIAMETER||FT2|UNCHANGED||MMAL|NOT DONE|||JAEGER EYE CHART|Y|NA|SIGNIFICANT OTHER|RATER 1|N|2||58||BASELINE|1967-02-04|
TRIAL STUDY 134XCP|TR|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||COPIES/UG|NORMAL||TORR|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|3||39||LONG-TERM FOLLOW-UP|1966-06-09|
TRIAL STUDY 134XCP|TR|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PMOL/DL|ABSENT||10^9 CFU/ML|NOT DONE|||IMPEDANCE CONDUCTIVITY|N|U|SIGNIFICANT OTHER|RADIOLOGIST 1|U|4||88||FOLLOW-UP|1962-02-08|
TRIAL STUDY 134XCP|TR|8C5C83B7-2373-4A72-8E55-A779EB08D9A9|5||||||SUMVOL|SUM OF VOLUME||MG/KG|PATHOLOGICAL||NKAT|NOT DONE|||ELECTROMYOGRAPHY|U|U|FAMILY MEMBER|READER 3|U|5||7||BASELINE|1962-04-08|
TRIAL STUDY 134XCP|TR|19394300-46A6-484F-AE02-50BDD39096E3|1||||||LMBFLIND|LIMB FAILURE INDICATOR||MET*H|DECREASED||L/S/KPA|NOT DONE|||CYSTOMETRY|NA|N|DOMESTIC PARTNER|HEMATOLOGIST|U|1||38||OPEN LABEL TREATMENT|1970-06-25|
TRIAL STUDY 134XCP|TR|19394300-46A6-484F-AE02-50BDD39096E3|2||||||ORSTATE|ORGAN STATE||10^9 CFU/ML|ENLARGEMENT||NMOL|NOT DONE|||CYSTOMETRY|Y|N|PARENT|ONCOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1966-03-11|
TRIAL STUDY 134XCP|TR|19394300-46A6-484F-AE02-50BDD39096E3|3||||||BNLNUM|NUMBER OF BONE LESIONS||PIXELS/IN|ENLARGEMENT FROM NADIR||MV/SEC|NOT DONE|||MAPH|N|U|PARENT|READER 3|Y|3||39||WASHOUT|1966-03-21|
TRIAL STUDY 134XCP|TR|19394300-46A6-484F-AE02-50BDD39096E3|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||C|TUMOR MERGED||MCI/L|NOT DONE|||TOTAL BODY IRRADIATION|NA|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|4||88||INDUCTION TREATMENT|1968-09-08|
TRIAL STUDY 134XCP|TR|19394300-46A6-484F-AE02-50BDD39096E3|5||||||LNSTATE|LYMPH NODE STATE||MV|UNEQUIVOCAL||DPM/MG|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|U|NA|HEALTH CARE PROFESSIONAL|RATER 2|Y|5||7||CONTINUATION TREATMENT|1970-08-05|
TRIAL STUDY 134XCP|TR|8C89BD60-3504-4F8B-8F33-7F0C949DB407|1||||||VSLPIND|VESSEL PATENCY INDICATOR||ML/ANIMAL|DECREASED||MMOL/DAY|NOT DONE|||GRAM STAIN|N|NA|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|1||38||FOLLOW-UP|1967-09-24|
TRIAL STUDY 134XCP|TR|8C89BD60-3504-4F8B-8F33-7F0C949DB407|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||JDF UNIT|UNCHANGED||PG/L|NOT DONE|||PUPILLOMETRY|Y|U|PROXY|CLINICAL PATHOLOGIST|Y|2||58||RUN-IN|1968-05-26|
TRIAL STUDY 134XCP|TR|8C89BD60-3504-4F8B-8F33-7F0C949DB407|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||PG/DL|EQUIVOCAL||UIU/L|NOT DONE|||REFRACTOMETRY|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3||39||INDUCTION TREATMENT|1963-07-02|
TRIAL STUDY 134XCP|TR|8C89BD60-3504-4F8B-8F33-7F0C949DB407|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||BEATS/MIN|FOCALLY INCREASED||GENEQ|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|NA|INTERVIEWER|INTERNIST|NA|4||88||LONG-TERM FOLLOW-UP|1972-05-07|
TRIAL STUDY 134XCP|TR|8C89BD60-3504-4F8B-8F33-7F0C949DB407|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||S/H|FURTHER ENLARGEMENT||10^12 IU/L|NOT DONE|||FLOCCULATION, CHARCOAL ENHANCED|NA|U|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||INDUCTION TREATMENT|1971-07-20|
TRIAL STUDY 134XCP|TR|4746A481-011E-4376-9D2F-5E57F560A6DE|1||||||LMBFLIND|LIMB FAILURE INDICATOR||/2500 WBC|PALPABLE||TCID 50/DOSE|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|U|U|PARENT|OTOLARYNGOLOGIST|N|1||38||RUN-IN|1963-09-05|
TRIAL STUDY 134XCP|TR|4746A481-011E-4376-9D2F-5E57F560A6DE|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^10/L|UNCHANGED||L/MIN/M2|NOT DONE|||CORONARY ANGIOGRAPHY|U|NA|SIBLING|READER|Y|2||58||FOLLOW-UP|1960-03-24|
TRIAL STUDY 134XCP|TR|4746A481-011E-4376-9D2F-5E57F560A6DE|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||S^-1(%O2)^-1|FURTHER ENLARGEMENT FROM NADIR||ML/DAY|NOT DONE|||MACRO BROTH DILUTION|NA|U|NON-HEALTH CARE PROFESSIONAL|READER 1|N|3||39||BASELINE|1963-10-04|
TRIAL STUDY 134XCP|TR|4746A481-011E-4376-9D2F-5E57F560A6DE|4||||||LDIAM|LONGEST DIAMETER||CD|ENLARGEMENT||LINEAR FT*LB|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|N|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|U|4||88||INDUCTION TREATMENT|1970-01-08|
TRIAL STUDY 134XCP|TR|4746A481-011E-4376-9D2F-5E57F560A6DE|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||FFU|PRESENT||S^-1(%O2)^-1|NOT DONE|||MACRO BROTH DILUTION|Y|U|INDEPENDENT ASSESSOR|READER 1|N|5||7||SCREENING|1969-05-03|
TRIAL STUDY 134XCP|TR|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||KG/MOL|DECREASED||CM/S|NOT DONE|||APPLANATION TONOMETRY|NA|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|1||38||LONG-TERM FOLLOW-UP|1972-08-27|
TRIAL STUDY 134XCP|TR|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UG/L DDU|EQUIVOCAL||P|NOT DONE|||ISHIHARA COLOR PLATES|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|2||58||INDUCTION TREATMENT|1965-09-14|
TRIAL STUDY 134XCP|TR|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|3||||||RADIODEN|RADIODENSITY||ML/S|INCREASED||DRUM|NOT DONE|||MECHANICAL CLOT DETECTION|N|NA|INTERVIEWER|PATHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1962-10-11|
TRIAL STUDY 134XCP|TR|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MG/MIN|UNCHANGED||MEQ/UG|NOT DONE|||CONTRAST ENHANCED PET SCAN|N|NA|GUARDIAN|MICROSCOPIST|NA|4||88||RUN-IN|1961-12-12|
TRIAL STUDY 134XCP|TR|CE1DB395-A3FC-4F3A-B039-411A6266F7C0|5||||||LNSTATE|LYMPH NODE STATE||ML/S/M2|UNCHANGED||BAR|NOT DONE|||ENDOSCOPY|Y|N|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|5||7||BLINDED TREATMENT|1965-04-15|
TRIAL STUDY 134XCP|TR|04F5220E-7A8C-4982-9379-496306612E33|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||CMOL|EQUIVOCAL||MCI/KG|NOT DONE|||KINETIC CHROMOGENIC ASSAY|U|Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||SCREENING|1968-03-16|
TRIAL STUDY 134XCP|TR|04F5220E-7A8C-4982-9379-496306612E33|2||||||VDIAM|VIABLE DIAMETER||BREATHS/MIN|UNEQUIVOCAL||DAYS|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|Y|PARENT|RATER 1|U|2||58||WASHOUT|1968-09-05|
TRIAL STUDY 134XCP|TR|04F5220E-7A8C-4982-9379-496306612E33|3||||||ORVERLN|ORGAN VERTICAL LENGTH||G/DAY|TUMOR MERGED||KUSP|NOT DONE|||CALIPER MEASUREMENT METHOD|NA|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|3||39||CONTINUATION TREATMENT|1966-08-06|
TRIAL STUDY 134XCP|TR|04F5220E-7A8C-4982-9379-496306612E33|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MEQ/UG|DIFFUSELY INCREASED||10^9 CFU/G|NOT DONE|||CISH|Y|Y|STUDY SUBJECT|NEUROLOGIST 2|Y|4||88||RUN-IN|1964-09-04|
TRIAL STUDY 134XCP|TR|04F5220E-7A8C-4982-9379-496306612E33|5||||||LDIAM|LONGEST DIAMETER||DAGU|ABSENT||MOL/ML|NOT DONE|||POLYGRAPHY|N|NA|SIGNIFICANT OTHER|INTERNIST|U|5||7||FOLLOW-UP|1968-01-14|
TRIAL STUDY 134XCP|TR|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||BAG|FURTHER ENLARGEMENT FROM NADIR||LOG10 COPIES/ML|NOT DONE|||CELLULAR PROLIFERATION ASSAY|NA|N|STUDY SUBJECT|HEMATOLOGIST|U|1||38||CONTINUATION TREATMENT|1961-04-11|
TRIAL STUDY 134XCP|TR|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|2||||||VDIAM|VIABLE DIAMETER||MG/DL|TUMOR MERGED||OZ EQ|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|NA|NA|ADJUDICATION COMMITTEE|DERMATOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1966-09-13|
TRIAL STUDY 134XCP|TR|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^6 COPIES/ML|NONPALPABLE||FINGERTIP UNIT|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|U|ADJUDICATOR|INTERNIST|NA|3||39||BLINDED TREATMENT|1962-02-28|
TRIAL STUDY 134XCP|TR|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ML/MMHG/MIN/L|PALPABLE||DIP|NOT DONE|||ICC|NA|N|DOMESTIC PARTNER|READER 3|Y|4||88||TREATMENT|1968-05-01|
TRIAL STUDY 134XCP|TR|2D77B739-5C67-443E-B7A1-5E6E11CFE19B|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MPL U/ML|ABSENT||NMOL|NOT DONE|||INFRARED SPECTROMETRY|NA|NA|HEALTH CARE PROFESSIONAL|READER 1|U|5||7||WASHOUT|1962-06-20|
TRIAL STUDY 134XCP|TR|73BDFAA2-6260-4E1D-8039-7523F0C52873|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||CM|ABSENT||MOL/L|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|Y|Y|SPOUSE|RATER 2|NA|1||38||OBSERVATION|1969-11-15|
TRIAL STUDY 134XCP|TR|73BDFAA2-6260-4E1D-8039-7523F0C52873|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||/VF|NORMAL||UG/G/MIN|NOT DONE|||SCANNING ELECTRON MICROSCOPY|U|NA|INTERVIEWER|MICROSCOPIST 2|N|2||58||OPEN LABEL TREATMENT|1968-05-07|
TRIAL STUDY 134XCP|TR|73BDFAA2-6260-4E1D-8039-7523F0C52873|3||||||LDIAM|LONGEST DIAMETER||L/L|PRESENT||KIT|NOT DONE|||POTENTIOMETRY|Y|Y|INTERVIEWER|MICROSCOPIST 3|U|3||39||WASHOUT|1965-02-21|
TRIAL STUDY 134XCP|TR|73BDFAA2-6260-4E1D-8039-7523F0C52873|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||M/SEC|EQUIVOCAL||BOWL|NOT DONE|||CHROMOGENIC ASSAY|Y|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1961-04-29|
TRIAL STUDY 134XCP|TR|73BDFAA2-6260-4E1D-8039-7523F0C52873|5||||||ORSTATE|ORGAN STATE||BQ/UG|DIFFUSELY INCREASED||IU/L|NOT DONE|||APPLANATION TONOMETRY|NA|Y|CHILD|DERMATOLOGIST|U|5||7||WASHOUT|1964-12-12|
TRIAL STUDY 134XCP|TR|147C2E77-A2C5-4219-9BB5-D209813E563B|1||||||PALPSTAT|PALPABLE STATE||MG/KG/MIN|NON-PATHOLOGICAL||ML/KG/MIN|NOT DONE|||MIGET|NA|NA|GUARDIAN|MICROSCOPIST 2|U|1||38||OPEN LABEL TREATMENT|1962-09-03|
TRIAL STUDY 134XCP|TR|147C2E77-A2C5-4219-9BB5-D209813E563B|2||||||SUMDIAM|SUM OF DIAMETER||10^6 ORGANISMS/G|PATHOLOGICAL||/DAY|NOT DONE|||HPLC-UV|U|N|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|2||58||BLINDED TREATMENT|1967-08-16|
TRIAL STUDY 134XCP|TR|147C2E77-A2C5-4219-9BB5-D209813E563B|3||||||SUMDIAM|SUM OF DIAMETER||SCM|EQUIVOCAL||ATM|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|NA|Y|CHILD|DERMATOLOGIST|Y|3||39||SCREENING|1960-05-21|
TRIAL STUDY 134XCP|TR|147C2E77-A2C5-4219-9BB5-D209813E563B|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||LOG10 CCID 50/DOSE|ENLARGEMENT||G/L|NOT DONE|||IMMUNOFLUORESCENT STAIN|Y|NA|FRIEND|PHYSIOTHERAPIST|Y|4||88||OBSERVATION|1967-02-15|
TRIAL STUDY 134XCP|TR|147C2E77-A2C5-4219-9BB5-D209813E563B|5||||||BNLNUM|NUMBER OF BONE LESIONS||COPIES/UG|UNEQUIVOCAL||SUPPOSITORY|NOT DONE|||JAFFE REACTION|Y|N|STUDY SUBJECT|PATHOLOGIST|Y|5||7||SCREENING|1960-06-25|
TRIAL STUDY 134XCP|TR|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||HENRY|FURTHER ENLARGEMENT||UGEQ|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|NA|N|CAREGIVER|PATHOLOGIST 2|N|1||38||WASHOUT|1966-04-26|
TRIAL STUDY 134XCP|TR|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||S/H|FURTHER ENLARGEMENT||ML/M2/DAY|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|NA|GUARDIAN|ADJUDICATOR 1|N|2||58||WASHOUT|1967-08-16|
TRIAL STUDY 134XCP|TR|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CUP EQ|INCREASED||ROENTGEN|NOT DONE|||TOLUIDINE BLUE STAIN|N|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1971-08-17|
TRIAL STUDY 134XCP|TR|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|4||||||ORVERLN|ORGAN VERTICAL LENGTH||UG/MIN|ABSENT||UKAT|NOT DONE|||SMEAR|U|NA|CHILD|FORENSIC PATHOLOGIST|NA|4||88||SCREENING|1973-01-01|
TRIAL STUDY 134XCP|TR|880428B0-DFA1-4CD6-B0C5-76D1192D46D6|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/KG/DAY|FURTHER ENLARGEMENT FROM NADIR||10^6 IU|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|N|NA|VENDOR|CLINICAL PATHOLOGIST|N|5||7||BLINDED TREATMENT|1964-06-14|
TRIAL STUDY 134XCP|TR|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||TUBE|PALPABLE||10^7/L|NOT DONE|||ENDPOINT DILUTION ASSAY|N|NA|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||SCREENING|1964-12-13|
TRIAL STUDY 134XCP|TR|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||G/L|PALPABLE||MG/KG/DAY|NOT DONE|||PET/SPECT SCAN|U|Y|PARENT|PHYSIOTHERAPIST|N|2||58||FOLLOW-UP|1962-12-30|
TRIAL STUDY 134XCP|TR|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|3||||||LESFLIND|LESION FAILURE INDICATOR||KIT|NORMAL||G/KG|NOT DONE|||AUDIOMETRY|N|N|CAREGIVER|ONCOLOGIST|N|3||39||BLINDED TREATMENT|1962-10-16|
TRIAL STUDY 134XCP|TR|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|4||||||VOLUME|VOLUME||HPA|FOCALLY INCREASED||PMOL|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|U|U|INDEPENDENT ASSESSOR|UROLOGIST|Y|4||88||SCREENING|1967-03-09|
TRIAL STUDY 134XCP|TR|BDDC8BA7-3EB9-44E8-91CC-D05391C1187E|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||/MONTH|EQUIVOCAL||DAYS/MONTH|NOT DONE|||ERGOSPIROMETRY|N|N|SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|5||7||SCREENING|1964-11-16|
TRIAL STUDY 134XCP|TR|25E17A89-8A2F-4870-B076-1D32634F5620|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ML/ANIMAL|PRESENT||PPM|NOT DONE|||SPIROMETRY|NA|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|1||38||INDUCTION TREATMENT|1968-06-03|
TRIAL STUDY 134XCP|TR|25E17A89-8A2F-4870-B076-1D32634F5620|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||VIRTUAL PIXEL|DIFFUSELY INCREASED||ML/CM H2O|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|U|U|INTERVIEWER|ENDOCRINOLOGIST|NA|2||58||FOLLOW-UP|1969-08-28|
TRIAL STUDY 134XCP|TR|25E17A89-8A2F-4870-B076-1D32634F5620|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||LOG10 ELISA UNIT/DOSE|FURTHER ENLARGEMENT||BAR|NOT DONE|||HPLC|NA|N|CAREGIVER|MICROSCOPIST|N|3||39||RUN-IN|1960-04-28|
TRIAL STUDY 134XCP|TR|25E17A89-8A2F-4870-B076-1D32634F5620|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||BQ/ML|FURTHER ENLARGEMENT||UMOL/L/MIN|NOT DONE|||MICROBIAL CONCENTRATION|NA|N|PROXY|CARDIOLOGIST|N|4||88||OBSERVATION|1968-02-04|
TRIAL STUDY 134XCP|TR|25E17A89-8A2F-4870-B076-1D32634F5620|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/KG|FOCALLY INCREASED||IU/MMOL|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|U|Y|GUARDIAN|PATHOLOGIST 2|N|5||7||RUN-IN|1961-06-26|
TRIAL STUDY 134XCP|TR|B7B67C06-0802-4E69-A5A1-469213BE7E48|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||BE/ML|EQUIVOCAL||BQ/L|NOT DONE|||X-RAY|U|NA|PROXY|ONCOLOGIST 1|N|1||38||OBSERVATION|1960-07-31|
TRIAL STUDY 134XCP|TR|B7B67C06-0802-4E69-A5A1-469213BE7E48|2||||||LDIAM|LONGEST DIAMETER||L/L|INCREASED||BE/ML|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|ADJUDICATION COMMITTEE|ADJUDICATOR|N|2||58||OBSERVATION|1967-08-27|
TRIAL STUDY 134XCP|TR|B7B67C06-0802-4E69-A5A1-469213BE7E48|3||||||LDIAM|LONGEST DIAMETER||NMOL|INCREASED||10^4/HPF|NOT DONE|||TRICHROME STAIN|Y|NA|SIBLING|OPTOMETRIST|N|3||39||CONTINUATION TREATMENT|1964-07-26|
TRIAL STUDY 134XCP|TR|B7B67C06-0802-4E69-A5A1-469213BE7E48|4||||||CALCFIND|CALCIFICATION INDICATOR||RING|ENLARGEMENT FROM NADIR||10^3/L|NOT DONE|||TONOMETRY|N|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|4||88||FOLLOW-UP|1970-06-30|
TRIAL STUDY 134XCP|TR|B7B67C06-0802-4E69-A5A1-469213BE7E48|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||VIRTUAL PIXEL|NONPALPABLE||MU/G|NOT DONE|||PELLI-ROBSON EYE CHART|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|5||7||OBSERVATION|1971-10-13|
TRIAL STUDY 134XCP|TR|626E3EA7-423B-434F-89E4-CA076A39B8DB|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||10^9 CFU|FURTHER ENLARGEMENT FROM NADIR||NG/L|NOT DONE|||SINGLE-MOLECULE ARRAY|N|N|GUARDIAN|ENDOCRINOLOGIST|U|1||38||WASHOUT|1971-06-25|
TRIAL STUDY 134XCP|TR|626E3EA7-423B-434F-89E4-CA076A39B8DB|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||/VF|EQUIVOCAL||ML/S|NOT DONE|||RAJI CELL EIA|NA|NA|FRIEND|ADJUDICATOR|NA|2||58||INDUCTION TREATMENT|1971-09-08|
TRIAL STUDY 134XCP|TR|626E3EA7-423B-434F-89E4-CA076A39B8DB|3||||||AREA|AREA||UG/L|ENLARGEMENT FROM NADIR||G/DL|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|N|NA|PROXY|PATHOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1966-05-15|
TRIAL STUDY 134XCP|TR|626E3EA7-423B-434F-89E4-CA076A39B8DB|4||||||LESSCIND|LESION SUCCESS INDICATOR||KBQ/UL|DIFFUSELY INCREASED||FOZ_BR|NOT DONE|||DYNAMOMETRY|N|U|STUDY SUBJECT|READER|NA|4||88||BASELINE|1967-02-05|
TRIAL STUDY 134XCP|TR|626E3EA7-423B-434F-89E4-CA076A39B8DB|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MBQ|FOCALLY INCREASED||AG|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|N|N|FRIEND|RADIOLOGIST|N|5||7||RUN-IN|1972-01-13|
TRIAL STUDY 134XCP|TR|98ED3A38-1E74-470E-BF45-0D1E905BEF36|1||||||DIAMETER|DIAMETER||MG|FOCALLY INCREASED||VG/ML|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|Y|Y|PARENT|READER|N|1||38||INDUCTION TREATMENT|1966-11-19|
TRIAL STUDY 134XCP|TR|98ED3A38-1E74-470E-BF45-0D1E905BEF36|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||10^9/L|ABSENT||MMOL2/L2|NOT DONE|||MRI|U|NA|SPOUSE|PHYSIOTHERAPIST|NA|2||58||TREATMENT|1969-02-01|
TRIAL STUDY 134XCP|TR|98ED3A38-1E74-470E-BF45-0D1E905BEF36|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^6 ORGANISMS|NORMAL||10^6 CFU/G|NOT DONE|||LINE PROBE ASSAY|Y|Y|PARENT|MICROSCOPIST 3|Y|3||39||BASELINE|1964-02-11|
TRIAL STUDY 134XCP|TR|98ED3A38-1E74-470E-BF45-0D1E905BEF36|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||/MS|UNCHANGED||CMOL/L|NOT DONE|||REFRACTOMETRY|U|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|4||88||RUN-IN|1970-04-12|
TRIAL STUDY 134XCP|TR|98ED3A38-1E74-470E-BF45-0D1E905BEF36|5||||||LMBFLIND|LIMB FAILURE INDICATOR||CD/M2|FOCALLY INCREASED||/7.5 ML|NOT DONE|||CRYOSCOPY|N|NA|SIBLING|ONCOLOGIST 1|N|5||7||OPEN LABEL TREATMENT|1972-04-24|
TRIAL STUDY 134XCP|TR|99DF7819-987E-4E55-89FD-FF49E7C02A5A|1||||||SUMVOL|SUM OF VOLUME||MG/DL|EQUIVOCAL||10^7 CFU|NOT DONE|||CELL BASED BIOASSAY|U|U|FAMILY MEMBER|UROLOGIST|NA|1||38||INDUCTION TREATMENT|1964-05-20|
TRIAL STUDY 134XCP|TR|99DF7819-987E-4E55-89FD-FF49E7C02A5A|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||OI50|NONPALPABLE||NG/DAY|NOT DONE|||LANDOLT RING|Y|NA|INVESTIGATOR|ADJUDICATOR 2|NA|2||58||OPEN LABEL TREATMENT|1960-05-08|
TRIAL STUDY 134XCP|TR|99DF7819-987E-4E55-89FD-FF49E7C02A5A|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||LOG10 CFU/ML|UNEQUIVOCAL||KPA|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|Y|NA|STUDY SUBJECT|READER 1|U|3||39||BLINDED TREATMENT|1972-06-06|
TRIAL STUDY 134XCP|TR|99DF7819-987E-4E55-89FD-FF49E7C02A5A|4||||||VSLPIND|VESSEL PATENCY INDICATOR||ML/M2|EQUIVOCAL||DRINK|NOT DONE|||HPLC/MS/MS|Y|NA|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|4||88||FOLLOW-UP|1964-11-25|
TRIAL STUDY 134XCP|TR|99DF7819-987E-4E55-89FD-FF49E7C02A5A|5||||||VOLUME|VOLUME||L|FURTHER ENLARGEMENT FROM NADIR||MMOL/DAY|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||FOLLOW-UP|1972-01-23|
TRIAL STUDY 134XCP|TR|05481BE7-9309-4356-B46E-9C2525D2C54E|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UKAT/L|PRESENT||/10^5|NOT DONE|||MRI WITHOUT CONTRAST|NA|N|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|1||38||WASHOUT|1968-03-25|
TRIAL STUDY 134XCP|TR|05481BE7-9309-4356-B46E-9C2525D2C54E|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||K|FURTHER ENLARGEMENT FROM NADIR||10^11/L|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|Y|PROXY|CARDIOLOGIST|U|2||58||WASHOUT|1969-06-10|
TRIAL STUDY 134XCP|TR|05481BE7-9309-4356-B46E-9C2525D2C54E|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ML/G/MIN|EQUIVOCAL||NMOL/G|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|U|U|GUARDIAN|INTERNIST|Y|3||39||OPEN LABEL TREATMENT|1963-01-15|
TRIAL STUDY 134XCP|TR|05481BE7-9309-4356-B46E-9C2525D2C54E|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MDFI|ENLARGEMENT FROM NADIR||KBQ/UL|NOT DONE|||WRIGHT-GIEMSA STAIN|N|NA|FRIEND|PEDIATRIC NEUROLOGIST|Y|4||88||OBSERVATION|1960-02-18|
TRIAL STUDY 134XCP|TR|05481BE7-9309-4356-B46E-9C2525D2C54E|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||NG/L|DECREASED||KHZ|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|U|U|CAREGIVER|READER 2|N|5||7||INDUCTION TREATMENT|1968-11-25|
TRIAL STUDY 134XCP|TR|2F49D512-0A23-4D2D-959B-A1756991E817|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MMHG/L/MIN|ENLARGEMENT FROM NADIR||MOL|NOT DONE|||ROMANOWSKY STAIN|U|Y|PARENT|READER 3|U|1||38||FOLLOW-UP|1964-03-04|
TRIAL STUDY 134XCP|TR|2F49D512-0A23-4D2D-959B-A1756991E817|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UL/ML|NONPALPABLE||OZ|NOT DONE|||CELL CYTOTOXICITY NEUTRALIZATION ASSAY|U|N|SPOUSE|RATER 2|N|2||58||CONTINUATION TREATMENT|1962-02-25|
TRIAL STUDY 134XCP|TR|2F49D512-0A23-4D2D-959B-A1756991E817|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MILE|FOCALLY INCREASED||MET*MIN|NOT DONE|||U-HPLC/MS/MS|Y|U|ADJUDICATOR|RADIOLOGIST|NA|3||39||FOLLOW-UP|1968-09-08|
TRIAL STUDY 134XCP|TR|2F49D512-0A23-4D2D-959B-A1756991E817|4||||||PALPSTAT|PALPABLE STATE||UM|PALPABLE||G/CAGE|NOT DONE|||PULMONARY ANGIOGRAPHY|N|U|CHILD|PATHOLOGIST 1|N|4||88||RUN-IN|1964-11-26|
TRIAL STUDY 134XCP|TR|2F49D512-0A23-4D2D-959B-A1756991E817|5||||||AREA|AREA||MGEQ|UNEQUIVOCAL||F|NOT DONE|||ERGOSPIROMETRY|N|Y|CLINICAL RESEARCH ASSOCIATE|READER 3|NA|5||7||LONG-TERM FOLLOW-UP|1966-08-14|
TRIAL STUDY 134XCP|TR|E884C56C-1612-49CC-A594-B65E7B354842|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||PKAT|FOCALLY INCREASED||BQ/MG|NOT DONE|||KNEMOMETRY|Y|Y|ADJUDICATION COMMITTEE|READER|N|1||38||FOLLOW-UP|1963-02-27|
TRIAL STUDY 134XCP|TR|E884C56C-1612-49CC-A594-B65E7B354842|2||||||LMBFLIND|LIMB FAILURE INDICATOR||L/DAY|NONPALPABLE||MET*H|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|N|Y|CHILD|RADIOLOGIST|U|2||58||RUN-IN|1964-06-08|
TRIAL STUDY 134XCP|TR|E884C56C-1612-49CC-A594-B65E7B354842|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||BQ/ML|PATHOLOGICAL||/4.0 ML|NOT DONE|||QUANTITATIVE ULTRASOUND|NA|NA|PROXY|ONCOLOGIST 2|NA|3||39||FOLLOW-UP|1970-09-09|
TRIAL STUDY 134XCP|TR|E884C56C-1612-49CC-A594-B65E7B354842|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||CUP|ENLARGEMENT||UG/ML/H|NOT DONE|||COLORIMETRY|N|N|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|4||88||BLINDED TREATMENT|1969-06-13|
TRIAL STUDY 134XCP|TR|E884C56C-1612-49CC-A594-B65E7B354842|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||YD|ENLARGEMENT||UMOL/MIN|NOT DONE|||LIGHT MICROSCOPY|N|U|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||RUN-IN|1972-05-11|
TRIAL STUDY 134XCP|TR|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|1||||||LESSCIND|LESION SUCCESS INDICATOR||NMOL BCE/MMOL|UNCHANGED||IU/KG|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|N|SPOUSE|PATHOLOGIST 2|Y|1||38||TREATMENT|1973-02-18|
TRIAL STUDY 134XCP|TR|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||SIEMENS|FURTHER ENLARGEMENT||DEG/S|NOT DONE|||COMPLEMENT FIXATION|NA|NA|VENDOR|HEMATOLOGIST|Y|2||58||TREATMENT|1973-09-01|
TRIAL STUDY 134XCP|TR|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|3||||||LPERP|LONGEST PERPENDICULAR||MAC50|FURTHER ENLARGEMENT FROM NADIR||ANSON U|NOT DONE|||ISHIHARA COLOR PLATES|N|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|3||39||SCREENING|1965-09-11|
TRIAL STUDY 134XCP|TR|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||NU/CL|PATHOLOGICAL||/SEC|NOT DONE|||PANENDOSCOPY|N|Y|INVESTIGATOR|RATER 1|NA|4||88||OBSERVATION|1961-10-31|
TRIAL STUDY 134XCP|TR|673EFD33-EEDA-4C97-A9F0-86377D7F8CDF|5||||||DIAMETER|DIAMETER||L/S/KPA|FURTHER ENLARGEMENT||HR/DAY|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|U|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|5||7||RUN-IN|1961-06-04|
TRIAL STUDY 134XCP|TR|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/KG|NONPALPABLE||CUP|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|NA|N|SIGNIFICANT OTHER|PATHOLOGIST 1|N|1||38||FOLLOW-UP|1961-09-09|
TRIAL STUDY 134XCP|TR|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MG/M2|ENLARGEMENT||CYLINDER|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|U|NA|PROXY|DERMATOLOGIST|U|2||58||BASELINE|1965-02-22|
TRIAL STUDY 134XCP|TR|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||G/ANIMAL/WK|EQUIVOCAL||ML/BEAT|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|N|U|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||OBSERVATION|1969-07-27|
TRIAL STUDY 134XCP|TR|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|4||||||AREA|AREA||IU/MG|FOCALLY INCREASED||HEP|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|N|N|SPOUSE|CLINICAL PATHOLOGIST|U|4||88||WASHOUT|1961-09-03|
TRIAL STUDY 134XCP|TR|38AFE156-84DA-4A6D-BF49-9B634D4DD27E|5||||||DIAMETER|DIAMETER||/10^3|DECREASED||UG/L DDU|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|U|N|CAREGIVER|OPHTHALMOLOGIST|N|5||7||OBSERVATION|1971-02-03|
TRIAL STUDY 134XCP|TR|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|1||||||NEWCONF|NEW TUMOR CONFIRMED||UM/S|FURTHER ENLARGEMENT||OZ EQ|NOT DONE|||KINYOUN STAIN|NA|NA|SIGNIFICANT OTHER|RATER|Y|1||38||BLINDED TREATMENT|1968-03-24|
TRIAL STUDY 134XCP|TR|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||OSM|PATHOLOGICAL||MN|NOT DONE|||NEPHELOMETRY|NA|N|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||RUN-IN|1961-04-05|
TRIAL STUDY 134XCP|TR|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CI/ML|PRESENT||10^4/HPF|NOT DONE|||PYROSEQUENCING|N|N|INTERVIEWER|RATER 1|N|3||39||BLINDED TREATMENT|1962-12-19|
TRIAL STUDY 134XCP|TR|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||FRAMES/S|NON-PATHOLOGICAL||TRANSDUCING UNIT/ML|NOT DONE|||PULSE OXIMETRY|U|N|SIBLING|ONCOLOGIST|NA|4||88||OPEN LABEL TREATMENT|1966-02-01|
TRIAL STUDY 134XCP|TR|4E8E9ED2-EC93-4023-8F5D-BCD759F92604|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||GRAIN|ENLARGEMENT||G/G/DAY|NOT DONE|||FUNDUS PHOTOGRAPHY|U|NA|STUDY SUBJECT|OPTOMETRIST|N|5||7||OPEN LABEL TREATMENT|1963-07-17|
TRIAL STUDY 134XCP|TR|0B140787-9458-4F66-B7E9-1FAFF239085E|1||||||SUMVOL|SUM OF VOLUME||OI50|FURTHER ENLARGEMENT FROM NADIR||U/KG/DAY|NOT DONE|||PHASE CONTRAST MICROSCOPY|NA|Y|FRIEND|READER 3|N|1||38||FOLLOW-UP|1968-09-20|
TRIAL STUDY 134XCP|TR|0B140787-9458-4F66-B7E9-1FAFF239085E|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MMOL/MIN/KPA/L|PRESENT||10^9 ORGANISMS/G|NOT DONE|||CONTRAST ENHANCED CT SCAN|U|N|FAMILY MEMBER|NEUROLOGIST 2|N|2||58||RUN-IN|1968-04-29|
TRIAL STUDY 134XCP|TR|0B140787-9458-4F66-B7E9-1FAFF239085E|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||TUBE|NON-PATHOLOGICAL||TAMPON|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|U|CLINICAL STUDY SPONSOR|RATER 1|NA|3||39||TREATMENT|1972-09-26|
TRIAL STUDY 134XCP|TR|0B140787-9458-4F66-B7E9-1FAFF239085E|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MG/MIN|DIFFUSELY INCREASED||10^6 CFU/G|NOT DONE|||TURBIDIMETRY|NA|N|CHILD|ADJUDICATOR 1|U|4||88||BLINDED TREATMENT|1965-05-21|
TRIAL STUDY 134XCP|TR|0B140787-9458-4F66-B7E9-1FAFF239085E|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||UEQ/L|NORMAL||MM|NOT DONE|||POTENTIOMETRY|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|5||7||FOLLOW-UP|1967-04-17|
TRIAL STUDY 134XCP|TR|FB91BADF-308B-4F6A-90D0-032E93E20C4A|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||SFC/10^6 PBMC|TUMOR MERGED||HOMEOPATHIC DILUTION|NOT DONE|||SANGER SEQUENCING|NA|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|1||38||BLINDED TREATMENT|1967-06-26|
TRIAL STUDY 134XCP|TR|FB91BADF-308B-4F6A-90D0-032E93E20C4A|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/M2|PALPABLE||MEQ/DL|NOT DONE|||HANSEL STAIN|U|Y|SPOUSE|RADIOLOGIST|Y|2||58||FOLLOW-UP|1969-10-28|
TRIAL STUDY 134XCP|TR|FB91BADF-308B-4F6A-90D0-032E93E20C4A|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||NG/L|FOCALLY INCREASED||NMOL/MOL|NOT DONE|||DIGITAL PCR|NA|Y|PROXY|NEUROLOGIST|U|3||39||CONTINUATION TREATMENT|1966-03-11|
TRIAL STUDY 134XCP|TR|FB91BADF-308B-4F6A-90D0-032E93E20C4A|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||FEU|UNEQUIVOCAL||U/G/MIN|NOT DONE|||CLIP|Y|U|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|4||88||FOLLOW-UP|1963-05-22|
TRIAL STUDY 134XCP|TR|FB91BADF-308B-4F6A-90D0-032E93E20C4A|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CAPLET|DIFFUSELY INCREASED||MG/M2/MIN|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|Y|INVESTIGATOR|ONCOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1965-08-09|
TRIAL STUDY 134XCP|TR|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|1||||||CALCFIND|CALCIFICATION INDICATOR||10^6 ORGANISMS|NON-PATHOLOGICAL||PPB|NOT DONE|||REFLECTANCE SPECTROSCOPY|U|N|PARENT|RATER|U|1||38||BASELINE|1966-09-25|
TRIAL STUDY 134XCP|TR|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MM/MIN|ENLARGEMENT||FL|NOT DONE|||FLUORESCENT MICROSCOPY|U|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2||58||LONG-TERM FOLLOW-UP|1965-05-30|
TRIAL STUDY 134XCP|TR|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^4 CFU|INCREASED||PIPE|NOT DONE|||MICRODENSITOMETRY|N|U|INVESTIGATOR|NEUROLOGIST 1|U|3||39||WASHOUT|1963-01-04|
TRIAL STUDY 134XCP|TR|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NKAT/L|NONPALPABLE||PMOL/10^9 CELLS|NOT DONE|||SLIT LAMP PHOTOGRAPHY|Y|Y|STUDY SUBJECT|RATER 2|Y|4||88||OPEN LABEL TREATMENT|1964-10-06|
TRIAL STUDY 134XCP|TR|5ECBD8DD-9C87-4FEC-9BFB-4D026F7870DC|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UKAT/L|INCREASED||DROP|NOT DONE|||FUNDUS PHOTOGRAPHY|Y|N|INVESTIGATOR|RADIOLOGIST 1|Y|5||7||OBSERVATION|1965-12-31|
TRIAL STUDY 134XCP|TR|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||%|EQUIVOCAL||10^6/HPF|NOT DONE|||CONTRAST ENHANCED PET SCAN|Y|N|CHILD|FORENSIC PATHOLOGIST|N|1||38||SCREENING|1967-01-20|
TRIAL STUDY 134XCP|TR|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ECL UNIT|PATHOLOGICAL||ABSORBANCE U/ML|NOT DONE|||CT SCAN|N|U|FRIEND|RATER|U|2||58||FOLLOW-UP|1972-02-27|
TRIAL STUDY 134XCP|TR|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MU/G|UNCHANGED||BEL|NOT DONE|||CARDIAC THERMODILUTION|Y|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|3||39||BLINDED TREATMENT|1971-03-22|
TRIAL STUDY 134XCP|TR|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|4||||||PALPSTAT|PALPABLE STATE||U/MMOL|FOCALLY INCREASED||MEQ/UL|NOT DONE|||MICROARRAY|U|Y|ADJUDICATION COMMITTEE|NEUROLOGIST|U|4||88||CONTINUATION TREATMENT|1961-03-30|
TRIAL STUDY 134XCP|TR|35FD6533-D67E-4A66-BB63-B9FC87E5B1D1|5||||||LESSCIND|LESION SUCCESS INDICATOR||TCID 50/DOSE|PRESENT||% INHIBITION|NOT DONE|||URANYL ACETATE STAIN|Y|U|GUARDIAN|PATHOLOGIST 2|U|5||7||FOLLOW-UP|1961-03-03|
TRIAL STUDY 134XCP|TR|3B583022-3A2C-4387-80A5-035E3FD111BD|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ML/100G/MIN|PALPABLE||NFIU|NOT DONE|||ETDRS EYE CHART|NA|Y|PROXY|RATER 2|N|1||38||WASHOUT|1964-05-01|
TRIAL STUDY 134XCP|TR|3B583022-3A2C-4387-80A5-035E3FD111BD|2||||||VSLPIND|VESSEL PATENCY INDICATOR||MANSON U/ML|ABSENT||10^6/G|NOT DONE|||IMMUNOTURBIDIMETRY|Y|N|SPOUSE|INTERNIST|U|2||58||INDUCTION TREATMENT|1971-08-01|
TRIAL STUDY 134XCP|TR|3B583022-3A2C-4387-80A5-035E3FD111BD|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PT_US|FURTHER ENLARGEMENT||PACK YEAR|NOT DONE|||RAJI CELL EIA|U|N|FAMILY MEMBER|NEUROLOGIST|Y|3||39||BLINDED TREATMENT|1964-12-04|
TRIAL STUDY 134XCP|TR|3B583022-3A2C-4387-80A5-035E3FD111BD|4||||||RADIODEN|RADIODENSITY||10^6/L|NORMAL||UKAT/L|NOT DONE|||MRI|Y|Y|CHILD|PATHOLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1961-12-13|
TRIAL STUDY 134XCP|TR|3B583022-3A2C-4387-80A5-035E3FD111BD|5||||||BNLNUM|NUMBER OF BONE LESIONS||SCOOPFUL|FURTHER ENLARGEMENT FROM NADIR||G/G|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|N|STUDY SUBJECT|INTERNIST|NA|5||7||INDUCTION TREATMENT|1971-04-30|
TRIAL STUDY 134XCP|TR|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|1||||||BNLNUM|NUMBER OF BONE LESIONS||TRANSDUCING UNIT/ML|EQUIVOCAL||U/DL|NOT DONE|||FISH|N|U|FAMILY MEMBER|READER 1|NA|1||38||CONTINUATION TREATMENT|1970-01-01|
TRIAL STUDY 134XCP|TR|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MESF|ABSENT||10^4 CFU|NOT DONE|||PHOTOGRAPHY|Y|Y|ADJUDICATOR|NEUROLOGIST|N|2||58||TREATMENT|1968-04-17|
TRIAL STUDY 134XCP|TR|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|3||||||LESFLIND|LESION FAILURE INDICATOR||CUP|ENLARGEMENT FROM NADIR||H*%|NOT DONE|||SMEAR|N|NA|GUARDIAN|NEUROLOGIST|Y|3||39||WASHOUT|1962-09-05|
TRIAL STUDY 134XCP|TR|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MMOL|INCREASED||F|NOT DONE|||MOUSE PROTECTION ASSAY|U|NA|SIGNIFICANT OTHER|READER 1|Y|4||88||TREATMENT|1973-08-11|
TRIAL STUDY 134XCP|TR|62435514-5F72-4B2C-A6CE-CD80C06BF5AC|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||ML/MMHG/MIN/L|FURTHER ENLARGEMENT||MOL/DAY|NOT DONE|||MASS SPECTROMETRY|U|NA|PROXY|OPTOMETRIST|U|5||7||FOLLOW-UP|1963-04-06|
TRIAL STUDY 134XCP|TR|B5370AC4-3185-48DC-B1BC-A00AE8496783|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||SFC/10^6 PBMC|PATHOLOGICAL||MN|NOT DONE|||CONTRAST ENHANCED MRI|N|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|1||38||BLINDED TREATMENT|1967-07-01|
TRIAL STUDY 134XCP|TR|B5370AC4-3185-48DC-B1BC-A00AE8496783|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^9 ORGANISMS/ML|INCREASED||DB|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|U|U|SPOUSE|PATHOLOGIST 1|NA|2||58||SCREENING|1960-12-06|
TRIAL STUDY 134XCP|TR|B5370AC4-3185-48DC-B1BC-A00AE8496783|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||G/M2/DAY|EQUIVOCAL||MS/MMHG|NOT DONE|||MAMMOGRAPHY|N|U|SPOUSE|READER|Y|3||39||RUN-IN|1968-08-31|
TRIAL STUDY 134XCP|TR|B5370AC4-3185-48DC-B1BC-A00AE8496783|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||BQ/G|INCREASED||DISK|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|NA|U|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4||88||OBSERVATION|1969-10-30|
TRIAL STUDY 134XCP|TR|B5370AC4-3185-48DC-B1BC-A00AE8496783|5||||||LESSCIND|LESION SUCCESS INDICATOR||PKAT|DECREASED||V/SEC|NOT DONE|||RADIOGRAPHY|NA|Y|ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|5||7||TREATMENT|1968-08-12|
TRIAL STUDY 134XCP|TR|1112A903-1F2A-4583-BB9A-41DD206D5B4A|1||||||VSLPIND|VESSEL PATENCY INDICATOR||ABSORBANCE U/ML|FURTHER ENLARGEMENT FROM NADIR||PNU/ML|NOT DONE|||FLUORESCENT MICROSCOPY|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|1||38||BLINDED TREATMENT|1972-05-29|
TRIAL STUDY 134XCP|TR|1112A903-1F2A-4583-BB9A-41DD206D5B4A|2||||||CALCFIND|CALCIFICATION INDICATOR||DYN|DIFFUSELY INCREASED||SEC|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|Y|N|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|2||58||BASELINE|1965-11-05|
TRIAL STUDY 134XCP|TR|1112A903-1F2A-4583-BB9A-41DD206D5B4A|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||FIU|PALPABLE||U/M2|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|U|NA|FRIEND|NEUROLOGIST 2|N|3||39||FOLLOW-UP|1963-08-19|
TRIAL STUDY 134XCP|TR|1112A903-1F2A-4583-BB9A-41DD206D5B4A|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MET*H|EQUIVOCAL||PKAT|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|U|4||88||TREATMENT|1963-10-31|
TRIAL STUDY 134XCP|TR|1112A903-1F2A-4583-BB9A-41DD206D5B4A|5||||||ORSTATE|ORGAN STATE||PLUG|PATHOLOGICAL||%/MIN|NOT DONE|||MASS SPECTROMETRY|N|NA|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|5||7||SCREENING|1971-06-10|
TRIAL STUDY 134XCP|TR|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|1||||||LMBFLIND|LIMB FAILURE INDICATOR||%(V/V)|ABSENT||PMOL/L/H|NOT DONE|||RULER MEASUREMENT METHOD|U|NA|VENDOR|RADIOLOGIST 1|N|1||38||BLINDED TREATMENT|1961-05-06|
TRIAL STUDY 134XCP|TR|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|2||||||SUMDIAM|SUM OF DIAMETER||YEARS|DIFFUSELY INCREASED||LOG10 ELISA UNIT|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|Y|N|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|2||58||SCREENING|1968-12-20|
TRIAL STUDY 134XCP|TR|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|3||||||LNSTATE|LYMPH NODE STATE||CP|ENLARGEMENT||MG/G/MIN|NOT DONE|||POLYMERASE CHAIN REACTION|U|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||INDUCTION TREATMENT|1971-04-09|
TRIAL STUDY 134XCP|TR|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||DNA COPIES/ML|UNCHANGED||/100 WBC|NOT DONE|||INDIA INK STAIN|NA|NA|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|Y|4||88||INDUCTION TREATMENT|1970-03-09|
TRIAL STUDY 134XCP|TR|9629DBBC-72CC-4724-B78A-1B0DF9D801C8|5||||||RADIODEN|RADIODENSITY||TBSP|UNCHANGED||UG/ANIMAL|NOT DONE|||PULSE OXIMETRY|NA|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||OBSERVATION|1969-08-04|
TRIAL STUDY 134XCP|TR|D09F047E-E380-453B-875D-FF3C8C5EA839|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||GLOBULE|FURTHER ENLARGEMENT FROM NADIR||GY/MIN|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|N|Y|PARENT|ADJUDICATOR 1|NA|1||38||OBSERVATION|1969-09-15|
TRIAL STUDY 134XCP|TR|D09F047E-E380-453B-875D-FF3C8C5EA839|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/MIN|PATHOLOGICAL||UG/M2/H|NOT DONE|||RADIAL IMMUNODIFFUSION|Y|N|PROXY|ENDOCRINOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-11-12|
TRIAL STUDY 134XCP|TR|D09F047E-E380-453B-875D-FF3C8C5EA839|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||H/WK|TUMOR MERGED||BISCUIT|NOT DONE|||HPLC|NA|Y|CAREGIVER|CARDIOLOGIST|U|3||39||TREATMENT|1972-05-05|
TRIAL STUDY 134XCP|TR|D09F047E-E380-453B-875D-FF3C8C5EA839|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||ML/100G/MIN|ENLARGEMENT FROM NADIR||VG/KG|NOT DONE|||FLUORESCEIN STAIN|NA|Y|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|4||88||CONTINUATION TREATMENT|1970-08-14|
TRIAL STUDY 134XCP|TR|D09F047E-E380-453B-875D-FF3C8C5EA839|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||EVENTS|NONPALPABLE||NG/L|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|N|Y|GUARDIAN|READER 1|N|5||7||WASHOUT|1965-10-07|
TRIAL STUDY 134XCP|TR|E1B16559-B9CA-4B14-A77A-4AD546EF5262|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||ML/SEC/1.73M2|FOCALLY INCREASED||CD|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|1||38||INDUCTION TREATMENT|1966-02-12|
TRIAL STUDY 134XCP|TR|E1B16559-B9CA-4B14-A77A-4AD546EF5262|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||PL|NORMAL||DAGU|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|Y|STUDY SUBJECT|READER 3|Y|2||58||OPEN LABEL TREATMENT|1973-04-09|
TRIAL STUDY 134XCP|TR|E1B16559-B9CA-4B14-A77A-4AD546EF5262|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CS|PALPABLE||EQ|NOT DONE|||POLYSOMNOGRAPHY|N|N|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|3||39||BASELINE|1968-01-12|
TRIAL STUDY 134XCP|TR|E1B16559-B9CA-4B14-A77A-4AD546EF5262|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||G/ANIMAL|PRESENT||ENZYME U/L|NOT DONE|||CARDIAC THERMODILUTION|N|N|PARENT|NEUROLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1971-09-05|
TRIAL STUDY 134XCP|TR|E1B16559-B9CA-4B14-A77A-4AD546EF5262|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||TBSP|DIFFUSELY INCREASED||PG/DL|NOT DONE|||TEMPLATE INCISION METHOD|U|U|STUDY SUBJECT|NEUROLOGIST 1|Y|5||7||BLINDED TREATMENT|1964-01-29|
TRIAL STUDY 134XCP|TR|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||VIAL|ENLARGEMENT||CI/ML|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|Y|FRIEND|ADJUDICATOR|N|1||38||OPEN LABEL TREATMENT|1966-12-02|
TRIAL STUDY 134XCP|TR|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|2||||||VOLUME|VOLUME||MMOL/DAY|PATHOLOGICAL||LOG10 IU/ML|NOT DONE|||CLAUSS METHOD|N|NA|ADJUDICATOR|ENDOCRINOLOGIST|N|2||58||RUN-IN|1971-04-12|
TRIAL STUDY 134XCP|TR|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||CM/S|PATHOLOGICAL||10^6/G|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|N|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|3||39||FOLLOW-UP|1962-09-22|
TRIAL STUDY 134XCP|TR|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|4||||||ORSTATE|ORGAN STATE||NG/L|NONPALPABLE||10^9 CFU/G|NOT DONE|||PET SCAN|NA|NA|ADJUDICATION COMMITTEE|READER 1|N|4||88||OBSERVATION|1961-04-04|
TRIAL STUDY 134XCP|TR|9B2E46E3-B769-40D8-8484-DA3D2BFF2EAA|5||||||DIAMETER|DIAMETER||PMOL/L/H|FURTHER ENLARGEMENT FROM NADIR||10^4/L|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|Y|SIBLING|ADJUDICATOR 1|N|5||7||BASELINE|1968-08-14|
TRIAL STUDY 134XCP|TR|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MMHG|DIFFUSELY INCREASED||PRESSOR UNITS|NOT DONE|||MIGET|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|1||38||BASELINE|1964-06-30|
TRIAL STUDY 134XCP|TR|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|2||||||LMBFLIND|LIMB FAILURE INDICATOR||CI/L|PATHOLOGICAL||G/ANIMAL/DAY|NOT DONE|||TURBIDIMETRY|U|U|VENDOR|RATER 1|Y|2||58||BASELINE|1972-07-22|
TRIAL STUDY 134XCP|TR|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||IMPLANT|UNEQUIVOCAL||UU/L|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|N|FRIEND|MICROSCOPIST|Y|3||39||INDUCTION TREATMENT|1961-07-04|
TRIAL STUDY 134XCP|TR|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||CCID 50/ML|FURTHER ENLARGEMENT||MM3/MM2/YEAR|NOT DONE|||PAP STAIN|NA|N|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1970-03-16|
TRIAL STUDY 134XCP|TR|7541A7A7-9A6D-4973-80B6-D4D85459C4D2|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||V/V|NONPALPABLE||YEARS|NOT DONE|||ACID FAST STAIN|NA|U|SIBLING|ADJUDICATOR 3|N|5||7||CONTINUATION TREATMENT|1964-05-18|
TRIAL STUDY 134XCP|TR|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||GY/H|INCREASED||GY/H|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1970-10-22|
TRIAL STUDY 134XCP|TR|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|2||||||LNSTATE|LYMPH NODE STATE||10^5/HPF|PATHOLOGICAL||CAPFUL|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|2||58||SCREENING|1966-03-28|
TRIAL STUDY 134XCP|TR|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|3||||||LDIAM|LONGEST DIAMETER||%/S|FURTHER ENLARGEMENT FROM NADIR||U/M2/DAY|NOT DONE|||STRESS ECHOCARDIOGRAPHY|U|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|3||39||SCREENING|1962-08-30|
TRIAL STUDY 134XCP|TR|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|4||||||NEWCONF|NEW TUMOR CONFIRMED||ML/CM|TUMOR MERGED||UKAT|NOT DONE|||MECHANICAL CLOT DETECTION|N|Y|GUARDIAN|PATHOLOGIST 2|Y|4||88||OBSERVATION|1964-12-25|
TRIAL STUDY 134XCP|TR|0EEE28CE-22B1-4908-9FCE-CE8BB4ED12D8|5||||||LPERP|LONGEST PERPENDICULAR||10^6/EJACULATE U|PALPABLE||UG/M2/MIN|NOT DONE|||CISH|U|U|PARENT|OPHTHALMOLOGIST|N|5||7||CONTINUATION TREATMENT|1960-06-22|
TRIAL STUDY 134XCP|TR|44199000-F1B7-4187-9E5A-AA5F69E831C3|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||L|NON-PATHOLOGICAL||TBSP|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|NA|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|1||38||TREATMENT|1967-10-05|
TRIAL STUDY 134XCP|TR|44199000-F1B7-4187-9E5A-AA5F69E831C3|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||P|PRESENT||/200 HPFS|NOT DONE|||MULTIPLE BREATH WASHOUT|U|NA|DOMESTIC PARTNER|NEUROLOGIST 2|U|2||58||FOLLOW-UP|1963-03-11|
TRIAL STUDY 134XCP|TR|44199000-F1B7-4187-9E5A-AA5F69E831C3|3||||||PALPSTAT|PALPABLE STATE||EID 50/DOSE|TUMOR MERGED||LOZENGE|NOT DONE|||TRANSVAGINAL ULTRASOUND|N|NA|PARENT|OTOLARYNGOLOGIST|NA|3||39||RUN-IN|1962-05-19|
TRIAL STUDY 134XCP|TR|44199000-F1B7-4187-9E5A-AA5F69E831C3|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||TAMPON|NONPALPABLE||MAMP|NOT DONE|||TOTAL BODY RADIOGRAPHY|U|N|INTERVIEWER|MICROSCOPIST 1|U|4||88||LONG-TERM FOLLOW-UP|1960-02-02|
TRIAL STUDY 134XCP|TR|44199000-F1B7-4187-9E5A-AA5F69E831C3|5||||||VSLPIND|VESSEL PATENCY INDICATOR||CM/S|PATHOLOGICAL||HR/DAY|NOT DONE|||RAJI CELL EIA|U|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5||7||OBSERVATION|1967-06-30|
TRIAL STUDY 134XCP|TR|1D487F49-92DB-4132-BD95-1B8797594DE7|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^7 PFU|TUMOR MERGED||/MM2|NOT DONE|||FLUORESCEIN STAIN|N|NA|VENDOR|PATHOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1960-01-10|
TRIAL STUDY 134XCP|TR|1D487F49-92DB-4132-BD95-1B8797594DE7|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||FG|TUMOR MERGED||KG/MOL|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|N|CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|2||58||RUN-IN|1963-04-28|
TRIAL STUDY 134XCP|TR|1D487F49-92DB-4132-BD95-1B8797594DE7|3||||||RADIODEN|RADIODENSITY||MET*MIN|NORMAL||NEWTON|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|U|CLINICAL STUDY SPONSOR|ADJUDICATOR|N|3||39||WASHOUT|1971-11-15|
TRIAL STUDY 134XCP|TR|1D487F49-92DB-4132-BD95-1B8797594DE7|4||||||PALPSTAT|PALPABLE STATE||PMOL/DAY|FURTHER ENLARGEMENT||PA|NOT DONE|||ORCHIDOMETERY|N|N|ADJUDICATOR|NEUROLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1960-04-29|
TRIAL STUDY 134XCP|TR|1D487F49-92DB-4132-BD95-1B8797594DE7|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MG/KG/H|PRESENT||PPTR|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|U|Y|INTERVIEWER|PATHOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1965-04-22|
TRIAL STUDY 134XCP|TR|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||APL U|INCREASED||TSP|NOT DONE|||SXA SCAN|NA|NA|PARENT|FORENSIC PATHOLOGIST|Y|1||38||BLINDED TREATMENT|1962-10-10|
TRIAL STUDY 134XCP|TR|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|2||||||PALPSTAT|PALPABLE STATE||FMOL/L|TUMOR MERGED||SIEMENS|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|NA|U|ADJUDICATOR|NEUROLOGIST|N|2||58||OPEN LABEL TREATMENT|1964-09-22|
TRIAL STUDY 134XCP|TR|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UM2|ABSENT||UM|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|U|Y|DOMESTIC PARTNER|MICROSCOPIST 3|U|3||39||BLINDED TREATMENT|1962-01-02|
TRIAL STUDY 134XCP|TR|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||U/G HB|NORMAL||MG/KG/DAY|NOT DONE|||URANYL ACETATE STAIN|N|N|NON-HEALTH CARE PROFESSIONAL|READER|U|4||88||FOLLOW-UP|1962-10-02|
TRIAL STUDY 134XCP|TR|D282956F-CE78-4E8D-B99C-A3D75E09D2F5|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||TCID 50/DOSE|TUMOR MERGED||NEBULE|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|U|GUARDIAN|ONCOLOGIST|Y|5||7||OBSERVATION|1969-04-13|
TRIAL STUDY 134XCP|TR|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||/10^5|ABSENT||MN|NOT DONE|||FLUORIMETRY|Y|U|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|1||38||WASHOUT|1963-11-22|
TRIAL STUDY 134XCP|TR|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||DIP|INCREASED||ROENTGEN|NOT DONE|||TEST STRIP|NA|N|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|2||58||LONG-TERM FOLLOW-UP|1961-03-28|
TRIAL STUDY 134XCP|TR|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|3||||||LDIAM|LONGEST DIAMETER||MU/L|ABSENT||PIXELS/CM|NOT DONE|||TEMPLATE INCISION METHOD|Y|U|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|U|3||39||CONTINUATION TREATMENT|1964-11-11|
TRIAL STUDY 134XCP|TR|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MV*MIN|TUMOR MERGED||ECL UNIT|NOT DONE|||COMPLEMENT FIXATION|NA|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1964-02-24|
TRIAL STUDY 134XCP|TR|C0A58AAC-7317-4204-9C9D-974DB1BB38EF|5||||||CALCFIND|CALCIFICATION INDICATOR||WEEKS|DECREASED||EIA UNIT|NOT DONE|||ACID FAST STAIN|Y|U|FRIEND|MICROSCOPIST 2|Y|5||7||OPEN LABEL TREATMENT|1965-04-07|
TRIAL STUDY 134XCP|TR|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||NMOL BCE/L|INCREASED||MM|NOT DONE|||HEMOCYTOMETRY|U|U|PROXY|ONCOLOGIST 2|N|1||38||WASHOUT|1967-10-05|
TRIAL STUDY 134XCP|TR|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||HPA|ABSENT||UG/M2|NOT DONE|||CISH|Y|NA|CAREGIVER|HEMATOLOGIST|U|2||58||FOLLOW-UP|1969-01-11|
TRIAL STUDY 134XCP|TR|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|3||||||PALPSTAT|PALPABLE STATE||HR/DAY|EQUIVOCAL||10^6 CFU/G|NOT DONE|||CELLULAR PROLIFERATION ASSAY|N|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|3||39||RUN-IN|1966-09-09|
TRIAL STUDY 134XCP|TR|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MMHG*MIN/L|DIFFUSELY INCREASED||ML/H|NOT DONE|||CINEANGIOGRAPHY|U|NA|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|U|4||88||RUN-IN|1965-01-03|
TRIAL STUDY 134XCP|TR|B4AA4759-A825-4E0A-B55D-39B8F473B6A5|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||CIGARETTE|UNEQUIVOCAL||NMOL/DAY|NOT DONE|||PHOTOMETRIC CLOT DETECTION|N|NA|GUARDIAN|INTERNIST|U|5||7||BLINDED TREATMENT|1961-12-24|
TRIAL STUDY 134XCP|TR|33233744-4E16-437D-852B-B5F2CCC94B1A|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UL/ML|DECREASED||CMOL/L|NOT DONE|||EIA|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 3|N|1||38||TREATMENT|1967-03-26|
TRIAL STUDY 134XCP|TR|33233744-4E16-437D-852B-B5F2CCC94B1A|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||BLOCKS|ABSENT||FMOL/L|NOT DONE|||CYSTOMETRY|N|U|PARENT|MICROSCOPIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1971-05-04|
TRIAL STUDY 134XCP|TR|33233744-4E16-437D-852B-B5F2CCC94B1A|3||||||VOLUME|VOLUME||MMOL/MOL|ENLARGEMENT FROM NADIR||KIU|NOT DONE|||WRIGHT STAIN|N|NA|INTERVIEWER|PEDIATRIC NEUROLOGIST|Y|3||39||SCREENING|1963-02-25|
TRIAL STUDY 134XCP|TR|33233744-4E16-437D-852B-B5F2CCC94B1A|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||KCAL|UNCHANGED||/40 HPFS|NOT DONE|||POPULATION SEQUENCING|NA|NA|DOMESTIC PARTNER|PATHOLOGIST 2|Y|4||88||WASHOUT|1970-08-17|
TRIAL STUDY 134XCP|TR|33233744-4E16-437D-852B-B5F2CCC94B1A|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||VP/DOSE|UNEQUIVOCAL||MOL/G|NOT DONE|||TEMPLATE INCISION METHOD|N|NA|SIBLING|RADIOLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1968-02-15|
TRIAL STUDY 134XCP|TR|B27DC754-F6E2-41E3-9804-0F92AE0006B4|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||CMH2O*S2/ML|TUMOR MERGED||DNA COPIES/ML|NOT DONE|||SCINTIGRAPHY|Y|U|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|1||38||TREATMENT|1962-06-27|
TRIAL STUDY 134XCP|TR|B27DC754-F6E2-41E3-9804-0F92AE0006B4|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/DAY|NONPALPABLE||KS|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|U|FAMILY MEMBER|RATER|NA|2||58||LONG-TERM FOLLOW-UP|1970-10-08|
TRIAL STUDY 134XCP|TR|B27DC754-F6E2-41E3-9804-0F92AE0006B4|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||DEG/MM|DECREASED||MEQ|NOT DONE|||WESTERN BLOT|U|U|SIBLING|MICROSCOPIST 2|Y|3||39||CONTINUATION TREATMENT|1960-09-09|
TRIAL STUDY 134XCP|TR|B27DC754-F6E2-41E3-9804-0F92AE0006B4|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MANSON U/ML|PRESENT||GLOBULE|NOT DONE|||LIGHT MICROSCOPY|Y|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|4||88||OBSERVATION|1963-04-17|
TRIAL STUDY 134XCP|TR|B27DC754-F6E2-41E3-9804-0F92AE0006B4|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UMOL/DL|UNCHANGED||BOWL|NOT DONE|||MIGET|Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|5||7||TREATMENT|1960-11-15|
TRIAL STUDY 134XCP|TR|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||EVENTS|ENLARGEMENT||U/G/MIN|NOT DONE|||AGAR DILUTION|N|N|VENDOR|MICROSCOPIST|NA|1||38||BLINDED TREATMENT|1968-12-20|
TRIAL STUDY 134XCP|TR|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|2||||||LESSCIND|LESION SUCCESS INDICATOR||MM/H|NON-PATHOLOGICAL||COPIES/UG|NOT DONE|||DXA SCAN|U|Y|INTERVIEWER|UROLOGIST|N|2||58||SCREENING|1971-08-31|
TRIAL STUDY 134XCP|TR|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||CUP EQ|FURTHER ENLARGEMENT||MMOL/KG|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|U|U|SPOUSE|PATHOLOGIST 1|U|3||39||INDUCTION TREATMENT|1961-09-09|
TRIAL STUDY 134XCP|TR|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|4||||||AREA|AREA||MPS U|FOCALLY INCREASED||OD UNIT|NOT DONE|||THICK SMEAR|U|U|CHILD|UROLOGIST|Y|4||88||BASELINE|1971-04-11|
TRIAL STUDY 134XCP|TR|7C02E71C-2BCF-4F4A-BC4C-1A7C72264CE6|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PG/CELL|NORMAL||MPA|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|NA|Y|INVESTIGATOR|ADJUDICATOR 3|NA|5||7||INDUCTION TREATMENT|1965-07-16|
TRIAL STUDY 134XCP|TR|BDE843D8-2F69-4542-BC47-D52302FD4898|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||KDA|DIFFUSELY INCREASED||%(W/W)|NOT DONE|||EEG|U|NA|INTERVIEWER|ONCOLOGIST 1|U|1||38||BLINDED TREATMENT|1965-07-12|
TRIAL STUDY 134XCP|TR|BDE843D8-2F69-4542-BC47-D52302FD4898|2||||||BNLNUM|NUMBER OF BONE LESIONS||IU/MG|NORMAL||CFU/ML|NOT DONE|||DYNAMOMETRY|N|Y|INVESTIGATOR|RATER|NA|2||58||BASELINE|1963-04-19|
TRIAL STUDY 134XCP|TR|BDE843D8-2F69-4542-BC47-D52302FD4898|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||DRAM|NORMAL||10^7 TCID 50/DOSE|NOT DONE|||MULTI-SLICE SPIRAL CT|NA|NA|SIBLING|NEUROLOGIST|Y|3||39||CONTINUATION TREATMENT|1963-02-20|
TRIAL STUDY 134XCP|TR|BDE843D8-2F69-4542-BC47-D52302FD4898|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MM|ENLARGEMENT FROM NADIR||MASK|NOT DONE|||GEL ELECTROPHORESIS|Y|NA|INTERVIEWER|RADIOLOGIST 1|N|4||88||TREATMENT|1966-02-18|
TRIAL STUDY 134XCP|TR|BDE843D8-2F69-4542-BC47-D52302FD4898|5||||||CALCFIND|CALCIFICATION INDICATOR||NG/L|INCREASED||PFU/ANIMAL|NOT DONE|||AUSCULTATION|Y|U|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|5||7||FOLLOW-UP|1967-07-17|
TRIAL STUDY 134XCP|TR|A8C8CB0C-C575-414C-BF1C-846361DB03BC|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||CAL|EQUIVOCAL||PT_BR|NOT DONE|||PHYSICAL EXAMINATION|Y|Y|SIGNIFICANT OTHER|INTERNIST|Y|1||38||FOLLOW-UP|1970-07-21|
TRIAL STUDY 134XCP|TR|A8C8CB0C-C575-414C-BF1C-846361DB03BC|2||||||ORVERLN|ORGAN VERTICAL LENGTH||ANTI-XA IU|ENLARGEMENT||DNA COPIES/UG|NOT DONE|||POTENTIOMETRY|N|NA|DOMESTIC PARTNER|ADJUDICATOR 2|NA|2||58||LONG-TERM FOLLOW-UP|1971-12-28|
TRIAL STUDY 134XCP|TR|A8C8CB0C-C575-414C-BF1C-846361DB03BC|3||||||DIAMETER|DIAMETER||APL U|FURTHER ENLARGEMENT||EVENTS|NOT DONE|||IMMUNOBLOT|NA|N|DOMESTIC PARTNER|PATHOLOGIST 1|NA|3||39||BLINDED TREATMENT|1969-05-09|
TRIAL STUDY 134XCP|TR|A8C8CB0C-C575-414C-BF1C-846361DB03BC|4||||||SUMVOL|SUM OF VOLUME||NMOL|FURTHER ENLARGEMENT||RNA COPIES/ML|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|U|N|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|4||88||INDUCTION TREATMENT|1968-07-29|
TRIAL STUDY 134XCP|TR|A8C8CB0C-C575-414C-BF1C-846361DB03BC|5||||||LESFLIND|LESION FAILURE INDICATOR||UG/M2|ENLARGEMENT||KCAL|NOT DONE|||DIRECT SEQUENCING|NA|Y|CAREGIVER|ADJUDICATOR|Y|5||7||OBSERVATION|1961-12-26|
TRIAL STUDY 134XCP|TR|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CI/UL|ENLARGEMENT FROM NADIR||CD*S/M2|NOT DONE|||SPECTROPHOTOMETRY|NA|U|ADJUDICATOR|MICROSCOPIST|NA|1||38||SCREENING|1967-09-04|
TRIAL STUDY 134XCP|TR|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||SFC/10^6 PBMC|UNEQUIVOCAL||KDA|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|N|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|U|2||58||RUN-IN|1966-10-11|
TRIAL STUDY 134XCP|TR|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|3||||||LNSTATE|LYMPH NODE STATE||CP|FURTHER ENLARGEMENT||SBE/ML|NOT DONE|||MRS|Y|NA|STUDY SUBJECT|ENDOCRINOLOGIST|N|3||39||BLINDED TREATMENT|1968-05-24|
TRIAL STUDY 134XCP|TR|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||OZ|FURTHER ENLARGEMENT FROM NADIR||L|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|NA|SPOUSE|NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1964-06-06|
TRIAL STUDY 134XCP|TR|77CD8958-0AEF-463F-8F72-2BD24B23AD3A|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||HOMEOPATHIC DILUTION|EQUIVOCAL||UCI/KG|NOT DONE|||FISH|U|NA|PROXY|UROLOGIST|N|5||7||OPEN LABEL TREATMENT|1960-07-28|
TRIAL STUDY 134XCP|TR|86198851-0F45-45E0-A0CE-C50FEC078456|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||SHOCK WAVE|TUMOR MERGED||10^7 TCID 50/DOSE|NOT DONE|||PALM METHOD|N|NA|ADJUDICATOR|PATHOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1968-01-06|
TRIAL STUDY 134XCP|TR|86198851-0F45-45E0-A0CE-C50FEC078456|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||FEU|DIFFUSELY INCREASED||V|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|U|U|FAMILY MEMBER|RADIOLOGIST 2|N|2||58||OBSERVATION|1962-11-19|
TRIAL STUDY 134XCP|TR|86198851-0F45-45E0-A0CE-C50FEC078456|3||||||VSLPIND|VESSEL PATENCY INDICATOR||GY|FURTHER ENLARGEMENT FROM NADIR||KIU|NOT DONE|||COLORIMETRY|N|N|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|3||39||WASHOUT|1970-07-29|
TRIAL STUDY 134XCP|TR|86198851-0F45-45E0-A0CE-C50FEC078456|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MM3/MM2/YEAR|NONPALPABLE||YEARS|NOT DONE|||ICC|U|U|INTERVIEWER|DERMATOLOGIST|U|4||88||OPEN LABEL TREATMENT|1961-03-21|
TRIAL STUDY 134XCP|TR|86198851-0F45-45E0-A0CE-C50FEC078456|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||SACHET|UNCHANGED||ML|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|N|N|CAREGIVER|ADJUDICATOR 3|U|5||7||LONG-TERM FOLLOW-UP|1961-04-01|
TRIAL STUDY 134XCP|TR|9CD28016-BED9-4159-9C1B-60821D74615B|1||||||LDIAM|LONGEST DIAMETER||U|UNCHANGED||L/MIN/M2|NOT DONE|||ACRIDINE ORANGE STAIN|NA|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1||38||LONG-TERM FOLLOW-UP|1961-03-09|
TRIAL STUDY 134XCP|TR|9CD28016-BED9-4159-9C1B-60821D74615B|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UU/DL|ENLARGEMENT FROM NADIR||MG/KG/DAY|NOT DONE|||SPECT SCAN|U|NA|CAREGIVER|ENDOCRINOLOGIST|U|2||58||BLINDED TREATMENT|1972-10-27|
TRIAL STUDY 134XCP|TR|9CD28016-BED9-4159-9C1B-60821D74615B|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||TAMPON|PRESENT||BLOCKS|NOT DONE|||ACRIDINE ORANGE STAIN|Y|U|INDEPENDENT ASSESSOR|PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1968-12-17|
TRIAL STUDY 134XCP|TR|9CD28016-BED9-4159-9C1B-60821D74615B|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ELISA UNIT/DOSE|FURTHER ENLARGEMENT FROM NADIR||MAC50|NOT DONE|||NUCLEIC ACID SEQUENCING|Y|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|4||88||FOLLOW-UP|1966-05-13|
TRIAL STUDY 134XCP|TR|9CD28016-BED9-4159-9C1B-60821D74615B|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||KG/CM2|PRESENT||UG/MIN|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|N|Y|INTERVIEWER|CLINICAL PATHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1973-06-10|
TRIAL STUDY 134XCP|TR|BE578D25-C23E-416F-8A57-C901F7B58596|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/CL|PATHOLOGICAL||DEG/S|NOT DONE|||DXA SCAN|Y|NA|PARENT|ONCOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1967-02-12|
TRIAL STUDY 134XCP|TR|BE578D25-C23E-416F-8A57-C901F7B58596|2||||||SUMDIAM|SUM OF DIAMETER||MG/DAY|TUMOR MERGED||APS U|NOT DONE|||HPLC/MS|N|Y|CAREGIVER|DERMATOLOGIST|Y|2||58||OBSERVATION|1965-02-21|
TRIAL STUDY 134XCP|TR|BE578D25-C23E-416F-8A57-C901F7B58596|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||GPL U|NORMAL||BQ|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|U|NA|FAMILY MEMBER|RADIOLOGIST 2|NA|3||39||TREATMENT|1970-08-09|
TRIAL STUDY 134XCP|TR|BE578D25-C23E-416F-8A57-C901F7B58596|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||GY/H|EQUIVOCAL||BOTTLE|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|U|N|DOMESTIC PARTNER|NEUROLOGIST|NA|4||88||BLINDED TREATMENT|1962-11-25|
TRIAL STUDY 134XCP|TR|BE578D25-C23E-416F-8A57-C901F7B58596|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||G/CAGE/DAY|ENLARGEMENT||U/M2/H|NOT DONE|||POLYGRAPHY|NA|U|SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|5||7||TREATMENT|1971-04-03|
TRIAL STUDY 134XCP|TR|A60D5FE6-26BA-487D-98E0-5F464305924C|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||PKAT/L|FURTHER ENLARGEMENT||HOMEOPATHIC DILUTION|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|NA|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1962-09-23|
TRIAL STUDY 134XCP|TR|A60D5FE6-26BA-487D-98E0-5F464305924C|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/DAY|EQUIVOCAL||KM|NOT DONE|||BIOPSY|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|2||58||INDUCTION TREATMENT|1960-08-30|
TRIAL STUDY 134XCP|TR|A60D5FE6-26BA-487D-98E0-5F464305924C|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||KALLIKREIN INHIBITOR UNIT|EQUIVOCAL||MM2|NOT DONE|||KLEIHAUER-BETKE|N|N|FAMILY MEMBER|PHYSIOTHERAPIST|Y|3||39||CONTINUATION TREATMENT|1961-07-24|
TRIAL STUDY 134XCP|TR|A60D5FE6-26BA-487D-98E0-5F464305924C|4||||||DIAMETER|DIAMETER||MM2|NONPALPABLE||CIGARETTE|NOT DONE|||PHOTOMETRIC CLOT DETECTION|N|Y|SPOUSE|MICROSCOPIST 3|U|4||88||TREATMENT|1965-02-09|
TRIAL STUDY 134XCP|TR|A60D5FE6-26BA-487D-98E0-5F464305924C|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||PT_US|PATHOLOGICAL||FG|NOT DONE|||SNELLEN EYE CHART|Y|NA|ADJUDICATOR|NEUROLOGIST|Y|5||7||LONG-TERM FOLLOW-UP|1967-09-11|
TRIAL STUDY 134XCP|TR|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||/10^5|UNCHANGED||BU|NOT DONE|||POLYSOMNOGRAPHY|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|1||38||OBSERVATION|1962-12-30|
TRIAL STUDY 134XCP|TR|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||FT|NONPALPABLE||10^10/L|NOT DONE|||CLAUSS METHOD|N|Y|CHILD|ONCOLOGIST 2|N|2||58||RUN-IN|1969-06-25|
TRIAL STUDY 134XCP|TR|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|3||||||ORVERLN|ORGAN VERTICAL LENGTH||GPL U|ENLARGEMENT FROM NADIR||FOZ_US|NOT DONE|||CALIPER MEASUREMENT METHOD|N|Y|INTERVIEWER|OTOLARYNGOLOGIST|NA|3||39||BLINDED TREATMENT|1970-01-05|
TRIAL STUDY 134XCP|TR|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||PMOL/DAY|INCREASED||FRAMES/S|NOT DONE|||PANENDOSCOPY|N|NA|SIBLING|ENDOCRINOLOGIST|U|4||88||INDUCTION TREATMENT|1972-10-16|
TRIAL STUDY 134XCP|TR|1984ECA3-6E24-44F0-AEDA-FC9772B60F82|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||AU/ML|FURTHER ENLARGEMENT FROM NADIR||UKAT/10^12 RBC|NOT DONE|||ANTIBIOTIC AGAR SCREEN|N|N|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||WASHOUT|1966-08-31|
TRIAL STUDY 134XCP|TR|89739AE0-A8B9-44DE-970E-9D679ED58C4F|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^12 IU/L|UNEQUIVOCAL||AMP|NOT DONE|||PHASE-CONTRAST MRI|U|U|STUDY SUBJECT|MICROSCOPIST|Y|1||38||RUN-IN|1973-07-29|
TRIAL STUDY 134XCP|TR|89739AE0-A8B9-44DE-970E-9D679ED58C4F|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CMH2O/ML|UNCHANGED||EQ|NOT DONE|||NUCLEIC ACID BASED METHOD|U|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|2||58||OPEN LABEL TREATMENT|1966-12-31|
TRIAL STUDY 134XCP|TR|89739AE0-A8B9-44DE-970E-9D679ED58C4F|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MIN/DAY|PATHOLOGICAL||KUSP|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|NA|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1973-03-07|
TRIAL STUDY 134XCP|TR|89739AE0-A8B9-44DE-970E-9D679ED58C4F|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||FMOL/L/SEC|FURTHER ENLARGEMENT||WEEKS|NOT DONE|||SICKLE CELL SOLUBILITY TEST|N|NA|STUDY SUBJECT|PATHOLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1969-11-28|
TRIAL STUDY 134XCP|TR|89739AE0-A8B9-44DE-970E-9D679ED58C4F|5||||||SUMVOL|SUM OF VOLUME||FMOL/L|EQUIVOCAL||UMOL/L/SEC|NOT DONE|||TRICHROME STAIN|N|Y|FRIEND|PEDIATRIC NEUROLOGIST|U|5||7||OPEN LABEL TREATMENT|1962-02-18|
TRIAL STUDY 134XCP|TR|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|1||||||RADIODEN|RADIODENSITY||CYCLE/MIN|DIFFUSELY INCREASED||CI/UG|NOT DONE|||CORONARY ANGIOGRAPHY|U|U|PARENT|ADJUDICATOR 2|U|1||38||CONTINUATION TREATMENT|1962-05-26|
TRIAL STUDY 134XCP|TR|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|2||||||SUMDIAM|SUM OF DIAMETER||DPM/ML|PRESENT||SACHET|NOT DONE|||LINE PROBE ASSAY|Y|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|2||58||BASELINE|1971-10-11|
TRIAL STUDY 134XCP|TR|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|3||||||ORSTATE|ORGAN STATE||MMOL2/L2|ENLARGEMENT||FT2|NOT DONE|||CELLULAR PROLIFERATION ASSAY|NA|Y|SPOUSE|ADJUDICATOR 3|U|3||39||BASELINE|1969-05-01|
TRIAL STUDY 134XCP|TR|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|4||||||DIAMETER|DIAMETER||OD UNIT|TUMOR MERGED||DMOL|NOT DONE|||CORONARY ANGIOGRAPHY|U|N|CLINICAL RESEARCH COORDINATOR|READER|N|4||88||BLINDED TREATMENT|1966-03-18|
TRIAL STUDY 134XCP|TR|FEDCB4C0-17C0-4252-A09E-602D7D863FF8|5||||||SUMVOL|SUM OF VOLUME||S^-1(%O2)^-1|NORMAL||V/V|NOT DONE|||ERGOSPIROMETRY|Y|N|DOMESTIC PARTNER|UROLOGIST|NA|5||7||SCREENING|1960-08-17|
TRIAL STUDY 134XCP|TR|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|1||||||DIAMETER|DIAMETER||KCAL|ABSENT||/40 HPFS|NOT DONE|||WESTERGREN|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|1||38||INDUCTION TREATMENT|1970-05-24|
TRIAL STUDY 134XCP|TR|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||IMPLANT|FOCALLY INCREASED||10^6 ORGANISMS/G|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|U|U|SIGNIFICANT OTHER|ONCOLOGIST 1|U|2||58||FOLLOW-UP|1967-01-04|
TRIAL STUDY 134XCP|TR|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||KALLIKREIN INHIBITOR UNIT|FURTHER ENLARGEMENT||ANTI-XA IU/ML|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|NA|Y|INVESTIGATOR|ENDOCRINOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1961-12-17|
TRIAL STUDY 134XCP|TR|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|4||||||VSLPIND|VESSEL PATENCY INDICATOR||PT_BR|FURTHER ENLARGEMENT FROM NADIR||JDF UNIT|NOT DONE|||CLOT DETECTION|N|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|4||88||TREATMENT|1962-09-24|
TRIAL STUDY 134XCP|TR|2ABA4AB2-E2E5-4C24-B73B-389EBB7EF427|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||APL U|NONPALPABLE||ML/CM|NOT DONE|||CLINICAL EVALUATION|Y|Y|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1965-09-05|
TRIAL STUDY 134XCP|TR|CED88848-769E-41C1-9ACD-99E45766D27B|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MG2/DL2|FOCALLY INCREASED||MM/H|NOT DONE|||PULSE OXIMETRY|N|Y|SPOUSE|HEMATOLOGIST|Y|1||38||CONTINUATION TREATMENT|1965-02-16|
TRIAL STUDY 134XCP|TR|CED88848-769E-41C1-9ACD-99E45766D27B|2||||||LNSTATE|LYMPH NODE STATE||10^6/HPF|ENLARGEMENT||UKAT|NOT DONE|||OBSERVATION|N|NA|FAMILY MEMBER|OPHTHALMOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1960-01-24|
TRIAL STUDY 134XCP|TR|CED88848-769E-41C1-9ACD-99E45766D27B|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||PFU/ML|TUMOR MERGED||ML/BREATH|NOT DONE|||KINYOUN STAIN|N|NA|SIBLING|INTERNIST|Y|3||39||WASHOUT|1967-03-22|
TRIAL STUDY 134XCP|TR|CED88848-769E-41C1-9ACD-99E45766D27B|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MMHG*MIN/L|NONPALPABLE||CCID 50/DOSE|NOT DONE|||RADIAL IMMUNODIFFUSION|U|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|NA|4||88||BASELINE|1966-02-21|
TRIAL STUDY 134XCP|TR|CED88848-769E-41C1-9ACD-99E45766D27B|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||G/CM2|FOCALLY INCREASED||SQU/ML|NOT DONE|||OLIGO ACGH|N|NA|INTERVIEWER|RADIOLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1970-05-11|
TRIAL STUDY 134XCP|TR|E7958F8B-D987-4929-993A-8960EB30A309|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||LENS|UNCHANGED||MAC50|NOT DONE|||POLYSOMNOGRAPHY|N|NA|CHILD|MICROSCOPIST 3|N|1||38||INDUCTION TREATMENT|1962-09-22|
TRIAL STUDY 134XCP|TR|E7958F8B-D987-4929-993A-8960EB30A309|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MBQ|ENLARGEMENT||MET*H|NOT DONE|||PERCUSSION|U|Y|STUDY SUBJECT|RATER 2|U|2||58||TREATMENT|1967-06-26|
TRIAL STUDY 134XCP|TR|E7958F8B-D987-4929-993A-8960EB30A309|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||AMPULE|ABSENT||10^7 CFU|NOT DONE|||SINGLE-SLICE SPIRAL CT|U|N|ADJUDICATION COMMITTEE|ONCOLOGIST|Y|3||39||OBSERVATION|1967-03-20|
TRIAL STUDY 134XCP|TR|E7958F8B-D987-4929-993A-8960EB30A309|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||KAT|UNEQUIVOCAL||ML/CM3/MIN|NOT DONE|||SANGER SEQUENCING|U|U|ADJUDICATOR|PATHOLOGIST 2|NA|4||88||BLINDED TREATMENT|1964-07-28|
TRIAL STUDY 134XCP|TR|E7958F8B-D987-4929-993A-8960EB30A309|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MBP|INCREASED||/5X10^4 WBC|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|N|N|NON-HEALTH CARE PROFESSIONAL|READER 2|N|5||7||CONTINUATION TREATMENT|1968-06-28|
TRIAL STUDY 134XCP|TR|A633D973-B611-4014-A43E-C8C2D21DBFC2|1||||||TUMSTATE|TUMOR STATE||10^6/HPF|NORMAL||CL|NOT DONE|||IN SITU HYBRIDIZATION|Y|N|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|NA|1||38||INDUCTION TREATMENT|1972-03-05|
TRIAL STUDY 134XCP|TR|A633D973-B611-4014-A43E-C8C2D21DBFC2|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||APL U/ML|ABSENT||BQ/UL|NOT DONE|||DISK DIFFUSION|N|Y|PROXY|UROLOGIST|N|2||58||OPEN LABEL TREATMENT|1968-05-06|
TRIAL STUDY 134XCP|TR|A633D973-B611-4014-A43E-C8C2D21DBFC2|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||PG/L|EQUIVOCAL||EID 50/ML|NOT DONE|||REFRACTOMETRY|U|N|VENDOR|PEDIATRIC NEUROLOGIST|NA|3||39||TREATMENT|1962-10-04|
TRIAL STUDY 134XCP|TR|A633D973-B611-4014-A43E-C8C2D21DBFC2|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MG/G/MIN|UNEQUIVOCAL||LB|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|N|Y|VENDOR|MICROSCOPIST 3|Y|4||88||SCREENING|1968-11-17|
TRIAL STUDY 134XCP|TR|A633D973-B611-4014-A43E-C8C2D21DBFC2|5||||||LMBFLIND|LIMB FAILURE INDICATOR||U/G HB|EQUIVOCAL||MV2/HZ|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|N|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|5||7||WASHOUT|1972-01-03|
TRIAL STUDY 134XCP|TR|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ABSORBANCE U/ML|PRESENT||ELISA UNIT|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|Y|N|SIGNIFICANT OTHER|NEUROLOGIST 2|NA|1||38||INDUCTION TREATMENT|1962-12-31|
TRIAL STUDY 134XCP|TR|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||UKAT/L|NON-PATHOLOGICAL||ML/S/M2|NOT DONE|||ELECTROMYOGRAPHY|NA|NA|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|2||58||OPEN LABEL TREATMENT|1964-10-27|
TRIAL STUDY 134XCP|TR|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||CUP|DECREASED||EVENTS|NOT DONE|||IRON HEMATOXYLIN STAIN|Y|NA|SIGNIFICANT OTHER|OPTOMETRIST|U|3||39||WASHOUT|1970-05-23|
TRIAL STUDY 134XCP|TR|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||KALLIKREIN INHIBITOR UNIT|FOCALLY INCREASED||H/WK|NOT DONE|||SPECT/CT SCAN|NA|U|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|4||88||TREATMENT|1966-09-02|
TRIAL STUDY 134XCP|TR|6F8063F9-DA4E-42F9-941B-3AA78FDE69F7|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||DEG/MM|NORMAL||FG|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|Y|ADJUDICATION COMMITTEE|READER 1|N|5||7||BASELINE|1964-07-20|
TRIAL STUDY 134XCP|TR|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||AU/ML|UNEQUIVOCAL||RNA COPIES/ML|NOT DONE|||COMPLEMENT FIXATION|NA|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1||38||FOLLOW-UP|1966-11-03|
TRIAL STUDY 134XCP|TR|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^3 DNA COPIES/ML|UNCHANGED||L/MIN/M2|NOT DONE|||SPECULAR MICROSCOPY|Y|U|FAMILY MEMBER|ENDOCRINOLOGIST|U|2||58||WASHOUT|1960-04-10|
TRIAL STUDY 134XCP|TR|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|3||||||RADIODEN|RADIODENSITY||/2000 RBC|DECREASED||MILE|NOT DONE|||PLETHYSMOGRAPHY|Y|Y|FAMILY MEMBER|ADJUDICATOR 2|Y|3||39||RUN-IN|1963-04-27|
TRIAL STUDY 134XCP|TR|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||APL U/ML|INCREASED||CM/MIN|NOT DONE|||PALM METHOD|Y|U|ADJUDICATOR|READER|Y|4||88||WASHOUT|1966-08-13|
TRIAL STUDY 134XCP|TR|FABDB6DB-1E35-4B0E-9D79-9F1207A3B0A6|5||||||LESSCIND|LESION SUCCESS INDICATOR||MPL U/ML|PATHOLOGICAL||GTT|NOT DONE|||PHOTOMETRIC CLOT DETECTION|N|U|ADJUDICATOR|PATHOLOGIST|Y|5||7||OBSERVATION|1960-07-24|
TRIAL STUDY 134XCP|TR|264AA652-A25E-43CE-A54F-6FEB54AB62F3|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UG/KG/MIN|NON-PATHOLOGICAL||RATIO|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|U|U|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|1||38||SCREENING|1971-08-25|
TRIAL STUDY 134XCP|TR|264AA652-A25E-43CE-A54F-6FEB54AB62F3|2||||||LPERP|LONGEST PERPENDICULAR||S*KPA|TUMOR MERGED||RAD|NOT DONE|||LANDOLT RING|U|U|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|N|2||58||BASELINE|1966-09-07|
TRIAL STUDY 134XCP|TR|264AA652-A25E-43CE-A54F-6FEB54AB62F3|3||||||VOLUME|VOLUME||10^6 DNA COPIES/ML|NON-PATHOLOGICAL||MNFI|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|Y|U|VENDOR|CARDIOLOGIST|NA|3||39||SCREENING|1962-05-25|
TRIAL STUDY 134XCP|TR|264AA652-A25E-43CE-A54F-6FEB54AB62F3|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||ANSON U|NORMAL||H*%|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|N|NA|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|N|4||88||OBSERVATION|1971-08-30|
TRIAL STUDY 134XCP|TR|264AA652-A25E-43CE-A54F-6FEB54AB62F3|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||GBQ/UG|NONPALPABLE||CAPFUL|NOT DONE|||TEMPLATE INCISION METHOD|U|N|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-02-06|
TRIAL STUDY 134XCP|TR|4DE042DC-2F1E-425C-BA36-F64A3493CE76|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ML/M2/H|ENLARGEMENT||KCAL/DAY|NOT DONE|||PLETHYSMOGRAPHY|N|NA|CAREGIVER|RATER 2|N|1||38||SCREENING|1961-05-19|
TRIAL STUDY 134XCP|TR|4DE042DC-2F1E-425C-BA36-F64A3493CE76|2||||||PALPSTAT|PALPABLE STATE||NFIU|DIFFUSELY INCREASED||G/G|NOT DONE|||PALM METHOD|N|N|INTERVIEWER|NEUROLOGIST|NA|2||58||INDUCTION TREATMENT|1965-06-26|
TRIAL STUDY 134XCP|TR|4DE042DC-2F1E-425C-BA36-F64A3493CE76|3||||||LNSTATE|LYMPH NODE STATE||/200 HPFS|PRESENT||NMOL BCE/L|NOT DONE|||CONGO RED STAIN|NA|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|3||39||FOLLOW-UP|1961-05-14|
TRIAL STUDY 134XCP|TR|4DE042DC-2F1E-425C-BA36-F64A3493CE76|4||||||LNSTATE|LYMPH NODE STATE||PMOL/DAY|INCREASED||U.CARR|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|N|N|DOMESTIC PARTNER|READER|Y|4||88||SCREENING|1968-03-02|
TRIAL STUDY 134XCP|TR|4DE042DC-2F1E-425C-BA36-F64A3493CE76|5||||||SUMDIAM|SUM OF DIAMETER||BLOCKS|NON-PATHOLOGICAL||ANSON U|NOT DONE|||BAC ACGH|N|NA|INTERVIEWER|ONCOLOGIST|N|5||7||SCREENING|1972-09-10|
TRIAL STUDY 134XCP|TR|872942E9-A575-4929-9B21-D30DE51B367B|1||||||VOLUME|VOLUME||LOG10 ELISA UNIT/DOSE|NONPALPABLE||SPRAY|NOT DONE|||SPECT SCAN|U|NA|SPOUSE|ONCOLOGIST|Y|1||38||TREATMENT|1963-10-16|
TRIAL STUDY 134XCP|TR|872942E9-A575-4929-9B21-D30DE51B367B|2||||||TUMSTATE|TUMOR STATE||GBQ/MG|ENLARGEMENT FROM NADIR||UL/ML|NOT DONE|||FARR ASSAY|NA|Y|ADJUDICATOR|PATHOLOGIST 1|N|2||58||BLINDED TREATMENT|1961-11-03|
TRIAL STUDY 134XCP|TR|872942E9-A575-4929-9B21-D30DE51B367B|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||10^4 CFU/ML|PALPABLE||10^7 CFU/ML|NOT DONE|||WHOLE EXOME SEQUENCING|N|N|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||WASHOUT|1968-07-31|
TRIAL STUDY 134XCP|TR|872942E9-A575-4929-9B21-D30DE51B367B|4||||||SUMDIAM|SUM OF DIAMETER||UEQ/L|PRESENT||KBQ|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|NA|INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|4||88||WASHOUT|1966-06-14|
TRIAL STUDY 134XCP|TR|872942E9-A575-4929-9B21-D30DE51B367B|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||PMOL/10^10 CELLS|NORMAL||EID 50/DOSE|NOT DONE|||ELECTROMYOGRAPHY|N|U|DOMESTIC PARTNER|OTOLARYNGOLOGIST|Y|5||7||BASELINE|1960-05-30|
TRIAL STUDY 134XCP|TR|628822F3-4983-44F8-B98D-7A35AAFF2962|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MPL U/ML|FOCALLY INCREASED||AMOL|NOT DONE|||SEQUENCING|U|U|STUDY SUBJECT|MICROSCOPIST 2|U|1||38||TREATMENT|1964-06-22|
TRIAL STUDY 134XCP|TR|628822F3-4983-44F8-B98D-7A35AAFF2962|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NU/CL|FURTHER ENLARGEMENT FROM NADIR||ML*CMH2O|NOT DONE|||MYELOPEROXIDASE STAIN|Y|Y|SIBLING|RADIOLOGIST|Y|2||58||SCREENING|1966-10-01|
TRIAL STUDY 134XCP|TR|628822F3-4983-44F8-B98D-7A35AAFF2962|3||||||NEWCONF|NEW TUMOR CONFIRMED||MOL/ML|INCREASED||UG/M2/MIN|NOT DONE|||ETDRS EYE CHART|U|NA|GUARDIAN|RATER 2|U|3||39||WASHOUT|1968-04-16|
TRIAL STUDY 134XCP|TR|628822F3-4983-44F8-B98D-7A35AAFF2962|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||SEC|ABSENT||MM3/MM2/YEAR|NOT DONE|||TRANSVAGINAL ULTRASOUND|U|NA|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4||88||RUN-IN|1962-12-07|
TRIAL STUDY 134XCP|TR|628822F3-4983-44F8-B98D-7A35AAFF2962|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||GPS U|NORMAL||ML/(MIN*100ML)|NOT DONE|||PHASE-CONTRAST MRI|NA|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||FOLLOW-UP|1960-06-11|
TRIAL STUDY 134XCP|TR|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|1||||||AREA|AREA||CI/UG|NORMAL||UG/H|NOT DONE|||DYNAMOMETRY|U|N|GUARDIAN|RADIOLOGIST|NA|1||38||RUN-IN|1968-01-20|
TRIAL STUDY 134XCP|TR|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||IU/MG|DECREASED||BQ|NOT DONE|||ETDRS EYE CHART|Y|Y|FRIEND|PHYSIOTHERAPIST|U|2||58||OBSERVATION|1966-05-12|
TRIAL STUDY 134XCP|TR|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||ML/DOSE|TUMOR MERGED||PIPE|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|U|CHILD|PATHOLOGIST|U|3||39||FOLLOW-UP|1966-05-10|
TRIAL STUDY 134XCP|TR|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MOSM|NORMAL||OZ EQ|NOT DONE|||PHOTOGRAPHY|U|U|SIBLING|ONCOLOGIST 2|NA|4||88||SCREENING|1962-07-09|
TRIAL STUDY 134XCP|TR|E711F224-DE78-4B2E-9BF7-A5FEAAC4AB1A|5||||||LESFLIND|LESION FAILURE INDICATOR||UMOL/KG/MIN|PALPABLE||10^3 CFU/ML|NOT DONE|||MICROBIAL CONCENTRATION|U|U|ADJUDICATOR|ONCOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1970-09-21|
TRIAL STUDY 134XCP|TR|6045DFAB-0734-4E6D-A492-34BD613EC783|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||FARAD|ENLARGEMENT FROM NADIR||DIOPTER|NOT DONE|||DIPSTICK|N|U|ADJUDICATOR|OTOLARYNGOLOGIST|N|1||38||CONTINUATION TREATMENT|1961-10-19|
TRIAL STUDY 134XCP|TR|6045DFAB-0734-4E6D-A492-34BD613EC783|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UKAT/10^12 RBC|UNEQUIVOCAL||LOG10 CCID 50/DOSE|NOT DONE|||ICP-MS|N|NA|CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|2||58||SCREENING|1973-03-31|
TRIAL STUDY 134XCP|TR|6045DFAB-0734-4E6D-A492-34BD613EC783|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||DDU|FURTHER ENLARGEMENT FROM NADIR||ML/CM|NOT DONE|||PET SCAN|NA|N|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||WASHOUT|1972-12-29|
TRIAL STUDY 134XCP|TR|6045DFAB-0734-4E6D-A492-34BD613EC783|4||||||BNLNUM|NUMBER OF BONE LESIONS||DROP|PRESENT||/10^5|NOT DONE|||MICRONEUTRALIZATION ASSAY|N|NA|SIBLING|NEUROLOGIST 2|NA|4||88||OBSERVATION|1969-05-19|
TRIAL STUDY 134XCP|TR|6045DFAB-0734-4E6D-A492-34BD613EC783|5||||||CALCFIND|CALCIFICATION INDICATOR||TRACE|FOCALLY INCREASED||PIXELS/IN|NOT DONE|||FUNCTIONAL MRI|N|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5||7||INDUCTION TREATMENT|1963-04-20|
TRIAL STUDY 134XCP|TR|482F0519-E738-46DE-A5C4-4AC76B6E7011|1||||||ORVERLN|ORGAN VERTICAL LENGTH||CL|NONPALPABLE||L/MIN/M2|NOT DONE|||PALM METHOD|Y|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1||38||BASELINE|1969-04-11|
TRIAL STUDY 134XCP|TR|482F0519-E738-46DE-A5C4-4AC76B6E7011|2||||||LNSTATE|LYMPH NODE STATE||UOSM|PRESENT||FMOL/G|NOT DONE|||SLOAN LETTER EYE CHART 100%|U|U|VENDOR|OPTOMETRIST|U|2||58||RUN-IN|1961-03-08|
TRIAL STUDY 134XCP|TR|482F0519-E738-46DE-A5C4-4AC76B6E7011|3||||||LNSTATE|LYMPH NODE STATE||HEP|PATHOLOGICAL||KHZ|NOT DONE|||IMPEDANCE CONDUCTIVITY|Y|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|3||39||TREATMENT|1968-06-23|
TRIAL STUDY 134XCP|TR|482F0519-E738-46DE-A5C4-4AC76B6E7011|4||||||LESFLIND|LESION FAILURE INDICATOR||MSEC|PATHOLOGICAL||L/KG|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|Y|U|PROXY|READER|N|4||88||CONTINUATION TREATMENT|1972-04-19|
TRIAL STUDY 134XCP|TR|482F0519-E738-46DE-A5C4-4AC76B6E7011|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PMOL/DL|ENLARGEMENT FROM NADIR||UG/M2|NOT DONE|||DOUBLE IMMUNODIFFUSION|U|N|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|5||7||RUN-IN|1970-10-24|
TRIAL STUDY 134XCP|TR|DFDD42F5-749C-4AF0-8351-780DB9614F61|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PMOL/L|UNEQUIVOCAL||IU/G HB|NOT DONE|||PULSE OXIMETRY|U|NA|GUARDIAN|OPTOMETRIST|NA|1||38||FOLLOW-UP|1971-03-16|
TRIAL STUDY 134XCP|TR|DFDD42F5-749C-4AF0-8351-780DB9614F61|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MMOL|DIFFUSELY INCREASED||SEC|NOT DONE|||WESTERGREN|NA|NA|PARENT|RATER|Y|2||58||SCREENING|1960-09-29|
TRIAL STUDY 134XCP|TR|DFDD42F5-749C-4AF0-8351-780DB9614F61|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||FRAMES/S|ENLARGEMENT FROM NADIR||CS|NOT DONE|||TRYPAN BLUE STAIN|Y|N|INVESTIGATOR|UROLOGIST|Y|3||39||TREATMENT|1969-10-21|
TRIAL STUDY 134XCP|TR|DFDD42F5-749C-4AF0-8351-780DB9614F61|4||||||ORVERLN|ORGAN VERTICAL LENGTH||MG/KG|INCREASED||UG/L DDU|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|Y|U|SIBLING|MICROSCOPIST 2|U|4||88||RUN-IN|1968-01-09|
TRIAL STUDY 134XCP|TR|DFDD42F5-749C-4AF0-8351-780DB9614F61|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||SQU/ML|DIFFUSELY INCREASED||G/ANIMAL/WK|NOT DONE|||OPTICAL MAPPING|N|NA|SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|5||7||INDUCTION TREATMENT|1969-11-16|
TRIAL STUDY 134XCP|TR|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|1||||||VOLUME|VOLUME||ML/CAGE/DAY|PATHOLOGICAL||STEPS|NOT DONE|||CELL BASED BIOASSAY|Y|N|FAMILY MEMBER|ONCOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-02-25|
TRIAL STUDY 134XCP|TR|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||%|PATHOLOGICAL||MS/MMHG|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|N|Y|SIBLING|ADJUDICATOR 1|NA|2||58||INDUCTION TREATMENT|1961-12-21|
TRIAL STUDY 134XCP|TR|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MOL|ENLARGEMENT||MG/KG/MIN|NOT DONE|||HPLC/MS|U|NA|STUDY SUBJECT|PATHOLOGIST 1|N|3||39||LONG-TERM FOLLOW-UP|1967-03-03|
TRIAL STUDY 134XCP|TR|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|4||||||ORVERLN|ORGAN VERTICAL LENGTH||MG/MIN|FURTHER ENLARGEMENT FROM NADIR||MHZ|NOT DONE|||GC/MS/MS|U|U|CLINICAL STUDY SPONSOR|INTERNIST|NA|4||88||BLINDED TREATMENT|1964-04-07|
TRIAL STUDY 134XCP|TR|34BCECC4-8420-4B88-BD2E-0A20C4DCC5E0|5||||||LDIAM|LONGEST DIAMETER||10^6/G|ENLARGEMENT FROM NADIR||G/KG|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|Y|CHILD|READER|NA|5||7||RUN-IN|1964-10-11|
TRIAL STUDY 134XCP|TR|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CIGAR|PATHOLOGICAL||LOG10 TCID 50/ML|NOT DONE|||IMMUNOPRECIPITATION|U|U|SIBLING|OPHTHALMOLOGIST|NA|1||38||TREATMENT|1962-05-08|
TRIAL STUDY 134XCP|TR|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|2||||||ORVERLN|ORGAN VERTICAL LENGTH||MPS U|UNEQUIVOCAL||FRACTION OF 1|NOT DONE|||FARR ASSAY|N|N|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|2||58||BASELINE|1967-09-26|
TRIAL STUDY 134XCP|TR|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|3||||||VOLUME|VOLUME||IMPLANT|DECREASED||V/SEC|NOT DONE|||ANGIOGRAPHY|N|U|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|3||39||WASHOUT|1961-03-16|
TRIAL STUDY 134XCP|TR|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|4||||||VDIAM|VIABLE DIAMETER||CD*S/M2|ABSENT||G/M2/DAY|NOT DONE|||RAJI CELL RIA|NA|N|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1972-09-16|
TRIAL STUDY 134XCP|TR|4C4DCB9C-A2FB-4648-B2EF-DD484D221099|5||||||LNSTATE|LYMPH NODE STATE||PFU/ML|ENLARGEMENT FROM NADIR||MG/KG|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|Y|N|SIGNIFICANT OTHER|ONCOLOGIST|NA|5||7||OBSERVATION|1973-05-28|
TRIAL STUDY 134XCP|TR|E0434C66-0F59-476F-9913-55766C4AED1B|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||/LPF|NON-PATHOLOGICAL||U/KG/DAY|NOT DONE|||DNA MICROARRAY|U|NA|ADJUDICATOR|ONCOLOGIST 2|U|1||38||WASHOUT|1968-12-03|
TRIAL STUDY 134XCP|TR|E0434C66-0F59-476F-9913-55766C4AED1B|2||||||VSLPIND|VESSEL PATENCY INDICATOR||10^6 ORGANISMS/G|DECREASED||COPIES/UL|NOT DONE|||PET/CT SCAN|N|U|ADJUDICATOR|FORENSIC PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1967-10-22|
TRIAL STUDY 134XCP|TR|E0434C66-0F59-476F-9913-55766C4AED1B|3||||||VOLUME|VOLUME||KCAL/DAY|ENLARGEMENT||BISCUIT|NOT DONE|||CARDIAC THERMODILUTION|N|U|INTERVIEWER|ADJUDICATOR 3|U|3||39||OBSERVATION|1968-03-30|
TRIAL STUDY 134XCP|TR|E0434C66-0F59-476F-9913-55766C4AED1B|4||||||PALPSTAT|PALPABLE STATE||CPM|NONPALPABLE||FOZ_BR|NOT DONE|||IMPULSE OSCILLOMETRY|U|U|CAREGIVER|INTERNIST|NA|4||88||SCREENING|1972-04-28|
TRIAL STUDY 134XCP|TR|E0434C66-0F59-476F-9913-55766C4AED1B|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||UGEQ|NORMAL||PIPE|NOT DONE|||IMPULSE OSCILLOMETRY|Y|Y|FAMILY MEMBER|RADIOLOGIST 2|NA|5||7||TREATMENT|1961-11-28|
TRIAL STUDY 134XCP|TR|60B57F98-61FF-4322-8084-7A536964F60A|1||||||TUMSTATE|TUMOR STATE||MG/ANIMAL|ENLARGEMENT FROM NADIR||10^3 ORGANISMS|NOT DONE|||GC/MS|N|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|NA|1||38||INDUCTION TREATMENT|1970-09-01|
TRIAL STUDY 134XCP|TR|60B57F98-61FF-4322-8084-7A536964F60A|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||IU/MG|FURTHER ENLARGEMENT FROM NADIR||BOTTLE|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|N|FAMILY MEMBER|RATER|Y|2||58||LONG-TERM FOLLOW-UP|1970-03-04|
TRIAL STUDY 134XCP|TR|60B57F98-61FF-4322-8084-7A536964F60A|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CYCLE/MIN|ENLARGEMENT FROM NADIR||UL/DOSE|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|NA|INDEPENDENT ASSESSOR|RATER|N|3||39||OPEN LABEL TREATMENT|1966-12-03|
TRIAL STUDY 134XCP|TR|60B57F98-61FF-4322-8084-7A536964F60A|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KM|ENLARGEMENT FROM NADIR||BOX|NOT DONE|||FUNDUS PHOTOGRAPHY|Y|N|DOMESTIC PARTNER|ONCOLOGIST 1|Y|4||88||OBSERVATION|1966-03-26|
TRIAL STUDY 134XCP|TR|60B57F98-61FF-4322-8084-7A536964F60A|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||LOG10 PFU|PRESENT||MG/M2/DAY|NOT DONE|||URANYL ACETATE STAIN|U|U|CHILD|MICROSCOPIST|U|5||7||RUN-IN|1966-10-27|
TRIAL STUDY 134XCP|TR|C79CA198-24E2-4A76-8C32-F3AA973EA41E|1||||||LPERP|LONGEST PERPENDICULAR||VP/ML|NORMAL||UG/DOSE|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|Y|Y|PROXY|RADIOLOGIST|NA|1||38||SCREENING|1964-08-13|
TRIAL STUDY 134XCP|TR|C79CA198-24E2-4A76-8C32-F3AA973EA41E|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||BU|UNCHANGED||DEG|NOT DONE|||WESTERN BLOT|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|2||58||OBSERVATION|1967-11-26|
TRIAL STUDY 134XCP|TR|C79CA198-24E2-4A76-8C32-F3AA973EA41E|3||||||AREA|AREA||U/M2/DAY|PRESENT||BEATS/MIN|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|U|Y|SIGNIFICANT OTHER|PATHOLOGIST 2|Y|3||39||TREATMENT|1970-07-29|
TRIAL STUDY 134XCP|TR|C79CA198-24E2-4A76-8C32-F3AA973EA41E|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||V/V|PATHOLOGICAL||BOTTLE|NOT DONE|||GC/FID|U|U|PARENT|ADJUDICATOR 3|Y|4||88||LONG-TERM FOLLOW-UP|1969-02-21|
TRIAL STUDY 134XCP|TR|C79CA198-24E2-4A76-8C32-F3AA973EA41E|5||||||TUMSTATE|TUMOR STATE||ML/MIN/MMHG|PRESENT||U/G HB|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|U|N|PARENT|RADIOLOGIST 2|U|5||7||FOLLOW-UP|1963-09-07|
TRIAL STUDY 134XCP|TR|D250194D-9BBD-40D3-A13B-BBCEB53DB450|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||RFU|PATHOLOGICAL||MU/L|NOT DONE|||FLOCCULATION|U|Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|1||38||BLINDED TREATMENT|1963-12-23|
TRIAL STUDY 134XCP|TR|D250194D-9BBD-40D3-A13B-BBCEB53DB450|2||||||ORSTATE|ORGAN STATE||OSM|DIFFUSELY INCREASED||NMOL/ML/MIN|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|N|SPOUSE|ADJUDICATOR 2|Y|2||58||OBSERVATION|1968-08-08|
TRIAL STUDY 134XCP|TR|D250194D-9BBD-40D3-A13B-BBCEB53DB450|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||UG/KG|NONPALPABLE||MG/G/MIN|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|U|U|FRIEND|RADIOLOGIST 2|NA|3||39||BLINDED TREATMENT|1967-09-20|
TRIAL STUDY 134XCP|TR|D250194D-9BBD-40D3-A13B-BBCEB53DB450|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/MG|PATHOLOGICAL||U/ML|NOT DONE|||JAFFE REACTION|U|N|SIBLING|ONCOLOGIST 2|NA|4||88||BLINDED TREATMENT|1963-01-29|
TRIAL STUDY 134XCP|TR|D250194D-9BBD-40D3-A13B-BBCEB53DB450|5||||||VSLPIND|VESSEL PATENCY INDICATOR||SYRINGE|FURTHER ENLARGEMENT FROM NADIR||BQ/L|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|U|N|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-12-01|
TRIAL STUDY 134XCP|TR|369AE0AF-8693-4363-9A6E-CD30567BD614|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MV*MIN|UNCHANGED||RAD|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|NA|NA|CLINICAL RESEARCH ASSOCIATE|RATER|Y|1||38||INDUCTION TREATMENT|1960-01-15|
TRIAL STUDY 134XCP|TR|369AE0AF-8693-4363-9A6E-CD30567BD614|2||||||ORSTATE|ORGAN STATE||ML/(MIN*100ML)|DECREASED||YEARS|NOT DONE|||CONTRAST ENHANCED X-RAY|N|N|ADJUDICATOR|ADJUDICATOR|U|2||58||SCREENING|1962-10-31|
TRIAL STUDY 134XCP|TR|369AE0AF-8693-4363-9A6E-CD30567BD614|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||U/G/DAY|TUMOR MERGED||PLUG|NOT DONE|||QUANTITATIVE ULTRASOUND|Y|N|FRIEND|CLINICAL PATHOLOGIST|NA|3||39||WASHOUT|1973-04-21|
TRIAL STUDY 134XCP|TR|369AE0AF-8693-4363-9A6E-CD30567BD614|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||PSEC|NORMAL||IU/KG/H|NOT DONE|||SMEAR|N|NA|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|4||88||RUN-IN|1964-02-22|
TRIAL STUDY 134XCP|TR|369AE0AF-8693-4363-9A6E-CD30567BD614|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PA|TUMOR MERGED||MG/KG/MIN|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|U|N|SPOUSE|NEUROLOGIST 2|N|5||7||RUN-IN|1967-10-02|
TRIAL STUDY 134XCP|TR|4497DB94-5B91-4169-9D73-73EE5C1D9B76|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||HOUNSFIELD UNIT|ABSENT||MG/DAY|NOT DONE|||DIGITAL PCR ARRAY|U|N|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|1||38||FOLLOW-UP|1963-09-26|
TRIAL STUDY 134XCP|TR|4497DB94-5B91-4169-9D73-73EE5C1D9B76|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||RNA COPIES/ML|INCREASED||/SEC|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|NA|N|VENDOR|READER 1|NA|2||58||SCREENING|1970-06-21|
TRIAL STUDY 134XCP|TR|4497DB94-5B91-4169-9D73-73EE5C1D9B76|3||||||NEWCONF|NEW TUMOR CONFIRMED||PPM|UNCHANGED||SPRAY|NOT DONE|||GC/MS|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|3||39||RUN-IN|1969-03-18|
TRIAL STUDY 134XCP|TR|4497DB94-5B91-4169-9D73-73EE5C1D9B76|4||||||CALCFIND|CALCIFICATION INDICATOR||OHM|ABSENT||MEQ/DAY|NOT DONE|||PERFUSION MRI|NA|Y|VENDOR|READER 3|U|4||88||OPEN LABEL TREATMENT|1962-08-26|
TRIAL STUDY 134XCP|TR|4497DB94-5B91-4169-9D73-73EE5C1D9B76|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^4 CFU|UNEQUIVOCAL||CI/L|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|U|Y|CAREGIVER|READER 2|U|5||7||WASHOUT|1966-02-21|
TRIAL STUDY 134XCP|TR|487D7E2D-6E7E-4A5E-ADC7-72B888746263|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||NMOL/DAY|PATHOLOGICAL||MU/G|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|N|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1||38||SCREENING|1966-04-21|
TRIAL STUDY 134XCP|TR|487D7E2D-6E7E-4A5E-ADC7-72B888746263|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||DEG|PRESENT||G/ANIMAL/DAY|NOT DONE|||CINEANGIOGRAPHY|NA|U|VENDOR|PATHOLOGIST|U|2||58||OPEN LABEL TREATMENT|1973-08-18|
TRIAL STUDY 134XCP|TR|487D7E2D-6E7E-4A5E-ADC7-72B888746263|3||||||LMBFLIND|LIMB FAILURE INDICATOR||MV*MIN|UNEQUIVOCAL||M/SEC2|NOT DONE|||ULTRASOUND|Y|N|PROXY|ADJUDICATOR 1|U|3||39||TREATMENT|1960-05-16|
TRIAL STUDY 134XCP|TR|487D7E2D-6E7E-4A5E-ADC7-72B888746263|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||USIEMENS|EQUIVOCAL||G/KG|NOT DONE|||MAMMOGRAPHY|Y|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|4||88||OPEN LABEL TREATMENT|1962-08-18|
TRIAL STUDY 134XCP|TR|487D7E2D-6E7E-4A5E-ADC7-72B888746263|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||H*%|ABSENT||DYN|NOT DONE|||PHOTOGRAPHY|Y|Y|VENDOR|RATER 1|Y|5||7||CONTINUATION TREATMENT|1968-01-04|
TRIAL STUDY 134XCP|TR|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NKAT/G HB|FOCALLY INCREASED||PUFF|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|NA|U|CLINICAL STUDY SPONSOR|READER 1|U|1||38||OPEN LABEL TREATMENT|1964-10-08|
TRIAL STUDY 134XCP|TR|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||PFU/DOSE|FURTHER ENLARGEMENT||IU/DAY|NOT DONE|||DIFFUSION TENSOR MRI|NA|N|FRIEND|OTOLARYNGOLOGIST|Y|2||58||CONTINUATION TREATMENT|1967-06-09|
TRIAL STUDY 134XCP|TR|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MMOL/G|FURTHER ENLARGEMENT||EP U|NOT DONE|||TRIPLE-PHASE MRI SCAN|Y|Y|CAREGIVER|PHYSIOTHERAPIST|N|3||39||LONG-TERM FOLLOW-UP|1964-11-04|
TRIAL STUDY 134XCP|TR|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||/4.0 ML|FURTHER ENLARGEMENT||BAU|NOT DONE|||IODINE STAIN|U|NA|FRIEND|RADIOLOGIST|U|4||88||BLINDED TREATMENT|1963-10-27|
TRIAL STUDY 134XCP|TR|7A0B521C-9CAB-4415-87C3-AF7A33AE9895|5||||||LNSTATE|LYMPH NODE STATE||MG/H|ENLARGEMENT FROM NADIR||MMOL/G|NOT DONE|||EPSILOMETER|NA|Y|INTERVIEWER|PATHOLOGIST 1|NA|5||7||OPEN LABEL TREATMENT|1964-11-12|
TRIAL STUDY 134XCP|TR|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||/10^3|PALPABLE||COULOMB|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|N|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|1||38||INDUCTION TREATMENT|1966-05-24|
TRIAL STUDY 134XCP|TR|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MJOULE/CM2|DIFFUSELY INCREASED||UV|NOT DONE|||OLIGO ACGH|U|NA|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||TREATMENT|1960-08-28|
TRIAL STUDY 134XCP|TR|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||/SEC|EQUIVOCAL||MBP|NOT DONE|||WESTERN BLOT|U|N|INTERVIEWER|PATHOLOGIST|U|3||39||BLINDED TREATMENT|1962-12-07|
TRIAL STUDY 134XCP|TR|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|4||||||AREA|AREA||CMOL/L|FURTHER ENLARGEMENT||JDF UNIT|NOT DONE|||PET SCAN|N|Y|INDEPENDENT ASSESSOR|RATER 2|NA|4||88||BLINDED TREATMENT|1973-07-08|
TRIAL STUDY 134XCP|TR|EA12FF8E-3FA0-4C21-8FA4-FFC1D6817D3A|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MM2|DIFFUSELY INCREASED||L/KG|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|N|PARENT|MICROSCOPIST 2|U|5||7||WASHOUT|1961-12-19|
TRIAL STUDY 134XCP|TR|8BF6E538-2F39-48E4-B115-AE1693843BBC|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||%(W/W)|FURTHER ENLARGEMENT||JDF UNIT|NOT DONE|||ETDRS EYE CHART|U|N|SIBLING|ENDOCRINOLOGIST|N|1||38||CONTINUATION TREATMENT|1962-09-16|
TRIAL STUDY 134XCP|TR|8BF6E538-2F39-48E4-B115-AE1693843BBC|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MCI/KG|NON-PATHOLOGICAL||HPA|NOT DONE|||INFRARED SPECTROMETRY|Y|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|2||58||BLINDED TREATMENT|1971-10-11|
TRIAL STUDY 134XCP|TR|8BF6E538-2F39-48E4-B115-AE1693843BBC|3||||||TUMSTATE|TUMOR STATE||RING|FOCALLY INCREASED||LOG10 TCID 50/DOSE|NOT DONE|||ELECTROMYOGRAPHY|N|N|SIBLING|ONCOLOGIST|N|3||39||WASHOUT|1960-05-28|
TRIAL STUDY 134XCP|TR|8BF6E538-2F39-48E4-B115-AE1693843BBC|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||USEC|UNEQUIVOCAL||NMOL/KG/DAY|NOT DONE|||SXA SCAN|N|Y|PROXY|MICROSCOPIST|N|4||88||TREATMENT|1968-07-30|
TRIAL STUDY 134XCP|TR|8BF6E538-2F39-48E4-B115-AE1693843BBC|5||||||SUMDIAM|SUM OF DIAMETER||ML/ANIMAL/DAY|EQUIVOCAL||PRESSOR UNITS|NOT DONE|||NO INFORMATION|Y|U|DOMESTIC PARTNER|HEMATOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1961-01-06|
TRIAL STUDY 134XCP|TR|57F001BC-36EB-44AF-9487-373FA31B7311|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||OZ|PALPABLE||/VF|NOT DONE|||KARYOTYPING|Y|Y|CHILD|ADJUDICATOR 2|NA|1||38||BLINDED TREATMENT|1964-03-30|
TRIAL STUDY 134XCP|TR|57F001BC-36EB-44AF-9487-373FA31B7311|2||||||AREA|AREA||CI/G|TUMOR MERGED||UV2|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|N|N|CAREGIVER|ADJUDICATOR 3|Y|2||58||SCREENING|1966-07-11|
TRIAL STUDY 134XCP|TR|57F001BC-36EB-44AF-9487-373FA31B7311|3||||||SUMDIAM|SUM OF DIAMETER||KG/M2|INCREASED||JDF UNIT|NOT DONE|||DIFFUSION WEIGHTED MRI|Y|N|GUARDIAN|RATER 1|Y|3||39||BASELINE|1962-07-17|
TRIAL STUDY 134XCP|TR|57F001BC-36EB-44AF-9487-373FA31B7311|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ELISA UNIT|ABSENT||OI50|NOT DONE|||U-HPLC/MS/MS|Y|N|ADJUDICATOR|CARDIOLOGIST|NA|4||88||INDUCTION TREATMENT|1963-01-10|
TRIAL STUDY 134XCP|TR|57F001BC-36EB-44AF-9487-373FA31B7311|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||L/S/KPA|INCREASED||MIU/L|NOT DONE|||LISSAMINE GREEN STAIN|NA|N|VENDOR|RADIOLOGIST|N|5||7||BASELINE|1964-06-15|
TRIAL STUDY 134XCP|TR|3FBDC961-EB02-4B28-8672-2A0A0A33529E|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||S^-1(%O2)^-1|INCREASED||STRIP|NOT DONE|||ANGIOGRAPHY|U|NA|INDEPENDENT ASSESSOR|RATER 2|N|1||38||RUN-IN|1969-07-12|
TRIAL STUDY 134XCP|TR|3FBDC961-EB02-4B28-8672-2A0A0A33529E|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UCI|DECREASED||DEG|NOT DONE|||CLIP SEQUENCING|Y|U|SPOUSE|READER|NA|2||58||CONTINUATION TREATMENT|1970-03-17|
TRIAL STUDY 134XCP|TR|3FBDC961-EB02-4B28-8672-2A0A0A33529E|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||USP U|TUMOR MERGED||BAG|NOT DONE|||NEXT GENERATION SEQUENCING|Y|N|STUDY SUBJECT|READER|N|3||39||RUN-IN|1970-11-24|
TRIAL STUDY 134XCP|TR|3FBDC961-EB02-4B28-8672-2A0A0A33529E|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CPM|DIFFUSELY INCREASED||KIU|NOT DONE|||MULTI-SLICE SPIRAL CT|NA|Y|PARENT|FORENSIC PATHOLOGIST|N|4||88||OBSERVATION|1964-05-13|
TRIAL STUDY 134XCP|TR|3FBDC961-EB02-4B28-8672-2A0A0A33529E|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MPA|DIFFUSELY INCREASED||MEQ/ML|NOT DONE|||CONGO RED STAIN|Y|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|5||7||BASELINE|1960-08-28|
TRIAL STUDY 134XCP|TR|1B524FC4-365B-4A16-A4D7-ED818C6E6086|1||||||SUMDIAM|SUM OF DIAMETER||/CMH2O|ENLARGEMENT||DAGU/ML|NOT DONE|||WRIGHT-GIEMSA STAIN|N|Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|1||38||SCREENING|1964-03-23|
TRIAL STUDY 134XCP|TR|1B524FC4-365B-4A16-A4D7-ED818C6E6086|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UG/G/DAY|NORMAL||BAU|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|NA|Y|ADJUDICATION COMMITTEE|READER 1|Y|2||58||OPEN LABEL TREATMENT|1963-08-14|
TRIAL STUDY 134XCP|TR|1B524FC4-365B-4A16-A4D7-ED818C6E6086|3||||||AREA|AREA||PG/DL|DIFFUSELY INCREASED||APL U|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|Y|FAMILY MEMBER|NEUROLOGIST|U|3||39||BASELINE|1973-05-30|
TRIAL STUDY 134XCP|TR|1B524FC4-365B-4A16-A4D7-ED818C6E6086|4||||||LNSTATE|LYMPH NODE STATE||VG/ML|UNCHANGED||TORR|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|N|NA|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|4||88||FOLLOW-UP|1960-05-04|
TRIAL STUDY 134XCP|TR|1B524FC4-365B-4A16-A4D7-ED818C6E6086|5||||||SUMVOL|SUM OF VOLUME||10^6 CFU|EQUIVOCAL||H/WK|NOT DONE|||U-HPLC/MS/MS|Y|U|FAMILY MEMBER|PHYSIOTHERAPIST|N|5||7||OBSERVATION|1966-10-10|
TRIAL STUDY 134XCP|TR|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MMHG/SEC|PATHOLOGICAL||U/KG/DAY|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|NA|U|FRIEND|RADIOLOGIST 1|N|1||38||WASHOUT|1960-06-11|
TRIAL STUDY 134XCP|TR|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|2||||||DIAMETER|DIAMETER||U/M2|NONPALPABLE||MJOULE/CM2|NOT DONE|||MRI|Y|U|CHILD|UROLOGIST|U|2||58||OPEN LABEL TREATMENT|1969-03-24|
TRIAL STUDY 134XCP|TR|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||AMFI|UNEQUIVOCAL||APL U|NOT DONE|||ICC|U|Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|3||39||BLINDED TREATMENT|1971-12-19|
TRIAL STUDY 134XCP|TR|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||KN/CM2|NON-PATHOLOGICAL||MU/G|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|U|SIBLING|PATHOLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1970-07-16|
TRIAL STUDY 134XCP|TR|CC020A55-6788-43C6-9D9F-91EFA1ECD46C|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||/KG|UNCHANGED||10^6/L|NOT DONE|||MYELOPEROXIDASE STAIN|U|U|INTERVIEWER|CLINICAL PATHOLOGIST|N|5||7||SCREENING|1972-08-14|
TRIAL STUDY 134XCP|TR|27671577-2C6D-429F-BED9-0EDAB15CCB33|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||TSP|NON-PATHOLOGICAL||SIEMENS|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|U|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|1||38||RUN-IN|1967-11-08|
TRIAL STUDY 134XCP|TR|27671577-2C6D-429F-BED9-0EDAB15CCB33|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||NEBULE|ENLARGEMENT FROM NADIR||DB|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|Y|N|SIGNIFICANT OTHER|NEUROLOGIST 2|N|2||58||OBSERVATION|1960-05-29|
TRIAL STUDY 134XCP|TR|27671577-2C6D-429F-BED9-0EDAB15CCB33|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||GRAVITATIONAL UNIT|FURTHER ENLARGEMENT||GAUSS|NOT DONE|||SPECT SCAN|U|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|3||39||FOLLOW-UP|1969-06-29|
TRIAL STUDY 134XCP|TR|27671577-2C6D-429F-BED9-0EDAB15CCB33|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||DPM/MG|PATHOLOGICAL||IU/G|NOT DONE|||LC/MS|Y|NA|VENDOR|PATHOLOGIST 1|N|4||88||BASELINE|1966-12-17|
TRIAL STUDY 134XCP|TR|27671577-2C6D-429F-BED9-0EDAB15CCB33|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||M|ABSENT||PMOL/DAY|NOT DONE|||PELLI-ROBSON EYE CHART|U|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||FOLLOW-UP|1964-06-07|
TRIAL STUDY 134XCP|TR|CD69750D-957B-405C-A397-AFA331D30535|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||NMOL/MOL|DECREASED||/2500 WBC|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|N|Y|FAMILY MEMBER|RADIOLOGIST 2|NA|1||38||BASELINE|1961-09-18|
TRIAL STUDY 134XCP|TR|CD69750D-957B-405C-A397-AFA331D30535|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||ML/G/H|DIFFUSELY INCREASED||EVENTS|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|NA|N|CHILD|OPTOMETRIST|NA|2||58||SCREENING|1972-08-17|
TRIAL STUDY 134XCP|TR|CD69750D-957B-405C-A397-AFA331D30535|3||||||BNLNUM|NUMBER OF BONE LESIONS||GBQ/MG|ABSENT||L/MIN/M2|NOT DONE|||LIQUID SCINTILLATION COUNTING|N|U|INTERVIEWER|ONCOLOGIST 2|NA|3||39||CONTINUATION TREATMENT|1969-11-27|
TRIAL STUDY 134XCP|TR|CD69750D-957B-405C-A397-AFA331D30535|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||10^4/HPF|INCREASED||G/U|NOT DONE|||VIRUS PLAQUE ASSAY|Y|U|GUARDIAN|READER 2|Y|4||88||BASELINE|1972-02-06|
TRIAL STUDY 134XCP|TR|CD69750D-957B-405C-A397-AFA331D30535|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MU/L|NORMAL||MS2|NOT DONE|||QUANTITATIVE ULTRASOUND|NA|U|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||SCREENING|1973-07-08|
TRIAL STUDY 134XCP|TR|5BFDDFC2-7D15-4B01-8140-62376D160EF0|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MET*H|UNEQUIVOCAL||CUP|NOT DONE|||DIPSTICK|Y|NA|FRIEND|CLINICAL PATHOLOGIST|U|1||38||TREATMENT|1970-09-21|
TRIAL STUDY 134XCP|TR|5BFDDFC2-7D15-4B01-8140-62376D160EF0|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||/40 HPFS|UNCHANGED||UL/DOSE|NOT DONE|||KNEMOMETRY|NA|N|HEALTH CARE PROFESSIONAL|INTERNIST|NA|2||58||FOLLOW-UP|1965-03-09|
TRIAL STUDY 134XCP|TR|5BFDDFC2-7D15-4B01-8140-62376D160EF0|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||USEC|UNCHANGED||ML/100G/MIN|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|3||39||WASHOUT|1966-07-22|
TRIAL STUDY 134XCP|TR|5BFDDFC2-7D15-4B01-8140-62376D160EF0|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||/500 WBC|EQUIVOCAL||ML/M2/H|NOT DONE|||CINEANGIOGRAPHY|U|Y|PARENT|PHYSIOTHERAPIST|U|4||88||OBSERVATION|1963-01-04|
TRIAL STUDY 134XCP|TR|5BFDDFC2-7D15-4B01-8140-62376D160EF0|5||||||SUMDIAM|SUM OF DIAMETER||10^6 ORGANISMS/MG|NORMAL||IU/G|NOT DONE|||TONOMETRY|NA|Y|SIBLING|PEDIATRIC NEUROLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1962-06-15|
TRIAL STUDY 134XCP|TR|DEA8E573-2709-41F9-AB0D-8C39F5169B48|1||||||CALCFIND|CALCIFICATION INDICATOR||MOSM|FURTHER ENLARGEMENT FROM NADIR||ML/KG/DAY|NOT DONE|||JAEGER EYE CHART|U|U|PARENT|NEUROLOGIST|NA|1||38||RUN-IN|1966-02-05|
TRIAL STUDY 134XCP|TR|DEA8E573-2709-41F9-AB0D-8C39F5169B48|2||||||LESFLIND|LESION FAILURE INDICATOR||CM|UNEQUIVOCAL||FG|NOT DONE|||ELASTOGRAPHY|NA|U|CAREGIVER|PATHOLOGIST 2|N|2||58||BASELINE|1965-11-07|
TRIAL STUDY 134XCP|TR|DEA8E573-2709-41F9-AB0D-8C39F5169B48|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UG/DAY|FURTHER ENLARGEMENT FROM NADIR||GENEQ/ML|NOT DONE|||FLUORESCENT MICROSCOPY|NA|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||INDUCTION TREATMENT|1972-04-17|
TRIAL STUDY 134XCP|TR|DEA8E573-2709-41F9-AB0D-8C39F5169B48|4||||||LPERP|LONGEST PERPENDICULAR||L/L|DECREASED||RING|NOT DONE|||DYNAMOMETRY|U|Y|CHILD|PATHOLOGIST 1|U|4||88||RUN-IN|1962-11-21|
TRIAL STUDY 134XCP|TR|DEA8E573-2709-41F9-AB0D-8C39F5169B48|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MG|NONPALPABLE||GRAVITATIONAL UNIT|NOT DONE|||COLORIMETRY|NA|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||SCREENING|1961-10-15|
TRIAL STUDY 134XCP|TR|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|1||||||DIAMETER|DIAMETER||CUP EQ|UNCHANGED||U/CL|NOT DONE|||IMMUNOFLUORESCENT STAIN|Y|N|STUDY SUBJECT|MICROSCOPIST 1|Y|1||38||INDUCTION TREATMENT|1969-09-08|
TRIAL STUDY 134XCP|TR|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||APL U|FURTHER ENLARGEMENT||%(W/V)|NOT DONE|||APPLANATION TONOMETRY|Y|N|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|2||58||SCREENING|1964-03-25|
TRIAL STUDY 134XCP|TR|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|3||||||SUMDIAM|SUM OF DIAMETER||L/KG|UNEQUIVOCAL||DNA COPIES/ML|NOT DONE|||DIGITAL PCR|NA|NA|FAMILY MEMBER|ENDOCRINOLOGIST|Y|3||39||WASHOUT|1964-04-20|
TRIAL STUDY 134XCP|TR|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|4||||||LNSTATE|LYMPH NODE STATE||ML/MMHG|UNCHANGED||MEQ/MMOL|NOT DONE|||POLYSOMNOGRAPHY|N|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|4||88||INDUCTION TREATMENT|1973-04-08|
TRIAL STUDY 134XCP|TR|7A5D0D82-4B9C-47A8-8BB1-C3DB4525942F|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UG/CM2|DIFFUSELY INCREASED||NMOL/L|NOT DONE|||INTERRUPTER TECHNIQUE|NA|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|5||7||SCREENING|1961-07-07|
TRIAL STUDY 134XCP|TR|77CF8795-CFF5-40C6-A811-624972806A38|1||||||LDIAM|LONGEST DIAMETER||CI/MG|UNCHANGED||GY|NOT DONE|||IMMUNOFLUORESCENT STAIN|NA|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|NA|1||38||BASELINE|1972-11-19|
TRIAL STUDY 134XCP|TR|77CF8795-CFF5-40C6-A811-624972806A38|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MM|TUMOR MERGED||S^-1(%O2)^-1|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|U|NA|DOMESTIC PARTNER|ADJUDICATOR 3|U|2||58||SCREENING|1971-05-17|
TRIAL STUDY 134XCP|TR|77CF8795-CFF5-40C6-A811-624972806A38|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||10^6 ORGANISMS/G|DIFFUSELY INCREASED||/MONTH|NOT DONE|||FLUORESCENT SPOT TEST|Y|Y|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|3||39||OBSERVATION|1966-01-05|
TRIAL STUDY 134XCP|TR|77CF8795-CFF5-40C6-A811-624972806A38|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||DIOPTER|TUMOR MERGED||IU/ML|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|NA|U|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|4||88||OBSERVATION|1972-06-21|
TRIAL STUDY 134XCP|TR|77CF8795-CFF5-40C6-A811-624972806A38|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||L/MIN|NONPALPABLE||IMPLANT|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|5||7||SCREENING|1966-03-03|
TRIAL STUDY 134XCP|TR|D43B827C-D393-41D4-81C5-AACB1A7673A1|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/U|DIFFUSELY INCREASED||10^9 CFU|NOT DONE|||FISH|Y|N|INVESTIGATOR|ADJUDICATOR 2|U|1||38||RUN-IN|1964-03-21|
TRIAL STUDY 134XCP|TR|D43B827C-D393-41D4-81C5-AACB1A7673A1|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UCI|PATHOLOGICAL||MMOL/S|NOT DONE|||CONTRAST ENHANCED PET SCAN|N|NA|GUARDIAN|MICROSCOPIST|Y|2||58||FOLLOW-UP|1960-11-03|
TRIAL STUDY 134XCP|TR|D43B827C-D393-41D4-81C5-AACB1A7673A1|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MET*H|PALPABLE||V|NOT DONE|||POPULATION SEQUENCING|Y|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|3||39||INDUCTION TREATMENT|1963-03-15|
TRIAL STUDY 134XCP|TR|D43B827C-D393-41D4-81C5-AACB1A7673A1|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MCI/KG|FURTHER ENLARGEMENT FROM NADIR||LENS|NOT DONE|||MACRO BROTH DILUTION|NA|Y|CHILD|OPTOMETRIST|NA|4||88||BASELINE|1966-06-08|
TRIAL STUDY 134XCP|TR|D43B827C-D393-41D4-81C5-AACB1A7673A1|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||M/SEC2|FURTHER ENLARGEMENT FROM NADIR||BAR|NOT DONE|||CRYOSCOPY|Y|NA|SPOUSE|RATER|Y|5||7||LONG-TERM FOLLOW-UP|1971-05-26|
TRIAL STUDY 134XCP|TR|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|1||||||BNLNUM|NUMBER OF BONE LESIONS||AMP|FURTHER ENLARGEMENT||U/M2/MIN|NOT DONE|||FLOCCULATION|N|N|NON-HEALTH CARE PROFESSIONAL|RATER|N|1||38||OBSERVATION|1961-01-06|
TRIAL STUDY 134XCP|TR|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||FL|NORMAL||VOXEL|NOT DONE|||MICROBIAL CONCENTRATION|U|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1970-11-22|
TRIAL STUDY 134XCP|TR|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MAC50|UNCHANGED||MMOL/MIN/KPA|NOT DONE|||SMEAR|U|N|STUDY SUBJECT|ADJUDICATOR 2|N|3||39||INDUCTION TREATMENT|1968-10-23|
TRIAL STUDY 134XCP|TR|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UMOL/MG/MIN|UNEQUIVOCAL||UU/DL|NOT DONE|||KLEIHAUER-BETKE|Y|N|STUDY SUBJECT|MICROSCOPIST|U|4||88||FOLLOW-UP|1967-11-06|
TRIAL STUDY 134XCP|TR|6F4B91C6-AFBB-49B6-BF12-22DD1B04F161|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||LINEAR FT*LB|UNEQUIVOCAL||FMOL|NOT DONE|||SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|NA|Y|FRIEND|ONCOLOGIST 2|U|5||7||INDUCTION TREATMENT|1965-09-06|
TRIAL STUDY 134XCP|TR|0671FB62-42B8-4882-93ED-0E11CFE07DE9|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MV/SEC|ABSENT||GLOBULE|NOT DONE|||DIPSTICK|N|NA|FRIEND|NEUROLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1964-07-10|
TRIAL STUDY 134XCP|TR|0671FB62-42B8-4882-93ED-0E11CFE07DE9|2||||||LDIAM|LONGEST DIAMETER||MIN/DAY|NONPALPABLE||UG/ML/H|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|NA|N|INTERVIEWER|NEUROLOGIST|N|2||58||CONTINUATION TREATMENT|1973-07-30|
TRIAL STUDY 134XCP|TR|0671FB62-42B8-4882-93ED-0E11CFE07DE9|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||NMOL/ML/MIN|UNCHANGED||10^9 ORGANISMS|NOT DONE|||GC/MS-CI|Y|Y|SIBLING|OTOLARYNGOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1962-01-31|
TRIAL STUDY 134XCP|TR|0671FB62-42B8-4882-93ED-0E11CFE07DE9|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||U/MMOL|NON-PATHOLOGICAL||MPL U/ML|NOT DONE|||PERCUSSION|Y|NA|PARENT|RATER 1|Y|4||88||OBSERVATION|1973-08-21|
TRIAL STUDY 134XCP|TR|0671FB62-42B8-4882-93ED-0E11CFE07DE9|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||COULOMB|FURTHER ENLARGEMENT FROM NADIR||PG/CELL|NOT DONE|||CALCULATION|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|5||7||BLINDED TREATMENT|1960-04-10|
TRIAL STUDY 134XCP|TR|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||CUP|TUMOR MERGED||GMFI|NOT DONE|||FLUORIMETRY|U|N|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|1||38||RUN-IN|1965-02-27|
TRIAL STUDY 134XCP|TR|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||UMOL/L/SEC|ENLARGEMENT||UMOL/DAY|NOT DONE|||AUSCULTATION|U|Y|INVESTIGATOR|OPHTHALMOLOGIST|N|2||58||BASELINE|1969-08-20|
TRIAL STUDY 134XCP|TR|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||UMOL/H/MMOL|PATHOLOGICAL||PNU/ML|NOT DONE|||MRS|NA|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|3||39||OBSERVATION|1972-07-15|
TRIAL STUDY 134XCP|TR|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||PMOL/10^9 CELLS|DECREASED||IN|NOT DONE|||ETDRS EYE CHART|Y|U|PROXY|OPHTHALMOLOGIST|U|4||88||RUN-IN|1963-01-07|
TRIAL STUDY 134XCP|TR|BB1EBF44-CC91-4B86-91E5-2B1000161DFD|5||||||AREA|AREA||UM/S|UNCHANGED||K|NOT DONE|||CELLULAR PROLIFERATION ASSAY|NA|NA|FRIEND|READER|Y|5||7||CONTINUATION TREATMENT|1971-11-06|
TRIAL STUDY 134XCP|TR|E9161164-3B91-4855-AFBA-12C6BD93F95F|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||TUBERCULIN UNIT|TUMOR MERGED||NCI|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|U|N|PARENT|OTOLARYNGOLOGIST|Y|1||38||INDUCTION TREATMENT|1967-12-01|
TRIAL STUDY 134XCP|TR|E9161164-3B91-4855-AFBA-12C6BD93F95F|2||||||VOLUME|VOLUME||BEL|INCREASED||PNU/ML|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|N|U|ADJUDICATOR|DERMATOLOGIST|NA|2||58||INDUCTION TREATMENT|1967-12-07|
TRIAL STUDY 134XCP|TR|E9161164-3B91-4855-AFBA-12C6BD93F95F|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||PPTR|PALPABLE||FMOL|NOT DONE|||U-HPLC/MS/MS|NA|Y|ADJUDICATOR|MICROSCOPIST 2|NA|3||39||CONTINUATION TREATMENT|1970-07-17|
TRIAL STUDY 134XCP|TR|E9161164-3B91-4855-AFBA-12C6BD93F95F|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MSEC|UNEQUIVOCAL||SPRAY|NOT DONE|||FLOCCULATION|NA|N|FRIEND|ONCOLOGIST|N|4||88||INDUCTION TREATMENT|1965-01-09|
TRIAL STUDY 134XCP|TR|E9161164-3B91-4855-AFBA-12C6BD93F95F|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^6 CFU/G|ABSENT||DAGU/ML|NOT DONE|||IMMUNORADIOMETRIC ASSAY|N|U|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|5||7||OPEN LABEL TREATMENT|1960-09-05|
TRIAL STUDY 134XCP|TR|FBB66C13-05F5-4337-B34A-9900EB5F50F3|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MNFI|NONPALPABLE||MG2/DL2|NOT DONE|||CISH|U|Y|CHILD|MICROSCOPIST|NA|1||38||LONG-TERM FOLLOW-UP|1964-08-03|
TRIAL STUDY 134XCP|TR|FBB66C13-05F5-4337-B34A-9900EB5F50F3|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||YD|ENLARGEMENT||NG|NOT DONE|||CALCOFLUOR WHITE STAIN|U|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|2||58||BLINDED TREATMENT|1967-04-13|
TRIAL STUDY 134XCP|TR|FBB66C13-05F5-4337-B34A-9900EB5F50F3|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||OZ|FURTHER ENLARGEMENT||EID 50/ML|NOT DONE|||IMPULSE OSCILLOMETRY|NA|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1973-06-11|
TRIAL STUDY 134XCP|TR|FBB66C13-05F5-4337-B34A-9900EB5F50F3|4||||||DIAMETER|DIAMETER||LOG10 CCID 50/DOSE|UNEQUIVOCAL||MG/MOL|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|N|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|U|4||88||TREATMENT|1963-03-09|
TRIAL STUDY 134XCP|TR|FBB66C13-05F5-4337-B34A-9900EB5F50F3|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||G|DIFFUSELY INCREASED||WATT|NOT DONE|||NUCLEIC ACID SEQUENCING|N|NA|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|5||7||BASELINE|1971-06-22|
TRIAL STUDY 134XCP|TR|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|1||||||LNSTATE|LYMPH NODE STATE||EQ|UNCHANGED||UG/KG/H|NOT DONE|||PEAK FLOWMETRY|Y|U|SPOUSE|OPHTHALMOLOGIST|N|1||38||BASELINE|1963-08-10|
TRIAL STUDY 134XCP|TR|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|2||||||NEWCONF|NEW TUMOR CONFIRMED||C|FURTHER ENLARGEMENT FROM NADIR||ML/DOSE|NOT DONE|||ICC|NA|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||CONTINUATION TREATMENT|1973-05-08|
TRIAL STUDY 134XCP|TR|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||BQ/ML|NONPALPABLE||DAGU/ML|NOT DONE|||JAEGER EYE CHART|N|N|ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|3||39||WASHOUT|1962-03-07|
TRIAL STUDY 134XCP|TR|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|4||||||NEWCONF|NEW TUMOR CONFIRMED||MSEC|ENLARGEMENT FROM NADIR||PMOL/10^9 CELLS|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4||88||SCREENING|1963-08-22|
TRIAL STUDY 134XCP|TR|FCBAAB24-FEC0-46F2-AA07-99B20123E67C|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CUP EQ|NORMAL||MCI|NOT DONE|||FLUORESCENT SPOT TEST|NA|U|DOMESTIC PARTNER|OPHTHALMOLOGIST|N|5||7||TREATMENT|1971-03-22|
TRIAL STUDY 134XCP|TR|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|1||||||PALPSTAT|PALPABLE STATE||MASK|NONPALPABLE||KHZ|NOT DONE|||RADIATION DOSIMETRY|NA|N|SPOUSE|ADJUDICATOR 3|NA|1||38||BASELINE|1968-10-14|
TRIAL STUDY 134XCP|TR|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|2||||||VOLUME|VOLUME||CIGARETTE|NORMAL||DAYS|NOT DONE|||CRYOSCOPY|NA|U|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|N|2||58||WASHOUT|1963-11-22|
TRIAL STUDY 134XCP|TR|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|3||||||NEWCONF|NEW TUMOR CONFIRMED||10^6 U|PALPABLE||MMOL/KG|NOT DONE|||URANYL ACETATE STAIN|Y|N|CAREGIVER|RADIOLOGIST 2|Y|3||39||OPEN LABEL TREATMENT|1969-09-02|
TRIAL STUDY 134XCP|TR|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||KG/MOL|ENLARGEMENT||G/ANIMAL|NOT DONE|||GRADIENT DIFFUSION|NA|Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|4||88||WASHOUT|1969-09-19|
TRIAL STUDY 134XCP|TR|2F1EE4FC-4E1F-4BB7-81AA-5AE6133A75A9|5||||||VDIAM|VIABLE DIAMETER||WAFER|PALPABLE||RING|NOT DONE|||OLIGO ACGH|N|U|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|5||7||BLINDED TREATMENT|1964-02-05|
TRIAL STUDY 134XCP|TR|21223189-5527-4B3F-AFD5-21F77AC0DEBE|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||G/L|EQUIVOCAL||FRACTION OF 1|NOT DONE|||MUGA|N|N|INTERVIEWER|MICROSCOPIST 3|Y|1||38||OPEN LABEL TREATMENT|1965-01-27|
TRIAL STUDY 134XCP|TR|21223189-5527-4B3F-AFD5-21F77AC0DEBE|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||BAU/ML|NORMAL||UG|NOT DONE|||MS/MS|N|NA|FRIEND|RADIOLOGIST 1|N|2||58||BLINDED TREATMENT|1963-07-13|
TRIAL STUDY 134XCP|TR|21223189-5527-4B3F-AFD5-21F77AC0DEBE|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||UG|PRESENT||KIU|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|N|U|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||OBSERVATION|1967-04-04|
TRIAL STUDY 134XCP|TR|21223189-5527-4B3F-AFD5-21F77AC0DEBE|4||||||LDIAM|LONGEST DIAMETER||AU/ML|UNEQUIVOCAL||MV|NOT DONE|||SINGLE-MOLECULE ARRAY|U|Y|FAMILY MEMBER|RADIOLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1969-11-22|
TRIAL STUDY 134XCP|TR|21223189-5527-4B3F-AFD5-21F77AC0DEBE|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||DRINK|UNCHANGED||G/M2|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|N|U|INVESTIGATOR|RATER|Y|5||7||LONG-TERM FOLLOW-UP|1973-03-24|
TRIAL STUDY 134XCP|TR|CA6ECC17-3E3B-435C-A485-8612C267E52B|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UG/KG/DAY|UNEQUIVOCAL||MCI/L|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|N|U|CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|1||38||BLINDED TREATMENT|1967-05-03|
TRIAL STUDY 134XCP|TR|CA6ECC17-3E3B-435C-A485-8612C267E52B|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||TRANSDUCING UNIT|NONPALPABLE||10^6 ORGANISMS/MG|NOT DONE|||ENDOSCOPY|U|U|SPOUSE|ENDOCRINOLOGIST|NA|2||58||CONTINUATION TREATMENT|1972-06-29|
TRIAL STUDY 134XCP|TR|CA6ECC17-3E3B-435C-A485-8612C267E52B|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||VG/KG|DECREASED||CIGARETTE|NOT DONE|||SPECULAR MICROSCOPY|U|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|3||39||BASELINE|1966-06-28|
TRIAL STUDY 134XCP|TR|CA6ECC17-3E3B-435C-A485-8612C267E52B|4||||||VDIAM|VIABLE DIAMETER||ML/DL|NON-PATHOLOGICAL||MG|NOT DONE|||ACRIDINE ORANGE STAIN|N|N|SIBLING|ENDOCRINOLOGIST|NA|4||88||SCREENING|1968-12-24|
TRIAL STUDY 134XCP|TR|CA6ECC17-3E3B-435C-A485-8612C267E52B|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MBQ/UL|FOCALLY INCREASED||ML/M2/H|NOT DONE|||RAJI CELL RIA|NA|Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|5||7||INDUCTION TREATMENT|1962-02-01|
TRIAL STUDY 134XCP|TR|BCB41507-87B3-4773-B1E5-AE039853DED0|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/M2/H|UNCHANGED||KG/CM|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|1||38||INDUCTION TREATMENT|1961-09-10|
TRIAL STUDY 134XCP|TR|BCB41507-87B3-4773-B1E5-AE039853DED0|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||CM|NON-PATHOLOGICAL||YD|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2||58||OPEN LABEL TREATMENT|1964-08-22|
TRIAL STUDY 134XCP|TR|BCB41507-87B3-4773-B1E5-AE039853DED0|3||||||LDIAM|LONGEST DIAMETER||/MM2|TUMOR MERGED||NMOL/G|NOT DONE|||NEXT GENERATION SEQUENCING|Y|U|FAMILY MEMBER|MICROSCOPIST 1|NA|3||39||WASHOUT|1968-02-09|
TRIAL STUDY 134XCP|TR|BCB41507-87B3-4773-B1E5-AE039853DED0|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||U/G/DAY|PALPABLE||NG/L|NOT DONE|||SLIT LAMP|Y|NA|SIGNIFICANT OTHER|RATER|NA|4||88||OPEN LABEL TREATMENT|1967-10-20|
TRIAL STUDY 134XCP|TR|BCB41507-87B3-4773-B1E5-AE039853DED0|5||||||ORVERLN|ORGAN VERTICAL LENGTH||PNU/ML|PRESENT||NKAT|NOT DONE|||BIOPSY|NA|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|5||7||CONTINUATION TREATMENT|1969-08-09|
TRIAL STUDY 134XCP|TR|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MMOL/MIN/KPA|UNCHANGED||BU/ML|NOT DONE|||THIN SMEAR|N|NA|CHILD|FORENSIC PATHOLOGIST|U|1||38||INDUCTION TREATMENT|1970-03-15|
TRIAL STUDY 134XCP|TR|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||10^9/G|PALPABLE||U/M2/DAY|NOT DONE|||IHC|U|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1970-02-12|
TRIAL STUDY 134XCP|TR|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|3||||||PALPSTAT|PALPABLE STATE||MG/ML/DAY|ENLARGEMENT FROM NADIR||VG/DOSE|NOT DONE|||PHOROPTER|U|N|INVESTIGATOR|OTOLARYNGOLOGIST|Y|3||39||BASELINE|1973-05-02|
TRIAL STUDY 134XCP|TR|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||TUBERCULIN UNIT/ML|EQUIVOCAL||/KG|NOT DONE|||CELLULOSE TAPE|Y|NA|CLINICAL RESEARCH ASSOCIATE|READER|Y|4||88||RUN-IN|1962-06-05|
TRIAL STUDY 134XCP|TR|A8F9A1A9-2348-4E0E-93E5-E11A9EBDE02A|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MPS U|PRESENT||UG/KG|NOT DONE|||NO INFORMATION|Y|NA|CHILD|PATHOLOGIST|NA|5||7||INDUCTION TREATMENT|1970-02-11|
TRIAL STUDY 134XCP|TR|EC726B09-0B0F-4933-94F4-8941DF68EDE6|1||||||LESFLIND|LESION FAILURE INDICATOR||M2|DIFFUSELY INCREASED||UKAT|NOT DONE|||ICC|U|U|SIBLING|ADJUDICATOR 3|U|1||38||LONG-TERM FOLLOW-UP|1963-10-18|
TRIAL STUDY 134XCP|TR|EC726B09-0B0F-4933-94F4-8941DF68EDE6|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||LINEAR FT*LB|INCREASED||MMOL/DAY|NOT DONE|||MULTI-SLICE SPIRAL CT|NA|N|STUDY SUBJECT|ONCOLOGIST|N|2||58||OBSERVATION|1967-09-09|
TRIAL STUDY 134XCP|TR|EC726B09-0B0F-4933-94F4-8941DF68EDE6|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||10^5/HPF|NONPALPABLE||AU/ML|NOT DONE|||MEDIASTINOSCOPY|U|U|PARENT|ONCOLOGIST|NA|3||39||BLINDED TREATMENT|1961-03-03|
TRIAL STUDY 134XCP|TR|EC726B09-0B0F-4933-94F4-8941DF68EDE6|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^3/HPF|DECREASED||TSP EQ|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|N|N|CAREGIVER|READER 2|U|4||88||RUN-IN|1966-03-11|
TRIAL STUDY 134XCP|TR|EC726B09-0B0F-4933-94F4-8941DF68EDE6|5||||||LESFLIND|LESION FAILURE INDICATOR||BAU/ML|UNEQUIVOCAL||GAUSS|NOT DONE|||DROPLET DIGITAL PCR|U|N|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|U|5||7||CONTINUATION TREATMENT|1965-01-28|
TRIAL STUDY 134XCP|TR|9F703096-9152-422E-AEAB-AD22F00863ED|1||||||LDIAM|LONGEST DIAMETER||MMOL/DAY|NORMAL||UG|NOT DONE|||THIN SMEAR|NA|NA|CHILD|ONCOLOGIST 2|N|1||38||FOLLOW-UP|1962-10-16|
TRIAL STUDY 134XCP|TR|9F703096-9152-422E-AEAB-AD22F00863ED|2||||||BNLNUM|NUMBER OF BONE LESIONS||U/G|FOCALLY INCREASED||MHZ|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|N|NA|CLINICAL STUDY SPONSOR|RATER 1|Y|2||58||BLINDED TREATMENT|1972-04-19|
TRIAL STUDY 134XCP|TR|9F703096-9152-422E-AEAB-AD22F00863ED|3||||||ORVERLN|ORGAN VERTICAL LENGTH||CAL|NONPALPABLE||BQ/L|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|NA|U|SPOUSE|NEUROLOGIST 2|NA|3||39||BASELINE|1970-10-02|
TRIAL STUDY 134XCP|TR|9F703096-9152-422E-AEAB-AD22F00863ED|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||LENS|NONPALPABLE||10^4 CFU/ML|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|NA|Y|INVESTIGATOR|ONCOLOGIST 1|Y|4||88||FOLLOW-UP|1968-05-11|
TRIAL STUDY 134XCP|TR|9F703096-9152-422E-AEAB-AD22F00863ED|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||TSP EQ|FURTHER ENLARGEMENT FROM NADIR||RING|NOT DONE|||MICROBIAL CULTURE, LIQUID|Y|Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|5||7||RUN-IN|1960-05-20|
TRIAL STUDY 134XCP|TR|57455593-8872-4B17-8B3F-8A02FE855290|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ML/MIN/MMHG|ENLARGEMENT||TESLA|NOT DONE|||MULTI-SLICE SPIRAL CT|NA|NA|PARENT|ADJUDICATOR 2|NA|1||38||WASHOUT|1972-05-27|
TRIAL STUDY 134XCP|TR|57455593-8872-4B17-8B3F-8A02FE855290|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||GLOBULE|DIFFUSELY INCREASED||APL U/ML|NOT DONE|||SNP ARRAY|U|U|CLINICAL STUDY SPONSOR|READER 2|U|2||58||OBSERVATION|1966-08-18|
TRIAL STUDY 134XCP|TR|57455593-8872-4B17-8B3F-8A02FE855290|3||||||LNSTATE|LYMPH NODE STATE||UM|DIFFUSELY INCREASED||MMOL/S|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|N|N|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|U|3||39||OBSERVATION|1960-03-21|
TRIAL STUDY 134XCP|TR|57455593-8872-4B17-8B3F-8A02FE855290|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||NMOL/L/H|FURTHER ENLARGEMENT FROM NADIR||CCID 50/ML|NOT DONE|||EPSILOMETER|U|NA|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|4||88||OBSERVATION|1964-08-07|
TRIAL STUDY 134XCP|TR|57455593-8872-4B17-8B3F-8A02FE855290|5||||||VOLUME|VOLUME||GPL U/ML|PRESENT||M/SEC|NOT DONE|||INDIA INK STAIN|NA|N|STUDY SUBJECT|MICROSCOPIST 1|U|5||7||RUN-IN|1973-03-04|
TRIAL STUDY 134XCP|TR|97F58005-7367-49DC-967B-FAD681B55DF8|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||BQ/UL|ENLARGEMENT FROM NADIR||LX|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|NA|U|CAREGIVER|ADJUDICATOR 1|N|1||38||SCREENING|1973-05-01|
TRIAL STUDY 134XCP|TR|97F58005-7367-49DC-967B-FAD681B55DF8|2||||||TUMSTATE|TUMOR STATE||ELISA UNIT|DIFFUSELY INCREASED||ANSON U|NOT DONE|||NUCLEAR RADIOLOGY|Y|U|PROXY|ONCOLOGIST|N|2||58||RUN-IN|1964-04-18|
TRIAL STUDY 134XCP|TR|97F58005-7367-49DC-967B-FAD681B55DF8|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||BP|PATHOLOGICAL||DMOL|NOT DONE|||REVERSE TRANSCRIPTASE PCR|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 2|U|3||39||LONG-TERM FOLLOW-UP|1965-01-14|
TRIAL STUDY 134XCP|TR|97F58005-7367-49DC-967B-FAD681B55DF8|4||||||DIAMETER|DIAMETER||GPS U|NONPALPABLE||U/G/H|NOT DONE|||U-HPLC/MS/MS|Y|Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|4||88||SCREENING|1963-11-21|
TRIAL STUDY 134XCP|TR|97F58005-7367-49DC-967B-FAD681B55DF8|5||||||RADIODEN|RADIODENSITY||KS|ABSENT||DPM/ML|NOT DONE|||IODINE STAIN|NA|Y|ADJUDICATOR|RADIOLOGIST 2|N|5||7||FOLLOW-UP|1962-01-12|
TRIAL STUDY 134XCP|TR|83AC0828-3C22-4F7C-9D22-F044BB5B630D|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UG/MIN|PRESENT||G/M2/DAY|NOT DONE|||ICP-MS|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 2|Y|1||38||OBSERVATION|1965-12-19|
TRIAL STUDY 134XCP|TR|83AC0828-3C22-4F7C-9D22-F044BB5B630D|2||||||RADIODEN|RADIODENSITY||KBQ|NORMAL||UG/KG|NOT DONE|||NUCLEIC ACID SEQUENCING|NA|NA|GUARDIAN|MICROSCOPIST 2|NA|2||58||WASHOUT|1966-04-14|
TRIAL STUDY 134XCP|TR|83AC0828-3C22-4F7C-9D22-F044BB5B630D|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||PA|PATHOLOGICAL||10^7 PFU|NOT DONE|||ELECTROGASTROGRAPHY|N|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|3||39||TREATMENT|1973-06-25|
TRIAL STUDY 134XCP|TR|83AC0828-3C22-4F7C-9D22-F044BB5B630D|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UG/MOL|ABSENT||MIN/DAY|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|N|NA|FRIEND|MICROSCOPIST|Y|4||88||LONG-TERM FOLLOW-UP|1963-01-05|
TRIAL STUDY 134XCP|TR|83AC0828-3C22-4F7C-9D22-F044BB5B630D|5||||||LMBFLIND|LIMB FAILURE INDICATOR||CAL|NONPALPABLE||SIEMENS|NOT DONE|||REVERSE TRANSCRIPTASE PCR|U|N|VENDOR|RATER 2|N|5||7||CONTINUATION TREATMENT|1972-07-09|
TRIAL STUDY 134XCP|TR|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMOL2/L2|DIFFUSELY INCREASED||H*%|NOT DONE|||PHOTOMETRY|NA|U|FRIEND|PATHOLOGIST 1|NA|1||38||FOLLOW-UP|1973-03-12|
TRIAL STUDY 134XCP|TR|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|2||||||TUMSTATE|TUMOR STATE||LOG10 TCID 50/UL|UNCHANGED||PMOL/DAY|NOT DONE|||ECHOCARDIOGRAPHY|NA|U|INTERVIEWER|OTOLARYNGOLOGIST|Y|2||58||OBSERVATION|1971-04-28|
TRIAL STUDY 134XCP|TR|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||/10^4|INCREASED||MG/M2/H|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|U|PROXY|RADIOLOGIST 1|N|3||39||OBSERVATION|1967-05-13|
TRIAL STUDY 134XCP|TR|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|4||||||LESFLIND|LESION FAILURE INDICATOR||ELISA UNIT/DOSE|FURTHER ENLARGEMENT FROM NADIR||IN2|NOT DONE|||OBSERVATION|N|N|INVESTIGATOR|UROLOGIST|U|4||88||CONTINUATION TREATMENT|1964-09-07|
TRIAL STUDY 134XCP|TR|1C380A81-79B1-48EA-9C50-9B1E3B401BCC|5||||||BNLNUM|NUMBER OF BONE LESIONS||MNFI|ABSENT||CI/UL|NOT DONE|||PATHOLOGICAL EVALUATION|U|N|NON-HEALTH CARE PROFESSIONAL|READER|Y|5||7||BASELINE|1967-09-28|
TRIAL STUDY 134XCP|TR|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||GPL U/ML|DIFFUSELY INCREASED||MOL/ML|NOT DONE|||CRYOSCOPY|U|N|PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||BASELINE|1965-03-04|
TRIAL STUDY 134XCP|TR|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||PMOL/G|FURTHER ENLARGEMENT FROM NADIR||UMOL|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|NA|N|PARENT|PATHOLOGIST 1|Y|2||58||INDUCTION TREATMENT|1963-11-12|
TRIAL STUDY 134XCP|TR|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CCID 50/DOSE|INCREASED||UG|NOT DONE|||WRIGHT-GIEMSA STAIN|N|N|CLINICAL RESEARCH COORDINATOR|READER|NA|3||39||BASELINE|1971-04-09|
TRIAL STUDY 134XCP|TR|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|4||||||PALPSTAT|PALPABLE STATE||UG/MOL|NORMAL||LM|NOT DONE|||ROMANOWSKY STAIN|N|Y|NON-HEALTH CARE PROFESSIONAL|READER 3|Y|4||88||SCREENING|1964-02-05|
TRIAL STUDY 134XCP|TR|E22C5D53-74B1-402F-9A9C-3E48F1A9AD5E|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MMOL/L|PRESENT||COAT|NOT DONE|||PANENDOSCOPY|Y|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||INDUCTION TREATMENT|1962-03-04|
TRIAL STUDY 134XCP|TR|B386B813-1175-4421-9C86-F9AB597877FA|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/DL|UNCHANGED||FINGERTIP UNIT|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|N|N|STUDY SUBJECT|PATHOLOGIST 2|N|1||38||INDUCTION TREATMENT|1967-06-03|
TRIAL STUDY 134XCP|TR|B386B813-1175-4421-9C86-F9AB597877FA|2||||||PALPSTAT|PALPABLE STATE||VG/KG|ENLARGEMENT FROM NADIR||G/M2/DAY|NOT DONE|||EEG|NA|N|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|2||58||SCREENING|1961-02-03|
TRIAL STUDY 134XCP|TR|B386B813-1175-4421-9C86-F9AB597877FA|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||JOULE|TUMOR MERGED||UMOL/L/MIN|NOT DONE|||ENDOSCOPY|Y|U|GUARDIAN|FORENSIC PATHOLOGIST|N|3||39||OPEN LABEL TREATMENT|1963-02-02|
TRIAL STUDY 134XCP|TR|B386B813-1175-4421-9C86-F9AB597877FA|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^6/HPF|INCREASED||KG/MOL|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|N|INVESTIGATOR|PATHOLOGIST|N|4||88||WASHOUT|1965-09-29|
TRIAL STUDY 134XCP|TR|B386B813-1175-4421-9C86-F9AB597877FA|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||HZ/S|NONPALPABLE||NKAT/L|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|Y|N|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||WASHOUT|1963-07-13|
TRIAL STUDY 134XCP|TR|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UG/L|FURTHER ENLARGEMENT FROM NADIR||10^9 ORGANISMS/G|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|N|U|PROXY|RADIOLOGIST 2|N|1||38||TREATMENT|1971-10-27|
TRIAL STUDY 134XCP|TR|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DIOPTER|PRESENT||G/U|NOT DONE|||OPTICAL DENSITY MEASUREMENT|N|NA|VENDOR|RADIOLOGIST 2|U|2||58||SCREENING|1964-03-29|
TRIAL STUDY 134XCP|TR|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|3||||||ORVERLN|ORGAN VERTICAL LENGTH||PIXEL|FOCALLY INCREASED||MAC50|NOT DONE|||ETDRS EYE CHART|N|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|3||39||WASHOUT|1968-06-15|
TRIAL STUDY 134XCP|TR|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||L/H/M2|FURTHER ENLARGEMENT||MU|NOT DONE|||SINGLE-MOLECULE ARRAY|Y|Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|4||88||CONTINUATION TREATMENT|1970-05-19|
TRIAL STUDY 134XCP|TR|5ADBD73B-1E68-466B-8CF6-D7FB85D80906|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/10^4|ENLARGEMENT||BREATHS/30S|NOT DONE|||MS/MS|Y|N|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|5||7||INDUCTION TREATMENT|1963-08-15|
TRIAL STUDY 134XCP|TR|7B33775D-1DFF-49A6-820E-7981F5C16AFF|1||||||ORSTATE|ORGAN STATE||MS2|PALPABLE||UMOL/L/SEC|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|Y|N|DOMESTIC PARTNER|PATHOLOGIST 1|U|1||38||OBSERVATION|1965-03-18|
TRIAL STUDY 134XCP|TR|7B33775D-1DFF-49A6-820E-7981F5C16AFF|2||||||NEWCONF|NEW TUMOR CONFIRMED||MPA|PRESENT||KG|NOT DONE|||TEST STRIP|NA|N|CAREGIVER|RADIOLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1968-08-25|
TRIAL STUDY 134XCP|TR|7B33775D-1DFF-49A6-820E-7981F5C16AFF|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||M3|UNCHANGED||/LPF|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|N|ADJUDICATOR|ENDOCRINOLOGIST|U|3||39||FOLLOW-UP|1969-03-30|
TRIAL STUDY 134XCP|TR|7B33775D-1DFF-49A6-820E-7981F5C16AFF|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LX|UNEQUIVOCAL||10^6/EJACULATE U|NOT DONE|||PANENDOSCOPY|Y|U|GUARDIAN|RATER 1|N|4||88||OPEN LABEL TREATMENT|1971-12-09|
TRIAL STUDY 134XCP|TR|7B33775D-1DFF-49A6-820E-7981F5C16AFF|5||||||PALPSTAT|PALPABLE STATE||U/KG/MIN|PRESENT||UGEQ|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|N|NA|STUDY SUBJECT|NEUROLOGIST 1|Y|5||7||FOLLOW-UP|1972-09-17|
TRIAL STUDY 134XCP|TR|DC48DD03-B87E-422D-A2EE-D87342260E19|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^4 CFU|EQUIVOCAL||CM2|NOT DONE|||CELL BASED BIOASSAY|NA|NA|PROXY|RADIOLOGIST 1|N|1||38||BLINDED TREATMENT|1973-08-17|
TRIAL STUDY 134XCP|TR|DC48DD03-B87E-422D-A2EE-D87342260E19|2||||||LMBFLIND|LIMB FAILURE INDICATOR||MMHG/L/MIN|UNEQUIVOCAL||ML/MIN/1.73M2|NOT DONE|||DIFFUSION TENSOR MRI|Y|N|SIGNIFICANT OTHER|MICROSCOPIST 1|N|2||58||CONTINUATION TREATMENT|1962-05-08|
TRIAL STUDY 134XCP|TR|DC48DD03-B87E-422D-A2EE-D87342260E19|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||UMOL/L/MIN|DECREASED||PHERESIS UNIT|NOT DONE|||ENZYMATIC COLORIMETRY|NA|NA|CAREGIVER|RADIOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1960-12-10|
TRIAL STUDY 134XCP|TR|DC48DD03-B87E-422D-A2EE-D87342260E19|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MS2|UNCHANGED||10^9/G|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|NA|N|VENDOR|ONCOLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1965-12-21|
TRIAL STUDY 134XCP|TR|DC48DD03-B87E-422D-A2EE-D87342260E19|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||LOG10 TCID 50/ML|INCREASED||LOG10 ELISA UNIT/DOSE|NOT DONE|||MRI WITHOUT CONTRAST|U|U|PARENT|RADIOLOGIST|Y|5||7||INDUCTION TREATMENT|1961-03-14|
TRIAL STUDY 134XCP|TR|2E084441-61A3-4B8B-9050-A5D7B38CA978|1||||||LMBFLIND|LIMB FAILURE INDICATOR||NCI|DIFFUSELY INCREASED||UMOL/L/MIN|NOT DONE|||MUGA|NA|N|VENDOR|HEMATOLOGIST|NA|1||38||SCREENING|1964-05-13|
TRIAL STUDY 134XCP|TR|2E084441-61A3-4B8B-9050-A5D7B38CA978|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UL|DIFFUSELY INCREASED||U.CARR|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|NA|FRIEND|READER 2|Y|2||58||BASELINE|1968-06-14|
TRIAL STUDY 134XCP|TR|2E084441-61A3-4B8B-9050-A5D7B38CA978|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||PLUG|PATHOLOGICAL||10^6 ORGANISMS|NOT DONE|||TEST STRIP|N|NA|GUARDIAN|MICROSCOPIST|NA|3||39||INDUCTION TREATMENT|1963-07-07|
TRIAL STUDY 134XCP|TR|2E084441-61A3-4B8B-9050-A5D7B38CA978|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||APL U|ENLARGEMENT||MET*H|NOT DONE|||PHOTOMETRIC CLOT DETECTION|NA|N|SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1969-09-05|
TRIAL STUDY 134XCP|TR|2E084441-61A3-4B8B-9050-A5D7B38CA978|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MG|UNCHANGED||MPH|NOT DONE|||APPLANATION TONOMETRY|N|NA|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|5||7||WASHOUT|1963-03-11|
TRIAL STUDY 134XCP|TR|601D563B-AA21-4859-A87E-B2068C1E3F53|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U/G/DAY|FOCALLY INCREASED||ANTI-XA IU/ML|NOT DONE|||ECHOCARDIOGRAPHY|NA|N|PROXY|OPHTHALMOLOGIST|N|1||38||BASELINE|1972-09-30|
TRIAL STUDY 134XCP|TR|601D563B-AA21-4859-A87E-B2068C1E3F53|2||||||AREA|AREA||10^6 U|FOCALLY INCREASED||DMOL|NOT DONE|||HPLC/MS/MS|N|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|2||58||FOLLOW-UP|1969-07-30|
TRIAL STUDY 134XCP|TR|601D563B-AA21-4859-A87E-B2068C1E3F53|3||||||LESFLIND|LESION FAILURE INDICATOR||MDFI|UNEQUIVOCAL||NMOL BCE/NMOL|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|U|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|3||39||FOLLOW-UP|1971-02-23|
TRIAL STUDY 134XCP|TR|601D563B-AA21-4859-A87E-B2068C1E3F53|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/100 WBC|INCREASED||G/L|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|NA|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1961-04-09|
TRIAL STUDY 134XCP|TR|601D563B-AA21-4859-A87E-B2068C1E3F53|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||LOZENGE|NONPALPABLE||LOG10 TCID 50/UL|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|NA|NA|VENDOR|OTOLARYNGOLOGIST|N|5||7||BLINDED TREATMENT|1963-12-14|
TRIAL STUDY 134XCP|TR|D8FE5979-24C7-478F-8612-0102F28F5ADE|1||||||VOLUME|VOLUME||MKAT|DECREASED||BEL|NOT DONE|||HPLC/IEX|U|NA|PARENT|OPTOMETRIST|U|1||38||FOLLOW-UP|1967-02-21|
TRIAL STUDY 134XCP|TR|D8FE5979-24C7-478F-8612-0102F28F5ADE|2||||||ORSTATE|ORGAN STATE||UG/KG|ENLARGEMENT||/10^3|NOT DONE|||GC/FID|Y|Y|INTERVIEWER|RATER 2|Y|2||58||INDUCTION TREATMENT|1966-03-26|
TRIAL STUDY 134XCP|TR|D8FE5979-24C7-478F-8612-0102F28F5ADE|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||UCI|EQUIVOCAL||SPRAY|NOT DONE|||FLOW MICROSCOPY|N|N|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|3||39||RUN-IN|1962-04-04|
TRIAL STUDY 134XCP|TR|D8FE5979-24C7-478F-8612-0102F28F5ADE|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/M2|ENLARGEMENT||MG/KG/WEEK|NOT DONE|||LANDOLT RING|Y|U|INVESTIGATOR|OPHTHALMOLOGIST|U|4||88||BASELINE|1964-01-09|
TRIAL STUDY 134XCP|TR|D8FE5979-24C7-478F-8612-0102F28F5ADE|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||L/MIN|INCREASED||DB|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|N|Y|PROXY|CARDIOLOGIST|NA|5||7||INDUCTION TREATMENT|1970-01-01|
TRIAL STUDY 134XCP|TR|D275315F-D3C5-4260-8BD6-37DDB67262B0|1||||||LDIAM|LONGEST DIAMETER||MPS U|UNCHANGED||IU/L|NOT DONE|||GEL ELECTROPHORESIS|NA|NA|SIBLING|OPTOMETRIST|U|1||38||LONG-TERM FOLLOW-UP|1972-05-03|
TRIAL STUDY 134XCP|TR|D275315F-D3C5-4260-8BD6-37DDB67262B0|2||||||VDIAM|VIABLE DIAMETER||10^9 CFU|ENLARGEMENT FROM NADIR||UL/KG/DAY|NOT DONE|||ORCHIDOMETERY|U|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1960-02-18|
TRIAL STUDY 134XCP|TR|D275315F-D3C5-4260-8BD6-37DDB67262B0|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UG/M2/DAY|PATHOLOGICAL||U/CL|NOT DONE|||RULER MEASUREMENT METHOD|Y|NA|SIBLING|ONCOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1963-03-07|
TRIAL STUDY 134XCP|TR|D275315F-D3C5-4260-8BD6-37DDB67262B0|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MBP|TUMOR MERGED||NG/MOL|NOT DONE|||ORCHIDOMETERY|Y|NA|CHILD|READER 1|U|4||88||WASHOUT|1968-09-03|
TRIAL STUDY 134XCP|TR|D275315F-D3C5-4260-8BD6-37DDB67262B0|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||ANTI-XA IU|PALPABLE||CFU/G|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|NA|Y|PROXY|ADJUDICATOR|NA|5||7||WASHOUT|1967-05-05|
TRIAL STUDY 134XCP|TR|34127CD2-378B-4335-AD4B-F305D0A21AF4|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UG/MOL|DIFFUSELY INCREASED||HZ|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|N|Y|DOMESTIC PARTNER|ONCOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1966-06-28|
TRIAL STUDY 134XCP|TR|34127CD2-378B-4335-AD4B-F305D0A21AF4|2||||||LPERP|LONGEST PERPENDICULAR||P|NORMAL||ML/CAGE/WK|NOT DONE|||ICC|U|N|SIBLING|ONCOLOGIST|NA|2||58||INDUCTION TREATMENT|1962-07-04|
TRIAL STUDY 134XCP|TR|34127CD2-378B-4335-AD4B-F305D0A21AF4|3||||||ORSTATE|ORGAN STATE||10^11/L|FURTHER ENLARGEMENT FROM NADIR||STEPS|NOT DONE|||MALDI-TOF|NA|U|SIGNIFICANT OTHER|RATER|NA|3||39||BASELINE|1962-08-13|
TRIAL STUDY 134XCP|TR|34127CD2-378B-4335-AD4B-F305D0A21AF4|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||CAN|PATHOLOGICAL||U/M2|NOT DONE|||CONFOCAL MICROSCOPY|N|N|VENDOR|RADIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1960-12-07|
TRIAL STUDY 134XCP|TR|34127CD2-378B-4335-AD4B-F305D0A21AF4|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||/4.0 ML|PALPABLE||MAMP|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|NA|NA|VENDOR|READER 3|N|5||7||FOLLOW-UP|1972-12-01|
TRIAL STUDY 134XCP|TR|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MV|PRESENT||L/S/KPA|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|N|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|1||38||LONG-TERM FOLLOW-UP|1962-10-03|
TRIAL STUDY 134XCP|TR|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^4/L|FOCALLY INCREASED||MKAT|NOT DONE|||PHYSICAL EXAMINATION|U|NA|CHILD|MICROSCOPIST 3|U|2||58||SCREENING|1960-03-13|
TRIAL STUDY 134XCP|TR|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UMOL/L|UNCHANGED||UG/KG|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|Y|U|CHILD|MICROSCOPIST 1|U|3||39||SCREENING|1961-07-05|
TRIAL STUDY 134XCP|TR|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||BOWL|ENLARGEMENT FROM NADIR||ML|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|N|DOMESTIC PARTNER|PATHOLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1967-03-16|
TRIAL STUDY 134XCP|TR|6A15A97E-5B6F-483A-A9C7-94AC81B977A3|5||||||LESSCIND|LESION SUCCESS INDICATOR||U/M2|PRESENT||OSM|NOT DONE|||PET/SPECT SCAN|Y|Y|INTERVIEWER|READER 2|U|5||7||BASELINE|1970-06-26|
TRIAL STUDY 134XCP|TR|6EE04A90-681B-439E-9783-04B40A4AF240|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ML/MIN|NON-PATHOLOGICAL||ML/MIN/1.73M2|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|U|SPOUSE|CLINICAL PATHOLOGIST|NA|1||38||TREATMENT|1965-06-16|
TRIAL STUDY 134XCP|TR|6EE04A90-681B-439E-9783-04B40A4AF240|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UG/KG|PATHOLOGICAL||MEQ/DL|NOT DONE|||POPULATION SEQUENCING|U|Y|FRIEND|INTERNIST|Y|2||58||WASHOUT|1971-08-08|
TRIAL STUDY 134XCP|TR|6EE04A90-681B-439E-9783-04B40A4AF240|3||||||LMBFLIND|LIMB FAILURE INDICATOR||U/ANIMAL|INCREASED||PATCH|NOT DONE|||PHOTOGRAPHY|U|NA|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|3||39||FOLLOW-UP|1962-03-23|
TRIAL STUDY 134XCP|TR|6EE04A90-681B-439E-9783-04B40A4AF240|4||||||NEWCONF|NEW TUMOR CONFIRMED||100 IU/ML|PATHOLOGICAL||M/SEC|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|NA|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|4||88||TREATMENT|1963-07-12|
TRIAL STUDY 134XCP|TR|6EE04A90-681B-439E-9783-04B40A4AF240|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||HOUNSFIELD UNIT|ENLARGEMENT||MG/KG/WEEK|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|NA|NA|STUDY SUBJECT|PATHOLOGIST 1|U|5||7||WASHOUT|1966-07-22|
TRIAL STUDY 134XCP|TR|A5C0B034-1226-40EE-87E3-D46A7342B550|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||HOURS|UNCHANGED||IU/G HB|NOT DONE|||GC/MS|U|NA|CHILD|READER 3|N|1||38||TREATMENT|1971-08-25|
TRIAL STUDY 134XCP|TR|A5C0B034-1226-40EE-87E3-D46A7342B550|2||||||LESFLIND|LESION FAILURE INDICATOR||/CMH2O|UNCHANGED||KPA|NOT DONE|||CONGO RED STAIN|N|U|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|2||58||OPEN LABEL TREATMENT|1964-03-18|
TRIAL STUDY 134XCP|TR|A5C0B034-1226-40EE-87E3-D46A7342B550|3||||||LESFLIND|LESION FAILURE INDICATOR||PG/DL|FOCALLY INCREASED||10^3 CFU/G|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|U|NA|ADJUDICATOR|UROLOGIST|N|3||39||OBSERVATION|1962-04-09|
TRIAL STUDY 134XCP|TR|A5C0B034-1226-40EE-87E3-D46A7342B550|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||POUCH|NONPALPABLE||/MM|NOT DONE|||FLUOROSCOPY|N|NA|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1969-12-18|
TRIAL STUDY 134XCP|TR|A5C0B034-1226-40EE-87E3-D46A7342B550|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^3 ORGANISMS/ML|DECREASED||CD/M2|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|U|INVESTIGATOR|ADJUDICATOR 2|Y|5||7||TREATMENT|1963-12-02|
TRIAL STUDY 134XCP|TR|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|1||||||LNSTATE|LYMPH NODE STATE||LOG10 COPIES/ML|ABSENT||UG/MOL|NOT DONE|||CHROMOGENIC ASSAY|U|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||TREATMENT|1969-04-01|
TRIAL STUDY 134XCP|TR|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/7.5 ML|DIFFUSELY INCREASED||ML/MIN/MMHG|NOT DONE|||LC/MS|N|U|FAMILY MEMBER|ADJUDICATOR 2|N|2||58||OBSERVATION|1970-09-17|
TRIAL STUDY 134XCP|TR|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|3||||||VSLPIND|VESSEL PATENCY INDICATOR||U/G/DAY|NONPALPABLE||APL U|NOT DONE|||CENTRIFUGATION|Y|N|ADJUDICATOR|RADIOLOGIST 2|N|3||39||FOLLOW-UP|1971-10-13|
TRIAL STUDY 134XCP|TR|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MV*MIN|PATHOLOGICAL||CI/MG|NOT DONE|||TRYPAN BLUE STAIN|Y|NA|STUDY SUBJECT|READER 3|NA|4||88||LONG-TERM FOLLOW-UP|1963-11-19|
TRIAL STUDY 134XCP|TR|215DE9E0-6E47-448D-BE13-7CF5DB1A3865|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||FMOL/L|DECREASED||10^3 RNA COPIES/ML|NOT DONE|||SPECULAR MICROSCOPY|N|Y|FAMILY MEMBER|ONCOLOGIST|NA|5||7||BLINDED TREATMENT|1971-03-03|
TRIAL STUDY 134XCP|TR|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||CAPLET|FURTHER ENLARGEMENT||ML/S/M2|NOT DONE|||REFRACTOMETRY|NA|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|1||38||OPEN LABEL TREATMENT|1971-09-16|
TRIAL STUDY 134XCP|TR|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|2||||||CALCFIND|CALCIFICATION INDICATOR||HZ/S|FURTHER ENLARGEMENT FROM NADIR||/VF|NOT DONE|||FORCED OSCILLATION TECHNIQUE|Y|NA|PARENT|RATER|NA|2||58||TREATMENT|1964-11-10|
TRIAL STUDY 134XCP|TR|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|3||||||SUMVOL|SUM OF VOLUME||10^6 ORGANISMS|DECREASED||PKAT/L|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|Y|STUDY SUBJECT|RADIOLOGIST|N|3||39||TREATMENT|1970-02-14|
TRIAL STUDY 134XCP|TR|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MEQ/G|NORMAL||NMOL/ML/MIN|NOT DONE|||GIEMSA STAIN|NA|U|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|4||88||FOLLOW-UP|1961-09-11|
TRIAL STUDY 134XCP|TR|A99FE1E2-ED93-4550-9AE7-3AC117D8619B|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PIPE|TUMOR MERGED||10^3 RNA COPIES/ML|NOT DONE|||CT SCAN|NA|U|VENDOR|ADJUDICATOR 2|NA|5||7||WASHOUT|1971-09-15|
TRIAL STUDY 134XCP|TR|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|1||||||LNSTATE|LYMPH NODE STATE||L/MIN/M2|PATHOLOGICAL||UOSM|NOT DONE|||ELLA|U|Y|SIGNIFICANT OTHER|CARDIOLOGIST|U|1||38||OBSERVATION|1969-09-18|
TRIAL STUDY 134XCP|TR|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||PIPE|FURTHER ENLARGEMENT||UG/ANIMAL|NOT DONE|||TRANSVAGINAL ULTRASOUND|N|NA|CAREGIVER|NEUROLOGIST|N|2||58||BASELINE|1968-10-29|
TRIAL STUDY 134XCP|TR|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|3||||||VDIAM|VIABLE DIAMETER||IU/DL|ENLARGEMENT FROM NADIR||EVENTS|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|NA|CAREGIVER|DERMATOLOGIST|NA|3||39||FOLLOW-UP|1966-04-26|
TRIAL STUDY 134XCP|TR|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||HOURS|INCREASED||/200 HPFS|NOT DONE|||COULOMETRIC TITRATION|Y|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BLINDED TREATMENT|1966-01-10|
TRIAL STUDY 134XCP|TR|2360DE4B-4EF2-4ECA-8663-9DA9306F1DB7|5||||||PALPSTAT|PALPABLE STATE||ML/(MIN*100ML)|DECREASED||KCAL|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|NA|N|PROXY|DERMATOLOGIST|N|5||7||TREATMENT|1962-05-23|
TRIAL STUDY 134XCP|TR|D58A8C37-6659-4B00-8BED-256E8754F93C|1||||||BNLNUM|NUMBER OF BONE LESIONS||PG/DL|DECREASED||10^7 CFU|NOT DONE|||AGAR PROPORTION|N|Y|ADJUDICATOR|ADJUDICATOR 1|NA|1||38||OBSERVATION|1967-08-28|
TRIAL STUDY 134XCP|TR|D58A8C37-6659-4B00-8BED-256E8754F93C|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MEQ/UL|DECREASED||PG/L|NOT DONE|||CLIP|N|NA|STUDY SUBJECT|MICROSCOPIST 1|N|2||58||TREATMENT|1970-02-23|
TRIAL STUDY 134XCP|TR|D58A8C37-6659-4B00-8BED-256E8754F93C|3||||||TUMSTATE|TUMOR STATE||AFU|FURTHER ENLARGEMENT FROM NADIR||DIOPTER|NOT DONE|||JAEGER EYE CHART|N|N|FRIEND|INTERNIST|Y|3||39||BLINDED TREATMENT|1964-07-26|
TRIAL STUDY 134XCP|TR|D58A8C37-6659-4B00-8BED-256E8754F93C|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^4/L|UNEQUIVOCAL||UV|NOT DONE|||PELLI-ROBSON EYE CHART|NA|U|VENDOR|READER 2|U|4||88||SCREENING|1968-04-04|
TRIAL STUDY 134XCP|TR|D58A8C37-6659-4B00-8BED-256E8754F93C|5||||||LESSCIND|LESION SUCCESS INDICATOR||RNA COPIES/ML|UNCHANGED||LX|NOT DONE|||PHASE-CONTRAST MRI|Y|N|SIBLING|CLINICAL PATHOLOGIST|N|5||7||RUN-IN|1967-03-15|
TRIAL STUDY 134XCP|TR|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|1||||||LNSTATE|LYMPH NODE STATE||LB|NONPALPABLE||USP U|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|U|GUARDIAN|MICROSCOPIST 2|Y|1||38||RUN-IN|1967-05-03|
TRIAL STUDY 134XCP|TR|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||BQ/UG|DECREASED||BP|NOT DONE|||GRAM STAIN|N|U|HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|2||58||INDUCTION TREATMENT|1964-07-30|
TRIAL STUDY 134XCP|TR|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MET*H|DECREASED||PATCH|NOT DONE|||NO INFORMATION|Y|NA|DOMESTIC PARTNER|ONCOLOGIST|NA|3||39||SCREENING|1969-05-08|
TRIAL STUDY 134XCP|TR|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|4||||||LESSCIND|LESION SUCCESS INDICATOR||ML/(MIN*100ML)|NON-PATHOLOGICAL||PACKAGE|NOT DONE|||LYMPHANGIOGRAPHY|N|U|CHILD|OTOLARYNGOLOGIST|Y|4||88||WASHOUT|1960-06-20|
TRIAL STUDY 134XCP|TR|F2649193-70EA-4B76-A08C-EBAFE4FE69BD|5||||||TUMSTATE|TUMOR STATE||MMOL|NONPALPABLE||NEBULE|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|NA|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|5||7||BASELINE|1970-01-12|
TRIAL STUDY 134XCP|TR|5440F45F-C220-46E7-8354-6AF34A003E5E|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||BQ/MG|NORMAL||U/10^12 RBC|NOT DONE|||WHOLE GENOME SEQUENCING|N|Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1||38||OPEN LABEL TREATMENT|1972-08-16|
TRIAL STUDY 134XCP|TR|5440F45F-C220-46E7-8354-6AF34A003E5E|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||NG|UNCHANGED||BEATS/MIN|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|Y|NA|FAMILY MEMBER|OPHTHALMOLOGIST|Y|2||58||TREATMENT|1968-01-28|
TRIAL STUDY 134XCP|TR|5440F45F-C220-46E7-8354-6AF34A003E5E|3||||||LNSTATE|LYMPH NODE STATE||NKAT/G HB|DIFFUSELY INCREASED||SQU/ML|NOT DONE|||PHASE-CONTRAST MRI|NA|N|FAMILY MEMBER|ADJUDICATOR 3|N|3||39||WASHOUT|1962-04-08|
TRIAL STUDY 134XCP|TR|5440F45F-C220-46E7-8354-6AF34A003E5E|4||||||PALPSTAT|PALPABLE STATE||10^10/L|FURTHER ENLARGEMENT||V/V|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|N|DOMESTIC PARTNER|RATER|U|4||88||WASHOUT|1966-08-30|
TRIAL STUDY 134XCP|TR|5440F45F-C220-46E7-8354-6AF34A003E5E|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BEAM BREAKS|EQUIVOCAL||MMHG/L/MIN|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|N|PARENT|OPTOMETRIST|N|5||7||INDUCTION TREATMENT|1968-06-06|
TRIAL STUDY 134XCP|TR|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|1||||||ORSTATE|ORGAN STATE||UG/MOL|FURTHER ENLARGEMENT||MG/G/H|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|U|PROXY|CLINICAL PATHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1962-07-28|
TRIAL STUDY 134XCP|TR|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|2||||||ORVERLN|ORGAN VERTICAL LENGTH||SV|PRESENT||KA_U/DL|NOT DONE|||RYAN BLUE STAIN|N|N|FRIEND|ADJUDICATOR 3|N|2||58||RUN-IN|1970-08-19|
TRIAL STUDY 134XCP|TR|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MJOULE/CM2|FOCALLY INCREASED||ABSORBANCE U/ML|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|U|N|PROXY|ONCOLOGIST 2|U|3||39||SCREENING|1961-02-26|
TRIAL STUDY 134XCP|TR|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MV/SEC|PALPABLE||KDA|NOT DONE|||SNELLEN EYE CHART|Y|N|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|4||88||WASHOUT|1968-12-16|
TRIAL STUDY 134XCP|TR|3B6FE075-9BC0-48D8-8DE9-0D3FB82B4B0C|5||||||ORVERLN|ORGAN VERTICAL LENGTH||FT3|FURTHER ENLARGEMENT FROM NADIR||OD UNIT|NOT DONE|||COMPLEMENT FIXATION|U|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|5||7||FOLLOW-UP|1971-10-08|
TRIAL STUDY 134XCP|TR|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|1||||||RADIODEN|RADIODENSITY||NMOL BCE/NMOL|ABSENT||UMOL/DL|NOT DONE|||HPLC-UV|Y|Y|SIBLING|ONCOLOGIST|Y|1||38||FOLLOW-UP|1964-06-22|
TRIAL STUDY 134XCP|TR|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MG/KG|INCREASED||MIN/DAY|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|U|GUARDIAN|RATER 1|U|2||58||BASELINE|1973-08-04|
TRIAL STUDY 134XCP|TR|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||BP|PATHOLOGICAL||MMOL/DAY|NOT DONE|||MRS|NA|Y|STUDY SUBJECT|PATHOLOGIST|N|3||39||OBSERVATION|1965-07-08|
TRIAL STUDY 134XCP|TR|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|4||||||TUMSTATE|TUMOR STATE||ABSORBANCE U/MIN|ABSENT||/10^3|NOT DONE|||CLIP|NA|N|INTERVIEWER|RADIOLOGIST 2|N|4||88||INDUCTION TREATMENT|1973-05-02|
TRIAL STUDY 134XCP|TR|A83EFC3A-F107-4FCE-96E7-0C327244F2F5|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MPL U/ML|PRESENT||KIT|NOT DONE|||DIPSTICK|U|N|CAREGIVER|PEDIATRIC NEUROLOGIST|N|5||7||SCREENING|1960-08-02|
TRIAL STUDY 134XCP|TR|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|1||||||VDIAM|VIABLE DIAMETER||MG/M2/DAY|UNEQUIVOCAL||10^9 CFU/G|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|NA|U|ADJUDICATOR|PHYSIOTHERAPIST|N|1||38||WASHOUT|1969-02-27|
TRIAL STUDY 134XCP|TR|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||NMOL/G|TUMOR MERGED||NCI|NOT DONE|||STRESS ECHOCARDIOGRAPHY|N|NA|SIGNIFICANT OTHER|DERMATOLOGIST|NA|2||58||CONTINUATION TREATMENT|1970-01-20|
TRIAL STUDY 134XCP|TR|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||UMOL|UNEQUIVOCAL||MOL|NOT DONE|||FLUORESCENT MICROSCOPY|NA|N|FRIEND|NEUROLOGIST|N|3||39||TREATMENT|1964-02-26|
TRIAL STUDY 134XCP|TR|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||GBQ/MG|ABSENT||U/ANIMAL|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|U|N|GUARDIAN|ONCOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1966-03-29|
TRIAL STUDY 134XCP|TR|274C7FAB-FC7F-4D2E-A2C4-32C202EB7A59|5||||||CALCFIND|CALCIFICATION INDICATOR||PIXELS/CM|FURTHER ENLARGEMENT||ARBITRARY U|NOT DONE|||FLUORESCENT IMMUNOASSAY|Y|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|5||7||FOLLOW-UP|1971-07-15|
TRIAL STUDY 134XCP|TR|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||OHM|PALPABLE||IU/KG/H|NOT DONE|||POLYSOMNOGRAPHY|Y|N|CAREGIVER|ONCOLOGIST 2|Y|1||38||RUN-IN|1960-07-17|
TRIAL STUDY 134XCP|TR|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||RATIO|PATHOLOGICAL||BQ|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|N|U|PROXY|ONCOLOGIST 2|U|2||58||BLINDED TREATMENT|1970-06-14|
TRIAL STUDY 134XCP|TR|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ML/MMHG|PATHOLOGICAL||RATIO|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|U|N|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|3||39||SCREENING|1966-10-08|
TRIAL STUDY 134XCP|TR|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^9 CFU/ML|TUMOR MERGED||10^9 CFU/G|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|U|CAREGIVER|ONCOLOGIST|N|4||88||BASELINE|1963-01-07|
TRIAL STUDY 134XCP|TR|EA7375B6-38F0-49AE-8AD7-65CB0D30147B|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CM/S|EQUIVOCAL||CCID 50/ML|NOT DONE|||CONTRAST ENHANCED MRI|N|Y|INVESTIGATOR|READER 1|NA|5||7||RUN-IN|1965-06-11|
TRIAL STUDY 134XCP|TR|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||GRAVITATIONAL UNIT|EQUIVOCAL||/H|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|U|FAMILY MEMBER|READER|U|1||38||SCREENING|1970-01-09|
TRIAL STUDY 134XCP|TR|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||PMOL/DAY|PRESENT||IU|NOT DONE|||FLUORESCENT SPOT TEST|U|Y|SPOUSE|READER 2|NA|2||58||LONG-TERM FOLLOW-UP|1972-12-05|
TRIAL STUDY 134XCP|TR|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||UG/L/H|FURTHER ENLARGEMENT FROM NADIR||UOSM|NOT DONE|||ELISPOT|Y|Y|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1971-09-09|
TRIAL STUDY 134XCP|TR|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|4||||||NEWCONF|NEW TUMOR CONFIRMED||APS U|ENLARGEMENT FROM NADIR||MG/ML/DAY|NOT DONE|||CINEANGIOGRAPHY|NA|N|STUDY SUBJECT|ENDOCRINOLOGIST|N|4||88||WASHOUT|1971-07-19|
TRIAL STUDY 134XCP|TR|78FC925A-2702-41B4-8F7D-D20AB74EE8A9|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||UM2|NORMAL||MCI|NOT DONE|||HILLMEN COLOR CHART|N|N|VENDOR|MICROSCOPIST|NA|5||7||FOLLOW-UP|1971-03-09|
TRIAL STUDY 134XCP|TR|1E9C7E41-8565-4C60-9EEB-814914081596|1||||||LMBFLIND|LIMB FAILURE INDICATOR||PG/CELL|NON-PATHOLOGICAL||U/KG/MIN|NOT DONE|||GEL ELECTROPHORESIS|Y|Y|INVESTIGATOR|RADIOLOGIST 2|N|1||38||OBSERVATION|1966-04-05|
TRIAL STUDY 134XCP|TR|1E9C7E41-8565-4C60-9EEB-814914081596|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||L/DAY|NON-PATHOLOGICAL||IU/L|NOT DONE|||VIRUS PLAQUE ASSAY|Y|Y|FAMILY MEMBER|INTERNIST|NA|2||58||INDUCTION TREATMENT|1966-02-24|
TRIAL STUDY 134XCP|TR|1E9C7E41-8565-4C60-9EEB-814914081596|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||TUBE|UNEQUIVOCAL||KCAL|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|N|NA|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|3||39||WASHOUT|1968-01-22|
TRIAL STUDY 134XCP|TR|1E9C7E41-8565-4C60-9EEB-814914081596|4||||||LDIAM|LONGEST DIAMETER||UG/KG/MIN|INCREASED||TRACE|NOT DONE|||RIA|N|NA|CAREGIVER|READER 1|Y|4||88||RUN-IN|1962-03-31|
TRIAL STUDY 134XCP|TR|1E9C7E41-8565-4C60-9EEB-814914081596|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||CL|DIFFUSELY INCREASED||MG/G/H|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|N|U|GUARDIAN|NEUROLOGIST|NA|5||7||BASELINE|1966-04-03|
TRIAL STUDY 134XCP|TR|D7A008CF-5990-4D74-934A-A4DD3180EBD4|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||AMP|UNCHANGED||FRAMES/S|NOT DONE|||OSCILLOMETRY|N|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|1||38||SCREENING|1960-10-14|
TRIAL STUDY 134XCP|TR|D7A008CF-5990-4D74-934A-A4DD3180EBD4|2||||||PALPSTAT|PALPABLE STATE||10^3 DNA COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||/CMH2O|NOT DONE|||SANGER SEQUENCING|N|Y|SIBLING|UROLOGIST|NA|2||58||WASHOUT|1966-03-28|
TRIAL STUDY 134XCP|TR|D7A008CF-5990-4D74-934A-A4DD3180EBD4|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||PMOL/L|NON-PATHOLOGICAL||FINGERTIP UNIT|NOT DONE|||ULTRASOUND|Y|NA|PROXY|ADJUDICATOR 2|U|3||39||RUN-IN|1968-11-05|
TRIAL STUDY 134XCP|TR|D7A008CF-5990-4D74-934A-A4DD3180EBD4|4||||||VDIAM|VIABLE DIAMETER||ML/KG/MIN|FURTHER ENLARGEMENT FROM NADIR||PFU/ANIMAL|NOT DONE|||EEG|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|4||88||TREATMENT|1960-11-22|
TRIAL STUDY 134XCP|TR|D7A008CF-5990-4D74-934A-A4DD3180EBD4|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||P|FURTHER ENLARGEMENT||NCI|NOT DONE|||RADIATION DOSIMETRY|U|NA|CAREGIVER|ADJUDICATOR 2|NA|5||7||INDUCTION TREATMENT|1960-09-23|
TRIAL STUDY 134XCP|TR|C168FA23-40EE-46D8-9A56-8B80490A0EFB|1||||||PALPSTAT|PALPABLE STATE||KIT|DECREASED||G/DL|NOT DONE|||SCINTIGRAPHY|Y|N|ADJUDICATION COMMITTEE|RATER 1|NA|1||38||SCREENING|1960-07-20|
TRIAL STUDY 134XCP|TR|C168FA23-40EE-46D8-9A56-8B80490A0EFB|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||SIEMENS|PALPABLE||MM/2H|NOT DONE|||MRS|N|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|2||58||INDUCTION TREATMENT|1963-06-23|
TRIAL STUDY 134XCP|TR|C168FA23-40EE-46D8-9A56-8B80490A0EFB|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||% INHIBITION|INCREASED||RFU|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|U|NA|FRIEND|READER 2|U|3||39||TREATMENT|1968-03-27|
TRIAL STUDY 134XCP|TR|C168FA23-40EE-46D8-9A56-8B80490A0EFB|4||||||AREA|AREA||CD*S/M2|NONPALPABLE||RATIO|NOT DONE|||PATHOLOGICAL EVALUATION|NA|N|ADJUDICATOR|CARDIOLOGIST|U|4||88||OPEN LABEL TREATMENT|1972-05-04|
TRIAL STUDY 134XCP|TR|C168FA23-40EE-46D8-9A56-8B80490A0EFB|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||STEPS/MIN|INCREASED||UMOL/MIN|NOT DONE|||DOPPLER ULTRASOUND|NA|U|STUDY SUBJECT|RADIOLOGIST|NA|5||7||INDUCTION TREATMENT|1962-11-08|
TRIAL STUDY 134XCP|TR|215E4E69-70C3-493C-9D67-F717363E8138|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UG|FURTHER ENLARGEMENT||/LSQN|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|U|N|CAREGIVER|CLINICAL PATHOLOGIST|U|1||38||OBSERVATION|1973-05-05|
TRIAL STUDY 134XCP|TR|215E4E69-70C3-493C-9D67-F717363E8138|2||||||LESFLIND|LESION FAILURE INDICATOR||/MM|UNEQUIVOCAL||BEAM BREAKS|NOT DONE|||SLIT LAMP|NA|N|SIBLING|ADJUDICATOR 1|U|2||58||INDUCTION TREATMENT|1968-05-06|
TRIAL STUDY 134XCP|TR|215E4E69-70C3-493C-9D67-F717363E8138|3||||||LNSTATE|LYMPH NODE STATE||CM H2O|PATHOLOGICAL||MEQ/ML|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|U|SPOUSE|ADJUDICATOR 3|U|3||39||INDUCTION TREATMENT|1967-07-02|
TRIAL STUDY 134XCP|TR|215E4E69-70C3-493C-9D67-F717363E8138|4||||||LMBFLIND|LIMB FAILURE INDICATOR||HR/DAY|UNCHANGED||FT2|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|NA|Y|ADJUDICATOR|INTERNIST|Y|4||88||LONG-TERM FOLLOW-UP|1968-07-09|
TRIAL STUDY 134XCP|TR|215E4E69-70C3-493C-9D67-F717363E8138|5||||||ORSTATE|ORGAN STATE||CGY|PATHOLOGICAL||CIGAR|NOT DONE|||SNP ARRAY|U|N|SIBLING|READER 1|Y|5||7||CONTINUATION TREATMENT|1973-07-24|
TRIAL STUDY 134XCP|TR|962CD4CA-AF22-42FB-ADB5-85F76850CA81|1||||||VOLUME|VOLUME||UM2|INCREASED||ML/MMHG/MIN/L|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|U|NA|CHILD|MICROSCOPIST 3|N|1||38||TREATMENT|1967-01-12|
TRIAL STUDY 134XCP|TR|962CD4CA-AF22-42FB-ADB5-85F76850CA81|2||||||VDIAM|VIABLE DIAMETER||ML/DAY|INCREASED||DL|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|N|Y|DOMESTIC PARTNER|NEUROLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1960-11-22|
TRIAL STUDY 134XCP|TR|962CD4CA-AF22-42FB-ADB5-85F76850CA81|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||NKAT|INCREASED||U/CL|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|Y|PROXY|ADJUDICATOR 1|N|3||39||FOLLOW-UP|1972-11-02|
TRIAL STUDY 134XCP|TR|962CD4CA-AF22-42FB-ADB5-85F76850CA81|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/LPF|FURTHER ENLARGEMENT FROM NADIR||GBQ/UG|NOT DONE|||HPLC-FL|U|NA|INVESTIGATOR|OPHTHALMOLOGIST|Y|4||88||BLINDED TREATMENT|1968-02-12|
TRIAL STUDY 134XCP|TR|962CD4CA-AF22-42FB-ADB5-85F76850CA81|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||BOLUS|DECREASED||WAFER|NOT DONE|||ELECTROCHEMILUMINESCENCE|Y|N|FRIEND|MICROSCOPIST|N|5||7||OPEN LABEL TREATMENT|1969-11-08|
TRIAL STUDY 134XCP|TR|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|1||||||ORSTATE|ORGAN STATE||10^7 PFU|FOCALLY INCREASED||G/DL|NOT DONE|||PULMONARY ANGIOGRAPHY|N|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1||38||INDUCTION TREATMENT|1972-12-08|
TRIAL STUDY 134XCP|TR|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|2||||||VOLUME|VOLUME||FMOL/L/SEC|TUMOR MERGED||UG/CM2|NOT DONE|||MICRONEUTRALIZATION ASSAY|N|NA|DOMESTIC PARTNER|MICROSCOPIST 1|U|2||58||SCREENING|1962-11-24|
TRIAL STUDY 134XCP|TR|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||LENS|DECREASED||RFU|NOT DONE|||WHOLE EXOME SEQUENCING|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|3||39||BASELINE|1967-09-12|
TRIAL STUDY 134XCP|TR|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|4||||||NEWCONF|NEW TUMOR CONFIRMED||MKAT|FURTHER ENLARGEMENT FROM NADIR||IU/MMOL|NOT DONE|||INFRARED SPECTROMETRY|U|NA|SIBLING|DERMATOLOGIST|NA|4||88||OBSERVATION|1968-04-10|
TRIAL STUDY 134XCP|TR|B77019D6-644D-4FAF-ACBF-B4DEB4C12792|5||||||LNSTATE|LYMPH NODE STATE||JAR|FURTHER ENLARGEMENT FROM NADIR||FOZ_BR|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|N|U|CHILD|OTOLARYNGOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1961-10-08|
TRIAL STUDY 134XCP|TR|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PRESSOR UNITS|PALPABLE||USEC|NOT DONE|||SPECT/CT SCAN|NA|NA|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||OPEN LABEL TREATMENT|1970-04-04|
TRIAL STUDY 134XCP|TR|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||DPM/0.5 ML|NON-PATHOLOGICAL||WATT|NOT DONE|||ICP-MS|U|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|2||58||FOLLOW-UP|1973-05-05|
TRIAL STUDY 134XCP|TR|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|3||||||RADIODEN|RADIODENSITY||BAG|ABSENT||UEQ|NOT DONE|||EIA|NA|N|SIBLING|PATHOLOGIST 2|Y|3||39||TREATMENT|1968-12-27|
TRIAL STUDY 134XCP|TR|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|4||||||VSLPIND|VESSEL PATENCY INDICATOR||PMOL/10^10 CELLS|PATHOLOGICAL||G/CAGE|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|U|NA|INDEPENDENT ASSESSOR|INTERNIST|U|4||88||OBSERVATION|1960-01-01|
TRIAL STUDY 134XCP|TR|681FAE2B-387D-4B58-B2A6-4682B9F18EAD|5||||||ORVERLN|ORGAN VERTICAL LENGTH||KG/CM|ABSENT||LOG10 ELISA UNIT/DOSE|NOT DONE|||REFLECTANCE SPECTROSCOPY|U|N|SIBLING|OPHTHALMOLOGIST|NA|5||7||FOLLOW-UP|1963-08-20|
TRIAL STUDY 134XCP|TR|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UKAT|UNEQUIVOCAL||U/G/DAY|NOT DONE|||AGAR DILUTION|N|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|1||38||BLINDED TREATMENT|1966-01-14|
TRIAL STUDY 134XCP|TR|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||KCAL/DAY|NONPALPABLE||MONTHS|NOT DONE|||LC-FL|U|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-06-14|
TRIAL STUDY 134XCP|TR|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ML/MIN/MMHG|ABSENT||TABLET|NOT DONE|||HPLC/MS|N|U|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|U|3||39||FOLLOW-UP|1964-10-13|
TRIAL STUDY 134XCP|TR|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||UG/M2/DAY|INCREASED||PMOL/L/H|NOT DONE|||CONTRAST ENHANCED X-RAY|NA|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|4||88||TREATMENT|1963-04-05|
TRIAL STUDY 134XCP|TR|EC3C1DFC-5FA4-4F2E-9486-C2D17486EEF7|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||SEC|UNEQUIVOCAL||INHALATION|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|Y|Y|DOMESTIC PARTNER|ONCOLOGIST 1|NA|5||7||INDUCTION TREATMENT|1973-01-03|
TRIAL STUDY 134XCP|TR|4A5A02C2-F875-4146-B58D-9E0E4F00527D|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||DPM/0.5 ML|TUMOR MERGED||KBQ|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|N|U|ADJUDICATION COMMITTEE|OPTOMETRIST|N|1||38||SCREENING|1972-11-03|
TRIAL STUDY 134XCP|TR|4A5A02C2-F875-4146-B58D-9E0E4F00527D|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||IU/ML|INCREASED||IU/DAY|NOT DONE|||PH METER MEASUREMENT METHOD|Y|N|PARENT|ONCOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1966-03-19|
TRIAL STUDY 134XCP|TR|4A5A02C2-F875-4146-B58D-9E0E4F00527D|3||||||SUMVOL|SUM OF VOLUME||ML/S/M2|NONPALPABLE||10^5/HPF|NOT DONE|||DYNAMIC LIGHT SCATTERING|N|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|3||39||RUN-IN|1960-01-19|
TRIAL STUDY 134XCP|TR|4A5A02C2-F875-4146-B58D-9E0E4F00527D|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CUP|TUMOR MERGED||G/CAGE|NOT DONE|||CELL OF ORIGIN ASSAY|Y|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1968-04-29|
TRIAL STUDY 134XCP|TR|4A5A02C2-F875-4146-B58D-9E0E4F00527D|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||TABLET|NORMAL||/DAY|NOT DONE|||ANGIOGRAPHY|Y|U|SPOUSE|READER 2|U|5||7||TREATMENT|1960-04-24|
TRIAL STUDY 134XCP|TR|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||NG/L|FURTHER ENLARGEMENT||OZ EQ|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|U|SPOUSE|READER 2|NA|1||38||OPEN LABEL TREATMENT|1967-08-28|
TRIAL STUDY 134XCP|TR|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||UG/M2/H|UNCHANGED||NMOL BCE/MMOL|NOT DONE|||CALIPER MEASUREMENT METHOD|N|Y|FRIEND|ADJUDICATOR|NA|2||58||LONG-TERM FOLLOW-UP|1961-10-02|
TRIAL STUDY 134XCP|TR|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|3||||||BNLNUM|NUMBER OF BONE LESIONS||MIU/L|ABSENT||/10^5|NOT DONE|||TONOMETRY|NA|NA|DOMESTIC PARTNER|ONCOLOGIST|NA|3||39||SCREENING|1962-11-24|
TRIAL STUDY 134XCP|TR|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|4||||||AREA|AREA||GPELISA UNIT/ML|TUMOR MERGED||KBQ|NOT DONE|||LEAD CITRATE STAIN|Y|Y|ADJUDICATOR|READER 1|Y|4||88||LONG-TERM FOLLOW-UP|1972-11-02|
TRIAL STUDY 134XCP|TR|5529CF4E-3210-4D8E-80E8-2D7DDFB81EA6|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^6 ORGANISMS/G|DECREASED||MU/G|NOT DONE|||THICK SMEAR|Y|U|CHILD|ADJUDICATOR 2|N|5||7||BLINDED TREATMENT|1973-09-03|
TRIAL STUDY 134XCP|TR|859D9297-58D0-4740-899D-E7BEC931D419|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MMOL|DIFFUSELY INCREASED||/HPF|NOT DONE|||ACRIDINE ORANGE STAIN|U|NA|INVESTIGATOR|MICROSCOPIST 2|NA|1||38||RUN-IN|1965-03-15|
TRIAL STUDY 134XCP|TR|859D9297-58D0-4740-899D-E7BEC931D419|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||BQ/ML|ABSENT||CM2|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|N|U|FRIEND|RADIOLOGIST 2|N|2||58||WASHOUT|1964-05-30|
TRIAL STUDY 134XCP|TR|859D9297-58D0-4740-899D-E7BEC931D419|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||DIOPTER|INCREASED||10^6/HPF|NOT DONE|||MEDIASTINOSCOPY|NA|Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|3||39||WASHOUT|1967-03-28|
TRIAL STUDY 134XCP|TR|859D9297-58D0-4740-899D-E7BEC931D419|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||G/M2/DAY|DECREASED||10^12 IU/L|NOT DONE|||MULTI-SLICE SPIRAL CT|U|U|GUARDIAN|RADIOLOGIST 1|U|4||88||CONTINUATION TREATMENT|1960-09-24|
TRIAL STUDY 134XCP|TR|859D9297-58D0-4740-899D-E7BEC931D419|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||VOXEL|ENLARGEMENT||KG/CM2|NOT DONE|||OLIGO ACGH|NA|NA|PROXY|ADJUDICATOR|N|5||7||SCREENING|1965-11-08|
TRIAL STUDY 134XCP|TR|A1E34C29-91C2-4C2B-942E-84CD6A10A056|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||UMOL/L/H|ENLARGEMENT||10^3 ORGANISMS/ML|NOT DONE|||CALIPER MEASUREMENT METHOD|NA|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1||38||WASHOUT|1964-01-20|
TRIAL STUDY 134XCP|TR|A1E34C29-91C2-4C2B-942E-84CD6A10A056|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/ANIMAL/DAY|PRESENT||MEQ/DAY|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|U|CAREGIVER|ADJUDICATOR 3|U|2||58||WASHOUT|1971-04-30|
TRIAL STUDY 134XCP|TR|A1E34C29-91C2-4C2B-942E-84CD6A10A056|3||||||LMBFLIND|LIMB FAILURE INDICATOR||MMHG*MIN/L|NON-PATHOLOGICAL||ML/MIN|NOT DONE|||KNEMOMETRY|NA|U|VENDOR|OPTOMETRIST|NA|3||39||FOLLOW-UP|1964-03-12|
TRIAL STUDY 134XCP|TR|A1E34C29-91C2-4C2B-942E-84CD6A10A056|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||COPIES/UL|DIFFUSELY INCREASED||10^9 ORGANISMS/G|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|N|N|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|4||88||CONTINUATION TREATMENT|1963-12-31|
TRIAL STUDY 134XCP|TR|A1E34C29-91C2-4C2B-942E-84CD6A10A056|5||||||LESSCIND|LESION SUCCESS INDICATOR||SV|EQUIVOCAL||TSP EQ|NOT DONE|||SMEAR|U|N|ADJUDICATOR|ONCOLOGIST|NA|5||7||SCREENING|1964-10-27|
TRIAL STUDY 134XCP|TR|4E5FF284-E15A-421D-BC13-94655EEFE540|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||FEU|PALPABLE||MEQ/G|NOT DONE|||BIOPSY|NA|U|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|1||38||BLINDED TREATMENT|1969-12-25|
TRIAL STUDY 134XCP|TR|4E5FF284-E15A-421D-BC13-94655EEFE540|2||||||LESFLIND|LESION FAILURE INDICATOR||ML/ANIMAL/WK|FURTHER ENLARGEMENT FROM NADIR||MEQ|NOT DONE|||WHOLE GENOME SEQUENCING|NA|N|VENDOR|ONCOLOGIST|N|2||58||SCREENING|1968-04-15|
TRIAL STUDY 134XCP|TR|4E5FF284-E15A-421D-BC13-94655EEFE540|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||CI/KG|ABSENT||CIGARETTE|NOT DONE|||FLUORESCENT IMMUNOASSAY|Y|N|VENDOR|PEDIATRIC NEUROLOGIST|U|3||39||WASHOUT|1962-03-14|
TRIAL STUDY 134XCP|TR|4E5FF284-E15A-421D-BC13-94655EEFE540|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MONTHS|NORMAL||PELLET|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|NA|NA|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|4||88||BLINDED TREATMENT|1968-09-19|
TRIAL STUDY 134XCP|TR|4E5FF284-E15A-421D-BC13-94655EEFE540|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||NMOL/G|FURTHER ENLARGEMENT||GRAVITATIONAL UNIT|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|U|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|NA|5||7||BLINDED TREATMENT|1967-07-05|
TRIAL STUDY 134XCP|TR|30BAB760-662A-41DF-9599-CBE0BC3A57D9|1||||||PALPSTAT|PALPABLE STATE||%(W/V)|ENLARGEMENT||GPS U|NOT DONE|||RULER MEASUREMENT METHOD|NA|NA|PARENT|RADIOLOGIST 1|U|1||38||FOLLOW-UP|1966-06-30|
TRIAL STUDY 134XCP|TR|30BAB760-662A-41DF-9599-CBE0BC3A57D9|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||RING|PALPABLE||NMOL/L/MIN|NOT DONE|||ISHIHARA COLOR PLATES|N|Y|FAMILY MEMBER|OPHTHALMOLOGIST|N|2||58||SCREENING|1960-07-12|
TRIAL STUDY 134XCP|TR|30BAB760-662A-41DF-9599-CBE0BC3A57D9|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KBQ|NONPALPABLE||OZ EQ|NOT DONE|||FUNCTIONAL MRI|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3||39||CONTINUATION TREATMENT|1964-03-05|
TRIAL STUDY 134XCP|TR|30BAB760-662A-41DF-9599-CBE0BC3A57D9|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||G|FURTHER ENLARGEMENT FROM NADIR||VG/KG|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|N|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4||88||CONTINUATION TREATMENT|1961-06-28|
TRIAL STUDY 134XCP|TR|30BAB760-662A-41DF-9599-CBE0BC3A57D9|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||UG/H|ENLARGEMENT FROM NADIR||UM/S|NOT DONE|||MULTI-SLICE SPIRAL CT|Y|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||OPEN LABEL TREATMENT|1973-07-23|
TRIAL STUDY 134XCP|TR|8747C2AB-18EB-430B-8E89-CF9183DBF322|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||APL U/ML|DIFFUSELY INCREASED||MOL/DAY|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|N|CAREGIVER|PHYSIOTHERAPIST|U|1||38||BASELINE|1968-08-22|
TRIAL STUDY 134XCP|TR|8747C2AB-18EB-430B-8E89-CF9183DBF322|2||||||NEWCONF|NEW TUMOR CONFIRMED||MM/MIN|PRESENT||M3|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|U|U|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|U|2||58||OPEN LABEL TREATMENT|1965-12-10|
TRIAL STUDY 134XCP|TR|8747C2AB-18EB-430B-8E89-CF9183DBF322|3||||||LESSCIND|LESION SUCCESS INDICATOR||1/(S*KPA)|DECREASED||ML/DOSE|NOT DONE|||IMMUNO-PET SCAN|N|U|ADJUDICATOR|PHYSIOTHERAPIST|Y|3||39||FOLLOW-UP|1969-10-26|
TRIAL STUDY 134XCP|TR|8747C2AB-18EB-430B-8E89-CF9183DBF322|4||||||VDIAM|VIABLE DIAMETER||10^3/HPF|INCREASED||DEG2|NOT DONE|||SPECTROPHOTOMETRY|U|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|4||88||OPEN LABEL TREATMENT|1972-09-23|
TRIAL STUDY 134XCP|TR|8747C2AB-18EB-430B-8E89-CF9183DBF322|5||||||AREA|AREA||IU/ML|UNCHANGED||CCID 50/ML|NOT DONE|||PATHOLOGICAL EVALUATION|N|Y|STUDY SUBJECT|MICROSCOPIST 2|N|5||7||FOLLOW-UP|1969-11-30|
TRIAL STUDY 134XCP|TR|5A0FF15D-E779-47BA-8D3C-247A0FA57854|1||||||BNLNUM|NUMBER OF BONE LESIONS||MIN|DIFFUSELY INCREASED||DISK|NOT DONE|||KLEIHAUER-BETKE|N|U|INTERVIEWER|ADJUDICATOR 1|N|1||38||INDUCTION TREATMENT|1962-09-30|
TRIAL STUDY 134XCP|TR|5A0FF15D-E779-47BA-8D3C-247A0FA57854|2||||||LPERP|LONGEST PERPENDICULAR||G/U|TUMOR MERGED||GRAVITATIONAL UNIT|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|Y|U|CLINICAL RESEARCH COORDINATOR|READER 2|N|2||58||SCREENING|1965-12-18|
TRIAL STUDY 134XCP|TR|5A0FF15D-E779-47BA-8D3C-247A0FA57854|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/KG/DAY|FURTHER ENLARGEMENT FROM NADIR||ML/G/DAY|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|Y|DOMESTIC PARTNER|READER 2|NA|3||39||BASELINE|1969-12-02|
TRIAL STUDY 134XCP|TR|5A0FF15D-E779-47BA-8D3C-247A0FA57854|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||KHZ|DIFFUSELY INCREASED||L/S|NOT DONE|||CHROMATOGRAPHY|NA|NA|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|4||88||TREATMENT|1962-11-07|
TRIAL STUDY 134XCP|TR|5A0FF15D-E779-47BA-8D3C-247A0FA57854|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||L/H/M2|DIFFUSELY INCREASED||10^8 PFU|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|NA|VENDOR|MICROSCOPIST 1|Y|5||7||INDUCTION TREATMENT|1971-02-01|
TRIAL STUDY 134XCP|TR|73260E60-6ADB-44DA-9A45-776B91F8B453|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CPM|PALPABLE||TCID 50/DOSE|NOT DONE|||WESTERGREN|NA|U|CAREGIVER|OPHTHALMOLOGIST|N|1||38||TREATMENT|1965-09-11|
TRIAL STUDY 134XCP|TR|73260E60-6ADB-44DA-9A45-776B91F8B453|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UV|FURTHER ENLARGEMENT||SYRINGE|NOT DONE|||PET/CT SCAN|N|Y|SIBLING|PHYSIOTHERAPIST|U|2||58||LONG-TERM FOLLOW-UP|1960-08-12|
TRIAL STUDY 134XCP|TR|73260E60-6ADB-44DA-9A45-776B91F8B453|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/LSQN|PATHOLOGICAL||UG/M2/MIN|NOT DONE|||DIGITAL PCR|NA|N|INTERVIEWER|ADJUDICATOR 2|N|3||39||FOLLOW-UP|1962-08-20|
TRIAL STUDY 134XCP|TR|73260E60-6ADB-44DA-9A45-776B91F8B453|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MG/KG/H|FURTHER ENLARGEMENT FROM NADIR||MU|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|N|NA|FRIEND|ADJUDICATOR 1|N|4||88||SCREENING|1967-08-07|
TRIAL STUDY 134XCP|TR|73260E60-6ADB-44DA-9A45-776B91F8B453|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||10^7/L|UNCHANGED||ML/MIN|NOT DONE|||CYSTOMETRY|Y|U|PARENT|ADJUDICATOR 3|NA|5||7||RUN-IN|1967-03-25|
TRIAL STUDY 134XCP|TR|7B64252E-9A08-4177-BFA9-45B0C0E53097|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ROENTGEN|UNEQUIVOCAL||UEQ|NOT DONE|||HIGH RESOLUTION CT|NA|Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|N|1||38||SCREENING|1971-04-05|
TRIAL STUDY 134XCP|TR|7B64252E-9A08-4177-BFA9-45B0C0E53097|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||TESLA|TUMOR MERGED||OI50|NOT DONE|||POTENTIOMETRY|N|N|PARENT|PATHOLOGIST 2|U|2||58||TREATMENT|1962-07-24|
TRIAL STUDY 134XCP|TR|7B64252E-9A08-4177-BFA9-45B0C0E53097|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||ELISA UNIT/DOSE|NON-PATHOLOGICAL||FMOL/G|NOT DONE|||MANUAL COUNT|N|U|SIGNIFICANT OTHER|READER 1|Y|3||39||WASHOUT|1964-06-27|
TRIAL STUDY 134XCP|TR|7B64252E-9A08-4177-BFA9-45B0C0E53097|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||U/KG/DAY|DIFFUSELY INCREASED||HOMEOPATHIC DILUTION|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|N|N|PARENT|RATER|Y|4||88||BLINDED TREATMENT|1964-04-29|
TRIAL STUDY 134XCP|TR|7B64252E-9A08-4177-BFA9-45B0C0E53097|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||PACKET|INCREASED||CM/S|NOT DONE|||MICROBIAL CULTURE, LIQUID|U|N|CHILD|ADJUDICATOR|U|5||7||RUN-IN|1968-08-27|
TRIAL STUDY 134XCP|TR|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ROENTGEN|UNCHANGED||UIU/L|NOT DONE|||FUNDUS PHOTOGRAPHY|Y|Y|INVESTIGATOR|READER 1|N|1||38||INDUCTION TREATMENT|1971-05-01|
TRIAL STUDY 134XCP|TR|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|2||||||LPERP|LONGEST PERPENDICULAR||MU/G|PRESENT||IU/KG/H|NOT DONE|||LEAD CITRATE STAIN|N|N|ADJUDICATOR|MICROSCOPIST 3|N|2||58||LONG-TERM FOLLOW-UP|1968-03-13|
TRIAL STUDY 134XCP|TR|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|3||||||CALCFIND|CALCIFICATION INDICATOR||CYCLE/MIN|EQUIVOCAL||CMHG|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|NA|U|HEALTH CARE PROFESSIONAL|RATER|U|3||39||CONTINUATION TREATMENT|1972-08-20|
TRIAL STUDY 134XCP|TR|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|4||||||AREA|AREA||U/ANIMAL|PRESENT||G/G/DAY|NOT DONE|||PANENDOSCOPY|Y|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|4||88||SCREENING|1961-12-31|
TRIAL STUDY 134XCP|TR|D56FE2B1-BCCC-4113-A1C1-CBFE9A46CB75|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||AFU|FURTHER ENLARGEMENT FROM NADIR||PRESSOR UNITS|NOT DONE|||ELECTROPHORESIS|N|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1973-05-23|
TRIAL STUDY 134XCP|TR|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MOL/MOL|FOCALLY INCREASED||FEU|NOT DONE|||ALCIAN BLUE STAIN|NA|Y|INVESTIGATOR|MICROSCOPIST 3|NA|1||38||CONTINUATION TREATMENT|1966-07-22|
TRIAL STUDY 134XCP|TR|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|2||||||RADIODEN|RADIODENSITY||MOL|TUMOR MERGED||NMOL|NOT DONE|||GRAM STAIN|U|NA|SIGNIFICANT OTHER|READER 2|NA|2||58||TREATMENT|1969-07-09|
TRIAL STUDY 134XCP|TR|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U/ML|UNEQUIVOCAL||CFU/ML|NOT DONE|||SNELLEN EYE CHART|Y|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||BASELINE|1971-10-30|
TRIAL STUDY 134XCP|TR|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|4||||||VSLPIND|VESSEL PATENCY INDICATOR||ARBITRARY U|NONPALPABLE||/100 HPFS|NOT DONE|||CLIP SEQUENCING|U|U|SIBLING|NEUROLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1962-08-04|
TRIAL STUDY 134XCP|TR|77F7428C-A160-4EC1-A2F5-96DACA1DEFA3|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||AMPULE|ENLARGEMENT FROM NADIR||MMOL/S|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|U|U|FAMILY MEMBER|OTOLARYNGOLOGIST|N|5||7||FOLLOW-UP|1966-10-20|
TRIAL STUDY 134XCP|TR|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||DROP|INCREASED||10^5/HPF|NOT DONE|||SPECULAR MICROSCOPY|U|Y|SPOUSE|ONCOLOGIST|U|1||38||OPEN LABEL TREATMENT|1971-03-04|
TRIAL STUDY 134XCP|TR|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||10^3 CFU/G|PRESENT||ML/CAGE/WK|NOT DONE|||GC/MS-EI|N|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|2||58||BLINDED TREATMENT|1966-03-03|
TRIAL STUDY 134XCP|TR|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CYLINDER|NON-PATHOLOGICAL||MG/CM2|NOT DONE|||MANUAL COUNT|Y|N|CHILD|CARDIOLOGIST|N|3||39||RUN-IN|1960-09-03|
TRIAL STUDY 134XCP|TR|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MCI/KG|ABSENT||ML/S/M2|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|U|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|4||88||CONTINUATION TREATMENT|1972-10-07|
TRIAL STUDY 134XCP|TR|4BB780B0-E326-44B5-8EA7-88C92CE5ABE1|5||||||TUMSTATE|TUMOR STATE||MET|FOCALLY INCREASED||NCI|NOT DONE|||MALDI|NA|N|ADJUDICATION COMMITTEE|READER 3|Y|5||7||TREATMENT|1968-04-07|
TRIAL STUDY 134XCP|TR|1B0EE182-6729-4333-BB9B-5561CAB31D26|1||||||ORVERLN|ORGAN VERTICAL LENGTH||UM/S|DECREASED||1/(S*KPA)|NOT DONE|||THIN SMEAR|N|U|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||BLINDED TREATMENT|1971-07-13|
TRIAL STUDY 134XCP|TR|1B0EE182-6729-4333-BB9B-5561CAB31D26|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||BREATHS/MIN|DECREASED||RAD|NOT DONE|||SPECTROPHOTOMETRY|NA|U|PROXY|PATHOLOGIST 1|U|2||58||CONTINUATION TREATMENT|1963-08-23|
TRIAL STUDY 134XCP|TR|1B0EE182-6729-4333-BB9B-5561CAB31D26|3||||||VOLUME|VOLUME||TRANSDUCING UNIT|PALPABLE||NMOL BCE/MMOL|NOT DONE|||QUANTITATIVE ULTRASOUND|Y|NA|CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|3||39||OPEN LABEL TREATMENT|1968-08-11|
TRIAL STUDY 134XCP|TR|1B0EE182-6729-4333-BB9B-5561CAB31D26|4||||||ORSTATE|ORGAN STATE||ML/MMHG|INCREASED||10^3/L|NOT DONE|||FISH|Y|U|SIGNIFICANT OTHER|READER|N|4||88||BASELINE|1965-04-18|
TRIAL STUDY 134XCP|TR|1B0EE182-6729-4333-BB9B-5561CAB31D26|5||||||LESSCIND|LESION SUCCESS INDICATOR||UIU/DL|NORMAL||UGEQ/L|NOT DONE|||MIGET|U|NA|GUARDIAN|PATHOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1961-09-08|
TRIAL STUDY 134XCP|TR|1F3AD620-4B16-4EFF-8F5A-45105841BE02|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CI/UG|ENLARGEMENT FROM NADIR||DPM/100MG|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|NA|ADJUDICATOR|HEMATOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1969-02-18|
TRIAL STUDY 134XCP|TR|1F3AD620-4B16-4EFF-8F5A-45105841BE02|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||ENZYME U/M2|ENLARGEMENT FROM NADIR||DRUM|NOT DONE|||VIRUS PLAQUE ASSAY|N|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|2||58||INDUCTION TREATMENT|1962-12-14|
TRIAL STUDY 134XCP|TR|1F3AD620-4B16-4EFF-8F5A-45105841BE02|3||||||ORVERLN|ORGAN VERTICAL LENGTH||UMOL/MG/MIN|ABSENT||10^6 COPIES/ML|NOT DONE|||PANENDOSCOPY|U|U|SIGNIFICANT OTHER|ONCOLOGIST|NA|3||39||OBSERVATION|1971-05-21|
TRIAL STUDY 134XCP|TR|1F3AD620-4B16-4EFF-8F5A-45105841BE02|4||||||SUMVOL|SUM OF VOLUME||NSEC|PALPABLE||10^7 CFU/ML|NOT DONE|||AURAMINE STAIN|N|NA|FRIEND|RADIOLOGIST 1|Y|4||88||SCREENING|1962-08-17|
TRIAL STUDY 134XCP|TR|1F3AD620-4B16-4EFF-8F5A-45105841BE02|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MG2/DL2|ABSENT||UCI|NOT DONE|||NUCLEIC ACID BASED METHOD|U|U|HEALTH CARE PROFESSIONAL|READER 3|U|5||7||BLINDED TREATMENT|1968-03-25|
TRIAL STUDY 134XCP|TR|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|1||||||ORSTATE|ORGAN STATE||BP|DIFFUSELY INCREASED||MASK|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|Y|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|1||38||CONTINUATION TREATMENT|1969-11-04|
TRIAL STUDY 134XCP|TR|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|2||||||CALCFIND|CALCIFICATION INDICATOR||U/ML|ENLARGEMENT||UMOL/MIN|NOT DONE|||PEAK FLOWMETRY|U|N|PARENT|ADJUDICATOR 2|NA|2||58||BLINDED TREATMENT|1968-06-24|
TRIAL STUDY 134XCP|TR|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMAL|NONPALPABLE||BAG|NOT DONE|||THICK SMEAR|Y|N|ADJUDICATOR|MICROSCOPIST 3|NA|3||39||RUN-IN|1968-09-22|
TRIAL STUDY 134XCP|TR|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||U/CL|PATHOLOGICAL||SCOOPFUL|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|Y|ADJUDICATOR|NEUROLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1961-11-01|
TRIAL STUDY 134XCP|TR|05C77EE2-E4D7-4C2F-AF32-55FA95F1C791|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MG/H|ENLARGEMENT||U/ANIMAL|NOT DONE|||LC/MS/MS|NA|NA|SIBLING|MICROSCOPIST|Y|5||7||CONTINUATION TREATMENT|1964-10-14|
TRIAL STUDY 134XCP|TR|152147B0-6EAD-4124-8E1A-BD7707850B60|1||||||SUMDIAM|SUM OF DIAMETER||CPM|NONPALPABLE||KA_U/DL|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|N|N|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||CONTINUATION TREATMENT|1969-09-04|
TRIAL STUDY 134XCP|TR|152147B0-6EAD-4124-8E1A-BD7707850B60|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||UM/S|UNCHANGED||ARBITRARY U|NOT DONE|||BAC ACGH|N|NA|SIBLING|ENDOCRINOLOGIST|NA|2||58||TREATMENT|1973-01-06|
TRIAL STUDY 134XCP|TR|152147B0-6EAD-4124-8E1A-BD7707850B60|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||FARAD|UNCHANGED||TORR|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|Y|NA|STUDY SUBJECT|RATER 1|Y|3||39||RUN-IN|1972-04-06|
TRIAL STUDY 134XCP|TR|152147B0-6EAD-4124-8E1A-BD7707850B60|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||L/S/KPA|NON-PATHOLOGICAL||/MM|NOT DONE|||GC/MS/MS|U|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|4||88||RUN-IN|1967-07-06|
TRIAL STUDY 134XCP|TR|152147B0-6EAD-4124-8E1A-BD7707850B60|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||ABSORBANCE U/ML|PATHOLOGICAL||FRACTION OF 1|NOT DONE|||OPHTHALMOSCOPY|N|N|STUDY SUBJECT|NEUROLOGIST 1|NA|5||7||BLINDED TREATMENT|1962-08-01|
TRIAL STUDY 134XCP|TR|3CCF019C-5663-4670-B2D1-EC01D6B58D06|1||||||LNSTATE|LYMPH NODE STATE||MOL/ML|FOCALLY INCREASED||TUBERCULIN UNIT/ML|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|Y|NA|CHILD|ADJUDICATOR 1|N|1||38||OPEN LABEL TREATMENT|1973-04-29|
TRIAL STUDY 134XCP|TR|3CCF019C-5663-4670-B2D1-EC01D6B58D06|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||H*%|EQUIVOCAL||MV2/HZ|NOT DONE|||CELL OF ORIGIN ASSAY|NA|Y|GUARDIAN|ADJUDICATOR 2|N|2||58||WASHOUT|1970-06-24|
TRIAL STUDY 134XCP|TR|3CCF019C-5663-4670-B2D1-EC01D6B58D06|3||||||DIAMETER|DIAMETER||PMOL/DL|ENLARGEMENT FROM NADIR||GBQ/G|NOT DONE|||MICROARRAY|U|Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|3||39||SCREENING|1968-10-12|
TRIAL STUDY 134XCP|TR|3CCF019C-5663-4670-B2D1-EC01D6B58D06|4||||||LESFLIND|LESION FAILURE INDICATOR||ENZYME U|DIFFUSELY INCREASED||NG/L|NOT DONE|||MACRO BROTH DILUTION|N|NA|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1970-10-03|
TRIAL STUDY 134XCP|TR|3CCF019C-5663-4670-B2D1-EC01D6B58D06|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||VOXEL|ENLARGEMENT FROM NADIR||MIN|NOT DONE|||MRI|N|NA|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|5||7||RUN-IN|1961-03-07|
TRIAL STUDY 134XCP|TR|6599D082-A8A0-412D-BBDF-CD786C581905|1||||||SUMDIAM|SUM OF DIAMETER||CMH2O*S2/ML|ABSENT||CAL|NOT DONE|||RIA|NA|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|1||38||SCREENING|1969-11-12|
TRIAL STUDY 134XCP|TR|6599D082-A8A0-412D-BBDF-CD786C581905|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MG/ANIMAL|FURTHER ENLARGEMENT||U/ANIMAL|NOT DONE|||SICKLE CELL SOLUBILITY TEST|U|Y|PROXY|OTOLARYNGOLOGIST|N|2||58||TREATMENT|1965-03-06|
TRIAL STUDY 134XCP|TR|6599D082-A8A0-412D-BBDF-CD786C581905|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||NGEQ/L|TUMOR MERGED||NMOL/L/MIN|NOT DONE|||MICROBIAL CULTURE, LIQUID|NA|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1969-10-21|
TRIAL STUDY 134XCP|TR|6599D082-A8A0-412D-BBDF-CD786C581905|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||UGEQ|PALPABLE||U/KG|NOT DONE|||DROPLET DIGITAL PCR|Y|Y|SPOUSE|ONCOLOGIST 2|NA|4||88||BASELINE|1966-05-02|
TRIAL STUDY 134XCP|TR|6599D082-A8A0-412D-BBDF-CD786C581905|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NEBULE|NONPALPABLE||MG/DOSE|NOT DONE|||OPHTHALMOSCOPY|Y|U|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1962-05-25|
TRIAL STUDY 134XCP|TR|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||M/SEC2|INCREASED||PMOL/DAY|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|1||38||BASELINE|1972-03-15|
TRIAL STUDY 134XCP|TR|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||APL U/ML|PRESENT||TUBERCULIN UNIT|NOT DONE|||OBSERVATION|U|U|PROXY|RATER 1|U|2||58||BLINDED TREATMENT|1963-10-23|
TRIAL STUDY 134XCP|TR|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UIU/DL|ENLARGEMENT FROM NADIR||RPM|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|Y|DOMESTIC PARTNER|RADIOLOGIST 1|NA|3||39||OBSERVATION|1973-03-14|
TRIAL STUDY 134XCP|TR|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/M2|NORMAL||FT2|NOT DONE|||HEMAGGLUTINATION ASSAY|N|N|DOMESTIC PARTNER|ONCOLOGIST 2|NA|4||88||INDUCTION TREATMENT|1961-07-17|
TRIAL STUDY 134XCP|TR|BC6984EB-5C48-4299-BDCB-2063BC44A1F4|5||||||PALPSTAT|PALPABLE STATE||SBE/ML|FURTHER ENLARGEMENT FROM NADIR||UG/DAY|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|U|NA|CHILD|ADJUDICATOR 3|N|5||7||OBSERVATION|1960-10-30|
TRIAL STUDY 134XCP|TR|AAC3113C-793D-43F4-87E9-111246E03003|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||G/CAGE/WK|ABSENT||10^9/G|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|NA|N|SIBLING|OPTOMETRIST|N|1||38||BASELINE|1963-04-11|
TRIAL STUDY 134XCP|TR|AAC3113C-793D-43F4-87E9-111246E03003|2||||||DIAMETER|DIAMETER||/100 WBC|DIFFUSELY INCREASED||CAN|NOT DONE|||NO INFORMATION|NA|U|DOMESTIC PARTNER|MICROSCOPIST 2|U|2||58||OBSERVATION|1967-01-08|
TRIAL STUDY 134XCP|TR|AAC3113C-793D-43F4-87E9-111246E03003|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||UMOL/MOL|INCREASED||DEG2|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|U|N|INTERVIEWER|PATHOLOGIST|U|3||39||BASELINE|1963-05-07|
TRIAL STUDY 134XCP|TR|AAC3113C-793D-43F4-87E9-111246E03003|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||NMOL|ABSENT||EP U|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|N|Y|FAMILY MEMBER|ONCOLOGIST 2|U|4||88||BASELINE|1964-03-22|
TRIAL STUDY 134XCP|TR|AAC3113C-793D-43F4-87E9-111246E03003|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UMOL/MG/MIN|NONPALPABLE||10^7 CFU/ML|NOT DONE|||CELL BASED BIOASSAY|N|Y|CHILD|READER|N|5||7||INDUCTION TREATMENT|1970-08-19|
TRIAL STUDY 134XCP|TR|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CONTAINER|FOCALLY INCREASED||GY|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|NA|INDEPENDENT ASSESSOR|READER 1|Y|1||38||CONTINUATION TREATMENT|1971-06-11|
TRIAL STUDY 134XCP|TR|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||GBQ/MG|DIFFUSELY INCREASED||10^3 CFU/G|NOT DONE|||LYMPHANGIOGRAPHY|Y|Y|CAREGIVER|OTOLARYNGOLOGIST|NA|2||58||WASHOUT|1960-11-09|
TRIAL STUDY 134XCP|TR|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UCI|FOCALLY INCREASED||ML/CM3/MIN|NOT DONE|||TRYPAN BLUE STAIN|N|NA|INTERVIEWER|OPHTHALMOLOGIST|N|3||39||INDUCTION TREATMENT|1966-07-08|
TRIAL STUDY 134XCP|TR|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MET*H|PATHOLOGICAL||NMOL/MOL|NOT DONE|||PERCUSSION|NA|U|ADJUDICATOR|ADJUDICATOR 2|NA|4||88||FOLLOW-UP|1966-04-22|
TRIAL STUDY 134XCP|TR|2A6524EE-F1E9-4D0C-8CA2-E03C6350849A|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||CAL|PATHOLOGICAL||BEAM BREAKS|NOT DONE|||PLETHYSMOGRAPHY|N|N|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|5||7||TREATMENT|1964-05-10|
TRIAL STUDY 134XCP|TR|941A9CF9-872C-42CF-A409-129BE5A88520|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||RNA COPIES/ML|DIFFUSELY INCREASED||10^6 ORGANISMS/G|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|N|DOMESTIC PARTNER|ADJUDICATOR 2|Y|1||38||OPEN LABEL TREATMENT|1970-02-08|
TRIAL STUDY 134XCP|TR|941A9CF9-872C-42CF-A409-129BE5A88520|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||/4.0 ML|EQUIVOCAL||MBQ|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|NA|NA|INTERVIEWER|RADIOLOGIST 2|Y|2||58||BASELINE|1972-09-25|
TRIAL STUDY 134XCP|TR|941A9CF9-872C-42CF-A409-129BE5A88520|3||||||LDIAM|LONGEST DIAMETER||UG/L FEU|PRESENT||M2|NOT DONE|||PALM METHOD|Y|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|3||39||BLINDED TREATMENT|1961-12-12|
TRIAL STUDY 134XCP|TR|941A9CF9-872C-42CF-A409-129BE5A88520|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||FIU|DIFFUSELY INCREASED||HR/DAY|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|NA|INVESTIGATOR|RATER|Y|4||88||LONG-TERM FOLLOW-UP|1967-12-20|
TRIAL STUDY 134XCP|TR|941A9CF9-872C-42CF-A409-129BE5A88520|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ENZYME U|UNEQUIVOCAL||M/SEC2|NOT DONE|||LEAD CITRATE STAIN|N|Y|CHILD|PEDIATRIC NEUROLOGIST|Y|5||7||FOLLOW-UP|1965-12-01|
TRIAL STUDY 134XCP|TR|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|1||||||AREA|AREA||FL|NORMAL||JOULE|NOT DONE|||PET/MRI SCAN|N|U|GUARDIAN|ADJUDICATOR 3|Y|1||38||SCREENING|1961-05-28|
TRIAL STUDY 134XCP|TR|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UL|UNEQUIVOCAL||FOZ_BR|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|N|N|DOMESTIC PARTNER|READER|NA|2||58||OBSERVATION|1971-11-09|
TRIAL STUDY 134XCP|TR|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|3||||||PALPSTAT|PALPABLE STATE||MG/ML/MIN|FURTHER ENLARGEMENT FROM NADIR||L/DAY|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|U|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||FOLLOW-UP|1968-09-05|
TRIAL STUDY 134XCP|TR|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||NL|DIFFUSELY INCREASED||ML|NOT DONE|||CALCOFLUOR WHITE STAIN|NA|N|VENDOR|RATER 1|N|4||88||LONG-TERM FOLLOW-UP|1970-11-11|
TRIAL STUDY 134XCP|TR|D7F3E205-CF5D-4724-ABE1-CE2DD560FB38|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||UEQ|TUMOR MERGED||RNA COPIES/ML|NOT DONE|||CALCULATION|NA|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|5||7||TREATMENT|1967-04-01|
TRIAL STUDY 134XCP|TR|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||KCAL/DAY|INCREASED||CS|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|Y|N|SIGNIFICANT OTHER|READER 3|NA|1||38||WASHOUT|1970-07-01|
TRIAL STUDY 134XCP|TR|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|2||||||VDIAM|VIABLE DIAMETER||MCI/L|DIFFUSELY INCREASED||10^6 CFU/G|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|N|U|INVESTIGATOR|ONCOLOGIST 1|N|2||58||OPEN LABEL TREATMENT|1972-04-26|
TRIAL STUDY 134XCP|TR|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UCI/KG|UNEQUIVOCAL||KG/CM2|NOT DONE|||DISK DIFFUSION|NA|NA|PROXY|NEUROLOGIST|Y|3||39||FOLLOW-UP|1972-05-06|
TRIAL STUDY 134XCP|TR|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MASK|NONPALPABLE||10^4 CFU/ML|NOT DONE|||AMSLER GRID|NA|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||OBSERVATION|1960-06-26|
TRIAL STUDY 134XCP|TR|10814ECC-AEDF-4B8C-B514-BADC4D388ADE|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/KG/MIN|ABSENT||UKAT/L|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|N|NA|ADJUDICATOR|RADIOLOGIST 1|Y|5||7||CONTINUATION TREATMENT|1964-12-27|
TRIAL STUDY 134XCP|TR|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CL|FOCALLY INCREASED||/40 HPFS|NOT DONE|||INTERRUPTER TECHNIQUE|U|NA|DOMESTIC PARTNER|RATER 2|NA|1||38||OPEN LABEL TREATMENT|1960-01-23|
TRIAL STUDY 134XCP|TR|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|2||||||SUMDIAM|SUM OF DIAMETER||STRIP|NONPALPABLE||MU/L|NOT DONE|||LAPAROSCOPY|N|NA|PARENT|INTERNIST|U|2||58||OBSERVATION|1965-07-27|
TRIAL STUDY 134XCP|TR|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|3||||||VSLPIND|VESSEL PATENCY INDICATOR||CM/S|NONPALPABLE||MOL/MG|NOT DONE|||LIQUID SCINTILLATION COUNTING|U|NA|SPOUSE|RADIOLOGIST 1|N|3||39||OPEN LABEL TREATMENT|1970-06-09|
TRIAL STUDY 134XCP|TR|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||IU/G|FOCALLY INCREASED||NMOL/KG/DAY|NOT DONE|||TOLUIDINE BLUE STAIN|Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||FOLLOW-UP|1964-07-18|
TRIAL STUDY 134XCP|TR|06000708-8EBA-4B6C-A8D3-1D0AC4D0E202|5||||||CALCFIND|CALCIFICATION INDICATOR||LOG10 CCID 50/DOSE|TUMOR MERGED||10^6 ORGANISMS/MG|NOT DONE|||LYMPHANGIOGRAPHY|N|NA|CHILD|ONCOLOGIST|NA|5||7||TREATMENT|1970-11-09|
TRIAL STUDY 134XCP|TR|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||CMOL/L|FURTHER ENLARGEMENT||VP/ML|NOT DONE|||MICROSCOPY|Y|N|FAMILY MEMBER|READER 1|NA|1||38||BLINDED TREATMENT|1962-01-03|
TRIAL STUDY 134XCP|TR|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UMOL/L/H|UNEQUIVOCAL||EP U|NOT DONE|||SINGLE-SLICE SPIRAL CT|N|N|SIGNIFICANT OTHER|OPTOMETRIST|Y|2||58||RUN-IN|1969-01-29|
TRIAL STUDY 134XCP|TR|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MMOL/S|FOCALLY INCREASED||DEG|NOT DONE|||HIGH RESOLUTION CT|Y|Y|INVESTIGATOR|NEUROLOGIST|U|3||39||BLINDED TREATMENT|1961-06-28|
TRIAL STUDY 134XCP|TR|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ANTI-XA IU|EQUIVOCAL||LOG10 ELISA UNIT/DOSE|NOT DONE|||NUCLEAR RADIOLOGY|U|U|FRIEND|PHYSIOTHERAPIST|N|4||88||OBSERVATION|1960-10-19|
TRIAL STUDY 134XCP|TR|0BD48B9C-D7D4-47CD-A61D-A4279898D87D|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||GY/H|DECREASED||G/M2/DAY|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|N|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OPEN LABEL TREATMENT|1967-06-15|
TRIAL STUDY 134XCP|TR|A4A5E66A-E65C-4234-8858-E69D04AB1593|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^9 CFU/G|PATHOLOGICAL||10^4 CFU/ML|NOT DONE|||COULOMETRIC TITRATION|U|U|SIBLING|PEDIATRIC NEUROLOGIST|U|1||38||BASELINE|1965-09-05|
TRIAL STUDY 134XCP|TR|A4A5E66A-E65C-4234-8858-E69D04AB1593|2||||||PALPSTAT|PALPABLE STATE||KIU|FURTHER ENLARGEMENT||/SEC|NOT DONE|||FLUORESCEIN STAIN|Y|Y|PROXY|ADJUDICATOR|U|2||58||RUN-IN|1964-05-20|
TRIAL STUDY 134XCP|TR|A4A5E66A-E65C-4234-8858-E69D04AB1593|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||SFC/10^6 PBMC|EQUIVOCAL||ML/M2/DAY|NOT DONE|||CISH|N|U|CAREGIVER|PHYSIOTHERAPIST|Y|3||39||OPEN LABEL TREATMENT|1965-02-19|
TRIAL STUDY 134XCP|TR|A4A5E66A-E65C-4234-8858-E69D04AB1593|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MG/KG|FOCALLY INCREASED||NMOL/L|NOT DONE|||FLUORESCEIN STAIN|Y|Y|INTERVIEWER|NEUROLOGIST|N|4||88||INDUCTION TREATMENT|1966-02-15|
TRIAL STUDY 134XCP|TR|A4A5E66A-E65C-4234-8858-E69D04AB1593|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||/MM|NON-PATHOLOGICAL||BEAM BREAKS|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|Y|U|SPOUSE|PATHOLOGIST 1|N|5||7||WASHOUT|1961-07-31|
TRIAL STUDY 134XCP|TR|0EA46DA5-4291-4585-9745-08BFA60BED3F|1||||||VSLPIND|VESSEL PATENCY INDICATOR||PMOL/G|FURTHER ENLARGEMENT||UG/KG/DAY|NOT DONE|||MICROBIAL CULTURE, SOLID|U|N|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|1||38||OPEN LABEL TREATMENT|1963-10-04|
TRIAL STUDY 134XCP|TR|0EA46DA5-4291-4585-9745-08BFA60BED3F|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MV*MIN|ABSENT||GENEQ/ML|NOT DONE|||DXA SCAN|N|N|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||FOLLOW-UP|1968-04-09|
TRIAL STUDY 134XCP|TR|0EA46DA5-4291-4585-9745-08BFA60BED3F|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/SEC|FOCALLY INCREASED||CUP|NOT DONE|||FLUORESCENT MICROSCOPY|NA|N|ADJUDICATION COMMITTEE|INTERNIST|U|3||39||BLINDED TREATMENT|1962-04-28|
TRIAL STUDY 134XCP|TR|0EA46DA5-4291-4585-9745-08BFA60BED3F|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MG/KG|DECREASED||MOSM/L|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|U|N|NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|4||88||RUN-IN|1962-04-07|
TRIAL STUDY 134XCP|TR|0EA46DA5-4291-4585-9745-08BFA60BED3F|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||CI/ML|NORMAL||MG/M2|NOT DONE|||MRI|U|Y|GUARDIAN|NEUROLOGIST|N|5||7||RUN-IN|1961-07-15|
TRIAL STUDY 134XCP|TR|F54E494F-7EC2-41E7-A969-DF7151EA08E9|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||OZ|ABSENT||CAN|NOT DONE|||ETDRS EYE CHART|U|N|SPOUSE|MICROSCOPIST 2|Y|1||38||OBSERVATION|1965-10-02|
TRIAL STUDY 134XCP|TR|F54E494F-7EC2-41E7-A969-DF7151EA08E9|2||||||RADIODEN|RADIODENSITY||QUANTITY SUFFICIENT|FURTHER ENLARGEMENT FROM NADIR||MEQ/UG|NOT DONE|||TEMPLATE INCISION METHOD|N|NA|SPOUSE|READER 3|NA|2||58||OBSERVATION|1968-04-11|
TRIAL STUDY 134XCP|TR|F54E494F-7EC2-41E7-A969-DF7151EA08E9|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UMOL/MOL|INCREASED||MG/CM2|NOT DONE|||TELLER ACUITY CARDS|NA|N|INVESTIGATOR|MICROSCOPIST 1|NA|3||39||FOLLOW-UP|1960-05-25|
TRIAL STUDY 134XCP|TR|F54E494F-7EC2-41E7-A969-DF7151EA08E9|4||||||LESFLIND|LESION FAILURE INDICATOR||U/KG/MIN|PATHOLOGICAL||MGEQ|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|U|HEALTH CARE PROFESSIONAL|READER|U|4||88||OBSERVATION|1968-05-15|
TRIAL STUDY 134XCP|TR|F54E494F-7EC2-41E7-A969-DF7151EA08E9|5||||||LNSTATE|LYMPH NODE STATE||G/U|FURTHER ENLARGEMENT||BISCUIT|NOT DONE|||HANSEL STAIN|U|N|CAREGIVER|MICROSCOPIST|N|5||7||BLINDED TREATMENT|1970-05-07|
TRIAL STUDY 134XCP|TR|3C4215F7-A7FA-4177-8B84-FD26FEB43039|1||||||ORSTATE|ORGAN STATE||VG/ML|PATHOLOGICAL||NKAT/G HB|NOT DONE|||TOLUIDINE BLUE STAIN|U|N|FAMILY MEMBER|RADIOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1964-11-15|
TRIAL STUDY 134XCP|TR|3C4215F7-A7FA-4177-8B84-FD26FEB43039|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CM|NON-PATHOLOGICAL||/200 HPFS|NOT DONE|||STATIC PERIMETRY|NA|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|2||58||FOLLOW-UP|1971-02-17|
TRIAL STUDY 134XCP|TR|3C4215F7-A7FA-4177-8B84-FD26FEB43039|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||ML/CAGE|FURTHER ENLARGEMENT FROM NADIR||G/M2/DAY|NOT DONE|||URANYL ACETATE STAIN|U|N|VENDOR|MICROSCOPIST 2|Y|3||39||WASHOUT|1963-08-23|
TRIAL STUDY 134XCP|TR|3C4215F7-A7FA-4177-8B84-FD26FEB43039|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||TRACE|FURTHER ENLARGEMENT FROM NADIR||JDF UNIT|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|NA|Y|DOMESTIC PARTNER|ADJUDICATOR|N|4||88||RUN-IN|1962-03-30|
TRIAL STUDY 134XCP|TR|3C4215F7-A7FA-4177-8B84-FD26FEB43039|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ML/DL|UNCHANGED||EIA UNIT|NOT DONE|||SISH|N|NA|INDEPENDENT ASSESSOR|READER 3|U|5||7||BLINDED TREATMENT|1966-01-25|
TRIAL STUDY 134XCP|TR|797C71A3-375E-466E-BDA8-A2828C9C45BB|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||FMOL/G|PATHOLOGICAL||WAFER|NOT DONE|||MRI WITHOUT CONTRAST|U|Y|PARENT|MICROSCOPIST|NA|1||38||WASHOUT|1968-07-25|
TRIAL STUDY 134XCP|TR|797C71A3-375E-466E-BDA8-A2828C9C45BB|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||TSP EQ|PRESENT||KG|NOT DONE|||SMEAR|NA|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|2||58||TREATMENT|1963-04-16|
TRIAL STUDY 134XCP|TR|797C71A3-375E-466E-BDA8-A2828C9C45BB|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||ANTI-XA IU|DECREASED||STEPS/MIN|NOT DONE|||FLUORIMETRY|Y|U|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||FOLLOW-UP|1969-10-15|
TRIAL STUDY 134XCP|TR|797C71A3-375E-466E-BDA8-A2828C9C45BB|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||LOG10 COPIES/ML|TUMOR MERGED||LOG10 PFU/ML|NOT DONE|||IMMUNOTURBIDIMETRY|Y|Y|SIBLING|FORENSIC PATHOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1960-05-11|
TRIAL STUDY 134XCP|TR|797C71A3-375E-466E-BDA8-A2828C9C45BB|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MMAL|DECREASED||/MM2|NOT DONE|||SPIROMETRY|Y|N|FRIEND|PHYSIOTHERAPIST|N|5||7||BLINDED TREATMENT|1971-07-17|
TRIAL STUDY 134XCP|TR|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||BQ/UL|EQUIVOCAL||KG/M2|NOT DONE|||SNP ARRAY|NA|NA|FAMILY MEMBER|ONCOLOGIST 1|NA|1||38||WASHOUT|1962-11-07|
TRIAL STUDY 134XCP|TR|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|2||||||AREA|AREA||ML/ANIMAL|DIFFUSELY INCREASED||IU/MMOL|NOT DONE|||ENDPOINT DILUTION ASSAY|Y|N|SIBLING|PHYSIOTHERAPIST|N|2||58||CONTINUATION TREATMENT|1969-11-23|
TRIAL STUDY 134XCP|TR|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MS/MMHG|PALPABLE||%|NOT DONE|||DROPLET DIGITAL PCR|Y|Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1971-06-30|
TRIAL STUDY 134XCP|TR|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|4||||||AREA|AREA||/10^4|EQUIVOCAL||U/MMOL|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|NA|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|4||88||TREATMENT|1965-11-13|
TRIAL STUDY 134XCP|TR|F70AD90E-59E4-4017-B23C-D411B5EE8BFA|5||||||LESSCIND|LESION SUCCESS INDICATOR||%(W/W)|ENLARGEMENT FROM NADIR||10^6 CFU/G|NOT DONE|||MRI|NA|U|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|5||7||SCREENING|1964-06-13|
TRIAL STUDY 134XCP|TR|5617A5B9-AEE0-4118-9113-3755ED8E961A|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^9 CFU|ABSENT||IU/G HB|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|U|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1||38||CONTINUATION TREATMENT|1967-03-21|
TRIAL STUDY 134XCP|TR|5617A5B9-AEE0-4118-9113-3755ED8E961A|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||NMOL/G|UNEQUIVOCAL||U/M2/MIN|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|Y|U|CAREGIVER|PEDIATRIC NEUROLOGIST|U|2||58||WASHOUT|1968-06-25|
TRIAL STUDY 134XCP|TR|5617A5B9-AEE0-4118-9113-3755ED8E961A|3||||||SUMDIAM|SUM OF DIAMETER||UKAT|UNEQUIVOCAL||MMHG*MIN/L|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|N|NA|CLINICAL STUDY SPONSOR|PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1962-08-07|
TRIAL STUDY 134XCP|TR|5617A5B9-AEE0-4118-9113-3755ED8E961A|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||/LPF|ENLARGEMENT FROM NADIR||10^3/HPF|NOT DONE|||FORCED OSCILLATION TECHNIQUE|Y|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|4||88||CONTINUATION TREATMENT|1963-04-10|
TRIAL STUDY 134XCP|TR|5617A5B9-AEE0-4118-9113-3755ED8E961A|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||U/MMOL|DIFFUSELY INCREASED||10^9 CFU/G|NOT DONE|||HPLC-UV|Y|Y|INTERVIEWER|RATER|Y|5||7||WASHOUT|1971-05-17|
TRIAL STUDY 134XCP|TR|7ECE0F95-910A-4FB3-9435-73805E498415|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||GAUSS|FURTHER ENLARGEMENT FROM NADIR||UG/M2/H|NOT DONE|||SINGLE-MOLECULE ARRAY|N|U|SPOUSE|MICROSCOPIST 3|U|1||38||SCREENING|1972-11-21|
TRIAL STUDY 134XCP|TR|7ECE0F95-910A-4FB3-9435-73805E498415|2||||||VDIAM|VIABLE DIAMETER||MMOL/S|UNCHANGED||UMOL/MIN|NOT DONE|||OPTICAL MAPPING|Y|N|PARENT|ONCOLOGIST|N|2||58||FOLLOW-UP|1968-08-05|
TRIAL STUDY 134XCP|TR|7ECE0F95-910A-4FB3-9435-73805E498415|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||UG/M2|INCREASED||DAGU/ML|NOT DONE|||ISHIHARA COLOR PLATES|N|NA|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1962-01-07|
TRIAL STUDY 134XCP|TR|7ECE0F95-910A-4FB3-9435-73805E498415|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MEQ/UL|ENLARGEMENT||U/KG|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|NA|NA|FRIEND|UROLOGIST|Y|4||88||FOLLOW-UP|1964-06-13|
TRIAL STUDY 134XCP|TR|7ECE0F95-910A-4FB3-9435-73805E498415|5||||||VSLPIND|VESSEL PATENCY INDICATOR||10^6 CFU/G|NORMAL||10^3 ORGANISMS/G|NOT DONE|||WESTERGREN|NA|U|INVESTIGATOR|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1970-03-14|
TRIAL STUDY 134XCP|TR|83EDB0FE-728D-453F-8DB2-7D44202EEB43|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ENZYME U|ABSENT||BQ|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|N|CLINICAL RESEARCH ASSOCIATE|RATER|N|1||38||WASHOUT|1963-10-25|
TRIAL STUDY 134XCP|TR|83EDB0FE-728D-453F-8DB2-7D44202EEB43|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||H/WK|DIFFUSELY INCREASED||NEEDLE GAUGE|NOT DONE|||RIA|NA|NA|GUARDIAN|PATHOLOGIST 2|Y|2||58||OPEN LABEL TREATMENT|1970-10-19|
TRIAL STUDY 134XCP|TR|83EDB0FE-728D-453F-8DB2-7D44202EEB43|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||/MONTH|ENLARGEMENT||ML/KG|NOT DONE|||ENZYMATIC COLORIMETRY|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|3||39||FOLLOW-UP|1969-11-16|
TRIAL STUDY 134XCP|TR|83EDB0FE-728D-453F-8DB2-7D44202EEB43|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||DEG2|FOCALLY INCREASED||SHOCK WAVE|NOT DONE|||BIOPSY|U|U|PARENT|CARDIOLOGIST|N|4||88||BLINDED TREATMENT|1962-06-03|
TRIAL STUDY 134XCP|TR|83EDB0FE-728D-453F-8DB2-7D44202EEB43|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||NMOL|NON-PATHOLOGICAL||UMOL/MOL|NOT DONE|||IMMUNORADIOMETRIC ASSAY|Y|U|NON-HEALTH CARE PROFESSIONAL|READER|U|5||7||OPEN LABEL TREATMENT|1965-01-27|
TRIAL STUDY 134XCP|TR|35589D89-B019-4C5E-8A4B-BFA58E894A9C|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||SHOCK WAVE|FURTHER ENLARGEMENT||ML/CAGE/DAY|NOT DONE|||IMMUNOCHROMATOGRAPHY|NA|Y|INVESTIGATOR|ADJUDICATOR 2|NA|1||38||CONTINUATION TREATMENT|1973-06-23|
TRIAL STUDY 134XCP|TR|35589D89-B019-4C5E-8A4B-BFA58E894A9C|2||||||AREA|AREA||CI|UNEQUIVOCAL||CAPSULE|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|NA|CHILD|UROLOGIST|N|2||58||FOLLOW-UP|1963-12-24|
TRIAL STUDY 134XCP|TR|35589D89-B019-4C5E-8A4B-BFA58E894A9C|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||PT_US|UNCHANGED||UG/G/H|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|NA|U|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|3||39||INDUCTION TREATMENT|1960-10-19|
TRIAL STUDY 134XCP|TR|35589D89-B019-4C5E-8A4B-BFA58E894A9C|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||TRANSDUCING UNIT|NORMAL||10^6 CFU/G|NOT DONE|||PHOTOMETRY|Y|U|PROXY|READER 1|U|4||88||INDUCTION TREATMENT|1965-07-10|
TRIAL STUDY 134XCP|TR|35589D89-B019-4C5E-8A4B-BFA58E894A9C|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ML/M2|NON-PATHOLOGICAL||MASK|NOT DONE|||CT SCAN WITHOUT CONTRAST|NA|N|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|5||7||RUN-IN|1966-11-23|
TRIAL STUDY 134XCP|TR|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||SACHET|NONPALPABLE||OZ|NOT DONE|||FLUORESCENT SPOT TEST|U|Y|CLINICAL STUDY SPONSOR|RATER 1|N|1||38||CONTINUATION TREATMENT|1971-09-08|
TRIAL STUDY 134XCP|TR|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|2||||||LESSCIND|LESION SUCCESS INDICATOR||ML/G/DAY|UNEQUIVOCAL||ML/M2|NOT DONE|||TEST STRIP|NA|NA|FAMILY MEMBER|ADJUDICATOR 1|Y|2||58||INDUCTION TREATMENT|1964-09-16|
TRIAL STUDY 134XCP|TR|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||TSP|ENLARGEMENT FROM NADIR||PMOL/L/H|NOT DONE|||MANUAL CLOT DETECTION|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST|U|3||39||INDUCTION TREATMENT|1966-11-30|
TRIAL STUDY 134XCP|TR|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||FINGERTIP UNIT|INCREASED||ML/G/H|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|N|INTERVIEWER|ADJUDICATOR 1|N|4||88||TREATMENT|1969-05-23|
TRIAL STUDY 134XCP|TR|45C05CC2-662A-4AB2-9342-7BE56AF1ABDF|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||KG/L|DECREASED||LOG EID 50/DOSE|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|N|NA|ADJUDICATION COMMITTEE|CARDIOLOGIST|U|5||7||OBSERVATION|1960-02-05|
TRIAL STUDY 134XCP|TR|21934F6E-8333-413B-931C-DF115519F394|1||||||VOLUME|VOLUME||COAT|EQUIVOCAL||MMOL/MOL|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|Y|NA|ADJUDICATOR|ENDOCRINOLOGIST|U|1||38||OPEN LABEL TREATMENT|1971-10-17|
TRIAL STUDY 134XCP|TR|21934F6E-8333-413B-931C-DF115519F394|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||F|NORMAL||10^6 ORGANISMS/ML|NOT DONE|||NEXT GENERATION SEQUENCING|N|U|VENDOR|NEUROLOGIST|Y|2||58||SCREENING|1963-06-15|
TRIAL STUDY 134XCP|TR|21934F6E-8333-413B-931C-DF115519F394|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||1/(S*KPA)|ABSENT||JOULE|NOT DONE|||ELECTROPHORESIS|Y|NA|CLINICAL RESEARCH COORDINATOR|READER|N|3||39||CONTINUATION TREATMENT|1962-04-26|
TRIAL STUDY 134XCP|TR|21934F6E-8333-413B-931C-DF115519F394|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||MOL/MOL|EQUIVOCAL||ECL UNIT|NOT DONE|||POLYMERASE CHAIN REACTION|Y|U|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|4||88||TREATMENT|1962-04-04|
TRIAL STUDY 134XCP|TR|21934F6E-8333-413B-931C-DF115519F394|5||||||PALPSTAT|PALPABLE STATE||10^3 COPIES/ML|UNCHANGED||NEEDLE GAUGE|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|N|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|5||7||RUN-IN|1967-06-04|
TRIAL STUDY 134XCP|TR|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||/500 WBC|PRESENT||NG/DAY|NOT DONE|||STATIC PERIMETRY|U|NA|STUDY SUBJECT|READER 2|Y|1||38||BLINDED TREATMENT|1969-04-17|
TRIAL STUDY 134XCP|TR|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||M3|ABSENT||/DAY|NOT DONE|||ULTRASOUND|N|N|GUARDIAN|DERMATOLOGIST|N|2||58||CONTINUATION TREATMENT|1964-08-01|
TRIAL STUDY 134XCP|TR|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|3||||||SUMVOL|SUM OF VOLUME||BQ/UL|NORMAL||SEC|NOT DONE|||OLIGO ACGH|NA|N|PROXY|ADJUDICATOR 2|U|3||39||BASELINE|1970-02-26|
TRIAL STUDY 134XCP|TR|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||SCOOPFUL|ENLARGEMENT FROM NADIR||UG/MIN|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|NA|Y|SIGNIFICANT OTHER|UROLOGIST|U|4||88||WASHOUT|1960-05-23|
TRIAL STUDY 134XCP|TR|2EF614BE-3AEA-4BDA-968D-2D2F4EB9A653|5||||||RADIODEN|RADIODENSITY||UG/CM2|NORMAL||MM/MIN|NOT DONE|||TRANSVAGINAL ULTRASOUND|U|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||OPEN LABEL TREATMENT|1964-09-10|
TRIAL STUDY 134XCP|TR|E31F3DEB-BCA2-4660-935D-BAEBC4238866|1||||||LDIAM|LONGEST DIAMETER||LB|FOCALLY INCREASED||NCI|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|N|N|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|1||38||LONG-TERM FOLLOW-UP|1970-11-28|
TRIAL STUDY 134XCP|TR|E31F3DEB-BCA2-4660-935D-BAEBC4238866|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||10^7 PFU|NORMAL||USIEMENS|NOT DONE|||FLUORESCEIN STAIN|NA|Y|GUARDIAN|OTOLARYNGOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1973-05-11|
TRIAL STUDY 134XCP|TR|E31F3DEB-BCA2-4660-935D-BAEBC4238866|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||UL/ML|FURTHER ENLARGEMENT FROM NADIR||MS2|NOT DONE|||IODINE STAIN|N|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|3||39||INDUCTION TREATMENT|1968-09-26|
TRIAL STUDY 134XCP|TR|E31F3DEB-BCA2-4660-935D-BAEBC4238866|4||||||LDIAM|LONGEST DIAMETER||LOG10 PFU/ML|FURTHER ENLARGEMENT FROM NADIR||EVENTS|NOT DONE|||FISH|NA|U|FAMILY MEMBER|HEMATOLOGIST|N|4||88||INDUCTION TREATMENT|1969-04-16|
TRIAL STUDY 134XCP|TR|E31F3DEB-BCA2-4660-935D-BAEBC4238866|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||FMOL/L|FURTHER ENLARGEMENT||U.CARR|NOT DONE|||TOTAL BODY IRRADIATION|NA|NA|SIBLING|PATHOLOGIST 1|NA|5||7||WASHOUT|1966-04-04|
TRIAL STUDY 134XCP|TR|8310989D-82CC-456C-965A-E38AC9EA073F|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||ML/CM|DECREASED||TITER|NOT DONE|||POTENTIOMETRY|U|N|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|1||38||BASELINE|1970-08-05|
TRIAL STUDY 134XCP|TR|8310989D-82CC-456C-965A-E38AC9EA073F|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||PFU/ANIMAL|TUMOR MERGED||BREATHS/MIN|NOT DONE|||MICROBIAL CULTURE, LIQUID|NA|NA|DOMESTIC PARTNER|NEUROLOGIST 1|U|2||58||FOLLOW-UP|1961-03-24|
TRIAL STUDY 134XCP|TR|8310989D-82CC-456C-965A-E38AC9EA073F|3||||||LDIAM|LONGEST DIAMETER||LOG10 ELISA UNIT|ENLARGEMENT FROM NADIR||CMHG|NOT DONE|||PHOTOMETRY|N|Y|CHILD|READER 3|N|3||39||BASELINE|1970-04-16|
TRIAL STUDY 134XCP|TR|8310989D-82CC-456C-965A-E38AC9EA073F|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/MIN|FURTHER ENLARGEMENT||PPB|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|NA|N|SIBLING|READER|NA|4||88||INDUCTION TREATMENT|1970-04-15|
TRIAL STUDY 134XCP|TR|8310989D-82CC-456C-965A-E38AC9EA073F|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||CAL|TUMOR MERGED||MG/H|NOT DONE|||FLOW MICROSCOPY|N|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|5||7||TREATMENT|1964-06-18|
TRIAL STUDY 134XCP|TR|826D8DC2-E407-481C-93D8-5169DBDF99C4|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||COPIES/ML|DIFFUSELY INCREASED||10^12/L|NOT DONE|||MICROBIAL CULTURE, LIQUID|U|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|1||38||SCREENING|1963-12-24|
TRIAL STUDY 134XCP|TR|826D8DC2-E407-481C-93D8-5169DBDF99C4|2||||||SUMVOL|SUM OF VOLUME||PRESSOR UNITS|NONPALPABLE||DRUM|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|N|N|PARENT|ONCOLOGIST 2|N|2||58||FOLLOW-UP|1962-04-13|
TRIAL STUDY 134XCP|TR|826D8DC2-E407-481C-93D8-5169DBDF99C4|3||||||VOLUME|VOLUME||LOG10 CFU/G|EQUIVOCAL||CCID 50/DOSE|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|NA|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||OPEN LABEL TREATMENT|1970-03-18|
TRIAL STUDY 134XCP|TR|826D8DC2-E407-481C-93D8-5169DBDF99C4|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||%(V/V)|PRESENT||VIRTUAL PIXEL|NOT DONE|||SXA SCAN|N|U|VENDOR|ONCOLOGIST 2|N|4||88||OBSERVATION|1965-11-15|
TRIAL STUDY 134XCP|TR|826D8DC2-E407-481C-93D8-5169DBDF99C4|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||UV*SEC|PATHOLOGICAL||PPM|NOT DONE|||LANDOLT RING|N|NA|VENDOR|ONCOLOGIST 1|U|5||7||BASELINE|1972-07-04|
TRIAL STUDY 134XCP|TR|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||PT_US|FOCALLY INCREASED||U|NOT DONE|||ENZYMATIC COLORIMETRY|U|U|FAMILY MEMBER|OPTOMETRIST|NA|1||38||INDUCTION TREATMENT|1961-02-25|
TRIAL STUDY 134XCP|TR|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|2||||||LMBFLIND|LIMB FAILURE INDICATOR||10^3 RNA COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||KCAL|NOT DONE|||CENTRIFUGATION|Y|U|SIGNIFICANT OTHER|MICROSCOPIST 1|NA|2||58||TREATMENT|1963-01-09|
TRIAL STUDY 134XCP|TR|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||BQ/L|INCREASED||STEPS|NOT DONE|||IMPEDANCE CONDUCTIVITY|NA|U|SIGNIFICANT OTHER|RATER|N|3||39||LONG-TERM FOLLOW-UP|1968-05-02|
TRIAL STUDY 134XCP|TR|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||U/DL|TUMOR MERGED||NG/MOL|NOT DONE|||RAJI CELL RIA|Y|U|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|4||88||OBSERVATION|1967-03-08|
TRIAL STUDY 134XCP|TR|F2CEE48B-51B0-4F3E-94B1-FBAC1D0B2CA3|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||BE/ML|DIFFUSELY INCREASED||MU/G|NOT DONE|||PH METER MEASUREMENT METHOD|Y|N|CAREGIVER|ONCOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1965-06-04|
TRIAL STUDY 134XCP|TR|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|1||||||SUMDIAM|SUM OF DIAMETER||GAUSS|EQUIVOCAL||GENEQ|NOT DONE|||CISH|Y|NA|INTERVIEWER|MICROSCOPIST 1|NA|1||38||FOLLOW-UP|1962-08-23|
TRIAL STUDY 134XCP|TR|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ML/SEC/1.73M2|EQUIVOCAL||SFC/10^6 PBMC|NOT DONE|||GC/MS-EI|NA|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2||58||LONG-TERM FOLLOW-UP|1968-09-23|
TRIAL STUDY 134XCP|TR|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||TROCHE|UNEQUIVOCAL||LOG10 ELISA UNIT/DOSE|NOT DONE|||DIRECT SEQUENCING|N|U|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|3||39||INDUCTION TREATMENT|1967-02-18|
TRIAL STUDY 134XCP|TR|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||/LPF|PRESENT||UG/G/MIN|NOT DONE|||PET/SPECT SCAN|N|N|FRIEND|READER 3|N|4||88||CONTINUATION TREATMENT|1963-10-28|
TRIAL STUDY 134XCP|TR|F8188B3C-FE9F-4589-BD6B-D313618C9FF6|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||/MM|UNEQUIVOCAL||COPIES/UG|NOT DONE|||PET/MRI SCAN|Y|U|CHILD|OTOLARYNGOLOGIST|NA|5||7||INDUCTION TREATMENT|1960-11-08|
TRIAL STUDY 134XCP|TR|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||GPL U|PATHOLOGICAL||FRACTION OF 1|NOT DONE|||PULSE OXIMETRY|U|N|INVESTIGATOR|HEMATOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1968-10-09|
TRIAL STUDY 134XCP|TR|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|2||||||LMBFLIND|LIMB FAILURE INDICATOR||GY/MIN|ENLARGEMENT||V/V|NOT DONE|||IMMUNOASSAY|NA|NA|GUARDIAN|CLINICAL PATHOLOGIST|U|2||58||WASHOUT|1969-03-15|
TRIAL STUDY 134XCP|TR|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|3||||||PALPSTAT|PALPABLE STATE||UG/L/H|INCREASED||SACHET|NOT DONE|||ANTIBIOTIC AGAR SCREEN|U|N|VENDOR|DERMATOLOGIST|Y|3||39||RUN-IN|1965-01-28|
TRIAL STUDY 134XCP|TR|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|4||||||LDIAM|LONGEST DIAMETER||NSEC|NORMAL||ML/ANIMAL/DAY|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|N|NA|INTERVIEWER|CLINICAL PATHOLOGIST|NA|4||88||FOLLOW-UP|1960-08-25|
TRIAL STUDY 134XCP|TR|4F34B7B4-59E4-4D16-A5DD-2D41253FAD5A|5||||||NEWCONF|NEW TUMOR CONFIRMED||%/S|UNEQUIVOCAL||CM2|NOT DONE|||INFRARED SPECTROMETRY|N|NA|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||OPEN LABEL TREATMENT|1971-09-16|
TRIAL STUDY 134XCP|TR|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|1||||||ORVERLN|ORGAN VERTICAL LENGTH||ABSORBANCE U/MIN|DIFFUSELY INCREASED||WATT|NOT DONE|||ANTIMICROBIAL COMBINATION TESTING|U|NA|GUARDIAN|RADIOLOGIST|N|1||38||SCREENING|1973-08-16|
TRIAL STUDY 134XCP|TR|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|2||||||SUMVOL|SUM OF VOLUME||UL/DOSE|TUMOR MERGED||10^8/L|NOT DONE|||FLUORESCENT IMMUNOASSAY|Y|N|STUDY SUBJECT|INTERNIST|Y|2||58||SCREENING|1961-04-06|
TRIAL STUDY 134XCP|TR|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UMOL/DL|ENLARGEMENT||MEQ/DAY|NOT DONE|||KLEIHAUER-BETKE|U|U|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|3||39||WASHOUT|1973-05-26|
TRIAL STUDY 134XCP|TR|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||CM/S|EQUIVOCAL||ML/M2|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|N|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|4||88||TREATMENT|1960-08-15|
TRIAL STUDY 134XCP|TR|E6D1E0A4-79DF-4964-81C0-09675B53FA6D|5||||||PALPSTAT|PALPABLE STATE||MG/G/MIN|ENLARGEMENT FROM NADIR||ML/BREATH|NOT DONE|||TWO-COLOR MICROARRAY|N|Y|CHILD|NEUROLOGIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1971-09-22|
TRIAL STUDY 134XCP|TR|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/4.0 ML|ABSENT||CD/M2|NOT DONE|||ELISA|Y|U|PARENT|OPTOMETRIST|U|1||38||RUN-IN|1966-10-07|
TRIAL STUDY 134XCP|TR|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|2||||||DIAMETER|DIAMETER||MONTHS|FURTHER ENLARGEMENT||G/M2/DAY|NOT DONE|||FLUORESCEIN STAIN|Y|Y|SIBLING|MICROSCOPIST 3|U|2||58||RUN-IN|1971-09-03|
TRIAL STUDY 134XCP|TR|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MPL U/ML|PATHOLOGICAL||AMPULE|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|NA|Y|HEALTH CARE PROFESSIONAL|INTERNIST|Y|3||39||LONG-TERM FOLLOW-UP|1972-04-03|
TRIAL STUDY 134XCP|TR|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PMOL/G|PATHOLOGICAL||KN/CM2|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|Y|INVESTIGATOR|RATER 2|U|4||88||FOLLOW-UP|1965-05-19|
TRIAL STUDY 134XCP|TR|5BF2DD06-0BDB-4893-9EF7-9248D9DCE772|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^6 CFU|EQUIVOCAL||MG/M2/DAY|NOT DONE|||SNELLEN EYE CHART|Y|NA|VENDOR|ADJUDICATOR 2|Y|5||7||INDUCTION TREATMENT|1967-07-15|
TRIAL STUDY 134XCP|TR|B396F12E-7BF5-47CC-AFD1-1B679066B106|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||UMOL/L|TUMOR MERGED||JDF UNIT|NOT DONE|||LEAD CITRATE STAIN|Y|N|STUDY SUBJECT|DERMATOLOGIST|NA|1||38||SCREENING|1970-11-20|
TRIAL STUDY 134XCP|TR|B396F12E-7BF5-47CC-AFD1-1B679066B106|2||||||RADIODEN|RADIODENSITY||%/MIN|DECREASED||NG/L|NOT DONE|||ECHOCARDIOGRAPHY|Y|U|FRIEND|READER 3|U|2||58||WASHOUT|1964-12-25|
TRIAL STUDY 134XCP|TR|B396F12E-7BF5-47CC-AFD1-1B679066B106|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MET|TUMOR MERGED||ANTIBODY UNIT|NOT DONE|||SPECULAR MICROSCOPY|N|N|DOMESTIC PARTNER|MICROSCOPIST 1|Y|3||39||BASELINE|1961-10-22|
TRIAL STUDY 134XCP|TR|B396F12E-7BF5-47CC-AFD1-1B679066B106|4||||||PALPSTAT|PALPABLE STATE||DDU|INCREASED||10^3 COPIES/ML|NOT DONE|||LYMPHANGIOGRAPHY|N|Y|GUARDIAN|NEUROLOGIST|U|4||88||INDUCTION TREATMENT|1969-07-24|
TRIAL STUDY 134XCP|TR|B396F12E-7BF5-47CC-AFD1-1B679066B106|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||DPM/0.5 ML|ENLARGEMENT||GBQ/G|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|N|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|5||7||WASHOUT|1965-10-09|
TRIAL STUDY 134XCP|TR|2936B26A-9A8D-4C28-90A7-6131837F255F|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||OZ|TUMOR MERGED||PFU|NOT DONE|||MICRO BROTH DILUTION|U|NA|GUARDIAN|NEUROLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1965-01-22|
TRIAL STUDY 134XCP|TR|2936B26A-9A8D-4C28-90A7-6131837F255F|2||||||LESSCIND|LESION SUCCESS INDICATOR||MN|UNCHANGED||MIN*MG/ML|NOT DONE|||CHROMOGENIC ASSAY|U|U|SPOUSE|NEUROLOGIST 1|N|2||58||TREATMENT|1972-01-16|
TRIAL STUDY 134XCP|TR|2936B26A-9A8D-4C28-90A7-6131837F255F|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||TUBERCULIN UNIT/ML|DECREASED||UL|NOT DONE|||CORONARY ANGIOGRAPHY|Y|Y|CLINICAL RESEARCH COORDINATOR|READER 1|NA|3||39||OBSERVATION|1971-11-03|
TRIAL STUDY 134XCP|TR|2936B26A-9A8D-4C28-90A7-6131837F255F|4||||||ORVERLN|ORGAN VERTICAL LENGTH||%(V/V)|NORMAL||VG/ML|NOT DONE|||MUGA|NA|NA|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|4||88||TREATMENT|1962-04-29|
TRIAL STUDY 134XCP|TR|2936B26A-9A8D-4C28-90A7-6131837F255F|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/DL|NONPALPABLE||/LSQN|NOT DONE|||MEDIASTINOSCOPY|N|Y|SIGNIFICANT OTHER|READER 1|U|5||7||OPEN LABEL TREATMENT|1970-08-10|
TRIAL STUDY 134XCP|TR|901A91DC-9EF3-4A20-A35D-9C426A5C640B|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||/KG|NORMAL||FMOL/L|NOT DONE|||FORCED OSCILLATION TECHNIQUE|N|Y|ADJUDICATOR|DERMATOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1961-08-06|
TRIAL STUDY 134XCP|TR|901A91DC-9EF3-4A20-A35D-9C426A5C640B|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^6 IU|ENLARGEMENT FROM NADIR||PG/CELL|NOT DONE|||ANALYTICAL ULTRACENTRIFUGATION|NA|NA|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|2||58||RUN-IN|1973-05-18|
TRIAL STUDY 134XCP|TR|901A91DC-9EF3-4A20-A35D-9C426A5C640B|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ML/CAGE/DAY|FURTHER ENLARGEMENT||NMOL/MOL|NOT DONE|||ANGIOGRAPHY|Y|U|PARENT|OPHTHALMOLOGIST|Y|3||39||FOLLOW-UP|1971-11-17|
TRIAL STUDY 134XCP|TR|901A91DC-9EF3-4A20-A35D-9C426A5C640B|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||WAFER|UNCHANGED||U/ML|NOT DONE|||HILLMEN COLOR CHART|N|Y|SIGNIFICANT OTHER|READER|U|4||88||WASHOUT|1967-08-06|
TRIAL STUDY 134XCP|TR|901A91DC-9EF3-4A20-A35D-9C426A5C640B|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MG/L FEU|UNCHANGED||10^6 IU|NOT DONE|||TEST STRIP|U|U|SIBLING|ADJUDICATOR 2|N|5||7||TREATMENT|1965-09-03|
TRIAL STUDY 134XCP|TR|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||KCAL/DAY|UNEQUIVOCAL||ELISA UNIT/DOSE|NOT DONE|||MAPH|N|U|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||BLINDED TREATMENT|1963-09-21|
TRIAL STUDY 134XCP|TR|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||LOG10 TCID 50/UL|ENLARGEMENT FROM NADIR||U/DL|NOT DONE|||GC/MS-CI|NA|N|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|N|2||58||WASHOUT|1973-07-26|
TRIAL STUDY 134XCP|TR|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|3||||||LESFLIND|LESION FAILURE INDICATOR||FT2|NON-PATHOLOGICAL||LOG10 TCID 50/ML|NOT DONE|||RADIOGRAPHY|Y|N|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|3||39||FOLLOW-UP|1965-04-26|
TRIAL STUDY 134XCP|TR|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||VG/DOSE|DECREASED||MMHG/L/MIN|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|N|U|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||LONG-TERM FOLLOW-UP|1964-02-04|
TRIAL STUDY 134XCP|TR|1944BDC6-B89D-4B9C-B33E-DD7D1D25E1A4|5||||||VDIAM|VIABLE DIAMETER||UG/L FEU|ABSENT||UMOL/MOL|NOT DONE|||PERCUSSION|U|NA|ADJUDICATOR|MICROSCOPIST|NA|5||7||LONG-TERM FOLLOW-UP|1972-02-15|
TRIAL STUDY 134XCP|TR|5A7F2C89-5398-4119-8EA0-B432FF8942A4|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MG|UNCHANGED||10^4 CFU|NOT DONE|||SPECT/CT SCAN|N|Y|CAREGIVER|ENDOCRINOLOGIST|U|1||38||SCREENING|1963-08-25|
TRIAL STUDY 134XCP|TR|5A7F2C89-5398-4119-8EA0-B432FF8942A4|2||||||BNLNUM|NUMBER OF BONE LESIONS||QUANTITY SUFFICIENT|FURTHER ENLARGEMENT||MMOL/DAY|NOT DONE|||IVY INCISION METHOD|N|NA|FAMILY MEMBER|OPHTHALMOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1961-11-13|
TRIAL STUDY 134XCP|TR|5A7F2C89-5398-4119-8EA0-B432FF8942A4|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||% INHIBITION|ABSENT||GTT|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|Y|SIGNIFICANT OTHER|DERMATOLOGIST|Y|3||39||FOLLOW-UP|1972-11-15|
TRIAL STUDY 134XCP|TR|5A7F2C89-5398-4119-8EA0-B432FF8942A4|4||||||LMBFLIND|LIMB FAILURE INDICATOR||/40 HPFS|INCREASED||DIP|NOT DONE|||OBSERVATION|U|NA|INDEPENDENT ASSESSOR|OPTOMETRIST|N|4||88||OPEN LABEL TREATMENT|1960-03-07|
TRIAL STUDY 134XCP|TR|5A7F2C89-5398-4119-8EA0-B432FF8942A4|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CFU/G|ENLARGEMENT||KPA/L/SEC|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|N|N|GUARDIAN|ADJUDICATOR|NA|5||7||FOLLOW-UP|1963-11-15|
TRIAL STUDY 134XCP|TR|898FB78B-63D1-4ECE-B6B8-34750E958D93|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||PA|NORMAL||MPH|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|Y|U|CHILD|READER 3|U|1||38||BASELINE|1963-06-07|
TRIAL STUDY 134XCP|TR|898FB78B-63D1-4ECE-B6B8-34750E958D93|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ML/MIN/1.73M2|ENLARGEMENT||HR/DAY|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|N|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|2||58||CONTINUATION TREATMENT|1972-10-04|
TRIAL STUDY 134XCP|TR|898FB78B-63D1-4ECE-B6B8-34750E958D93|3||||||AREA|AREA||MPL U/ML|DIFFUSELY INCREASED||MV|NOT DONE|||KINYOUN STAIN|N|NA|FAMILY MEMBER|RATER 2|U|3||39||BLINDED TREATMENT|1973-06-26|
TRIAL STUDY 134XCP|TR|898FB78B-63D1-4ECE-B6B8-34750E958D93|4||||||RADIODEN|RADIODENSITY||MPS U|ENLARGEMENT||10^6 DNA COPIES/ML|NOT DONE|||PATHOLOGICAL EVALUATION|N|N|GUARDIAN|NEUROLOGIST 1|U|4||88||WASHOUT|1964-11-09|
TRIAL STUDY 134XCP|TR|898FB78B-63D1-4ECE-B6B8-34750E958D93|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^7 CFU/ML|ABSENT||FINGERTIP UNIT|NOT DONE|||ELECTROMYOGRAPHY|Y|U|SPOUSE|NEUROLOGIST 2|N|5||7||OBSERVATION|1963-02-10|
TRIAL STUDY 134XCP|TR|AF1E7141-5390-4928-9F49-94E1C7464A63|1||||||SUMVOL|SUM OF VOLUME||L/MIN/M2|DIFFUSELY INCREASED||MG/L FEU|NOT DONE|||HEMAGGLUTINATION ASSAY|NA|N|HEALTH CARE PROFESSIONAL|READER|N|1||38||RUN-IN|1972-03-03|
TRIAL STUDY 134XCP|TR|AF1E7141-5390-4928-9F49-94E1C7464A63|2||||||SUMDIAM|SUM OF DIAMETER||MIN|ENLARGEMENT FROM NADIR||VIAL|NOT DONE|||QUANTITATIVE ULTRASOUND|NA|N|CLINICAL RESEARCH COORDINATOR|INTERNIST|N|2||58||BASELINE|1961-12-02|
TRIAL STUDY 134XCP|TR|AF1E7141-5390-4928-9F49-94E1C7464A63|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||GBQ/UG|NON-PATHOLOGICAL||UG/L DDU|NOT DONE|||TOTAL BODY RADIOGRAPHY|N|U|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|3||39||CONTINUATION TREATMENT|1970-05-04|
TRIAL STUDY 134XCP|TR|AF1E7141-5390-4928-9F49-94E1C7464A63|4||||||ORVERLN|ORGAN VERTICAL LENGTH||PIXEL|PALPABLE||U/G/H|NOT DONE|||JAFFE REACTION|Y|N|DOMESTIC PARTNER|RATER 2|Y|4||88||FOLLOW-UP|1971-03-08|
TRIAL STUDY 134XCP|TR|AF1E7141-5390-4928-9F49-94E1C7464A63|5||||||LPERP|LONGEST PERPENDICULAR||U/KG/MIN|PATHOLOGICAL||SHOCK WAVE|NOT DONE|||SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|NA|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|5||7||INDUCTION TREATMENT|1963-02-08|
TRIAL STUDY 134XCP|TR|2188CADE-EE6F-4F14-8049-5EDD72020185|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||10^9 ORGANISMS/MG|FURTHER ENLARGEMENT||UMOL/L/H|NOT DONE|||OLIGO ACGH|U|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|NA|1||38||BLINDED TREATMENT|1965-12-31|
TRIAL STUDY 134XCP|TR|2188CADE-EE6F-4F14-8049-5EDD72020185|2||||||LPERP|LONGEST PERPENDICULAR||GY/H|FURTHER ENLARGEMENT||L/DAY|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|NA|U|PARENT|NEUROLOGIST 1|N|2||58||WASHOUT|1961-01-24|
TRIAL STUDY 134XCP|TR|2188CADE-EE6F-4F14-8049-5EDD72020185|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||L|NORMAL||PL|NOT DONE|||FISH|U|N|CAREGIVER|PATHOLOGIST 1|N|3||39||BASELINE|1965-07-07|
TRIAL STUDY 134XCP|TR|2188CADE-EE6F-4F14-8049-5EDD72020185|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/CMH2O|UNEQUIVOCAL||UMOL|NOT DONE|||DIRECT SEQUENCING|N|N|SIBLING|RATER 1|Y|4||88||OPEN LABEL TREATMENT|1965-08-17|
TRIAL STUDY 134XCP|TR|2188CADE-EE6F-4F14-8049-5EDD72020185|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML/ANIMAL/WK|DECREASED||PACK YEAR|NOT DONE|||PHASE CONTRAST MICROSCOPY|NA|U|STUDY SUBJECT|OPTOMETRIST|Y|5||7||OBSERVATION|1967-06-27|
TRIAL STUDY 134XCP|TR|DFF30783-4496-4134-8201-67C727683A7D|1||||||NEWCONF|NEW TUMOR CONFIRMED||NMOL/L/MIN|ENLARGEMENT FROM NADIR||/SEC|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|N|FAMILY MEMBER|ADJUDICATOR 3|N|1||38||LONG-TERM FOLLOW-UP|1965-07-02|
TRIAL STUDY 134XCP|TR|DFF30783-4496-4134-8201-67C727683A7D|2||||||LESSCIND|LESION SUCCESS INDICATOR||AFU|INCREASED||LOG10 PFU|NOT DONE|||MICRONEUTRALIZATION ASSAY|U|N|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||FOLLOW-UP|1968-02-01|
TRIAL STUDY 134XCP|TR|DFF30783-4496-4134-8201-67C727683A7D|3||||||LNSTATE|LYMPH NODE STATE||CMOL/L|NONPALPABLE||MG/KG/WEEK|NOT DONE|||SLOAN LETTER EYE CHART 100%|NA|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||SCREENING|1965-02-13|
TRIAL STUDY 134XCP|TR|DFF30783-4496-4134-8201-67C727683A7D|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||GRAIN|ENLARGEMENT FROM NADIR||ECL UNIT|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|U|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|4||88||OPEN LABEL TREATMENT|1973-01-12|
TRIAL STUDY 134XCP|TR|DFF30783-4496-4134-8201-67C727683A7D|5||||||VDIAM|VIABLE DIAMETER||PSI|PRESENT||KPA/L/SEC|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|N|CAREGIVER|MICROSCOPIST|N|5||7||LONG-TERM FOLLOW-UP|1967-08-23|
TRIAL STUDY 134XCP|TR|970170C0-8FF0-4D24-84E8-1195272D55C0|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MCI/KG|FURTHER ENLARGEMENT FROM NADIR||NG/MOL|NOT DONE|||OSCILLOMETRY|U|Y|GUARDIAN|RADIOLOGIST 2|N|1||38||SCREENING|1961-02-18|
TRIAL STUDY 134XCP|TR|970170C0-8FF0-4D24-84E8-1195272D55C0|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||G/ANIMAL|UNEQUIVOCAL||CMOL/L|NOT DONE|||RYAN BLUE STAIN|U|NA|SIGNIFICANT OTHER|READER|U|2||58||FOLLOW-UP|1965-02-12|
TRIAL STUDY 134XCP|TR|970170C0-8FF0-4D24-84E8-1195272D55C0|3||||||NEWCONF|NEW TUMOR CONFIRMED||MG/KG/H|EQUIVOCAL||WEEKS|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|N|INVESTIGATOR|NEUROLOGIST 2|Y|3||39||INDUCTION TREATMENT|1972-02-06|
TRIAL STUDY 134XCP|TR|970170C0-8FF0-4D24-84E8-1195272D55C0|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||OI50|INCREASED||KG/L|NOT DONE|||MICROARRAY|NA|Y|CLINICAL RESEARCH ASSOCIATE|READER 2|NA|4||88||TREATMENT|1969-11-17|
TRIAL STUDY 134XCP|TR|970170C0-8FF0-4D24-84E8-1195272D55C0|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||AFU|UNCHANGED||MOL/MOL|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|U|SIBLING|CARDIOLOGIST|N|5||7||RUN-IN|1964-05-26|
TRIAL STUDY 134XCP|TR|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||PACKET|TUMOR MERGED||10^8/L|NOT DONE|||POLYGRAPHY|U|U|SPOUSE|PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1961-07-07|
TRIAL STUDY 134XCP|TR|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|2||||||ORSTATE|ORGAN STATE||UM|PATHOLOGICAL||COPIES/ML|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|U|NA|STUDY SUBJECT|MICROSCOPIST 2|NA|2||58||INDUCTION TREATMENT|1970-02-21|
TRIAL STUDY 134XCP|TR|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||DAMOL/L|DECREASED||ENZYME U/G HB|NOT DONE|||STATIC PERIMETRY|Y|N|CHILD|RADIOLOGIST|U|3||39||OBSERVATION|1961-08-21|
TRIAL STUDY 134XCP|TR|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|4||||||VDIAM|VIABLE DIAMETER||UG/L|PALPABLE||VG/ML|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|N|Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||FOLLOW-UP|1964-05-05|
TRIAL STUDY 134XCP|TR|F8D52828-1C5E-4958-BFDE-77F5171FEFBE|5||||||LDIAM|LONGEST DIAMETER||DNA COPIES/UG|ENLARGEMENT||ML/(MIN*100ML)|NOT DONE|||PET/MRI SCAN|NA|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|5||7||OPEN LABEL TREATMENT|1960-08-07|
TRIAL STUDY 134XCP|TR|69CC47A3-DA90-4919-889E-E0008ED689FA|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||LOG10 ELISA UNIT|NON-PATHOLOGICAL||LOG10 CCID 50/DOSE|NOT DONE|||HPLC-FL|NA|N|SPOUSE|PATHOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1968-05-06|
TRIAL STUDY 134XCP|TR|69CC47A3-DA90-4919-889E-E0008ED689FA|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||CI/UL|UNEQUIVOCAL||G/ANIMAL|NOT DONE|||MYELOPEROXIDASE STAIN|N|U|HEALTH CARE PROFESSIONAL|UROLOGIST|U|2||58||RUN-IN|1972-01-20|
TRIAL STUDY 134XCP|TR|69CC47A3-DA90-4919-889E-E0008ED689FA|3||||||LESFLIND|LESION FAILURE INDICATOR||HEP|FURTHER ENLARGEMENT||U/MMOL|NOT DONE|||FUNCTIONAL MRI|U|U|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|3||39||BASELINE|1962-01-23|
TRIAL STUDY 134XCP|TR|69CC47A3-DA90-4919-889E-E0008ED689FA|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||DMOL|ABSENT||APL U/ML|NOT DONE|||CLIP|Y|N|SPOUSE|NEUROLOGIST 2|NA|4||88||OPEN LABEL TREATMENT|1963-05-21|
TRIAL STUDY 134XCP|TR|69CC47A3-DA90-4919-889E-E0008ED689FA|5||||||TUMSTATE|TUMOR STATE||UG/H|DIFFUSELY INCREASED||UMOL/L|NOT DONE|||PHOTOGRAPHY|Y|Y|PROXY|OTOLARYNGOLOGIST|U|5||7||CONTINUATION TREATMENT|1966-06-10|
TRIAL STUDY 134XCP|TR|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|1||||||VSLPIND|VESSEL PATENCY INDICATOR||LOG10 COPIES/ML|DECREASED||UV|NOT DONE|||ICC|U|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|1||38||OPEN LABEL TREATMENT|1969-01-25|
TRIAL STUDY 134XCP|TR|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^3 ORGANISMS|FURTHER ENLARGEMENT||MIN|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|N|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||INDUCTION TREATMENT|1971-01-14|
TRIAL STUDY 134XCP|TR|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||L/S|PRESENT||CAN|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|NA|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||OBSERVATION|1972-12-26|
TRIAL STUDY 134XCP|TR|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ABSORBANCE U|ENLARGEMENT FROM NADIR||CD*S/M2|NOT DONE|||HEMOCYTOMETRY|Y|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 1|NA|4||88||INDUCTION TREATMENT|1971-02-16|
TRIAL STUDY 134XCP|TR|D4BB8CC7-4EB2-4FCA-94EB-E08D8FE00577|5||||||PALPSTAT|PALPABLE STATE||BAU/ML|DIFFUSELY INCREASED||UEQ/L|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|Y|ADJUDICATOR|ADJUDICATOR 3|Y|5||7||CONTINUATION TREATMENT|1972-12-02|
TRIAL STUDY 134XCP|TR|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||NMOL/G|UNEQUIVOCAL||ML/H|NOT DONE|||OPHTHALMOSCOPY|NA|U|FRIEND|NEUROLOGIST 2|U|1||38||BASELINE|1963-06-19|
TRIAL STUDY 134XCP|TR|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UG/L/H|INCREASED||10^9 CFU|NOT DONE|||PATHOLOGICAL EVALUATION|Y|U|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|2||58||OBSERVATION|1966-12-20|
TRIAL STUDY 134XCP|TR|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||F|PALPABLE||ABSORBANCE U/MIN|NOT DONE|||NUCLEIC ACID SEQUENCING|U|U|INDEPENDENT ASSESSOR|RATER|N|3||39||CONTINUATION TREATMENT|1969-07-08|
TRIAL STUDY 134XCP|TR|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||TRANSDUCING UNIT|ENLARGEMENT||ENZYME U|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|U|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|4||88||SCREENING|1961-07-03|
TRIAL STUDY 134XCP|TR|72FDC7C1-2734-4CA6-8A9B-CC20E39CD834|5||||||ORVERLN|ORGAN VERTICAL LENGTH||BREATHS/30S|ENLARGEMENT||IU/ML|NOT DONE|||AGAR PROPORTION|U|NA|HEALTH CARE PROFESSIONAL|READER 1|U|5||7||OBSERVATION|1964-02-29|
TRIAL STUDY 134XCP|TR|0281E055-F419-4BA2-89CE-23EC7428CDA0|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/CAGE/DAY|UNCHANGED||ML/KG/H|NOT DONE|||MULTIPLE BREATH WASHOUT|N|NA|STUDY SUBJECT|OPHTHALMOLOGIST|N|1||38||WASHOUT|1965-09-28|
TRIAL STUDY 134XCP|TR|0281E055-F419-4BA2-89CE-23EC7428CDA0|2||||||ORVERLN|ORGAN VERTICAL LENGTH||GPELISA UNIT/ML|NONPALPABLE||AMPULE|NOT DONE|||HPLC-UV|N|NA|HEALTH CARE PROFESSIONAL|READER|U|2||58||RUN-IN|1962-04-07|
TRIAL STUDY 134XCP|TR|0281E055-F419-4BA2-89CE-23EC7428CDA0|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||DRUM|ENLARGEMENT FROM NADIR||PHERESIS UNIT|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|N|Y|DOMESTIC PARTNER|ADJUDICATOR 2|NA|3||39||BASELINE|1964-05-14|
TRIAL STUDY 134XCP|TR|0281E055-F419-4BA2-89CE-23EC7428CDA0|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^9 ORGANISMS/G|NORMAL||UG/L DDU|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|U|U|FRIEND|PEDIATRIC NEUROLOGIST|U|4||88||WASHOUT|1973-07-12|
TRIAL STUDY 134XCP|TR|0281E055-F419-4BA2-89CE-23EC7428CDA0|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||WEEKS|PALPABLE||UMOL/MOL|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|NA|SIBLING|MICROSCOPIST 3|Y|5||7||OPEN LABEL TREATMENT|1961-11-21|
TRIAL STUDY 134XCP|TR|23CE1310-DBB3-4135-8E11-2A870CE42D50|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||G/M2/DAY|ABSENT||LOG10 CCID 50/DOSE|NOT DONE|||MRS|U|N|FRIEND|MICROSCOPIST|U|1||38||BLINDED TREATMENT|1968-03-07|
TRIAL STUDY 134XCP|TR|23CE1310-DBB3-4135-8E11-2A870CE42D50|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||UG/H|PRESENT||BE/ML|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|NA|INVESTIGATOR|ONCOLOGIST 2|NA|2||58||BASELINE|1964-04-13|
TRIAL STUDY 134XCP|TR|23CE1310-DBB3-4135-8E11-2A870CE42D50|3||||||LPERP|LONGEST PERPENDICULAR||TAMPON|FURTHER ENLARGEMENT||CMH2O*S/ML|NOT DONE|||STRESS ECHOCARDIOGRAPHY|U|N|FAMILY MEMBER|RADIOLOGIST 2|U|3||39||CONTINUATION TREATMENT|1964-01-21|
TRIAL STUDY 134XCP|TR|23CE1310-DBB3-4135-8E11-2A870CE42D50|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/10^5|FOCALLY INCREASED||DAYS/WK|NOT DONE|||CHROMATOGRAPHY|Y|N|PROXY|RATER 2|N|4||88||TREATMENT|1964-06-07|
TRIAL STUDY 134XCP|TR|23CE1310-DBB3-4135-8E11-2A870CE42D50|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||PRESSOR UNITS|DIFFUSELY INCREASED||PT_BR|NOT DONE|||SPECTROPHOTOMETRY|U|NA|CHILD|READER|U|5||7||BASELINE|1965-01-16|
TRIAL STUDY 134XCP|TR|CC80D8A2-7D71-428B-9599-C0D0312B8691|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MV2/HZ|ENLARGEMENT FROM NADIR||ML/DOSE|NOT DONE|||SCANNING ELECTRON MICROSCOPY|U|Y|ADJUDICATOR|READER 2|N|1||38||TREATMENT|1962-08-26|
TRIAL STUDY 134XCP|TR|CC80D8A2-7D71-428B-9599-C0D0312B8691|2||||||NEWCONF|NEW TUMOR CONFIRMED||CIGARETTE|PRESENT||QUANTITY SUFFICIENT|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|N|NA|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||FOLLOW-UP|1962-12-22|
TRIAL STUDY 134XCP|TR|CC80D8A2-7D71-428B-9599-C0D0312B8691|3||||||LESSCIND|LESION SUCCESS INDICATOR||MPA|ENLARGEMENT||EID 50/ML|NOT DONE|||SEQUENCING|Y|N|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1966-06-15|
TRIAL STUDY 134XCP|TR|CC80D8A2-7D71-428B-9599-C0D0312B8691|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||ANTIBODY UNIT|DECREASED||AMOL|NOT DONE|||AUTOMATED COUNT|N|N|SPOUSE|DERMATOLOGIST|N|4||88||INDUCTION TREATMENT|1962-09-12|
TRIAL STUDY 134XCP|TR|CC80D8A2-7D71-428B-9599-C0D0312B8691|5||||||LESSCIND|LESION SUCCESS INDICATOR||DEG/S|ENLARGEMENT FROM NADIR||CFU/G|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|NA|U|FRIEND|HEMATOLOGIST|N|5||7||BASELINE|1971-07-29|
TRIAL STUDY 134XCP|TR|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||EID 50/DOSE|EQUIVOCAL||SQU/ML|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|U|NA|ADJUDICATION COMMITTEE|RATER 1|N|1||38||OPEN LABEL TREATMENT|1972-01-29|
TRIAL STUDY 134XCP|TR|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MEQ/ML|DIFFUSELY INCREASED||TRACE|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|NA|Y|VENDOR|ADJUDICATOR 1|NA|2||58||OBSERVATION|1966-01-29|
TRIAL STUDY 134XCP|TR|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|3||||||ORSTATE|ORGAN STATE||ANSON U|DECREASED||10^7/L|NOT DONE|||TONOMETRY|U|Y|FAMILY MEMBER|RATER|NA|3||39||FOLLOW-UP|1963-08-20|
TRIAL STUDY 134XCP|TR|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||BEATS/MIN|INCREASED||VOXEL|NOT DONE|||PERIODIC ACID SCHIFF STAIN|U|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|4||88||LONG-TERM FOLLOW-UP|1963-01-19|
TRIAL STUDY 134XCP|TR|EB6EE887-79FE-4CD1-BA61-C5F29C54830C|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UV|NON-PATHOLOGICAL||MEQ/UG|NOT DONE|||ANTIMICROBIAL COMBINATION TESTING|N|NA|SPOUSE|HEMATOLOGIST|U|5||7||SCREENING|1965-10-04|
TRIAL STUDY 134XCP|TR|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|1||||||LESSCIND|LESION SUCCESS INDICATOR||UG/L|DECREASED||MEQ/L|NOT DONE|||HEMOCYTOMETRY|NA|Y|CHILD|RATER 1|Y|1||38||CONTINUATION TREATMENT|1970-11-28|
TRIAL STUDY 134XCP|TR|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||H*%|UNCHANGED||MEQ/UG|NOT DONE|||CELLULOSE TAPE|Y|NA|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||INDUCTION TREATMENT|1962-09-05|
TRIAL STUDY 134XCP|TR|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||10^8/L|DECREASED||PIPE|NOT DONE|||TRIPLE-PHASE MRI SCAN|Y|Y|VENDOR|READER 1|Y|3||39||RUN-IN|1966-01-29|
TRIAL STUDY 134XCP|TR|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||DL|UNCHANGED||G/DL|NOT DONE|||PHOTOGRAPHY|NA|N|INVESTIGATOR|RATER|Y|4||88||CONTINUATION TREATMENT|1968-06-21|
TRIAL STUDY 134XCP|TR|CFD063DA-DB51-45EC-ACCA-8AAB90DC1B82|5||||||SUMVOL|SUM OF VOLUME||UKAT|FURTHER ENLARGEMENT FROM NADIR||AGU/ML|NOT DONE|||KARYOTYPING|N|NA|PARENT|ONCOLOGIST 2|Y|5||7||SCREENING|1964-03-05|
TRIAL STUDY 134XCP|TR|3D25A735-6298-4AF4-91CC-AE8D481DF552|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MNFI|FURTHER ENLARGEMENT||UMOL/KG/MIN|NOT DONE|||COMPLEMENT FIXATION|NA|U|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|1||38||CONTINUATION TREATMENT|1963-06-09|
TRIAL STUDY 134XCP|TR|3D25A735-6298-4AF4-91CC-AE8D481DF552|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||GY|PRESENT||KDA|NOT DONE|||IMMUNOPRECIPITATION|U|NA|PROXY|MICROSCOPIST 3|Y|2||58||OBSERVATION|1963-04-14|
TRIAL STUDY 134XCP|TR|3D25A735-6298-4AF4-91CC-AE8D481DF552|3||||||NEWCONF|NEW TUMOR CONFIRMED||FOZ_BR|FURTHER ENLARGEMENT||MJOULE/CM2|NOT DONE|||DOPPLER ULTRASOUND|U|U|GUARDIAN|OPHTHALMOLOGIST|Y|3||39||RUN-IN|1972-11-21|
TRIAL STUDY 134XCP|TR|3D25A735-6298-4AF4-91CC-AE8D481DF552|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||FT3|ENLARGEMENT||10^9 ORGANISMS/MG|NOT DONE|||LINE PROBE ASSAY|NA|U|GUARDIAN|NEUROLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1966-05-25|
TRIAL STUDY 134XCP|TR|3D25A735-6298-4AF4-91CC-AE8D481DF552|5||||||BNLNUM|NUMBER OF BONE LESIONS||MIN/DAY|EQUIVOCAL||CI/UL|NOT DONE|||COULOMETRIC TITRATION|U|U|STUDY SUBJECT|RATER|NA|5||7||BASELINE|1964-02-11|
TRIAL STUDY 134XCP|TR|C249E38B-B454-47D9-8D8B-E2F6A434BA21|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MMOL/S|FOCALLY INCREASED||CI/MG|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|Y|VENDOR|CARDIOLOGIST|Y|1||38||BLINDED TREATMENT|1963-03-27|
TRIAL STUDY 134XCP|TR|C249E38B-B454-47D9-8D8B-E2F6A434BA21|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MNFI|UNCHANGED||10^6 ORGANISMS|NOT DONE|||HPLC/MS/MS|U|U|FAMILY MEMBER|MICROSCOPIST 1|NA|2||58||OPEN LABEL TREATMENT|1970-07-01|
TRIAL STUDY 134XCP|TR|C249E38B-B454-47D9-8D8B-E2F6A434BA21|3||||||DIAMETER|DIAMETER||G/CAGE|NONPALPABLE||NG|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|U|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||OPEN LABEL TREATMENT|1968-12-19|
TRIAL STUDY 134XCP|TR|C249E38B-B454-47D9-8D8B-E2F6A434BA21|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MG/H|EQUIVOCAL||PPTH|NOT DONE|||SICKLE CELL SOLUBILITY TEST|U|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|4||88||CONTINUATION TREATMENT|1962-03-25|
TRIAL STUDY 134XCP|TR|C249E38B-B454-47D9-8D8B-E2F6A434BA21|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PIPE|NON-PATHOLOGICAL||SPRAY|NOT DONE|||RULER MEASUREMENT METHOD|NA|NA|INTERVIEWER|PATHOLOGIST|NA|5||7||BASELINE|1966-05-10|
TRIAL STUDY 134XCP|TR|4540D569-1DD0-4984-89DB-6F9A391397FE|1||||||ORVERLN|ORGAN VERTICAL LENGTH||MSEC|DIFFUSELY INCREASED||MG/CM2|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|NA|U|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1||38||RUN-IN|1962-09-28|
TRIAL STUDY 134XCP|TR|4540D569-1DD0-4984-89DB-6F9A391397FE|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||DL|PRESENT||UG/G/H|NOT DONE|||RULER MEASUREMENT METHOD|N|Y|CLINICAL RESEARCH ASSOCIATE|READER|N|2||58||WASHOUT|1960-04-19|
TRIAL STUDY 134XCP|TR|4540D569-1DD0-4984-89DB-6F9A391397FE|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||/7.5 ML|NORMAL||LM|NOT DONE|||FUNDUS PHOTOGRAPHY|U|NA|PROXY|RATER|U|3||39||LONG-TERM FOLLOW-UP|1971-11-22|
TRIAL STUDY 134XCP|TR|4540D569-1DD0-4984-89DB-6F9A391397FE|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PFU/ANIMAL|UNCHANGED||CM H2O|NOT DONE|||MICROBIAL CONCENTRATION|Y|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|4||88||SCREENING|1966-03-06|
TRIAL STUDY 134XCP|TR|4540D569-1DD0-4984-89DB-6F9A391397FE|5||||||VDIAM|VIABLE DIAMETER||PMOL/L|DIFFUSELY INCREASED||IU/DL|NOT DONE|||AUDIOMETRY|NA|Y|ADJUDICATOR|PATHOLOGIST 1|U|5||7||OBSERVATION|1970-05-23|
TRIAL STUDY 134XCP|TR|DC1D666E-4920-4B60-A520-D183BCDE0E85|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||DAYS/MONTH|ENLARGEMENT FROM NADIR||AFU|NOT DONE|||REBOUND TONOMETRY|NA|NA|INVESTIGATOR|ADJUDICATOR|U|1||38||BLINDED TREATMENT|1970-10-23|
TRIAL STUDY 134XCP|TR|DC1D666E-4920-4B60-A520-D183BCDE0E85|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UKAT|PRESENT||MET|NOT DONE|||CLIP SEQUENCING|Y|Y|VENDOR|MICROSCOPIST 3|NA|2||58||OBSERVATION|1961-10-30|
TRIAL STUDY 134XCP|TR|DC1D666E-4920-4B60-A520-D183BCDE0E85|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||10^4 CFU|EQUIVOCAL||MMU/ML|NOT DONE|||CLIP|N|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|3||39||OBSERVATION|1965-03-15|
TRIAL STUDY 134XCP|TR|DC1D666E-4920-4B60-A520-D183BCDE0E85|4||||||ORVERLN|ORGAN VERTICAL LENGTH||IU/DAY|PATHOLOGICAL||LOZENGE|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|Y|Y|PROXY|ADJUDICATOR 1|NA|4||88||LONG-TERM FOLLOW-UP|1968-04-07|
TRIAL STUDY 134XCP|TR|DC1D666E-4920-4B60-A520-D183BCDE0E85|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UG/DOSE|ABSENT||HPA|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|N|N|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|5||7||CONTINUATION TREATMENT|1968-08-06|
TRIAL STUDY 134XCP|TR|A015D12B-C03B-4371-8D1F-F03D60542BA7|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^9 CFU|UNCHANGED||U/L|NOT DONE|||NUCLEAR RADIOLOGY|Y|U|PARENT|RADIOLOGIST|Y|1||38||CONTINUATION TREATMENT|1972-10-29|
TRIAL STUDY 134XCP|TR|A015D12B-C03B-4371-8D1F-F03D60542BA7|2||||||TUMSTATE|TUMOR STATE||CMOL/L|UNEQUIVOCAL||ML/CAGE|NOT DONE|||KARYOTYPING|N|N|CAREGIVER|RATER 1|N|2||58||FOLLOW-UP|1964-02-11|
TRIAL STUDY 134XCP|TR|A015D12B-C03B-4371-8D1F-F03D60542BA7|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||M/SEC|UNCHANGED||FEU|NOT DONE|||FUNDUS PHOTOGRAPHY|N|NA|VENDOR|RATER 1|Y|3||39||BASELINE|1969-08-05|
TRIAL STUDY 134XCP|TR|A015D12B-C03B-4371-8D1F-F03D60542BA7|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||AMPULE|PALPABLE||PIPE|NOT DONE|||TRANSVAGINAL ULTRASOUND|N|U|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|4||88||WASHOUT|1964-07-15|
TRIAL STUDY 134XCP|TR|A015D12B-C03B-4371-8D1F-F03D60542BA7|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||10^4/HPF|UNEQUIVOCAL||IU|NOT DONE|||SXA SCAN|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|5||7||SCREENING|1962-03-29|
TRIAL STUDY 134XCP|TR|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MG/KG/H|UNEQUIVOCAL||ML/MMHG/MIN/L|NOT DONE|||BALLPOINT PEN TECHNIQUE|NA|Y|SIBLING|RADIOLOGIST|NA|1||38||CONTINUATION TREATMENT|1965-07-21|
TRIAL STUDY 134XCP|TR|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||ML*CMH2O|PRESENT||MCI|NOT DONE|||BALLPOINT PEN TECHNIQUE|Y|U|INTERVIEWER|HEMATOLOGIST|U|2||58||SCREENING|1967-03-13|
TRIAL STUDY 134XCP|TR|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|3||||||LESFLIND|LESION FAILURE INDICATOR||PHERESIS UNIT|TUMOR MERGED||ECL UNIT|NOT DONE|||POLYSOMNOGRAPHY|N|U|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||BASELINE|1971-04-12|
TRIAL STUDY 134XCP|TR|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||TABLET|EQUIVOCAL||ML/CM|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|N|U|VENDOR|ADJUDICATOR 1|Y|4||88||OPEN LABEL TREATMENT|1962-09-11|
TRIAL STUDY 134XCP|TR|EB15F3FF-8414-4D5B-A305-EA5B1FE8B8AF|5||||||ORSTATE|ORGAN STATE||COPIES/UL|NORMAL||KG/CM|NOT DONE|||CELLULOSE TAPE|Y|N|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5||7||OBSERVATION|1970-07-30|
TRIAL STUDY 134XCP|TR|34AC7973-686F-45A2-999A-1A36C7874F91|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PG/L|ENLARGEMENT FROM NADIR||NGEQ/L|NOT DONE|||GC/MS/MS|U|N|CAREGIVER|ADJUDICATOR 2|Y|1||38||BASELINE|1964-09-03|
TRIAL STUDY 134XCP|TR|34AC7973-686F-45A2-999A-1A36C7874F91|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||10^6 U|NORMAL||COPIES/ML|NOT DONE|||WRIGHT STAIN|U|U|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||INDUCTION TREATMENT|1964-08-25|
TRIAL STUDY 134XCP|TR|34AC7973-686F-45A2-999A-1A36C7874F91|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MG/CM2|INCREASED||10^3 ORGANISMS|NOT DONE|||TOTAL BODY IRRADIATION|NA|U|INVESTIGATOR|READER 3|NA|3||39||RUN-IN|1965-04-11|
TRIAL STUDY 134XCP|TR|34AC7973-686F-45A2-999A-1A36C7874F91|4||||||PALPSTAT|PALPABLE STATE||GLOBULE|PATHOLOGICAL||10^3 ORGANISMS|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|U|SIBLING|OPTOMETRIST|N|4||88||CONTINUATION TREATMENT|1965-03-15|
TRIAL STUDY 134XCP|TR|34AC7973-686F-45A2-999A-1A36C7874F91|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||PT_US|ABSENT||L/H|NOT DONE|||STATIC PERIMETRY|N|NA|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|5||7||OBSERVATION|1965-05-31|
TRIAL STUDY 134XCP|TR|5AE66AC0-ECB6-49A2-859F-871B9A15E624|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UMOL|INCREASED||CM2|NOT DONE|||SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|U|STUDY SUBJECT|READER|NA|1||38||BASELINE|1960-03-26|
TRIAL STUDY 134XCP|TR|5AE66AC0-ECB6-49A2-859F-871B9A15E624|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||FOZ_US|PALPABLE||UM/S|NOT DONE|||WEBER GREEN STAIN|Y|Y|SPOUSE|NEUROLOGIST|U|2||58||RUN-IN|1963-02-18|
TRIAL STUDY 134XCP|TR|5AE66AC0-ECB6-49A2-859F-871B9A15E624|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||FEU|PALPABLE||UG/L|NOT DONE|||OLIGO ACGH|Y|U|VENDOR|RADIOLOGIST|N|3||39||BASELINE|1961-04-02|
TRIAL STUDY 134XCP|TR|5AE66AC0-ECB6-49A2-859F-871B9A15E624|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MG/M2|PATHOLOGICAL||/MBP|NOT DONE|||GRADIENT DIFFUSION|NA|NA|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1961-12-24|
TRIAL STUDY 134XCP|TR|5AE66AC0-ECB6-49A2-859F-871B9A15E624|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||PNU/ML|NORMAL||10^6 IU/ML|NOT DONE|||POTENTIOMETRY|Y|Y|INVESTIGATOR|CARDIOLOGIST|U|5||7||TREATMENT|1964-08-04|
TRIAL STUDY 134XCP|TR|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||RAD|NON-PATHOLOGICAL||MG/DOSE|NOT DONE|||SLOAN LETTER EYE CHART 100%|U|NA|SPOUSE|PEDIATRIC NEUROLOGIST|NA|1||38||FOLLOW-UP|1971-03-08|
TRIAL STUDY 134XCP|TR|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MM/SEC|FURTHER ENLARGEMENT||BEL|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|NA|STUDY SUBJECT|PATHOLOGIST 2|NA|2||58||OBSERVATION|1967-02-03|
TRIAL STUDY 134XCP|TR|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|3||||||RADIODEN|RADIODENSITY||PSEC|UNCHANGED||U/ANIMAL|NOT DONE|||GEL ELECTROPHORESIS|NA|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1965-04-25|
TRIAL STUDY 134XCP|TR|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|4||||||ORVERLN|ORGAN VERTICAL LENGTH||FL|ABSENT||KS|NOT DONE|||JAEGER EYE CHART|NA|NA|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|4||88||WASHOUT|1972-03-15|
TRIAL STUDY 134XCP|TR|31C4E0AA-B36B-411C-ABAA-CDEE1190AA22|5||||||LNSTATE|LYMPH NODE STATE||BOX|NORMAL||10^7 TCID 50/DOSE|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|N|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|5||7||OBSERVATION|1960-07-12|
TRIAL STUDY 134XCP|TR|59A9826F-4C2F-482A-8888-F649544318BE|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MKAT|PALPABLE||L|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|1||38||BASELINE|1971-07-20|
TRIAL STUDY 134XCP|TR|59A9826F-4C2F-482A-8888-F649544318BE|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||/10^4|TUMOR MERGED||PNU/ML|NOT DONE|||CONTRAST ENHANCED X-RAY|N|NA|CAREGIVER|ADJUDICATOR|N|2||58||BASELINE|1966-09-29|
TRIAL STUDY 134XCP|TR|59A9826F-4C2F-482A-8888-F649544318BE|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CI/UG|DIFFUSELY INCREASED||CCID 50/DOSE|NOT DONE|||ENDPOINT DILUTION ASSAY|Y|U|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|3||39||OBSERVATION|1962-08-08|
TRIAL STUDY 134XCP|TR|59A9826F-4C2F-482A-8888-F649544318BE|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MPA|FURTHER ENLARGEMENT||MG/G/MIN|NOT DONE|||FUNCTIONAL MRI|U|Y|CAREGIVER|PATHOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1970-08-14|
TRIAL STUDY 134XCP|TR|59A9826F-4C2F-482A-8888-F649544318BE|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||KG/M2|PATHOLOGICAL||MU|NOT DONE|||KINETIC CHROMOGENIC ASSAY|NA|NA|STUDY SUBJECT|RATER 2|NA|5||7||RUN-IN|1968-08-18|
TRIAL STUDY 134XCP|TR|B6E55A62-CF0B-4BC6-84DC-038F29518909|1||||||AREA|AREA||HENRY|TUMOR MERGED||UG/G/H|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|N|STUDY SUBJECT|OPHTHALMOLOGIST|Y|1||38||INDUCTION TREATMENT|1970-09-04|
TRIAL STUDY 134XCP|TR|B6E55A62-CF0B-4BC6-84DC-038F29518909|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||LM|EQUIVOCAL||AMP|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|NA|NA|PROXY|CARDIOLOGIST|N|2||58||TREATMENT|1965-06-11|
TRIAL STUDY 134XCP|TR|B6E55A62-CF0B-4BC6-84DC-038F29518909|3||||||LESSCIND|LESION SUCCESS INDICATOR||AGU/ML|EQUIVOCAL||MOL/G|NOT DONE|||IMMUNOCHROMATOGRAPHY|Y|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|3||39||OPEN LABEL TREATMENT|1968-06-03|
TRIAL STUDY 134XCP|TR|B6E55A62-CF0B-4BC6-84DC-038F29518909|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||CI/G|FURTHER ENLARGEMENT||KG/CM2|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|U|N|CLINICAL RESEARCH COORDINATOR|RATER 1|Y|4||88||CONTINUATION TREATMENT|1971-07-23|
TRIAL STUDY 134XCP|TR|B6E55A62-CF0B-4BC6-84DC-038F29518909|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||KG/M2|PATHOLOGICAL||U/L|NOT DONE|||PHOTOMETRY|N|NA|PROXY|READER 2|Y|5||7||LONG-TERM FOLLOW-UP|1966-08-23|
TRIAL STUDY 134XCP|TR|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|1||||||ORVERLN|ORGAN VERTICAL LENGTH||10^6 CFU/ML|DECREASED||QUANTITY SUFFICIENT|NOT DONE|||GC/FID|NA|NA|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1970-12-21|
TRIAL STUDY 134XCP|TR|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MG/DOSE|DECREASED||L/S|NOT DONE|||HPLC/MS/MS|NA|NA|STUDY SUBJECT|ADJUDICATOR|U|2||58||OBSERVATION|1961-12-12|
TRIAL STUDY 134XCP|TR|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||BQ/G|DIFFUSELY INCREASED||/KG|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|U|Y|VENDOR|RATER|NA|3||39||BASELINE|1962-01-03|
TRIAL STUDY 134XCP|TR|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||C|TUMOR MERGED||LOG10 TCID 50/UL|NOT DONE|||ENZYMATIC COLORIMETRY|NA|NA|STUDY SUBJECT|ADJUDICATOR 1|Y|4||88||RUN-IN|1961-05-03|
TRIAL STUDY 134XCP|TR|3B5E776E-C267-4F99-80AB-AAD96A6B1DA7|5||||||CALCFIND|CALCIFICATION INDICATOR||PIPE|ABSENT||ML/CM|NOT DONE|||VIRUS PLAQUE ASSAY|U|Y|SIGNIFICANT OTHER|READER|NA|5||7||TREATMENT|1969-08-06|
TRIAL STUDY 134XCP|TR|5577E914-C90D-4CC4-A7A8-D919C29A61D1|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||IU/ML|NON-PATHOLOGICAL||PRESSOR UNITS|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|NA|CLINICAL RESEARCH ASSOCIATE|READER 1|U|1||38||OPEN LABEL TREATMENT|1973-04-08|
TRIAL STUDY 134XCP|TR|5577E914-C90D-4CC4-A7A8-D919C29A61D1|2||||||RADIODEN|RADIODENSITY||DL|PRESENT||10^12 IU/L|NOT DONE|||KARYOTYPING|U|U|INDEPENDENT ASSESSOR|READER 3|Y|2||58||OPEN LABEL TREATMENT|1973-02-25|
TRIAL STUDY 134XCP|TR|5577E914-C90D-4CC4-A7A8-D919C29A61D1|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||LOG10 COPIES/ML|NORMAL||KALLIKREIN INHIBITOR UNIT|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|NA|NA|FRIEND|UROLOGIST|U|3||39||RUN-IN|1961-06-12|
TRIAL STUDY 134XCP|TR|5577E914-C90D-4CC4-A7A8-D919C29A61D1|4||||||BNLNUM|NUMBER OF BONE LESIONS||MS/MMHG|ENLARGEMENT||UL/DOSE|NOT DONE|||QUANTITATIVE ULTRASOUND|Y|NA|CAREGIVER|ENDOCRINOLOGIST|Y|4||88||RUN-IN|1970-08-09|
TRIAL STUDY 134XCP|TR|5577E914-C90D-4CC4-A7A8-D919C29A61D1|5||||||LESSCIND|LESION SUCCESS INDICATOR||DEG/S|DIFFUSELY INCREASED||CM/MIN|NOT DONE|||PH METER MEASUREMENT METHOD|U|NA|STUDY SUBJECT|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1969-05-11|
TRIAL STUDY 134XCP|TR|2DBA8940-F59E-4A0D-8858-408D71DD9753|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||KEV|PRESENT||PSEC|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|NA|N|STUDY SUBJECT|RADIOLOGIST|NA|1||38||BLINDED TREATMENT|1966-03-24|
TRIAL STUDY 134XCP|TR|2DBA8940-F59E-4A0D-8858-408D71DD9753|2||||||PALPSTAT|PALPABLE STATE||AMP|UNCHANGED||MOSM/L|NOT DONE|||POLYSOMNOGRAPHY|NA|N|SIBLING|PHYSIOTHERAPIST|Y|2||58||INDUCTION TREATMENT|1968-06-01|
TRIAL STUDY 134XCP|TR|2DBA8940-F59E-4A0D-8858-408D71DD9753|3||||||TUMSTATE|TUMOR STATE||MEQ/DL|PALPABLE||UMOL/L/SEC|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|Y|GUARDIAN|RADIOLOGIST 2|N|3||39||INDUCTION TREATMENT|1965-05-15|
TRIAL STUDY 134XCP|TR|2DBA8940-F59E-4A0D-8858-408D71DD9753|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MG/MIN|ABSENT||MG2/DL2|NOT DONE|||MRI|U|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|4||88||BASELINE|1962-10-18|
TRIAL STUDY 134XCP|TR|2DBA8940-F59E-4A0D-8858-408D71DD9753|5||||||ORVERLN|ORGAN VERTICAL LENGTH||ML|DIFFUSELY INCREASED||GLOBULE|NOT DONE|||IMMUNO-PET SCAN|NA|N|FAMILY MEMBER|RATER 2|Y|5||7||BLINDED TREATMENT|1970-11-11|
TRIAL STUDY 134XCP|TR|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^9 ORGANISMS/G|UNEQUIVOCAL||PL|NOT DONE|||LASER CAPTURE MICRODISSECTION|NA|U|GUARDIAN|NEUROLOGIST 2|NA|1||38||SCREENING|1963-08-29|
TRIAL STUDY 134XCP|TR|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|2||||||AREA|AREA||MEQ/G|DIFFUSELY INCREASED||%|NOT DONE|||MICROSCOPY|N|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|2||58||FOLLOW-UP|1969-03-23|
TRIAL STUDY 134XCP|TR|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||CD|DIFFUSELY INCREASED||MM/2H|NOT DONE|||CENTRIFUGATION|Y|N|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|3||39||WASHOUT|1962-06-01|
TRIAL STUDY 134XCP|TR|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||BOTTLE|ABSENT||NMOL BCE/L|NOT DONE|||RULER MEASUREMENT METHOD|Y|Y|VENDOR|MICROSCOPIST|U|4||88||TREATMENT|1972-07-19|
TRIAL STUDY 134XCP|TR|F62D63CA-BCD9-4D81-B789-0CABDA5F8A99|5||||||VOLUME|VOLUME||KPA|PRESENT||UCI/KG|NOT DONE|||TWO-COLOR MICROARRAY|NA|N|SIGNIFICANT OTHER|ADJUDICATOR 2|U|5||7||OBSERVATION|1970-05-16|
TRIAL STUDY 134XCP|TR|0250EC5D-B08F-4010-9653-95E20EDD0CCA|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||/LPF|ABSENT||U/G/DAY|NOT DONE|||FLUORESCENT SPOT TEST|N|U|ADJUDICATOR|ADJUDICATOR 2|NA|1||38||INDUCTION TREATMENT|1967-07-23|
TRIAL STUDY 134XCP|TR|0250EC5D-B08F-4010-9653-95E20EDD0CCA|2||||||ORSTATE|ORGAN STATE||10^9/G|UNEQUIVOCAL||DMOL|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|U|NA|SIGNIFICANT OTHER|NEUROLOGIST|Y|2||58||TREATMENT|1963-06-17|
TRIAL STUDY 134XCP|TR|0250EC5D-B08F-4010-9653-95E20EDD0CCA|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||AFU|ENLARGEMENT||SV|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|U|N|CAREGIVER|NEUROLOGIST|Y|3||39||WASHOUT|1967-08-05|
TRIAL STUDY 134XCP|TR|0250EC5D-B08F-4010-9653-95E20EDD0CCA|4||||||ORSTATE|ORGAN STATE||CM/S|ABSENT||%(V/V)|NOT DONE|||CLIP SEQUENCING|NA|U|SIGNIFICANT OTHER|NEUROLOGIST 1|NA|4||88||LONG-TERM FOLLOW-UP|1962-01-31|
TRIAL STUDY 134XCP|TR|0250EC5D-B08F-4010-9653-95E20EDD0CCA|5||||||LESFLIND|LESION FAILURE INDICATOR||GBQ/UG|PRESENT||10^5/L|NOT DONE|||OPTICAL DENSITY MEASUREMENT|N|N|INTERVIEWER|OPHTHALMOLOGIST|NA|5||7||TREATMENT|1961-09-28|
TRIAL STUDY 134XCP|TR|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||KPA|NORMAL||MG/G/MIN|NOT DONE|||SPECT SCAN|N|NA|FAMILY MEMBER|RATER|NA|1||38||CONTINUATION TREATMENT|1972-02-16|
TRIAL STUDY 134XCP|TR|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|2||||||LNSTATE|LYMPH NODE STATE||CY/CM|TUMOR MERGED||TABLET|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|U|U|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|2||58||OBSERVATION|1961-09-03|
TRIAL STUDY 134XCP|TR|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|3||||||LESSCIND|LESION SUCCESS INDICATOR||APS U|EQUIVOCAL||NMOL/ML/MIN|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|NA|N|INTERVIEWER|NEUROLOGIST|NA|3||39||TREATMENT|1963-03-06|
TRIAL STUDY 134XCP|TR|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||PMOL/L/H|ABSENT||CYCLE/MIN|NOT DONE|||COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|Y|GUARDIAN|HEMATOLOGIST|U|4||88||SCREENING|1967-04-02|
TRIAL STUDY 134XCP|TR|C06524C5-BA81-4AC0-9E8A-112D7B7112A6|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||NSEC|FURTHER ENLARGEMENT FROM NADIR||/LPF|NOT DONE|||WESTERGREN|NA|U|CHILD|RADIOLOGIST 2|N|5||7||OPEN LABEL TREATMENT|1967-08-21|
TRIAL STUDY 134XCP|TR|140FFC83-72C9-4BD4-AA44-C98CA42147F3|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MEQ|PRESENT||UG/L|NOT DONE|||MRI WITHOUT CONTRAST|N|U|NON-HEALTH CARE PROFESSIONAL|READER 2|N|1||38||RUN-IN|1963-09-10|
TRIAL STUDY 134XCP|TR|140FFC83-72C9-4BD4-AA44-C98CA42147F3|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||UG/G/H|UNEQUIVOCAL||ELISA UNIT/ML|NOT DONE|||WHOLE EXOME SEQUENCING|NA|N|PARENT|RADIOLOGIST 2|U|2||58||OPEN LABEL TREATMENT|1969-06-21|
TRIAL STUDY 134XCP|TR|140FFC83-72C9-4BD4-AA44-C98CA42147F3|3||||||RADIODEN|RADIODENSITY||HZ|TUMOR MERGED||LOG10 ELISA UNIT|NOT DONE|||CLIP|NA|NA|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|3||39||TREATMENT|1961-09-10|
TRIAL STUDY 134XCP|TR|140FFC83-72C9-4BD4-AA44-C98CA42147F3|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||KIT|FURTHER ENLARGEMENT||MG/KG/MIN|NOT DONE|||SNP ARRAY|Y|N|FAMILY MEMBER|UROLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1966-08-25|
TRIAL STUDY 134XCP|TR|140FFC83-72C9-4BD4-AA44-C98CA42147F3|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||IU|FURTHER ENLARGEMENT FROM NADIR||10^3 DNA COPIES/ML|NOT DONE|||U-HPLC/MS/MS|U|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|Y|5||7||OPEN LABEL TREATMENT|1961-11-26|
TRIAL STUDY 134XCP|TR|7BAC399A-0523-476E-A294-C57309E573AF|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^6 IU/ML|ABSENT||MMOL/MIN/KPA|NOT DONE|||HPLC/MS|NA|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1||38||BLINDED TREATMENT|1970-06-02|
TRIAL STUDY 134XCP|TR|7BAC399A-0523-476E-A294-C57309E573AF|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MMOL/MIN/KPA/L|ABSENT||NEEDLE GAUGE|NOT DONE|||PERFUSION MRI|NA|Y|VENDOR|ADJUDICATOR 1|U|2||58||TREATMENT|1973-02-13|
TRIAL STUDY 134XCP|TR|7BAC399A-0523-476E-A294-C57309E573AF|3||||||ORVERLN|ORGAN VERTICAL LENGTH||MM/2H|FOCALLY INCREASED||L|NOT DONE|||PET/CT SCAN|Y|Y|SPOUSE|PEDIATRIC NEUROLOGIST|N|3||39||RUN-IN|1972-08-27|
TRIAL STUDY 134XCP|TR|7BAC399A-0523-476E-A294-C57309E573AF|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/10^5|INCREASED||MHZ|NOT DONE|||ELECTROGASTROGRAPHY|Y|Y|SPOUSE|READER 3|U|4||88||OPEN LABEL TREATMENT|1965-03-13|
TRIAL STUDY 134XCP|TR|7BAC399A-0523-476E-A294-C57309E573AF|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||EP U|ENLARGEMENT FROM NADIR||UU/DL|NOT DONE|||ACID FAST STAIN|U|U|CHILD|ADJUDICATOR 3|NA|5||7||FOLLOW-UP|1961-11-30|
TRIAL STUDY 134XCP|TR|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|1||||||SUMDIAM|SUM OF DIAMETER||LOG10 CCID 50/DOSE|DIFFUSELY INCREASED||MG/M2/H|NOT DONE|||HILLMEN COLOR CHART|N|N|CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|1||38||FOLLOW-UP|1970-03-18|
TRIAL STUDY 134XCP|TR|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||KHZ|FOCALLY INCREASED||EIA UNIT|NOT DONE|||CORONARY ANGIOGRAPHY|NA|NA|PARENT|ADJUDICATOR 2|N|2||58||RUN-IN|1961-09-08|
TRIAL STUDY 134XCP|TR|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MEQ/KG|NONPALPABLE||IU/DAY|NOT DONE|||TRIPLE-PHASE MRI SCAN|NA|Y|DOMESTIC PARTNER|ONCOLOGIST 1|N|3||39||RUN-IN|1962-05-22|
TRIAL STUDY 134XCP|TR|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BU|UNCHANGED||MM/MIN|NOT DONE|||SINGLE-SLICE SPIRAL CT|Y|NA|SIBLING|READER 1|NA|4||88||OBSERVATION|1963-12-18|
TRIAL STUDY 134XCP|TR|D23869D2-DBE2-4687-BE8C-AD4458FD49F5|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||LENS|DECREASED||FINGERTIP UNIT|NOT DONE|||WRIGHT STAIN|Y|Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1962-11-03|
TRIAL STUDY 134XCP|TR|0F180E62-F840-490F-8EB3-F7DDB7132401|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CM|FURTHER ENLARGEMENT FROM NADIR||IU/DAY|NOT DONE|||IRON HEMATOXYLIN STAIN|NA|Y|SIGNIFICANT OTHER|RATER 2|U|1||38||INDUCTION TREATMENT|1964-01-14|
TRIAL STUDY 134XCP|TR|0F180E62-F840-490F-8EB3-F7DDB7132401|2||||||DIAMETER|DIAMETER||10^9/L|ENLARGEMENT||ECL UNIT|NOT DONE|||CELLULOSE TAPE|NA|N|SPOUSE|ONCOLOGIST 1|NA|2||58||SCREENING|1961-09-23|
TRIAL STUDY 134XCP|TR|0F180E62-F840-490F-8EB3-F7DDB7132401|3||||||AREA|AREA||CM H2O|DIFFUSELY INCREASED||UG/L/H|NOT DONE|||PHOROPTER|U|U|CAREGIVER|ONCOLOGIST 2|N|3||39||LONG-TERM FOLLOW-UP|1968-04-24|
TRIAL STUDY 134XCP|TR|0F180E62-F840-490F-8EB3-F7DDB7132401|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||FG|PRESENT||IU/ML|NOT DONE|||CISH|N|N|INTERVIEWER|MICROSCOPIST 3|NA|4||88||BLINDED TREATMENT|1965-02-25|
TRIAL STUDY 134XCP|TR|0F180E62-F840-490F-8EB3-F7DDB7132401|5||||||LESFLIND|LESION FAILURE INDICATOR||/KG|FOCALLY INCREASED||KEV|NOT DONE|||GIEMSA STAIN|Y|Y|SPOUSE|UROLOGIST|U|5||7||RUN-IN|1966-10-18|
TRIAL STUDY 134XCP|TR|80E7A428-CDDE-453F-B7D1-1B282A1835BF|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PG/DL|PALPABLE||M3|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|NA|U|VENDOR|OTOLARYNGOLOGIST|NA|1||38||OBSERVATION|1973-08-27|
TRIAL STUDY 134XCP|TR|80E7A428-CDDE-453F-B7D1-1B282A1835BF|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MG/DL|FURTHER ENLARGEMENT||PPTR|NOT DONE|||ALCIAN BLUE STAIN|N|Y|CHILD|PEDIATRIC NEUROLOGIST|NA|2||58||WASHOUT|1969-05-28|
TRIAL STUDY 134XCP|TR|80E7A428-CDDE-453F-B7D1-1B282A1835BF|3||||||RADIODEN|RADIODENSITY||LOG EID 50/DOSE|FURTHER ENLARGEMENT||APL U|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|U|U|INVESTIGATOR|MICROSCOPIST 2|U|3||39||BASELINE|1972-06-24|
TRIAL STUDY 134XCP|TR|80E7A428-CDDE-453F-B7D1-1B282A1835BF|4||||||ORVERLN|ORGAN VERTICAL LENGTH||OZ EQ|FURTHER ENLARGEMENT||G/CAGE|NOT DONE|||MODIFIED ACID FAST STAIN|NA|N|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|4||88||BLINDED TREATMENT|1964-10-04|
TRIAL STUDY 134XCP|TR|80E7A428-CDDE-453F-B7D1-1B282A1835BF|5||||||VDIAM|VIABLE DIAMETER||G/CM2|TUMOR MERGED||UMOL/L/MIN|NOT DONE|||X-RAY|Y|Y|ADJUDICATOR|RATER 2|U|5||7||OPEN LABEL TREATMENT|1961-03-09|
TRIAL STUDY 134XCP|TR|F1D265C4-B975-4E74-9545-122A10FE100F|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MOL|ENLARGEMENT||NSEC|NOT DONE|||PERIPHERAL ANGIOGRAPHY|U|U|SIGNIFICANT OTHER|NEUROLOGIST 1|U|1||38||CONTINUATION TREATMENT|1970-07-13|
TRIAL STUDY 134XCP|TR|F1D265C4-B975-4E74-9545-122A10FE100F|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UL|FURTHER ENLARGEMENT FROM NADIR||OHM|NOT DONE|||TRYPAN BLUE STAIN|Y|Y|PROXY|ENDOCRINOLOGIST|NA|2||58||TREATMENT|1960-06-21|
TRIAL STUDY 134XCP|TR|F1D265C4-B975-4E74-9545-122A10FE100F|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UG/DAY|FOCALLY INCREASED||BOX|NOT DONE|||DIFFUSION WEIGHTED MRI|U|N|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|3||39||OPEN LABEL TREATMENT|1961-12-24|
TRIAL STUDY 134XCP|TR|F1D265C4-B975-4E74-9545-122A10FE100F|4||||||VOLUME|VOLUME||CMOL/L|FOCALLY INCREASED||EQ|NOT DONE|||REFRACTOMETRY|Y|N|HEALTH CARE PROFESSIONAL|READER 2|Y|4||88||CONTINUATION TREATMENT|1965-05-04|
TRIAL STUDY 134XCP|TR|F1D265C4-B975-4E74-9545-122A10FE100F|5||||||VDIAM|VIABLE DIAMETER||UMOL/L/SEC|ENLARGEMENT||1/(S*KPA)|NOT DONE|||ELECTRONEUROGRAPHY|U|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5||7||SCREENING|1960-10-01|
TRIAL STUDY 134XCP|TR|7A272C35-DB2C-429D-AF31-CC7386DC8F07|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||WATT|FURTHER ENLARGEMENT||10^10/L|NOT DONE|||DARK FIELD MICROSCOPY|Y|N|FRIEND|HEMATOLOGIST|U|1||38||TREATMENT|1961-01-31|
TRIAL STUDY 134XCP|TR|7A272C35-DB2C-429D-AF31-CC7386DC8F07|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||TUBE|EQUIVOCAL||CUP EQ|NOT DONE|||OBSERVATION|Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|2||58||SCREENING|1972-12-28|
TRIAL STUDY 134XCP|TR|7A272C35-DB2C-429D-AF31-CC7386DC8F07|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||F|UNEQUIVOCAL||S*KPA|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|U|N|CLINICAL RESEARCH ASSOCIATE|READER 1|U|3||39||OPEN LABEL TREATMENT|1964-04-22|
TRIAL STUDY 134XCP|TR|7A272C35-DB2C-429D-AF31-CC7386DC8F07|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||CG|ENLARGEMENT FROM NADIR||MEQ/UL|NOT DONE|||EEG|U|U|INVESTIGATOR|ADJUDICATOR 2|U|4||88||RUN-IN|1968-11-23|
TRIAL STUDY 134XCP|TR|7A272C35-DB2C-429D-AF31-CC7386DC8F07|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||/4.0 ML|FOCALLY INCREASED||KHZ|NOT DONE|||PLETHYSMOGRAPHY|NA|N|CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|5||7||OPEN LABEL TREATMENT|1963-04-20|
TRIAL STUDY 134XCP|TR|FBF95CF9-933D-406A-8D67-B1F643C5F554|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CM H2O|NON-PATHOLOGICAL||KN/CM2|NOT DONE|||ULTRASOUND|N|U|ADJUDICATOR|DERMATOLOGIST|N|1||38||BASELINE|1969-06-29|
TRIAL STUDY 134XCP|TR|FBF95CF9-933D-406A-8D67-B1F643C5F554|2||||||LESSCIND|LESION SUCCESS INDICATOR||TUBE|PALPABLE||/10^5|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|U|NA|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||BASELINE|1962-07-27|
TRIAL STUDY 134XCP|TR|FBF95CF9-933D-406A-8D67-B1F643C5F554|3||||||LESSCIND|LESION SUCCESS INDICATOR||MM|FOCALLY INCREASED||10^3 DNA COPIES/ML|NOT DONE|||ELECTROCHEMILUMINESCENCE|Y|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|3||39||BASELINE|1962-06-14|
TRIAL STUDY 134XCP|TR|FBF95CF9-933D-406A-8D67-B1F643C5F554|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UG/M2/DAY|FURTHER ENLARGEMENT||BQ/G|NOT DONE|||SNP ARRAY|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|NA|4||88||OPEN LABEL TREATMENT|1969-06-12|
TRIAL STUDY 134XCP|TR|FBF95CF9-933D-406A-8D67-B1F643C5F554|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||IU/L|NONPALPABLE||CMOL|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|U|U|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|5||7||OPEN LABEL TREATMENT|1970-04-26|
TRIAL STUDY 134XCP|TR|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||U/ML|ENLARGEMENT||STEPS/MIN|NOT DONE|||AGAR PROPORTION|NA|Y|STUDY SUBJECT|OPTOMETRIST|N|1||38||TREATMENT|1970-11-04|
TRIAL STUDY 134XCP|TR|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||LOG10 PFU/ML|DIFFUSELY INCREASED||BREATHS/30S|NOT DONE|||HPLC-FL|Y|U|VENDOR|PATHOLOGIST 1|N|2||58||INDUCTION TREATMENT|1967-02-07|
TRIAL STUDY 134XCP|TR|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^3 ORGANISMS/ML|INCREASED||LOG10 TCID 50/UL|NOT DONE|||THIN SMEAR|N|Y|CHILD|ADJUDICATOR 2|NA|3||39||INDUCTION TREATMENT|1970-01-01|
TRIAL STUDY 134XCP|TR|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|4||||||LESSCIND|LESION SUCCESS INDICATOR||AFU|PALPABLE||CMHG|NOT DONE|||THICK SMEAR|Y|N|SPOUSE|PHYSIOTHERAPIST|N|4||88||INDUCTION TREATMENT|1969-02-16|
TRIAL STUDY 134XCP|TR|21E51AFC-91F0-4187-A5DC-9DA9A8C20D09|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MG/G/H|EQUIVOCAL||CIGAR|NOT DONE|||FLOW CYTOMETRY|NA|U|SIGNIFICANT OTHER|RATER|NA|5||7||FOLLOW-UP|1970-11-11|
TRIAL STUDY 134XCP|TR|391D2418-5359-457B-AEC5-6A48DE04DAFD|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||ML/MIN/MMHG|ENLARGEMENT||MMOL2/L2|NOT DONE|||PUPILLOMETRY|Y|U|SPOUSE|MICROSCOPIST|N|1||38||OPEN LABEL TREATMENT|1960-01-31|
TRIAL STUDY 134XCP|TR|391D2418-5359-457B-AEC5-6A48DE04DAFD|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML/S/M2|DECREASED||U/M2/DAY|NOT DONE|||ROMANOWSKY STAIN|U|Y|CAREGIVER|ADJUDICATOR 3|Y|2||58||FOLLOW-UP|1966-08-03|
TRIAL STUDY 134XCP|TR|391D2418-5359-457B-AEC5-6A48DE04DAFD|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MV2/HZ|UNEQUIVOCAL||L/MIN/M2|NOT DONE|||ROMANOWSKY STAIN|NA|NA|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|3||39||BASELINE|1969-12-18|
TRIAL STUDY 134XCP|TR|391D2418-5359-457B-AEC5-6A48DE04DAFD|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||DIP|PATHOLOGICAL||/MM|NOT DONE|||PAP STAIN|N|U|HEALTH CARE PROFESSIONAL|READER 1|NA|4||88||OBSERVATION|1971-06-24|
TRIAL STUDY 134XCP|TR|391D2418-5359-457B-AEC5-6A48DE04DAFD|5||||||DIAMETER|DIAMETER||MM2|FOCALLY INCREASED||SEC|NOT DONE|||FUNDUS PHOTOGRAPHY|N|NA|STUDY SUBJECT|MICROSCOPIST 2|Y|5||7||TREATMENT|1972-09-15|
TRIAL STUDY 134XCP|TR|68F706F0-2F0B-4D50-B15C-2DFDD186112E|1||||||PALPSTAT|PALPABLE STATE||IU/L|PRESENT||TORR|NOT DONE|||PALPATION|U|N|PROXY|ADJUDICATOR|U|1||38||BASELINE|1965-05-19|
TRIAL STUDY 134XCP|TR|68F706F0-2F0B-4D50-B15C-2DFDD186112E|2||||||DIAMETER|DIAMETER||DEG/MM|ENLARGEMENT||ARBITRARY U|NOT DONE|||SMEAR|NA|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|2||58||INDUCTION TREATMENT|1964-06-24|
TRIAL STUDY 134XCP|TR|68F706F0-2F0B-4D50-B15C-2DFDD186112E|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MIN|ABSENT||PACKAGE|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|N|STUDY SUBJECT|PHYSIOTHERAPIST|N|3||39||OBSERVATION|1961-10-17|
TRIAL STUDY 134XCP|TR|68F706F0-2F0B-4D50-B15C-2DFDD186112E|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||L/MIN/M2|FOCALLY INCREASED||ENZYME U/M2|NOT DONE|||JAEGER EYE CHART|Y|Y|FRIEND|CLINICAL PATHOLOGIST|U|4||88||BLINDED TREATMENT|1972-03-14|
TRIAL STUDY 134XCP|TR|68F706F0-2F0B-4D50-B15C-2DFDD186112E|5||||||VDIAM|VIABLE DIAMETER||PMOL/10^9 CELLS|PRESENT||STEPS/MIN|NOT DONE|||PYROSEQUENCING|U|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||BASELINE|1973-02-08|
TRIAL STUDY 134XCP|TR|E8D4AACE-0832-482D-8266-96B7423F9459|1||||||VDIAM|VIABLE DIAMETER||AU/ML|DIFFUSELY INCREASED||ECL UNIT|NOT DONE|||SNP ARRAY|N|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1960-03-15|
TRIAL STUDY 134XCP|TR|E8D4AACE-0832-482D-8266-96B7423F9459|2||||||VDIAM|VIABLE DIAMETER||U/G|FURTHER ENLARGEMENT FROM NADIR||DPM|NOT DONE|||CRYOSCOPY|Y|U|DOMESTIC PARTNER|ONCOLOGIST|Y|2||58||RUN-IN|1969-05-05|
TRIAL STUDY 134XCP|TR|E8D4AACE-0832-482D-8266-96B7423F9459|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UMOL/MG/MIN|FURTHER ENLARGEMENT FROM NADIR||UG|NOT DONE|||NUCLEAR RADIOLOGY|NA|N|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|3||39||SCREENING|1963-05-10|
TRIAL STUDY 134XCP|TR|E8D4AACE-0832-482D-8266-96B7423F9459|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||/4.0 ML|ENLARGEMENT||S^-1(%O2)^-1|NOT DONE|||CORONARY ANGIOGRAPHY|U|Y|CLINICAL RESEARCH COORDINATOR|RATER 2|N|4||88||SCREENING|1972-07-22|
TRIAL STUDY 134XCP|TR|E8D4AACE-0832-482D-8266-96B7423F9459|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MEQ/L|FURTHER ENLARGEMENT||1/(S*KPA)|NOT DONE|||DISK DIFFUSION|NA|N|FRIEND|RATER 1|N|5||7||BASELINE|1968-03-08|
TRIAL STUDY 134XCP|TR|F358E69F-9B9A-4637-9063-B8FECFF000B2|1||||||NEWCONF|NEW TUMOR CONFIRMED||BREATHS/MIN|EQUIVOCAL||U/MG|NOT DONE|||HPLC/MS|U|U|FAMILY MEMBER|NEUROLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1960-11-13|
TRIAL STUDY 134XCP|TR|F358E69F-9B9A-4637-9063-B8FECFF000B2|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MMHG|PRESENT||BQ|NOT DONE|||TEMPLATE INCISION METHOD|N|U|INTERVIEWER|NEUROLOGIST|U|2||58||CONTINUATION TREATMENT|1972-09-21|
TRIAL STUDY 134XCP|TR|F358E69F-9B9A-4637-9063-B8FECFF000B2|3||||||PALPSTAT|PALPABLE STATE||SPRAY|FOCALLY INCREASED||AGU/ML|NOT DONE|||ELECTRONEUROGRAPHY|U|NA|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|3||39||TREATMENT|1968-12-10|
TRIAL STUDY 134XCP|TR|F358E69F-9B9A-4637-9063-B8FECFF000B2|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||L/S/KPA|UNEQUIVOCAL||QUANTITY SUFFICIENT|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|NA|DOMESTIC PARTNER|RATER 1|Y|4||88||LONG-TERM FOLLOW-UP|1962-06-02|
TRIAL STUDY 134XCP|TR|F358E69F-9B9A-4637-9063-B8FECFF000B2|5||||||PALPSTAT|PALPABLE STATE||AU/ML|UNCHANGED||MOSM|NOT DONE|||DYNAMOMETRY|NA|Y|SIGNIFICANT OTHER|RATER|Y|5||7||OPEN LABEL TREATMENT|1960-05-01|
TRIAL STUDY 134XCP|TR|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||M/SEC|NON-PATHOLOGICAL||PMOL/DAY|NOT DONE|||AUTOMATED COUNT|NA|Y|PARENT|FORENSIC PATHOLOGIST|Y|1||38||OBSERVATION|1968-01-30|
TRIAL STUDY 134XCP|TR|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||LOG10 ELISA UNIT|FURTHER ENLARGEMENT FROM NADIR||/MM|NOT DONE|||MS/MS|U|Y|CAREGIVER|RADIOLOGIST 2|NA|2||58||TREATMENT|1960-01-13|
TRIAL STUDY 134XCP|TR|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ML/M2/H|FURTHER ENLARGEMENT FROM NADIR||BISCUIT|NOT DONE|||SPIRAL CT|U|U|CHILD|CLINICAL PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1966-11-11|
TRIAL STUDY 134XCP|TR|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MV|DECREASED||U/10^12 RBC|NOT DONE|||CT SCAN WITHOUT CONTRAST|Y|Y|SPOUSE|NEUROLOGIST|Y|4||88||OPEN LABEL TREATMENT|1972-06-09|
TRIAL STUDY 134XCP|TR|A9B86D67-C9B1-471F-AC6D-2C3F9A7ECB44|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||GPELISA UNIT/ML|UNCHANGED||OZ|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|N|NA|INTERVIEWER|RADIOLOGIST 2|Y|5||7||TREATMENT|1969-04-24|
TRIAL STUDY 134XCP|TR|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BQ/UL|ENLARGEMENT FROM NADIR||MG/KG/WEEK|NOT DONE|||SCINTIGRAPHY|U|N|STUDY SUBJECT|ONCOLOGIST 2|Y|1||38||BLINDED TREATMENT|1972-11-11|
TRIAL STUDY 134XCP|TR|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|2||||||CALCFIND|CALCIFICATION INDICATOR||GBQ/UG|PALPABLE||TSP|NOT DONE|||INFRARED SPECTROMETRY|U|U|FRIEND|MICROSCOPIST 3|U|2||58||RUN-IN|1968-01-21|
TRIAL STUDY 134XCP|TR|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||G/L|DIFFUSELY INCREASED||ML/G/DAY|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|N|U|INDEPENDENT ASSESSOR|RATER 1|N|3||39||FOLLOW-UP|1969-01-28|
TRIAL STUDY 134XCP|TR|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||PIPE|INCREASED||GTT|NOT DONE|||FLUORESCENT IMMUNOASSAY|U|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|N|4||88||TREATMENT|1970-12-15|
TRIAL STUDY 134XCP|TR|F67596BD-D8EC-4B25-A39C-BD6455F0C0F4|5||||||SUMVOL|SUM OF VOLUME||PT_BR|INCREASED||UG/G/DAY|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|U|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|5||7||BASELINE|1969-04-11|
TRIAL STUDY 134XCP|TR|586B4529-9808-4205-B3D6-5C4A1DAFA922|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||KDA|UNEQUIVOCAL||PMOL/10^9 CELLS|NOT DONE|||TWO-COLOR MICROARRAY|N|N|STUDY SUBJECT|READER 1|U|1||38||SCREENING|1969-10-02|
TRIAL STUDY 134XCP|TR|586B4529-9808-4205-B3D6-5C4A1DAFA922|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^6 IU/ML|UNCHANGED||GAUSS|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|U|U|DOMESTIC PARTNER|ONCOLOGIST 1|NA|2||58||FOLLOW-UP|1961-05-22|
TRIAL STUDY 134XCP|TR|586B4529-9808-4205-B3D6-5C4A1DAFA922|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||CYCLE/MIN|NON-PATHOLOGICAL||MPH|NOT DONE|||FLUOROSCOPY|N|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|3||39||SCREENING|1970-07-12|
TRIAL STUDY 134XCP|TR|586B4529-9808-4205-B3D6-5C4A1DAFA922|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PMOL/L/H|PALPABLE||NMOL/MOL|NOT DONE|||CLIP|NA|N|FAMILY MEMBER|ADJUDICATOR 3|Y|4||88||SCREENING|1971-08-03|
TRIAL STUDY 134XCP|TR|586B4529-9808-4205-B3D6-5C4A1DAFA922|5||||||SUMDIAM|SUM OF DIAMETER||U/10^12 RBC|NORMAL||SEC|NOT DONE|||KLEIHAUER-BETKE|U|NA|FAMILY MEMBER|READER 3|NA|5||7||BASELINE|1963-08-28|
TRIAL STUDY 134XCP|TR|54685EFC-EE92-4591-B059-24145A3E6D69|1||||||RADIODEN|RADIODENSITY||LOG10 TCID 50/ML|NON-PATHOLOGICAL||10^7 TCID 50/DOSE|NOT DONE|||U-HPLC/MS/MS|NA|Y|CAREGIVER|MICROSCOPIST 2|N|1||38||CONTINUATION TREATMENT|1967-11-04|
TRIAL STUDY 134XCP|TR|54685EFC-EE92-4591-B059-24145A3E6D69|2||||||LDIAM|LONGEST DIAMETER||PRESSOR UNITS|ABSENT||UKAT/L|NOT DONE|||FLUORESCENT IMMUNOASSAY|NA|Y|ADJUDICATION COMMITTEE|PATHOLOGIST|N|2||58||TREATMENT|1969-11-05|
TRIAL STUDY 134XCP|TR|54685EFC-EE92-4591-B059-24145A3E6D69|3||||||PALPSTAT|PALPABLE STATE||FIU|PRESENT||ENZYME U/G HB|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|U|CLINICAL RESEARCH ASSOCIATE|RATER|U|3||39||INDUCTION TREATMENT|1964-08-18|
TRIAL STUDY 134XCP|TR|54685EFC-EE92-4591-B059-24145A3E6D69|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UMOL/KG/MIN|ABSENT||BQ/KG|NOT DONE|||BALLPOINT PEN TECHNIQUE|U|N|HEALTH CARE PROFESSIONAL|INTERNIST|N|4||88||SCREENING|1961-09-12|
TRIAL STUDY 134XCP|TR|54685EFC-EE92-4591-B059-24145A3E6D69|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||NGEQ/L|EQUIVOCAL||PACK|NOT DONE|||RULER MEASUREMENT METHOD|U|N|INTERVIEWER|OPTOMETRIST|NA|5||7||BLINDED TREATMENT|1967-06-15|
TRIAL STUDY 134XCP|TR|7BD32505-61D5-4862-8896-B3E41D3EE779|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MGEQ|ENLARGEMENT||MU|NOT DONE|||BETA LACTAMASE|Y|U|HEALTH CARE PROFESSIONAL|INTERNIST|N|1||38||FOLLOW-UP|1972-12-27|
TRIAL STUDY 134XCP|TR|7BD32505-61D5-4862-8896-B3E41D3EE779|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MILE|PATHOLOGICAL||MV|NOT DONE|||TRANSVAGINAL ULTRASOUND|NA|N|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|2||58||BASELINE|1970-10-27|
TRIAL STUDY 134XCP|TR|7BD32505-61D5-4862-8896-B3E41D3EE779|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||STRIP|NORMAL||10^8 PFU|NOT DONE|||CALCOFLUOR WHITE STAIN|N|Y|PROXY|ADJUDICATOR 1|NA|3||39||SCREENING|1965-05-01|
TRIAL STUDY 134XCP|TR|7BD32505-61D5-4862-8896-B3E41D3EE779|4||||||LNSTATE|LYMPH NODE STATE||CD|EQUIVOCAL||U/L|NOT DONE|||CHROMATOGRAPHY|NA|NA|PROXY|MICROSCOPIST 2|Y|4||88||FOLLOW-UP|1966-05-21|
TRIAL STUDY 134XCP|TR|7BD32505-61D5-4862-8896-B3E41D3EE779|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MG/G/MIN|ENLARGEMENT FROM NADIR||CI/ML|NOT DONE|||JAEGER EYE CHART|N|N|SIBLING|ENDOCRINOLOGIST|N|5||7||OPEN LABEL TREATMENT|1969-10-02|
TRIAL STUDY 134XCP|TR|3461C227-E30F-482B-B404-026FE0CA3549|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MG/KG/DAY|PALPABLE||MMOL|NOT DONE|||LYMPHANGIOGRAPHY|Y|U|STUDY SUBJECT|RATER 1|Y|1||38||CONTINUATION TREATMENT|1966-05-12|
TRIAL STUDY 134XCP|TR|3461C227-E30F-482B-B404-026FE0CA3549|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||PNU/ML|NORMAL||ELISA UNIT/DOSE|NOT DONE|||KINETIC CHROMOGENIC ASSAY|NA|N|GUARDIAN|PEDIATRIC NEUROLOGIST|NA|2||58||OBSERVATION|1970-04-02|
TRIAL STUDY 134XCP|TR|3461C227-E30F-482B-B404-026FE0CA3549|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UEQ/L|NORMAL||UGEQ|NOT DONE|||COULOMETRIC TITRATION|N|N|VENDOR|UROLOGIST|NA|3||39||WASHOUT|1968-03-20|
TRIAL STUDY 134XCP|TR|3461C227-E30F-482B-B404-026FE0CA3549|4||||||LPERP|LONGEST PERPENDICULAR||%/S|ENLARGEMENT||MEQ/G|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|NA|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||OPEN LABEL TREATMENT|1971-08-28|
TRIAL STUDY 134XCP|TR|3461C227-E30F-482B-B404-026FE0CA3549|5||||||CALCFIND|CALCIFICATION INDICATOR||G/DL|DECREASED||MEQ/MMOL|NOT DONE|||PLETHYSMOGRAPHY|Y|NA|GUARDIAN|MICROSCOPIST 3|U|5||7||BLINDED TREATMENT|1962-04-14|
TRIAL STUDY 134XCP|TR|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||INHALATION|NON-PATHOLOGICAL||MANSON U/ML|NOT DONE|||FLUORESCEIN STAIN|NA|U|HEALTH CARE PROFESSIONAL|READER 3|NA|1||38||FOLLOW-UP|1966-01-07|
TRIAL STUDY 134XCP|TR|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|2||||||LESSCIND|LESION SUCCESS INDICATOR||MEQ|INCREASED||MS/MMHG|NOT DONE|||WHOLE GENOME SEQUENCING|Y|U|INVESTIGATOR|ADJUDICATOR 3|U|2||58||BASELINE|1964-10-15|
TRIAL STUDY 134XCP|TR|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||CCID 50/ML|ABSENT||EID 50/DOSE|NOT DONE|||TRICHROME STAIN|NA|Y|INTERVIEWER|PATHOLOGIST|NA|3||39||FOLLOW-UP|1966-02-19|
TRIAL STUDY 134XCP|TR|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|4||||||LNSTATE|LYMPH NODE STATE||10^6 CFU/ML|ENLARGEMENT FROM NADIR||UG/L/H|NOT DONE|||WESTERGREN|U|NA|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|4||88||OBSERVATION|1964-09-21|
TRIAL STUDY 134XCP|TR|4688A17D-8429-4AE7-B3FB-FDCA7EE6C10F|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||DEG|UNCHANGED||KG|NOT DONE|||RAJI CELL RIA|N|NA|INTERVIEWER|ONCOLOGIST|N|5||7||TREATMENT|1963-11-01|
TRIAL STUDY 134XCP|TR|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|1||||||VSLPIND|VESSEL PATENCY INDICATOR||MV2/HZ|DECREASED||PATCH|NOT DONE|||IODINE STAIN|NA|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|1||38||INDUCTION TREATMENT|1973-08-14|
TRIAL STUDY 134XCP|TR|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MAC50|DECREASED||MU/G|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST|N|2||58||OBSERVATION|1969-03-14|
TRIAL STUDY 134XCP|TR|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||FT|TUMOR MERGED||MET|NOT DONE|||NEXT GENERATION SEQUENCING|N|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|3||39||OPEN LABEL TREATMENT|1969-04-08|
TRIAL STUDY 134XCP|TR|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ANTIBODY UNIT|FURTHER ENLARGEMENT||ANTI-XA IU/ML|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|Y|PARENT|NEUROLOGIST 2|N|4||88||INDUCTION TREATMENT|1961-11-05|
TRIAL STUDY 134XCP|TR|5B4CCDE8-49E3-40B4-ACB8-721D9E110AB4|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MNFI|NORMAL||CM H2O|NOT DONE|||ACID FAST STAIN|Y|U|SPOUSE|ONCOLOGIST 1|NA|5||7||SCREENING|1972-10-12|
TRIAL STUDY 134XCP|TR|C7C91F63-87B7-4E62-B5F3-39979F74E955|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ECL UNIT|NONPALPABLE||UM|NOT DONE|||OPHTHALMOSCOPY|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|1||38||LONG-TERM FOLLOW-UP|1972-10-07|
TRIAL STUDY 134XCP|TR|C7C91F63-87B7-4E62-B5F3-39979F74E955|2||||||SUMDIAM|SUM OF DIAMETER||CP|FOCALLY INCREASED||FT3|NOT DONE|||IMMUNOTURBIDIMETRY|U|N|CLINICAL RESEARCH ASSOCIATE|READER|N|2||58||OBSERVATION|1963-07-30|
TRIAL STUDY 134XCP|TR|C7C91F63-87B7-4E62-B5F3-39979F74E955|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||IU/MMOL|DIFFUSELY INCREASED||AMP|NOT DONE|||DISK DIFFUSION|NA|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3||39||TREATMENT|1961-06-14|
TRIAL STUDY 134XCP|TR|C7C91F63-87B7-4E62-B5F3-39979F74E955|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||IU/MMOL|DIFFUSELY INCREASED||U/G HB|NOT DONE|||NUCLEIC ACID BASED METHOD|NA|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||FOLLOW-UP|1962-05-25|
TRIAL STUDY 134XCP|TR|C7C91F63-87B7-4E62-B5F3-39979F74E955|5||||||RADIODEN|RADIODENSITY||1/(S*KPA)|FURTHER ENLARGEMENT FROM NADIR||%(W/V)|NOT DONE|||GRAM STAIN|U|N|VENDOR|HEMATOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1965-07-05|
TRIAL STUDY 134XCP|TR|D6659F53-6DF6-4F88-BF9A-160E2D057028|1||||||LPERP|LONGEST PERPENDICULAR||UCI|NON-PATHOLOGICAL||UMOL/DL|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|N|N|INTERVIEWER|INTERNIST|Y|1||38||SCREENING|1967-08-04|
TRIAL STUDY 134XCP|TR|D6659F53-6DF6-4F88-BF9A-160E2D057028|2||||||VSLPIND|VESSEL PATENCY INDICATOR||CCID 50/ML|UNEQUIVOCAL||CI|NOT DONE|||AGAR DILUTION|Y|NA|SPOUSE|ADJUDICATOR 2|NA|2||58||FOLLOW-UP|1963-11-09|
TRIAL STUDY 134XCP|TR|D6659F53-6DF6-4F88-BF9A-160E2D057028|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||WAFER|ENLARGEMENT FROM NADIR||UG/G/DAY|NOT DONE|||DIGITAL PCR ARRAY|NA|N|PARENT|ADJUDICATOR 3|N|3||39||CONTINUATION TREATMENT|1962-07-11|
TRIAL STUDY 134XCP|TR|D6659F53-6DF6-4F88-BF9A-160E2D057028|4||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CM2|INCREASED||MBQ/UL|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|4||88||OPEN LABEL TREATMENT|1973-03-10|
TRIAL STUDY 134XCP|TR|D6659F53-6DF6-4F88-BF9A-160E2D057028|5||||||LMBFLIND|LIMB FAILURE INDICATOR||PG/L|ABSENT||MONTHS|NOT DONE|||JAFFE REACTION|NA|U|STUDY SUBJECT|NEUROLOGIST 1|Y|5||7||FOLLOW-UP|1973-05-19|
TRIAL STUDY 134XCP|TR|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|1||||||DIAMETER|DIAMETER||ABSORBANCE U/MIN|NORMAL||%/S|NOT DONE|||LINE PROBE ASSAY|Y|NA|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|1||38||WASHOUT|1968-10-15|
TRIAL STUDY 134XCP|TR|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||CONTAINER|UNEQUIVOCAL||GPL U|NOT DONE|||WHOLE GENOME SEQUENCING|N|NA|CAREGIVER|RADIOLOGIST 2|NA|2||58||BLINDED TREATMENT|1964-02-21|
TRIAL STUDY 134XCP|TR|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|3||||||AREA|AREA||MG/L FEU|EQUIVOCAL||FOZ_BR|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|NA|NA|CAREGIVER|NEUROLOGIST|U|3||39||FOLLOW-UP|1971-07-31|
TRIAL STUDY 134XCP|TR|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||APL U/ML|ENLARGEMENT||BREATHS/30S|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|NA|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|4||88||INDUCTION TREATMENT|1968-12-31|
TRIAL STUDY 134XCP|TR|AF6FDB1B-0B61-4D2A-8874-808DD5A5B286|5||||||SUMDIAM|SUM OF DIAMETER||UMOL/H/MMOL|DIFFUSELY INCREASED||/DAY|NOT DONE|||ORCHIDOMETERY|Y|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|5||7||BASELINE|1972-03-03|
TRIAL STUDY 134XCP|TR|91B36C93-3ADF-4570-B355-BC81B097EEFC|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UG/L DDU|PRESENT||PMOL/10^10 CELLS|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|U|NA|SIBLING|ADJUDICATOR 1|NA|1||38||BASELINE|1967-03-15|
TRIAL STUDY 134XCP|TR|91B36C93-3ADF-4570-B355-BC81B097EEFC|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||PA|NON-PATHOLOGICAL||U/M2|NOT DONE|||DIFFUSION TENSOR MRI|N|NA|SIGNIFICANT OTHER|DERMATOLOGIST|Y|2||58||BLINDED TREATMENT|1963-01-01|
TRIAL STUDY 134XCP|TR|91B36C93-3ADF-4570-B355-BC81B097EEFC|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||BREATHS/MIN|ABSENT||KCAL|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|N|N|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3||39||OPEN LABEL TREATMENT|1971-12-29|
TRIAL STUDY 134XCP|TR|91B36C93-3ADF-4570-B355-BC81B097EEFC|4||||||LMBFLIND|LIMB FAILURE INDICATOR||PKAT/L|NON-PATHOLOGICAL||DAYS|NOT DONE|||AUTOMATED COUNT|U|U|STUDY SUBJECT|RATER 1|Y|4||88||OPEN LABEL TREATMENT|1965-10-28|
TRIAL STUDY 134XCP|TR|91B36C93-3ADF-4570-B355-BC81B097EEFC|5||||||PALPSTAT|PALPABLE STATE||PMOL/G|ABSENT||SACHET|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|U|N|SPOUSE|CLINICAL PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1962-01-29|
TRIAL STUDY 134XCP|TR|ADD0DDE5-166F-4C20-B3C3-31B131509771|1||||||BNLNUM|NUMBER OF BONE LESIONS||PFU/ML|TUMOR MERGED||NMOL/L|NOT DONE|||MAPH|U|Y|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|1||38||RUN-IN|1967-11-18|
TRIAL STUDY 134XCP|TR|ADD0DDE5-166F-4C20-B3C3-31B131509771|2||||||DIAMETER|DIAMETER||MHZ|TUMOR MERGED||GY/MIN|NOT DONE|||TOTAL BODY RADIOGRAPHY|Y|U|CHILD|DERMATOLOGIST|N|2||58||FOLLOW-UP|1963-09-16|
TRIAL STUDY 134XCP|TR|ADD0DDE5-166F-4C20-B3C3-31B131509771|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MG2/DL2|ENLARGEMENT||10^9 ORGANISMS/MG|NOT DONE|||TONOMETRY|NA|N|FAMILY MEMBER|ENDOCRINOLOGIST|N|3||39||RUN-IN|1962-02-09|
TRIAL STUDY 134XCP|TR|ADD0DDE5-166F-4C20-B3C3-31B131509771|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||CMOL|NON-PATHOLOGICAL||CMOL/L|NOT DONE|||REFRACTOMETRY|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|4||88||SCREENING|1961-10-15|
TRIAL STUDY 134XCP|TR|ADD0DDE5-166F-4C20-B3C3-31B131509771|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||NG/DL|FURTHER ENLARGEMENT||MMOL/MOL|NOT DONE|||AUDIOMETRY|N|NA|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|5||7||WASHOUT|1960-01-24|
TRIAL STUDY 134XCP|TR|4265CC9E-26AF-4A14-B9AA-04A246E2523C|1||||||LPERP|LONGEST PERPENDICULAR||PA|NONPALPABLE||MMOL/MIN/KPA|NOT DONE|||POPULATION SEQUENCING|NA|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1||38||BLINDED TREATMENT|1971-01-15|
TRIAL STUDY 134XCP|TR|4265CC9E-26AF-4A14-B9AA-04A246E2523C|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KHZ|TUMOR MERGED||ELISA UNIT/ML|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|Y|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||FOLLOW-UP|1964-10-19|
TRIAL STUDY 134XCP|TR|4265CC9E-26AF-4A14-B9AA-04A246E2523C|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MMOL|PRESENT||CMH2O/ML|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|NA|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|3||39||LONG-TERM FOLLOW-UP|1971-03-30|
TRIAL STUDY 134XCP|TR|4265CC9E-26AF-4A14-B9AA-04A246E2523C|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MM/SEC|ENLARGEMENT FROM NADIR||CI/G|NOT DONE|||REFLECTANCE SPECTROSCOPY|U|U|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|4||88||OPEN LABEL TREATMENT|1971-12-02|
TRIAL STUDY 134XCP|TR|4265CC9E-26AF-4A14-B9AA-04A246E2523C|5||||||CALCFIND|CALCIFICATION INDICATOR||BQ/L|PALPABLE||FT3|NOT DONE|||WRIGHT-GIEMSA STAIN|U|Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|5||7||OBSERVATION|1967-06-11|
TRIAL STUDY 134XCP|TR|96F268D3-7441-415C-95C9-A6B70C1718D5|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MG/MIN|NONPALPABLE||MG/KG/H|NOT DONE|||LC/MS/MS|NA|Y|ADJUDICATOR|NEUROLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1967-01-28|
TRIAL STUDY 134XCP|TR|96F268D3-7441-415C-95C9-A6B70C1718D5|2||||||ORVERLN|ORGAN VERTICAL LENGTH||10^6/G|ENLARGEMENT||OHM|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|NA|U|PROXY|ADJUDICATOR|NA|2||58||CONTINUATION TREATMENT|1963-07-19|
TRIAL STUDY 134XCP|TR|96F268D3-7441-415C-95C9-A6B70C1718D5|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MM/2H|NORMAL||UG/DL|NOT DONE|||HPLC-UV|N|Y|VENDOR|CLINICAL PATHOLOGIST|N|3||39||INDUCTION TREATMENT|1967-03-30|
TRIAL STUDY 134XCP|TR|96F268D3-7441-415C-95C9-A6B70C1718D5|4||||||LESSCIND|LESION SUCCESS INDICATOR||VIRTUAL PIXEL|NONPALPABLE||PACK|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y|SIBLING|PATHOLOGIST 1|N|4||88||SCREENING|1962-05-17|
TRIAL STUDY 134XCP|TR|96F268D3-7441-415C-95C9-A6B70C1718D5|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MG/M2|DECREASED||ML/M2|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|NA|Y|ADJUDICATOR|READER 3|Y|5||7||OPEN LABEL TREATMENT|1971-01-03|
TRIAL STUDY 134XCP|TR|15D32D1F-AEE2-474C-956E-461FB087D7B0|1||||||LESFLIND|LESION FAILURE INDICATOR||M/SEC|UNEQUIVOCAL||CCID 50/ML|NOT DONE|||ANGIOGRAPHY|N|N|VENDOR|RATER 2|NA|1||38||WASHOUT|1968-11-21|
TRIAL STUDY 134XCP|TR|15D32D1F-AEE2-474C-956E-461FB087D7B0|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||DAYS/MONTH|PATHOLOGICAL||AMFI|NOT DONE|||OPTICAL MAPPING|Y|Y|VENDOR|FORENSIC PATHOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1963-01-12|
TRIAL STUDY 134XCP|TR|15D32D1F-AEE2-474C-956E-461FB087D7B0|3||||||ORSTATE|ORGAN STATE||U/10^12 RBC|PATHOLOGICAL||PT_US|NOT DONE|||PYROSEQUENCING|Y|NA|STUDY SUBJECT|RATER 1|NA|3||39||RUN-IN|1971-08-11|
TRIAL STUDY 134XCP|TR|15D32D1F-AEE2-474C-956E-461FB087D7B0|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MM/SEC|ABSENT||FOZ_BR|NOT DONE|||ELISA|N|U|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|4||88||FOLLOW-UP|1960-01-21|
TRIAL STUDY 134XCP|TR|15D32D1F-AEE2-474C-956E-461FB087D7B0|5||||||RADIODEN|RADIODENSITY||NEBULE|PALPABLE||MG/M2/MIN|NOT DONE|||CT SCAN WITHOUT CONTRAST|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 2|NA|5||7||RUN-IN|1973-06-29|
TRIAL STUDY 134XCP|TR|DB42C81A-D644-455D-9D95-42131EF2BFE5|1||||||VSLPIND|VESSEL PATENCY INDICATOR||KUSP|INCREASED||U/M2/DAY|NOT DONE|||DIFFUSION WEIGHTED MRI|U|NA|GUARDIAN|UROLOGIST|N|1||38||FOLLOW-UP|1965-01-17|
TRIAL STUDY 134XCP|TR|DB42C81A-D644-455D-9D95-42131EF2BFE5|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||GY|DIFFUSELY INCREASED||PG/DL|NOT DONE|||CLIP|N|U|DOMESTIC PARTNER|INTERNIST|N|2||58||LONG-TERM FOLLOW-UP|1963-08-25|
TRIAL STUDY 134XCP|TR|DB42C81A-D644-455D-9D95-42131EF2BFE5|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MCI|EQUIVOCAL||MESF|NOT DONE|||SINGLE-SLICE SPIRAL CT|U|U|SIGNIFICANT OTHER|PATHOLOGIST|U|3||39||BASELINE|1964-12-29|
TRIAL STUDY 134XCP|TR|DB42C81A-D644-455D-9D95-42131EF2BFE5|4||||||LESFLIND|LESION FAILURE INDICATOR||MG/KG/WEEK|ENLARGEMENT||10^3/L|NOT DONE|||IN SITU HYBRIDIZATION|N|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|4||88||TREATMENT|1972-12-25|
TRIAL STUDY 134XCP|TR|DB42C81A-D644-455D-9D95-42131EF2BFE5|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MET*MIN|UNCHANGED||PM|NOT DONE|||FLUORESCENT MICROSCOPY|Y|U|DOMESTIC PARTNER|HEMATOLOGIST|Y|5||7||BASELINE|1970-07-07|
TRIAL STUDY 134XCP|TR|4B01CC59-51D3-4499-9AB1-DF446006CB8D|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||G/M2|FOCALLY INCREASED||FMOL/L|NOT DONE|||MICRO BROTH DILUTION|Y|N|PROXY|MICROSCOPIST 1|NA|1||38||WASHOUT|1960-08-07|
TRIAL STUDY 134XCP|TR|4B01CC59-51D3-4499-9AB1-DF446006CB8D|2||||||LDIAM|LONGEST DIAMETER||ML/CAGE|NORMAL||FFU|NOT DONE|||CT SCAN|Y|NA|CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|2||58||INDUCTION TREATMENT|1970-05-01|
TRIAL STUDY 134XCP|TR|4B01CC59-51D3-4499-9AB1-DF446006CB8D|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MV*MIN|NORMAL||FEU|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|U|NA|STUDY SUBJECT|RADIOLOGIST 1|N|3||39||BASELINE|1968-03-15|
TRIAL STUDY 134XCP|TR|4B01CC59-51D3-4499-9AB1-DF446006CB8D|4||||||BNLNUM|NUMBER OF BONE LESIONS||PACK YEAR|NONPALPABLE||M|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|U|NA|FRIEND|ADJUDICATOR|U|4||88||TREATMENT|1970-06-09|
TRIAL STUDY 134XCP|TR|4B01CC59-51D3-4499-9AB1-DF446006CB8D|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||RNA COPIES/ML|PALPABLE||DMOL|NOT DONE|||MIGET|U|Y|CHILD|MICROSCOPIST 2|NA|5||7||BLINDED TREATMENT|1968-10-02|
TRIAL STUDY 134XCP|TR|B69774FC-1151-45DD-B329-6C21C2F29603|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML/H|DIFFUSELY INCREASED||MMHG|NOT DONE|||GC/MS-CI|N|Y|FAMILY MEMBER|PATHOLOGIST 1|Y|1||38||BASELINE|1960-06-27|
TRIAL STUDY 134XCP|TR|B69774FC-1151-45DD-B329-6C21C2F29603|2||||||LESSCIND|LESION SUCCESS INDICATOR||ABSORBANCE U|TUMOR MERGED||M/SEC|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|U|GUARDIAN|READER|NA|2||58||BASELINE|1962-05-14|
TRIAL STUDY 134XCP|TR|B69774FC-1151-45DD-B329-6C21C2F29603|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML/DAY|TUMOR MERGED||MG/KG|NOT DONE|||PERIPHERAL ANGIOGRAPHY|NA|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1963-09-03|
TRIAL STUDY 134XCP|TR|B69774FC-1151-45DD-B329-6C21C2F29603|4||||||AREA|AREA||LOG10 IU/ML|FURTHER ENLARGEMENT FROM NADIR||10^4 CFU/ML|NOT DONE|||DISK DIFFUSION|NA|Y|ADJUDICATOR|READER 2|N|4||88||BASELINE|1972-04-01|
TRIAL STUDY 134XCP|TR|B69774FC-1151-45DD-B329-6C21C2F29603|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||POUCH|NONPALPABLE||U/G/DAY|NOT DONE|||CONTRAST ENHANCED PET SCAN|N|NA|SIGNIFICANT OTHER|RADIOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1972-07-05|
TRIAL STUDY 134XCP|TR|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|1||||||TUMSTATE|TUMOR STATE||RATIO|ENLARGEMENT||U/M2/H|NOT DONE|||SEQUENCING|NA|Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|1||38||RUN-IN|1961-06-23|
TRIAL STUDY 134XCP|TR|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||UV2|TUMOR MERGED||BOTTLE|NOT DONE|||GC/MS-EI|U|Y|VENDOR|NEUROLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1965-06-06|
TRIAL STUDY 134XCP|TR|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|3||||||LMBFLIND|LIMB FAILURE INDICATOR||COPIES/UG|NORMAL||STEPS/MIN|NOT DONE|||THICK SMEAR|NA|N|STUDY SUBJECT|PATHOLOGIST 2|U|3||39||TREATMENT|1967-10-28|
TRIAL STUDY 134XCP|TR|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UL|NORMAL||MEQ/G|NOT DONE|||NUCLEIC ACID SEQUENCING|NA|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4||88||OBSERVATION|1964-07-01|
TRIAL STUDY 134XCP|TR|E65C6FBC-3399-4EC7-8802-8AA6BB3FA4E5|5||||||LDIAM|LONGEST DIAMETER||TORR|DECREASED||SHOCK WAVE|NOT DONE|||RULER MEASUREMENT METHOD|Y|Y|CAREGIVER|NEUROLOGIST 2|NA|5||7||OPEN LABEL TREATMENT|1964-03-20|
TRIAL STUDY 134XCP|TR|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||SBE/ML|UNEQUIVOCAL||U/M2|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|INVESTIGATOR|DERMATOLOGIST|NA|1||38||SCREENING|1961-08-05|
TRIAL STUDY 134XCP|TR|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ML/M2/H|DIFFUSELY INCREASED||U/G/DAY|NOT DONE|||LAPAROSCOPY|Y|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|2||58||BASELINE|1963-05-08|
TRIAL STUDY 134XCP|TR|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MG/DOSE|PATHOLOGICAL||MBQ/UL|NOT DONE|||SXA SCAN|N|U|ADJUDICATOR|NEUROLOGIST 1|NA|3||39||BASELINE|1961-10-08|
TRIAL STUDY 134XCP|TR|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||GY/H|PATHOLOGICAL||U/G/MIN|NOT DONE|||ACID FAST STAIN|N|Y|DOMESTIC PARTNER|NEUROLOGIST 2|U|4||88||BLINDED TREATMENT|1969-11-20|
TRIAL STUDY 134XCP|TR|4133B8C8-6594-4E12-81C7-0E1C1BEA59D9|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||PL|ENLARGEMENT||RATIO|NOT DONE|||PHASE-CONTRAST MRI|Y|N|INVESTIGATOR|OPHTHALMOLOGIST|U|5||7||CONTINUATION TREATMENT|1966-12-03|
TRIAL STUDY 134XCP|TR|674B4474-6D52-4DE2-8342-EDB28F577BB5|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||JDF UNIT|TUMOR MERGED||PIPE|NOT DONE|||AUTOMATED COUNT|Y|NA|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|1||38||WASHOUT|1962-06-14|
TRIAL STUDY 134XCP|TR|674B4474-6D52-4DE2-8342-EDB28F577BB5|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/KG/MIN|ENLARGEMENT FROM NADIR||UG/DAY|NOT DONE|||AUTOMATED COUNT|NA|N|GUARDIAN|ADJUDICATOR 1|Y|2||58||CONTINUATION TREATMENT|1961-01-11|
TRIAL STUDY 134XCP|TR|674B4474-6D52-4DE2-8342-EDB28F577BB5|3||||||VSLPIND|VESSEL PATENCY INDICATOR||IU/ML|DECREASED||MEQ/G|NOT DONE|||ELECTROGASTROGRAPHY|N|N|SPOUSE|RADIOLOGIST|U|3||39||INDUCTION TREATMENT|1965-03-26|
TRIAL STUDY 134XCP|TR|674B4474-6D52-4DE2-8342-EDB28F577BB5|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||NMOL/L|NORMAL||/HPF|NOT DONE|||PHYSICAL EXAMINATION|U|U|INTERVIEWER|HEMATOLOGIST|Y|4||88||FOLLOW-UP|1972-02-18|
TRIAL STUDY 134XCP|TR|674B4474-6D52-4DE2-8342-EDB28F577BB5|5||||||RADIODEN|RADIODENSITY||SUPPOSITORY|DECREASED||GENEQ/ML|NOT DONE|||PHOTOGRAPHY|Y|U|HEALTH CARE PROFESSIONAL|READER 3|NA|5||7||FOLLOW-UP|1965-01-12|
TRIAL STUDY 134XCP|TR|AF634AD4-086A-47EE-A5DB-A4B6833356C7|1||||||CALCFIND|CALCIFICATION INDICATOR||SCOOPFUL|FOCALLY INCREASED||U/KG|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|Y|N|ADJUDICATOR|FORENSIC PATHOLOGIST|Y|1||38||LONG-TERM FOLLOW-UP|1970-01-28|
TRIAL STUDY 134XCP|TR|AF634AD4-086A-47EE-A5DB-A4B6833356C7|2||||||AREA|AREA||CD/M2|UNEQUIVOCAL||G/M2/DAY|NOT DONE|||DIFFUSION TENSOR MRI|N|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|2||58||BASELINE|1961-11-05|
TRIAL STUDY 134XCP|TR|AF634AD4-086A-47EE-A5DB-A4B6833356C7|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||CD|PRESENT||YD|NOT DONE|||URANYL ACETATE STAIN|Y|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1968-08-31|
TRIAL STUDY 134XCP|TR|AF634AD4-086A-47EE-A5DB-A4B6833356C7|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||CG|ENLARGEMENT||SQU/ML|NOT DONE|||ANTIBIOTIC AGAR SCREEN|U|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|4||88||CONTINUATION TREATMENT|1960-12-13|
TRIAL STUDY 134XCP|TR|AF634AD4-086A-47EE-A5DB-A4B6833356C7|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||PFU/ML|NON-PATHOLOGICAL||CAPLET|NOT DONE|||DIGITAL PCR ARRAY|Y|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|U|5||7||CONTINUATION TREATMENT|1964-10-11|
TRIAL STUDY 134XCP|TR|89298058-EB86-4892-97D6-1B87277DF7FC|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||BQ/MG|NORMAL||BU/ML|NOT DONE|||PHOTOGRAPHY|U|N|SIGNIFICANT OTHER|RADIOLOGIST|Y|1||38||WASHOUT|1960-08-02|
TRIAL STUDY 134XCP|TR|89298058-EB86-4892-97D6-1B87277DF7FC|2||||||BNLNUM|NUMBER OF BONE LESIONS||OD UNIT|ABSENT||TSP EQ|NOT DONE|||DC SHEATH FLOW|N|NA|VENDOR|ONCOLOGIST 2|N|2||58||TREATMENT|1969-01-16|
TRIAL STUDY 134XCP|TR|89298058-EB86-4892-97D6-1B87277DF7FC|3||||||SUMDIAM|SUM OF DIAMETER||UEQ|INCREASED||MV|NOT DONE|||PUPILLOMETRY|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|3||39||WASHOUT|1972-03-22|
TRIAL STUDY 134XCP|TR|89298058-EB86-4892-97D6-1B87277DF7FC|4||||||SUMDIAM|SUM OF DIAMETER||ENZYME U|TUMOR MERGED||BP|NOT DONE|||BIOPSY|N|NA|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|4||88||BASELINE|1970-09-21|
TRIAL STUDY 134XCP|TR|89298058-EB86-4892-97D6-1B87277DF7FC|5||||||ORVERLN|ORGAN VERTICAL LENGTH||APL U/ML|DIFFUSELY INCREASED||10^6 IU/ML|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|NA|U|INTERVIEWER|MICROSCOPIST 3|NA|5||7||OBSERVATION|1970-03-09|
TRIAL STUDY 134XCP|TR|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||V|INCREASED||EP U|NOT DONE|||TWO-COLOR MICROARRAY|NA|N|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|1||38||INDUCTION TREATMENT|1971-09-01|
TRIAL STUDY 134XCP|TR|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||DPM|UNCHANGED||TUBE|NOT DONE|||CONTRAST ENHANCED MRI|U|NA|GUARDIAN|DERMATOLOGIST|U|2||58||RUN-IN|1973-07-23|
TRIAL STUDY 134XCP|TR|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|3||||||ORSTATE|ORGAN STATE||GRAVITATIONAL UNIT|PATHOLOGICAL||PRESSOR UNITS|NOT DONE|||INFRARED SPECTROMETRY|NA|Y|CAREGIVER|NEUROLOGIST|U|3||39||BLINDED TREATMENT|1963-06-03|
TRIAL STUDY 134XCP|TR|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||IU/DAY|PATHOLOGICAL||MCI|NOT DONE|||RIA|NA|Y|INTERVIEWER|MICROSCOPIST 1|Y|4||88||OPEN LABEL TREATMENT|1969-08-12|
TRIAL STUDY 134XCP|TR|E41FF3D9-9D68-4A3A-BBFB-B4D9030423E5|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LOG10 TCID 50/ML|UNEQUIVOCAL||MOL/MG|NOT DONE|||COLORIMETRY|N|NA|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|5||7||WASHOUT|1970-02-10|
TRIAL STUDY 134XCP|TR|D5235188-810B-431F-A6EF-E50DAA57F5E7|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||NMOL/ML/MIN|DECREASED||HOMEOPATHIC DILUTION|NOT DONE|||EEG|NA|N|PARENT|DERMATOLOGIST|Y|1||38||RUN-IN|1972-06-15|
TRIAL STUDY 134XCP|TR|D5235188-810B-431F-A6EF-E50DAA57F5E7|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||SUPPOSITORY|PRESENT||CMOL/L|NOT DONE|||CRYOSCOPY|U|NA|ADJUDICATOR|NEUROLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1968-07-14|
TRIAL STUDY 134XCP|TR|D5235188-810B-431F-A6EF-E50DAA57F5E7|3||||||VSLPIND|VESSEL PATENCY INDICATOR||KIU|EQUIVOCAL||UIU/DL|NOT DONE|||HPLC-FL|U|NA|DOMESTIC PARTNER|ONCOLOGIST 1|U|3||39||LONG-TERM FOLLOW-UP|1970-10-21|
TRIAL STUDY 134XCP|TR|D5235188-810B-431F-A6EF-E50DAA57F5E7|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||GBQ|ABSENT||IU/L|NOT DONE|||SNELLEN EYE CHART|U|NA|CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|4||88||WASHOUT|1961-07-31|
TRIAL STUDY 134XCP|TR|D5235188-810B-431F-A6EF-E50DAA57F5E7|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||IU/DAY|DECREASED||FT2|NOT DONE|||MICROSCOPY|U|Y|PROXY|ENDOCRINOLOGIST|Y|5||7||WASHOUT|1967-06-15|
TRIAL STUDY 134XCP|TR|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||NMOL/L/H|FURTHER ENLARGEMENT FROM NADIR||/10^5|NOT DONE|||DIPSTICK|Y|NA|FAMILY MEMBER|ONCOLOGIST 2|NA|1||38||OPEN LABEL TREATMENT|1964-05-05|
TRIAL STUDY 134XCP|TR|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MOL/G|UNEQUIVOCAL||F|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|Y|N|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|2||58||BASELINE|1964-05-01|
TRIAL STUDY 134XCP|TR|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|3||||||CALCFIND|CALCIFICATION INDICATOR||L/S/KPA|UNEQUIVOCAL||MG/DL|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|Y|N|GUARDIAN|CLINICAL PATHOLOGIST|N|3||39||TREATMENT|1964-11-03|
TRIAL STUDY 134XCP|TR|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PMOL/DL|FURTHER ENLARGEMENT||ML/KG/DAY|NOT DONE|||FISH|Y|N|SIGNIFICANT OTHER|RADIOLOGIST 1|N|4||88||TREATMENT|1965-06-09|
TRIAL STUDY 134XCP|TR|05CEDBB3-C2F4-4069-A8B0-EF2080C7D1F1|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||FMOL|DIFFUSELY INCREASED||/VF|NOT DONE|||ELECTRONEUROGRAPHY|U|N|FAMILY MEMBER|NEUROLOGIST 1|Y|5||7||INDUCTION TREATMENT|1970-06-05|
TRIAL STUDY 134XCP|TR|E3BB136E-0913-43FB-B760-CBE939F0C4D2|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||PA|UNEQUIVOCAL||GRAIN|NOT DONE|||URANYL ACETATE STAIN|U|U|INVESTIGATOR|DERMATOLOGIST|N|1||38||INDUCTION TREATMENT|1967-06-25|
TRIAL STUDY 134XCP|TR|E3BB136E-0913-43FB-B760-CBE939F0C4D2|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||GY/MIN|FURTHER ENLARGEMENT||10^3 ORGANISMS/ML|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|U|N|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|2||58||FOLLOW-UP|1967-03-01|
TRIAL STUDY 134XCP|TR|E3BB136E-0913-43FB-B760-CBE939F0C4D2|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MAMP|TUMOR MERGED||10^6 ORGANISMS/ML|NOT DONE|||LIQUID SCINTILLATION COUNTING|N|NA|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|3||39||TREATMENT|1968-04-17|
TRIAL STUDY 134XCP|TR|E3BB136E-0913-43FB-B760-CBE939F0C4D2|4||||||DIAMETER|DIAMETER||KBQ/UL|NON-PATHOLOGICAL||%/S|NOT DONE|||FORCED OSCILLATION TECHNIQUE|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 2|N|4||88||FOLLOW-UP|1963-12-08|
TRIAL STUDY 134XCP|TR|E3BB136E-0913-43FB-B760-CBE939F0C4D2|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||G/DAY|PATHOLOGICAL||TUBE|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|NA|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1968-06-29|
TRIAL STUDY 134XCP|TR|60C25341-42CE-4532-8F99-25B8305C4ED5|1||||||SUMVOL|SUM OF VOLUME||NCI|FOCALLY INCREASED||MBQ|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|U|NA|ADJUDICATOR|PATHOLOGIST 2|NA|1||38||LONG-TERM FOLLOW-UP|1971-07-29|
TRIAL STUDY 134XCP|TR|60C25341-42CE-4532-8F99-25B8305C4ED5|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||SQU/ML|UNEQUIVOCAL||PSEC|NOT DONE|||FARR ASSAY|Y|Y|DOMESTIC PARTNER|ADJUDICATOR|NA|2||58||RUN-IN|1964-01-25|
TRIAL STUDY 134XCP|TR|60C25341-42CE-4532-8F99-25B8305C4ED5|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/ANIMAL|ENLARGEMENT||UMOL/L/SEC|NOT DONE|||PALPATION|N|NA|VENDOR|ONCOLOGIST|NA|3||39||OBSERVATION|1970-09-23|
TRIAL STUDY 134XCP|TR|60C25341-42CE-4532-8F99-25B8305C4ED5|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UMOL/L/MIN|ABSENT||BQ/KG|NOT DONE|||ELLA|U|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|4||88||OPEN LABEL TREATMENT|1962-11-03|
TRIAL STUDY 134XCP|TR|60C25341-42CE-4532-8F99-25B8305C4ED5|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UMOL/H/MMOL|UNCHANGED||MMAL|NOT DONE|||POLYSOMNOGRAPHY|Y|Y|GUARDIAN|INTERNIST|Y|5||7||FOLLOW-UP|1960-11-15|
TRIAL STUDY 134XCP|TR|42B54D88-E5B5-4828-958B-4B64F07E34B3|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MAC50|ENLARGEMENT FROM NADIR||ML/ANIMAL|NOT DONE|||SLOAN LETTER EYE CHART 100%|U|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1||38||RUN-IN|1967-03-12|
TRIAL STUDY 134XCP|TR|42B54D88-E5B5-4828-958B-4B64F07E34B3|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UIU/L|ENLARGEMENT||UG/M2/MIN|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|Y|N|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|Y|2||58||BASELINE|1971-05-08|
TRIAL STUDY 134XCP|TR|42B54D88-E5B5-4828-958B-4B64F07E34B3|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||TITER|ENLARGEMENT||YEARS|NOT DONE|||MRI WITHOUT CONTRAST|U|NA|SPOUSE|PATHOLOGIST 2|U|3||39||FOLLOW-UP|1969-05-11|
TRIAL STUDY 134XCP|TR|42B54D88-E5B5-4828-958B-4B64F07E34B3|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||L/MIN/M2|ENLARGEMENT||U/KG/H|NOT DONE|||PERFUSION MRI|NA|U|GUARDIAN|READER|NA|4||88||FOLLOW-UP|1973-01-13|
TRIAL STUDY 134XCP|TR|42B54D88-E5B5-4828-958B-4B64F07E34B3|5||||||LDIAM|LONGEST DIAMETER||U/DL|ENLARGEMENT FROM NADIR||NG/MOL|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|U|NA|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|5||7||FOLLOW-UP|1964-11-27|
TRIAL STUDY 134XCP|TR|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||GPELISA UNIT/ML|PRESENT||ML/M2/DAY|NOT DONE|||LC/MS|U|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|NA|1||38||RUN-IN|1971-07-28|
TRIAL STUDY 134XCP|TR|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||ANTI-XA IU|DIFFUSELY INCREASED||KPA/L/SEC|NOT DONE|||MRI|Y|Y|INTERVIEWER|READER 2|N|2||58||CONTINUATION TREATMENT|1967-04-12|
TRIAL STUDY 134XCP|TR|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|3||||||LESFLIND|LESION FAILURE INDICATOR||/MBP|ENLARGEMENT||WAFER|NOT DONE|||HEMAGGLUTINATION ASSAY|U|Y|GUARDIAN|READER 3|NA|3||39||BLINDED TREATMENT|1960-10-12|
TRIAL STUDY 134XCP|TR|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PPTH|FURTHER ENLARGEMENT||/CMH2O|NOT DONE|||WESTERN BLOT|NA|NA|CHILD|READER 2|U|4||88||OBSERVATION|1970-05-15|
TRIAL STUDY 134XCP|TR|A48E4CF0-E6BA-415A-9B09-4A14C81AD7D6|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CI/ML|NONPALPABLE||KCAL|NOT DONE|||ACID FAST STAIN|Y|N|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||RUN-IN|1969-04-01|
TRIAL STUDY 134XCP|TR|1FD985ED-A573-4A00-8902-214A7F182F28|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||CMHG|FURTHER ENLARGEMENT FROM NADIR||ML/MMHG/MIN/L|NOT DONE|||NUCLEAR RADIOLOGY|U|NA|CLINICAL STUDY SPONSOR|RATER 1|U|1||38||OBSERVATION|1960-12-28|
TRIAL STUDY 134XCP|TR|1FD985ED-A573-4A00-8902-214A7F182F28|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||GENEQ/ML|INCREASED||/7.5 ML|NOT DONE|||SLIT LAMP|N|U|DOMESTIC PARTNER|UROLOGIST|NA|2||58||FOLLOW-UP|1965-01-17|
TRIAL STUDY 134XCP|TR|1FD985ED-A573-4A00-8902-214A7F182F28|3||||||PALPSTAT|PALPABLE STATE||HPA|EQUIVOCAL||KG/CM2|NOT DONE|||ELISA|Y|NA|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|3||39||OBSERVATION|1971-03-22|
TRIAL STUDY 134XCP|TR|1FD985ED-A573-4A00-8902-214A7F182F28|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^3 ORGANISMS|PATHOLOGICAL||CI|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|N|N|CHILD|ONCOLOGIST 2|Y|4||88||SCREENING|1971-05-20|
TRIAL STUDY 134XCP|TR|1FD985ED-A573-4A00-8902-214A7F182F28|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||10^5/HPF|NONPALPABLE||MM|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|N|NA|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|5||7||BLINDED TREATMENT|1967-10-06|
TRIAL STUDY 134XCP|TR|A2FD338A-F994-4399-BD02-99CB299F768E|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||V/SEC|FURTHER ENLARGEMENT||UOSM|NOT DONE|||REVERSE TRANSCRIPTASE PCR|U|NA|DOMESTIC PARTNER|RATER|NA|1||38||LONG-TERM FOLLOW-UP|1960-07-28|
TRIAL STUDY 134XCP|TR|A2FD338A-F994-4399-BD02-99CB299F768E|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||CM/MIN|PALPABLE||FT|NOT DONE|||CRYOSCOPY|U|N|INTERVIEWER|PHYSIOTHERAPIST|U|2||58||OBSERVATION|1970-04-23|
TRIAL STUDY 134XCP|TR|A2FD338A-F994-4399-BD02-99CB299F768E|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||KUSP|UNCHANGED||BE/ML|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|N|U|INVESTIGATOR|RADIOLOGIST 2|Y|3||39||BASELINE|1970-12-29|
TRIAL STUDY 134XCP|TR|A2FD338A-F994-4399-BD02-99CB299F768E|4||||||ORVERLN|ORGAN VERTICAL LENGTH||PACKET|DIFFUSELY INCREASED||MM/SEC|NOT DONE|||ORCHIDOMETERY|N|NA|CAREGIVER|ONCOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1972-11-17|
TRIAL STUDY 134XCP|TR|A2FD338A-F994-4399-BD02-99CB299F768E|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||COPIES/UL|FOCALLY INCREASED||10^6 CFU|NOT DONE|||KARYOTYPING|NA|U|PARENT|MICROSCOPIST|N|5||7||RUN-IN|1963-12-01|
TRIAL STUDY 134XCP|TR|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||HZ|ENLARGEMENT FROM NADIR||U/KG/DAY|NOT DONE|||OPTICAL DENSITY MEASUREMENT|Y|U|FAMILY MEMBER|ONCOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1964-01-03|
TRIAL STUDY 134XCP|TR|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||PACK|NONPALPABLE||MG/MIN|NOT DONE|||EEG|N|Y|VENDOR|INTERNIST|N|2||58||OPEN LABEL TREATMENT|1968-10-18|
TRIAL STUDY 134XCP|TR|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|3||||||LNSTATE|LYMPH NODE STATE||ENZYME U|INCREASED||NG/DL|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|NA|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1966-12-24|
TRIAL STUDY 134XCP|TR|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|4||||||AREA|AREA||MIN|UNEQUIVOCAL||LOG10 PFU|NOT DONE|||NO INFORMATION|U|N|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1960-09-06|
TRIAL STUDY 134XCP|TR|3FE264AB-FCE4-4EEE-8550-1C43B1B1DF4E|5||||||RADIODEN|RADIODENSITY||BE/ML|INCREASED||ML/KG|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|NA|N|VENDOR|UROLOGIST|U|5||7||WASHOUT|1970-06-05|
TRIAL STUDY 134XCP|TR|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|1||||||LDIAM|LONGEST DIAMETER||COULOMB|ENLARGEMENT FROM NADIR||POINT|NOT DONE|||BALLPOINT PEN TECHNIQUE|U|U|ADJUDICATOR|CARDIOLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1962-08-15|
TRIAL STUDY 134XCP|TR|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^3 CFU/G|PATHOLOGICAL||CFU/ML|NOT DONE|||TRIPLE-PHASE MRI SCAN|Y|N|CHILD|NEUROLOGIST|N|2||58||SCREENING|1969-05-19|
TRIAL STUDY 134XCP|TR|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MEQ/L|DECREASED||UG/H|NOT DONE|||HIGH RESOLUTION CT|Y|Y|FRIEND|RADIOLOGIST 2|U|3||39||BLINDED TREATMENT|1966-03-14|
TRIAL STUDY 134XCP|TR|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UV*SEC|FOCALLY INCREASED||CARTRIDGE|NOT DONE|||MRS|U|Y|GUARDIAN|OPHTHALMOLOGIST|U|4||88||BASELINE|1965-10-20|
TRIAL STUDY 134XCP|TR|284A96C9-F0ED-4B2C-BEEC-A6D24788912C|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||BOX|UNCHANGED||/2500 WBC|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|N|Y|INTERVIEWER|READER 2|U|5||7||TREATMENT|1967-09-10|
TRIAL STUDY 134XCP|TR|A8821AEE-49EB-4687-BB63-361BC3B8B182|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^8 PFU|UNCHANGED||CFU/ML|NOT DONE|||SPECULAR MICROSCOPY|N|U|INDEPENDENT ASSESSOR|PATHOLOGIST|Y|1||38||TREATMENT|1967-07-06|
TRIAL STUDY 134XCP|TR|A8821AEE-49EB-4687-BB63-361BC3B8B182|2||||||ORSTATE|ORGAN STATE||100 IU/ML|NORMAL||FOZ_US|NOT DONE|||X-RAY|Y|Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|U|2||58||OPEN LABEL TREATMENT|1969-05-25|
TRIAL STUDY 134XCP|TR|A8821AEE-49EB-4687-BB63-361BC3B8B182|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MG/L FEU|PRESENT||CI/UG|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|U|SIBLING|MICROSCOPIST 1|NA|3||39||RUN-IN|1964-07-11|
TRIAL STUDY 134XCP|TR|A8821AEE-49EB-4687-BB63-361BC3B8B182|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BAG|UNEQUIVOCAL||MM2|NOT DONE|||CHROMATOGRAPHY|NA|NA|VENDOR|OTOLARYNGOLOGIST|NA|4||88||WASHOUT|1972-12-31|
TRIAL STUDY 134XCP|TR|A8821AEE-49EB-4687-BB63-361BC3B8B182|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MCI/KG|FOCALLY INCREASED||UG/DL|NOT DONE|||FLOCCULATION|U|N|PROXY|ADJUDICATOR 2|Y|5||7||OPEN LABEL TREATMENT|1965-10-03|
TRIAL STUDY 134XCP|TR|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||OHM|ABSENT||U.CARR|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|NA|INVESTIGATOR|RATER 2|U|1||38||TREATMENT|1965-07-04|
TRIAL STUDY 134XCP|TR|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|2||||||NEWCONF|NEW TUMOR CONFIRMED||ML/CAGE/DAY|PATHOLOGICAL||DIP|NOT DONE|||SPIRAL CT|U|Y|FRIEND|FORENSIC PATHOLOGIST|U|2||58||BLINDED TREATMENT|1960-06-23|
TRIAL STUDY 134XCP|TR|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CAL|INCREASED||G/U|NOT DONE|||INFRARED SPECTROMETRY|N|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|3||39||SCREENING|1964-03-31|
TRIAL STUDY 134XCP|TR|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||FT|FOCALLY INCREASED||EIA UNIT|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|N|FRIEND|DERMATOLOGIST|NA|4||88||SCREENING|1972-12-01|
TRIAL STUDY 134XCP|TR|B2FE7511-A275-4E2E-85C3-5454FA1C02D1|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^6 IU|NONPALPABLE||APL U/ML|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|Y|INVESTIGATOR|READER 2|N|5||7||LONG-TERM FOLLOW-UP|1967-07-24|
TRIAL STUDY 134XCP|TR|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||PELLET|INCREASED||YEARS|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|U|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|U|1||38||FOLLOW-UP|1966-07-06|
TRIAL STUDY 134XCP|TR|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|2||||||SUMVOL|SUM OF VOLUME||FOZ_BR|UNCHANGED||CMH2O*S/ML|NOT DONE|||ICC|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|2||58||INDUCTION TREATMENT|1966-10-23|
TRIAL STUDY 134XCP|TR|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ML/G/H|NONPALPABLE||ML/DL|NOT DONE|||JAEGER EYE CHART|NA|N|ADJUDICATOR|ADJUDICATOR 1|NA|3||39||BASELINE|1973-08-05|
TRIAL STUDY 134XCP|TR|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||TRANSDUCING UNIT|NONPALPABLE||MMHG/SEC|NOT DONE|||SICKLE CELL SOLUBILITY TEST|Y|N|STUDY SUBJECT|PATHOLOGIST 1|NA|4||88||SCREENING|1963-05-25|
TRIAL STUDY 134XCP|TR|5F155D7F-6FE9-4AD2-92A2-64A009167BFC|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PNU/ML|ABSENT||U/KG/H|NOT DONE|||SANGER SEQUENCING|U|U|CLINICAL STUDY SPONSOR|ADJUDICATOR|N|5||7||WASHOUT|1964-03-16|
TRIAL STUDY 134XCP|TR|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||IU/DL|PRESENT||UG/KG/DAY|NOT DONE|||HANSEL STAIN|U|N|NON-HEALTH CARE PROFESSIONAL|READER 3|U|1||38||TREATMENT|1964-04-01|
TRIAL STUDY 134XCP|TR|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||IMPLANT|PRESENT||YD|NOT DONE|||CENTRIFUGATION|NA|U|ADJUDICATOR|READER 2|U|2||58||CONTINUATION TREATMENT|1967-05-31|
TRIAL STUDY 134XCP|TR|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^7 CFU|UNEQUIVOCAL||MV|NOT DONE|||OPHTHALMOSCOPY|NA|Y|STUDY SUBJECT|ONCOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1965-11-01|
TRIAL STUDY 134XCP|TR|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||KCAL|ENLARGEMENT||NFIU|NOT DONE|||AURAMINE STAIN|Y|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|4||88||RUN-IN|1972-07-29|
TRIAL STUDY 134XCP|TR|33CC5FBC-A2B0-4DA3-8DE7-B2281B98511B|5||||||LPERP|LONGEST PERPENDICULAR||DEG/S|PATHOLOGICAL||SFC/10^6 PBMC|NOT DONE|||RYAN BLUE STAIN|NA|U|SPOUSE|ONCOLOGIST 2|NA|5||7||CONTINUATION TREATMENT|1961-07-10|
TRIAL STUDY 134XCP|TR|E711C534-E58F-4B41-95CC-24E938D89B61|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||VP/DOSE|DIFFUSELY INCREASED||DISK|NOT DONE|||WESTERN BLOT|Y|Y|CAREGIVER|FORENSIC PATHOLOGIST|U|1||38||OPEN LABEL TREATMENT|1968-11-23|
TRIAL STUDY 134XCP|TR|E711C534-E58F-4B41-95CC-24E938D89B61|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||DNA COPIES/UG|ABSENT||PHERESIS UNIT|NOT DONE|||TOTAL BODY RADIOGRAPHY|NA|NA|SPOUSE|RADIOLOGIST|NA|2||58||OBSERVATION|1961-11-24|
TRIAL STUDY 134XCP|TR|E711C534-E58F-4B41-95CC-24E938D89B61|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||10^3 COPIES/ML|ENLARGEMENT||PNU/ML|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|N|ADJUDICATOR|NEUROLOGIST 1|Y|3||39||OPEN LABEL TREATMENT|1972-03-10|
TRIAL STUDY 134XCP|TR|E711C534-E58F-4B41-95CC-24E938D89B61|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||IN|FOCALLY INCREASED||MM/MIN|NOT DONE|||POPULATION SEQUENCING|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|4||88||TREATMENT|1962-01-31|
TRIAL STUDY 134XCP|TR|E711C534-E58F-4B41-95CC-24E938D89B61|5||||||ORSTATE|ORGAN STATE||%(W/V)|FOCALLY INCREASED||FOZ_BR|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|N|Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5||7||WASHOUT|1960-12-06|
TRIAL STUDY 134XCP|TR|83938342-C01F-491A-84A7-F85D327F112D|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MM/2H|EQUIVOCAL||MV|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|N|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|1||38||LONG-TERM FOLLOW-UP|1963-10-29|
TRIAL STUDY 134XCP|TR|83938342-C01F-491A-84A7-F85D327F112D|2||||||DIAMETER|DIAMETER||INHALATION|FURTHER ENLARGEMENT||U/ML|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1960-03-29|
TRIAL STUDY 134XCP|TR|83938342-C01F-491A-84A7-F85D327F112D|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||IU/MMOL|DECREASED||MMOL/L|NOT DONE|||COLORIMETRY|U|NA|DOMESTIC PARTNER|NEUROLOGIST 1|NA|3||39||INDUCTION TREATMENT|1965-02-15|
TRIAL STUDY 134XCP|TR|83938342-C01F-491A-84A7-F85D327F112D|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^3 RNA COPIES/ML|PATHOLOGICAL||/MS|NOT DONE|||CALIPER MEASUREMENT METHOD|U|NA|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|4||88||CONTINUATION TREATMENT|1970-06-23|
TRIAL STUDY 134XCP|TR|83938342-C01F-491A-84A7-F85D327F112D|5||||||AREA|AREA||L/H|ENLARGEMENT FROM NADIR||L/L|NOT DONE|||LYMPHANGIOGRAPHY|NA|NA|PARENT|UROLOGIST|Y|5||7||INDUCTION TREATMENT|1965-06-30|
TRIAL STUDY 134XCP|TR|731665AB-4418-4943-BFC5-D78F03C8D423|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MG/M2|PRESENT||10^6 CFU/ML|NOT DONE|||WRIGHT-GIEMSA STAIN|N|N|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|1||38||BASELINE|1963-10-02|
TRIAL STUDY 134XCP|TR|731665AB-4418-4943-BFC5-D78F03C8D423|2||||||LESFLIND|LESION FAILURE INDICATOR||ML/DOSE|FURTHER ENLARGEMENT FROM NADIR||NM|NOT DONE|||CONTACT SPECULAR MICROSCOPY|N|Y|SPOUSE|MICROSCOPIST 3|Y|2||58||OBSERVATION|1963-06-25|
TRIAL STUDY 134XCP|TR|731665AB-4418-4943-BFC5-D78F03C8D423|3||||||TUMSTATE|TUMOR STATE||G/DAY|UNCHANGED||MEQ/MMOL|NOT DONE|||LASER CAPTURE MICRODISSECTION|NA|Y|CHILD|ENDOCRINOLOGIST|N|3||39||TREATMENT|1960-12-08|
TRIAL STUDY 134XCP|TR|731665AB-4418-4943-BFC5-D78F03C8D423|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ECL UNIT|ABSENT||G|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|Y|U|STUDY SUBJECT|ONCOLOGIST 2|U|4||88||LONG-TERM FOLLOW-UP|1969-10-29|
TRIAL STUDY 134XCP|TR|731665AB-4418-4943-BFC5-D78F03C8D423|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||NMOL/L/H|FURTHER ENLARGEMENT FROM NADIR||PMOL/10^9 CELLS|NOT DONE|||CONTACT SPECULAR MICROSCOPY|Y|NA|SPOUSE|RATER 1|NA|5||7||BASELINE|1971-04-24|
TRIAL STUDY 134XCP|TR|3E337B9F-D718-4FE6-83D8-E05BC77CA872|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||CMOL|ENLARGEMENT||UL|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|U|Y|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|1||38||RUN-IN|1971-04-28|
TRIAL STUDY 134XCP|TR|3E337B9F-D718-4FE6-83D8-E05BC77CA872|2||||||DIAMETER|DIAMETER||CFU/ML|DIFFUSELY INCREASED||KAT|NOT DONE|||CALCOFLUOR WHITE STAIN|Y|Y|PARENT|HEMATOLOGIST|Y|2||58||INDUCTION TREATMENT|1970-07-13|
TRIAL STUDY 134XCP|TR|3E337B9F-D718-4FE6-83D8-E05BC77CA872|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||/MIN|NON-PATHOLOGICAL||MG/ANIMAL|NOT DONE|||AUTOMATED COUNT|Y|NA|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|U|3||39||RUN-IN|1963-01-16|
TRIAL STUDY 134XCP|TR|3E337B9F-D718-4FE6-83D8-E05BC77CA872|4||||||CALCFIND|CALCIFICATION INDICATOR||ML/KG|ABSENT||IU/ML|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|Y|U|GUARDIAN|MICROSCOPIST 3|N|4||88||LONG-TERM FOLLOW-UP|1967-05-08|
TRIAL STUDY 134XCP|TR|3E337B9F-D718-4FE6-83D8-E05BC77CA872|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||IU/L|FURTHER ENLARGEMENT FROM NADIR||TITER|NOT DONE|||COULOMETRIC TITRATION|U|N|PARENT|HEMATOLOGIST|Y|5||7||TREATMENT|1967-11-16|
TRIAL STUDY 134XCP|TR|D5243E6E-2521-4331-ABFB-75112D06F771|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||/CMH2O|NONPALPABLE||U/G|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|Y|FAMILY MEMBER|RADIOLOGIST|Y|1||38||INDUCTION TREATMENT|1964-07-16|
TRIAL STUDY 134XCP|TR|D5243E6E-2521-4331-ABFB-75112D06F771|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/M2|FURTHER ENLARGEMENT FROM NADIR||CM H2O|NOT DONE|||MEDIASTINOSCOPY|N|N|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|2||58||TREATMENT|1969-10-01|
TRIAL STUDY 134XCP|TR|D5243E6E-2521-4331-ABFB-75112D06F771|3||||||VSLPIND|VESSEL PATENCY INDICATOR||L/H|UNCHANGED||LOG10 TCID 50/DOSE|NOT DONE|||ANTIBIOTIC AGAR SCREEN|U|Y|SIBLING|ONCOLOGIST|N|3||39||CONTINUATION TREATMENT|1972-08-09|
TRIAL STUDY 134XCP|TR|D5243E6E-2521-4331-ABFB-75112D06F771|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||FG|ABSENT||PMOL/L|NOT DONE|||WHOLE EXOME SEQUENCING|Y|N|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|4||88||CONTINUATION TREATMENT|1969-04-05|
TRIAL STUDY 134XCP|TR|D5243E6E-2521-4331-ABFB-75112D06F771|5||||||LPERP|LONGEST PERPENDICULAR||UG/L DDU|TUMOR MERGED||CI/G|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|N|N|PARENT|ADJUDICATOR 3|NA|5||7||WASHOUT|1963-11-12|
TRIAL STUDY 134XCP|TR|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||LOG10 ELISA UNIT|ABSENT||PT_US|NOT DONE|||NUCLEIC ACID BASED METHOD|U|Y|FRIEND|DERMATOLOGIST|N|1||38||INDUCTION TREATMENT|1964-06-19|
TRIAL STUDY 134XCP|TR|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||YD|DECREASED||L/DAY|NOT DONE|||WEBER GREEN STAIN|NA|U|SIBLING|PATHOLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1972-03-06|
TRIAL STUDY 134XCP|TR|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|3||||||LESFLIND|LESION FAILURE INDICATOR||CARTRIDGE|PATHOLOGICAL||MMHG*MIN/L|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|U|N|VENDOR|DERMATOLOGIST|U|3||39||FOLLOW-UP|1960-06-14|
TRIAL STUDY 134XCP|TR|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|4||||||LESSCIND|LESION SUCCESS INDICATOR||SCOOPFUL|DIFFUSELY INCREASED||10^10/L|NOT DONE|||PERCUSSION|U|U|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|4||88||RUN-IN|1961-03-07|
TRIAL STUDY 134XCP|TR|AD9332D4-879F-4CD3-BA96-C6FF69CF85AC|5||||||NEWCONF|NEW TUMOR CONFIRMED||SV|EQUIVOCAL||ML*CMH2O|NOT DONE|||LC/MS|U|U|FAMILY MEMBER|NEUROLOGIST|NA|5||7||RUN-IN|1970-02-04|
TRIAL STUDY 134XCP|TR|5B3E406E-F2A5-4F25-8271-DC1FABA40138|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UM|ENLARGEMENT FROM NADIR||BQ/UL|NOT DONE|||SCANNING ELECTRON MICROSCOPY|Y|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|1||38||INDUCTION TREATMENT|1966-01-19|
TRIAL STUDY 134XCP|TR|5B3E406E-F2A5-4F25-8271-DC1FABA40138|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||G|EQUIVOCAL||CPM|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|U|Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||WASHOUT|1972-12-07|
TRIAL STUDY 134XCP|TR|5B3E406E-F2A5-4F25-8271-DC1FABA40138|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||HOUNSFIELD UNIT|TUMOR MERGED||/LPF|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|NA|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|U|3||39||OBSERVATION|1972-08-17|
TRIAL STUDY 134XCP|TR|5B3E406E-F2A5-4F25-8271-DC1FABA40138|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||CP|ABSENT||CI/KG|NOT DONE|||CONGO RED STAIN|N|NA|PARENT|ONCOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1969-10-14|
TRIAL STUDY 134XCP|TR|5B3E406E-F2A5-4F25-8271-DC1FABA40138|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MDFI|UNCHANGED||WEEKS|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|Y|N|SPOUSE|ADJUDICATOR 2|NA|5||7||SCREENING|1966-12-26|
TRIAL STUDY 134XCP|TR|D5262627-52D7-42F5-B4BA-D7E6FA243959|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||UMOL/MG/MIN|DECREASED||MMOL/S|NOT DONE|||AMSLER GRID|Y|NA|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||RUN-IN|1966-09-29|
TRIAL STUDY 134XCP|TR|D5262627-52D7-42F5-B4BA-D7E6FA243959|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UG/ANIMAL|UNCHANGED||PKAT/L|NOT DONE|||IMPEDANCE CONDUCTIVITY|U|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||RUN-IN|1971-10-10|
TRIAL STUDY 134XCP|TR|D5262627-52D7-42F5-B4BA-D7E6FA243959|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KAT|TUMOR MERGED||UG/CM2|NOT DONE|||MICROSCOPY|NA|NA|CAREGIVER|NEUROLOGIST|U|3||39||BLINDED TREATMENT|1971-07-18|
TRIAL STUDY 134XCP|TR|D5262627-52D7-42F5-B4BA-D7E6FA243959|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||1/(S*KPA)|ABSENT||HPA|NOT DONE|||OSCILLOMETRY|N|Y|SIGNIFICANT OTHER|ADJUDICATOR|NA|4||88||OBSERVATION|1969-02-08|
TRIAL STUDY 134XCP|TR|D5262627-52D7-42F5-B4BA-D7E6FA243959|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MMOL|EQUIVOCAL||DROP|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|Y|U|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OBSERVATION|1970-04-17|
TRIAL STUDY 134XCP|TR|C550278D-F171-42D0-8C34-D60824A3FE98|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||BOX|ENLARGEMENT FROM NADIR||CP|NOT DONE|||SISH|Y|N|STUDY SUBJECT|UROLOGIST|Y|1||38||SCREENING|1964-06-17|
TRIAL STUDY 134XCP|TR|C550278D-F171-42D0-8C34-D60824A3FE98|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MMOL/MIN/KPA|FOCALLY INCREASED||LOG10 IU/ML|NOT DONE|||AUTOREFRACTION|N|Y|SPOUSE|NEUROLOGIST 1|NA|2||58||BASELINE|1966-05-29|
TRIAL STUDY 134XCP|TR|C550278D-F171-42D0-8C34-D60824A3FE98|3||||||ORSTATE|ORGAN STATE||MMOL/KG|ENLARGEMENT FROM NADIR||FARAD|NOT DONE|||PERIODIC ACID SCHIFF STAIN|N|U|DOMESTIC PARTNER|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1969-12-14|
TRIAL STUDY 134XCP|TR|C550278D-F171-42D0-8C34-D60824A3FE98|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||GY/H|ENLARGEMENT||TUBERCULIN UNIT/ML|NOT DONE|||FLOW MICROSCOPY|Y|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||INDUCTION TREATMENT|1970-11-13|
TRIAL STUDY 134XCP|TR|C550278D-F171-42D0-8C34-D60824A3FE98|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||10^9/G|PALPABLE||G/G/DAY|NOT DONE|||PHYSICAL EXAMINATION|Y|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|Y|5||7||FOLLOW-UP|1969-10-12|
TRIAL STUDY 134XCP|TR|5E76262E-FE1E-40C9-B147-3C792F768F48|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^5/L|DIFFUSELY INCREASED||10^6 CFU/G|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|U|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|1||38||SCREENING|1960-03-01|
TRIAL STUDY 134XCP|TR|5E76262E-FE1E-40C9-B147-3C792F768F48|2||||||AREA|AREA||ML/CAGE|PATHOLOGICAL||MMOL/MIN/KPA/L|NOT DONE|||RAJI CELL EIA|NA|N|SIGNIFICANT OTHER|ADJUDICATOR|Y|2||58||BASELINE|1965-02-07|
TRIAL STUDY 134XCP|TR|5E76262E-FE1E-40C9-B147-3C792F768F48|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||UL|PATHOLOGICAL||UIU/DL|NOT DONE|||KINYOUN STAIN|U|NA|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3||39||LONG-TERM FOLLOW-UP|1966-07-14|
TRIAL STUDY 134XCP|TR|5E76262E-FE1E-40C9-B147-3C792F768F48|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||UG/L DDU|UNEQUIVOCAL||BOTTLE|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|N|U|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|4||88||OPEN LABEL TREATMENT|1965-05-02|
TRIAL STUDY 134XCP|TR|5E76262E-FE1E-40C9-B147-3C792F768F48|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UG/M2/DAY|NONPALPABLE||MOSM|NOT DONE|||KLEIHAUER-BETKE|NA|Y|FRIEND|READER 2|N|5||7||TREATMENT|1968-02-04|
TRIAL STUDY 134XCP|TR|2F21921D-D18C-43EE-A39E-91A93B262B8C|1||||||VSLPIND|VESSEL PATENCY INDICATOR||TITER|FOCALLY INCREASED||DPM/MG|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|U|U|ADJUDICATION COMMITTEE|NEUROLOGIST 2|N|1||38||OBSERVATION|1968-10-19|
TRIAL STUDY 134XCP|TR|2F21921D-D18C-43EE-A39E-91A93B262B8C|2||||||NEWCONF|NEW TUMOR CONFIRMED||ML/MMHG|ENLARGEMENT||PUFF|NOT DONE|||ACID FAST STAIN|Y|N|DOMESTIC PARTNER|RADIOLOGIST 2|N|2||58||SCREENING|1963-12-05|
TRIAL STUDY 134XCP|TR|2F21921D-D18C-43EE-A39E-91A93B262B8C|3||||||RADIODEN|RADIODENSITY||10^3 DNA COPIES/ML|NORMAL||MG/MOL|NOT DONE|||GC/MS|Y|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|3||39||OPEN LABEL TREATMENT|1961-12-31|
TRIAL STUDY 134XCP|TR|2F21921D-D18C-43EE-A39E-91A93B262B8C|4||||||LMBFLIND|LIMB FAILURE INDICATOR||USIEMENS|FURTHER ENLARGEMENT||CI|NOT DONE|||CYSTOMETRY|NA|U|STUDY SUBJECT|OTOLARYNGOLOGIST|NA|4||88||FOLLOW-UP|1965-02-17|
TRIAL STUDY 134XCP|TR|2F21921D-D18C-43EE-A39E-91A93B262B8C|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||TUBE|ABSENT||L/L|NOT DONE|||FLUORESCENT MICROSCOPY|U|U|FAMILY MEMBER|INTERNIST|NA|5||7||OBSERVATION|1965-08-28|
TRIAL STUDY 134XCP|TR|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||/SEC|DIFFUSELY INCREASED||CI/UL|NOT DONE|||FLUOROSCOPY|U|N|DOMESTIC PARTNER|MICROSCOPIST 3|N|1||38||TREATMENT|1971-02-21|
TRIAL STUDY 134XCP|TR|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|2||||||CALCFIND|CALCIFICATION INDICATOR||UG/L/H|NONPALPABLE||EVENTS|NOT DONE|||PHYSICAL EXAMINATION|U|Y|SIBLING|INTERNIST|Y|2||58||LONG-TERM FOLLOW-UP|1971-03-17|
TRIAL STUDY 134XCP|TR|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|3||||||DIAMETER|DIAMETER||U.CARR|ENLARGEMENT FROM NADIR||10^7 PFU|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|U|Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|3||39||BASELINE|1961-03-03|
TRIAL STUDY 134XCP|TR|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/100G/MIN|PRESENT||G/CAGE/DAY|NOT DONE|||LC/MS/MS|NA|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|4||88||FOLLOW-UP|1971-07-28|
TRIAL STUDY 134XCP|TR|B2AAF3FD-AA9B-4BA9-8DE5-4C4BA12ECEBC|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MEQ/UG|ENLARGEMENT FROM NADIR||HOURS|NOT DONE|||CLAUSS METHOD|N|U|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|5||7||FOLLOW-UP|1970-12-01|
TRIAL STUDY 134XCP|TR|55985646-0224-4442-90C5-EFEDF990E88C|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||ARBITRARY U|ENLARGEMENT||1/(S*KPA)|NOT DONE|||CELL BASED BIOASSAY|U|N|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|1||38||WASHOUT|1970-06-05|
TRIAL STUDY 134XCP|TR|55985646-0224-4442-90C5-EFEDF990E88C|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||BEATS/MIN|EQUIVOCAL||10^10/L|NOT DONE|||SPECT SCAN|Y|NA|FAMILY MEMBER|NEUROLOGIST|N|2||58||FOLLOW-UP|1971-12-10|
TRIAL STUDY 134XCP|TR|55985646-0224-4442-90C5-EFEDF990E88C|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MPS U|FOCALLY INCREASED||MG/M2/H|NOT DONE|||PHASE-CONTRAST MRI|NA|NA|GUARDIAN|FORENSIC PATHOLOGIST|U|3||39||FOLLOW-UP|1972-02-26|
TRIAL STUDY 134XCP|TR|55985646-0224-4442-90C5-EFEDF990E88C|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||/40 HPFS|ENLARGEMENT FROM NADIR||TRANSDUCING UNIT/ML|NOT DONE|||IMMUNOCHROMATOGRAPHY|Y|N|STUDY SUBJECT|OPHTHALMOLOGIST|N|4||88||OPEN LABEL TREATMENT|1964-05-12|
TRIAL STUDY 134XCP|TR|55985646-0224-4442-90C5-EFEDF990E88C|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||BQ/KG|ENLARGEMENT||10^5/L|NOT DONE|||NUCLEIC ACID SEQUENCING|U|Y|SIBLING|READER 1|Y|5||7||SCREENING|1961-09-12|
TRIAL STUDY 134XCP|TR|86509C90-3C57-4755-A06F-79C620779371|1||||||SUMDIAM|SUM OF DIAMETER||UMOL/H/MMOL|EQUIVOCAL||UGEQ/L|NOT DONE|||ICC|N|N|DOMESTIC PARTNER|OPHTHALMOLOGIST|U|1||38||RUN-IN|1967-03-15|
TRIAL STUDY 134XCP|TR|86509C90-3C57-4755-A06F-79C620779371|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/LPF|DIFFUSELY INCREASED||UIU/L|NOT DONE|||CONTRAST ENHANCED PET SCAN|Y|N|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|2||58||WASHOUT|1973-09-08|
TRIAL STUDY 134XCP|TR|86509C90-3C57-4755-A06F-79C620779371|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||SQU/ML|ENLARGEMENT FROM NADIR||BOLUS|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|NA|N|INDEPENDENT ASSESSOR|ONCOLOGIST|U|3||39||OPEN LABEL TREATMENT|1972-11-26|
TRIAL STUDY 134XCP|TR|86509C90-3C57-4755-A06F-79C620779371|4||||||RADIODEN|RADIODENSITY||OD UNIT|DIFFUSELY INCREASED||MM/MIN|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|NA|SPOUSE|OPTOMETRIST|Y|4||88||OPEN LABEL TREATMENT|1970-09-17|
TRIAL STUDY 134XCP|TR|86509C90-3C57-4755-A06F-79C620779371|5||||||ORVERLN|ORGAN VERTICAL LENGTH||MMOL/L|DECREASED||CIGAR|NOT DONE|||DIFFUSION TENSOR MRI|Y|Y|FRIEND|READER 2|U|5||7||FOLLOW-UP|1973-03-28|
TRIAL STUDY 134XCP|TR|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MOL|PRESENT||/MM2|NOT DONE|||ULTRASOUND|U|U|SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|1||38||RUN-IN|1965-10-05|
TRIAL STUDY 134XCP|TR|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KPA/L/SEC|PRESENT||10^6 ORGANISMS/MG|NOT DONE|||FLOW MICROSCOPY|Y|NA|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|2||58||TREATMENT|1967-05-05|
TRIAL STUDY 134XCP|TR|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|3||||||VDIAM|VIABLE DIAMETER||GPELISA UNIT/ML|NON-PATHOLOGICAL||CARTRIDGE|NOT DONE|||WRIGHT STAIN|N|N|GUARDIAN|PATHOLOGIST 1|U|3||39||SCREENING|1966-07-14|
TRIAL STUDY 134XCP|TR|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|4||||||VSLPIND|VESSEL PATENCY INDICATOR||KIU|PALPABLE||MEQ/DL|NOT DONE|||PERCUSSION|Y|Y|PROXY|ADJUDICATOR 3|N|4||88||OPEN LABEL TREATMENT|1972-03-18|
TRIAL STUDY 134XCP|TR|8C9966BC-922D-4F74-9057-B2DE1DEF21E3|5||||||LMBFLIND|LIMB FAILURE INDICATOR||MHZ|UNCHANGED||BQ/KG|NOT DONE|||PERCUSSION|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR|U|5||7||INDUCTION TREATMENT|1967-11-17|
TRIAL STUDY 134XCP|TR|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||U/G HB|PATHOLOGICAL||MM2|NOT DONE|||COMPLEMENT FIXATION|NA|NA|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||FOLLOW-UP|1963-08-30|
TRIAL STUDY 134XCP|TR|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||IU/ML|EQUIVOCAL||BE/ML|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|U|NA|DOMESTIC PARTNER|NEUROLOGIST 1|N|2||58||SCREENING|1967-09-17|
TRIAL STUDY 134XCP|TR|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|3||||||PALPSTAT|PALPABLE STATE||10^4 CFU/ML|FOCALLY INCREASED||L/H/M2|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|U|FAMILY MEMBER|PATHOLOGIST|NA|3||39||CONTINUATION TREATMENT|1966-04-02|
TRIAL STUDY 134XCP|TR|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||RNA COPIES/ML|PALPABLE||LOG10 TCID 50/UL|NOT DONE|||LC/MS/MS|U|U|SIBLING|RADIOLOGIST|U|4||88||BASELINE|1966-07-03|
TRIAL STUDY 134XCP|TR|FDE870DC-5091-4CAE-9E47-88F2F4D95FE1|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||SCOOPFUL|ENLARGEMENT||KBQ/UL|NOT DONE|||TWO-COLOR MICROARRAY|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST|N|5||7||CONTINUATION TREATMENT|1960-06-27|
TRIAL STUDY 134XCP|TR|0FFBFF7C-7C64-411E-8D07-C959F0886023|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||NKAT/L|FURTHER ENLARGEMENT FROM NADIR||MG/M2/H|NOT DONE|||MULTIPLE BREATH WASHOUT|NA|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|1||38||TREATMENT|1964-03-09|
TRIAL STUDY 134XCP|TR|0FFBFF7C-7C64-411E-8D07-C959F0886023|2||||||BNLNUM|NUMBER OF BONE LESIONS||10^9/G|TUMOR MERGED||JAR|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|N|U|VENDOR|NEUROLOGIST 1|U|2||58||FOLLOW-UP|1966-02-12|
TRIAL STUDY 134XCP|TR|0FFBFF7C-7C64-411E-8D07-C959F0886023|3||||||DIAMETER|DIAMETER||LOG10 ELISA UNIT|ENLARGEMENT FROM NADIR||CIGARETTE|NOT DONE|||MALDI|NA|NA|CAREGIVER|NEUROLOGIST 1|U|3||39||WASHOUT|1972-09-22|
TRIAL STUDY 134XCP|TR|0FFBFF7C-7C64-411E-8D07-C959F0886023|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||S*KPA|EQUIVOCAL||BOTTLE|NOT DONE|||PAP STAIN|U|U|VENDOR|PATHOLOGIST|N|4||88||CONTINUATION TREATMENT|1961-01-27|
TRIAL STUDY 134XCP|TR|0FFBFF7C-7C64-411E-8D07-C959F0886023|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||INHALATION|DECREASED||ML/CM|NOT DONE|||PELLI-ROBSON EYE CHART|U|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|5||7||LONG-TERM FOLLOW-UP|1965-05-26|
TRIAL STUDY 134XCP|TR|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||L/S|NONPALPABLE||OHM|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|U|Y|CAREGIVER|CLINICAL PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1966-05-07|
TRIAL STUDY 134XCP|TR|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|2||||||ORSTATE|ORGAN STATE||APL U|NON-PATHOLOGICAL||APL U|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|N|GUARDIAN|CARDIOLOGIST|NA|2||58||RUN-IN|1965-04-14|
TRIAL STUDY 134XCP|TR|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|3||||||VOLUME|VOLUME||MV2/HZ|INCREASED||FMOL/L|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|U|U|CHILD|ADJUDICATOR 3|Y|3||39||BLINDED TREATMENT|1963-04-15|
TRIAL STUDY 134XCP|TR|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||DAMOL/L|NORMAL||NSEC|NOT DONE|||MICROSCOPY|Y|Y|STUDY SUBJECT|ADJUDICATOR 2|NA|4||88||WASHOUT|1968-05-05|
TRIAL STUDY 134XCP|TR|75BC43A6-C796-48F7-9F2B-B24E7D5D5C51|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MMOL/KG|NORMAL||LOG10 CCID 50/DOSE|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|NA|N|STUDY SUBJECT|OPTOMETRIST|U|5||7||OPEN LABEL TREATMENT|1963-06-09|
TRIAL STUDY 134XCP|TR|5DC5F780-264A-4EB1-BEA5-28209D416FEB|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^11/L|INCREASED||MANSON U/ML|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|NA|U|SIBLING|OPTOMETRIST|NA|1||38||LONG-TERM FOLLOW-UP|1964-02-24|
TRIAL STUDY 134XCP|TR|5DC5F780-264A-4EB1-BEA5-28209D416FEB|2||||||LPERP|LONGEST PERPENDICULAR||10^3 CFU/ML|FURTHER ENLARGEMENT||CUP EQ|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|U|SIGNIFICANT OTHER|ONCOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1964-07-11|
TRIAL STUDY 134XCP|TR|5DC5F780-264A-4EB1-BEA5-28209D416FEB|3||||||TUMSTATE|TUMOR STATE||10^6 ORGANISMS/ML|FURTHER ENLARGEMENT FROM NADIR||U.CARR|NOT DONE|||HPLC|N|Y|FAMILY MEMBER|PATHOLOGIST 2|N|3||39||WASHOUT|1963-10-21|
TRIAL STUDY 134XCP|TR|5DC5F780-264A-4EB1-BEA5-28209D416FEB|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||ML/BREATH|FURTHER ENLARGEMENT FROM NADIR||UG/L|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|NA|CAREGIVER|HEMATOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1968-10-15|
TRIAL STUDY 134XCP|TR|5DC5F780-264A-4EB1-BEA5-28209D416FEB|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MU/L|DECREASED||/WK|NOT DONE|||NUCLEIC ACID BASED METHOD|Y|Y|SPOUSE|READER 1|N|5||7||FOLLOW-UP|1961-11-17|
TRIAL STUDY 134XCP|TR|DDBCA084-DD05-4FA0-9083-7CD31CECA420|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UL|EQUIVOCAL||PFU/ANIMAL|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|NA|NA|DOMESTIC PARTNER|ONCOLOGIST|Y|1||38||TREATMENT|1973-04-30|
TRIAL STUDY 134XCP|TR|DDBCA084-DD05-4FA0-9083-7CD31CECA420|2||||||AREA|AREA||FL|TUMOR MERGED||MJOULE/CM2|NOT DONE|||NUCLEIC ACID SEQUENCING|N|NA|CHILD|PATHOLOGIST 2|NA|2||58||TREATMENT|1969-11-27|
TRIAL STUDY 134XCP|TR|DDBCA084-DD05-4FA0-9083-7CD31CECA420|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||G/ANIMAL|DIFFUSELY INCREASED||WATT|NOT DONE|||PULSE OXIMETRY|NA|Y|INVESTIGATOR|ADJUDICATOR 2|NA|3||39||BLINDED TREATMENT|1963-09-22|
TRIAL STUDY 134XCP|TR|DDBCA084-DD05-4FA0-9083-7CD31CECA420|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||S^-1(%O2)^-1|ABSENT||G/KG/DAY|NOT DONE|||POLYSOMNOGRAPHY|Y|NA|ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|4||88||OPEN LABEL TREATMENT|1973-04-16|
TRIAL STUDY 134XCP|TR|DDBCA084-DD05-4FA0-9083-7CD31CECA420|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||V/V|PALPABLE||PT_US|NOT DONE|||IVY INCISION METHOD|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|5||7||SCREENING|1961-12-25|
TRIAL STUDY 134XCP|TR|65A5AAA6-A817-45F8-9BA8-584E9627AB26|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||CMH2O*S2/ML|NONPALPABLE||MOSM/KG|NOT DONE|||SPIROMETRY|N|Y|GUARDIAN|DERMATOLOGIST|Y|1||38||FOLLOW-UP|1971-12-14|
TRIAL STUDY 134XCP|TR|65A5AAA6-A817-45F8-9BA8-584E9627AB26|2||||||VSLPIND|VESSEL PATENCY INDICATOR||CARTRIDGE|FOCALLY INCREASED||H/WK|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|U|NA|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|2||58||CONTINUATION TREATMENT|1960-06-21|
TRIAL STUDY 134XCP|TR|65A5AAA6-A817-45F8-9BA8-584E9627AB26|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||SHOCK WAVE|PALPABLE||NMOL BCE/NMOL|NOT DONE|||REVERSE TRANSCRIPTASE PCR|N|NA|INVESTIGATOR|ONCOLOGIST|U|3||39||INDUCTION TREATMENT|1960-09-30|
TRIAL STUDY 134XCP|TR|65A5AAA6-A817-45F8-9BA8-584E9627AB26|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ML/MIN/MMHG|DIFFUSELY INCREASED||NKAT/G HB|NOT DONE|||MASS SPECTROMETRY|NA|NA|SIBLING|READER 3|Y|4||88||BLINDED TREATMENT|1961-05-29|
TRIAL STUDY 134XCP|TR|65A5AAA6-A817-45F8-9BA8-584E9627AB26|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||/WK|FURTHER ENLARGEMENT FROM NADIR||BREATHS/30S|NOT DONE|||VIRUS PLAQUE ASSAY|N|U|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|5||7||SCREENING|1969-01-21|
TRIAL STUDY 134XCP|TR|854AD9A5-A869-41C7-9AF0-43383CE64B86|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||H/WK|NONPALPABLE||10^9 CFU/ML|NOT DONE|||NUCLEIC ACID SEQUENCING|U|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1||38||SCREENING|1961-07-22|
TRIAL STUDY 134XCP|TR|854AD9A5-A869-41C7-9AF0-43383CE64B86|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ML/100G/MIN|DIFFUSELY INCREASED||COPIES/ML|NOT DONE|||KINETIC CHROMOGENIC ASSAY|N|U|NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|2||58||RUN-IN|1961-09-07|
TRIAL STUDY 134XCP|TR|854AD9A5-A869-41C7-9AF0-43383CE64B86|3||||||LESSCIND|LESION SUCCESS INDICATOR||MV|NON-PATHOLOGICAL||KPA|NOT DONE|||PET/CT SCAN|N|NA|STUDY SUBJECT|FORENSIC PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1968-02-25|
TRIAL STUDY 134XCP|TR|854AD9A5-A869-41C7-9AF0-43383CE64B86|4||||||SUMVOL|SUM OF VOLUME||LINEAR FT*LB|UNCHANGED||10^9 ORGANISMS/ML|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|NA|INTERVIEWER|RADIOLOGIST 2|Y|4||88||WASHOUT|1969-07-06|
TRIAL STUDY 134XCP|TR|854AD9A5-A869-41C7-9AF0-43383CE64B86|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||FOZ_US|PRESENT||WEEKS|NOT DONE|||ISHIHARA COLOR PLATES|NA|U|ADJUDICATOR|RADIOLOGIST 1|NA|5||7||BLINDED TREATMENT|1964-06-17|
TRIAL STUDY 134XCP|TR|008F02C8-B28A-490E-A77A-F32584DA06FA|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^3 ORGANISMS/ML|ABSENT||FARAD|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|U|NA|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|1||38||BLINDED TREATMENT|1970-05-27|
TRIAL STUDY 134XCP|TR|008F02C8-B28A-490E-A77A-F32584DA06FA|2||||||AREA|AREA||BAU/ML|UNCHANGED||NMOL BCE/L|NOT DONE|||AGAR DILUTION|Y|Y|STUDY SUBJECT|PHYSIOTHERAPIST|Y|2||58||OBSERVATION|1965-04-11|
TRIAL STUDY 134XCP|TR|008F02C8-B28A-490E-A77A-F32584DA06FA|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MN|NON-PATHOLOGICAL||DEG|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|NA|STUDY SUBJECT|ONCOLOGIST|NA|3||39||CONTINUATION TREATMENT|1965-02-18|
TRIAL STUDY 134XCP|TR|008F02C8-B28A-490E-A77A-F32584DA06FA|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^7 PFU|FOCALLY INCREASED||PA|NOT DONE|||CALCOFLUOR WHITE STAIN|U|U|CHILD|ONCOLOGIST 2|Y|4||88||SCREENING|1960-10-23|
TRIAL STUDY 134XCP|TR|008F02C8-B28A-490E-A77A-F32584DA06FA|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||OHM|PRESENT||UL|NOT DONE|||CELL BASED BIOASSAY|U|N|FRIEND|PEDIATRIC NEUROLOGIST|NA|5||7||RUN-IN|1961-04-27|
TRIAL STUDY 134XCP|TR|7C06549D-596C-4C47-BD0B-119DF6CD67AC|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||DL|EQUIVOCAL||G/CAGE/WK|NOT DONE|||ECHOCARDIOGRAPHY|N|N|FRIEND|DERMATOLOGIST|Y|1||38||SCREENING|1962-03-06|
TRIAL STUDY 134XCP|TR|7C06549D-596C-4C47-BD0B-119DF6CD67AC|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||DROP|DECREASED||SACHET|NOT DONE|||PHASE-CONTRAST MRI|NA|Y|INTERVIEWER|RATER 2|U|2||58||INDUCTION TREATMENT|1962-08-25|
TRIAL STUDY 134XCP|TR|7C06549D-596C-4C47-BD0B-119DF6CD67AC|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ATM|UNCHANGED||HPA|NOT DONE|||TRYPAN BLUE STAIN|NA|U|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|3||39||RUN-IN|1970-11-13|
TRIAL STUDY 134XCP|TR|7C06549D-596C-4C47-BD0B-119DF6CD67AC|4||||||LDIAM|LONGEST DIAMETER||CM/MIN|EQUIVOCAL||TUBERCULIN UNIT/ML|NOT DONE|||DIRECT SEQUENCING|Y|Y|INVESTIGATOR|ADJUDICATOR 3|U|4||88||INDUCTION TREATMENT|1970-04-15|
TRIAL STUDY 134XCP|TR|7C06549D-596C-4C47-BD0B-119DF6CD67AC|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UG/L DDU|NORMAL||UG/L FEU|NOT DONE|||IMMUNOPRECIPITATION|Y|U|SPOUSE|RATER 2|U|5||7||BLINDED TREATMENT|1964-07-05|
TRIAL STUDY 134XCP|TR|39A00D93-61B9-44C5-9672-005A1F9A93EB|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MEQ|ENLARGEMENT FROM NADIR||ML/CAGE/DAY|NOT DONE|||ELECTROCHEMILUMINESCENCE|N|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|1||38||TREATMENT|1970-11-01|
TRIAL STUDY 134XCP|TR|39A00D93-61B9-44C5-9672-005A1F9A93EB|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||FEU|DECREASED||PIXELS/IN|NOT DONE|||ELECTRONEUROGRAPHY|U|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2||58||CONTINUATION TREATMENT|1960-02-27|
TRIAL STUDY 134XCP|TR|39A00D93-61B9-44C5-9672-005A1F9A93EB|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||ELISA UNIT/ML|ABSENT||%/S|NOT DONE|||GC/MS/MS|Y|N|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|3||39||FOLLOW-UP|1963-05-03|
TRIAL STUDY 134XCP|TR|39A00D93-61B9-44C5-9672-005A1F9A93EB|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||U|PATHOLOGICAL||MNFI|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|Y|U|INTERVIEWER|OPTOMETRIST|N|4||88||OBSERVATION|1973-08-04|
TRIAL STUDY 134XCP|TR|39A00D93-61B9-44C5-9672-005A1F9A93EB|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||UV*SEC|UNEQUIVOCAL||GMFI|NOT DONE|||IMPEDANCE CONDUCTIVITY|Y|Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|5||7||FOLLOW-UP|1960-12-03|
TRIAL STUDY 134XCP|TR|71B78EFA-AE7A-4248-9A59-63885131F1D1|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||FIU|EQUIVOCAL||UG/MIN|NOT DONE|||IHC|N|N|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|1||38||TREATMENT|1961-06-21|
TRIAL STUDY 134XCP|TR|71B78EFA-AE7A-4248-9A59-63885131F1D1|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||KG/M2|ENLARGEMENT FROM NADIR||G/L|NOT DONE|||INDIA INK STAIN|Y|NA|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|2||58||TREATMENT|1963-09-19|
TRIAL STUDY 134XCP|TR|71B78EFA-AE7A-4248-9A59-63885131F1D1|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||GRAIN|ENLARGEMENT FROM NADIR||BQ/G|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|N|GUARDIAN|OPHTHALMOLOGIST|NA|3||39||BASELINE|1966-11-01|
TRIAL STUDY 134XCP|TR|71B78EFA-AE7A-4248-9A59-63885131F1D1|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||CM H2O|DIFFUSELY INCREASED||LOG10 PFU/ML|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|NA|U|PARENT|PATHOLOGIST 2|U|4||88||LONG-TERM FOLLOW-UP|1970-06-25|
TRIAL STUDY 134XCP|TR|71B78EFA-AE7A-4248-9A59-63885131F1D1|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MMOL/L|NONPALPABLE||10^6 IU|NOT DONE|||COMPLEMENT FIXATION|Y|NA|CLINICAL RESEARCH ASSOCIATE|READER 3|U|5||7||OPEN LABEL TREATMENT|1961-11-30|
TRIAL STUDY 134XCP|TR|CE28B885-422E-471D-895C-DE8F41CD9FE9|1||||||LDIAM|LONGEST DIAMETER||MOSM/KG|PRESENT||PPM|NOT DONE|||AUTOREFRACTION|U|NA|PROXY|OTOLARYNGOLOGIST|NA|1||38||INDUCTION TREATMENT|1965-06-19|
TRIAL STUDY 134XCP|TR|CE28B885-422E-471D-895C-DE8F41CD9FE9|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||U/MMOL|NON-PATHOLOGICAL||M3|NOT DONE|||DIFFUSION TENSOR MRI|U|U|CAREGIVER|NEUROLOGIST 2|U|2||58||INDUCTION TREATMENT|1964-03-26|
TRIAL STUDY 134XCP|TR|CE28B885-422E-471D-895C-DE8F41CD9FE9|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||M|FURTHER ENLARGEMENT FROM NADIR||NMOL BCE/MMOL|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|N|SPOUSE|DERMATOLOGIST|NA|3||39||BLINDED TREATMENT|1973-06-02|
TRIAL STUDY 134XCP|TR|CE28B885-422E-471D-895C-DE8F41CD9FE9|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CPM|INCREASED||MMHG|NOT DONE|||AGAR PROPORTION|U|Y|CHILD|READER|Y|4||88||BLINDED TREATMENT|1969-02-10|
TRIAL STUDY 134XCP|TR|CE28B885-422E-471D-895C-DE8F41CD9FE9|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||BQ/UG|UNCHANGED||STRIP|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|Y|SIBLING|READER 1|Y|5||7||CONTINUATION TREATMENT|1970-05-04|
TRIAL STUDY 134XCP|TR|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|1||||||ORSTATE|ORGAN STATE||U/G|UNCHANGED||H*%|NOT DONE|||TWO-COLOR MICROARRAY|N|U|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|1||38||SCREENING|1969-05-17|
TRIAL STUDY 134XCP|TR|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|2||||||LDIAM|LONGEST DIAMETER||UG/KG/DAY|ABSENT||TSP|NOT DONE|||CALCOFLUOR WHITE STAIN|Y|U|INVESTIGATOR|RATER|NA|2||58||BASELINE|1969-04-06|
TRIAL STUDY 134XCP|TR|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|3||||||LDIAM|LONGEST DIAMETER||/MONTH|PATHOLOGICAL||DEG|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|N|U|DOMESTIC PARTNER|RADIOLOGIST 2|U|3||39||OPEN LABEL TREATMENT|1973-07-29|
TRIAL STUDY 134XCP|TR|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||%/S|INCREASED||UG/L FEU|NOT DONE|||FUNCTIONAL MRI|NA|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|4||88||CONTINUATION TREATMENT|1964-02-13|
TRIAL STUDY 134XCP|TR|FF7391DA-13A3-4548-BFB3-E79A2E9698E5|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||1/(S*KPA)|PRESENT||MG/CM2|NOT DONE|||KLEIHAUER-BETKE|N|Y|FRIEND|ENDOCRINOLOGIST|Y|5||7||OBSERVATION|1962-11-11|
TRIAL STUDY 134XCP|TR|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||GBQ/UG|PALPABLE||MAMP|NOT DONE|||MEDIASTINOSCOPY|NA|U|PROXY|HEMATOLOGIST|U|1||38||CONTINUATION TREATMENT|1962-06-12|
TRIAL STUDY 134XCP|TR|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||FMOL/L|NORMAL||MBQ/UL|NOT DONE|||IMMUNO-PET SCAN|Y|U|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||OBSERVATION|1960-02-20|
TRIAL STUDY 134XCP|TR|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||LOG10 COPIES/ML|ENLARGEMENT FROM NADIR||JDF UNIT|NOT DONE|||ETDRS EYE CHART|N|N|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|3||39||WASHOUT|1972-10-10|
TRIAL STUDY 134XCP|TR|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ENZYME U/M2|NONPALPABLE||%(W/V)|NOT DONE|||LIGHT MICROSCOPY|U|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|4||88||CONTINUATION TREATMENT|1963-12-28|
TRIAL STUDY 134XCP|TR|CE23E4F1-2E6F-42A8-964C-E7D3810F3982|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/L|NORMAL||PACK|NOT DONE|||ORCHIDOMETERY|U|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|5||7||BASELINE|1967-05-27|
TRIAL STUDY 134XCP|TR|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||IN2|NONPALPABLE||KG/CM|NOT DONE|||INDIA INK STAIN|Y|U|GUARDIAN|ONCOLOGIST 2|N|1||38||BASELINE|1963-03-14|
TRIAL STUDY 134XCP|TR|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|2||||||CALCFIND|CALCIFICATION INDICATOR||BE/ML|ENLARGEMENT||ML/BREATH|NOT DONE|||X-RAY|NA|U|ADJUDICATION COMMITTEE|READER|U|2||58||INDUCTION TREATMENT|1966-01-27|
TRIAL STUDY 134XCP|TR|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|3||||||ORVERLN|ORGAN VERTICAL LENGTH||MMHG*MIN/L|ENLARGEMENT||MPA|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|N|CAREGIVER|PATHOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1968-07-06|
TRIAL STUDY 134XCP|TR|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||IU|ENLARGEMENT FROM NADIR||OI50|NOT DONE|||WESTERN BLOT|U|N|INTERVIEWER|MICROSCOPIST 3|NA|4||88||TREATMENT|1965-03-01|
TRIAL STUDY 134XCP|TR|A9F69F2E-28FD-4581-BC39-9BAE2CFAA862|5||||||LPERP|LONGEST PERPENDICULAR||CMOL/L|PRESENT||AG|NOT DONE|||TONOMETRY|U|NA|CLINICAL RESEARCH COORDINATOR|READER 1|U|5||7||BASELINE|1968-02-03|
TRIAL STUDY 134XCP|TR|3AA56307-0D09-4C82-91B6-717A7C503EFE|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||10^5/L|EQUIVOCAL||ARBITRARY U|NOT DONE|||CARDIAC THERMODILUTION|U|Y|ADJUDICATOR|RADIOLOGIST 2|NA|1||38||FOLLOW-UP|1968-07-28|
TRIAL STUDY 134XCP|TR|3AA56307-0D09-4C82-91B6-717A7C503EFE|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||/MBP|NONPALPABLE||DPM/ML|NOT DONE|||AUDIOMETRY|NA|Y|HEALTH CARE PROFESSIONAL|READER 3|U|2||58||SCREENING|1965-09-20|
TRIAL STUDY 134XCP|TR|3AA56307-0D09-4C82-91B6-717A7C503EFE|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||SIEMENS|ENLARGEMENT FROM NADIR||ML/ANIMAL/DAY|NOT DONE|||KINYOUN STAIN|N|N|VENDOR|ENDOCRINOLOGIST|N|3||39||RUN-IN|1972-05-23|
TRIAL STUDY 134XCP|TR|3AA56307-0D09-4C82-91B6-717A7C503EFE|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MEQ/DL|DIFFUSELY INCREASED||CONTAINER|NOT DONE|||ORCHIDOMETERY|Y|Y|SIBLING|READER 1|NA|4||88||CONTINUATION TREATMENT|1970-07-25|
TRIAL STUDY 134XCP|TR|3AA56307-0D09-4C82-91B6-717A7C503EFE|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||/CMH2O|NONPALPABLE||U/G/MIN|NOT DONE|||PALPATION|N|NA|PARENT|ONCOLOGIST|U|5||7||RUN-IN|1972-05-08|
TRIAL STUDY 134XCP|TR|811AE318-625A-4913-8B18-2D318AF04EAC|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||NMOL BCE/NMOL|EQUIVOCAL||KG/CM2|NOT DONE|||FREEZING POINT DEPRESSION|N|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|1||38||WASHOUT|1966-11-13|
TRIAL STUDY 134XCP|TR|811AE318-625A-4913-8B18-2D318AF04EAC|2||||||LESFLIND|LESION FAILURE INDICATOR||PT_BR|NONPALPABLE||10^3 DNA COPIES/ML|NOT DONE|||NEXT GENERATION SEQUENCING|N|Y|PARENT|CLINICAL PATHOLOGIST|NA|2||58||OBSERVATION|1972-01-04|
TRIAL STUDY 134XCP|TR|811AE318-625A-4913-8B18-2D318AF04EAC|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||DIOPTER|ABSENT||NMOL/MOL|NOT DONE|||MASS SPECTROMETRY|NA|U|SIBLING|CLINICAL PATHOLOGIST|Y|3||39||SCREENING|1973-05-17|
TRIAL STUDY 134XCP|TR|811AE318-625A-4913-8B18-2D318AF04EAC|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/KG/DAY|ENLARGEMENT FROM NADIR||UL/DOSE|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|U|N|SPOUSE|RATER 1|NA|4||88||CONTINUATION TREATMENT|1961-03-18|
TRIAL STUDY 134XCP|TR|811AE318-625A-4913-8B18-2D318AF04EAC|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||RATIO|ENLARGEMENT||PLUG|NOT DONE|||LYMPHANGIOGRAPHY|U|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|5||7||INDUCTION TREATMENT|1965-05-16|
TRIAL STUDY 134XCP|TR|E8F0AF72-5DB4-41D5-814E-5E280A027E94|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||%(W/V)|NORMAL||MU/G|NOT DONE|||DIFFUSION WEIGHTED MRI|U|U|SPOUSE|DERMATOLOGIST|N|1||38||CONTINUATION TREATMENT|1972-02-26|
TRIAL STUDY 134XCP|TR|E8F0AF72-5DB4-41D5-814E-5E280A027E94|2||||||DIAMETER|DIAMETER||TITER|PATHOLOGICAL||HZ|NOT DONE|||RADIOGRAPHY|U|Y|PROXY|OTOLARYNGOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1967-08-07|
TRIAL STUDY 134XCP|TR|E8F0AF72-5DB4-41D5-814E-5E280A027E94|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UKAT/L|ENLARGEMENT FROM NADIR||TSP EQ|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y|CAREGIVER|ONCOLOGIST 1|Y|3||39||FOLLOW-UP|1963-03-15|
TRIAL STUDY 134XCP|TR|E8F0AF72-5DB4-41D5-814E-5E280A027E94|4||||||SUMVOL|SUM OF VOLUME||MG/M2|FURTHER ENLARGEMENT FROM NADIR||BAU/ML|NOT DONE|||TRANSVAGINAL ULTRASOUND|NA|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||FOLLOW-UP|1966-04-04|
TRIAL STUDY 134XCP|TR|E8F0AF72-5DB4-41D5-814E-5E280A027E94|5||||||ORSTATE|ORGAN STATE||/LPF|EQUIVOCAL||ML/CAGE/DAY|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|NA|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||SCREENING|1971-04-27|
TRIAL STUDY 134XCP|TR|3B726736-01B3-4A69-ABFB-C6255E341E69|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NGEQ/L|UNCHANGED||ENZYME U|NOT DONE|||THIN SMEAR|NA|U|STUDY SUBJECT|MICROSCOPIST 2|U|1||38||TREATMENT|1967-07-22|
TRIAL STUDY 134XCP|TR|3B726736-01B3-4A69-ABFB-C6255E341E69|2||||||DIAMETER|DIAMETER||U/G HB|ENLARGEMENT FROM NADIR||G/ANIMAL/WK|NOT DONE|||IN SITU HYBRIDIZATION|Y|NA|CLINICAL RESEARCH ASSOCIATE|RATER 1|N|2||58||WASHOUT|1969-07-20|
TRIAL STUDY 134XCP|TR|3B726736-01B3-4A69-ABFB-C6255E341E69|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||APL U|PATHOLOGICAL||AMU|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|U|Y|HEALTH CARE PROFESSIONAL|READER 2|N|3||39||SCREENING|1965-04-20|
TRIAL STUDY 134XCP|TR|3B726736-01B3-4A69-ABFB-C6255E341E69|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||DDU|FURTHER ENLARGEMENT FROM NADIR||10^5/L|NOT DONE|||MICRO BROTH DILUTION|NA|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|N|4||88||OBSERVATION|1970-05-22|
TRIAL STUDY 134XCP|TR|3B726736-01B3-4A69-ABFB-C6255E341E69|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||ML/M2/MIN|ENLARGEMENT||U/G/DAY|NOT DONE|||GC/MS/MS|NA|U|SIBLING|HEMATOLOGIST|U|5||7||RUN-IN|1968-04-23|
TRIAL STUDY 134XCP|TR|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^6 ORGANISMS/MG|ABSENT||UIU/L|NOT DONE|||DROPLET DIGITAL PCR|Y|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|U|1||38||OBSERVATION|1962-05-09|
TRIAL STUDY 134XCP|TR|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|2||||||AREA|AREA||PIXEL|DIFFUSELY INCREASED||10^6 CFU/G|NOT DONE|||IMMUNOTURBIDIMETRY|Y|U|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||INDUCTION TREATMENT|1964-04-30|
TRIAL STUDY 134XCP|TR|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|3||||||SUMDIAM|SUM OF DIAMETER||IU/G|INCREASED||IU/ML|NOT DONE|||CELLULAR PROLIFERATION ASSAY|Y|N|INTERVIEWER|READER 2|NA|3||39||FOLLOW-UP|1967-06-11|
TRIAL STUDY 134XCP|TR|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|4||||||LESFLIND|LESION FAILURE INDICATOR||ML/KG/MIN|FURTHER ENLARGEMENT FROM NADIR||AG|NOT DONE|||COLORIMETRY|N|N|VENDOR|FORENSIC PATHOLOGIST|NA|4||88||OBSERVATION|1968-09-16|
TRIAL STUDY 134XCP|TR|C96A9C9D-3EFF-4675-8B75-9B38D4D94AF0|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MG/DAY|NONPALPABLE||BQ/UG|NOT DONE|||LAPAROSCOPY|U|N|GUARDIAN|MICROSCOPIST 2|NA|5||7||OBSERVATION|1962-06-22|
TRIAL STUDY 134XCP|TR|0535EF31-5388-4CC0-8567-44F4C20975EC|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||/DAY|FOCALLY INCREASED||GY/MIN|NOT DONE|||CT SCAN WITHOUT CONTRAST|N|U|INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1960-08-02|
TRIAL STUDY 134XCP|TR|0535EF31-5388-4CC0-8567-44F4C20975EC|2||||||SUMVOL|SUM OF VOLUME||EU|FURTHER ENLARGEMENT||CG|NOT DONE|||MECHANICAL CLOT DETECTION|Y|Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|2||58||RUN-IN|1966-08-20|
TRIAL STUDY 134XCP|TR|0535EF31-5388-4CC0-8567-44F4C20975EC|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NMOL BCE/NMOL|DIFFUSELY INCREASED||SIEMENS|NOT DONE|||MICROBIAL CONCENTRATION|NA|U|INVESTIGATOR|ADJUDICATOR 2|Y|3||39||LONG-TERM FOLLOW-UP|1960-07-07|
TRIAL STUDY 134XCP|TR|0535EF31-5388-4CC0-8567-44F4C20975EC|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||G/KG|DIFFUSELY INCREASED||AMFI|NOT DONE|||MAPH|NA|N|CLINICAL RESEARCH COORDINATOR|RATER 2|N|4||88||OPEN LABEL TREATMENT|1969-05-29|
TRIAL STUDY 134XCP|TR|0535EF31-5388-4CC0-8567-44F4C20975EC|5||||||CALCFIND|CALCIFICATION INDICATOR||KIT|UNEQUIVOCAL||PMOL/L/H|NOT DONE|||PAP STAIN|U|N|STUDY SUBJECT|MICROSCOPIST 1|U|5||7||LONG-TERM FOLLOW-UP|1964-02-14|
TRIAL STUDY 134XCP|TR|F149BD98-0802-4C18-8599-426C5258D513|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^6/G|FOCALLY INCREASED||DPM/100MG|NOT DONE|||ERGOSPIROMETRY|NA|N|SIBLING|CLINICAL PATHOLOGIST|N|1||38||BLINDED TREATMENT|1971-04-19|
TRIAL STUDY 134XCP|TR|F149BD98-0802-4C18-8599-426C5258D513|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MCI/KG|PRESENT||BAG|NOT DONE|||MAMMOGRAPHY|U|U|SPOUSE|MICROSCOPIST 1|N|2||58||SCREENING|1962-04-10|
TRIAL STUDY 134XCP|TR|F149BD98-0802-4C18-8599-426C5258D513|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||DPM/ML|ENLARGEMENT FROM NADIR||BAG|NOT DONE|||MICROSCOPY|U|NA|PROXY|RADIOLOGIST 1|U|3||39||WASHOUT|1972-11-09|
TRIAL STUDY 134XCP|TR|F149BD98-0802-4C18-8599-426C5258D513|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MMOL/G|UNCHANGED||GBQ/UG|NOT DONE|||IMMUNOFLUORESCENT STAIN|Y|N|ADJUDICATOR|MICROSCOPIST 2|Y|4||88||INDUCTION TREATMENT|1968-12-27|
TRIAL STUDY 134XCP|TR|F149BD98-0802-4C18-8599-426C5258D513|5||||||ORSTATE|ORGAN STATE||MMOL/MOL|TUMOR MERGED||IU/MG|NOT DONE|||NUCLEIC ACID BASED METHOD|U|Y|PROXY|CLINICAL PATHOLOGIST|NA|5||7||TREATMENT|1960-09-11|
TRIAL STUDY 134XCP|TR|5A31D035-90D2-4BD0-AE08-839862D6E0DF|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PNU/ML|ENLARGEMENT||ML/CAGE/DAY|NOT DONE|||NUCLEAR RADIOLOGY|Y|U|ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|1||38||BLINDED TREATMENT|1971-06-24|
TRIAL STUDY 134XCP|TR|5A31D035-90D2-4BD0-AE08-839862D6E0DF|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||DL|PRESENT||KHZ|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|U|NA|CLINICAL STUDY SPONSOR|READER 1|N|2||58||BLINDED TREATMENT|1968-01-19|
TRIAL STUDY 134XCP|TR|5A31D035-90D2-4BD0-AE08-839862D6E0DF|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||SCM|INCREASED||10^9 ORGANISMS/MG|NOT DONE|||IMMUNOCHROMATOGRAPHY|U|N|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|3||39||INDUCTION TREATMENT|1966-01-30|
TRIAL STUDY 134XCP|TR|5A31D035-90D2-4BD0-AE08-839862D6E0DF|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||CAPLET|ENLARGEMENT FROM NADIR||MG/ML/MIN|NOT DONE|||IN SITU HYBRIDIZATION|Y|N|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|4||88||BASELINE|1966-05-22|
TRIAL STUDY 134XCP|TR|5A31D035-90D2-4BD0-AE08-839862D6E0DF|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||DIOPTER|FURTHER ENLARGEMENT||USP U|NOT DONE|||MICROBIAL CONCENTRATION|U|N|CAREGIVER|CLINICAL PATHOLOGIST|U|5||7||RUN-IN|1968-12-21|
TRIAL STUDY 134XCP|TR|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||IU/MG|EQUIVOCAL||ML/CAGE/DAY|NOT DONE|||DYNAMIC LIGHT SCATTERING|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|1||38||LONG-TERM FOLLOW-UP|1961-04-22|
TRIAL STUDY 134XCP|TR|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MMHG|FURTHER ENLARGEMENT FROM NADIR||PM|NOT DONE|||HPLC-FL|N|NA|SIBLING|READER 1|NA|2||58||WASHOUT|1968-10-12|
TRIAL STUDY 134XCP|TR|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||OZ|ABSENT||AMOL|NOT DONE|||NEXT GENERATION SEQUENCING|Y|Y|INVESTIGATOR|RADIOLOGIST 2|Y|3||39||OPEN LABEL TREATMENT|1962-01-03|
TRIAL STUDY 134XCP|TR|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|4||||||LPERP|LONGEST PERPENDICULAR||KIT|ABSENT||MMOL/DAY|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|Y|NA|INDEPENDENT ASSESSOR|READER 2|N|4||88||WASHOUT|1965-09-27|
TRIAL STUDY 134XCP|TR|B337DBF1-53AC-4DA1-B1AE-A023F8189A49|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||SV|INCREASED||MOL/ML|NOT DONE|||HPLC/MS/MS|N|N|INDEPENDENT ASSESSOR|RADIOLOGIST 2|NA|5||7||BASELINE|1960-07-27|
TRIAL STUDY 134XCP|TR|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||GENEQ|FOCALLY INCREASED||UM/S|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|U|U|SIGNIFICANT OTHER|ONCOLOGIST 1|U|1||38||WASHOUT|1961-02-18|
TRIAL STUDY 134XCP|TR|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||VP/ML|ENLARGEMENT FROM NADIR||MET*H|NOT DONE|||OLIGO ACGH|NA|Y|FAMILY MEMBER|ADJUDICATOR 1|U|2||58||BASELINE|1966-10-19|
TRIAL STUDY 134XCP|TR|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CI/L|PRESENT||UG/KG/H|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|NA|U|CHILD|PATHOLOGIST 1|N|3||39||OPEN LABEL TREATMENT|1972-12-05|
TRIAL STUDY 134XCP|TR|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||NCI|ENLARGEMENT||FOZ_BR|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|NA|FAMILY MEMBER|HEMATOLOGIST|N|4||88||OBSERVATION|1960-01-07|
TRIAL STUDY 134XCP|TR|A6E5EEA6-957D-40C8-9D9E-99FEB525A355|5||||||ORVERLN|ORGAN VERTICAL LENGTH||MG|NONPALPABLE||FRACTION OF 1|NOT DONE|||MOUSE PROTECTION ASSAY|N|U|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|5||7||SCREENING|1966-08-22|
TRIAL STUDY 134XCP|TR|9C9398A4-38BC-40A7-880D-4549A676F69B|1||||||SUMVOL|SUM OF VOLUME||10^6 DNA COPIES/ML|PATHOLOGICAL||KV|NOT DONE|||BALLPOINT PEN TECHNIQUE|U|N|HEALTH CARE PROFESSIONAL|READER 2|N|1||38||BASELINE|1962-03-09|
TRIAL STUDY 134XCP|TR|9C9398A4-38BC-40A7-880D-4549A676F69B|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||IU/G|PALPABLE||TBSP|NOT DONE|||MALDI-TOF|NA|Y|ADJUDICATOR|PATHOLOGIST 1|U|2||58||BASELINE|1971-01-21|
TRIAL STUDY 134XCP|TR|9C9398A4-38BC-40A7-880D-4549A676F69B|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MG/KG/WEEK|TUMOR MERGED||ML/G/MIN|NOT DONE|||SMEAR|NA|U|PROXY|MICROSCOPIST 3|Y|3||39||FOLLOW-UP|1970-05-09|
TRIAL STUDY 134XCP|TR|9C9398A4-38BC-40A7-880D-4549A676F69B|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UIU/L|PATHOLOGICAL||MDFI|NOT DONE|||KARYOTYPING|U|N|INVESTIGATOR|READER 2|N|4||88||CONTINUATION TREATMENT|1962-01-26|
TRIAL STUDY 134XCP|TR|9C9398A4-38BC-40A7-880D-4549A676F69B|5||||||BNLNUM|NUMBER OF BONE LESIONS||LOZENGE|NON-PATHOLOGICAL||UIU/DL|NOT DONE|||DIGITAL PCR ARRAY|N|N|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5||7||BASELINE|1973-07-28|
TRIAL STUDY 134XCP|TR|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||LOG10 TCID 50/UL|ABSENT||DRUM|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|N|INVESTIGATOR|NEUROLOGIST 1|Y|1||38||TREATMENT|1973-01-23|
TRIAL STUDY 134XCP|TR|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||/MM|DIFFUSELY INCREASED||KN/CM2|NOT DONE|||GIEMSA STAIN|U|N|GUARDIAN|ADJUDICATOR 3|N|2||58||TREATMENT|1964-11-24|
TRIAL STUDY 134XCP|TR|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MG/G/H|PALPABLE||IU/KG/H|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|U|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1973-01-22|
TRIAL STUDY 134XCP|TR|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|4||||||TUMSTATE|TUMOR STATE||10^3 CFU/G|NONPALPABLE||MEQ/KG|NOT DONE|||PHASE CONTRAST MICROSCOPY|U|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|4||88||LONG-TERM FOLLOW-UP|1964-05-02|
TRIAL STUDY 134XCP|TR|4FDE7F38-E0DD-40E7-B193-E2BEC4D3B549|5||||||RADIODEN|RADIODENSITY||U/DL|DIFFUSELY INCREASED||10^5/HPF|NOT DONE|||FORCED OSCILLATION TECHNIQUE|NA|U|ADJUDICATOR|NEUROLOGIST|NA|5||7||TREATMENT|1963-12-11|
TRIAL STUDY 134XCP|TR|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ML/G/MIN|ABSENT||UKAT|NOT DONE|||CONGO RED STAIN|N|Y|INDEPENDENT ASSESSOR|RATER|U|1||38||TREATMENT|1970-05-01|
TRIAL STUDY 134XCP|TR|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|2||||||LNSTATE|LYMPH NODE STATE||PACKET|NON-PATHOLOGICAL||CGY|NOT DONE|||MICROARRAY|U|U|SPOUSE|READER 2|Y|2||58||CONTINUATION TREATMENT|1968-10-24|
TRIAL STUDY 134XCP|TR|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|3||||||LDIAM|LONGEST DIAMETER||%/S|TUMOR MERGED||10^7 CFU/ML|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|N|Y|ADJUDICATOR|NEUROLOGIST 2|Y|3||39||OPEN LABEL TREATMENT|1964-06-05|
TRIAL STUDY 134XCP|TR|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||L/MIN/M2|EQUIVOCAL||PMOL/DAY|NOT DONE|||MICROBIAL CULTURE, LIQUID|NA|NA|FRIEND|PATHOLOGIST 2|U|4||88||TREATMENT|1963-02-16|
TRIAL STUDY 134XCP|TR|DFFEFBCE-D68C-4BE3-99AA-5866EF7F2824|5||||||ORSTATE|ORGAN STATE||MMOL/MIN/KPA/L|PALPABLE||KV|NOT DONE|||DUCTOGRAPHY|N|NA|ADJUDICATOR|READER|NA|5||7||CONTINUATION TREATMENT|1962-10-12|
TRIAL STUDY 134XCP|TR|1E049F70-8E29-458F-BF37-13450BC9227E|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||DPM/0.5 ML|FOCALLY INCREASED||DEG/S|NOT DONE|||MICROBIAL CULTURE, LIQUID|NA|Y|GUARDIAN|UROLOGIST|U|1||38||OPEN LABEL TREATMENT|1965-07-22|
TRIAL STUDY 134XCP|TR|1E049F70-8E29-458F-BF37-13450BC9227E|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||ANTIBODY UNIT|PRESENT||EQ|NOT DONE|||AUSCULTATION|NA|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|2||58||OBSERVATION|1964-09-09|
TRIAL STUDY 134XCP|TR|1E049F70-8E29-458F-BF37-13450BC9227E|3||||||LESSCIND|LESION SUCCESS INDICATOR||MG/M2/DAY|PATHOLOGICAL||MBQ|NOT DONE|||MODIFIED ACID FAST STAIN|Y|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|3||39||OPEN LABEL TREATMENT|1964-07-11|
TRIAL STUDY 134XCP|TR|1E049F70-8E29-458F-BF37-13450BC9227E|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||GRAIN|UNEQUIVOCAL||MEQ/DL|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|Y|U|PROXY|MICROSCOPIST 2|N|4||88||INDUCTION TREATMENT|1962-01-30|
TRIAL STUDY 134XCP|TR|1E049F70-8E29-458F-BF37-13450BC9227E|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MG/MIN|NON-PATHOLOGICAL||U/ML|NOT DONE|||HPLC-UV|Y|U|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|5||7||RUN-IN|1968-02-22|
TRIAL STUDY 134XCP|TR|7A612F0F-943A-4283-9A11-B8E8E8D68D66|1||||||DIAMETER|DIAMETER||UL/KG/DAY|PALPABLE||10^4 CFU/ML|NOT DONE|||CISH|U|NA|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|NA|1||38||OBSERVATION|1973-01-23|
TRIAL STUDY 134XCP|TR|7A612F0F-943A-4283-9A11-B8E8E8D68D66|2||||||LMBFLIND|LIMB FAILURE INDICATOR||UG/DAY|UNEQUIVOCAL||OHM|NOT DONE|||DOPPLER ULTRASOUND|NA|NA|SIGNIFICANT OTHER|RADIOLOGIST|N|2||58||OBSERVATION|1972-06-03|
TRIAL STUDY 134XCP|TR|7A612F0F-943A-4283-9A11-B8E8E8D68D66|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||NKAT/L|ENLARGEMENT||10^9 CFU/ML|NOT DONE|||IMPEDANCE CONDUCTIVITY|Y|N|SIBLING|ENDOCRINOLOGIST|U|3||39||SCREENING|1968-05-24|
TRIAL STUDY 134XCP|TR|7A612F0F-943A-4283-9A11-B8E8E8D68D66|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||NMOL/MOL|PATHOLOGICAL||GENEQ/ML|NOT DONE|||GC/MS/MS|U|N|ADJUDICATOR|NEUROLOGIST 2|NA|4||88||RUN-IN|1964-01-24|
TRIAL STUDY 134XCP|TR|7A612F0F-943A-4283-9A11-B8E8E8D68D66|5||||||LPERP|LONGEST PERPENDICULAR||UG/KG/MIN|ENLARGEMENT FROM NADIR||RPM|NOT DONE|||LINE PROBE ASSAY|U|N|CHILD|RADIOLOGIST 1|NA|5||7||BASELINE|1968-07-04|
TRIAL STUDY 134XCP|TR|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|1||||||LNSTATE|LYMPH NODE STATE||10^11/L|DIFFUSELY INCREASED||/2000 RBC|NOT DONE|||MICROBIAL CULTURE, LIQUID|N|Y|HEALTH CARE PROFESSIONAL|READER 2|NA|1||38||BLINDED TREATMENT|1966-03-03|
TRIAL STUDY 134XCP|TR|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||GRAVITATIONAL UNIT|FURTHER ENLARGEMENT||S^-1(%O2)^-1|NOT DONE|||RYAN BLUE STAIN|U|Y|SPOUSE|ENDOCRINOLOGIST|Y|2||58||WASHOUT|1964-10-24|
TRIAL STUDY 134XCP|TR|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||KIU|FURTHER ENLARGEMENT||UG/ANIMAL|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|U|N|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|3||39||SCREENING|1970-10-06|
TRIAL STUDY 134XCP|TR|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||NMOL|PALPABLE||MG/DAY|NOT DONE|||ELASTOGRAPHY|U|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|4||88||INDUCTION TREATMENT|1960-11-03|
TRIAL STUDY 134XCP|TR|DBFC7D83-4E1D-47FA-9DD9-35923025B44B|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||DAMOL/L|EQUIVOCAL||10^3 DNA COPIES/ML|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|NA|U|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|5||7||BLINDED TREATMENT|1972-09-23|
TRIAL STUDY 134XCP|TR|8C86A799-2717-46E8-99C2-76D11AAB54D7|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||KG/CM2|ABSENT||/SEC|NOT DONE|||IMPEDANCE CONDUCTIVITY|U|Y|ADJUDICATOR|RADIOLOGIST 2|U|1||38||SCREENING|1966-01-27|
TRIAL STUDY 134XCP|TR|8C86A799-2717-46E8-99C2-76D11AAB54D7|2||||||LESSCIND|LESION SUCCESS INDICATOR||CM/S|UNEQUIVOCAL||QUANTITY SUFFICIENT|NOT DONE|||IMMUNOFLUORESCENT STAIN|U|Y|INTERVIEWER|UROLOGIST|U|2||58||INDUCTION TREATMENT|1973-05-30|
TRIAL STUDY 134XCP|TR|8C86A799-2717-46E8-99C2-76D11AAB54D7|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||LOG10 COPIES/ML|FURTHER ENLARGEMENT||MMOL/KG|NOT DONE|||ENDPOINT DILUTION ASSAY|N|Y|FRIEND|RADIOLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1965-05-11|
TRIAL STUDY 134XCP|TR|8C86A799-2717-46E8-99C2-76D11AAB54D7|4||||||SUMDIAM|SUM OF DIAMETER||MS/MMHG|ENLARGEMENT||10^9 CFU/ML|NOT DONE|||WHOLE GENOME SEQUENCING|NA|NA|CHILD|DERMATOLOGIST|NA|4||88||WASHOUT|1960-07-10|
TRIAL STUDY 134XCP|TR|8C86A799-2717-46E8-99C2-76D11AAB54D7|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||TRANSDUCING UNIT|NON-PATHOLOGICAL||MG/DAY|NOT DONE|||TRICHROME STAIN|N|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|5||7||BASELINE|1961-11-05|
TRIAL STUDY 134XCP|TR|727807A8-A180-4589-A553-E3C82E1D3CF2|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||WAFER|ABSENT||IU|NOT DONE|||CISH|N|NA|SPOUSE|MICROSCOPIST 3|N|1||38||OPEN LABEL TREATMENT|1966-02-03|
TRIAL STUDY 134XCP|TR|727807A8-A180-4589-A553-E3C82E1D3CF2|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||APS U|DIFFUSELY INCREASED||USEC|NOT DONE|||POLYGRAPHY|Y|NA|VENDOR|CLINICAL PATHOLOGIST|Y|2||58||SCREENING|1961-05-06|
TRIAL STUDY 134XCP|TR|727807A8-A180-4589-A553-E3C82E1D3CF2|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||U/CL|NON-PATHOLOGICAL||MANSON U/ML|NOT DONE|||DIGITAL PCR|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|3||39||TREATMENT|1961-04-17|
TRIAL STUDY 134XCP|TR|727807A8-A180-4589-A553-E3C82E1D3CF2|4||||||LMBFLIND|LIMB FAILURE INDICATOR||CGY|FOCALLY INCREASED||BEATS/MIN|NOT DONE|||POPULATION SEQUENCING|NA|NA|INDEPENDENT ASSESSOR|ONCOLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1972-07-10|
TRIAL STUDY 134XCP|TR|727807A8-A180-4589-A553-E3C82E1D3CF2|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||PM|PALPABLE||CM H2O|NOT DONE|||TEST STRIP|U|NA|GUARDIAN|ADJUDICATOR 3|U|5||7||OPEN LABEL TREATMENT|1960-12-11|
TRIAL STUDY 134XCP|TR|BFFB5321-5FC7-4465-8579-D75865306359|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PFU/DOSE|NORMAL||10^8/L|NOT DONE|||GRADIENT DIFFUSION|NA|N|PARENT|PHYSIOTHERAPIST|Y|1||38||BLINDED TREATMENT|1961-02-15|
TRIAL STUDY 134XCP|TR|BFFB5321-5FC7-4465-8579-D75865306359|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||KUSP|PATHOLOGICAL||LM|NOT DONE|||SMEAR|Y|Y|FRIEND|DERMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1973-04-19|
TRIAL STUDY 134XCP|TR|BFFB5321-5FC7-4465-8579-D75865306359|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||UMOL/L/SEC|ENLARGEMENT||COPIES/UG|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|N|Y|ADJUDICATOR|ONCOLOGIST 2|N|3||39||RUN-IN|1966-10-30|
TRIAL STUDY 134XCP|TR|BFFB5321-5FC7-4465-8579-D75865306359|4||||||VOLUME|VOLUME||PACK YEAR|UNEQUIVOCAL||L/H/M2|NOT DONE|||PHYSICAL EXAMINATION|NA|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|4||88||CONTINUATION TREATMENT|1968-07-07|
TRIAL STUDY 134XCP|TR|BFFB5321-5FC7-4465-8579-D75865306359|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||%/MIN|DECREASED||MEQ/L|NOT DONE|||MECHANICAL CLOT DETECTION|NA|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||BASELINE|1968-11-21|
TRIAL STUDY 134XCP|TR|12F9A745-F76D-4222-B37E-22AF93981ECE|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||UG/MOL|UNCHANGED||LOG EID 50/DOSE|NOT DONE|||WHOLE EXOME SEQUENCING|NA|NA|ADJUDICATOR|MICROSCOPIST 2|NA|1||38||RUN-IN|1967-05-14|
TRIAL STUDY 134XCP|TR|12F9A745-F76D-4222-B37E-22AF93981ECE|2||||||ORVERLN|ORGAN VERTICAL LENGTH||MM/SEC|FURTHER ENLARGEMENT FROM NADIR||KG/L|NOT DONE|||PALPATION|Y|NA|CLINICAL RESEARCH ASSOCIATE|RATER|U|2||58||OBSERVATION|1962-05-15|
TRIAL STUDY 134XCP|TR|12F9A745-F76D-4222-B37E-22AF93981ECE|3||||||NEWCONF|NEW TUMOR CONFIRMED||USEC|ENLARGEMENT FROM NADIR||APL U/ML|NOT DONE|||EIA|U|U|VENDOR|PHYSIOTHERAPIST|Y|3||39||OPEN LABEL TREATMENT|1969-12-06|
TRIAL STUDY 134XCP|TR|12F9A745-F76D-4222-B37E-22AF93981ECE|4||||||RADIODEN|RADIODENSITY||10^9 CFU/ML|TUMOR MERGED||KG/M2|NOT DONE|||DIFFUSION WEIGHTED MRI|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|4||88||OBSERVATION|1965-09-11|
TRIAL STUDY 134XCP|TR|12F9A745-F76D-4222-B37E-22AF93981ECE|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||AMU|EQUIVOCAL||MEQ/G|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|5||7||RUN-IN|1968-07-24|
TRIAL STUDY 134XCP|TR|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^3 COPIES/ML|UNEQUIVOCAL||IU/DL|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|U|NA|PROXY|RADIOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1968-12-30|
TRIAL STUDY 134XCP|TR|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MPA|PALPABLE||KDA|NOT DONE|||MRI WITHOUT CONTRAST|NA|Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|2||58||WASHOUT|1963-11-15|
TRIAL STUDY 134XCP|TR|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||U/MG|FURTHER ENLARGEMENT FROM NADIR||BQ/KG|NOT DONE|||SMEAR|NA|U|INVESTIGATOR|RADIOLOGIST|N|3||39||FOLLOW-UP|1966-05-30|
TRIAL STUDY 134XCP|TR|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||ANTIBODY UNIT|NONPALPABLE||PIXEL|NOT DONE|||FUNCTIONAL MRI|U|N|CAREGIVER|RADIOLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1968-01-03|
TRIAL STUDY 134XCP|TR|BA8BF93F-ECC0-4EE9-A5C0-554DC9A0D297|5||||||LNSTATE|LYMPH NODE STATE||DAYS/MONTH|TUMOR MERGED||MEQ/DAY|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|U|NA|GUARDIAN|OTOLARYNGOLOGIST|NA|5||7||OBSERVATION|1966-02-06|
TRIAL STUDY 134XCP|TR|37693A38-D8A0-4313-A4D1-56E282579636|1||||||ORSTATE|ORGAN STATE||MG/M2/DAY|FURTHER ENLARGEMENT||10^6/EJACULATE U|NOT DONE|||MS/MS|NA|Y|SIBLING|OPTOMETRIST|N|1||38||OPEN LABEL TREATMENT|1965-12-04|
TRIAL STUDY 134XCP|TR|37693A38-D8A0-4313-A4D1-56E282579636|2||||||VSLPIND|VESSEL PATENCY INDICATOR||MMOL/MOL|PALPABLE||UL|NOT DONE|||BIOPSY|U|U|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|2||58||CONTINUATION TREATMENT|1973-01-27|
TRIAL STUDY 134XCP|TR|37693A38-D8A0-4313-A4D1-56E282579636|3||||||VOLUME|VOLUME||FRAMES/S|PRESENT||LOG10 CFU/ML|NOT DONE|||NUCLEIC ACID BASED METHOD|Y|U|PARENT|OTOLARYNGOLOGIST|N|3||39||INDUCTION TREATMENT|1965-03-22|
TRIAL STUDY 134XCP|TR|37693A38-D8A0-4313-A4D1-56E282579636|4||||||VOLUME|VOLUME||PT_US|FOCALLY INCREASED||DB|NOT DONE|||COMPLEMENT FIXATION|NA|N|INVESTIGATOR|RADIOLOGIST 2|Y|4||88||SCREENING|1972-12-29|
TRIAL STUDY 134XCP|TR|37693A38-D8A0-4313-A4D1-56E282579636|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||U/KG/DAY|FURTHER ENLARGEMENT||ML/MMHG/MIN/L|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|U|U|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1964-05-26|
TRIAL STUDY 134XCP|TR|5C48E0BB-FD52-47F5-8759-6126ECB47B80|1||||||SUMDIAM|SUM OF DIAMETER||IU/KG|NON-PATHOLOGICAL||TRACE|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|U|DOMESTIC PARTNER|READER|N|1||38||SCREENING|1969-12-30|
TRIAL STUDY 134XCP|TR|5C48E0BB-FD52-47F5-8759-6126ECB47B80|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PPTR|ENLARGEMENT FROM NADIR||NEEDLE GAUGE|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|U|NA|FAMILY MEMBER|ADJUDICATOR 3|Y|2||58||SCREENING|1972-03-09|
TRIAL STUDY 134XCP|TR|5C48E0BB-FD52-47F5-8759-6126ECB47B80|3||||||NEWCONF|NEW TUMOR CONFIRMED||10^9/DOSE|PATHOLOGICAL||V|NOT DONE|||MICROBIAL CONCENTRATION|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|3||39||CONTINUATION TREATMENT|1968-09-04|
TRIAL STUDY 134XCP|TR|5C48E0BB-FD52-47F5-8759-6126ECB47B80|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||BEATS/MIN|NONPALPABLE||MMOL/KG|NOT DONE|||FLUORESCENT ENZYME IMMUNOASSAY|NA|N|VENDOR|INTERNIST|Y|4||88||BASELINE|1962-09-05|
TRIAL STUDY 134XCP|TR|5C48E0BB-FD52-47F5-8759-6126ECB47B80|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||CI/UL|PRESENT||ML/M2|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|U|NA|GUARDIAN|CARDIOLOGIST|N|5||7||INDUCTION TREATMENT|1965-06-04|
TRIAL STUDY 134XCP|TR|5B420A5A-DB2C-48D2-8E9B-97639F49F182|1||||||LDIAM|LONGEST DIAMETER||MEQ/ML|PALPABLE||APL U/ML|NOT DONE|||GRAM STAIN|N|N|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1973-03-29|
TRIAL STUDY 134XCP|TR|5B420A5A-DB2C-48D2-8E9B-97639F49F182|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||ML/SEC/1.73M2|FURTHER ENLARGEMENT FROM NADIR||UM/DAY|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|NA|NA|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2||58||CONTINUATION TREATMENT|1963-01-20|
TRIAL STUDY 134XCP|TR|5B420A5A-DB2C-48D2-8E9B-97639F49F182|3||||||LNSTATE|LYMPH NODE STATE||/10^3|UNEQUIVOCAL||10^9/G|NOT DONE|||PULMONARY ANGIOGRAPHY|Y|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|3||39||WASHOUT|1972-11-06|
TRIAL STUDY 134XCP|TR|5B420A5A-DB2C-48D2-8E9B-97639F49F182|4||||||SUMDIAM|SUM OF DIAMETER||ML/MMHG/MIN/L|UNCHANGED||G/G|NOT DONE|||IODINE STAIN|NA|Y|GUARDIAN|ADJUDICATOR|N|4||88||CONTINUATION TREATMENT|1960-03-12|
TRIAL STUDY 134XCP|TR|5B420A5A-DB2C-48D2-8E9B-97639F49F182|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CAPFUL|ENLARGEMENT||10^12/L|NOT DONE|||IVY INCISION METHOD|U|NA|NON-HEALTH CARE PROFESSIONAL|RATER|U|5||7||BLINDED TREATMENT|1963-02-10|
TRIAL STUDY 134XCP|TR|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||ML/KG|NON-PATHOLOGICAL||10^3 ORGANISMS/G|NOT DONE|||PAP STAIN|U|U|DOMESTIC PARTNER|READER 2|NA|1||38||OBSERVATION|1966-09-01|
TRIAL STUDY 134XCP|TR|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/MIN/1.73M2|PRESENT||NEEDLE GAUGE|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|Y|SIGNIFICANT OTHER|RATER 1|U|2||58||LONG-TERM FOLLOW-UP|1960-05-01|
TRIAL STUDY 134XCP|TR|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||TRANSDUCING UNIT|PATHOLOGICAL||UG/CM2|NOT DONE|||GIEMSA STAIN|Y|N|FRIEND|ADJUDICATOR 3|N|3||39||BASELINE|1965-04-20|
TRIAL STUDY 134XCP|TR|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NGEQ/L|PATHOLOGICAL||G/U|NOT DONE|||PERIODIC ACID SCHIFF STAIN|U|U|PARENT|RATER 2|U|4||88||FOLLOW-UP|1967-07-03|
TRIAL STUDY 134XCP|TR|F21F3E77-82CF-44D8-AE5A-FAC04EACD019|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||FT2|ABSENT||/CMH2O|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|N|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1969-10-07|
TRIAL STUDY 134XCP|TR|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|1||||||VDIAM|VIABLE DIAMETER||G/M2|INCREASED||DAMOL/L|NOT DONE|||DOUBLE IMMUNODIFFUSION|U|Y|PROXY|RADIOLOGIST 2|NA|1||38||WASHOUT|1970-03-17|
TRIAL STUDY 134XCP|TR|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|2||||||VDIAM|VIABLE DIAMETER||NU/CL|NORMAL||NMOL|NOT DONE|||CONTRAST ENHANCED CT SCAN|Y|Y|SPOUSE|READER|Y|2||58||FOLLOW-UP|1973-07-28|
TRIAL STUDY 134XCP|TR|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ML/M2/DAY|ABSENT||10^6/G|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|Y|CHILD|ONCOLOGIST 1|U|3||39||CONTINUATION TREATMENT|1971-09-02|
TRIAL STUDY 134XCP|TR|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||RNA COPIES/ML|UNCHANGED||KHZ|NOT DONE|||NEPHELOMETRY|U|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|Y|4||88||WASHOUT|1963-07-18|
TRIAL STUDY 134XCP|TR|6AB33EBF-5C5B-4040-9A18-0AF864BC490F|5||||||PALPSTAT|PALPABLE STATE||10^7 TCID 50/DOSE|INCREASED||NMOL BCE/MMOL|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|Y|Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||RUN-IN|1968-06-09|
TRIAL STUDY 134XCP|TR|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||DL|FURTHER ENLARGEMENT||BAU|NOT DONE|||FLUOROSCOPY|NA|NA|SPOUSE|RADIOLOGIST 2|Y|1||38||RUN-IN|1972-10-02|
TRIAL STUDY 134XCP|TR|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|2||||||TUMSTATE|TUMOR STATE||ML/BEAT|TUMOR MERGED||OSM|NOT DONE|||BIOPSY|U|N|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1967-07-19|
TRIAL STUDY 134XCP|TR|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|3||||||SUMDIAM|SUM OF DIAMETER||NMOL/G|NORMAL||UV*SEC|NOT DONE|||HPLC|NA|N|CLINICAL STUDY SPONSOR|ONCOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1961-12-08|
TRIAL STUDY 134XCP|TR|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||WATT|ENLARGEMENT||CAN|NOT DONE|||MACRO BROTH DILUTION|N|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|4||88||SCREENING|1972-08-27|
TRIAL STUDY 134XCP|TR|0D4B685D-9C50-416C-B5B3-A17B7653AAEB|5||||||LESFLIND|LESION FAILURE INDICATOR||10^10/L|FOCALLY INCREASED||DROP|NOT DONE|||SANGER SEQUENCING|NA|NA|STUDY SUBJECT|INTERNIST|U|5||7||INDUCTION TREATMENT|1968-11-20|
TRIAL STUDY 134XCP|TR|9B95CE9F-E755-463A-92EC-07A55EE8A58F|1||||||ORVERLN|ORGAN VERTICAL LENGTH||MGEQ|FURTHER ENLARGEMENT FROM NADIR||UU/L|NOT DONE|||ELLA|NA|N|CLINICAL STUDY SPONSOR|DERMATOLOGIST|N|1||38||OPEN LABEL TREATMENT|1973-05-24|
TRIAL STUDY 134XCP|TR|9B95CE9F-E755-463A-92EC-07A55EE8A58F|2||||||SUMVOL|SUM OF VOLUME||10^9 CFU|ENLARGEMENT FROM NADIR||ML/M2/DAY|NOT DONE|||SURFACE PLASMON RESONANCE|N|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|2||58||OBSERVATION|1967-07-08|
TRIAL STUDY 134XCP|TR|9B95CE9F-E755-463A-92EC-07A55EE8A58F|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||CAPFUL|ABSENT||LOG10 CCID 50/DOSE|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|U|FAMILY MEMBER|PATHOLOGIST|NA|3||39||BLINDED TREATMENT|1967-04-21|
TRIAL STUDY 134XCP|TR|9B95CE9F-E755-463A-92EC-07A55EE8A58F|4||||||NEWCONF|NEW TUMOR CONFIRMED||MG/M2/DAY|PALPABLE||EID 50/DOSE|NOT DONE|||IRON HEMATOXYLIN STAIN|U|Y|SIGNIFICANT OTHER|RADIOLOGIST|NA|4||88||OBSERVATION|1973-04-29|
TRIAL STUDY 134XCP|TR|9B95CE9F-E755-463A-92EC-07A55EE8A58F|5||||||DIAMETER|DIAMETER||MMOL/DAY|EQUIVOCAL||NMOL/DAY|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|N|NA|FAMILY MEMBER|RATER 1|N|5||7||OBSERVATION|1968-08-05|
TRIAL STUDY 134XCP|TR|ED388A78-3B06-4529-861A-0174E7F345C2|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MG/G/H|NONPALPABLE||NMOL/DAY|NOT DONE|||CRYOSCOPY|U|U|SIBLING|NEUROLOGIST 2|U|1||38||RUN-IN|1972-11-27|
TRIAL STUDY 134XCP|TR|ED388A78-3B06-4529-861A-0174E7F345C2|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^9 CFU/ML|UNEQUIVOCAL||BQ/ML|NOT DONE|||ISHIHARA COLOR PLATES|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1972-01-09|
TRIAL STUDY 134XCP|TR|ED388A78-3B06-4529-861A-0174E7F345C2|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||U/KG/DAY|TUMOR MERGED||DNA COPIES/ML|NOT DONE|||SEQUENCING|NA|U|VENDOR|MICROSCOPIST 3|N|3||39||WASHOUT|1971-04-08|
TRIAL STUDY 134XCP|TR|ED388A78-3B06-4529-861A-0174E7F345C2|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||FINGERTIP UNIT|DIFFUSELY INCREASED||MPH|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|N|N|INVESTIGATOR|ADJUDICATOR|N|4||88||FOLLOW-UP|1971-01-27|
TRIAL STUDY 134XCP|TR|ED388A78-3B06-4529-861A-0174E7F345C2|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||CAPFUL|NONPALPABLE||PFU/DOSE|NOT DONE|||TARGETED GENOME SEQUENCING|Y|Y|CAREGIVER|READER 3|U|5||7||OPEN LABEL TREATMENT|1962-12-11|
TRIAL STUDY 134XCP|TR|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|1||||||TUMSTATE|TUMOR STATE||IU/DAY|DECREASED||NKAT|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|Y|NA|FRIEND|OPHTHALMOLOGIST|N|1||38||WASHOUT|1968-05-30|
TRIAL STUDY 134XCP|TR|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MMOL/MIN/KPA|NORMAL||MG/KG/DAY|NOT DONE|||LC-FL|NA|NA|ADJUDICATOR|PATHOLOGIST 1|NA|2||58||OPEN LABEL TREATMENT|1969-05-17|
TRIAL STUDY 134XCP|TR|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||PL|EQUIVOCAL||FT3|NOT DONE|||MYELOPEROXIDASE STAIN|N|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3||39||CONTINUATION TREATMENT|1969-03-08|
TRIAL STUDY 134XCP|TR|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|4||||||SUMDIAM|SUM OF DIAMETER||ENZYME U|PALPABLE||ML/MIN/MMHG|NOT DONE|||WEBER GREEN STAIN|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|4||88||OBSERVATION|1969-07-27|
TRIAL STUDY 134XCP|TR|F73DB6D9-A860-4250-ABF8-017C4E62FCFA|5||||||SUMVOL|SUM OF VOLUME||NL|FURTHER ENLARGEMENT FROM NADIR||10^3 ORGANISMS/G|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|NA|CAREGIVER|RATER 1|Y|5||7||SCREENING|1961-09-11|
TRIAL STUDY 134XCP|TR|172AB680-362D-488C-9DF1-E1C8E386980D|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||PACK|FURTHER ENLARGEMENT FROM NADIR||DROP|NOT DONE|||MICROBIAL CULTURE, SOLID|N|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|1||38||OBSERVATION|1969-11-27|
TRIAL STUDY 134XCP|TR|172AB680-362D-488C-9DF1-E1C8E386980D|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||10^6/L|TUMOR MERGED||GBQ|NOT DONE|||PERFUSION MRI|NA|NA|FAMILY MEMBER|RADIOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1968-07-07|
TRIAL STUDY 134XCP|TR|172AB680-362D-488C-9DF1-E1C8E386980D|3||||||PALPSTAT|PALPABLE STATE||NMOL BCE/MMOL|UNEQUIVOCAL||HZ/S|NOT DONE|||DUKE INCISION METHOD|U|Y|INTERVIEWER|PATHOLOGIST|U|3||39||CONTINUATION TREATMENT|1962-03-08|
TRIAL STUDY 134XCP|TR|172AB680-362D-488C-9DF1-E1C8E386980D|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MMOL/DAY|PATHOLOGICAL||ML/G/H|NOT DONE|||DYNAMIC LIGHT SCATTERING|U|U|SPOUSE|MICROSCOPIST 1|NA|4||88||OPEN LABEL TREATMENT|1971-08-28|
TRIAL STUDY 134XCP|TR|172AB680-362D-488C-9DF1-E1C8E386980D|5||||||BNLNUM|NUMBER OF BONE LESIONS||AMOL|DIFFUSELY INCREASED||KS|NOT DONE|||FLOCCULATION|NA|NA|FRIEND|CLINICAL PATHOLOGIST|Y|5||7||CONTINUATION TREATMENT|1964-12-09|
TRIAL STUDY 134XCP|TR|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||FARAD|ABSENT||/40 HPFS|NOT DONE|||DARK FIELD MICROSCOPY|Y|NA|ADJUDICATOR|READER 3|Y|1||38||CONTINUATION TREATMENT|1963-01-25|
TRIAL STUDY 134XCP|TR|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|2||||||RADIODEN|RADIODENSITY||NKAT|FURTHER ENLARGEMENT FROM NADIR||DL|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|U|DOMESTIC PARTNER|NEUROLOGIST 1|Y|2||58||LONG-TERM FOLLOW-UP|1964-07-24|
TRIAL STUDY 134XCP|TR|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||10^11/L|UNEQUIVOCAL||NMOL BCE/MMOL|NOT DONE|||OPTICAL MAPPING|Y|Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||CONTINUATION TREATMENT|1961-08-13|
TRIAL STUDY 134XCP|TR|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||KUSP|FOCALLY INCREASED||COPIES/ML|NOT DONE|||FLUORESCENT SPOT TEST|Y|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1962-05-01|
TRIAL STUDY 134XCP|TR|833FAF15-E8F8-47C9-AA1A-1454DC00FA78|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||G/M2/DAY|PATHOLOGICAL||STRIP|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|N|NA|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|5||7||OPEN LABEL TREATMENT|1969-08-13|
TRIAL STUDY 134XCP|TR|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|1||||||CALCFIND|CALCIFICATION INDICATOR||ML/M2/DAY|INCREASED||/MBP|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|N|Y|STUDY SUBJECT|NEUROLOGIST 1|U|1||38||SCREENING|1961-07-31|
TRIAL STUDY 134XCP|TR|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||TITER|UNEQUIVOCAL||G/CAGE/WK|NOT DONE|||PHOROPTER|N|Y|PROXY|OTOLARYNGOLOGIST|U|2||58||CONTINUATION TREATMENT|1963-11-08|
TRIAL STUDY 134XCP|TR|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||GLOBULE|UNCHANGED||PKAT/L|NOT DONE|||PULSE OXIMETRY|U|NA|PARENT|ENDOCRINOLOGIST|U|3||39||OBSERVATION|1965-10-27|
TRIAL STUDY 134XCP|TR|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||TSP|ABSENT||GENEQ|NOT DONE|||IMMUNO-PET SCAN|Y|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|4||88||LONG-TERM FOLLOW-UP|1966-03-05|
TRIAL STUDY 134XCP|TR|8317AFA6-2E45-4B5B-AFE9-31AE86761BAC|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||DNA COPIES/UG|TUMOR MERGED||10^11/L|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|Y|N|INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|5||7||SCREENING|1961-12-01|
TRIAL STUDY 134XCP|TR|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|1||||||LESFLIND|LESION FAILURE INDICATOR||L/MIN/M2|ENLARGEMENT FROM NADIR||NEWTON|NOT DONE|||CONGO RED STAIN|NA|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|1||38||RUN-IN|1963-12-30|
TRIAL STUDY 134XCP|TR|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||U/10^12 RBC|ABSENT||10^5/L|NOT DONE|||PANENDOSCOPY|U|N|FRIEND|INTERNIST|NA|2||58||OPEN LABEL TREATMENT|1963-04-10|
TRIAL STUDY 134XCP|TR|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||AGU/ML|ENLARGEMENT FROM NADIR||MMAL|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|N|SIGNIFICANT OTHER|RATER 1|U|3||39||BLINDED TREATMENT|1972-02-20|
TRIAL STUDY 134XCP|TR|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ML/G/DAY|PRESENT||MDFI|NOT DONE|||KINYOUN STAIN|N|Y|DOMESTIC PARTNER|OPTOMETRIST|Y|4||88||LONG-TERM FOLLOW-UP|1968-05-16|
TRIAL STUDY 134XCP|TR|9C06CFC3-5D87-4717-89D0-172EA17ABDAB|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||GENEQ|NONPALPABLE||HR/DAY|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|NA|INTERVIEWER|DERMATOLOGIST|N|5||7||BLINDED TREATMENT|1968-03-24|
TRIAL STUDY 134XCP|TR|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||IU/MG|PRESENT||PMOL/10^9 CELLS|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|Y|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||WASHOUT|1965-07-15|
TRIAL STUDY 134XCP|TR|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|2||||||ORSTATE|ORGAN STATE||IU/G|ENLARGEMENT||MM|NOT DONE|||PULSE OXIMETRY|N|Y|FRIEND|NEUROLOGIST|NA|2||58||OBSERVATION|1961-02-07|
TRIAL STUDY 134XCP|TR|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||CYLINDER|PATHOLOGICAL||UMOL/L|NOT DONE|||CLINICAL EVALUATION|N|N|PARENT|PATHOLOGIST|N|3||39||SCREENING|1962-05-03|
TRIAL STUDY 134XCP|TR|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML*CMH2O|UNCHANGED||G/ANIMAL/WK|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|Y|U|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|4||88||OBSERVATION|1961-11-13|
TRIAL STUDY 134XCP|TR|AE7EAB81-A12F-4135-A64A-E89CD55E0AFE|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MPL U/ML|ENLARGEMENT FROM NADIR||FMOL|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|N|NA|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|NA|5||7||BLINDED TREATMENT|1971-12-07|
TRIAL STUDY 134XCP|TR|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||L/S|UNCHANGED||UL|NOT DONE|||DUCTOGRAPHY|U|N|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|1||38||BLINDED TREATMENT|1970-08-10|
TRIAL STUDY 134XCP|TR|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||VOXEL|EQUIVOCAL||DRINK|NOT DONE|||MICROBIAL CONCENTRATION|NA|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|2||58||INDUCTION TREATMENT|1966-02-14|
TRIAL STUDY 134XCP|TR|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||V/SEC|FURTHER ENLARGEMENT||MG/L FEU|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|N|CLINICAL RESEARCH COORDINATOR|READER 3|N|3||39||BASELINE|1961-07-11|
TRIAL STUDY 134XCP|TR|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||YEARS|PATHOLOGICAL||MASK|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|Y|Y|SPOUSE|PEDIATRIC NEUROLOGIST|N|4||88||OBSERVATION|1971-05-16|
TRIAL STUDY 134XCP|TR|2DF1D841-0B0E-477D-A73E-BE3F73F0DDA3|5||||||VDIAM|VIABLE DIAMETER||10^6/HPF|ENLARGEMENT FROM NADIR||MNFI|NOT DONE|||IMMUNOCHROMATOGRAPHY|U|Y|INTERVIEWER|READER 1|Y|5||7||TREATMENT|1965-01-21|
TRIAL STUDY 134XCP|TR|740D80F1-8BD5-4409-8087-E48F94363362|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||HOMEOPATHIC DILUTION|FURTHER ENLARGEMENT||G/U|NOT DONE|||CONTRAST ENHANCED X-RAY|NA|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1||38||BLINDED TREATMENT|1960-08-03|
TRIAL STUDY 134XCP|TR|740D80F1-8BD5-4409-8087-E48F94363362|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MEQ|EQUIVOCAL||FEU|NOT DONE|||ELECTROPHORESIS|U|NA|INVESTIGATOR|NEUROLOGIST 2|U|2||58||WASHOUT|1967-02-25|
TRIAL STUDY 134XCP|TR|740D80F1-8BD5-4409-8087-E48F94363362|3||||||LPERP|LONGEST PERPENDICULAR||M/SEC|UNCHANGED||MEQ/G|NOT DONE|||FLUOROSCOPY|N|NA|DOMESTIC PARTNER|CARDIOLOGIST|Y|3||39||RUN-IN|1967-04-29|
TRIAL STUDY 134XCP|TR|740D80F1-8BD5-4409-8087-E48F94363362|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||UEQ|TUMOR MERGED||V/V|NOT DONE|||FLUORIMETRY|N|Y|INVESTIGATOR|OPTOMETRIST|NA|4||88||CONTINUATION TREATMENT|1970-11-22|
TRIAL STUDY 134XCP|TR|740D80F1-8BD5-4409-8087-E48F94363362|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KEV|INCREASED||KHZ|NOT DONE|||HIGH RESOLUTION MELT ANALYSIS|Y|NA|ADJUDICATION COMMITTEE|ONCOLOGIST|NA|5||7||WASHOUT|1969-01-24|
TRIAL STUDY 134XCP|TR|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|1||||||AREA|AREA||UIU/DL|UNCHANGED||UL|NOT DONE|||PHASE CONTRAST MICROSCOPY|U|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|1||38||SCREENING|1967-09-03|
TRIAL STUDY 134XCP|TR|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||JOULE|TUMOR MERGED||MM/H|NOT DONE|||SPIROMETRY|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|2||58||FOLLOW-UP|1973-08-08|
TRIAL STUDY 134XCP|TR|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|3||||||ORVERLN|ORGAN VERTICAL LENGTH||SPRAY|PALPABLE||10^9/G|NOT DONE|||HPLC-FL|Y|U|CLINICAL STUDY SPONSOR|RATER 1|Y|3||39||RUN-IN|1963-01-23|
TRIAL STUDY 134XCP|TR|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UM/DAY|NON-PATHOLOGICAL||V/V|NOT DONE|||REBOUND TONOMETRY|N|Y|GUARDIAN|MICROSCOPIST|Y|4||88||BASELINE|1962-08-24|
TRIAL STUDY 134XCP|TR|39FB0A16-25B8-4D51-B9F5-9ADACCEF6A87|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||L/MIN/M2|PRESENT||TABLET|NOT DONE|||CINEANGIOGRAPHY|N|N|INTERVIEWER|RADIOLOGIST 1|Y|5||7||TREATMENT|1968-07-29|
TRIAL STUDY 134XCP|TR|12AD3838-F986-4A27-8AEE-59C387988B0F|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||DPM/100MG|ABSENT||L/KG|NOT DONE|||DYNAMOMETRY|NA|U|SPOUSE|READER 2|Y|1||38||LONG-TERM FOLLOW-UP|1963-11-26|
TRIAL STUDY 134XCP|TR|12AD3838-F986-4A27-8AEE-59C387988B0F|2||||||PALPSTAT|PALPABLE STATE||L/S/KPA|PATHOLOGICAL||IU/MMOL|NOT DONE|||TONOMETRY|Y|N|FRIEND|RATER|NA|2||58||BASELINE|1960-05-27|
TRIAL STUDY 134XCP|TR|12AD3838-F986-4A27-8AEE-59C387988B0F|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||GMFI|EQUIVOCAL||/500 WBC|NOT DONE|||LISSAMINE GREEN STAIN|Y|U|ADJUDICATOR|ADJUDICATOR|Y|3||39||OBSERVATION|1965-05-24|
TRIAL STUDY 134XCP|TR|12AD3838-F986-4A27-8AEE-59C387988B0F|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||LX|ABSENT||DISK|NOT DONE|||MULTIPLE BREATH WASHOUT|NA|NA|FAMILY MEMBER|PATHOLOGIST|N|4||88||INDUCTION TREATMENT|1962-06-29|
TRIAL STUDY 134XCP|TR|12AD3838-F986-4A27-8AEE-59C387988B0F|5||||||SUMDIAM|SUM OF DIAMETER||%(W/W)|NORMAL||10^9/DOSE|NOT DONE|||ANGIOGRAPHY|N|U|CHILD|NEUROLOGIST|U|5||7||OBSERVATION|1960-03-02|
TRIAL STUDY 134XCP|TR|441F1A21-6350-478A-9719-75B053182B78|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||OZ|FOCALLY INCREASED||SBE/ML|NOT DONE|||ECHOCARDIOGRAPHY|NA|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|1||38||RUN-IN|1962-09-05|
TRIAL STUDY 134XCP|TR|441F1A21-6350-478A-9719-75B053182B78|2||||||RADIODEN|RADIODENSITY||L/H/M2|UNEQUIVOCAL||SV|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|NA|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|2||58||RUN-IN|1960-05-08|
TRIAL STUDY 134XCP|TR|441F1A21-6350-478A-9719-75B053182B78|3||||||LPERP|LONGEST PERPENDICULAR||PT_US|ENLARGEMENT||NG/DAY|NOT DONE|||PELLI-ROBSON EYE CHART|U|N|GUARDIAN|UROLOGIST|U|3||39||RUN-IN|1961-10-31|
TRIAL STUDY 134XCP|TR|441F1A21-6350-478A-9719-75B053182B78|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||IU/MMOL|UNCHANGED||MG/H|NOT DONE|||HPLC/IEX|N|N|CHILD|READER|U|4||88||WASHOUT|1972-11-10|
TRIAL STUDY 134XCP|TR|441F1A21-6350-478A-9719-75B053182B78|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||10^8 PFU|PALPABLE||MG/M2/H|NOT DONE|||ELECTROMYOGRAPHY|Y|Y|ADJUDICATOR|CARDIOLOGIST|N|5||7||FOLLOW-UP|1961-12-06|
TRIAL STUDY 134XCP|TR|A69520E2-01A5-4CBC-AFC9-00324531779F|1||||||VSLPIND|VESSEL PATENCY INDICATOR||APL U|ABSENT||/WK|NOT DONE|||DIRECT SEQUENCING|N|N|NON-HEALTH CARE PROFESSIONAL|READER 2|U|1||38||CONTINUATION TREATMENT|1968-06-24|
TRIAL STUDY 134XCP|TR|A69520E2-01A5-4CBC-AFC9-00324531779F|2||||||DIAMETER|DIAMETER||VG/ML|UNEQUIVOCAL||GPL U|NOT DONE|||HIGH RESOLUTION CT|N|N|VENDOR|ONCOLOGIST 2|Y|2||58||FOLLOW-UP|1973-07-17|
TRIAL STUDY 134XCP|TR|A69520E2-01A5-4CBC-AFC9-00324531779F|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||TRACE|NONPALPABLE||DPM/0.5 ML|NOT DONE|||IMMUNOCHROMATOGRAPHY|N|N|CAREGIVER|MICROSCOPIST 1|Y|3||39||OPEN LABEL TREATMENT|1968-09-25|
TRIAL STUDY 134XCP|TR|A69520E2-01A5-4CBC-AFC9-00324531779F|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||NMOL|EQUIVOCAL||PMOL|NOT DONE|||KARYOTYPING|NA|N|ADJUDICATOR|INTERNIST|NA|4||88||SCREENING|1968-03-04|
TRIAL STUDY 134XCP|TR|A69520E2-01A5-4CBC-AFC9-00324531779F|5||||||LMBFLIND|LIMB FAILURE INDICATOR||MOL|FURTHER ENLARGEMENT||QUANTITY SUFFICIENT|NOT DONE|||INTRAVASCULAR ULTRASOUND|U|N|PARENT|MICROSCOPIST 2|U|5||7||OPEN LABEL TREATMENT|1972-05-13|
TRIAL STUDY 134XCP|TR|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||/VF|UNCHANGED||IU/MMOL|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|U|SIBLING|OTOLARYNGOLOGIST|U|1||38||OBSERVATION|1967-06-03|
TRIAL STUDY 134XCP|TR|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|2||||||RADIODEN|RADIODENSITY||CAPLET|PATHOLOGICAL||10^9/G|NOT DONE|||IRON HEMATOXYLIN STAIN|NA|Y|INTERVIEWER|RATER|N|2||58||LONG-TERM FOLLOW-UP|1961-02-03|
TRIAL STUDY 134XCP|TR|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||AMU|PATHOLOGICAL||UG/M2|NOT DONE|||HANSEL STAIN|U|N|INTERVIEWER|RADIOLOGIST 1|U|3||39||RUN-IN|1967-10-10|
TRIAL STUDY 134XCP|TR|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||CS|TUMOR MERGED||UIU/L|NOT DONE|||IMMUNOASSAY|U|NA|STUDY SUBJECT|NEUROLOGIST 2|Y|4||88||SCREENING|1967-07-19|
TRIAL STUDY 134XCP|TR|1BCAEE81-9148-4D99-93E7-8B9CC9C9C1E7|5||||||BNLNUM|NUMBER OF BONE LESIONS||NG/L|ABSENT||CM/MIN|NOT DONE|||ICP-MS|N|N|PARENT|ADJUDICATOR|U|5||7||OBSERVATION|1972-02-18|
TRIAL STUDY 134XCP|TR|C361B153-4623-4F03-9D81-8316B1046F35|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||GTT|TUMOR MERGED||MG/G/MIN|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|N|INTERVIEWER|FORENSIC PATHOLOGIST|U|1||38||TREATMENT|1969-02-08|
TRIAL STUDY 134XCP|TR|C361B153-4623-4F03-9D81-8316B1046F35|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||VP/DOSE|PALPABLE||BE/ML|NOT DONE|||GC/MS|NA|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|2||58||TREATMENT|1966-03-16|
TRIAL STUDY 134XCP|TR|C361B153-4623-4F03-9D81-8316B1046F35|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^9/DOSE|DIFFUSELY INCREASED||%(V/V)|NOT DONE|||REVERSE TRANSCRIPTASE PCR|NA|Y|INVESTIGATOR|CARDIOLOGIST|N|3||39||BASELINE|1962-09-20|
TRIAL STUDY 134XCP|TR|C361B153-4623-4F03-9D81-8316B1046F35|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||IU/KG|ABSENT||KN/CM2|NOT DONE|||SINGLE-MOLECULE ARRAY|U|Y|DOMESTIC PARTNER|PATHOLOGIST 2|NA|4||88||WASHOUT|1973-02-02|
TRIAL STUDY 134XCP|TR|C361B153-4623-4F03-9D81-8316B1046F35|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||GPS U|ABSENT||MET|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|NA|NA|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|5||7||BLINDED TREATMENT|1971-08-18|
TRIAL STUDY 134XCP|TR|8FF0A93C-26D1-49E9-853F-B063A958FE1E|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||MOSM/L|ABSENT||MM/2H|NOT DONE|||MACRO BROTH DILUTION|U|U|INVESTIGATOR|ONCOLOGIST|N|1||38||SCREENING|1961-07-09|
TRIAL STUDY 134XCP|TR|8FF0A93C-26D1-49E9-853F-B063A958FE1E|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||U/M2/H|UNEQUIVOCAL||GY/MIN|NOT DONE|||DIFFUSION WEIGHTED MRI|U|Y|GUARDIAN|ADJUDICATOR|NA|2||58||WASHOUT|1965-07-25|
TRIAL STUDY 134XCP|TR|8FF0A93C-26D1-49E9-853F-B063A958FE1E|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MM/H|FOCALLY INCREASED||WATT|NOT DONE|||LIGHT MICROSCOPY|Y|U|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|3||39||FOLLOW-UP|1970-10-19|
TRIAL STUDY 134XCP|TR|8FF0A93C-26D1-49E9-853F-B063A958FE1E|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||U/DL|PATHOLOGICAL||SFC/10^6 PBMC|NOT DONE|||LISSAMINE GREEN STAIN|Y|NA|SIGNIFICANT OTHER|RADIOLOGIST 1|U|4||88||TREATMENT|1960-01-12|
TRIAL STUDY 134XCP|TR|8FF0A93C-26D1-49E9-853F-B063A958FE1E|5||||||ORSTATE|ORGAN STATE||MG/MIN|FURTHER ENLARGEMENT FROM NADIR||MMHG/SEC|NOT DONE|||DARK FIELD MICROSCOPY|NA|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|5||7||OBSERVATION|1962-05-14|
TRIAL STUDY 134XCP|TR|31D8814B-5542-4540-B955-24410D42F1EF|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||10^6 CFU/G|UNCHANGED||ML/MMHG/MIN/L|NOT DONE|||POLYGRAPHY|U|NA|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|1||38||FOLLOW-UP|1961-10-08|
TRIAL STUDY 134XCP|TR|31D8814B-5542-4540-B955-24410D42F1EF|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ELISA UNIT/DOSE|PRESENT||PA|NOT DONE|||DUCTOGRAPHY|N|NA|STUDY SUBJECT|HEMATOLOGIST|NA|2||58||LONG-TERM FOLLOW-UP|1968-03-04|
TRIAL STUDY 134XCP|TR|31D8814B-5542-4540-B955-24410D42F1EF|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MV*MIN|ENLARGEMENT||LOG10 CFU/ML|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|Y|PARENT|RADIOLOGIST 2|N|3||39||FOLLOW-UP|1961-05-05|
TRIAL STUDY 134XCP|TR|31D8814B-5542-4540-B955-24410D42F1EF|4||||||SUMVOL|SUM OF VOLUME||UU/DL|FURTHER ENLARGEMENT FROM NADIR||10^9 ORGANISMS/G|NOT DONE|||PHASE-CONTRAST MRI|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|4||88||OPEN LABEL TREATMENT|1960-04-23|
TRIAL STUDY 134XCP|TR|31D8814B-5542-4540-B955-24410D42F1EF|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MILE|PALPABLE||MG/CM2|NOT DONE|||DYNAMOMETRY|U|N|STUDY SUBJECT|DERMATOLOGIST|Y|5||7||INDUCTION TREATMENT|1968-11-07|
TRIAL STUDY 134XCP|TR|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||VG/DOSE|ENLARGEMENT FROM NADIR||RFU|NOT DONE|||CONTACT SPECULAR MICROSCOPY|NA|U|GUARDIAN|HEMATOLOGIST|NA|1||38||BLINDED TREATMENT|1964-09-19|
TRIAL STUDY 134XCP|TR|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|2||||||RADIODEN|RADIODENSITY||MEQ/UG|FURTHER ENLARGEMENT||CCID 50/ML|NOT DONE|||HEMAGGLUTINATION ASSAY|N|U|SPOUSE|READER 1|NA|2||58||OBSERVATION|1961-02-27|
TRIAL STUDY 134XCP|TR|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|3||||||RADIODEN|RADIODENSITY||10^3 ORGANISMS/ML|FURTHER ENLARGEMENT||MG/DOSE|NOT DONE|||SEQUENCING|U|NA|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|3||39||SCREENING|1961-10-11|
TRIAL STUDY 134XCP|TR|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|4||||||PALPSTAT|PALPABLE STATE||JAR|INCREASED||BQ/G|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|U|N|VENDOR|ONCOLOGIST 2|NA|4||88||TREATMENT|1961-01-20|
TRIAL STUDY 134XCP|TR|F49BC9E7-45A5-4482-AA39-EC49857B2B6A|5||||||ORVERLN|ORGAN VERTICAL LENGTH||MKAT|ENLARGEMENT||/H|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|Y|ADJUDICATOR|ONCOLOGIST 1|N|5||7||SCREENING|1966-04-19|
TRIAL STUDY 134XCP|TR|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|1||||||LDIAM|LONGEST DIAMETER||MMOL2/L2|NONPALPABLE||ML/BREATH|NOT DONE|||DC SHEATH FLOW|Y|NA|CAREGIVER|ONCOLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1963-09-22|
TRIAL STUDY 134XCP|TR|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|2||||||ORSTATE|ORGAN STATE||MMU/ML|FOCALLY INCREASED||U/M2/H|NOT DONE|||HPLC/MS|U|Y|DOMESTIC PARTNER|HEMATOLOGIST|U|2||58||CONTINUATION TREATMENT|1973-04-16|
TRIAL STUDY 134XCP|TR|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|3||||||LDIAM|LONGEST DIAMETER||MPS U|TUMOR MERGED||CMH2O/ML|NOT DONE|||EEG|U|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|3||39||TREATMENT|1970-09-15|
TRIAL STUDY 134XCP|TR|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||10^3 ORGANISMS/G|TUMOR MERGED||UG/KG/DAY|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|N|N|SPOUSE|ENDOCRINOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1969-11-18|
TRIAL STUDY 134XCP|TR|A55BBD57-6AD2-4D49-9377-7CD13BFF800C|5||||||DIAMETER|DIAMETER||MG/ANIMAL|TUMOR MERGED||ML/ANIMAL/WK|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|U|5||7||SCREENING|1968-03-05|
TRIAL STUDY 134XCP|TR|15BFC17A-2F55-441A-AB99-76D270D62367|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||MG/G/H|FURTHER ENLARGEMENT FROM NADIR||IU/DAY|NOT DONE|||DARK FIELD MICROSCOPY|N|NA|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||BLINDED TREATMENT|1971-05-08|
TRIAL STUDY 134XCP|TR|15BFC17A-2F55-441A-AB99-76D270D62367|2||||||LMBFLIND|LIMB FAILURE INDICATOR||EJACULATE U|ENLARGEMENT FROM NADIR||PPB|NOT DONE|||FLUORIMETRY|U|NA|GUARDIAN|ONCOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1961-12-01|
TRIAL STUDY 134XCP|TR|15BFC17A-2F55-441A-AB99-76D270D62367|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MG/MOL|PATHOLOGICAL||10^7 CFU|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|N|U|GUARDIAN|MICROSCOPIST 1|N|3||39||RUN-IN|1969-04-16|
TRIAL STUDY 134XCP|TR|15BFC17A-2F55-441A-AB99-76D270D62367|4||||||BNLNUM|NUMBER OF BONE LESIONS||SACHET|UNCHANGED||MEQ/ML|NOT DONE|||CINEANGIOGRAPHY|Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|4||88||RUN-IN|1969-07-14|
TRIAL STUDY 134XCP|TR|15BFC17A-2F55-441A-AB99-76D270D62367|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CI/ML|FOCALLY INCREASED||ML/CAGE|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|Y|N|SIGNIFICANT OTHER|OPTOMETRIST|N|5||7||RUN-IN|1970-03-24|
TRIAL STUDY 134XCP|TR|CA231D77-1A1F-49F3-8172-06709A1330B7|1||||||LMBFLIND|LIMB FAILURE INDICATOR||M/SEC|EQUIVOCAL||SIEMENS|NOT DONE|||AUTOREFRACTION|NA|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|1||38||BLINDED TREATMENT|1967-09-21|
TRIAL STUDY 134XCP|TR|CA231D77-1A1F-49F3-8172-06709A1330B7|2||||||VSLPIND|VESSEL PATENCY INDICATOR||KBQ/UL|DIFFUSELY INCREASED||MOL/G|NOT DONE|||FLUORESCENT MICROSCOPY|N|NA|INDEPENDENT ASSESSOR|RATER 2|Y|2||58||INDUCTION TREATMENT|1961-10-18|
TRIAL STUDY 134XCP|TR|CA231D77-1A1F-49F3-8172-06709A1330B7|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||DEG|NON-PATHOLOGICAL||MG2/DL2|NOT DONE|||BAC ACGH|NA|N|INVESTIGATOR|READER 2|N|3||39||RUN-IN|1964-07-16|
TRIAL STUDY 134XCP|TR|CA231D77-1A1F-49F3-8172-06709A1330B7|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||BQ/KG|FURTHER ENLARGEMENT FROM NADIR||L/MIN|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|U|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||RUN-IN|1967-04-30|
TRIAL STUDY 134XCP|TR|CA231D77-1A1F-49F3-8172-06709A1330B7|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MG/M2/DAY|PRESENT||MV*MIN|NOT DONE|||CELL BASED BIOASSAY|NA|Y|SIGNIFICANT OTHER|NEUROLOGIST|NA|5||7||OPEN LABEL TREATMENT|1965-06-08|
TRIAL STUDY 134XCP|TR|7A4D6074-E870-40E8-B567-D069BCB7DA9F|1||||||LNSTATE|LYMPH NODE STATE||COULOMB|TUMOR MERGED||PIXELS/IN|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|Y|CAREGIVER|PATHOLOGIST 1|U|1||38||CONTINUATION TREATMENT|1966-05-01|
TRIAL STUDY 134XCP|TR|7A4D6074-E870-40E8-B567-D069BCB7DA9F|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MV/SEC|ABSENT||DRUM|NOT DONE|||BALLPOINT PEN TECHNIQUE|NA|U|SIBLING|INTERNIST|NA|2||58||LONG-TERM FOLLOW-UP|1966-07-30|
TRIAL STUDY 134XCP|TR|7A4D6074-E870-40E8-B567-D069BCB7DA9F|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||IU/DAY|NON-PATHOLOGICAL||10^6 CFU|NOT DONE|||BIOIMPEDANCE SPECTROSCOPY|N|Y|INVESTIGATOR|ONCOLOGIST|U|3||39||TREATMENT|1968-12-31|
TRIAL STUDY 134XCP|TR|7A4D6074-E870-40E8-B567-D069BCB7DA9F|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||/VF|ENLARGEMENT FROM NADIR||HOURS|NOT DONE|||ANTIBIOTIC AGAR SCREEN|NA|U|INVESTIGATOR|CARDIOLOGIST|NA|4||88||TREATMENT|1969-03-12|
TRIAL STUDY 134XCP|TR|7A4D6074-E870-40E8-B567-D069BCB7DA9F|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||EP U|UNCHANGED||UG/L FEU|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1962-04-12|
TRIAL STUDY 134XCP|TR|3DDD2A7E-B955-424B-B485-54E81D0E0699|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||UM/S|UNEQUIVOCAL||ML/KG/DAY|NOT DONE|||RAJI CELL EIA|U|U|ADJUDICATOR|PATHOLOGIST 2|U|1||38||OBSERVATION|1971-04-23|
TRIAL STUDY 134XCP|TR|3DDD2A7E-B955-424B-B485-54E81D0E0699|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MCI/L|EQUIVOCAL||CD|NOT DONE|||SLOAN LETTER EYE CHART 100%|Y|N|STUDY SUBJECT|UROLOGIST|Y|2||58||SCREENING|1963-09-11|
TRIAL STUDY 134XCP|TR|3DDD2A7E-B955-424B-B485-54E81D0E0699|3||||||NEWCONF|NEW TUMOR CONFIRMED||NMOL|FURTHER ENLARGEMENT FROM NADIR||UL/KG/DAY|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|NA|FRIEND|OTOLARYNGOLOGIST|N|3||39||BASELINE|1970-12-08|
TRIAL STUDY 134XCP|TR|3DDD2A7E-B955-424B-B485-54E81D0E0699|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^6 CFU/ML|FOCALLY INCREASED||GPS U|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|N|CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|4||88||TREATMENT|1969-12-31|
TRIAL STUDY 134XCP|TR|3DDD2A7E-B955-424B-B485-54E81D0E0699|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||ANTIBODY UNIT|DIFFUSELY INCREASED||CI/G|NOT DONE|||BALLPOINT PEN TECHNIQUE|N|Y|ADJUDICATION COMMITTEE|INTERNIST|Y|5||7||LONG-TERM FOLLOW-UP|1964-09-17|
TRIAL STUDY 134XCP|TR|D6757E79-3104-468E-BADC-8CCB51BFAE87|1||||||VSLPIND|VESSEL PATENCY INDICATOR||/10^4|NORMAL||MMHG/SEC|NOT DONE|||RAJI CELL EIA|Y|N|HEALTH CARE PROFESSIONAL|RATER|U|1||38||CONTINUATION TREATMENT|1968-01-22|
TRIAL STUDY 134XCP|TR|D6757E79-3104-468E-BADC-8CCB51BFAE87|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||AMOL|NON-PATHOLOGICAL||/LPF|NOT DONE|||DIGITAL PCR|U|Y|CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1961-09-22|
TRIAL STUDY 134XCP|TR|D6757E79-3104-468E-BADC-8CCB51BFAE87|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||VP/ML|NORMAL||NG/MOL|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|U|N|INTERVIEWER|ENDOCRINOLOGIST|N|3||39||BASELINE|1960-02-17|
TRIAL STUDY 134XCP|TR|D6757E79-3104-468E-BADC-8CCB51BFAE87|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||BREATHS/30S|FURTHER ENLARGEMENT FROM NADIR||10^3/HPF|NOT DONE|||RADIOGRAPHY|U|NA|ADJUDICATOR|MICROSCOPIST 2|N|4||88||FOLLOW-UP|1970-05-26|
TRIAL STUDY 134XCP|TR|D6757E79-3104-468E-BADC-8CCB51BFAE87|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||CI/UG|NONPALPABLE||CL|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|NA|NA|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5||7||OBSERVATION|1962-06-05|
TRIAL STUDY 134XCP|TR|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|1||||||VOLUME|VOLUME||NGEQ/L|FOCALLY INCREASED||SYRINGE|NOT DONE|||HPLC|Y|NA|STUDY SUBJECT|PATHOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1960-08-08|
TRIAL STUDY 134XCP|TR|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||FT|NORMAL||CI/ML|NOT DONE|||CALCOFLUOR WHITE STAIN|N|NA|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|2||58||OPEN LABEL TREATMENT|1969-02-13|
TRIAL STUDY 134XCP|TR|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||L/KG|FOCALLY INCREASED||NMOL BCE/L|NOT DONE|||SPECT SCAN|NA|NA|PARENT|OTOLARYNGOLOGIST|N|3||39||RUN-IN|1963-10-18|
TRIAL STUDY 134XCP|TR|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||G/MOL|ABSENT||DPM/100MG|NOT DONE|||FARR ASSAY|NA|Y|SPOUSE|ONCOLOGIST|Y|4||88||TREATMENT|1970-08-29|
TRIAL STUDY 134XCP|TR|1AD25253-DE25-4DB8-A2C6-04763FEEB73E|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UM|UNCHANGED||10^6 ORGANISMS|NOT DONE|||OBSERVATION|N|Y|PARENT|READER|NA|5||7||RUN-IN|1964-11-19|
TRIAL STUDY 134XCP|TR|FBAA59F4-154C-40CC-B740-A87769BFEC45|1||||||VOLUME|VOLUME||UMOL/H/MMOL|PRESENT||CM2|NOT DONE|||MALDI|Y|U|CAREGIVER|OPTOMETRIST|NA|1||38||FOLLOW-UP|1966-03-31|
TRIAL STUDY 134XCP|TR|FBAA59F4-154C-40CC-B740-A87769BFEC45|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||10^6 CFU|ENLARGEMENT FROM NADIR||SBE/ML|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|NA|FRIEND|MICROSCOPIST 2|Y|2||58||RUN-IN|1965-02-02|
TRIAL STUDY 134XCP|TR|FBAA59F4-154C-40CC-B740-A87769BFEC45|3||||||ORVERLN|ORGAN VERTICAL LENGTH||MEQ/UG|ENLARGEMENT FROM NADIR||PPB|NOT DONE|||SCANNING ELECTRON MICROSCOPY|U|N|CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|3||39||FOLLOW-UP|1961-10-26|
TRIAL STUDY 134XCP|TR|FBAA59F4-154C-40CC-B740-A87769BFEC45|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MG/ML/MIN|ABSENT||UG/ANIMAL|NOT DONE|||GRADIENT DIFFUSION|N|U|GUARDIAN|PATHOLOGIST 1|Y|4||88||BLINDED TREATMENT|1966-10-14|
TRIAL STUDY 134XCP|TR|FBAA59F4-154C-40CC-B740-A87769BFEC45|5||||||VSLPIND|VESSEL PATENCY INDICATOR||ML/CM H2O|PRESENT||UG/M2/H|NOT DONE|||IMMUNO-PET SCAN|NA|N|PROXY|ONCOLOGIST 2|N|5||7||FOLLOW-UP|1968-08-02|
TRIAL STUDY 134XCP|TR|9A9E638B-426B-4F3E-8363-50DC2617FD63|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CIGARETTE|DIFFUSELY INCREASED||10^5/HPF|NOT DONE|||TOTAL BODY RADIOGRAPHY|NA|Y|INTERVIEWER|ADJUDICATOR 1|U|1||38||CONTINUATION TREATMENT|1965-10-20|
TRIAL STUDY 134XCP|TR|9A9E638B-426B-4F3E-8363-50DC2617FD63|2||||||AREA|AREA||COPIES/UG|TUMOR MERGED||ML/MIN/MMHG|NOT DONE|||CONTRAST ENHANCED X-RAY|N|N|ADJUDICATOR|RADIOLOGIST 1|N|2||58||INDUCTION TREATMENT|1972-12-20|
TRIAL STUDY 134XCP|TR|9A9E638B-426B-4F3E-8363-50DC2617FD63|3||||||RADIODEN|RADIODENSITY||EID 50/DOSE|FURTHER ENLARGEMENT||MET|NOT DONE|||SXA SCAN|NA|Y|VENDOR|ADJUDICATOR 2|NA|3||39||BLINDED TREATMENT|1972-07-21|
TRIAL STUDY 134XCP|TR|9A9E638B-426B-4F3E-8363-50DC2617FD63|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MPS U|PALPABLE||NKAT/L|NOT DONE|||IMMUNOPRECIPITATION|Y|N|INDEPENDENT ASSESSOR|HEMATOLOGIST|U|4||88||OBSERVATION|1960-12-14|
TRIAL STUDY 134XCP|TR|9A9E638B-426B-4F3E-8363-50DC2617FD63|5||||||VSLPIND|VESSEL PATENCY INDICATOR||KCAL|UNCHANGED||TESLA|NOT DONE|||IN SITU HYBRIDIZATION|N|U|FRIEND|MICROSCOPIST 2|Y|5||7||BLINDED TREATMENT|1972-04-26|
TRIAL STUDY 134XCP|TR|9995CD08-2650-4711-8F04-E41183E28B21|1||||||SUMVOL|SUM OF VOLUME||GBQ/MG|ENLARGEMENT FROM NADIR||AMP|NOT DONE|||SURFACE PLASMON RESONANCE|N|NA|FRIEND|RADIOLOGIST 2|NA|1||38||TREATMENT|1966-11-04|
TRIAL STUDY 134XCP|TR|9995CD08-2650-4711-8F04-E41183E28B21|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MASK|NONPALPABLE||10^3 RNA COPIES/ML|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|U|DOMESTIC PARTNER|READER 3|N|2||58||FOLLOW-UP|1963-01-28|
TRIAL STUDY 134XCP|TR|9995CD08-2650-4711-8F04-E41183E28B21|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||CM H2O|UNCHANGED||BOWL|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|NA|STUDY SUBJECT|OPTOMETRIST|U|3||39||BLINDED TREATMENT|1961-12-14|
TRIAL STUDY 134XCP|TR|9995CD08-2650-4711-8F04-E41183E28B21|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||NEWTON|NON-PATHOLOGICAL||ML/ANIMAL|NOT DONE|||IMMUNOPRECIPITATION|Y|N|HEALTH CARE PROFESSIONAL|READER 3|NA|4||88||LONG-TERM FOLLOW-UP|1961-09-30|
TRIAL STUDY 134XCP|TR|9995CD08-2650-4711-8F04-E41183E28B21|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||UG/KG/H|ENLARGEMENT||ANSON U|NOT DONE|||TEMPLATE INCISION METHOD|NA|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|5||7||WASHOUT|1966-02-22|
TRIAL STUDY 134XCP|TR|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ECL UNIT|DIFFUSELY INCREASED||COPIES/UL|NOT DONE|||PH METER MEASUREMENT METHOD|Y|N|CAREGIVER|READER 2|Y|1||38||BLINDED TREATMENT|1968-08-19|
TRIAL STUDY 134XCP|TR|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|2||||||CALCFIND|CALCIFICATION INDICATOR||MCI|ENLARGEMENT||ML/M2/H|NOT DONE|||LC/MS|NA|NA|SIGNIFICANT OTHER|ENDOCRINOLOGIST|NA|2||58||SCREENING|1964-01-04|
TRIAL STUDY 134XCP|TR|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|3||||||RADIODEN|RADIODENSITY||NFIU|NON-PATHOLOGICAL||DEG/S|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|U|SIBLING|ADJUDICATOR 3|NA|3||39||WASHOUT|1966-10-08|
TRIAL STUDY 134XCP|TR|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|4||||||LESFLIND|LESION FAILURE INDICATOR||AMFI|ENLARGEMENT||AMOL|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|Y|Y|STUDY SUBJECT|MICROSCOPIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1972-09-03|
TRIAL STUDY 134XCP|TR|B7ED8BAC-7627-43FE-AF13-DB7398A6AF9A|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||GENEQ/ML|UNCHANGED||10^6 IU|NOT DONE|||SPECT/CT SCAN|U|N|FAMILY MEMBER|RADIOLOGIST 1|NA|5||7||RUN-IN|1972-10-04|
TRIAL STUDY 134XCP|TR|DE805225-C632-46E6-B673-DA0D864D47F7|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||UKAT/10^12 RBC|UNEQUIVOCAL||DPM/100MG|NOT DONE|||IMPEDANCE CONDUCTIVITY|U|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|1||38||WASHOUT|1961-02-09|
TRIAL STUDY 134XCP|TR|DE805225-C632-46E6-B673-DA0D864D47F7|2||||||VDIAM|VIABLE DIAMETER||10^8/L|ENLARGEMENT FROM NADIR||10^6 COPIES/ML|NOT DONE|||TARGETED GENOME SEQUENCING|Y|Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||FOLLOW-UP|1969-05-03|
TRIAL STUDY 134XCP|TR|DE805225-C632-46E6-B673-DA0D864D47F7|3||||||ORSTATE|ORGAN STATE||10^3 CFU/G|PATHOLOGICAL||MOL|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|Y|U|SPOUSE|READER 3|U|3||39||RUN-IN|1965-03-23|
TRIAL STUDY 134XCP|TR|DE805225-C632-46E6-B673-DA0D864D47F7|4||||||TUMSTATE|TUMOR STATE||UEQ/L|ENLARGEMENT||ML/(MIN*100ML)|NOT DONE|||MALDI|U|NA|VENDOR|NEUROLOGIST|NA|4||88||OBSERVATION|1962-11-19|
TRIAL STUDY 134XCP|TR|DE805225-C632-46E6-B673-DA0D864D47F7|5||||||BNLNUM|NUMBER OF BONE LESIONS||ML/KG|ABSENT||CYLINDER|NOT DONE|||SEQUENCING|NA|Y|SIGNIFICANT OTHER|MICROSCOPIST|NA|5||7||CONTINUATION TREATMENT|1961-10-13|
TRIAL STUDY 134XCP|TR|9C921E89-706F-46E8-ADE3-A806289D43A5|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||10^12/L|UNEQUIVOCAL||SIEMENS|NOT DONE|||JAEGER EYE CHART|Y|NA|PROXY|CLINICAL PATHOLOGIST|U|1||38||TREATMENT|1961-01-30|
TRIAL STUDY 134XCP|TR|9C921E89-706F-46E8-ADE3-A806289D43A5|2||||||TUMSTATE|TUMOR STATE||MG/ANIMAL|DIFFUSELY INCREASED||G/ANIMAL/WK|NOT DONE|||JAEGER EYE CHART|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|Y|2||58||TREATMENT|1962-06-20|
TRIAL STUDY 134XCP|TR|9C921E89-706F-46E8-ADE3-A806289D43A5|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MM/H|UNEQUIVOCAL||UG/L DDU|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|N|FAMILY MEMBER|READER|NA|3||39||LONG-TERM FOLLOW-UP|1966-08-18|
TRIAL STUDY 134XCP|TR|9C921E89-706F-46E8-ADE3-A806289D43A5|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UG/CM2|PATHOLOGICAL||MIN|NOT DONE|||GC/MS-CI|N|NA|ADJUDICATOR|RADIOLOGIST 1|U|4||88||BASELINE|1968-12-22|
TRIAL STUDY 134XCP|TR|9C921E89-706F-46E8-ADE3-A806289D43A5|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||CPM|FOCALLY INCREASED||IU/G HB|NOT DONE|||DNA MICROARRAY|N|U|SPOUSE|NEUROLOGIST 1|N|5||7||SCREENING|1963-10-25|
TRIAL STUDY 134XCP|TR|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||IMPLANT|DECREASED||HOUNSFIELD UNIT|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|U|U|INTERVIEWER|OPHTHALMOLOGIST|N|1||38||FOLLOW-UP|1962-02-05|
TRIAL STUDY 134XCP|TR|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||/KG|PRESENT||CAN|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|NA|N|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|2||58||RUN-IN|1971-09-06|
TRIAL STUDY 134XCP|TR|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|3||||||ORVERLN|ORGAN VERTICAL LENGTH||10^6 IU|TUMOR MERGED||IU/L|NOT DONE|||HANSEL STAIN|NA|U|FAMILY MEMBER|PATHOLOGIST|N|3||39||FOLLOW-UP|1960-06-27|
TRIAL STUDY 134XCP|TR|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UG/CM2|DECREASED||NKAT/G HB|NOT DONE|||GC/FID|NA|N|PROXY|ADJUDICATOR 1|NA|4||88||BLINDED TREATMENT|1970-12-08|
TRIAL STUDY 134XCP|TR|9EB82D4E-DE71-49D9-AA9E-C52EC90D64BB|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^6 IU|FOCALLY INCREASED||H*%|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|NA|NA|CAREGIVER|OPTOMETRIST|NA|5||7||BLINDED TREATMENT|1962-12-12|
TRIAL STUDY 134XCP|TR|17C2A52E-1232-4CBB-A809-9DC2C863366A|1||||||ORVERLN|ORGAN VERTICAL LENGTH||MV2/HZ|UNEQUIVOCAL||FMOL|NOT DONE|||SPIROMETRY|U|U|INVESTIGATOR|PATHOLOGIST 2|N|1||38||BLINDED TREATMENT|1963-08-26|
TRIAL STUDY 134XCP|TR|17C2A52E-1232-4CBB-A809-9DC2C863366A|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||NG/DL|UNEQUIVOCAL||PATCH|NOT DONE|||SPECTROPHOTOMETRY|U|N|STUDY SUBJECT|ADJUDICATOR|N|2||58||CONTINUATION TREATMENT|1972-05-02|
TRIAL STUDY 134XCP|TR|17C2A52E-1232-4CBB-A809-9DC2C863366A|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||LOG10 ELISA UNIT/DOSE|FOCALLY INCREASED||MV2/HZ|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|Y|N|GUARDIAN|ADJUDICATOR 2|NA|3||39||OPEN LABEL TREATMENT|1963-10-27|
TRIAL STUDY 134XCP|TR|17C2A52E-1232-4CBB-A809-9DC2C863366A|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||KM|PRESENT||PKAT|NOT DONE|||PHOTOGRAPHY|Y|U|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|U|4||88||BASELINE|1966-10-05|
TRIAL STUDY 134XCP|TR|17C2A52E-1232-4CBB-A809-9DC2C863366A|5||||||RADIODEN|RADIODENSITY||NG/L|NON-PATHOLOGICAL||MU/L|NOT DONE|||IMMUNOBLOT|NA|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|5||7||RUN-IN|1973-07-10|
TRIAL STUDY 134XCP|TR|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MGEQ|PATHOLOGICAL||MG/ML/DAY|NOT DONE|||OSCILLOMETRY|U|N|FRIEND|ADJUDICATOR 3|N|1||38||WASHOUT|1962-05-12|
TRIAL STUDY 134XCP|TR|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UG/G/MIN|FURTHER ENLARGEMENT||DNA COPIES/ML|NOT DONE|||SLOAN LETTER EYE CHART 100%|NA|U|VENDOR|ONCOLOGIST 1|NA|2||58||RUN-IN|1970-12-16|
TRIAL STUDY 134XCP|TR|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|3||||||SUMDIAM|SUM OF DIAMETER||KM|ENLARGEMENT FROM NADIR||FG|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|N|NA|STUDY SUBJECT|OPHTHALMOLOGIST|U|3||39||SCREENING|1972-11-22|
TRIAL STUDY 134XCP|TR|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|4||||||SUMVOL|SUM OF VOLUME||MG/KG/DAY|UNCHANGED||UKAT/10^12 RBC|NOT DONE|||CELLULOSE TAPE|NA|NA|SIBLING|NEUROLOGIST 2|Y|4||88||CONTINUATION TREATMENT|1966-06-23|
TRIAL STUDY 134XCP|TR|32B58BED-E5BF-4E10-8DBB-36DC44F68C26|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||CAPLET|NONPALPABLE||% INHIBITION|NOT DONE|||ENDPOINT DILUTION ASSAY|U|U|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||LONG-TERM FOLLOW-UP|1960-01-09|
TRIAL STUDY 134XCP|TR|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||/2500 WBC|ABSENT||UG/KG/MIN|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|U|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||TREATMENT|1970-09-08|
TRIAL STUDY 134XCP|TR|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|2||||||VOLUME|VOLUME||UG/DAY|ENLARGEMENT FROM NADIR||MG/DOSE|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|N|N|DOMESTIC PARTNER|ONCOLOGIST 1|NA|2||58||BASELINE|1973-07-12|
TRIAL STUDY 134XCP|TR|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||TABLET|NORMAL||KPA|NOT DONE|||SANGER SEQUENCING|NA|U|ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|3||39||TREATMENT|1972-03-22|
TRIAL STUDY 134XCP|TR|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|4||||||CALCFIND|CALCIFICATION INDICATOR||CGY|PALPABLE||BREATHS/30S|NOT DONE|||FLUORIMETRY|NA|NA|FAMILY MEMBER|UROLOGIST|U|4||88||BLINDED TREATMENT|1969-04-29|
TRIAL STUDY 134XCP|TR|AC14DD26-89BB-4F9D-BAD5-F2C8E62CC93B|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||DROP|NON-PATHOLOGICAL||BAG|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|NA|U|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|5||7||LONG-TERM FOLLOW-UP|1973-02-28|
TRIAL STUDY 134XCP|TR|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||U/10^12 RBC|ABSENT||BQ/MG|NOT DONE|||FLUORESCENT MICROSCOPY|NA|Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1||38||CONTINUATION TREATMENT|1961-03-02|
TRIAL STUDY 134XCP|TR|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|2||||||VDIAM|VIABLE DIAMETER||MESF|ENLARGEMENT||PIPE|NOT DONE|||CRYOSCOPY|NA|NA|INDEPENDENT ASSESSOR|READER 2|N|2||58||RUN-IN|1961-01-18|
TRIAL STUDY 134XCP|TR|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UV*SEC|UNCHANGED||MMOL/G|NOT DONE|||DARK FIELD MICROSCOPY|NA|NA|SIBLING|MICROSCOPIST 1|Y|3||39||RUN-IN|1966-04-23|
TRIAL STUDY 134XCP|TR|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|4||||||BNLNUM|NUMBER OF BONE LESIONS||10^6 DNA COPIES/ML|PRESENT||10^6 CFU/G|NOT DONE|||TRYPAN BLUE STAIN|U|U|PROXY|NEUROLOGIST|Y|4||88||WASHOUT|1960-12-03|
TRIAL STUDY 134XCP|TR|93324DA9-7BD9-4CCA-B575-57A81E5F0C33|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^6 CFU|ENLARGEMENT||GBQ|NOT DONE|||POLYSOMNOGRAPHY|U|NA|DOMESTIC PARTNER|ONCOLOGIST 2|Y|5||7||SCREENING|1966-09-29|
TRIAL STUDY 134XCP|TR|585A17D7-12A3-40C8-811F-339497B9D09C|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||U.CARR|EQUIVOCAL||LOG10 CFU/ML|NOT DONE|||HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y|VENDOR|FORENSIC PATHOLOGIST|Y|1||38||OBSERVATION|1960-11-28|
TRIAL STUDY 134XCP|TR|585A17D7-12A3-40C8-811F-339497B9D09C|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||KM|ENLARGEMENT||ML/G/H|NOT DONE|||LC/MS|Y|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|2||58||OBSERVATION|1971-06-16|
TRIAL STUDY 134XCP|TR|585A17D7-12A3-40C8-811F-339497B9D09C|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||LB|DIFFUSELY INCREASED||MANSON U/ML|NOT DONE|||PHOTOGRAPHY|Y|N|DOMESTIC PARTNER|READER 1|Y|3||39||OBSERVATION|1962-06-18|
TRIAL STUDY 134XCP|TR|585A17D7-12A3-40C8-811F-339497B9D09C|4||||||SUMVOL|SUM OF VOLUME||LOG10 CFU/ML|FOCALLY INCREASED||C|NOT DONE|||GIEMSA STAIN|U|U|ADJUDICATION COMMITTEE|RATER|N|4||88||RUN-IN|1965-11-21|
TRIAL STUDY 134XCP|TR|585A17D7-12A3-40C8-811F-339497B9D09C|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UG/KG/MIN|NON-PATHOLOGICAL||WAFER|NOT DONE|||REBOUND TONOMETRY|NA|N|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|5||7||FOLLOW-UP|1967-02-04|
TRIAL STUDY 134XCP|TR|D777661E-DF03-4221-88CC-34EB805EF5DB|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||BREATHS/MIN|NORMAL||TSP|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|NA|NA|CAREGIVER|CLINICAL PATHOLOGIST|U|1||38||SCREENING|1962-09-02|
TRIAL STUDY 134XCP|TR|D777661E-DF03-4221-88CC-34EB805EF5DB|2||||||VDIAM|VIABLE DIAMETER||NG/L|PRESENT||TSP|NOT DONE|||ICC|U|U|PARENT|RADIOLOGIST|NA|2||58||RUN-IN|1968-12-12|
TRIAL STUDY 134XCP|TR|D777661E-DF03-4221-88CC-34EB805EF5DB|3||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||GBQ/UG|INCREASED||MEQ/KG|NOT DONE|||CELL BASED BIOASSAY|U|NA|INVESTIGATOR|ENDOCRINOLOGIST|U|3||39||FOLLOW-UP|1963-05-08|
TRIAL STUDY 134XCP|TR|D777661E-DF03-4221-88CC-34EB805EF5DB|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MG/H|NONPALPABLE||UG/CM2|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|U|Y|VENDOR|ADJUDICATOR 1|Y|4||88||CONTINUATION TREATMENT|1964-01-28|
TRIAL STUDY 134XCP|TR|D777661E-DF03-4221-88CC-34EB805EF5DB|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||CAN|ABSENT||G/ANIMAL/WK|NOT DONE|||RADIATION DOSIMETRY|U|U|STUDY SUBJECT|RADIOLOGIST 2|NA|5||7||BLINDED TREATMENT|1960-04-21|
TRIAL STUDY 134XCP|TR|67828FC5-94DE-4A68-83DE-F86AA8F86D72|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||AGU/ML|FOCALLY INCREASED||MMHG/SEC|NOT DONE|||ELECTROGASTROGRAPHY|NA|N|VENDOR|ADJUDICATOR 2|Y|1||38||FOLLOW-UP|1963-01-20|
TRIAL STUDY 134XCP|TR|67828FC5-94DE-4A68-83DE-F86AA8F86D72|2||||||DIAMETER|DIAMETER||IN|TUMOR MERGED||U/DL|NOT DONE|||CONTRAST ENHANCED CT SCAN|N|N|SPOUSE|RATER|Y|2||58||OBSERVATION|1964-07-06|
TRIAL STUDY 134XCP|TR|67828FC5-94DE-4A68-83DE-F86AA8F86D72|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||TROCHE|TUMOR MERGED||PACKAGE|NOT DONE|||RIA|U|N|GUARDIAN|RADIOLOGIST|NA|3||39||BLINDED TREATMENT|1965-06-17|
TRIAL STUDY 134XCP|TR|67828FC5-94DE-4A68-83DE-F86AA8F86D72|4||||||PALPSTAT|PALPABLE STATE||MBQ/UL|UNEQUIVOCAL||ML/CAGE/WK|NOT DONE|||WEBER GREEN STAIN|N|U|DOMESTIC PARTNER|ONCOLOGIST 1|Y|4||88||TREATMENT|1967-01-15|
TRIAL STUDY 134XCP|TR|67828FC5-94DE-4A68-83DE-F86AA8F86D72|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||FT2|PALPABLE||BU|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|U|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|5||7||SCREENING|1964-07-21|
TRIAL STUDY 134XCP|TR|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|1||||||TUMSTATE|TUMOR STATE||KG/CM2|ABSENT||DB|NOT DONE|||FUNCTIONAL MRI|U|N|CAREGIVER|PHYSIOTHERAPIST|Y|1||38||LONG-TERM FOLLOW-UP|1971-10-05|
TRIAL STUDY 134XCP|TR|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|2||||||TUMSTATE|TUMOR STATE||IMPLANT|NONPALPABLE||KAT|NOT DONE|||LC-FL|U|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|2||58||BLINDED TREATMENT|1962-05-11|
TRIAL STUDY 134XCP|TR|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||/500 WBC|NONPALPABLE||TESLA|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|N|Y|STUDY SUBJECT|PATHOLOGIST 2|U|3||39||SCREENING|1964-11-21|
TRIAL STUDY 134XCP|TR|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|4||||||LESSCIND|LESION SUCCESS INDICATOR||ML*CMH2O|PRESENT||ML/MIN|NOT DONE|||PHOTOMETRY|NA|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||TREATMENT|1961-07-14|
TRIAL STUDY 134XCP|TR|A0DEC4FD-123D-41A0-8357-81496BB5B2DC|5||||||LESSCIND|LESION SUCCESS INDICATOR||YEARS|PATHOLOGICAL||NEEDLE GAUGE|NOT DONE|||FARR ASSAY|NA|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|Y|5||7||WASHOUT|1963-01-21|
TRIAL STUDY 134XCP|TR|650E5DFA-08CC-413C-B43D-070E61353E6E|1||||||PALPSTAT|PALPABLE STATE||UCI/KG|UNEQUIVOCAL||KG/L|NOT DONE|||SNELLEN EYE CHART|N|Y|FRIEND|ADJUDICATOR 2|NA|1||38||BLINDED TREATMENT|1972-04-09|
TRIAL STUDY 134XCP|TR|650E5DFA-08CC-413C-B43D-070E61353E6E|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MG/DOSE|UNCHANGED||ROENTGEN|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|N|U|FRIEND|ADJUDICATOR 3|NA|2||58||CONTINUATION TREATMENT|1966-10-23|
TRIAL STUDY 134XCP|TR|650E5DFA-08CC-413C-B43D-070E61353E6E|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||OI50|ENLARGEMENT||ELISA UNIT|NOT DONE|||NUCLEAR RADIOLOGY|N|N|GUARDIAN|READER 2|Y|3||39||INDUCTION TREATMENT|1973-07-03|
TRIAL STUDY 134XCP|TR|650E5DFA-08CC-413C-B43D-070E61353E6E|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||/10^4|TUMOR MERGED||MG/M2/DAY|NOT DONE|||SINGLE-SLICE SPIRAL CT|Y|N|FRIEND|UROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1962-07-10|
TRIAL STUDY 134XCP|TR|650E5DFA-08CC-413C-B43D-070E61353E6E|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||PT_BR|ENLARGEMENT FROM NADIR||UCI/KG|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|NA|N|SIBLING|MICROSCOPIST 2|U|5||7||TREATMENT|1962-01-03|
TRIAL STUDY 134XCP|TR|71716F05-3ABE-4A2A-B9DD-2201A63087ED|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CMOL|FURTHER ENLARGEMENT FROM NADIR||BISCUIT|NOT DONE|||REVERSE TRANSCRIPTASE PCR|U|U|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|1||38||SCREENING|1968-09-21|
TRIAL STUDY 134XCP|TR|71716F05-3ABE-4A2A-B9DD-2201A63087ED|2||||||DIAMETER|DIAMETER||STEPS/MIN|FOCALLY INCREASED||CCID 50/DOSE|NOT DONE|||ELLA|U|NA|HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2||58||WASHOUT|1966-01-13|
TRIAL STUDY 134XCP|TR|71716F05-3ABE-4A2A-B9DD-2201A63087ED|3||||||PALPSTAT|PALPABLE STATE||DL|NORMAL||MM/H|NOT DONE|||FLUORESCENT SPOT TEST|NA|NA|VENDOR|ADJUDICATOR 3|U|3||39||SCREENING|1960-02-20|
TRIAL STUDY 134XCP|TR|71716F05-3ABE-4A2A-B9DD-2201A63087ED|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||UMOL/H/MMOL|DECREASED||MV/SEC|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|U|NA|CLINICAL RESEARCH COORDINATOR|READER 2|U|4||88||BLINDED TREATMENT|1964-01-24|
TRIAL STUDY 134XCP|TR|71716F05-3ABE-4A2A-B9DD-2201A63087ED|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||ML/KG|ENLARGEMENT||UV2|NOT DONE|||TRANSVAGINAL ULTRASOUND|Y|NA|FAMILY MEMBER|RADIOLOGIST|N|5||7||TREATMENT|1972-08-18|
TRIAL STUDY 134XCP|TR|EF9208B0-4DF0-4029-AB67-8F87662D3E90|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||10^9 ORGANISMS/G|FURTHER ENLARGEMENT||FIU|NOT DONE|||IMMUNOPRECIPITATION|N|NA|FAMILY MEMBER|DERMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1971-08-30|
TRIAL STUDY 134XCP|TR|EF9208B0-4DF0-4029-AB67-8F87662D3E90|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||RAD|NONPALPABLE||MG/MOL|NOT DONE|||MICRO BROTH DILUTION|U|Y|GUARDIAN|RADIOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1972-09-09|
TRIAL STUDY 134XCP|TR|EF9208B0-4DF0-4029-AB67-8F87662D3E90|3||||||SUMDIAM|SUM OF DIAMETER||GY/H|FOCALLY INCREASED||G/ANIMAL|NOT DONE|||GC/FID|U|U|INDEPENDENT ASSESSOR|READER 3|NA|3||39||WASHOUT|1970-10-26|
TRIAL STUDY 134XCP|TR|EF9208B0-4DF0-4029-AB67-8F87662D3E90|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UCI|ENLARGEMENT FROM NADIR||10^9 CFU/ML|NOT DONE|||AUTOMATED COUNT|U|NA|CAREGIVER|CARDIOLOGIST|N|4||88||RUN-IN|1968-01-23|
TRIAL STUDY 134XCP|TR|EF9208B0-4DF0-4029-AB67-8F87662D3E90|5||||||CALCFIND|CALCIFICATION INDICATOR||UG/ANIMAL|FURTHER ENLARGEMENT||10^8/L|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|U|Y|INDEPENDENT ASSESSOR|READER 2|Y|5||7||CONTINUATION TREATMENT|1972-05-20|
TRIAL STUDY 134XCP|TR|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|1||||||VOLUME|VOLUME||TCID 50/DOSE|NORMAL||PMOL/G|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|U|N|INDEPENDENT ASSESSOR|READER 1|Y|1||38||OBSERVATION|1963-06-17|
TRIAL STUDY 134XCP|TR|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UCI|ENLARGEMENT||IN|NOT DONE|||SURFACE PLASMON RESONANCE|NA|NA|GUARDIAN|UROLOGIST|U|2||58||BLINDED TREATMENT|1972-02-17|
TRIAL STUDY 134XCP|TR|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||/MONTH|TUMOR MERGED||TUBERCULIN UNIT|NOT DONE|||CAPILLARY ELECTROPHORESIS|U|NA|SPOUSE|READER|Y|3||39||BASELINE|1965-07-22|
TRIAL STUDY 134XCP|TR|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|4||||||PALPSTAT|PALPABLE STATE||LENS|NONPALPABLE||MEQ/L|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|Y|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|4||88||RUN-IN|1971-03-26|
TRIAL STUDY 134XCP|TR|6A9F1495-1ECD-44FA-BAEE-29C96EF238E5|5||||||SUMDIAM|SUM OF DIAMETER||V|NON-PATHOLOGICAL||COPIES/UG|NOT DONE|||X-RAY FLUORESCENCE SPECTROMETRY|N|NA|FAMILY MEMBER|INTERNIST|U|5||7||LONG-TERM FOLLOW-UP|1968-05-11|
TRIAL STUDY 134XCP|TR|25580765-CB09-4BE3-8DED-C0068C69E9C4|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ML/CM H2O|PALPABLE||BOWL|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|N|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|1||38||BASELINE|1970-12-05|
TRIAL STUDY 134XCP|TR|25580765-CB09-4BE3-8DED-C0068C69E9C4|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||DISK|ENLARGEMENT||MG/M2/H|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|NA|GUARDIAN|ONCOLOGIST 1|NA|2||58||INDUCTION TREATMENT|1972-10-14|
TRIAL STUDY 134XCP|TR|25580765-CB09-4BE3-8DED-C0068C69E9C4|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||PMOL/10^9 CELLS|UNEQUIVOCAL||TUBERCULIN UNIT|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|N|CHILD|FORENSIC PATHOLOGIST|Y|3||39||SCREENING|1963-02-18|
TRIAL STUDY 134XCP|TR|25580765-CB09-4BE3-8DED-C0068C69E9C4|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||10^6/HPF|DECREASED||KN/CM2|NOT DONE|||CELLULAR PROLIFERATION ASSAY|Y|N|SIGNIFICANT OTHER|CARDIOLOGIST|N|4||88||BASELINE|1970-10-12|
TRIAL STUDY 134XCP|TR|25580765-CB09-4BE3-8DED-C0068C69E9C4|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||GY/H|FOCALLY INCREASED||CM H2O|NOT DONE|||DYNAMIC LIGHT SCATTERING|Y|Y|ADJUDICATOR|ADJUDICATOR 2|NA|5||7||LONG-TERM FOLLOW-UP|1973-03-20|
TRIAL STUDY 134XCP|TR|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||RNA COPIES/ML|PATHOLOGICAL||MS2|NOT DONE|||MICRONEUTRALIZATION ASSAY|N|Y|STUDY SUBJECT|PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1962-07-05|
TRIAL STUDY 134XCP|TR|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||LX|ENLARGEMENT||10^6 CFU/ML|NOT DONE|||BAC ACGH|U|NA|STUDY SUBJECT|READER|Y|2||58||INDUCTION TREATMENT|1967-08-19|
TRIAL STUDY 134XCP|TR|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||G/ANIMAL|DIFFUSELY INCREASED||SCM|NOT DONE|||MAPH|Y|N|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|3||39||RUN-IN|1961-09-20|
TRIAL STUDY 134XCP|TR|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|4||||||LESSCIND|LESION SUCCESS INDICATOR||TCID 50/DOSE|DECREASED||10^9 CFU/G|NOT DONE|||PHASE-CONTRAST MRI|Y|U|ADJUDICATOR|NEUROLOGIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1971-02-03|
TRIAL STUDY 134XCP|TR|98A99811-9439-4BC7-BDE8-CCF6DD7DF4A3|5||||||PALPSTAT|PALPABLE STATE||CI/ML|DECREASED||USIEMENS|NOT DONE|||REFRACTOMETRY|NA|N|SPOUSE|OPHTHALMOLOGIST|NA|5||7||OBSERVATION|1967-05-25|
TRIAL STUDY 134XCP|TR|A902F087-3BF4-4387-80F9-DDCDDCE1813E|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MESF|UNCHANGED||WEEKS|NOT DONE|||LIQUID SCINTILLATION COUNTING|N|Y|CHILD|RADIOLOGIST 1|NA|1||38||WASHOUT|1961-07-30|
TRIAL STUDY 134XCP|TR|A902F087-3BF4-4387-80F9-DDCDDCE1813E|2||||||TUMSTATE|TUMOR STATE||TSP|NORMAL||ML/DL|NOT DONE|||AUTOMATED COUNT|NA|NA|CLINICAL RESEARCH ASSOCIATE|READER|U|2||58||OBSERVATION|1961-09-10|
TRIAL STUDY 134XCP|TR|A902F087-3BF4-4387-80F9-DDCDDCE1813E|3||||||LDIAM|LONGEST DIAMETER||CYCLE/MIN|NORMAL||DRINK|NOT DONE|||IN SITU HYBRIDIZATION|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST|U|3||39||OPEN LABEL TREATMENT|1962-08-16|
TRIAL STUDY 134XCP|TR|A902F087-3BF4-4387-80F9-DDCDDCE1813E|4||||||NEWCONF|NEW TUMOR CONFIRMED||M|ENLARGEMENT FROM NADIR||USEC|NOT DONE|||HPLC/IEX|U|U|PROXY|CARDIOLOGIST|Y|4||88||RUN-IN|1966-02-15|
TRIAL STUDY 134XCP|TR|A902F087-3BF4-4387-80F9-DDCDDCE1813E|5||||||LMBFLIND|LIMB FAILURE INDICATOR||10^7 CFU/ML|PATHOLOGICAL||PELLET|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|Y|NA|FAMILY MEMBER|MICROSCOPIST 3|Y|5||7||CONTINUATION TREATMENT|1964-03-02|
TRIAL STUDY 134XCP|TR|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KCAL/DAY|EQUIVOCAL||CIGAR|NOT DONE|||CISH|NA|Y|CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|1||38||LONG-TERM FOLLOW-UP|1971-03-24|
TRIAL STUDY 134XCP|TR|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||LINEAR FT*LB|NORMAL||SHOCK WAVE|NOT DONE|||FUNDUS PHOTOGRAPHY|Y|U|SIBLING|OTOLARYNGOLOGIST|Y|2||58||RUN-IN|1961-04-06|
TRIAL STUDY 134XCP|TR|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MG/ML/DAY|ABSENT||UEQ|NOT DONE|||SPIRAL CT|NA|Y|PARENT|NEUROLOGIST 1|Y|3||39||SCREENING|1968-03-02|
TRIAL STUDY 134XCP|TR|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|4||||||AREA|AREA||LOG10 CCID 50/DOSE|FURTHER ENLARGEMENT||PG/CELL|NOT DONE|||JAEGER EYE CHART|N|Y|HEALTH CARE PROFESSIONAL|RATER|U|4||88||FOLLOW-UP|1962-01-30|
TRIAL STUDY 134XCP|TR|BC88F32F-FEB6-46D0-8B45-4A30BA4625E9|5||||||VSLPIND|VESSEL PATENCY INDICATOR||U/10^12 RBC|UNCHANGED||ML|NOT DONE|||LEAD CITRATE STAIN|N|U|ADJUDICATION COMMITTEE|NEUROLOGIST|Y|5||7||SCREENING|1968-07-12|
TRIAL STUDY 134XCP|TR|415F9206-A793-437C-B227-BD245DBF40AB|1||||||PALPSTAT|PALPABLE STATE||PMOL/10^10 CELLS|PATHOLOGICAL||/4.0 ML|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|NA|INVESTIGATOR|ONCOLOGIST|U|1||38||OBSERVATION|1972-05-08|
TRIAL STUDY 134XCP|TR|415F9206-A793-437C-B227-BD245DBF40AB|2||||||SUMDIAM|SUM OF DIAMETER||FOZ_US|UNCHANGED||UG/L DDU|NOT DONE|||CALCOFLUOR WHITE STAIN|NA|NA|CHILD|ONCOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1962-12-08|
TRIAL STUDY 134XCP|TR|415F9206-A793-437C-B227-BD245DBF40AB|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||IU/KG/H|NON-PATHOLOGICAL||U/MMOL|NOT DONE|||JAEGER EYE CHART|Y|Y|SPOUSE|RADIOLOGIST 1|N|3||39||WASHOUT|1970-07-27|
TRIAL STUDY 134XCP|TR|415F9206-A793-437C-B227-BD245DBF40AB|4||||||RADIODEN|RADIODENSITY||UCI|NONPALPABLE||ML/MMHG|NOT DONE|||CELL BASED BIOASSAY|Y|Y|FRIEND|NEUROLOGIST 2|U|4||88||INDUCTION TREATMENT|1961-06-29|
TRIAL STUDY 134XCP|TR|415F9206-A793-437C-B227-BD245DBF40AB|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UU/DL|DIFFUSELY INCREASED||AU/ML|NOT DONE|||LISSAMINE GREEN STAIN|Y|NA|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|5||7||BASELINE|1967-12-14|
TRIAL STUDY 134XCP|TR|C580BA02-D031-4875-AC02-347AA65C4C6C|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||G/G|UNEQUIVOCAL||PACKAGE|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|N|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|1||38||SCREENING|1960-05-16|
TRIAL STUDY 134XCP|TR|C580BA02-D031-4875-AC02-347AA65C4C6C|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MEQ/L|INCREASED||BQ/UG|NOT DONE|||IMMUNO-PET SCAN|N|NA|PARENT|NEUROLOGIST 1|U|2||58||SCREENING|1969-07-08|
TRIAL STUDY 134XCP|TR|C580BA02-D031-4875-AC02-347AA65C4C6C|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||NL|ENLARGEMENT||U/G/DAY|NOT DONE|||DIGITAL PCR ARRAY|Y|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||INDUCTION TREATMENT|1965-04-29|
TRIAL STUDY 134XCP|TR|C580BA02-D031-4875-AC02-347AA65C4C6C|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||GBQ/MG|UNCHANGED||IU/MMOL|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4||88||LONG-TERM FOLLOW-UP|1965-12-07|
TRIAL STUDY 134XCP|TR|C580BA02-D031-4875-AC02-347AA65C4C6C|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MBP|ENLARGEMENT||TAMPON|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|NA|Y|CLINICAL STUDY SPONSOR|RATER 1|N|5||7||CONTINUATION TREATMENT|1968-02-14|
TRIAL STUDY 134XCP|TR|4DD6944D-662E-4C9A-A663-601B657BCF5E|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||PFU|FURTHER ENLARGEMENT||L/L|NOT DONE|||IMPULSE OSCILLOMETRY|U|NA|SIGNIFICANT OTHER|HEMATOLOGIST|Y|1||38||RUN-IN|1968-02-09|
TRIAL STUDY 134XCP|TR|4DD6944D-662E-4C9A-A663-601B657BCF5E|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ML/KG/MIN|PRESENT||AU/ML|NOT DONE|||DXA SCAN|NA|U|DOMESTIC PARTNER|RATER 2|U|2||58||TREATMENT|1963-07-10|
TRIAL STUDY 134XCP|TR|4DD6944D-662E-4C9A-A663-601B657BCF5E|3||||||SUMVOL|SUM OF VOLUME||DPM/100MG|PATHOLOGICAL||ML/(MIN*100ML)|NOT DONE|||FLAME PHOTOMETRY|NA|N|SIBLING|RADIOLOGIST|NA|3||39||RUN-IN|1973-06-04|
TRIAL STUDY 134XCP|TR|4DD6944D-662E-4C9A-A663-601B657BCF5E|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ML/100G/MIN|INCREASED||PMOL|NOT DONE|||CORONARY ANGIOGRAPHY|U|N|SIGNIFICANT OTHER|CARDIOLOGIST|Y|4||88||RUN-IN|1972-07-08|
TRIAL STUDY 134XCP|TR|4DD6944D-662E-4C9A-A663-601B657BCF5E|5||||||LPERP|LONGEST PERPENDICULAR||MG/KG/DAY|PRESENT||ML/DOSE|NOT DONE|||MICROBIAL CULTURE, SOLID|U|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|5||7||BASELINE|1973-05-10|
TRIAL STUDY 134XCP|TR|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||U/KG/MIN|UNCHANGED||MEQ/KG|NOT DONE|||KLEIHAUER-BETKE|Y|Y|FAMILY MEMBER|ENDOCRINOLOGIST|NA|1||38||BASELINE|1968-11-09|
TRIAL STUDY 134XCP|TR|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||KG|NON-PATHOLOGICAL||UMOL/MG/MIN|NOT DONE|||HEMOCYTOMETRY|Y|NA|INTERVIEWER|ADJUDICATOR 2|Y|2||58||RUN-IN|1963-10-09|
TRIAL STUDY 134XCP|TR|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MKAT|FOCALLY INCREASED||UG/G/H|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|N|NA|SPOUSE|READER 3|N|3||39||TREATMENT|1970-09-28|
TRIAL STUDY 134XCP|TR|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|4||||||LPERP|LONGEST PERPENDICULAR||RFU|ENLARGEMENT FROM NADIR||NEWTON|NOT DONE|||ECHOCARDIOGRAPHY|NA|N|INTERVIEWER|MICROSCOPIST|N|4||88||CONTINUATION TREATMENT|1964-08-02|
TRIAL STUDY 134XCP|TR|24DD8893-87F9-44E9-8F9D-3E8CCD5EA2AB|5||||||CALCFIND|CALCIFICATION INDICATOR||ML/ANIMAL/WK|TUMOR MERGED||/500 WBC|NOT DONE|||ISHIHARA COLOR PLATES|Y|Y|INVESTIGATOR|NEUROLOGIST 1|Y|5||7||TREATMENT|1968-03-21|
TRIAL STUDY 134XCP|TR|69A130F1-44A1-4091-BF0C-FF8087CC9940|1||||||PALPSTAT|PALPABLE STATE||S/H|ABSENT||CAPFUL|NOT DONE|||MS/MS|U|U|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||SCREENING|1964-09-03|
TRIAL STUDY 134XCP|TR|69A130F1-44A1-4091-BF0C-FF8087CC9940|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||GTT|EQUIVOCAL||UMOL/DL|NOT DONE|||PET SCAN|NA|U|SPOUSE|CLINICAL PATHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1960-07-31|
TRIAL STUDY 134XCP|TR|69A130F1-44A1-4091-BF0C-FF8087CC9940|3||||||CALCFIND|CALCIFICATION INDICATOR||PFU/DOSE|FURTHER ENLARGEMENT||10^6 ORGANISMS/G|NOT DONE|||AUTOREFRACTION|NA|Y|GUARDIAN|PATHOLOGIST 2|N|3||39||OPEN LABEL TREATMENT|1970-02-13|
TRIAL STUDY 134XCP|TR|69A130F1-44A1-4091-BF0C-FF8087CC9940|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||10^9 ORGANISMS/MG|NON-PATHOLOGICAL||PIXELS/IN|NOT DONE|||ELECTRONEUROGRAPHY|N|Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|4||88||RUN-IN|1967-11-21|
TRIAL STUDY 134XCP|TR|69A130F1-44A1-4091-BF0C-FF8087CC9940|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||CONTAINER|UNEQUIVOCAL||ANTI-XA IU|NOT DONE|||GC/FID|NA|Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1965-11-04|
TRIAL STUDY 134XCP|TR|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||CFU/ML|PALPABLE||G/DL|NOT DONE|||MS/MS|Y|NA|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|1||38||WASHOUT|1965-07-30|
TRIAL STUDY 134XCP|TR|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MEQ/MMOL|ENLARGEMENT||U/MMOL|NOT DONE|||DROPLET DIGITAL PCR|NA|N|FRIEND|HEMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1973-07-03|
TRIAL STUDY 134XCP|TR|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||PUFF|FURTHER ENLARGEMENT||MG2/DL2|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y|SIGNIFICANT OTHER|ONCOLOGIST|NA|3||39||BLINDED TREATMENT|1969-06-21|
TRIAL STUDY 134XCP|TR|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|4||||||LMBFLIND|LIMB FAILURE INDICATOR||USP U|TUMOR MERGED||MONTHS|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|NA|N|INVESTIGATOR|PATHOLOGIST 2|NA|4||88||INDUCTION TREATMENT|1962-02-15|
TRIAL STUDY 134XCP|TR|EAEBBD6C-E86D-4865-AE17-82BF5F3823DF|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MMOL/KG|UNEQUIVOCAL||UG|NOT DONE|||BAC ACGH|Y|Y|CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|5||7||CONTINUATION TREATMENT|1967-11-18|
TRIAL STUDY 134XCP|TR|96C60715-2EDE-40FD-B41C-ECD1E5065C81|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||MEQ/UG|UNEQUIVOCAL||KA_U/DL|NOT DONE|||MEDIASTINOSCOPY|N|N|STUDY SUBJECT|MICROSCOPIST 3|U|1||38||RUN-IN|1961-01-04|
TRIAL STUDY 134XCP|TR|96C60715-2EDE-40FD-B41C-ECD1E5065C81|2||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||NL|ENLARGEMENT||LINEAR FT*LB|NOT DONE|||MRI|NA|N|SIBLING|READER 1|U|2||58||OBSERVATION|1960-12-15|
TRIAL STUDY 134XCP|TR|96C60715-2EDE-40FD-B41C-ECD1E5065C81|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||L/MIN|PATHOLOGICAL||GPS U|NOT DONE|||KNEMOMETRY|U|U|GUARDIAN|ADJUDICATOR 1|U|3||39||LONG-TERM FOLLOW-UP|1963-09-27|
TRIAL STUDY 134XCP|TR|96C60715-2EDE-40FD-B41C-ECD1E5065C81|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||MG/ANIMAL|UNEQUIVOCAL||BQ/KG|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|Y|Y|ADJUDICATOR|MICROSCOPIST 3|U|4||88||LONG-TERM FOLLOW-UP|1973-06-01|
TRIAL STUDY 134XCP|TR|96C60715-2EDE-40FD-B41C-ECD1E5065C81|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||CONTAINER|NONPALPABLE||PA|NOT DONE|||HPLC/MS/MS|NA|Y|DOMESTIC PARTNER|RATER 1|NA|5||7||LONG-TERM FOLLOW-UP|1961-10-14|
TRIAL STUDY 134XCP|TR|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||/10^3|PATHOLOGICAL||%|NOT DONE|||DROPLET DIGITAL PCR|U|NA|FAMILY MEMBER|RATER 1|Y|1||38||BLINDED TREATMENT|1972-06-09|
TRIAL STUDY 134XCP|TR|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/MIN|NONPALPABLE||KUSP|NOT DONE|||IMMUNOCHROMATOGRAPHY|Y|N|SIBLING|ADJUDICATOR 3|U|2||58||TREATMENT|1971-05-14|
TRIAL STUDY 134XCP|TR|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|3||||||SUMVOL|SUM OF VOLUME||MG/ML/MIN|PALPABLE||MG/G/H|NOT DONE|||HILLMEN COLOR CHART|N|NA|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|3||39||BASELINE|1966-11-24|
TRIAL STUDY 134XCP|TR|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ML/MIN/1.73M2|FURTHER ENLARGEMENT FROM NADIR||NGEQ/L|NOT DONE|||IMMUNORADIOMETRIC ASSAY|NA|N|STUDY SUBJECT|NEUROLOGIST 1|U|4||88||TREATMENT|1966-09-23|
TRIAL STUDY 134XCP|TR|61C29FFE-8EA1-47B9-A060-37D70EDCB88D|5||||||TUMSTATE|TUMOR STATE||MHZ|PRESENT||GPL U/ML|NOT DONE|||IRON HEMATOXYLIN STAIN|NA|U|CLINICAL STUDY SPONSOR|RATER 2|N|5||7||BLINDED TREATMENT|1966-02-16|
TRIAL STUDY 134XCP|TR|8452DD7A-4DC9-4BDF-B670-AE5B49292805|1||||||LESSCIND|LESION SUCCESS INDICATOR||MG/KG/WEEK|PALPABLE||UM/S|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|U|U|PARENT|MICROSCOPIST 3|U|1||38||OBSERVATION|1961-04-20|
TRIAL STUDY 134XCP|TR|8452DD7A-4DC9-4BDF-B670-AE5B49292805|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||COAT|NONPALPABLE||SEC|NOT DONE|||PATHOLOGICAL EVALUATION|N|NA|SIBLING|READER 2|Y|2||58||WASHOUT|1964-10-28|
TRIAL STUDY 134XCP|TR|8452DD7A-4DC9-4BDF-B670-AE5B49292805|3||||||VOLUME|VOLUME||ROENTGEN|UNCHANGED||/10^5|NOT DONE|||ANTIMICROBIAL COMBINATION TESTING|N|Y|FAMILY MEMBER|NEUROLOGIST 1|N|3||39||BASELINE|1970-02-23|
TRIAL STUDY 134XCP|TR|8452DD7A-4DC9-4BDF-B670-AE5B49292805|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||KG/CM2|UNCHANGED||DPM/0.5 ML|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|4||88||SCREENING|1971-10-02|
TRIAL STUDY 134XCP|TR|8452DD7A-4DC9-4BDF-B670-AE5B49292805|5||||||SUMDIAM|SUM OF DIAMETER||DAGU|UNCHANGED||PMOL/G|NOT DONE|||MICROSCOPY|U|N|SIBLING|RATER 2|N|5||7||BLINDED TREATMENT|1969-11-12|
TRIAL STUDY 134XCP|TR|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|1||||||LESSCIND|LESION SUCCESS INDICATOR||UG/L|INCREASED||FIU|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|U|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|1||38||WASHOUT|1963-02-23|
TRIAL STUDY 134XCP|TR|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ANTI-XA IU|PALPABLE||KCAL|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|N|DOMESTIC PARTNER|PATHOLOGIST 2|Y|2||58||SCREENING|1973-06-18|
TRIAL STUDY 134XCP|TR|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MM/SEC|INCREASED||/WK|NOT DONE|||ALCIAN BLUE STAIN|N|NA|INDEPENDENT ASSESSOR|INTERNIST|Y|3||39||BASELINE|1968-10-19|
TRIAL STUDY 134XCP|TR|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MAC50|PATHOLOGICAL||NMOL/L|NOT DONE|||QUANTITATIVE ULTRASOUND|U|Y|PARENT|INTERNIST|N|4||88||BASELINE|1972-05-17|
TRIAL STUDY 134XCP|TR|F955EF3A-FE2C-4F03-9384-9FBCF637DB0E|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MPH|FOCALLY INCREASED||TUBERCULIN UNIT/ML|NOT DONE|||FUNDUS PHOTOGRAPHY|N|NA|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|5||7||CONTINUATION TREATMENT|1970-01-03|
TRIAL STUDY 134XCP|TR|30108497-140B-499E-8924-8BFCDC57457A|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MOL/MG|FURTHER ENLARGEMENT FROM NADIR||MIU/L|NOT DONE|||MICROBIAL CONCENTRATION|U|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1||38||WASHOUT|1962-08-02|
TRIAL STUDY 134XCP|TR|30108497-140B-499E-8924-8BFCDC57457A|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||EID 50/DOSE|ENLARGEMENT FROM NADIR||SQU/ML|NOT DONE|||IN SITU HYBRIDIZATION|U|U|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|2||58||INDUCTION TREATMENT|1970-07-02|
TRIAL STUDY 134XCP|TR|30108497-140B-499E-8924-8BFCDC57457A|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MMOL/MIN/KPA|PATHOLOGICAL||G/U|NOT DONE|||ACRIDINE ORANGE STAIN|U|NA|VENDOR|READER 1|Y|3||39||SCREENING|1962-01-02|
TRIAL STUDY 134XCP|TR|30108497-140B-499E-8924-8BFCDC57457A|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||10^3 CFU|UNEQUIVOCAL||CI/KG|NOT DONE|||DIGITAL PCR ARRAY|N|NA|FAMILY MEMBER|OTOLARYNGOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1962-07-15|
TRIAL STUDY 134XCP|TR|30108497-140B-499E-8924-8BFCDC57457A|5||||||LPERP|LONGEST PERPENDICULAR||ML/G/H|INCREASED||FINGERTIP UNIT|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|N|CHILD|OPTOMETRIST|U|5||7||SCREENING|1970-08-21|
TRIAL STUDY 134XCP|TR|5FFEF358-5014-497F-A091-6EF27A1BCF7D|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||10^11/L|NON-PATHOLOGICAL||EIA UNIT|NOT DONE|||TWO-COLOR MICROARRAY|U|U|DOMESTIC PARTNER|PATHOLOGIST|N|1||38||OPEN LABEL TREATMENT|1973-02-17|
TRIAL STUDY 134XCP|TR|5FFEF358-5014-497F-A091-6EF27A1BCF7D|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||LOG10 IU/ML|ENLARGEMENT||CMOL/L|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|U|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|2||58||OBSERVATION|1971-07-28|
TRIAL STUDY 134XCP|TR|5FFEF358-5014-497F-A091-6EF27A1BCF7D|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^12/L|ENLARGEMENT FROM NADIR||/MM|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|U|N|FRIEND|PATHOLOGIST|NA|3||39||BASELINE|1963-09-28|
TRIAL STUDY 134XCP|TR|5FFEF358-5014-497F-A091-6EF27A1BCF7D|4||||||LESFLIND|LESION FAILURE INDICATOR||MG/KG|ENLARGEMENT FROM NADIR||OI50|NOT DONE|||OBSERVATION|Y|U|ADJUDICATOR|READER|N|4||88||SCREENING|1972-07-14|
TRIAL STUDY 134XCP|TR|5FFEF358-5014-497F-A091-6EF27A1BCF7D|5||||||VSLPIND|VESSEL PATENCY INDICATOR||SQU/ML|PALPABLE||ML/KG|NOT DONE|||MALDI-TOF|Y|Y|STUDY SUBJECT|RADIOLOGIST|NA|5||7||BLINDED TREATMENT|1960-03-02|
TRIAL STUDY 134XCP|TR|9DFBE459-22E4-4BA7-A993-AC06D6644562|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MOL|NONPALPABLE||PMOL/10^10 CELLS|NOT DONE|||LIQUID SCINTILLATION COUNTING|N|U|SPOUSE|RADIOLOGIST 2|NA|1||38||WASHOUT|1962-06-09|
TRIAL STUDY 134XCP|TR|9DFBE459-22E4-4BA7-A993-AC06D6644562|2||||||NEWCONF|NEW TUMOR CONFIRMED||/HPF|ENLARGEMENT FROM NADIR||EP U|NOT DONE|||ZIEHL NEELSEN ACID FAST STAIN|Y|U|VENDOR|PEDIATRIC NEUROLOGIST|Y|2||58||BASELINE|1968-11-08|
TRIAL STUDY 134XCP|TR|9DFBE459-22E4-4BA7-A993-AC06D6644562|3||||||TUMSTATE|TUMOR STATE||U/G/DAY|PALPABLE||CI/ML|NOT DONE|||PET SCAN|U|NA|SIBLING|CLINICAL PATHOLOGIST|N|3||39||OBSERVATION|1968-07-14|
TRIAL STUDY 134XCP|TR|9DFBE459-22E4-4BA7-A993-AC06D6644562|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UMOL/MIN|ENLARGEMENT||ML/S|NOT DONE|||GIEMSA STAIN|NA|Y|SIBLING|MICROSCOPIST 2|U|4||88||CONTINUATION TREATMENT|1966-04-19|
TRIAL STUDY 134XCP|TR|9DFBE459-22E4-4BA7-A993-AC06D6644562|5||||||SUMVOL|SUM OF VOLUME||UV|FURTHER ENLARGEMENT||POINT|NOT DONE|||OPTICAL MAPPING|U|U|DOMESTIC PARTNER|RATER 1|U|5||7||LONG-TERM FOLLOW-UP|1971-09-10|
TRIAL STUDY 134XCP|TR|850B35FA-69C7-44AD-A471-964C59C4CFD8|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UKAT/L|NORMAL||DIP|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|N|Y|STUDY SUBJECT|READER 3|U|1||38||BLINDED TREATMENT|1965-09-10|
TRIAL STUDY 134XCP|TR|850B35FA-69C7-44AD-A471-964C59C4CFD8|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||AMOL|EQUIVOCAL||SCOOPFUL|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|Y|STUDY SUBJECT|INTERNIST|NA|2||58||FOLLOW-UP|1961-03-14|
TRIAL STUDY 134XCP|TR|850B35FA-69C7-44AD-A471-964C59C4CFD8|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||DISK|TUMOR MERGED||U/KG|NOT DONE|||POPULATION SEQUENCING|N|NA|PROXY|FORENSIC PATHOLOGIST|U|3||39||LONG-TERM FOLLOW-UP|1971-06-27|
TRIAL STUDY 134XCP|TR|850B35FA-69C7-44AD-A471-964C59C4CFD8|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CP|EQUIVOCAL||10^3/L|NOT DONE|||SPIRAL CT|Y|NA|VENDOR|MICROSCOPIST 2|Y|4||88||LONG-TERM FOLLOW-UP|1960-07-25|
TRIAL STUDY 134XCP|TR|850B35FA-69C7-44AD-A471-964C59C4CFD8|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CM|ENLARGEMENT||FMOL/G|NOT DONE|||DUKE INCISION METHOD|N|U|SPOUSE|READER 3|N|5||7||RUN-IN|1961-12-29|
TRIAL STUDY 134XCP|TR|981B890E-1257-4F04-A974-6006401F78CC|1||||||VSLFLIND|VESSEL FAILURE INDICATOR||DPM/100MG|NON-PATHOLOGICAL||TSP|NOT DONE|||IMMUNOCHROMATOGRAPHY|Y|U|PARENT|ADJUDICATOR 1|Y|1||38||BLINDED TREATMENT|1960-02-19|
TRIAL STUDY 134XCP|TR|981B890E-1257-4F04-A974-6006401F78CC|2||||||TUMSTATE|TUMOR STATE||GBQ/UG|PATHOLOGICAL||S*KPA|NOT DONE|||ANGIOGRAPHY|N|U|FAMILY MEMBER|ADJUDICATOR 1|Y|2||58||SCREENING|1964-12-13|
TRIAL STUDY 134XCP|TR|981B890E-1257-4F04-A974-6006401F78CC|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||UG/CM2|EQUIVOCAL||UMOL/MOL|NOT DONE|||PULMONARY ANGIOGRAPHY|U|NA|CHILD|RADIOLOGIST|N|3||39||BLINDED TREATMENT|1965-07-20|
TRIAL STUDY 134XCP|TR|981B890E-1257-4F04-A974-6006401F78CC|4||||||NEWCONF|NEW TUMOR CONFIRMED||NG/DAY|FURTHER ENLARGEMENT||MM2|NOT DONE|||AUDIOMETRY|NA|Y|INTERVIEWER|ADJUDICATOR|Y|4||88||OBSERVATION|1969-11-01|
TRIAL STUDY 134XCP|TR|981B890E-1257-4F04-A974-6006401F78CC|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||ML/DAY|ENLARGEMENT||AU/ML|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|NA|Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|5||7||OPEN LABEL TREATMENT|1967-05-05|
TRIAL STUDY 134XCP|TR|52FF8D96-64AD-498D-8B28-3DDD015796E3|1||||||LESSCIND|LESION SUCCESS INDICATOR||U/KG/MIN|ABSENT||%/S|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|NA|STUDY SUBJECT|RATER 1|U|1||38||LONG-TERM FOLLOW-UP|1960-05-08|
TRIAL STUDY 134XCP|TR|52FF8D96-64AD-498D-8B28-3DDD015796E3|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MG/H|UNEQUIVOCAL||/100 WBC|NOT DONE|||VIRUS PLAQUE ASSAY|N|U|INVESTIGATOR|CARDIOLOGIST|NA|2||58||OPEN LABEL TREATMENT|1962-08-26|
TRIAL STUDY 134XCP|TR|52FF8D96-64AD-498D-8B28-3DDD015796E3|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||EJACULATE U|NON-PATHOLOGICAL||MG/ANIMAL|NOT DONE|||POLYSOMNOGRAPHY|U|N|PROXY|NEUROLOGIST 2|NA|3||39||OBSERVATION|1963-01-08|
TRIAL STUDY 134XCP|TR|52FF8D96-64AD-498D-8B28-3DDD015796E3|4||||||LPERP|LONGEST PERPENDICULAR||ANTI-XA IU|PALPABLE||DAYS/WK|NOT DONE|||SPECT SCAN|U|NA|DOMESTIC PARTNER|RADIOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1966-08-03|
TRIAL STUDY 134XCP|TR|52FF8D96-64AD-498D-8B28-3DDD015796E3|5||||||VDIAM|VIABLE DIAMETER||/10^5|TUMOR MERGED||MESF|NOT DONE|||WHOLE GENOME SEQUENCING|U|N|INVESTIGATOR|ONCOLOGIST 1|N|5||7||OBSERVATION|1970-06-10|
TRIAL STUDY 134XCP|TR|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|1||||||CALCFIND|CALCIFICATION INDICATOR||10^6/L|EQUIVOCAL||USEC|NOT DONE|||DIPSTICK|Y|N|CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|1||38||TREATMENT|1965-02-27|
TRIAL STUDY 134XCP|TR|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UG/ANIMAL|FOCALLY INCREASED||MMHG|NOT DONE|||VIRUS PLAQUE ASSAY|U|NA|SIGNIFICANT OTHER|DERMATOLOGIST|NA|2||58||OBSERVATION|1960-04-24|
TRIAL STUDY 134XCP|TR|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MAMP|DECREASED||GPS U|NOT DONE|||DIRECT SEQUENCING|NA|N|DOMESTIC PARTNER|PATHOLOGIST 1|N|3||39||INDUCTION TREATMENT|1960-02-19|
TRIAL STUDY 134XCP|TR|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CPM|TUMOR MERGED||KPA/L/SEC|NOT DONE|||IMPULSE OSCILLOMETRY|Y|NA|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4||88||INDUCTION TREATMENT|1968-09-10|
TRIAL STUDY 134XCP|TR|B017565E-4AF2-4B01-B65A-2A9FB3B96F40|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||VOXEL|PALPABLE||G/ANIMAL|NOT DONE|||PERFUSION MRI|NA|N|INDEPENDENT ASSESSOR|READER 1|NA|5||7||INDUCTION TREATMENT|1967-09-03|
TRIAL STUDY 134XCP|TR|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|1||||||SUMDIAM|SUM OF DIAMETER||DDU|ENLARGEMENT FROM NADIR||OZ|NOT DONE|||PALPATION|U|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|1||38||SCREENING|1967-09-06|
TRIAL STUDY 134XCP|TR|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||WEBER|FURTHER ENLARGEMENT||ML/M2/MIN|NOT DONE|||PERCUSSION|NA|Y|VENDOR|PHYSIOTHERAPIST|NA|2||58||WASHOUT|1973-09-08|
TRIAL STUDY 134XCP|TR|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||RAD|PALPABLE||UG/M2|NOT DONE|||MODIFIED ACID FAST STAIN|Y|N|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|3||39||BLINDED TREATMENT|1970-10-05|
TRIAL STUDY 134XCP|TR|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CMOL/L|DECREASED||PIXEL|NOT DONE|||TARGETED TRANSCRIPTOME SEQUENCING|N|U|PROXY|UROLOGIST|N|4||88||CONTINUATION TREATMENT|1964-09-05|
TRIAL STUDY 134XCP|TR|7DC0EC29-9F24-4851-A953-1EC6490D8ACD|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||CI/UG|UNCHANGED||%(V/V)|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|N|U|DOMESTIC PARTNER|ONCOLOGIST|N|5||7||RUN-IN|1961-10-27|
TRIAL STUDY 134XCP|TR|CD65CBB8-D056-4738-93A8-FF465534961B|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||LOG10 CFU/G|UNEQUIVOCAL||TAMPON|NOT DONE|||HEMOCYTOMETRY|NA|Y|CHILD|OTOLARYNGOLOGIST|NA|1||38||OBSERVATION|1970-03-23|
TRIAL STUDY 134XCP|TR|CD65CBB8-D056-4738-93A8-FF465534961B|2||||||VDIAM|VIABLE DIAMETER||% INHIBITION|DECREASED||/H|NOT DONE|||CALCULATION|N|N|CHILD|RATER 1|Y|2||58||LONG-TERM FOLLOW-UP|1968-11-02|
TRIAL STUDY 134XCP|TR|CD65CBB8-D056-4738-93A8-FF465534961B|3||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||DAMOL/L|ABSENT||NG/MOL|NOT DONE|||CLIP|Y|NA|DOMESTIC PARTNER|PHYSIOTHERAPIST|N|3||39||FOLLOW-UP|1969-10-17|
TRIAL STUDY 134XCP|TR|CD65CBB8-D056-4738-93A8-FF465534961B|4||||||LMBFLIND|LIMB FAILURE INDICATOR||TORR|INCREASED||MV/SEC|NOT DONE|||CONGO RED STAIN|NA|NA|CAREGIVER|ONCOLOGIST 1|Y|4||88||INDUCTION TREATMENT|1965-04-20|
TRIAL STUDY 134XCP|TR|CD65CBB8-D056-4738-93A8-FF465534961B|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MM/H|ABSENT||CL|NOT DONE|||MALDI-TOF|NA|Y|HEALTH CARE PROFESSIONAL|RATER|U|5||7||BLINDED TREATMENT|1972-12-24|
TRIAL STUDY 134XCP|TR|7F014394-ABE2-45F8-891F-2DE808762532|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||CAPLET|ENLARGEMENT FROM NADIR||MG/M2/H|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|Y|U|VENDOR|MICROSCOPIST 1|Y|1||38||FOLLOW-UP|1971-02-27|
TRIAL STUDY 134XCP|TR|7F014394-ABE2-45F8-891F-2DE808762532|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^6 ORGANISMS/ML|UNEQUIVOCAL||CMH2O*S/ML|NOT DONE|||WRIGHT-GIEMSA STAIN|NA|Y|SPOUSE|ONCOLOGIST 2|N|2||58||BASELINE|1970-11-01|
TRIAL STUDY 134XCP|TR|7F014394-ABE2-45F8-891F-2DE808762532|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MG/DAY|PALPABLE||PRESSOR UNITS|NOT DONE|||HEMOCYTOMETRY|U|N|PARENT|RADIOLOGIST|U|3||39||FOLLOW-UP|1973-05-01|
TRIAL STUDY 134XCP|TR|7F014394-ABE2-45F8-891F-2DE808762532|4||||||RADIODEN|RADIODENSITY||IU/ML|EQUIVOCAL||MV*MIN|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|N|NA|PARENT|READER 2|U|4||88||SCREENING|1971-07-16|
TRIAL STUDY 134XCP|TR|7F014394-ABE2-45F8-891F-2DE808762532|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||BU|EQUIVOCAL||%(W/W)|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|U|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||SCREENING|1963-07-08|
TRIAL STUDY 134XCP|TR|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||STEPS/MIN|FURTHER ENLARGEMENT FROM NADIR||MG/ML/MIN|NOT DONE|||AUDIOMETRY|U|Y|FAMILY MEMBER|CARDIOLOGIST|U|1||38||WASHOUT|1963-06-05|
TRIAL STUDY 134XCP|TR|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|2||||||LESFLIND|LESION FAILURE INDICATOR||CCID 50/ML|FOCALLY INCREASED||/100 HPFS|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|N|N|CHILD|RADIOLOGIST 1|N|2||58||FOLLOW-UP|1972-07-08|
TRIAL STUDY 134XCP|TR|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||10^8 PFU|ENLARGEMENT||BREATHS/MIN|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|N|N|ADJUDICATOR|MICROSCOPIST 3|Y|3||39||BLINDED TREATMENT|1963-04-01|
TRIAL STUDY 134XCP|TR|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||RNA COPIES/ML|UNEQUIVOCAL||NMOL/L/H|NOT DONE|||MASS SPECTROMETRY|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|4||88||BLINDED TREATMENT|1966-10-13|
TRIAL STUDY 134XCP|TR|523E40AD-3C19-46E6-B839-0BF83AFB5EF4|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||BE/ML|TUMOR MERGED||GRAVITATIONAL UNIT|NOT DONE|||TRANSVAGINAL ULTRASOUND|U|N|INTERVIEWER|FORENSIC PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1960-10-02|
TRIAL STUDY 134XCP|TR|FB781158-BB8A-4A75-BD55-00D6A5C72720|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UL/KG/DAY|PATHOLOGICAL||UG/G/DAY|NOT DONE|||CELL OF ORIGIN ASSAY|Y|U|FAMILY MEMBER|OPHTHALMOLOGIST|Y|1||38||RUN-IN|1960-06-11|
TRIAL STUDY 134XCP|TR|FB781158-BB8A-4A75-BD55-00D6A5C72720|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||ML/MIN|UNEQUIVOCAL||PMOL/L/H|NOT DONE|||SPECT/CT SCAN|N|NA|SIBLING|RATER 1|NA|2||58||RUN-IN|1963-07-17|
TRIAL STUDY 134XCP|TR|FB781158-BB8A-4A75-BD55-00D6A5C72720|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||M3|PATHOLOGICAL||LINEAR FT*LB|NOT DONE|||ELECTROPHORESIS|Y|N|SIBLING|PATHOLOGIST 2|N|3||39||INDUCTION TREATMENT|1965-03-04|
TRIAL STUDY 134XCP|TR|FB781158-BB8A-4A75-BD55-00D6A5C72720|4||||||ORVERLN|ORGAN VERTICAL LENGTH||MV|DIFFUSELY INCREASED||ENZYME U/L|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|Y|DOMESTIC PARTNER|MICROSCOPIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1968-05-18|
TRIAL STUDY 134XCP|TR|FB781158-BB8A-4A75-BD55-00D6A5C72720|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MMOL/L|ENLARGEMENT||ML/CAGE/WK|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|N|N|CAREGIVER|NEUROLOGIST 1|N|5||7||OPEN LABEL TREATMENT|1960-03-24|
TRIAL STUDY 134XCP|TR|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||POUCH|NORMAL||YD|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|Y|NA|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|1||38||OPEN LABEL TREATMENT|1969-10-06|
TRIAL STUDY 134XCP|TR|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|2||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||HENRY|FURTHER ENLARGEMENT||DEG2|NOT DONE|||AURAMINE STAIN|Y|Y|PROXY|READER 1|NA|2||58||OBSERVATION|1963-10-04|
TRIAL STUDY 134XCP|TR|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||NKAT/L|PATHOLOGICAL||10^9 ORGANISMS/G|NOT DONE|||CONTACT SPECULAR MICROSCOPY|Y|N|SIGNIFICANT OTHER|INTERNIST|N|3||39||TREATMENT|1972-05-03|
TRIAL STUDY 134XCP|TR|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ATM|PATHOLOGICAL||MMHG*MIN/L|NOT DONE|||PEAK FLOWMETRY|N|U|HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|4||88||WASHOUT|1965-08-01|
TRIAL STUDY 134XCP|TR|F9A4A196-CB1F-48A3-9CA7-F1F3483062F0|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||SV|FURTHER ENLARGEMENT||MANSON U/ML|NOT DONE|||REFRACTOMETRY|N|N|ADJUDICATOR|PATHOLOGIST 2|N|5||7||TREATMENT|1962-11-07|
TRIAL STUDY 134XCP|TR|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MBQ/UL|DIFFUSELY INCREASED||DAYS/WK|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|NA|DOMESTIC PARTNER|RADIOLOGIST|N|1||38||BLINDED TREATMENT|1962-03-31|
TRIAL STUDY 134XCP|TR|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||GENEQ/ML|NON-PATHOLOGICAL||ML/CM|NOT DONE|||MECHANICAL CLOT DETECTION|NA|NA|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|2||58||CONTINUATION TREATMENT|1967-12-15|
TRIAL STUDY 134XCP|TR|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MANSON U/ML|NON-PATHOLOGICAL||ABSORBANCE U/MIN|NOT DONE|||CAPILLARY ELECTROPHORESIS|N|N|VENDOR|ADJUDICATOR 1|N|3||39||RUN-IN|1961-09-15|
TRIAL STUDY 134XCP|TR|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^6 U|PRESENT||RFU|NOT DONE|||MANUAL COUNT|NA|N|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|4||88||CONTINUATION TREATMENT|1960-06-07|
TRIAL STUDY 134XCP|TR|90D79875-49B9-4EE2-A23D-5DBC7AA489FA|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CFU/ML|PRESENT||ML|NOT DONE|||GEL ELECTROPHORESIS|U|NA|INTERVIEWER|PEDIATRIC NEUROLOGIST|N|5||7||OBSERVATION|1973-02-20|
TRIAL STUDY 134XCP|TR|505A1BB6-135A-4839-BB9E-6DD37F49DC45|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||CL|INCREASED||CFU/ML|NOT DONE|||ETDRS EYE CHART|NA|U|SPOUSE|PEDIATRIC NEUROLOGIST|Y|1||38||RUN-IN|1965-09-18|
TRIAL STUDY 134XCP|TR|505A1BB6-135A-4839-BB9E-6DD37F49DC45|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||SEC|TUMOR MERGED||STEPS/MIN|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|N|Y|PROXY|ADJUDICATOR 2|N|2||58||OPEN LABEL TREATMENT|1968-12-17|
TRIAL STUDY 134XCP|TR|505A1BB6-135A-4839-BB9E-6DD37F49DC45|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||10^6 CFU/G|ENLARGEMENT||BQ/L|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|U|N|SPOUSE|ADJUDICATOR 2|U|3||39||CONTINUATION TREATMENT|1960-05-02|
TRIAL STUDY 134XCP|TR|505A1BB6-135A-4839-BB9E-6DD37F49DC45|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||/MBP|FURTHER ENLARGEMENT FROM NADIR||C|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|NA|Y|FAMILY MEMBER|ENDOCRINOLOGIST|N|4||88||FOLLOW-UP|1971-10-29|
TRIAL STUDY 134XCP|TR|505A1BB6-135A-4839-BB9E-6DD37F49DC45|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^11/L|DIFFUSELY INCREASED||LM|NOT DONE|||IMMUNOCHROMATOGRAPHY|N|N|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|5||7||BASELINE|1965-03-08|
TRIAL STUDY 134XCP|TR|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||NG/L|FOCALLY INCREASED||BQ/MG|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|NA|N|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|1||38||CONTINUATION TREATMENT|1971-04-01|
TRIAL STUDY 134XCP|TR|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|2||||||CALCFIND|CALCIFICATION INDICATOR||UG/H|UNCHANGED||ML*CMH2O|NOT DONE|||KARYOTYPING|U|U|VENDOR|ONCOLOGIST|NA|2||58||SCREENING|1973-04-07|
TRIAL STUDY 134XCP|TR|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|3||||||LPERP|LONGEST PERPENDICULAR||G/MOL|FURTHER ENLARGEMENT FROM NADIR||DPM/0.5 ML|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|N|U|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|3||39||SCREENING|1963-11-19|
TRIAL STUDY 134XCP|TR|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|4||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||KG/L|TUMOR MERGED||L/S|NOT DONE|||IHC|NA|U|INDEPENDENT ASSESSOR|INTERNIST|U|4||88||RUN-IN|1963-09-09|
TRIAL STUDY 134XCP|TR|E0889B7B-923D-4AFF-ACB7-952B7BAF912F|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||M/SEC2|PRESENT||KG/MOL|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|U|NA|SIGNIFICANT OTHER|MICROSCOPIST 3|Y|5||7||BLINDED TREATMENT|1966-02-09|
TRIAL STUDY 134XCP|TR|16F375DC-DC27-461B-969E-1269DC53F4D9|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||COAT|DECREASED||EID 50/DOSE|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|NA|Y|VENDOR|ADJUDICATOR 3|Y|1||38||CONTINUATION TREATMENT|1962-06-07|
TRIAL STUDY 134XCP|TR|16F375DC-DC27-461B-969E-1269DC53F4D9|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/SEC/1.73M2|DECREASED||MIN/DAY|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|NA|Y|FRIEND|UROLOGIST|U|2||58||RUN-IN|1966-01-06|
TRIAL STUDY 134XCP|TR|16F375DC-DC27-461B-969E-1269DC53F4D9|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||RAD|PRESENT||MIN/DAY|NOT DONE|||BIOPSY|N|N|CAREGIVER|FORENSIC PATHOLOGIST|U|3||39||SCREENING|1968-11-20|
TRIAL STUDY 134XCP|TR|16F375DC-DC27-461B-969E-1269DC53F4D9|4||||||CALCFIND|CALCIFICATION INDICATOR||MG/ML/DAY|PRESENT||ML/BEAT|NOT DONE|||PHOROPTER|U|N|CHILD|OPHTHALMOLOGIST|Y|4||88||OPEN LABEL TREATMENT|1973-09-01|
TRIAL STUDY 134XCP|TR|16F375DC-DC27-461B-969E-1269DC53F4D9|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||KIT|NONPALPABLE||KG/MOL|NOT DONE|||LIQUID SCINTILLATION COUNTING|NA|NA|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|5||7||BLINDED TREATMENT|1966-04-19|
TRIAL STUDY 134XCP|TR|17BF9A68-265F-4FCC-A499-615A1B71A8D6|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^8/L|PATHOLOGICAL||APPLICATION|NOT DONE|||MRI WITHOUT CONTRAST|U|N|VENDOR|OPHTHALMOLOGIST|Y|1||38||FOLLOW-UP|1964-09-30|
TRIAL STUDY 134XCP|TR|17BF9A68-265F-4FCC-A499-615A1B71A8D6|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ML/S|PATHOLOGICAL||DPM/ML|NOT DONE|||ANTIBIOTIC AGAR SCREEN|N|NA|CAREGIVER|ADJUDICATOR 2|N|2||58||BLINDED TREATMENT|1971-01-08|
TRIAL STUDY 134XCP|TR|17BF9A68-265F-4FCC-A499-615A1B71A8D6|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MG/MOL|NONPALPABLE||HZ/S|NOT DONE|||NUCLEIC ACID BASED METHOD|N|NA|GUARDIAN|ADJUDICATOR 1|N|3||39||LONG-TERM FOLLOW-UP|1970-08-18|
TRIAL STUDY 134XCP|TR|17BF9A68-265F-4FCC-A499-615A1B71A8D6|4||||||CALCFIND|CALCIFICATION INDICATOR||CMH2O/ML|UNCHANGED||/MONTH|NOT DONE|||AGAR PROPORTION|N|NA|ADJUDICATOR|READER|U|4||88||BLINDED TREATMENT|1960-10-18|
TRIAL STUDY 134XCP|TR|17BF9A68-265F-4FCC-A499-615A1B71A8D6|5||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||DNA COPIES/UG|PRESENT||TESLA|NOT DONE|||INTERRUPTER TECHNIQUE|Y|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|5||7||BLINDED TREATMENT|1963-01-19|
TRIAL STUDY 134XCP|TR|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MG/G/H|EQUIVOCAL||CM/S|NOT DONE|||MRS|NA|Y|CLINICAL RESEARCH ASSOCIATE|READER 2|N|1||38||SCREENING|1962-11-24|
TRIAL STUDY 134XCP|TR|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ATM|PATHOLOGICAL||MG/H|NOT DONE|||SLIT LAMP|Y|Y|HEALTH CARE PROFESSIONAL|READER|Y|2||58||FOLLOW-UP|1968-02-15|
TRIAL STUDY 134XCP|TR|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MET|NORMAL||WAFER|NOT DONE|||ICP-MS|Y|Y|ADJUDICATOR|FORENSIC PATHOLOGIST|U|3||39||SCREENING|1969-05-04|
TRIAL STUDY 134XCP|TR|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||10^5/HPF|UNCHANGED||PMOL/10^9 CELLS|NOT DONE|||TRIPLE-PHASE SPIRAL CT SCAN|N|NA|CAREGIVER|ADJUDICATOR 3|NA|4||88||SCREENING|1965-07-21|
TRIAL STUDY 134XCP|TR|327E38A8-FEAD-4868-AA3B-3DF2225E7CDF|5||||||TUMSTATE|TUMOR STATE||FMOL/L|ENLARGEMENT FROM NADIR||UG/M2/DAY|NOT DONE|||TELLER ACUITY CARDS|NA|Y|CHILD|ADJUDICATOR 1|Y|5||7||TREATMENT|1969-08-15|
TRIAL STUDY 134XCP|TR|B842981B-AD7A-4A03-8E84-D5FC887BAD60|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||IU/DL|FOCALLY INCREASED||ML/MMHG/MIN/L|NOT DONE|||KINETIC CHROMOGENIC ASSAY|NA|Y|INDEPENDENT ASSESSOR|RATER 2|Y|1||38||LONG-TERM FOLLOW-UP|1961-11-24|
TRIAL STUDY 134XCP|TR|B842981B-AD7A-4A03-8E84-D5FC887BAD60|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||MU|ENLARGEMENT||M/SEC|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|Y|U|HEALTH CARE PROFESSIONAL|INTERNIST|NA|2||58||RUN-IN|1973-05-19|
TRIAL STUDY 134XCP|TR|B842981B-AD7A-4A03-8E84-D5FC887BAD60|3||||||ORVERLN|ORGAN VERTICAL LENGTH||JOULE|FURTHER ENLARGEMENT FROM NADIR||AMFI|NOT DONE|||ICC|NA|NA|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|3||39||LONG-TERM FOLLOW-UP|1962-08-30|
TRIAL STUDY 134XCP|TR|B842981B-AD7A-4A03-8E84-D5FC887BAD60|4||||||NEWCONF|NEW TUMOR CONFIRMED||UG/G/MIN|NONPALPABLE||ML/KG/H|NOT DONE|||ICP-MS|Y|NA|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|4||88||OBSERVATION|1970-09-08|
TRIAL STUDY 134XCP|TR|B842981B-AD7A-4A03-8E84-D5FC887BAD60|5||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||CI|PATHOLOGICAL||MEQ/DAY|NOT DONE|||SNELLEN EYE CHART|U|U|CHILD|RATER 2|NA|5||7||WASHOUT|1970-07-04|
TRIAL STUDY 134XCP|TR|07F7C4E7-7722-4916-AB89-46EF540E2BD7|1||||||ORSTATE|ORGAN STATE||10^8/L|INCREASED||CMH2O*S/ML|NOT DONE|||GC/MS-CI|U|U|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|1||38||FOLLOW-UP|1961-06-23|
TRIAL STUDY 134XCP|TR|07F7C4E7-7722-4916-AB89-46EF540E2BD7|2||||||LDIAM|LONGEST DIAMETER||ENZYME U/M2|ENLARGEMENT FROM NADIR||JAR|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|Y|N|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|2||58||TREATMENT|1968-11-15|
TRIAL STUDY 134XCP|TR|07F7C4E7-7722-4916-AB89-46EF540E2BD7|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MMOL/L|PATHOLOGICAL||MEQ|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|NA|NA|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|3||39||SCREENING|1963-01-16|
TRIAL STUDY 134XCP|TR|07F7C4E7-7722-4916-AB89-46EF540E2BD7|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||GRAIN|UNEQUIVOCAL||BISCUIT|NOT DONE|||PHOROPTER|Y|NA|VENDOR|CARDIOLOGIST|U|4||88||LONG-TERM FOLLOW-UP|1972-03-25|
TRIAL STUDY 134XCP|TR|07F7C4E7-7722-4916-AB89-46EF540E2BD7|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||SV|ENLARGEMENT||FMOL/L|NOT DONE|||RADIAL IMMUNODIFFUSION|U|NA|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|5||7||SCREENING|1970-08-27|
TRIAL STUDY 134XCP|TR|58661394-906E-43F3-8935-150DF240A04C|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMOL/MOL|FURTHER ENLARGEMENT FROM NADIR||TSP|NOT DONE|||DUKE INCISION METHOD|N|U|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1||38||CONTINUATION TREATMENT|1963-07-07|
TRIAL STUDY 134XCP|TR|58661394-906E-43F3-8935-150DF240A04C|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MV*MIN|NONPALPABLE||CI/KG|NOT DONE|||PERCUSSION|U|U|PROXY|RADIOLOGIST|U|2||58||CONTINUATION TREATMENT|1973-01-24|
TRIAL STUDY 134XCP|TR|58661394-906E-43F3-8935-150DF240A04C|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/G/DAY|FOCALLY INCREASED||KBQ/UL|NOT DONE|||AGAR DILUTION|NA|Y|CLINICAL RESEARCH ASSOCIATE|READER|Y|3||39||TREATMENT|1969-10-10|
TRIAL STUDY 134XCP|TR|58661394-906E-43F3-8935-150DF240A04C|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||NEWTON|NONPALPABLE||MOL|NOT DONE|||LIGHT MICROSCOPY|Y|N|DOMESTIC PARTNER|PATHOLOGIST 1|Y|4||88||CONTINUATION TREATMENT|1970-02-03|
TRIAL STUDY 134XCP|TR|58661394-906E-43F3-8935-150DF240A04C|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MEQ/G|ENLARGEMENT||10^3 RNA COPIES/ML|NOT DONE|||NO INFORMATION|U|N|GUARDIAN|CARDIOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1960-01-02|
TRIAL STUDY 134XCP|TR|B70F3694-B764-4B39-BFB9-B1281ED091B8|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PPTH|NON-PATHOLOGICAL||MG/DOSE|NOT DONE|||CONGO RED STAIN|Y|N|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|1||38||INDUCTION TREATMENT|1971-04-11|
TRIAL STUDY 134XCP|TR|B70F3694-B764-4B39-BFB9-B1281ED091B8|2||||||BNLNUM|NUMBER OF BONE LESIONS||10^3 RNA COPIES/ML|FURTHER ENLARGEMENT FROM NADIR||/MIN|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|N|N|HEALTH CARE PROFESSIONAL|READER 1|NA|2||58||BLINDED TREATMENT|1971-06-24|
TRIAL STUDY 134XCP|TR|B70F3694-B764-4B39-BFB9-B1281ED091B8|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||10^4/L|ENLARGEMENT FROM NADIR||CMH2O/ML|NOT DONE|||CLAUSS METHOD|U|U|CHILD|PATHOLOGIST 1|U|3||39||OPEN LABEL TREATMENT|1963-06-12|
TRIAL STUDY 134XCP|TR|B70F3694-B764-4B39-BFB9-B1281ED091B8|4||||||TUMSTATE|TUMOR STATE||MMOL|PRESENT||CMHG|NOT DONE|||IN SITU HYBRIDIZATION|U|Y|SIBLING|ONCOLOGIST|Y|4||88||WASHOUT|1963-05-29|
TRIAL STUDY 134XCP|TR|B70F3694-B764-4B39-BFB9-B1281ED091B8|5||||||PALPSTAT|PALPABLE STATE||/500 WBC|EQUIVOCAL||CM H2O|NOT DONE|||AURAMINE STAIN|Y|NA|PROXY|RADIOLOGIST 1|Y|5||7||FOLLOW-UP|1964-03-25|
TRIAL STUDY 134XCP|TR|5B2471DB-807A-44F8-9529-D2319CCFE017|1||||||VOLUME|VOLUME||KHZ|PATHOLOGICAL||SBE/ML|NOT DONE|||ELASTOGRAPHY|N|NA|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|1||38||RUN-IN|1971-08-05|
TRIAL STUDY 134XCP|TR|5B2471DB-807A-44F8-9529-D2319CCFE017|2||||||DIAMETER|DIAMETER||10^3 ORGANISMS/G|DIFFUSELY INCREASED||MG2/DL2|NOT DONE|||IMMUNORADIOMETRIC ASSAY|NA|U|ADJUDICATION COMMITTEE|RATER 1|NA|2||58||TREATMENT|1966-11-08|
TRIAL STUDY 134XCP|TR|5B2471DB-807A-44F8-9529-D2319CCFE017|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||10^5/L|UNEQUIVOCAL||FL|NOT DONE|||SPECTROPHOTOMETRY|U|Y|SIGNIFICANT OTHER|PATHOLOGIST|N|3||39||RUN-IN|1968-04-19|
TRIAL STUDY 134XCP|TR|5B2471DB-807A-44F8-9529-D2319CCFE017|4||||||ORSTATE|ORGAN STATE||INHALATION|PRESENT||UG/G/H|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|Y|Y|STUDY SUBJECT|READER 3|NA|4||88||CONTINUATION TREATMENT|1964-05-18|
TRIAL STUDY 134XCP|TR|5B2471DB-807A-44F8-9529-D2319CCFE017|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MG/CM2|NON-PATHOLOGICAL||M|NOT DONE|||IMMUNOPRECIPITATION|Y|Y|INTERVIEWER|FORENSIC PATHOLOGIST|NA|5||7||TREATMENT|1961-04-29|
TRIAL STUDY 134XCP|TR|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|1||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||BAU/ML|UNEQUIVOCAL||PPM|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|U|Y|CHILD|RATER 2|U|1||38||BASELINE|1971-06-15|
TRIAL STUDY 134XCP|TR|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^6 COPIES/ML|PATHOLOGICAL||KBQ|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|Y|N|DOMESTIC PARTNER|ADJUDICATOR 3|U|2||58||SCREENING|1960-04-24|
TRIAL STUDY 134XCP|TR|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||G/G|NORMAL||CY/CM|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|U|NA|STUDY SUBJECT|MICROSCOPIST|U|3||39||SCREENING|1960-11-16|
TRIAL STUDY 134XCP|TR|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|4||||||RADIODEN|RADIODENSITY||MV2/HZ|DIFFUSELY INCREASED||/HPF|NOT DONE|||IMMUNOASSAY|U|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|4||88||CONTINUATION TREATMENT|1962-03-27|
TRIAL STUDY 134XCP|TR|14D63A01-8418-4F72-ABE4-6E5DE30AE4C2|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||NM|TUMOR MERGED||%|NOT DONE|||FLOW CYTOMETRY|NA|N|PROXY|ADJUDICATOR 3|U|5||7||BLINDED TREATMENT|1968-06-20|
TRIAL STUDY 134XCP|TR|A6E00A2C-7DBC-4577-8873-C780F5A6B400|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||ML/CAGE|NORMAL||KEV|NOT DONE|||RADIAL IMMUNODIFFUSION|U|U|CAREGIVER|ONCOLOGIST 1|U|1||38||RUN-IN|1967-01-14|
TRIAL STUDY 134XCP|TR|A6E00A2C-7DBC-4577-8873-C780F5A6B400|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||CONTAINER|INCREASED||MEQ/MMOL|NOT DONE|||BAC ACGH|N|NA|SIGNIFICANT OTHER|RATER 2|U|2||58||INDUCTION TREATMENT|1968-10-24|
TRIAL STUDY 134XCP|TR|A6E00A2C-7DBC-4577-8873-C780F5A6B400|3||||||LDIAM|LONGEST DIAMETER||MG|PATHOLOGICAL||/SEC|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|N|N|INTERVIEWER|RATER|U|3||39||INDUCTION TREATMENT|1972-08-25|
TRIAL STUDY 134XCP|TR|A6E00A2C-7DBC-4577-8873-C780F5A6B400|4||||||LESSCIND|LESION SUCCESS INDICATOR||ROENTGEN|ENLARGEMENT||ML/ANIMAL/WK|NOT DONE|||AGAR PROPORTION|Y|U|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|4||88||RUN-IN|1971-05-21|
TRIAL STUDY 134XCP|TR|A6E00A2C-7DBC-4577-8873-C780F5A6B400|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||KV|NORMAL||CM|NOT DONE|||PHYSICAL EXAMINATION|U|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|5||7||BLINDED TREATMENT|1968-02-01|
TRIAL STUDY 134XCP|TR|06611015-E99C-466B-B0B3-EBE10EA9E627|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||EQ|UNCHANGED||USIEMENS|NOT DONE|||HPLC-UV|U|N|VENDOR|READER 2|N|1||38||LONG-TERM FOLLOW-UP|1968-12-23|
TRIAL STUDY 134XCP|TR|06611015-E99C-466B-B0B3-EBE10EA9E627|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||/100 HPFS|ABSENT||IU|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|NA|NA|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|2||58||BASELINE|1966-04-15|
TRIAL STUDY 134XCP|TR|06611015-E99C-466B-B0B3-EBE10EA9E627|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||BREATHS/MIN|UNEQUIVOCAL||UL/KG/DAY|NOT DONE|||ORCHIDOMETERY|U|U|SIBLING|ADJUDICATOR 1|Y|3||39||RUN-IN|1973-02-07|
TRIAL STUDY 134XCP|TR|06611015-E99C-466B-B0B3-EBE10EA9E627|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^3 CFU|FOCALLY INCREASED||CMH2O/ML|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|STUDY SUBJECT|PATHOLOGIST|U|4||88||OPEN LABEL TREATMENT|1963-01-17|
TRIAL STUDY 134XCP|TR|06611015-E99C-466B-B0B3-EBE10EA9E627|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MN|DECREASED||OSM|NOT DONE|||FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y|N|INVESTIGATOR|CARDIOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1971-03-22|
TRIAL STUDY 134XCP|TR|5AF91C46-87FC-4714-B956-A4ECFC87C30A|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CIGAR|TUMOR MERGED||KCAL/DAY|NOT DONE|||PERIPHERAL ANGIOGRAPHY|N|N|STUDY SUBJECT|MICROSCOPIST 1|U|1||38||SCREENING|1967-02-28|
TRIAL STUDY 134XCP|TR|5AF91C46-87FC-4714-B956-A4ECFC87C30A|2||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||U/G/DAY|EQUIVOCAL||/2500 WBC|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|NA|U|FAMILY MEMBER|CARDIOLOGIST|U|2||58||WASHOUT|1968-08-05|
TRIAL STUDY 134XCP|TR|5AF91C46-87FC-4714-B956-A4ECFC87C30A|3||||||AREA|AREA||G/M2|NORMAL||M/SEC|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|N|N|CAREGIVER|PEDIATRIC NEUROLOGIST|NA|3||39||FOLLOW-UP|1962-10-23|
TRIAL STUDY 134XCP|TR|5AF91C46-87FC-4714-B956-A4ECFC87C30A|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||UGEQ/L|FURTHER ENLARGEMENT||ML/G/MIN|NOT DONE|||GEL ELECTROPHORESIS|Y|U|CAREGIVER|ONCOLOGIST 1|NA|4||88||BASELINE|1971-04-19|
TRIAL STUDY 134XCP|TR|5AF91C46-87FC-4714-B956-A4ECFC87C30A|5||||||DIAMETER|DIAMETER||G/G/DAY|FOCALLY INCREASED||DNA COPIES/ML|NOT DONE|||ELECTRONEUROGRAPHY|Y|Y|PROXY|MICROSCOPIST|N|5||7||TREATMENT|1963-07-17|
TRIAL STUDY 134XCP|TR|3DEA7E00-77B9-4710-A37E-577F925BFBD8|1||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||G/G|NORMAL||CMOL/L|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|1||38||INDUCTION TREATMENT|1967-10-27|
TRIAL STUDY 134XCP|TR|3DEA7E00-77B9-4710-A37E-577F925BFBD8|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MET*MIN|NONPALPABLE||MM/MIN|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|U|NA|CLINICAL STUDY SPONSOR|READER 2|Y|2||58||TREATMENT|1969-12-18|
TRIAL STUDY 134XCP|TR|3DEA7E00-77B9-4710-A37E-577F925BFBD8|3||||||SUMDIAM|SUM OF DIAMETER||MBQ|UNEQUIVOCAL||VG/ML|NOT DONE|||CRYOSCOPY|N|N|CHILD|OPTOMETRIST|U|3||39||SCREENING|1967-12-16|
TRIAL STUDY 134XCP|TR|3DEA7E00-77B9-4710-A37E-577F925BFBD8|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||FL|ENLARGEMENT||QUANTITY SUFFICIENT|NOT DONE|||FLOW CYTOMETRY|N|N|CAREGIVER|OPTOMETRIST|U|4||88||BLINDED TREATMENT|1970-09-09|
TRIAL STUDY 134XCP|TR|3DEA7E00-77B9-4710-A37E-577F925BFBD8|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||ML/G/H|DIFFUSELY INCREASED||/2500 WBC|NOT DONE|||LANDOLT RING|N|N|HEALTH CARE PROFESSIONAL|INTERNIST|N|5||7||FOLLOW-UP|1967-12-01|
TRIAL STUDY 134XCP|TR|DC79E350-1B89-4518-8B42-5858F5270928|1||||||VOLUME|VOLUME||BOLUS|ENLARGEMENT||U|NOT DONE|||THIN SMEAR|Y|U|SPOUSE|ONCOLOGIST|Y|1||38||BLINDED TREATMENT|1966-09-26|
TRIAL STUDY 134XCP|TR|DC79E350-1B89-4518-8B42-5858F5270928|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||MV*MIN|PATHOLOGICAL||SBE/ML|NOT DONE|||SEQUENCING|U|Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|2||58||LONG-TERM FOLLOW-UP|1965-02-21|
TRIAL STUDY 134XCP|TR|DC79E350-1B89-4518-8B42-5858F5270928|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||CI/MG|FURTHER ENLARGEMENT||NMOL/DAY|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|N|Y|SPOUSE|RADIOLOGIST 2|NA|3||39||CONTINUATION TREATMENT|1960-07-07|
TRIAL STUDY 134XCP|TR|DC79E350-1B89-4518-8B42-5858F5270928|4||||||RADIODEN|RADIODENSITY||PT_US|EQUIVOCAL||/500 WBC|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|NA|U|SIBLING|NEUROLOGIST 2|U|4||88||TREATMENT|1963-02-07|
TRIAL STUDY 134XCP|TR|DC79E350-1B89-4518-8B42-5858F5270928|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||LINEAR FT*LB|UNCHANGED||MMOL2/L2|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|NA|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1970-12-29|
TRIAL STUDY 134XCP|TR|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||U/G/H|UNCHANGED||ML/M2/H|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|NA|PROXY|NEUROLOGIST|U|1||38||RUN-IN|1967-01-02|
TRIAL STUDY 134XCP|TR|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||G/U|TUMOR MERGED||COPIES/ML|NOT DONE|||PHASE-CONTRAST MRI|U|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|2||58||WASHOUT|1966-04-07|
TRIAL STUDY 134XCP|TR|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||10^8/L|FURTHER ENLARGEMENT||G/CAGE|NOT DONE|||ANGIOGRAPHY|Y|U|FRIEND|RATER|NA|3||39||OPEN LABEL TREATMENT|1961-02-02|
TRIAL STUDY 134XCP|TR|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|4||||||PALPSTAT|PALPABLE STATE||NKAT|DIFFUSELY INCREASED||BLOCKS|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|U|NA|GUARDIAN|MICROSCOPIST 2|U|4||88||OBSERVATION|1960-03-20|
TRIAL STUDY 134XCP|TR|9B8B6DCE-AF08-40AC-90BB-87CCC5592726|5||||||VDIAM|VIABLE DIAMETER||DIP|TUMOR MERGED||UG/ANIMAL|NOT DONE|||FLUORESCENT MICROSCOPY|NA|Y|VENDOR|ADJUDICATOR 2|U|5||7||LONG-TERM FOLLOW-UP|1963-07-05|
TRIAL STUDY 134XCP|TR|7F51014D-D2B5-4956-9DD6-52676EB66ED7|1||||||LNSTATE|LYMPH NODE STATE||%/S|FURTHER ENLARGEMENT||%(W/W)|NOT DONE|||SLIT LAMP|Y|U|SIBLING|MICROSCOPIST 1|N|1||38||FOLLOW-UP|1966-07-31|
TRIAL STUDY 134XCP|TR|7F51014D-D2B5-4956-9DD6-52676EB66ED7|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ENZYME U/M2|UNCHANGED||UOSM|NOT DONE|||HPLC|Y|U|VENDOR|PATHOLOGIST|U|2||58||CONTINUATION TREATMENT|1969-12-01|
TRIAL STUDY 134XCP|TR|7F51014D-D2B5-4956-9DD6-52676EB66ED7|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||10^4 CFU|NON-PATHOLOGICAL||MMOL/S|NOT DONE|||AUSCULTATION|N|NA|VENDOR|CARDIOLOGIST|U|3||39||OBSERVATION|1962-10-11|
TRIAL STUDY 134XCP|TR|7F51014D-D2B5-4956-9DD6-52676EB66ED7|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MCI/KG|EQUIVOCAL||LINEAR FT*LB|NOT DONE|||MUGA|NA|NA|INVESTIGATOR|ONCOLOGIST|U|4||88||TREATMENT|1968-12-26|
TRIAL STUDY 134XCP|TR|7F51014D-D2B5-4956-9DD6-52676EB66ED7|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||HZ|ENLARGEMENT FROM NADIR||TSP|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|NA|ADJUDICATOR|ONCOLOGIST 1|NA|5||7||TREATMENT|1964-04-21|
TRIAL STUDY 134XCP|TR|0568B2DD-3184-472D-89C6-66A5CE8AE00F|1||||||ORSTATE|ORGAN STATE||MANSON U/ML|UNEQUIVOCAL||BAR|NOT DONE|||SINGLE-SLICE SPIRAL CT|NA|Y|VENDOR|READER|N|1||38||LONG-TERM FOLLOW-UP|1966-06-24|
TRIAL STUDY 134XCP|TR|0568B2DD-3184-472D-89C6-66A5CE8AE00F|2||||||SUMVOL|SUM OF VOLUME||%/S|NORMAL||BQ/MG|NOT DONE|||DNA MICROARRAY|N|Y|PARENT|ONCOLOGIST 2|NA|2||58||INDUCTION TREATMENT|1971-09-24|
TRIAL STUDY 134XCP|TR|0568B2DD-3184-472D-89C6-66A5CE8AE00F|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||NMOL BCE/NMOL|FURTHER ENLARGEMENT||POINT|NOT DONE|||CONFOCAL MICROSCOPY|NA|N|INVESTIGATOR|ENDOCRINOLOGIST|N|3||39||WASHOUT|1968-05-16|
TRIAL STUDY 134XCP|TR|0568B2DD-3184-472D-89C6-66A5CE8AE00F|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||AMFI|DECREASED||ENZYME U/M2|NOT DONE|||PET/SPECT SCAN|Y|Y|INTERVIEWER|PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1965-01-14|
TRIAL STUDY 134XCP|TR|0568B2DD-3184-472D-89C6-66A5CE8AE00F|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||RFU|FURTHER ENLARGEMENT FROM NADIR||MAMP|NOT DONE|||LC/MS|Y|Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|5||7||SCREENING|1973-08-16|
TRIAL STUDY 134XCP|TR|275DC6A6-598C-4997-A442-4A3916AC42BD|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||BQ/KG|DIFFUSELY INCREASED||MMHG/L/MIN|NOT DONE|||CELL BASED BIOASSAY|Y|N|DOMESTIC PARTNER|READER 3|Y|1||38||BASELINE|1970-09-08|
TRIAL STUDY 134XCP|TR|275DC6A6-598C-4997-A442-4A3916AC42BD|2||||||SUMVOL|SUM OF VOLUME||UV2|UNCHANGED||CAPSULE|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|NA|N|CAREGIVER|INTERNIST|U|2||58||SCREENING|1964-07-31|
TRIAL STUDY 134XCP|TR|275DC6A6-598C-4997-A442-4A3916AC42BD|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MIN*MG/ML|ABSENT||DB|NOT DONE|||KLEIHAUER-BETKE|NA|N|CLINICAL RESEARCH COORDINATOR|READER|NA|3||39||OBSERVATION|1965-05-27|
TRIAL STUDY 134XCP|TR|275DC6A6-598C-4997-A442-4A3916AC42BD|4||||||LESFLIND|LESION FAILURE INDICATOR||PMOL/L/H|FOCALLY INCREASED||MG/MOL|NOT DONE|||BETA LACTAMASE|N|N|CAREGIVER|RADIOLOGIST|NA|4||88||CONTINUATION TREATMENT|1970-02-21|
TRIAL STUDY 134XCP|TR|275DC6A6-598C-4997-A442-4A3916AC42BD|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||DB|FURTHER ENLARGEMENT FROM NADIR||GY|NOT DONE|||WRIGHT STAIN|U|N|INTERVIEWER|READER 3|N|5||7||TREATMENT|1970-06-10|
TRIAL STUDY 134XCP|TR|B949F90F-524D-4494-A63C-A05F56421EA1|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||ML/M2/MIN|FOCALLY INCREASED||NG/L|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|U|Y|VENDOR|HEMATOLOGIST|Y|1||38||RUN-IN|1968-05-08|
TRIAL STUDY 134XCP|TR|B949F90F-524D-4494-A63C-A05F56421EA1|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||DRUM|ABSENT||QUANTITY SUFFICIENT|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|U|Y|GUARDIAN|RATER|NA|2||58||OBSERVATION|1968-01-01|
TRIAL STUDY 134XCP|TR|B949F90F-524D-4494-A63C-A05F56421EA1|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||RFU|UNEQUIVOCAL||UMOL/L/SEC|NOT DONE|||FREEZING POINT DEPRESSION|NA|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|3||39||WASHOUT|1973-03-15|
TRIAL STUDY 134XCP|TR|B949F90F-524D-4494-A63C-A05F56421EA1|4||||||ORVERLN|ORGAN VERTICAL LENGTH||ML/MMHG|ENLARGEMENT||KG/CM|NOT DONE|||AUTOREFRACTION|U|NA|VENDOR|ADJUDICATOR 1|N|4||88||OPEN LABEL TREATMENT|1960-01-04|
TRIAL STUDY 134XCP|TR|B949F90F-524D-4494-A63C-A05F56421EA1|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UKAT/10^12 RBC|UNEQUIVOCAL||UG/G/DAY|NOT DONE|||LC/MS|Y|N|INVESTIGATOR|NEUROLOGIST 1|Y|5||7||INDUCTION TREATMENT|1962-12-28|
TRIAL STUDY 134XCP|TR|152411EA-E7DA-4230-A8A6-163C8A8C0A58|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||HOMEOPATHIC DILUTION|DECREASED||UG/M2/DAY|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|U|SPOUSE|ADJUDICATOR 2|N|1||38||WASHOUT|1973-08-30|
TRIAL STUDY 134XCP|TR|152411EA-E7DA-4230-A8A6-163C8A8C0A58|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MNFI|ENLARGEMENT||INHALATION|NOT DONE|||PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|NA|U|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|2||58||RUN-IN|1971-12-11|
TRIAL STUDY 134XCP|TR|152411EA-E7DA-4230-A8A6-163C8A8C0A58|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MMOL/MOL|NORMAL||L/MIN/M2|NOT DONE|||MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|U|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|3||39||LONG-TERM FOLLOW-UP|1970-11-15|
TRIAL STUDY 134XCP|TR|152411EA-E7DA-4230-A8A6-163C8A8C0A58|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||ML/(MIN*100ML)|PRESENT||/MS|NOT DONE|||SANGER SEQUENCING|NA|Y|FAMILY MEMBER|OPTOMETRIST|NA|4||88||SCREENING|1967-12-07|
TRIAL STUDY 134XCP|TR|152411EA-E7DA-4230-A8A6-163C8A8C0A58|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||LOG10 CCID 50/DOSE|TUMOR MERGED||ML/H|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|U|SPOUSE|ADJUDICATOR 1|N|5||7||SCREENING|1969-12-07|
TRIAL STUDY 134XCP|TR|AB78662C-F90A-4193-9AC7-5621B497A18F|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MEQ/UG|PATHOLOGICAL||YEARS|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|N|N|FRIEND|RATER 2|Y|1||38||WASHOUT|1961-10-03|
TRIAL STUDY 134XCP|TR|AB78662C-F90A-4193-9AC7-5621B497A18F|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||POUCH|INCREASED||KEV|NOT DONE|||RYAN BLUE STAIN|NA|N|SPOUSE|ONCOLOGIST|U|2||58||BLINDED TREATMENT|1961-11-15|
TRIAL STUDY 134XCP|TR|AB78662C-F90A-4193-9AC7-5621B497A18F|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||CMH2O*S/ML|PRESENT||MV*MIN|NOT DONE|||ELECTROGASTROGRAPHY|Y|N|PARENT|READER 2|U|3||39||OPEN LABEL TREATMENT|1967-10-08|
TRIAL STUDY 134XCP|TR|AB78662C-F90A-4193-9AC7-5621B497A18F|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||GBQ/G|NORMAL||LOG10 CFU/G|NOT DONE|||HILLMEN COLOR CHART|U|U|VENDOR|CLINICAL PATHOLOGIST|NA|4||88||BLINDED TREATMENT|1967-10-03|
TRIAL STUDY 134XCP|TR|AB78662C-F90A-4193-9AC7-5621B497A18F|5||||||VDIAM|VIABLE DIAMETER||ENZYME U/M2|DECREASED||U/MG|NOT DONE|||PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|N|NA|FRIEND|FORENSIC PATHOLOGIST|NA|5||7||BLINDED TREATMENT|1964-06-23|
TRIAL STUDY 134XCP|TR|84CD31FD-BCB9-4439-84F7-11C63D578108|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||USIEMENS|ABSENT||MBP|NOT DONE|||TRYPAN BLUE STAIN|Y|N|INTERVIEWER|MICROSCOPIST|N|1||38||BASELINE|1967-04-10|
TRIAL STUDY 134XCP|TR|84CD31FD-BCB9-4439-84F7-11C63D578108|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MMOL/L|ENLARGEMENT FROM NADIR||MKAT|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|N|U|SIGNIFICANT OTHER|READER|U|2||58||SCREENING|1967-12-25|
TRIAL STUDY 134XCP|TR|84CD31FD-BCB9-4439-84F7-11C63D578108|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||FG|ABSENT||G/CAGE|NOT DONE|||TONOMETRY|Y|Y|CAREGIVER|MICROSCOPIST 1|NA|3||39||BASELINE|1965-06-04|
TRIAL STUDY 134XCP|TR|84CD31FD-BCB9-4439-84F7-11C63D578108|4||||||VSLFLIND|VESSEL FAILURE INDICATOR||BAU|ABSENT||KG/MOL|NOT DONE|||SPECT/CT SCAN|NA|NA|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|4||88||CONTINUATION TREATMENT|1965-02-10|
TRIAL STUDY 134XCP|TR|84CD31FD-BCB9-4439-84F7-11C63D578108|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||M3|ABSENT||10^12 IU/L|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|N|PARENT|RADIOLOGIST|Y|5||7||TREATMENT|1972-05-02|
TRIAL STUDY 134XCP|TR|BB9A976D-48AC-4618-9BA1-683D97240F2B|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||PG/L|NONPALPABLE||ML/M2/MIN|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|U|U|GUARDIAN|ADJUDICATOR 3|N|1||38||TREATMENT|1966-08-11|
TRIAL STUDY 134XCP|TR|BB9A976D-48AC-4618-9BA1-683D97240F2B|2||||||TUMSTATE|TUMOR STATE||P|DIFFUSELY INCREASED||L/L|NOT DONE|||GC/MS/MS|N|N|DOMESTIC PARTNER|ADJUDICATOR 3|Y|2||58||RUN-IN|1967-09-27|
TRIAL STUDY 134XCP|TR|BB9A976D-48AC-4618-9BA1-683D97240F2B|3||||||LESSCIND|LESION SUCCESS INDICATOR||UG/L FEU|TUMOR MERGED||MGEQ|NOT DONE|||MANUAL CLOT DETECTION|U|Y|VENDOR|CARDIOLOGIST|N|3||39||OPEN LABEL TREATMENT|1967-12-16|
TRIAL STUDY 134XCP|TR|BB9A976D-48AC-4618-9BA1-683D97240F2B|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||DMOL|PRESENT||NCI|NOT DONE|||HPLC-UV|U|Y|SIBLING|RADIOLOGIST|U|4||88||SCREENING|1971-04-24|
TRIAL STUDY 134XCP|TR|BB9A976D-48AC-4618-9BA1-683D97240F2B|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||NEEDLE GAUGE|ENLARGEMENT||MOL/DAY|NOT DONE|||POLYSOMNOGRAPHY|Y|N|VENDOR|INTERNIST|NA|5||7||SCREENING|1965-05-12|
TRIAL STUDY 134XCP|TR|FA440C9B-0D7A-4656-BF17-D46289567FB0|1||||||LESSCIND|LESION SUCCESS INDICATOR||CONTAINER|PALPABLE||10^6 ORGANISMS/ML|NOT DONE|||GC/MS|N|U|ADJUDICATION COMMITTEE|ADJUDICATOR|U|1||38||TREATMENT|1969-01-13|
TRIAL STUDY 134XCP|TR|FA440C9B-0D7A-4656-BF17-D46289567FB0|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||HOURS|FOCALLY INCREASED||MOSM/KG|NOT DONE|||PHOROPTER|U|U|VENDOR|ADJUDICATOR 3|U|2||58||WASHOUT|1968-04-25|
TRIAL STUDY 134XCP|TR|FA440C9B-0D7A-4656-BF17-D46289567FB0|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UCI|FURTHER ENLARGEMENT||CIGARETTE|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|NA|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|3||39||BLINDED TREATMENT|1961-11-19|
TRIAL STUDY 134XCP|TR|FA440C9B-0D7A-4656-BF17-D46289567FB0|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||ML/G/H|UNCHANGED||10^9 CFU/ML|NOT DONE|||RIA|Y|Y|SPOUSE|RATER|NA|4||88||WASHOUT|1965-03-01|
TRIAL STUDY 134XCP|TR|FA440C9B-0D7A-4656-BF17-D46289567FB0|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||KBQ/UL|UNCHANGED||PACK YEAR|NOT DONE|||IMPEDANCE CONDUCTIVITY|N|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|5||7||TREATMENT|1960-06-13|
TRIAL STUDY 134XCP|TR|1706BA4E-D2AB-4877-974A-17BDBD834FFF|1||||||SUMVOL|SUM OF VOLUME||NMOL BCE/L|TUMOR MERGED||DAMOL/L|NOT DONE|||NO INFORMATION|NA|N|PROXY|HEMATOLOGIST|N|1||38||BASELINE|1964-07-17|
TRIAL STUDY 134XCP|TR|1706BA4E-D2AB-4877-974A-17BDBD834FFF|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||NU/CL|FOCALLY INCREASED||PA|NOT DONE|||LYMPHANGIOGRAPHY|N|N|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|2||58||OBSERVATION|1962-08-26|
TRIAL STUDY 134XCP|TR|1706BA4E-D2AB-4877-974A-17BDBD834FFF|3||||||PALPSTAT|PALPABLE STATE||BAR|FURTHER ENLARGEMENT FROM NADIR||ABSORBANCE U/MIN|NOT DONE|||CONTRAST ENHANCED X-RAY|Y|NA|STUDY SUBJECT|CARDIOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1960-04-30|
TRIAL STUDY 134XCP|TR|1706BA4E-D2AB-4877-974A-17BDBD834FFF|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MMOL/G|ENLARGEMENT||G/CAGE|NOT DONE|||BETA LACTAMASE|N|Y|SIBLING|READER 1|N|4||88||LONG-TERM FOLLOW-UP|1964-04-22|
TRIAL STUDY 134XCP|TR|1706BA4E-D2AB-4877-974A-17BDBD834FFF|5||||||NEWCONF|NEW TUMOR CONFIRMED||BOLUS|DECREASED||UG/G/MIN|NOT DONE|||LANDOLT RING|Y|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|5||7||CONTINUATION TREATMENT|1972-05-29|
TRIAL STUDY 134XCP|TR|15E3DD06-7F28-499B-9CF5-6EE5875095B5|1||||||RADIODEN|RADIODENSITY||/2000 RBC|PALPABLE||ML/MMHG/MIN/L|NOT DONE|||ACRIDINE ORANGE STAIN|Y|U|CHILD|ONCOLOGIST|Y|1||38||INDUCTION TREATMENT|1969-03-24|
TRIAL STUDY 134XCP|TR|15E3DD06-7F28-499B-9CF5-6EE5875095B5|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||GPL U/ML|INCREASED||U/KG/H|NOT DONE|||THICK SMEAR|NA|Y|INTERVIEWER|RATER 1|N|2||58||WASHOUT|1966-07-21|
TRIAL STUDY 134XCP|TR|15E3DD06-7F28-499B-9CF5-6EE5875095B5|3||||||LESSCIND|LESION SUCCESS INDICATOR||L/KG|NONPALPABLE||10^3/L|NOT DONE|||LIQUID SCINTILLATION COUNTING|Y|N|PROXY|RATER|U|3||39||OPEN LABEL TREATMENT|1962-01-06|
TRIAL STUDY 134XCP|TR|15E3DD06-7F28-499B-9CF5-6EE5875095B5|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||S/H|ENLARGEMENT FROM NADIR||GY|NOT DONE|||NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|NA|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|4||88||WASHOUT|1961-01-08|
TRIAL STUDY 134XCP|TR|15E3DD06-7F28-499B-9CF5-6EE5875095B5|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||FMOL/G|DECREASED||CUP EQ|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|Y|NA|PARENT|MICROSCOPIST 2|N|5||7||LONG-TERM FOLLOW-UP|1972-01-14|
TRIAL STUDY 134XCP|TR|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|1||||||LNSTATE|LYMPH NODE STATE||KDA|UNCHANGED||PSEC|NOT DONE|||WESTERN BLOT|NA|Y|SIBLING|DERMATOLOGIST|NA|1||38||RUN-IN|1969-05-10|
TRIAL STUDY 134XCP|TR|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MPH|ABSENT||OSM|NOT DONE|||DIFFUSION WEIGHTED MRI|N|Y|PARENT|FORENSIC PATHOLOGIST|NA|2||58||OBSERVATION|1963-05-11|
TRIAL STUDY 134XCP|TR|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||ML/ANIMAL/WK|PATHOLOGICAL||GY/H|NOT DONE|||ENDPOINT DILUTION ASSAY|Y|Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|3||39||RUN-IN|1961-01-08|
TRIAL STUDY 134XCP|TR|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|4||||||TUMSTATE|TUMOR STATE||AMU|DIFFUSELY INCREASED||L/S/KPA|NOT DONE|||SLIT LAMP PHOTOGRAPHY|Y|U|INDEPENDENT ASSESSOR|ADJUDICATOR|U|4||88||FOLLOW-UP|1964-03-24|
TRIAL STUDY 134XCP|TR|D6201F20-A9DD-4F72-9FB2-9F238819A0BD|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MG/M2/DAY|PRESENT||MET*H|NOT DONE|||STRESS ECHOCARDIOGRAPHY|NA|Y|FAMILY MEMBER|READER|N|5||7||LONG-TERM FOLLOW-UP|1962-02-18|
TRIAL STUDY 134XCP|TR|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|1||||||LNSTATE|LYMPH NODE STATE||MG/ML/DAY|PALPABLE||10^6/G|NOT DONE|||LAPAROSCOPY|N|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|1||38||BLINDED TREATMENT|1973-04-01|
TRIAL STUDY 134XCP|TR|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|2||||||VSLPIND|VESSEL PATENCY INDICATOR||NEWTON|DECREASED||APPLICATION|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|U|PARENT|READER|NA|2||58||INDUCTION TREATMENT|1973-02-01|
TRIAL STUDY 134XCP|TR|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||IU/L|PATHOLOGICAL||BEATS/MIN|NOT DONE|||CLIP SEQUENCING|NA|NA|INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|3||39||SCREENING|1962-11-20|
TRIAL STUDY 134XCP|TR|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||RPM|DECREASED||UG/L FEU|NOT DONE|||U-HPLC/MS/MS|U|Y|DOMESTIC PARTNER|ONCOLOGIST|U|4||88||SCREENING|1962-09-07|
TRIAL STUDY 134XCP|TR|787ADEF3-A20C-4977-A06E-1A4BE008C3AB|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||/LPF|PRESENT||G/MOL|NOT DONE|||HILLMEN COLOR CHART|Y|NA|INVESTIGATOR|NEUROLOGIST 1|N|5||7||OBSERVATION|1965-02-27|
TRIAL STUDY 134XCP|TR|87ED1C08-AF47-4827-A897-E8FC24A69ECC|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||V|ABSENT||UL/KG/DAY|NOT DONE|||IODINE STAIN|U|N|HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1||38||RUN-IN|1973-05-13|
TRIAL STUDY 134XCP|TR|87ED1C08-AF47-4827-A897-E8FC24A69ECC|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MJOULE/CM2|FURTHER ENLARGEMENT FROM NADIR||MEQ/ML|NOT DONE|||MANUAL COUNT|N|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||TREATMENT|1971-07-18|
TRIAL STUDY 134XCP|TR|87ED1C08-AF47-4827-A897-E8FC24A69ECC|3||||||SUMDIAM|SUM OF DIAMETER||GPELISA UNIT/ML|NONPALPABLE||UG/KG|NOT DONE|||WEBER GREEN STAIN|Y|U|VENDOR|ADJUDICATOR 1|U|3||39||OBSERVATION|1962-09-04|
TRIAL STUDY 134XCP|TR|87ED1C08-AF47-4827-A897-E8FC24A69ECC|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||HZ|EQUIVOCAL||GBQ|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|N|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4||88||CONTINUATION TREATMENT|1968-06-26|
TRIAL STUDY 134XCP|TR|87ED1C08-AF47-4827-A897-E8FC24A69ECC|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||GPL U/ML|NON-PATHOLOGICAL||CCID 50/ML|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|NA|U|CHILD|ADJUDICATOR 2|N|5||7||FOLLOW-UP|1964-05-31|
TRIAL STUDY 134XCP|TR|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MOL/DAY|UNEQUIVOCAL||PIPE|NOT DONE|||WRIGHT STAIN|Y|Y|ADJUDICATOR|PHYSIOTHERAPIST|Y|1||38||OPEN LABEL TREATMENT|1969-03-11|
TRIAL STUDY 134XCP|TR|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|2||||||LNSTATE|LYMPH NODE STATE||BQ/KG|TUMOR MERGED||FRACTION OF 1|NOT DONE|||DUCTOGRAPHY|Y|NA|VENDOR|PATHOLOGIST 2|NA|2||58||RUN-IN|1961-10-30|
TRIAL STUDY 134XCP|TR|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||ROENTGEN|INCREASED||FL|NOT DONE|||SISH|U|U|STUDY SUBJECT|ADJUDICATOR 1|N|3||39||INDUCTION TREATMENT|1963-03-10|
TRIAL STUDY 134XCP|TR|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|4||||||PALPSTAT|PALPABLE STATE||VG/DOSE|EQUIVOCAL||CS|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|N|Y|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|NA|4||88||SCREENING|1973-06-03|
TRIAL STUDY 134XCP|TR|47389FD4-FB17-4BD9-9B08-0F2C6FF60D9A|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||%(W/V)|UNCHANGED||UG/H|NOT DONE|||CT SCAN WITHOUT CONTRAST|N|N|HEALTH CARE PROFESSIONAL|READER|NA|5||7||BASELINE|1973-04-14|
TRIAL STUDY 134XCP|TR|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|1||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MG/M2/DAY|ENLARGEMENT FROM NADIR||/10^4|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|N|U|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|1||38||SCREENING|1969-08-08|
TRIAL STUDY 134XCP|TR|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||U/G HB|FOCALLY INCREASED||IN|NOT DONE|||DUKE INCISION METHOD|U|Y|CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|2||58||WASHOUT|1963-03-28|
TRIAL STUDY 134XCP|TR|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||DEG/S|PALPABLE||ML/CAGE/WK|NOT DONE|||MICRODENSITOMETRY|N|Y|PARENT|ONCOLOGIST 2|NA|3||39||INDUCTION TREATMENT|1966-01-07|
TRIAL STUDY 134XCP|TR|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|4||||||VDIAM|VIABLE DIAMETER||AMPULE|FURTHER ENLARGEMENT FROM NADIR||ML/MIN/MMHG|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|U|NA|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|4||88||BASELINE|1960-06-11|
TRIAL STUDY 134XCP|TR|719A3C37-C9C2-4A84-BEC2-CE3033AB5D2F|5||||||ORVERLN|ORGAN VERTICAL LENGTH||G/U|NORMAL||EQ|NOT DONE|||ENDPOINT DILUTION ASSAY|U|NA|SIBLING|MICROSCOPIST 3|N|5||7||BLINDED TREATMENT|1971-05-04|
TRIAL STUDY 134XCP|TR|C817A043-1331-47AB-A627-D85893F9D61A|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||CG|UNCHANGED||10^4/L|NOT DONE|||RADIOGRAPHY|NA|N|GUARDIAN|PATHOLOGIST 1|N|1||38||TREATMENT|1966-03-11|
TRIAL STUDY 134XCP|TR|C817A043-1331-47AB-A627-D85893F9D61A|2||||||TUMSTATE|TUMOR STATE||/SEC|DIFFUSELY INCREASED||CY/CM|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|N|Y|STUDY SUBJECT|RATER|U|2||58||FOLLOW-UP|1971-11-17|
TRIAL STUDY 134XCP|TR|C817A043-1331-47AB-A627-D85893F9D61A|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||BAU/ML|PALPABLE||10^9 ORGANISMS|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|NA|U|SIGNIFICANT OTHER|READER 1|U|3||39||BLINDED TREATMENT|1972-09-14|
TRIAL STUDY 134XCP|TR|C817A043-1331-47AB-A627-D85893F9D61A|4||||||VDIAM|VIABLE DIAMETER||PMOL/L/H|ENLARGEMENT||WEEKS|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|U|CLINICAL RESEARCH COORDINATOR|RATER 2|N|4||88||BASELINE|1964-01-11|
TRIAL STUDY 134XCP|TR|C817A043-1331-47AB-A627-D85893F9D61A|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||UKAT/10^12 RBC|ENLARGEMENT FROM NADIR||UMOL/L/H|NOT DONE|||IMMUNOPRECIPITATION|U|NA|ADJUDICATOR|READER 1|N|5||7||FOLLOW-UP|1970-08-05|
TRIAL STUDY 134XCP|TR|DDD6F5D1-AE97-412C-A161-869C4178223A|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MMOL/MIN/KPA/L|PALPABLE||DAYS|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|U|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|1||38||TREATMENT|1972-02-01|
TRIAL STUDY 134XCP|TR|DDD6F5D1-AE97-412C-A161-869C4178223A|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||G/CAGE/DAY|ABSENT||COAT|NOT DONE|||DOPPLER ULTRASOUND|U|Y|STUDY SUBJECT|PHYSIOTHERAPIST|Y|2||58||BASELINE|1967-04-26|
TRIAL STUDY 134XCP|TR|DDD6F5D1-AE97-412C-A161-869C4178223A|3||||||TUMSTATE|TUMOR STATE||/MBP|ENLARGEMENT||OZ EQ|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|U|N|PARENT|CLINICAL PATHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1967-10-22|
TRIAL STUDY 134XCP|TR|DDD6F5D1-AE97-412C-A161-869C4178223A|4||||||NEWCONF|NEW TUMOR CONFIRMED||KAT|UNCHANGED||MBQ|NOT DONE|||DIRECT SEQUENCING|U|U|CAREGIVER|NEUROLOGIST|N|4||88||FOLLOW-UP|1968-12-26|
TRIAL STUDY 134XCP|TR|DDD6F5D1-AE97-412C-A161-869C4178223A|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||GRAIN|NORMAL||10^3 COPIES/ML|NOT DONE|||MS/MS|N|Y|PROXY|RATER|U|5||7||TREATMENT|1966-03-26|
TRIAL STUDY 134XCP|TR|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MET*H|TUMOR MERGED||MS/MMHG|NOT DONE|||CONFOCAL MICROSCOPY|NA|U|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|1||38||OPEN LABEL TREATMENT|1965-02-04|
TRIAL STUDY 134XCP|TR|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^7 CFU|ENLARGEMENT FROM NADIR||PG/CELL|NOT DONE|||CLOT DETECTION|U|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|2||58||OPEN LABEL TREATMENT|1962-07-11|
TRIAL STUDY 134XCP|TR|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MMOL/S|TUMOR MERGED||/DAY|NOT DONE|||ETDRS EYE CHART|N|NA|INTERVIEWER|ONCOLOGIST|U|3||39||BLINDED TREATMENT|1970-09-27|
TRIAL STUDY 134XCP|TR|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||KAT|NON-PATHOLOGICAL||AMOL|NOT DONE|||PH METER MEASUREMENT METHOD|U|Y|GUARDIAN|INTERNIST|N|4||88||WASHOUT|1969-05-11|
TRIAL STUDY 134XCP|TR|D41D9F0A-56BF-46E5-A936-3B4AD5210C18|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||H/WK|PRESENT||C|NOT DONE|||JAFFE REACTION|NA|NA|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|5||7||INDUCTION TREATMENT|1973-05-25|
TRIAL STUDY 134XCP|TR|25FB07EA-3CB8-430D-B775-CA0E9918C069|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MG/M2/DAY|NON-PATHOLOGICAL||UV2|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|NA|N|DOMESTIC PARTNER|MICROSCOPIST 1|U|1||38||BLINDED TREATMENT|1969-02-12|
TRIAL STUDY 134XCP|TR|25FB07EA-3CB8-430D-B775-CA0E9918C069|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||PIXEL|NONPALPABLE||BEL|NOT DONE|||NUCLEIC ACID SEQUENCING|Y|N|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|2||58||RUN-IN|1965-08-09|
TRIAL STUDY 134XCP|TR|25FB07EA-3CB8-430D-B775-CA0E9918C069|3||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NG/DL|FOCALLY INCREASED||GPL U|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|N|N|INVESTIGATOR|READER 3|Y|3||39||RUN-IN|1971-09-11|
TRIAL STUDY 134XCP|TR|25FB07EA-3CB8-430D-B775-CA0E9918C069|4||||||DIAMETER|DIAMETER||MHZ|TUMOR MERGED||ML/CAGE/DAY|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|4||88||BLINDED TREATMENT|1971-03-18|
TRIAL STUDY 134XCP|TR|25FB07EA-3CB8-430D-B775-CA0E9918C069|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||WEBER|FOCALLY INCREASED||UG/CM2|NOT DONE|||MIGET|Y|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1970-03-28|
TRIAL STUDY 134XCP|TR|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||FFU|NON-PATHOLOGICAL||ARBITRARY U|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|1||38||CONTINUATION TREATMENT|1970-06-30|
TRIAL STUDY 134XCP|TR|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|2||||||BNLNUM|NUMBER OF BONE LESIONS||/MS|FURTHER ENLARGEMENT||/VF|NOT DONE|||STRESS ECHOCARDIOGRAPHY|NA|NA|INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|2||58||LONG-TERM FOLLOW-UP|1963-09-11|
TRIAL STUDY 134XCP|TR|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||ML/M2/DAY|ENLARGEMENT FROM NADIR||NMOL/DAY|NOT DONE|||DIRECT SEQUENCING|NA|NA|ADJUDICATION COMMITTEE|READER 3|NA|3||39||INDUCTION TREATMENT|1963-11-27|
TRIAL STUDY 134XCP|TR|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ANSON U|TUMOR MERGED||MBP|NOT DONE|||PALPATION|Y|U|SIBLING|DERMATOLOGIST|Y|4||88||TREATMENT|1964-02-26|
TRIAL STUDY 134XCP|TR|21F6CB0B-3483-4BFF-AEC7-FCF14873077A|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ANSON U|FURTHER ENLARGEMENT||MBQ|NOT DONE|||MS/MS|N|N|PARENT|HEMATOLOGIST|U|5||7||BLINDED TREATMENT|1973-01-08|
TRIAL STUDY 134XCP|TR|B49B9695-9815-4B7B-9F96-4EE6A4432062|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MASK|ENLARGEMENT||MS2|NOT DONE|||IN SITU HYBRIDIZATION|N|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|1||38||BLINDED TREATMENT|1960-12-09|
TRIAL STUDY 134XCP|TR|B49B9695-9815-4B7B-9F96-4EE6A4432062|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||OD UNIT|PALPABLE||BQ/L|NOT DONE|||CELL BASED BIOASSAY|N|U|FAMILY MEMBER|NEUROLOGIST 1|U|2||58||BASELINE|1966-10-22|
TRIAL STUDY 134XCP|TR|B49B9695-9815-4B7B-9F96-4EE6A4432062|3||||||AREA|AREA||SV|NON-PATHOLOGICAL||NMOL/KG/DAY|NOT DONE|||MRI|N|U|SIBLING|MICROSCOPIST|NA|3||39||BASELINE|1966-05-08|
TRIAL STUDY 134XCP|TR|B49B9695-9815-4B7B-9F96-4EE6A4432062|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||NL|NONPALPABLE||M2|NOT DONE|||THICK SMEAR|N|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|4||88||SCREENING|1971-09-19|
TRIAL STUDY 134XCP|TR|B49B9695-9815-4B7B-9F96-4EE6A4432062|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||DAYS/MONTH|INCREASED||PIXELS/CM|NOT DONE|||RULER MEASUREMENT METHOD|Y|NA|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|5||7||BLINDED TREATMENT|1963-03-20|
TRIAL STUDY 134XCP|TR|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||FRAMES/S|TUMOR MERGED||COPIES/UL|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|NA|N|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|1||38||WASHOUT|1973-06-16|
TRIAL STUDY 134XCP|TR|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|2||||||LNSTATE|LYMPH NODE STATE||AFU|NON-PATHOLOGICAL||CIGAR|NOT DONE|||ENDOSCOPY|Y|N|PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1971-08-28|
TRIAL STUDY 134XCP|TR|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||CAL|FURTHER ENLARGEMENT||MOSM|NOT DONE|||CALIPER MEASUREMENT METHOD|U|NA|INDEPENDENT ASSESSOR|RATER 2|N|3||39||WASHOUT|1968-03-22|
TRIAL STUDY 134XCP|TR|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||PLUG|NONPALPABLE||ML*CMH2O|NOT DONE|||DOPPLER ULTRASOUND|NA|U|SPOUSE|ENDOCRINOLOGIST|U|4||88||BASELINE|1972-12-21|
TRIAL STUDY 134XCP|TR|E1A56CAC-35A4-4EC1-8F3C-8E117E667D44|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||GPELISA UNIT/ML|NONPALPABLE||CI/KG|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|NA|CLINICAL RESEARCH COORDINATOR|RATER 1|U|5||7||BLINDED TREATMENT|1969-04-25|
TRIAL STUDY 134XCP|TR|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||AMOL|FOCALLY INCREASED||ML/G/DAY|NOT DONE|||IMMUNOASSAY|U|NA|DOMESTIC PARTNER|CARDIOLOGIST|NA|1||38||LONG-TERM FOLLOW-UP|1968-04-06|
TRIAL STUDY 134XCP|TR|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|2||||||CALCFIND|CALCIFICATION INDICATOR||VG/ML|PRESENT||U/G/DAY|NOT DONE|||ELISPOT|Y|N|GUARDIAN|OTOLARYNGOLOGIST|U|2||58||CONTINUATION TREATMENT|1967-09-26|
TRIAL STUDY 134XCP|TR|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||G/U|EQUIVOCAL||GRAIN|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|N|INTERVIEWER|DERMATOLOGIST|NA|3||39||RUN-IN|1969-12-22|
TRIAL STUDY 134XCP|TR|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|4||||||AREA|AREA||10^6 CFU/G|DECREASED||V|NOT DONE|||ANGIOGRAPHY|Y|N|CLINICAL STUDY SPONSOR|RATER 2|U|4||88||LONG-TERM FOLLOW-UP|1967-06-24|
TRIAL STUDY 134XCP|TR|BCA460B7-5102-41F9-BCA7-B7BC0A4A9A53|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||DRAM|NON-PATHOLOGICAL||BEL|NOT DONE|||ELASTOGRAPHY|U|Y|PROXY|OTOLARYNGOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1960-08-31|
TRIAL STUDY 134XCP|TR|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||VIAL|PRESENT||VOXEL|NOT DONE|||DUKE INCISION METHOD|U|Y|FAMILY MEMBER|READER 3|N|1||38||SCREENING|1964-11-25|
TRIAL STUDY 134XCP|TR|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||CYCLE/MIN|NON-PATHOLOGICAL||IN|NOT DONE|||IMMUNOTURBIDIMETRY|NA|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|2||58||BLINDED TREATMENT|1960-08-09|
TRIAL STUDY 134XCP|TR|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||H*%|FURTHER ENLARGEMENT FROM NADIR||MHZ|NOT DONE|||FLUORESCENT MICROSCOPY|U|NA|PARENT|READER 3|Y|3||39||FOLLOW-UP|1960-05-23|
TRIAL STUDY 134XCP|TR|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/M2/H|NONPALPABLE||MOL/G|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|4||88||OPEN LABEL TREATMENT|1968-06-02|
TRIAL STUDY 134XCP|TR|5FFAB7D3-39FC-4429-9DBA-B1A1B972708B|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||U/G/MIN|UNEQUIVOCAL||U/MMOL|NOT DONE|||FLUORIMETRY|N|NA|DOMESTIC PARTNER|RATER|Y|5||7||TREATMENT|1968-04-10|
TRIAL STUDY 134XCP|TR|07A934C8-0237-4B37-9FDD-503B8BF94357|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||SACHET|UNCHANGED||DEG/S|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|Y|SPOUSE|INTERNIST|NA|1||38||TREATMENT|1966-08-04|
TRIAL STUDY 134XCP|TR|07A934C8-0237-4B37-9FDD-503B8BF94357|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||10^9/L|PALPABLE||ML/M2|NOT DONE|||ERGOSPIROMETRY|Y|NA|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|2||58||BASELINE|1964-04-30|
TRIAL STUDY 134XCP|TR|07A934C8-0237-4B37-9FDD-503B8BF94357|3||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||FG|FOCALLY INCREASED||G/G/DAY|NOT DONE|||MODIFIED ACID FAST STAIN|N|U|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||SCREENING|1962-11-13|
TRIAL STUDY 134XCP|TR|07A934C8-0237-4B37-9FDD-503B8BF94357|4||||||NEWCONF|NEW TUMOR CONFIRMED||PHERESIS UNIT|ENLARGEMENT FROM NADIR||UGEQ/L|NOT DONE|||GRADIENT DIFFUSION|U|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||CONTINUATION TREATMENT|1970-01-20|
TRIAL STUDY 134XCP|TR|07A934C8-0237-4B37-9FDD-503B8BF94357|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||IU/DAY|INCREASED||APPLICATION|NOT DONE|||RADIOGRAPHY|Y|U|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5||7||BLINDED TREATMENT|1960-07-28|
TRIAL STUDY 134XCP|TR|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||GAUSS|FURTHER ENLARGEMENT||CMH2O*S2/ML|NOT DONE|||PULMONARY ANGIOGRAPHY|N|N|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|N|1||38||TREATMENT|1971-05-15|
TRIAL STUDY 134XCP|TR|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||IU/G|ABSENT||MPA|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|Y|NA|SPOUSE|MICROSCOPIST 1|Y|2||58||OBSERVATION|1966-01-16|
TRIAL STUDY 134XCP|TR|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|3||||||AREA|AREA||GPS U|ENLARGEMENT||BAG|NOT DONE|||MALDI|Y|U|CLINICAL RESEARCH ASSOCIATE|READER 3|U|3||39||LONG-TERM FOLLOW-UP|1969-05-01|
TRIAL STUDY 134XCP|TR|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|4||||||LNSTATE|LYMPH NODE STATE||U/MMOL|UNCHANGED||LOG10 IU/ML|NOT DONE|||SISH|Y|NA|INVESTIGATOR|NEUROLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1972-02-26|
TRIAL STUDY 134XCP|TR|DB1EA2BE-FBA7-4E37-8F23-3156A349D8FF|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||NKAT/L|TUMOR MERGED||IU/KG/H|NOT DONE|||CYSTOSCOPY|N|Y|FRIEND|CLINICAL PATHOLOGIST|U|5||7||BASELINE|1972-03-02|
TRIAL STUDY 134XCP|TR|10E1249E-10AC-45E8-9896-84C7B0F548BC|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||10^12/L|PATHOLOGICAL||NFIU|NOT DONE|||REFRACTOMETRY|NA|N|PROXY|CARDIOLOGIST|N|1||38||SCREENING|1970-12-15|
TRIAL STUDY 134XCP|TR|10E1249E-10AC-45E8-9896-84C7B0F548BC|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^7 CFU|DECREASED||MMOL/L|NOT DONE|||TARGETED GENOME SEQUENCING|Y|NA|STUDY SUBJECT|MICROSCOPIST 3|N|2||58||BASELINE|1965-03-25|
TRIAL STUDY 134XCP|TR|10E1249E-10AC-45E8-9896-84C7B0F548BC|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||IU/ML|ABSENT||G/M2|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|N|N|GUARDIAN|OPTOMETRIST|U|3||39||FOLLOW-UP|1967-09-04|
TRIAL STUDY 134XCP|TR|10E1249E-10AC-45E8-9896-84C7B0F548BC|4||||||PALPSTAT|PALPABLE STATE||10^3 CFU|NORMAL||PSEC|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|N|U|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|4||88||TREATMENT|1971-08-18|
TRIAL STUDY 134XCP|TR|10E1249E-10AC-45E8-9896-84C7B0F548BC|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||KG/MOL|PRESENT||10^10/L|NOT DONE|||PUPILLOMETRY|U|U|HEALTH CARE PROFESSIONAL|READER 2|U|5||7||BLINDED TREATMENT|1967-10-21|
TRIAL STUDY 134XCP|TR|6CA97CE0-D120-4E14-A82F-4799D2699110|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||NG/L|PALPABLE||HZ|NOT DONE|||FLOW CYTOMETRY|N|NA|SIBLING|RADIOLOGIST|N|1||38||INDUCTION TREATMENT|1968-12-30|
TRIAL STUDY 134XCP|TR|6CA97CE0-D120-4E14-A82F-4799D2699110|2||||||TUMSTATE|TUMOR STATE||UEQ|UNEQUIVOCAL||GPL U/ML|NOT DONE|||GC/MS/MS|U|Y|SIGNIFICANT OTHER|ONCOLOGIST 2|U|2||58||FOLLOW-UP|1973-06-11|
TRIAL STUDY 134XCP|TR|6CA97CE0-D120-4E14-A82F-4799D2699110|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BEATS/MIN|UNCHANGED||MNFI|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|N|Y|PROXY|ONCOLOGIST 2|NA|3||39||LONG-TERM FOLLOW-UP|1973-02-21|
TRIAL STUDY 134XCP|TR|6CA97CE0-D120-4E14-A82F-4799D2699110|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||CAPLET|UNCHANGED||CUP EQ|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|U|NA|INTERVIEWER|PATHOLOGIST 1|N|4||88||OBSERVATION|1960-07-19|
TRIAL STUDY 134XCP|TR|6CA97CE0-D120-4E14-A82F-4799D2699110|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||M/SEC2|PALPABLE||EJACULATE U|NOT DONE|||OPTICAL MAPPING|Y|NA|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5||7||OBSERVATION|1973-08-11|
TRIAL STUDY 134XCP|TR|D807C3F6-0955-4742-A29B-815682559530|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||KUSP|PALPABLE||PACKAGE|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|N|PROXY|ADJUDICATOR 1|U|1||38||OBSERVATION|1969-09-10|
TRIAL STUDY 134XCP|TR|D807C3F6-0955-4742-A29B-815682559530|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||L|ABSENT||GRAIN|NOT DONE|||FLUORESCENT IMMUNOASSAY|Y|N|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|2||58||RUN-IN|1971-06-12|
TRIAL STUDY 134XCP|TR|D807C3F6-0955-4742-A29B-815682559530|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||UU/L|DECREASED||GPS U|NOT DONE|||RAJI CELL RIA|U|N|PROXY|CARDIOLOGIST|U|3||39||CONTINUATION TREATMENT|1965-03-25|
TRIAL STUDY 134XCP|TR|D807C3F6-0955-4742-A29B-815682559530|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PACK|UNCHANGED||LOG10 PFU|NOT DONE|||FLOCCULATION, CHARCOAL ENHANCED|U|U|INTERVIEWER|ENDOCRINOLOGIST|N|4||88||OPEN LABEL TREATMENT|1972-02-01|
TRIAL STUDY 134XCP|TR|D807C3F6-0955-4742-A29B-815682559530|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||VG/DOSE|DIFFUSELY INCREASED||P|NOT DONE|||SANGER SEQUENCING|NA|NA|CAREGIVER|PATHOLOGIST|U|5||7||SCREENING|1969-03-15|
TRIAL STUDY 134XCP|TR|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||10^6 IU|DIFFUSELY INCREASED||UMOL/H/MMOL|NOT DONE|||INTRAVASCULAR ULTRASOUND|U|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|1||38||LONG-TERM FOLLOW-UP|1962-05-01|
TRIAL STUDY 134XCP|TR|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ENZYME U/L|DECREASED||UG/G/MIN|NOT DONE|||ANGIOGRAPHY|NA|N|ADJUDICATION COMMITTEE|HEMATOLOGIST|U|2||58||INDUCTION TREATMENT|1965-04-04|
TRIAL STUDY 134XCP|TR|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|3||||||TUMSTATE|TUMOR STATE||/H|TUMOR MERGED||KM/H|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|N|N|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|NA|3||39||INDUCTION TREATMENT|1962-12-20|
TRIAL STUDY 134XCP|TR|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||UMOL/L/H|FURTHER ENLARGEMENT||CS|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|N|Y|SIGNIFICANT OTHER|PATHOLOGIST 1|Y|4||88||OBSERVATION|1965-02-07|
TRIAL STUDY 134XCP|TR|EA95AD62-1630-43A0-ABA5-ADD7C2F31F75|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/G/MIN|ENLARGEMENT FROM NADIR||GPL U|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|U|Y|INVESTIGATOR|ENDOCRINOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1962-05-22|
TRIAL STUDY 134XCP|TR|38C36B22-EC60-4D40-A1B6-71B17F8C8625|1||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^7/L|NON-PATHOLOGICAL||MNFI|NOT DONE|||DOUBLE IMMUNODIFFUSION|Y|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|1||38||OBSERVATION|1965-11-14|
TRIAL STUDY 134XCP|TR|38C36B22-EC60-4D40-A1B6-71B17F8C8625|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PMOL/DL|PALPABLE||MG/KG/WEEK|NOT DONE|||MICROBIAL CULTURE, SOLID|U|N|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|NA|2||58||INDUCTION TREATMENT|1960-06-09|
TRIAL STUDY 134XCP|TR|38C36B22-EC60-4D40-A1B6-71B17F8C8625|3||||||AREA|AREA||NG/MOL|EQUIVOCAL||10^6 RNA COPIES/ML|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|NA|SIBLING|RADIOLOGIST|Y|3||39||BLINDED TREATMENT|1965-03-07|
TRIAL STUDY 134XCP|TR|38C36B22-EC60-4D40-A1B6-71B17F8C8625|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||DYN|INCREASED||MM3/MM2/YEAR|NOT DONE|||CHROMATOGRAPHY|NA|U|SPOUSE|ADJUDICATOR 2|U|4||88||BLINDED TREATMENT|1971-01-22|
TRIAL STUDY 134XCP|TR|38C36B22-EC60-4D40-A1B6-71B17F8C8625|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||10^6 ORGANISMS/ML|ABSENT||MDFI|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|NA|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|5||7||CONTINUATION TREATMENT|1972-07-26|
TRIAL STUDY 134XCP|TR|E2F4144C-543D-4F55-A94E-58F244FB21D1|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U.CARR|NON-PATHOLOGICAL||KDA|NOT DONE|||SMEAR|N|N|STUDY SUBJECT|ONCOLOGIST 2|N|1||38||OBSERVATION|1970-01-28|
TRIAL STUDY 134XCP|TR|E2F4144C-543D-4F55-A94E-58F244FB21D1|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MKAT|PRESENT||NMOL BCE/NMOL|NOT DONE|||MECHANICAL CLOT DETECTION|NA|U|INDEPENDENT ASSESSOR|PATHOLOGIST|NA|2||58||INDUCTION TREATMENT|1973-08-09|
TRIAL STUDY 134XCP|TR|E2F4144C-543D-4F55-A94E-58F244FB21D1|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||VG/DOSE|EQUIVOCAL||UG/G/DAY|NOT DONE|||RIA|Y|U|CHILD|READER 1|U|3||39||CONTINUATION TREATMENT|1960-06-28|
TRIAL STUDY 134XCP|TR|E2F4144C-543D-4F55-A94E-58F244FB21D1|4||||||AREA|AREA||%(W/W)|ABSENT||FT2|NOT DONE|||FORCED OSCILLATION TECHNIQUE|NA|Y|STUDY SUBJECT|OPTOMETRIST|NA|4||88||INDUCTION TREATMENT|1963-09-18|
TRIAL STUDY 134XCP|TR|E2F4144C-543D-4F55-A94E-58F244FB21D1|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||EJACULATE U|INCREASED||CI/L|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|NA|Y|DOMESTIC PARTNER|OPTOMETRIST|Y|5||7||OPEN LABEL TREATMENT|1973-04-08|
TRIAL STUDY 134XCP|TR|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UM/DAY|NONPALPABLE||FMOL/L/SEC|NOT DONE|||SCINTIGRAPHY|U|NA|SIGNIFICANT OTHER|UROLOGIST|U|1||38||OBSERVATION|1962-08-02|
TRIAL STUDY 134XCP|TR|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|2||||||ORSTATE|ORGAN STATE||/MM2|ENLARGEMENT||MBQ|NOT DONE|||SPECT/CT SCAN|U|Y|PARENT|RATER|N|2||58||RUN-IN|1969-03-15|
TRIAL STUDY 134XCP|TR|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||MMOL/DAY|DIFFUSELY INCREASED||PA|NOT DONE|||CONGO RED STAIN|U|N|SIGNIFICANT OTHER|ADJUDICATOR 3|N|3||39||TREATMENT|1969-03-31|
TRIAL STUDY 134XCP|TR|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|4||||||ORSTATE|ORGAN STATE||U/ML|UNCHANGED||PPTH|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|NA|VENDOR|ONCOLOGIST|Y|4||88||TREATMENT|1962-06-30|
TRIAL STUDY 134XCP|TR|CA59C4CD-E3E7-46C8-8B88-3D00E448B1D8|5||||||TUMSTATE|TUMOR STATE||JAR|DIFFUSELY INCREASED||PMOL/L|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|N|U|FRIEND|ADJUDICATOR 2|N|5||7||WASHOUT|1972-05-27|
TRIAL STUDY 134XCP|TR|49B857CF-22F2-406F-A269-54944B23C236|1||||||ORSTATE|ORGAN STATE||TSP|NORMAL||UG/KG/H|NOT DONE|||PEAK FLOWMETRY|U|NA|CHILD|RADIOLOGIST|NA|1||38||OBSERVATION|1965-06-16|
TRIAL STUDY 134XCP|TR|49B857CF-22F2-406F-A269-54944B23C236|2||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^3/L|ENLARGEMENT FROM NADIR||ANSON U|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|N|NA|INTERVIEWER|FORENSIC PATHOLOGIST|N|2||58||BLINDED TREATMENT|1965-04-15|
TRIAL STUDY 134XCP|TR|49B857CF-22F2-406F-A269-54944B23C236|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||MOSM/L|PRESENT||OZ|NOT DONE|||LAPAROSCOPY|U|N|INDEPENDENT ASSESSOR|RADIOLOGIST 1|N|3||39||SCREENING|1962-12-13|
TRIAL STUDY 134XCP|TR|49B857CF-22F2-406F-A269-54944B23C236|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||GBQ|FOCALLY INCREASED||LOZENGE|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|4||88||OBSERVATION|1964-11-05|
TRIAL STUDY 134XCP|TR|49B857CF-22F2-406F-A269-54944B23C236|5||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||MEQ/UG|ENLARGEMENT FROM NADIR||M3|NOT DONE|||LIQUID SCINTILLATION COUNTING|U|N|ADJUDICATION COMMITTEE|RATER 1|N|5||7||BLINDED TREATMENT|1972-10-24|
TRIAL STUDY 134XCP|TR|E09B394B-9E48-4132-B430-991DF1953A81|1||||||LESSCIND|LESION SUCCESS INDICATOR||CM/S|NORMAL||CY/CM|NOT DONE|||ARTERIAL SPIN LABELING FUNCTIONAL MRI|NA|N|ADJUDICATOR|RADIOLOGIST|Y|1||38||WASHOUT|1966-03-22|
TRIAL STUDY 134XCP|TR|E09B394B-9E48-4132-B430-991DF1953A81|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||QUANTITY SUFFICIENT|DECREASED||/HPF|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|N|U|FAMILY MEMBER|MICROSCOPIST 1|Y|2||58||FOLLOW-UP|1971-02-18|
TRIAL STUDY 134XCP|TR|E09B394B-9E48-4132-B430-991DF1953A81|3||||||ORSTATE|ORGAN STATE||BOWL|FOCALLY INCREASED||HEP|NOT DONE|||QUANTITATIVE ULTRASOUND|NA|Y|ADJUDICATOR|MICROSCOPIST|NA|3||39||TREATMENT|1965-12-27|
TRIAL STUDY 134XCP|TR|E09B394B-9E48-4132-B430-991DF1953A81|4||||||PALPSTAT|PALPABLE STATE||G/CAGE|PALPABLE||NKAT/L|NOT DONE|||MEDIASTINOSCOPY|U|U|FRIEND|READER 3|N|4||88||TREATMENT|1964-07-26|
TRIAL STUDY 134XCP|TR|E09B394B-9E48-4132-B430-991DF1953A81|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||ML/ANIMAL/DAY|DECREASED||NMOL BCE/L|NOT DONE|||DUKE INCISION METHOD|Y|N|FAMILY MEMBER|RATER 1|Y|5||7||OPEN LABEL TREATMENT|1963-01-11|
TRIAL STUDY 134XCP|TR|5FB65CB2-DB12-4D00-818E-C51992DC7273|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||CUP|INCREASED||EQ|NOT DONE|||THIN SMEAR|U|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|Y|1||38||LONG-TERM FOLLOW-UP|1964-08-30|
TRIAL STUDY 134XCP|TR|5FB65CB2-DB12-4D00-818E-C51992DC7273|2||||||LESSCIND|LESION SUCCESS INDICATOR||/2500 WBC|NONPALPABLE||MMOL/G|NOT DONE|||EPSILOMETER|NA|Y|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|2||58||RUN-IN|1970-03-13|
TRIAL STUDY 134XCP|TR|5FB65CB2-DB12-4D00-818E-C51992DC7273|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MG/DOSE|TUMOR MERGED||10^4/L|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|NA|NA|SPOUSE|OPHTHALMOLOGIST|N|3||39||BASELINE|1962-05-12|
TRIAL STUDY 134XCP|TR|5FB65CB2-DB12-4D00-818E-C51992DC7273|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MDFI|PALPABLE||LOG10 ELISA UNIT|NOT DONE|||SNELLEN EYE CHART|U|N|NON-HEALTH CARE PROFESSIONAL|RATER|N|4||88||LONG-TERM FOLLOW-UP|1963-08-11|
TRIAL STUDY 134XCP|TR|5FB65CB2-DB12-4D00-818E-C51992DC7273|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||DISK|INCREASED||U/KG/DAY|NOT DONE|||KINYOUN STAIN|N|U|DOMESTIC PARTNER|ONCOLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1966-02-26|
TRIAL STUDY 134XCP|TR|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||HZ|PRESENT||/5X10^4 WBC|NOT DONE|||POLYMERASE CHAIN REACTION|NA|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|1||38||OPEN LABEL TREATMENT|1968-02-01|
TRIAL STUDY 134XCP|TR|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|2||||||LPERP|LONGEST PERPENDICULAR||BLOCKS|TUMOR MERGED||MET|NOT DONE|||GC/MS-EI|N|N|SIGNIFICANT OTHER|READER 1|U|2||58||INDUCTION TREATMENT|1965-05-07|
TRIAL STUDY 134XCP|TR|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|3||||||PCHGBL|PERCENT CHANGE FROM BASELINE||M/SEC|FURTHER ENLARGEMENT FROM NADIR||TUBE|NOT DONE|||TURBIDIMETRY|N|NA|VENDOR|MICROSCOPIST|U|3||39||OPEN LABEL TREATMENT|1966-07-14|
TRIAL STUDY 134XCP|TR|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UMOL/DAY|ENLARGEMENT FROM NADIR||ML|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|NA|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|4||88||BASELINE|1963-06-02|
TRIAL STUDY 134XCP|TR|ADACD31B-F89B-4920-9E0C-7C58FA00DEF6|5||||||VSLPIND|VESSEL PATENCY INDICATOR||SIEMENS|TUMOR MERGED||/10^5|NOT DONE|||MICROBIAL CONCENTRATION|U|Y|INVESTIGATOR|NEUROLOGIST|U|5||7||OPEN LABEL TREATMENT|1962-07-23|
TRIAL STUDY 134XCP|TR|CB6A1101-1EF8-476D-BD15-B60EF323D740|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||U/ANIMAL|DIFFUSELY INCREASED||CL|NOT DONE|||CENTRIFUGATION|NA|U|HEALTH CARE PROFESSIONAL|UROLOGIST|U|1||38||BLINDED TREATMENT|1964-11-25|
TRIAL STUDY 134XCP|TR|CB6A1101-1EF8-476D-BD15-B60EF323D740|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||TESLA|PALPABLE||U/KG/DAY|NOT DONE|||DC SHEATH FLOW|NA|N|SIGNIFICANT OTHER|INTERNIST|U|2||58||WASHOUT|1966-11-26|
TRIAL STUDY 134XCP|TR|CB6A1101-1EF8-476D-BD15-B60EF323D740|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MOL/G|PRESENT||HPA|NOT DONE|||DOPPLER ULTRASOUND|N|N|INVESTIGATOR|NEUROLOGIST 2|Y|3||39||FOLLOW-UP|1964-11-28|
TRIAL STUDY 134XCP|TR|CB6A1101-1EF8-476D-BD15-B60EF323D740|4||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||U/M2/MIN|DIFFUSELY INCREASED||BISCUIT|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|NA|Y|INTERVIEWER|ADJUDICATOR 3|N|4||88||TREATMENT|1967-07-11|
TRIAL STUDY 134XCP|TR|CB6A1101-1EF8-476D-BD15-B60EF323D740|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MMOL/L|DECREASED||G/ANIMAL/DAY|NOT DONE|||LINE PROBE ASSAY|Y|N|NON-HEALTH CARE PROFESSIONAL|READER 2|U|5||7||WASHOUT|1971-09-06|
TRIAL STUDY 134XCP|TR|3AED1654-6D9A-40EE-A560-99F51C469D63|1||||||LDIAM|LONGEST DIAMETER||HOMEOPATHIC DILUTION|INCREASED||GLOBULE|NOT DONE|||LC/MS/MS|Y|Y|INTERVIEWER|ADJUDICATOR 2|U|1||38||RUN-IN|1963-05-01|
TRIAL STUDY 134XCP|TR|3AED1654-6D9A-40EE-A560-99F51C469D63|2||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ANSON U|DIFFUSELY INCREASED||ATM|NOT DONE|||CALCULATION|U|U|CHILD|NEUROLOGIST 2|Y|2||58||LONG-TERM FOLLOW-UP|1961-02-18|
TRIAL STUDY 134XCP|TR|3AED1654-6D9A-40EE-A560-99F51C469D63|3||||||CALCFIND|CALCIFICATION INDICATOR||QUANTITY SUFFICIENT|INCREASED||MASK|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|U|GUARDIAN|PATHOLOGIST|Y|3||39||RUN-IN|1965-11-09|
TRIAL STUDY 134XCP|TR|3AED1654-6D9A-40EE-A560-99F51C469D63|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||GENEQ/ML|FURTHER ENLARGEMENT||10^9 CFU/ML|NOT DONE|||TWO-COLOR MICROARRAY|Y|NA|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|4||88||FOLLOW-UP|1960-08-28|
TRIAL STUDY 134XCP|TR|3AED1654-6D9A-40EE-A560-99F51C469D63|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||G/ANIMAL/DAY|NONPALPABLE||UOSM|NOT DONE|||BETA LACTAMASE|Y|NA|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5||7||TREATMENT|1970-11-06|
TRIAL STUDY 134XCP|TR|4C13FD80-8950-4194-B76C-F46B643BED82|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||GBQ/MG|DIFFUSELY INCREASED||10^3 ORGANISMS/G|NOT DONE|||CENTRIFUGATION|Y|U|GUARDIAN|PATHOLOGIST|NA|1||38||CONTINUATION TREATMENT|1962-01-27|
TRIAL STUDY 134XCP|TR|4C13FD80-8950-4194-B76C-F46B643BED82|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||S*KPA|NORMAL||UEQ/L|NOT DONE|||CONGO RED STAIN|Y|Y|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|2||58||OBSERVATION|1961-10-22|
TRIAL STUDY 134XCP|TR|4C13FD80-8950-4194-B76C-F46B643BED82|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||/100 WBC|UNEQUIVOCAL||MG/ANIMAL|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|N|U|VENDOR|DERMATOLOGIST|U|3||39||BASELINE|1963-03-16|
TRIAL STUDY 134XCP|TR|4C13FD80-8950-4194-B76C-F46B643BED82|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||10^6 DNA COPIES/ML|PALPABLE||UU/DL|NOT DONE|||PERIPHERAL ANGIOGRAPHY|Y|NA|CHILD|MICROSCOPIST 1|NA|4||88||OBSERVATION|1964-03-15|
TRIAL STUDY 134XCP|TR|4C13FD80-8950-4194-B76C-F46B643BED82|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||UIU/L|ENLARGEMENT||CONTAINER|NOT DONE|||IMMUNORADIOMETRIC ASSAY|Y|Y|FAMILY MEMBER|DERMATOLOGIST|N|5||7||SCREENING|1969-04-02|
TRIAL STUDY 134XCP|TR|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|1||||||CALCFIND|CALCIFICATION INDICATOR||EVENTS|PATHOLOGICAL||PPTH|NOT DONE|||DIGITAL PCR|U|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|1||38||TREATMENT|1968-07-01|
TRIAL STUDY 134XCP|TR|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||TRANSDUCING UNIT/ML|PATHOLOGICAL||NCI|NOT DONE|||CYSTOSCOPY|NA|NA|FRIEND|UROLOGIST|Y|2||58||CONTINUATION TREATMENT|1964-03-01|
TRIAL STUDY 134XCP|TR|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|3||||||LESSCIND|LESION SUCCESS INDICATOR||GENEQ|ENLARGEMENT||MMHG/SEC|NOT DONE|||NUCLEIC ACID HYBRIDIZATION|U|NA|CHILD|NEUROLOGIST 2|N|3||39||OBSERVATION|1969-03-20|
TRIAL STUDY 134XCP|TR|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|4||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||RNA COPIES/ML|ENLARGEMENT||UMOL/KG/MIN|NOT DONE|||JAFFE REACTION|U|N|ADJUDICATOR|RADIOLOGIST 1|NA|4||88||OBSERVATION|1967-09-06|
TRIAL STUDY 134XCP|TR|AE059FB8-BE8F-4F4A-88A0-4EF300F692D2|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||UG/M2|UNCHANGED||/5X10^4 WBC|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|U|VENDOR|UROLOGIST|U|5||7||BASELINE|1962-05-20|
TRIAL STUDY 134XCP|TR|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|1||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UG/G/MIN|PRESENT||SUPPOSITORY|NOT DONE|||APPLANATION TONOMETRY|Y|NA|FAMILY MEMBER|ADJUDICATOR 3|NA|1||38||WASHOUT|1966-10-11|
TRIAL STUDY 134XCP|TR|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|2||||||SUMDIAM|SUM OF DIAMETER||MM3/MM2/YEAR|PALPABLE||U/MMOL|NOT DONE|||PERIPHERAL ANGIOGRAPHY|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1972-04-18|
TRIAL STUDY 134XCP|TR|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||P|FURTHER ENLARGEMENT||MU/L|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|NA|N|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||WASHOUT|1965-10-06|
TRIAL STUDY 134XCP|TR|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||NG/L|ABSENT||10^9 ORGANISMS|NOT DONE|||PHASE CONTRAST MICROSCOPY|Y|Y|INTERVIEWER|ONCOLOGIST 2|N|4||88||OPEN LABEL TREATMENT|1963-12-18|
TRIAL STUDY 134XCP|TR|2A3D5CAE-6BC2-4B96-A36C-67C885C519D2|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||VG/KG|ENLARGEMENT FROM NADIR||L/S|NOT DONE|||CELL OF ORIGIN ASSAY|U|U|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|5||7||RUN-IN|1960-12-11|
TRIAL STUDY 134XCP|TR|CFFA0003-098B-486E-82DB-30838F6541DD|1||||||LDIAM|LONGEST DIAMETER||JDF UNIT|FURTHER ENLARGEMENT||10^4/HPF|NOT DONE|||LC-FL|NA|NA|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|1||38||INDUCTION TREATMENT|1964-08-21|
TRIAL STUDY 134XCP|TR|CFFA0003-098B-486E-82DB-30838F6541DD|2||||||DIAMETER|DIAMETER||MPL U/ML|FURTHER ENLARGEMENT FROM NADIR||IU/ML|NOT DONE|||DOPPLER ULTRASOUND|Y|NA|INTERVIEWER|INTERNIST|NA|2||58||INDUCTION TREATMENT|1965-11-18|
TRIAL STUDY 134XCP|TR|CFFA0003-098B-486E-82DB-30838F6541DD|3||||||TUMSTATE|TUMOR STATE||FRACTION OF 1|FOCALLY INCREASED||MM/2H|NOT DONE|||SXA SCAN|Y|N|VENDOR|PEDIATRIC NEUROLOGIST|Y|3||39||BLINDED TREATMENT|1965-05-07|
TRIAL STUDY 134XCP|TR|CFFA0003-098B-486E-82DB-30838F6541DD|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||JOULE|INCREASED||RFU|NOT DONE|||FLOCCULATION|N|NA|FAMILY MEMBER|HEMATOLOGIST|N|4||88||OBSERVATION|1971-09-16|
TRIAL STUDY 134XCP|TR|CFFA0003-098B-486E-82DB-30838F6541DD|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||FT|INCREASED||MEQ|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|N|INVESTIGATOR|RATER|U|5||7||LONG-TERM FOLLOW-UP|1964-05-22|
TRIAL STUDY 134XCP|TR|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UG/MOL|TUMOR MERGED||UV*SEC|NOT DONE|||PET/CT SCAN|Y|Y|CHILD|READER 1|NA|1||38||INDUCTION TREATMENT|1972-12-10|
TRIAL STUDY 134XCP|TR|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|2||||||LDIAM|LONGEST DIAMETER||IU|UNCHANGED||/5X10^4 WBC|NOT DONE|||MALDI|Y|N|CLINICAL RESEARCH COORDINATOR|READER 2|N|2||58||TREATMENT|1961-01-16|
TRIAL STUDY 134XCP|TR|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|3||||||SUMDIAM|SUM OF DIAMETER||CI/MG|NORMAL||LOG10 TCID 50/ML|NOT DONE|||ERGOSPIROMETRY|Y|Y|VENDOR|ENDOCRINOLOGIST|N|3||39||TREATMENT|1972-01-14|
TRIAL STUDY 134XCP|TR|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||KCAL/DAY|ENLARGEMENT||TESLA|NOT DONE|||BRDU CELLULAR PROLIFERATION ASSAY|Y|NA|SPOUSE|READER 3|N|4||88||OBSERVATION|1960-10-23|
TRIAL STUDY 134XCP|TR|C5505069-530E-44CE-BD90-D0F7B0CF9C2D|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UMOL/MIN|FURTHER ENLARGEMENT FROM NADIR||NCI|NOT DONE|||ELASTOGRAPHY|Y|U|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|5||7||TREATMENT|1963-12-10|
TRIAL STUDY 134XCP|TR|3F29184F-1963-4EC7-881A-61C9DEF95D2D|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||10^5/L|INCREASED||SYRINGE|NOT DONE|||PHOTOMETRY|Y|NA|PROXY|RATER 2|Y|1||38||LONG-TERM FOLLOW-UP|1969-12-05|
TRIAL STUDY 134XCP|TR|3F29184F-1963-4EC7-881A-61C9DEF95D2D|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||EIA UNIT|TUMOR MERGED||NMOL/DAY|NOT DONE|||CARDIAC THERMODILUTION|U|U|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||BASELINE|1969-11-01|
TRIAL STUDY 134XCP|TR|3F29184F-1963-4EC7-881A-61C9DEF95D2D|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||/KG|INCREASED||YD|NOT DONE|||DOPPLER ULTRASOUND|U|U|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|3||39||WASHOUT|1966-11-26|
TRIAL STUDY 134XCP|TR|3F29184F-1963-4EC7-881A-61C9DEF95D2D|4||||||DIAMETER|DIAMETER||/4.0 ML|ABSENT||USP U|NOT DONE|||OPTICAL DENSITY MEASUREMENT|N|N|VENDOR|RATER 1|N|4||88||OBSERVATION|1964-07-29|
TRIAL STUDY 134XCP|TR|3F29184F-1963-4EC7-881A-61C9DEF95D2D|5||||||NEWCONF|NEW TUMOR CONFIRMED||NG|PRESENT||PNU/ML|NOT DONE|||TRIPLE-PHASE MRI SCAN|Y|Y|CAREGIVER|MICROSCOPIST 1|NA|5||7||LONG-TERM FOLLOW-UP|1960-04-24|
TRIAL STUDY 134XCP|TR|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|1||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||10^9 CFU/G|ENLARGEMENT FROM NADIR||EID 50/DOSE|NOT DONE|||IMMUNO-PET SCAN|N|U|HEALTH CARE PROFESSIONAL|READER|N|1||38||WASHOUT|1960-11-09|
TRIAL STUDY 134XCP|TR|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||MG/H|NORMAL||LM|NOT DONE|||IMMUNORADIOMETRIC ASSAY|NA|U|DOMESTIC PARTNER|RADIOLOGIST 2|Y|2||58||RUN-IN|1970-09-06|
TRIAL STUDY 134XCP|TR|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|3||||||ORVERLN|ORGAN VERTICAL LENGTH||10^6/L|PALPABLE||/100 WBC|NOT DONE|||STATIC PERIMETRY|N|U|FAMILY MEMBER|RADIOLOGIST|N|3||39||WASHOUT|1967-02-25|
TRIAL STUDY 134XCP|TR|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PL|UNEQUIVOCAL||KEV|NOT DONE|||POLYGRAPHY|N|NA|ADJUDICATOR|PATHOLOGIST 2|U|4||88||FOLLOW-UP|1972-11-08|
TRIAL STUDY 134XCP|TR|A962AE4A-1E74-4CC7-8201-A8DF9A1AA8D3|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CM/S|EQUIVOCAL||ML/(MIN*100ML)|NOT DONE|||CORONARY ANGIOGRAPHY|NA|U|GUARDIAN|MICROSCOPIST 1|N|5||7||OPEN LABEL TREATMENT|1969-06-25|
TRIAL STUDY 134XCP|TR|D9C32CF1-51C7-412D-A030-682B2860F89D|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||CYLINDER|TUMOR MERGED||UG/KG|NOT DONE|||WESTERGREN|U|N|PROXY|READER 2|Y|1||38||OPEN LABEL TREATMENT|1960-03-20|
TRIAL STUDY 134XCP|TR|D9C32CF1-51C7-412D-A030-682B2860F89D|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||10^9 ORGANISMS|NON-PATHOLOGICAL||AGU/ML|NOT DONE|||ACRIDINE ORANGE STAIN|Y|Y|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||CONTINUATION TREATMENT|1961-07-03|
TRIAL STUDY 134XCP|TR|D9C32CF1-51C7-412D-A030-682B2860F89D|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||IU/ML|ENLARGEMENT FROM NADIR||G/DL|NOT DONE|||CLIP|U|NA|SPOUSE|RADIOLOGIST|U|3||39||BASELINE|1962-09-17|
TRIAL STUDY 134XCP|TR|D9C32CF1-51C7-412D-A030-682B2860F89D|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||NMOL/ML/MIN|FURTHER ENLARGEMENT FROM NADIR||CM/S|NOT DONE|||CALIPER MEASUREMENT METHOD|Y|U|INDEPENDENT ASSESSOR|READER|Y|4||88||RUN-IN|1965-08-15|
TRIAL STUDY 134XCP|TR|D9C32CF1-51C7-412D-A030-682B2860F89D|5||||||LNSTATE|LYMPH NODE STATE||CM2|ENLARGEMENT||LOG10 ELISA UNIT|NOT DONE|||HEMOCYTOMETRY|NA|N|INDEPENDENT ASSESSOR|UROLOGIST|NA|5||7||BLINDED TREATMENT|1971-05-23|
TRIAL STUDY 134XCP|TR|102F6B51-5A86-497B-A36D-13FB77928C39|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||KS|ENLARGEMENT||BOLUS|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|NA|INVESTIGATOR|DERMATOLOGIST|U|1||38||CONTINUATION TREATMENT|1968-01-01|
TRIAL STUDY 134XCP|TR|102F6B51-5A86-497B-A36D-13FB77928C39|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||10^6 CFU/ML|UNEQUIVOCAL||FMOL|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|N|U|CLINICAL STUDY SPONSOR|INTERNIST|NA|2||58||RUN-IN|1962-05-18|
TRIAL STUDY 134XCP|TR|102F6B51-5A86-497B-A36D-13FB77928C39|3||||||LMBFLIND|LIMB FAILURE INDICATOR||KDA|FURTHER ENLARGEMENT FROM NADIR||MMHG/L/MIN|NOT DONE|||WRIGHT STAIN|U|Y|PROXY|CLINICAL PATHOLOGIST|Y|3||39||BLINDED TREATMENT|1963-08-21|
TRIAL STUDY 134XCP|TR|102F6B51-5A86-497B-A36D-13FB77928C39|4||||||LMBFLIND|LIMB FAILURE INDICATOR||PIXEL|INCREASED||%(V/V)|NOT DONE|||QUANTITATIVE ULTRASOUND|U|Y|VENDOR|ONCOLOGIST 2|N|4||88||TREATMENT|1964-09-21|
TRIAL STUDY 134XCP|TR|102F6B51-5A86-497B-A36D-13FB77928C39|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||KIT|FOCALLY INCREASED||KA_U/DL|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|U|U|INTERVIEWER|RATER|N|5||7||LONG-TERM FOLLOW-UP|1961-07-28|
TRIAL STUDY 134XCP|TR|C123D04C-1AA4-418D-B68C-EC9D410376F0|1||||||AREA|AREA||/200 HPFS|NONPALPABLE||UMOL/H/MMOL|NOT DONE|||HPLC/MS/MS|U|NA|PROXY|ONCOLOGIST 2|Y|1||38||TREATMENT|1965-01-13|
TRIAL STUDY 134XCP|TR|C123D04C-1AA4-418D-B68C-EC9D410376F0|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/L|INCREASED||UG/KG/MIN|NOT DONE|||GC/MS-CI|Y|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|2||58||SCREENING|1967-03-20|
TRIAL STUDY 134XCP|TR|C123D04C-1AA4-418D-B68C-EC9D410376F0|3||||||VDIAM|VIABLE DIAMETER||LOG10 IU/ML|FURTHER ENLARGEMENT||L/H/M2|NOT DONE|||PHOTOMETRIC CLOT DETECTION|Y|N|VENDOR|UROLOGIST|N|3||39||WASHOUT|1972-11-06|
TRIAL STUDY 134XCP|TR|C123D04C-1AA4-418D-B68C-EC9D410376F0|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||FG|FURTHER ENLARGEMENT||UU/DL|NOT DONE|||TURBIDIMETRY|N|NA|CHILD|RATER|Y|4||88||OBSERVATION|1962-05-09|
TRIAL STUDY 134XCP|TR|C123D04C-1AA4-418D-B68C-EC9D410376F0|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||ANTI-XA IU/ML|FURTHER ENLARGEMENT FROM NADIR||KPA/L/SEC|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|NA|NA|DOMESTIC PARTNER|OPTOMETRIST|N|5||7||SCREENING|1962-08-22|
TRIAL STUDY 134XCP|TR|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||CY/CM|EQUIVOCAL||U/MMOL|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|U|U|STUDY SUBJECT|ADJUDICATOR 1|NA|1||38||OBSERVATION|1962-07-30|
TRIAL STUDY 134XCP|TR|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||FINGERTIP UNIT|NON-PATHOLOGICAL||USIEMENS|NOT DONE|||KLEIHAUER-BETKE|Y|Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|2||58||OBSERVATION|1970-10-21|
TRIAL STUDY 134XCP|TR|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||HOUNSFIELD UNIT|UNEQUIVOCAL||CG|NOT DONE|||HPLC|Y|Y|ADJUDICATOR|ADJUDICATOR 3|N|3||39||WASHOUT|1968-08-15|
TRIAL STUDY 134XCP|TR|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MEQ/KG|ENLARGEMENT||10^9 CFU|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|N|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|4||88||BLINDED TREATMENT|1973-03-10|
TRIAL STUDY 134XCP|TR|30352D31-4A96-4B1C-9BE8-BA4E0DC5A4C6|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UG/DAY|DECREASED||10^8/L|NOT DONE|||DOUBLE IMMUNODIFFUSION|N|U|GUARDIAN|READER 1|NA|5||7||RUN-IN|1970-05-26|
TRIAL STUDY 134XCP|TR|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|1||||||SUMDIAM|SUM OF DIAMETER||10^9 ORGANISMS|UNEQUIVOCAL||ML/MIN/MMHG|NOT DONE|||NUCLEIC ACID BASED METHOD|U|Y|CHILD|NEUROLOGIST|Y|1||38||FOLLOW-UP|1962-07-16|
TRIAL STUDY 134XCP|TR|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|2||||||LNSTATE|LYMPH NODE STATE||AMPULE|PRESENT||FOZ_US|NOT DONE|||HPLC/MS|N|NA|FAMILY MEMBER|PATHOLOGIST 2|U|2||58||FOLLOW-UP|1968-08-10|
TRIAL STUDY 134XCP|TR|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||TSP EQ|NORMAL||UMOL/DL|NOT DONE|||PERFUSION MRI|U|U|INDEPENDENT ASSESSOR|RATER 2|NA|3||39||OPEN LABEL TREATMENT|1971-07-17|
TRIAL STUDY 134XCP|TR|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|4||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||MPH|ENLARGEMENT FROM NADIR||NMOL/ML/MIN|NOT DONE|||FUNDUS PHOTOGRAPHY|NA|Y|VENDOR|RADIOLOGIST 2|Y|4||88||BLINDED TREATMENT|1962-03-09|
TRIAL STUDY 134XCP|TR|079A46B1-EEB3-4524-AC5F-60E2A9E16DB4|5||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PA|EQUIVOCAL||UCI/L|NOT DONE|||CRYOSCOPY|NA|Y|INDEPENDENT ASSESSOR|RATER 2|Y|5||7||WASHOUT|1972-11-21|
TRIAL STUDY 134XCP|TR|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||FT3|PRESENT||MMAL|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y|FAMILY MEMBER|PATHOLOGIST 2|Y|1||38||BLINDED TREATMENT|1967-06-12|
TRIAL STUDY 134XCP|TR|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^6 DNA COPIES/ML|NONPALPABLE||RATIO|NOT DONE|||CELLULOSE TAPE|NA|U|INVESTIGATOR|ONCOLOGIST 1|U|2||58||TREATMENT|1966-03-17|
TRIAL STUDY 134XCP|TR|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||TBSP|DECREASED||PMOL/10^9 CELLS|NOT DONE|||LIGHT MICROSCOPY|N|N|SPOUSE|HEMATOLOGIST|U|3||39||TREATMENT|1967-12-22|
TRIAL STUDY 134XCP|TR|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||L/H/M2|NORMAL||PFU/ML|NOT DONE|||CELLULOSE TAPE|Y|U|SIGNIFICANT OTHER|RADIOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1971-08-07|
TRIAL STUDY 134XCP|TR|82BB0613-BBBB-4EA2-90F8-EDCA19A637A5|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ENZYME U/G HB|PRESENT||GPELISA UNIT/ML|NOT DONE|||VIRUS PLAQUE ASSAY|Y|U|CHILD|READER 3|N|5||7||WASHOUT|1963-10-21|
TRIAL STUDY 134XCP|TR|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|1||||||DIAMETER|DIAMETER||CAPFUL|NON-PATHOLOGICAL||AMPULE|NOT DONE|||SPECULAR MICROSCOPY|U|N|INTERVIEWER|NEUROLOGIST 2|U|1||38||SCREENING|1965-05-22|
TRIAL STUDY 134XCP|TR|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|2||||||BNLNUM|NUMBER OF BONE LESIONS||KPA|NORMAL||DB|NOT DONE|||DXA SCAN|U|N|VENDOR|HEMATOLOGIST|NA|2||58||OBSERVATION|1969-11-21|
TRIAL STUDY 134XCP|TR|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||CPM|NONPALPABLE||MOSM/L|NOT DONE|||ROMANOWSKY STAIN|U|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||OPEN LABEL TREATMENT|1968-06-19|
TRIAL STUDY 134XCP|TR|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ML/M2/H|DIFFUSELY INCREASED||10^3 CFU|NOT DONE|||MASS SPECTROMETRY|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|U|4||88||SCREENING|1963-08-09|
TRIAL STUDY 134XCP|TR|5F368FD6-5F04-490E-9720-5BE0FE34C1FC|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||KG/M2|ENLARGEMENT FROM NADIR||ML/KG/DAY|NOT DONE|||CONFOCAL MICROSCOPY|Y|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5||7||LONG-TERM FOLLOW-UP|1970-04-26|
TRIAL STUDY 134XCP|TR|E3310689-5727-4970-A675-A58931E406FA|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^6 DNA COPIES/ML|PALPABLE||NMOL/G|NOT DONE|||TWO-COLOR MICROARRAY|NA|NA|GUARDIAN|READER 1|NA|1||38||BASELINE|1970-10-15|
TRIAL STUDY 134XCP|TR|E3310689-5727-4970-A675-A58931E406FA|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UIU/DL|DECREASED||GY/H|NOT DONE|||NEPHELOMETRY|U|Y|PARENT|NEUROLOGIST 2|Y|2||58||SCREENING|1968-05-14|
TRIAL STUDY 134XCP|TR|E3310689-5727-4970-A675-A58931E406FA|3||||||VOLUME|VOLUME||CD|PALPABLE||10^9 ORGANISMS/ML|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|NA|SPOUSE|ADJUDICATOR 3|N|3||39||RUN-IN|1962-07-15|
TRIAL STUDY 134XCP|TR|E3310689-5727-4970-A675-A58931E406FA|4||||||AREA|AREA||MET*MIN|DIFFUSELY INCREASED||UL/DOSE|NOT DONE|||MOUSE PROTECTION ASSAY|U|Y|SPOUSE|ADJUDICATOR 1|N|4||88||TREATMENT|1961-10-28|
TRIAL STUDY 134XCP|TR|E3310689-5727-4970-A675-A58931E406FA|5||||||LNSTATE|LYMPH NODE STATE||SBE/ML|ENLARGEMENT FROM NADIR||USEC|NOT DONE|||IMPEDANCE CONDUCTIVITY|N|NA|FAMILY MEMBER|DERMATOLOGIST|N|5||7||RUN-IN|1971-06-19|
TRIAL STUDY 134XCP|TR|D5359BBA-960E-4392-996A-BCDD8637894A|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||UKAT/10^12 RBC|UNEQUIVOCAL||10^9 ORGANISMS/ML|NOT DONE|||LASER CAPTURE MICRODISSECTION|NA|U|GUARDIAN|OPHTHALMOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1968-06-18|
TRIAL STUDY 134XCP|TR|D5359BBA-960E-4392-996A-BCDD8637894A|2||||||LDIAM|LONGEST DIAMETER||10^9/L|ENLARGEMENT||G|NOT DONE|||FUNDUS PHOTOGRAPHY|Y|Y|DOMESTIC PARTNER|READER 2|NA|2||58||INDUCTION TREATMENT|1970-10-15|
TRIAL STUDY 134XCP|TR|D5359BBA-960E-4392-996A-BCDD8637894A|3||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||MM|UNEQUIVOCAL||SBE/ML|NOT DONE|||ANTIMICROBIAL COMBINATION TESTING|N|NA|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|3||39||SCREENING|1969-08-24|
TRIAL STUDY 134XCP|TR|D5359BBA-960E-4392-996A-BCDD8637894A|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UL|UNEQUIVOCAL||EID 50/ML|NOT DONE|||INFRARED SPECTROMETRY|Y|N|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4||88||INDUCTION TREATMENT|1967-12-05|
TRIAL STUDY 134XCP|TR|D5359BBA-960E-4392-996A-BCDD8637894A|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MMHG*MIN/L|UNEQUIVOCAL||BAG|NOT DONE|||IN SITU HYBRIDIZATION|U|U|CAREGIVER|FORENSIC PATHOLOGIST|N|5||7||BLINDED TREATMENT|1965-04-15|
TRIAL STUDY 134XCP|TR|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||S^-1(%O2)^-1|ENLARGEMENT FROM NADIR||G/MOL|NOT DONE|||MYELOPEROXIDASE STAIN|N|Y|INTERVIEWER|UROLOGIST|U|1||38||CONTINUATION TREATMENT|1968-01-07|
TRIAL STUDY 134XCP|TR|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|2||||||TUMSTATE|TUMOR STATE||UL/ML|ENLARGEMENT||UEQ/L|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|U|NA|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||TREATMENT|1971-04-21|
TRIAL STUDY 134XCP|TR|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||ANTIBODY UNIT|FOCALLY INCREASED||10^8/L|NOT DONE|||REVERSE TRANSCRIPTASE PCR|U|NA|PARENT|PEDIATRIC NEUROLOGIST|Y|3||39||FOLLOW-UP|1973-08-17|
TRIAL STUDY 134XCP|TR|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MM2|DECREASED||BEAM BREAKS|NOT DONE|||CT SCAN WITHOUT CONTRAST|N|Y|PARENT|RADIOLOGIST|NA|4||88||BASELINE|1961-11-07|
TRIAL STUDY 134XCP|TR|C3022BA6-BC2B-4553-A02A-C2FB6B3CBFF5|5||||||RADIODEN|RADIODENSITY||NMOL/L/H|INCREASED||CI|NOT DONE|||RADIATION DOSIMETRY|NA|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|5||7||SCREENING|1966-06-13|
TRIAL STUDY 134XCP|TR|EED3F55E-892E-46C6-8B0A-30D2E1112072|1||||||VDIAM|VIABLE DIAMETER||U/KG|UNEQUIVOCAL||CI/L|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|NA|NA|INTERVIEWER|HEMATOLOGIST|Y|1||38||OPEN LABEL TREATMENT|1967-11-03|
TRIAL STUDY 134XCP|TR|EED3F55E-892E-46C6-8B0A-30D2E1112072|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||PMOL/L|NON-PATHOLOGICAL||SCM|NOT DONE|||HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|N|SIGNIFICANT OTHER|ONCOLOGIST 2|U|2||58||LONG-TERM FOLLOW-UP|1967-08-13|
TRIAL STUDY 134XCP|TR|EED3F55E-892E-46C6-8B0A-30D2E1112072|3||||||BNLNUM|NUMBER OF BONE LESIONS||U/KG|DIFFUSELY INCREASED||MG/ML/DAY|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|NA|Y|FRIEND|HEMATOLOGIST|Y|3||39||INDUCTION TREATMENT|1972-10-15|
TRIAL STUDY 134XCP|TR|EED3F55E-892E-46C6-8B0A-30D2E1112072|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||G/KG/DAY|INCREASED||ML/CM|NOT DONE|||ENZYMATIC COLORIMETRY|U|NA|DOMESTIC PARTNER|READER 3|Y|4||88||LONG-TERM FOLLOW-UP|1965-06-15|
TRIAL STUDY 134XCP|TR|EED3F55E-892E-46C6-8B0A-30D2E1112072|5||||||SUMLDIAM|SUM OF LONGEST DIAMETER||COULOMB|ENLARGEMENT||HOMEOPATHIC DILUTION|NOT DONE|||OSCILLOMETRY|Y|U|INTERVIEWER|OPTOMETRIST|U|5||7||TREATMENT|1968-05-20|
TRIAL STUDY 134XCP|TR|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||PFU/ML|TUMOR MERGED||ML/(MIN*100ML)|NOT DONE|||ENZYMATIC SPECTROPHOTOMETRY|U|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|1||38||INDUCTION TREATMENT|1961-12-06|
TRIAL STUDY 134XCP|TR|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||U/ML|PALPABLE||CUP EQ|NOT DONE|||AMSLER GRID|U|N|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|2||58||BLINDED TREATMENT|1964-12-03|
TRIAL STUDY 134XCP|TR|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||ANTI-XA IU|PATHOLOGICAL||KG/CM2|NOT DONE|||AUDIOMETRY|N|U|SIGNIFICANT OTHER|CARDIOLOGIST|U|3||39||RUN-IN|1965-07-12|
TRIAL STUDY 134XCP|TR|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|4||||||VOLUME|VOLUME||ABSORBANCE U/ML|ENLARGEMENT||UKAT/L|NOT DONE|||U-HPLC/MS/MS|U|N|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||TREATMENT|1966-08-15|
TRIAL STUDY 134XCP|TR|1CE2AE1C-B0E4-4303-AAE5-F877A133D9CF|5||||||AREA|AREA||MN|DIFFUSELY INCREASED||MG/G/H|NOT DONE|||THICK SMEAR|NA|N|DOMESTIC PARTNER|HEMATOLOGIST|Y|5||7||INDUCTION TREATMENT|1971-11-19|
TRIAL STUDY 134XCP|TR|B865DADD-9A4E-4521-A2E8-104D709F4144|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||NU/CL|UNCHANGED||G/G|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|U|INDEPENDENT ASSESSOR|READER|Y|1||38||CONTINUATION TREATMENT|1967-05-12|
TRIAL STUDY 134XCP|TR|B865DADD-9A4E-4521-A2E8-104D709F4144|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||POINT|ENLARGEMENT||WATT|NOT DONE|||IMPEDANCE CONDUCTIVITY|Y|U|ADJUDICATOR|MICROSCOPIST 3|N|2||58||BASELINE|1963-10-31|
TRIAL STUDY 134XCP|TR|B865DADD-9A4E-4521-A2E8-104D709F4144|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||KA_U/DL|ABSENT||RAD|NOT DONE|||CYSTOSCOPY|NA|NA|ADJUDICATOR|READER 1|Y|3||39||RUN-IN|1973-09-03|
TRIAL STUDY 134XCP|TR|B865DADD-9A4E-4521-A2E8-104D709F4144|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||UMOL/DL|ENLARGEMENT FROM NADIR||GTT|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|NA|N|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|4||88||SCREENING|1964-11-05|
TRIAL STUDY 134XCP|TR|B865DADD-9A4E-4521-A2E8-104D709F4144|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||CIGAR|DIFFUSELY INCREASED||IU/KG/H|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|N|N|CAREGIVER|MICROSCOPIST 1|N|5||7||WASHOUT|1968-05-09|
TRIAL STUDY 134XCP|TR|D8C78860-7893-4239-8F29-A0EE98C90310|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||GBQ/MG|PALPABLE||MV/SEC|NOT DONE|||IMMUNOASSAY|N|NA|FRIEND|ONCOLOGIST 1|U|1||38||OBSERVATION|1970-10-23|
TRIAL STUDY 134XCP|TR|D8C78860-7893-4239-8F29-A0EE98C90310|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||KG/M2|FURTHER ENLARGEMENT FROM NADIR||AMOL|NOT DONE|||URANYL ACETATE STAIN|U|NA|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|2||58||TREATMENT|1969-08-19|
TRIAL STUDY 134XCP|TR|D8C78860-7893-4239-8F29-A0EE98C90310|3||||||SUMVOL|SUM OF VOLUME||10^5/L|NORMAL||CI/ML|NOT DONE|||PHASE CONTRAST MICROSCOPY|Y|N|INVESTIGATOR|ONCOLOGIST 2|Y|3||39||RUN-IN|1971-09-08|
TRIAL STUDY 134XCP|TR|D8C78860-7893-4239-8F29-A0EE98C90310|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||LOG10 PFU|FURTHER ENLARGEMENT||CS|NOT DONE|||NUCLEIC ACID BASED METHOD|Y|NA|SPOUSE|READER 3|N|4||88||CONTINUATION TREATMENT|1962-12-24|
TRIAL STUDY 134XCP|TR|D8C78860-7893-4239-8F29-A0EE98C90310|5||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UKAT|NON-PATHOLOGICAL||GENEQ|NOT DONE|||ALCIAN BLUE STAIN|Y|N|INDEPENDENT ASSESSOR|CARDIOLOGIST|N|5||7||FOLLOW-UP|1964-11-18|
TRIAL STUDY 134XCP|TR|841D0118-C3F9-4169-B43E-D88CEB2795BA|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||CM/MIN|INCREASED||NEEDLE GAUGE|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|NA|NA|SIGNIFICANT OTHER|READER 3|U|1||38||CONTINUATION TREATMENT|1967-10-25|
TRIAL STUDY 134XCP|TR|841D0118-C3F9-4169-B43E-D88CEB2795BA|2||||||VSLFLIND|VESSEL FAILURE INDICATOR||/MIN|ENLARGEMENT FROM NADIR||MG/DL|NOT DONE|||IN SITU HYBRIDIZATION|NA|N|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||BASELINE|1971-01-09|
TRIAL STUDY 134XCP|TR|841D0118-C3F9-4169-B43E-D88CEB2795BA|3||||||TUMSTATE|TUMOR STATE||RING|INCREASED||USIEMENS|NOT DONE|||THIN SMEAR|U|U|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1972-06-20|
TRIAL STUDY 134XCP|TR|841D0118-C3F9-4169-B43E-D88CEB2795BA|4||||||SUMDIAM|SUM OF DIAMETER||DAYS/WK|INCREASED||SFC/10^6 PBMC|NOT DONE|||CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|N|U|INVESTIGATOR|FORENSIC PATHOLOGIST|NA|4||88||WASHOUT|1962-08-27|
TRIAL STUDY 134XCP|TR|841D0118-C3F9-4169-B43E-D88CEB2795BA|5||||||SUMDIAM|SUM OF DIAMETER||ML/CAGE/DAY|FURTHER ENLARGEMENT FROM NADIR||CM/MIN|NOT DONE|||GC/FID|NA|Y|FRIEND|INTERNIST|N|5||7||BLINDED TREATMENT|1962-05-07|
TRIAL STUDY 134XCP|TR|9C3C0334-F7A4-4530-A6D3-574C039979E7|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||GAUSS|DIFFUSELY INCREASED||UG/DOSE|NOT DONE|||ICC|Y|Y|FRIEND|PATHOLOGIST|N|1||38||BASELINE|1960-09-06|
TRIAL STUDY 134XCP|TR|9C3C0334-F7A4-4530-A6D3-574C039979E7|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||UMOL/L/MIN|ENLARGEMENT||UG/M2/MIN|NOT DONE|||PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|U|NA|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|2||58||SCREENING|1973-04-26|
TRIAL STUDY 134XCP|TR|9C3C0334-F7A4-4530-A6D3-574C039979E7|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||G/G|PALPABLE||GPS U|NOT DONE|||WEBER GREEN STAIN|U|N|ADJUDICATOR|OPTOMETRIST|U|3||39||BASELINE|1960-10-25|
TRIAL STUDY 134XCP|TR|9C3C0334-F7A4-4530-A6D3-574C039979E7|4||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ML/KG/H|UNCHANGED||NMOL/G|NOT DONE|||GRAM STAIN|NA|U|ADJUDICATOR|UROLOGIST|NA|4||88||OBSERVATION|1970-12-20|
TRIAL STUDY 134XCP|TR|9C3C0334-F7A4-4530-A6D3-574C039979E7|5||||||LPERP|LONGEST PERPENDICULAR||L/DAY|FURTHER ENLARGEMENT||NSEC|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|Y|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5||7||LONG-TERM FOLLOW-UP|1962-02-08|
TRIAL STUDY 134XCP|TR|FE955CB9-9992-4521-8788-7597AF40F214|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||/H|PRESENT||NMOL/L/MIN|NOT DONE|||PET SCAN|U|N|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|1||38||INDUCTION TREATMENT|1969-11-13|
TRIAL STUDY 134XCP|TR|FE955CB9-9992-4521-8788-7597AF40F214|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CAPLET|FURTHER ENLARGEMENT||CI/ML|NOT DONE|||PHOTOMETRIC CLOT DETECTION|U|NA|CAREGIVER|MICROSCOPIST 2|Y|2||58||OBSERVATION|1971-12-18|
TRIAL STUDY 134XCP|TR|FE955CB9-9992-4521-8788-7597AF40F214|3||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||DROP|DECREASED||/H|NOT DONE|||ISHIHARA COLOR PLATES|Y|U|DOMESTIC PARTNER|RADIOLOGIST 1|Y|3||39||TREATMENT|1969-04-21|
TRIAL STUDY 134XCP|TR|FE955CB9-9992-4521-8788-7597AF40F214|4||||||AREA|AREA||KBQ|UNEQUIVOCAL||ML/MMHG/MIN/L|NOT DONE|||HPLC/MS|Y|N|ADJUDICATION COMMITTEE|NEUROLOGIST|NA|4||88||RUN-IN|1961-08-05|
TRIAL STUDY 134XCP|TR|FE955CB9-9992-4521-8788-7597AF40F214|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||G/DL|PALPABLE||CONTAINER|NOT DONE|||AUTOREFRACTION|N|U|VENDOR|NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1961-08-01|
TRIAL STUDY 134XCP|TR|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|1||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||NMOL BCE/L|ENLARGEMENT FROM NADIR||UMOL/L/SEC|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|Y|Y|FAMILY MEMBER|ENDOCRINOLOGIST|NA|1||38||FOLLOW-UP|1962-03-14|
TRIAL STUDY 134XCP|TR|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||ELISA UNIT/ML|PRESENT||10^7 TCID 50/DOSE|NOT DONE|||PERIODIC ACID SCHIFF STAIN|U|U|PARENT|ADJUDICATOR 3|U|2||58||RUN-IN|1970-09-30|
TRIAL STUDY 134XCP|TR|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^9 CFU|UNCHANGED||U/MG|NOT DONE|||LAPAROSCOPY|Y|NA|INDEPENDENT ASSESSOR|DERMATOLOGIST|U|3||39||FOLLOW-UP|1965-04-11|
TRIAL STUDY 134XCP|TR|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|4||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||NMOL/L/H|FURTHER ENLARGEMENT FROM NADIR||L/L|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|NA|N|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|4||88||INDUCTION TREATMENT|1969-07-15|
TRIAL STUDY 134XCP|TR|C4C89E29-ADFC-4883-87BA-FA0BDD37AB4D|5||||||VSLPIND|VESSEL PATENCY INDICATOR||UM2|NON-PATHOLOGICAL||NMOL BCE/L|NOT DONE|||REFLECTANCE SPECTROSCOPY|N|N|DOMESTIC PARTNER|RADIOLOGIST|U|5||7||INDUCTION TREATMENT|1971-03-16|
TRIAL STUDY 134XCP|TR|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|1||||||LESSCIND|LESION SUCCESS INDICATOR||WATT|FURTHER ENLARGEMENT||ML/KG|NOT DONE|||ANTIBIOTIC AGAR SCREEN|U|N|PARENT|INTERNIST|Y|1||38||INDUCTION TREATMENT|1960-09-03|
TRIAL STUDY 134XCP|TR|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|2||||||LPERP|LONGEST PERPENDICULAR||ML/MIN/1.73M2|FOCALLY INCREASED||KS|NOT DONE|||LIQUID SCINTILLATION COUNTING|Y|N|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|2||58||SCREENING|1971-07-06|
TRIAL STUDY 134XCP|TR|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|3||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||NM|UNCHANGED||10^3/L|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|Y|N|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|3||39||BLINDED TREATMENT|1972-02-10|
TRIAL STUDY 134XCP|TR|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||HR/DAY|EQUIVOCAL||U/KG|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|NA|N|CHILD|CLINICAL PATHOLOGIST|NA|4||88||OBSERVATION|1973-03-07|
TRIAL STUDY 134XCP|TR|FF087F6A-E9C7-4A01-B6CD-A95FF609F13E|5||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||/100 HPFS|NONPALPABLE||ENZYME U/G HB|NOT DONE|||CONTRAST ENHANCED MRI|NA|Y|FRIEND|ADJUDICATOR|N|5||7||WASHOUT|1971-08-20|
TRIAL STUDY 134XCP|TR|28B6CF51-A007-4CED-8247-37BD468F41C5|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MG/ML/DAY|ENLARGEMENT||PACKET|NOT DONE|||MICROARRAY|U|U|VENDOR|MICROSCOPIST 3|U|1||38||LONG-TERM FOLLOW-UP|1966-11-22|
TRIAL STUDY 134XCP|TR|28B6CF51-A007-4CED-8247-37BD468F41C5|2||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||PG|ENLARGEMENT||MG/ML/DAY|NOT DONE|||POTENTIOMETRY|N|NA|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|2||58||FOLLOW-UP|1962-04-16|
TRIAL STUDY 134XCP|TR|28B6CF51-A007-4CED-8247-37BD468F41C5|3||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UG/M2/MIN|ABSENT||L/H|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|NA|SPOUSE|MICROSCOPIST 3|NA|3||39||RUN-IN|1966-03-29|
TRIAL STUDY 134XCP|TR|28B6CF51-A007-4CED-8247-37BD468F41C5|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||MEQ|ENLARGEMENT FROM NADIR||CP|NOT DONE|||DXA SCAN|NA|U|DOMESTIC PARTNER|ADJUDICATOR 2|NA|4||88||WASHOUT|1968-06-03|
TRIAL STUDY 134XCP|TR|28B6CF51-A007-4CED-8247-37BD468F41C5|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PATCH|ABSENT||MS2|NOT DONE|||KNEMOMETRY|Y|U|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|5||7||CONTINUATION TREATMENT|1969-05-27|
TRIAL STUDY 134XCP|TR|4E600C41-1B27-4042-B48E-B60489701D2D|1||||||SUMVOL|SUM OF VOLUME||ABSORBANCE U/ML|ENLARGEMENT FROM NADIR||GBQ/MG|NOT DONE|||DYNAMOMETRY|Y|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|1||38||LONG-TERM FOLLOW-UP|1966-10-26|
TRIAL STUDY 134XCP|TR|4E600C41-1B27-4042-B48E-B60489701D2D|2||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||UMOL/MOL|NORMAL||FIU|NOT DONE|||EEG|N|U|CHILD|OPHTHALMOLOGIST|Y|2||58||WASHOUT|1969-12-04|
TRIAL STUDY 134XCP|TR|4E600C41-1B27-4042-B48E-B60489701D2D|3||||||SUMVOL|SUM OF VOLUME||IU/KG|NORMAL||MIN/DAY|NOT DONE|||WHOLE TRANSCRIPTOME SEQUENCING|U|Y|PARENT|PEDIATRIC NEUROLOGIST|N|3||39||TREATMENT|1971-12-08|
TRIAL STUDY 134XCP|TR|4E600C41-1B27-4042-B48E-B60489701D2D|4||||||LESFLIND|LESION FAILURE INDICATOR||DROP|UNEQUIVOCAL||UGEQ|NOT DONE|||ELECTROMYOGRAPHY|N|U|INVESTIGATOR|CLINICAL PATHOLOGIST|U|4||88||CONTINUATION TREATMENT|1972-07-24|
TRIAL STUDY 134XCP|TR|4E600C41-1B27-4042-B48E-B60489701D2D|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UG/L/H|EQUIVOCAL||NMOL/L|NOT DONE|||TRANSESOPHAGEAL ECHOCARDIOGRAPHY|U|NA|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|5||7||RUN-IN|1969-09-01|
TRIAL STUDY 134XCP|TR|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|1||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||G/G/DAY|NONPALPABLE||YEARS|NOT DONE|||RAJI CELL RIA|Y|N|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1||38||INDUCTION TREATMENT|1971-07-09|
TRIAL STUDY 134XCP|TR|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MMOL/KG|UNEQUIVOCAL||PG|NOT DONE|||ECHOCARDIOGRAPHY|Y|N|INTERVIEWER|ADJUDICATOR 2|U|2||58||CONTINUATION TREATMENT|1963-12-21|
TRIAL STUDY 134XCP|TR|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PA|NORMAL||DDU|NOT DONE|||FUNCTIONAL MRI|NA|N|FAMILY MEMBER|HEMATOLOGIST|Y|3||39||BLINDED TREATMENT|1973-04-10|
TRIAL STUDY 134XCP|TR|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|4||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||KHZ|FOCALLY INCREASED||MV/SEC|NOT DONE|||ELECTRONEUROGRAPHY|Y|U|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|4||88||WASHOUT|1971-09-16|
TRIAL STUDY 134XCP|TR|1E162E13-C5F0-4892-BE7E-A2E6A2191DAD|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||ML/MMHG|PALPABLE||MEQ/UL|NOT DONE|||MICROARRAY|NA|Y|SPOUSE|MICROSCOPIST|NA|5||7||OPEN LABEL TREATMENT|1962-08-08|
TRIAL STUDY 134XCP|TR|00D760E7-DC21-41A8-AD28-FF48A5C21E83|1||||||RADIODEN|RADIODENSITY||CYLINDER|FURTHER ENLARGEMENT||10^4/HPF|NOT DONE|||ELECTRICAL IMPEDANCE MYOGRAPHY|N|N|DOMESTIC PARTNER|RATER|U|1||38||RUN-IN|1965-09-14|
TRIAL STUDY 134XCP|TR|00D760E7-DC21-41A8-AD28-FF48A5C21E83|2||||||LESFLIND|LESION FAILURE INDICATOR||STEPS|NON-PATHOLOGICAL||UMOL/L/H|NOT DONE|||CELL BASED BIOASSAY|N|NA|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||BLINDED TREATMENT|1967-03-30|
TRIAL STUDY 134XCP|TR|00D760E7-DC21-41A8-AD28-FF48A5C21E83|3||||||LPERP|LONGEST PERPENDICULAR||NM|DECREASED||UG/DOSE|NOT DONE|||IMPULSE OSCILLOMETRY|NA|NA|FAMILY MEMBER|NEUROLOGIST|U|3||39||SCREENING|1969-11-12|
TRIAL STUDY 134XCP|TR|00D760E7-DC21-41A8-AD28-FF48A5C21E83|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||TUBERCULIN UNIT|FOCALLY INCREASED||PMOL/10^9 CELLS|NOT DONE|||CHROMATOGRAPHY|N|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|4||88||OBSERVATION|1972-10-16|
TRIAL STUDY 134XCP|TR|00D760E7-DC21-41A8-AD28-FF48A5C21E83|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ML/DL|DECREASED||PL|NOT DONE|||GEL ELECTROPHORESIS|Y|NA|CHILD|RATER|N|5||7||FOLLOW-UP|1967-10-07|
TRIAL STUDY 134XCP|TR|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||BQ/MG|ABSENT||MIN*MG/ML|NOT DONE|||AURAMINE STAIN|Y|NA|DOMESTIC PARTNER|READER 2|Y|1||38||OPEN LABEL TREATMENT|1964-07-21|
TRIAL STUDY 134XCP|TR|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|2||||||VOLUME|VOLUME||10^9 CFU/G|FOCALLY INCREASED||K|NOT DONE|||INDIRECT IMMUNOFLUORESCENCE|NA|N|CHILD|NEUROLOGIST 1|U|2||58||WASHOUT|1967-08-19|
TRIAL STUDY 134XCP|TR|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|3||||||AREA|AREA||MPH|UNEQUIVOCAL||LOG10 TCID 50/DOSE|NOT DONE|||BIOPSY|U|U|INVESTIGATOR|RADIOLOGIST 1|NA|3||39||INDUCTION TREATMENT|1971-06-21|
TRIAL STUDY 134XCP|TR|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||DAYS/WK|FOCALLY INCREASED||UGEQ|NOT DONE|||VIRUS PLAQUE ASSAY|U|NA|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|4||88||RUN-IN|1962-02-18|
TRIAL STUDY 134XCP|TR|946ABDE0-2C2B-48BB-8003-1BAEE37264F3|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||FRAMES/S|NON-PATHOLOGICAL||GENEQ|NOT DONE|||CYSTOMETRY|N|NA|FRIEND|READER 2|U|5||7||OPEN LABEL TREATMENT|1964-10-01|
TRIAL STUDY 134XCP|TR|4EC25C9E-F259-405B-8B7D-3C9640FB9748|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KIT|UNEQUIVOCAL||CS|NOT DONE|||HEMOCYTOMETRY|NA|NA|CAREGIVER|OTOLARYNGOLOGIST|U|1||38||CONTINUATION TREATMENT|1964-10-25|
TRIAL STUDY 134XCP|TR|4EC25C9E-F259-405B-8B7D-3C9640FB9748|2||||||DIAMETER|DIAMETER||PACKAGE|NON-PATHOLOGICAL||10^3 ORGANISMS/ML|NOT DONE|||ICP-MS|U|U|INVESTIGATOR|PATHOLOGIST 2|N|2||58||TREATMENT|1967-05-14|
TRIAL STUDY 134XCP|TR|4EC25C9E-F259-405B-8B7D-3C9640FB9748|3||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||UG/MOL|DIFFUSELY INCREASED||ENZYME U/M2|NOT DONE|||SCANNING ELECTRON MICROSCOPY|Y|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3||39||LONG-TERM FOLLOW-UP|1961-10-30|
TRIAL STUDY 134XCP|TR|4EC25C9E-F259-405B-8B7D-3C9640FB9748|4||||||LMBFLIND|LIMB FAILURE INDICATOR||MG/M2/DAY|PATHOLOGICAL||MMOL/KG|NOT DONE|||SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|N|NA|SPOUSE|NEUROLOGIST 1|U|4||88||WASHOUT|1973-01-06|
TRIAL STUDY 134XCP|TR|4EC25C9E-F259-405B-8B7D-3C9640FB9748|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MG/M2/DAY|EQUIVOCAL||MDFI|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|NA|INTERVIEWER|RADIOLOGIST 2|N|5||7||BLINDED TREATMENT|1972-05-22|
TRIAL STUDY 134XCP|TR|FF1CC617-040D-42E9-AD31-32E7B8DAED24|1||||||LESFLIND|LESION FAILURE INDICATOR||NKAT/L|PATHOLOGICAL||CFU/ML|NOT DONE|||IMMUNOBLOT|U|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1||38||TREATMENT|1968-08-07|
TRIAL STUDY 134XCP|TR|FF1CC617-040D-42E9-AD31-32E7B8DAED24|2||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||BOLUS|ABSENT||FMOL/L/SEC|NOT DONE|||LEAD CITRATE STAIN|NA|NA|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2||58||TREATMENT|1964-01-29|
TRIAL STUDY 134XCP|TR|FF1CC617-040D-42E9-AD31-32E7B8DAED24|3||||||PALPSTAT|PALPABLE STATE||1/(S*KPA)|PALPABLE||LOG10 CCID 50/DOSE|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|NA|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|3||39||OPEN LABEL TREATMENT|1965-04-30|
TRIAL STUDY 134XCP|TR|FF1CC617-040D-42E9-AD31-32E7B8DAED24|4||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||LOZENGE|TUMOR MERGED||10^3 CFU/G|NOT DONE|||MICROBIAL CULTURE, SOLID|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|4||88||FOLLOW-UP|1961-03-15|
TRIAL STUDY 134XCP|TR|FF1CC617-040D-42E9-AD31-32E7B8DAED24|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||PIXELS/CM|ENLARGEMENT FROM NADIR||RATIO|NOT DONE|||ACID FAST STAIN|U|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|5||7||TREATMENT|1970-12-29|
TRIAL STUDY 134XCP|TR|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||10^6 COPIES/ML|ENLARGEMENT||ECL UNIT|NOT DONE|||AUDIOMETRY|NA|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|1||38||RUN-IN|1965-09-29|
TRIAL STUDY 134XCP|TR|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|2||||||SUMDIAM|SUM OF DIAMETER||UV*SEC|FURTHER ENLARGEMENT FROM NADIR||MG/M2/DAY|NOT DONE|||OPHTHALMOSCOPY|NA|NA|DOMESTIC PARTNER|RATER|NA|2||58||SCREENING|1968-03-23|
TRIAL STUDY 134XCP|TR|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||TCID 50/DOSE|FOCALLY INCREASED||10^3/HPF|NOT DONE|||IVY INCISION METHOD|N|NA|CLINICAL RESEARCH COORDINATOR|RATER|Y|3||39||CONTINUATION TREATMENT|1965-05-02|
TRIAL STUDY 134XCP|TR|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||U/M2/DAY|ENLARGEMENT FROM NADIR||L/MIN|NOT DONE|||MAMMOGRAPHY|U|Y|SPOUSE|ADJUDICATOR 2|NA|4||88||WASHOUT|1973-06-11|
TRIAL STUDY 134XCP|TR|F8A4AF92-256A-4ECF-9C87-036FA7E5BF53|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||COPIES/ML|DIFFUSELY INCREASED||PM|NOT DONE|||HPLC/MS|NA|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|5||7||SCREENING|1962-10-15|
TRIAL STUDY 134XCP|TR|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|1||||||ORSTATE|ORGAN STATE||FEU|DECREASED||PMOL/G|NOT DONE|||CELLULAR PROLIFERATION ASSAY|Y|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|1||38||SCREENING|1966-01-29|
TRIAL STUDY 134XCP|TR|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|2||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||COAT|TUMOR MERGED||MG/KG/WEEK|NOT DONE|||IMPEDANCE CONDUCTIVITY|NA|Y|FAMILY MEMBER|ENDOCRINOLOGIST|U|2||58||BLINDED TREATMENT|1971-07-25|
TRIAL STUDY 134XCP|TR|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||MESF|ENLARGEMENT FROM NADIR||MM|NOT DONE|||JAEGER EYE CHART|NA|NA|VENDOR|INTERNIST|U|3||39||LONG-TERM FOLLOW-UP|1963-04-04|
TRIAL STUDY 134XCP|TR|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|4||||||LNSTATE|LYMPH NODE STATE||CMH2O*S/ML|PATHOLOGICAL||FG|NOT DONE|||ICP-MS|NA|Y|CLINICAL RESEARCH COORDINATOR|READER|U|4||88||RUN-IN|1968-01-15|
TRIAL STUDY 134XCP|TR|BD3E97D8-A24F-49AA-8C3D-23C708A1B62F|5||||||LESFLIND|LESION FAILURE INDICATOR||INHALATION|UNEQUIVOCAL||MET*H|NOT DONE|||DYNAMIC CONTRAST ENHANCED MRI|N|Y|ADJUDICATOR|MICROSCOPIST|U|5||7||BASELINE|1971-01-30|
TRIAL STUDY 134XCP|TR|BFA83769-F31F-49AE-8C43-49046C719D69|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||/H|ABSENT||PMOL/G|NOT DONE|||GEL ELECTROPHORESIS|N|Y|CAREGIVER|ADJUDICATOR 1|Y|1||38||LONG-TERM FOLLOW-UP|1966-04-26|
TRIAL STUDY 134XCP|TR|BFA83769-F31F-49AE-8C43-49046C719D69|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||NMOL/ML/MIN|UNEQUIVOCAL||10^7 CFU/ML|NOT DONE|||PET SCAN|N|U|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|2||58||OPEN LABEL TREATMENT|1973-07-30|
TRIAL STUDY 134XCP|TR|BFA83769-F31F-49AE-8C43-49046C719D69|3||||||VDIAM|VIABLE DIAMETER||KV|FOCALLY INCREASED||ML/G/DAY|NOT DONE|||ACRIDINE ORANGE STAIN|N|Y|FAMILY MEMBER|INTERNIST|U|3||39||LONG-TERM FOLLOW-UP|1966-08-02|
TRIAL STUDY 134XCP|TR|BFA83769-F31F-49AE-8C43-49046C719D69|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||CY/CM|NONPALPABLE||KS|NOT DONE|||COULOMETRIC TITRATION|N|NA|DOMESTIC PARTNER|ADJUDICATOR|NA|4||88||OBSERVATION|1964-08-22|
TRIAL STUDY 134XCP|TR|BFA83769-F31F-49AE-8C43-49046C719D69|5||||||VDIAM|VIABLE DIAMETER||DAYS/MONTH|PRESENT||UG/DAY|NOT DONE|||DIGITAL PCR|U|N|CHILD|RATER|N|5||7||WASHOUT|1960-05-21|
TRIAL STUDY 134XCP|TR|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||10^6 CFU/G|PATHOLOGICAL||TCID 50/DOSE|NOT DONE|||PANENDOSCOPY|U|U|INDEPENDENT ASSESSOR|PATHOLOGIST 1|N|1||38||OPEN LABEL TREATMENT|1971-03-05|
TRIAL STUDY 134XCP|TR|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||TITER|FURTHER ENLARGEMENT||USEC|NOT DONE|||IMMUNO-PET SCAN|Y|Y|CLINICAL STUDY SPONSOR|RATER|NA|2||58||FOLLOW-UP|1966-02-01|
TRIAL STUDY 134XCP|TR|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|3||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/BREATH|PRESENT||EID 50/ML|NOT DONE|||CLAUSS METHOD|U|NA|FRIEND|RATER 1|NA|3||39||TREATMENT|1966-09-16|
TRIAL STUDY 134XCP|TR|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|4||||||CALCFIND|CALCIFICATION INDICATOR||QUANTITY SUFFICIENT|PALPABLE||MHZ|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|NA|NA|GUARDIAN|PATHOLOGIST 2|N|4||88||SCREENING|1968-01-04|
TRIAL STUDY 134XCP|TR|6D52A8E1-CC3D-4D85-AAEC-264743FDA85E|5||||||VSLPIND|VESSEL PATENCY INDICATOR||ENZYME U/G HB|NONPALPABLE||ML/ANIMAL/DAY|NOT DONE|||KLEIHAUER-BETKE|NA|Y|CAREGIVER|ADJUDICATOR 3|U|5||7||LONG-TERM FOLLOW-UP|1968-09-27|
TRIAL STUDY 134XCP|TR|91838668-D463-4728-A581-2E1987592885|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||FT2|EQUIVOCAL||ML/MIN|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|U|U|INTERVIEWER|ONCOLOGIST 1|NA|1||38||BASELINE|1963-02-11|
TRIAL STUDY 134XCP|TR|91838668-D463-4728-A581-2E1987592885|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PMOL|PATHOLOGICAL||MG/MOL|NOT DONE|||SPECULAR MICROSCOPY|U|N|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|2||58||BASELINE|1971-04-07|
TRIAL STUDY 134XCP|TR|91838668-D463-4728-A581-2E1987592885|3||||||SUMDIAM|SUM OF DIAMETER||BISCUIT|FURTHER ENLARGEMENT||WEEKS|NOT DONE|||REFRACTOMETRY|U|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|3||39||SCREENING|1971-06-14|
TRIAL STUDY 134XCP|TR|91838668-D463-4728-A581-2E1987592885|4||||||PALPSTAT|PALPABLE STATE||GPL U|PRESENT||PG/DL|NOT DONE|||CALCOFLUOR WHITE STAIN|Y|U|CHILD|READER|Y|4||88||CONTINUATION TREATMENT|1962-02-27|
TRIAL STUDY 134XCP|TR|91838668-D463-4728-A581-2E1987592885|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||V|EQUIVOCAL||PG/DL|NOT DONE|||MACRO BROTH DILUTION|N|NA|CAREGIVER|INTERNIST|Y|5||7||CONTINUATION TREATMENT|1960-08-14|
TRIAL STUDY 134XCP|TR|DE440A90-82D5-4269-A48B-47E2F5495440|1||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||STEPS/MIN|FOCALLY INCREASED||LOG EID 50/DOSE|NOT DONE|||RAJI CELL RIA|N|NA|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|1||38||OBSERVATION|1970-04-27|
TRIAL STUDY 134XCP|TR|DE440A90-82D5-4269-A48B-47E2F5495440|2||||||LNSTATE|LYMPH NODE STATE||/500 WBC|NON-PATHOLOGICAL||AG|NOT DONE|||HPLC-FL|U|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|2||58||LONG-TERM FOLLOW-UP|1966-12-02|
TRIAL STUDY 134XCP|TR|DE440A90-82D5-4269-A48B-47E2F5495440|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||NMOL BCE/MMOL|ENLARGEMENT FROM NADIR||10^9 ORGANISMS/G|NOT DONE|||CONTRAST ENHANCED CT SCAN|U|NA|ADJUDICATION COMMITTEE|NEUROLOGIST|Y|3||39||CONTINUATION TREATMENT|1967-02-07|
TRIAL STUDY 134XCP|TR|DE440A90-82D5-4269-A48B-47E2F5495440|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||PPM|INCREASED||IU/G HB|NOT DONE|||ERGOSPIROMETRY|N|N|ADJUDICATION COMMITTEE|RATER 1|U|4||88||INDUCTION TREATMENT|1963-01-28|
TRIAL STUDY 134XCP|TR|DE440A90-82D5-4269-A48B-47E2F5495440|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||C|PALPABLE||ML/DOSE|NOT DONE|||BETA LACTAMASE|Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|5||7||OBSERVATION|1961-07-26|
TRIAL STUDY 134XCP|TR|74CA3A61-3179-43F1-8721-2582F50C44EF|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UU/DL|TUMOR MERGED||100 IU/ML|NOT DONE|||HPLC-UV|N|N|FRIEND|PATHOLOGIST 1|N|1||38||FOLLOW-UP|1966-10-18|
TRIAL STUDY 134XCP|TR|74CA3A61-3179-43F1-8721-2582F50C44EF|2||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||U/MG|ABSENT||KN/CM2|NOT DONE|||SMEAR|U|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|2||58||OBSERVATION|1972-05-31|
TRIAL STUDY 134XCP|TR|74CA3A61-3179-43F1-8721-2582F50C44EF|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||G/KG|FOCALLY INCREASED||UG/DOSE|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|NA|Y|FAMILY MEMBER|ADJUDICATOR 2|N|3||39||LONG-TERM FOLLOW-UP|1969-07-16|
TRIAL STUDY 134XCP|TR|74CA3A61-3179-43F1-8721-2582F50C44EF|4||||||LESSCIND|LESION SUCCESS INDICATOR||U.CARR|EQUIVOCAL||UL|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|U|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1973-02-21|
TRIAL STUDY 134XCP|TR|74CA3A61-3179-43F1-8721-2582F50C44EF|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||ENZYME U|TUMOR MERGED||IU/L|NOT DONE|||TRYPAN BLUE STAIN|N|U|CLINICAL RESEARCH COORDINATOR|READER 1|NA|5||7||OBSERVATION|1973-02-01|
TRIAL STUDY 134XCP|TR|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||STEPS/MIN|UNCHANGED||MS2|NOT DONE|||MANUAL CLOT DETECTION|Y|Y|INTERVIEWER|RATER 1|Y|1||38||OBSERVATION|1973-03-24|
TRIAL STUDY 134XCP|TR|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||ENZYME U/M2|FURTHER ENLARGEMENT||U/M2|NOT DONE|||WEBER GREEN STAIN|N|Y|PARENT|READER 2|U|2||58||OBSERVATION|1967-03-28|
TRIAL STUDY 134XCP|TR|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||MILE|TUMOR MERGED||KG/CM|NOT DONE|||IMMUNOASSAY|U|N|CHILD|INTERNIST|N|3||39||WASHOUT|1962-07-15|
TRIAL STUDY 134XCP|TR|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|4||||||ORVERLN|ORGAN VERTICAL LENGTH||MMOL2/L2|NONPALPABLE||UL/KG/DAY|NOT DONE|||ERGOSPIROMETRY|Y|NA|SPOUSE|RADIOLOGIST 1|N|4||88||OPEN LABEL TREATMENT|1960-05-28|
TRIAL STUDY 134XCP|TR|B16F2A3D-7DA3-4E50-AC6D-CA9F209A86CE|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||KAT|FOCALLY INCREASED||BQ/G|NOT DONE|||MICROBIAL CULTURE|Y|NA|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|5||7||INDUCTION TREATMENT|1963-07-09|
TRIAL STUDY 134XCP|TR|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||PG/DL|UNEQUIVOCAL||TESLA|NOT DONE|||EPSILOMETER|U|NA|FAMILY MEMBER|RATER|U|1||38||OBSERVATION|1963-11-27|
TRIAL STUDY 134XCP|TR|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UMOL/H/MMOL|NORMAL||10^6 U|NOT DONE|||MICROBIAL CULTURE|U|NA|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|2||58||CONTINUATION TREATMENT|1972-04-21|
TRIAL STUDY 134XCP|TR|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|3||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||10^6 DNA COPIES/ML|DECREASED||PUFF|NOT DONE|||PHOROPTER|U|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|3||39||WASHOUT|1967-10-11|
TRIAL STUDY 134XCP|TR|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||AMP|UNCHANGED||SV|NOT DONE|||EEG|Y|N|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|U|4||88||CONTINUATION TREATMENT|1962-11-03|
TRIAL STUDY 134XCP|TR|AE1FC2A0-5A47-4AB3-B1A5-0E5D033598BE|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MV2/HZ|ENLARGEMENT||ML/CM3/MIN|NOT DONE|||IMMUNOPRECIPITATION|N|Y|GUARDIAN|MICROSCOPIST|U|5||7||OBSERVATION|1961-05-03|
TRIAL STUDY 134XCP|TR|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MMOL|NORMAL||MMOL2/L2|NOT DONE|||TRYPAN BLUE STAIN|NA|NA|SIBLING|PATHOLOGIST 2|Y|1||38||OPEN LABEL TREATMENT|1962-02-04|
TRIAL STUDY 134XCP|TR|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||UMOL/DAY|ABSENT||KG|NOT DONE|||AGAR PROPORTION|Y|NA|INDEPENDENT ASSESSOR|INTERNIST|NA|2||58||WASHOUT|1964-02-14|
TRIAL STUDY 134XCP|TR|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|3||||||CALCFIND|CALCIFICATION INDICATOR||BEL|PRESENT||10^6/G|NOT DONE|||WRIGHT-GIEMSA STAIN|N|Y|CLINICAL RESEARCH COORDINATOR|READER 3|Y|3||39||CONTINUATION TREATMENT|1966-10-27|
TRIAL STUDY 134XCP|TR|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|4||||||TUMSTATE|TUMOR STATE||/MM|DIFFUSELY INCREASED||SV|NOT DONE|||REFRACTOMETRY|NA|NA|CAREGIVER|PATHOLOGIST|N|4||88||RUN-IN|1971-08-15|
TRIAL STUDY 134XCP|TR|3F3D60F6-E32A-46FA-9A55-396F9A19AD27|5||||||TUMSTATE|TUMOR STATE||10^3 CFU/G|PALPABLE||VG/ML|NOT DONE|||MAGNETIC RESONANCE ENTEROGRAPHY|NA|NA|SIBLING|OPTOMETRIST|Y|5||7||INDUCTION TREATMENT|1965-09-25|
TRIAL STUDY 134XCP|TR|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||GPS U|UNEQUIVOCAL||ENZYME U/G HB|NOT DONE|||ICP-MS|Y|Y|PARENT|MICROSCOPIST 3|N|1||38||INDUCTION TREATMENT|1964-03-17|
TRIAL STUDY 134XCP|TR|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UG/M2/DAY|ABSENT||EIA UNIT|NOT DONE|||ELECTROPHORESIS|N|Y|SIBLING|RADIOLOGIST 2|U|2||58||SCREENING|1973-05-09|
TRIAL STUDY 134XCP|TR|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||MMOL/L|NON-PATHOLOGICAL||ENZYME U/L|NOT DONE|||TOTAL BODY RADIOGRAPHY|NA|Y|CAREGIVER|NEUROLOGIST|NA|3||39||WASHOUT|1962-06-16|
TRIAL STUDY 134XCP|TR|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||FMOL/G|INCREASED||ML/CM3/MIN|NOT DONE|||SPECTROPHOTOMETRY|U|Y|SIBLING|OTOLARYNGOLOGIST|NA|4||88||WASHOUT|1967-05-29|
TRIAL STUDY 134XCP|TR|7EDE94C5-F4F6-41A0-B0A8-89F5E13ACE86|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||MEQ|PRESENT||SIEMENS|NOT DONE|||SNP ARRAY|NA|N|GUARDIAN|READER|N|5||7||BLINDED TREATMENT|1968-09-09|
TRIAL STUDY 134XCP|TR|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||ML/MIN/MMHG|NORMAL||CIGAR|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|Y|N|SPOUSE|RADIOLOGIST 1|U|1||38||WASHOUT|1972-01-11|
TRIAL STUDY 134XCP|TR|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|2||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||10^6 ORGANISMS|NON-PATHOLOGICAL||MMOL/L|NOT DONE|||GRADIENT DIFFUSION|N|N|VENDOR|ONCOLOGIST|N|2||58||INDUCTION TREATMENT|1962-06-07|
TRIAL STUDY 134XCP|TR|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|3||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||FT3|NONPALPABLE||WATT|NOT DONE|||NUCLEIC ACID BASED METHOD|NA|N|CHILD|FORENSIC PATHOLOGIST|U|3||39||RUN-IN|1963-05-27|
TRIAL STUDY 134XCP|TR|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|4||||||TUMSTATE|TUMOR STATE||SCM|NONPALPABLE||%|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|NA|NA|SIGNIFICANT OTHER|PATHOLOGIST 2|NA|4||88||RUN-IN|1964-04-27|
TRIAL STUDY 134XCP|TR|70ECA05B-727E-4B2B-A9DF-7F60C40FCEE2|5||||||VSLFLIND|VESSEL FAILURE INDICATOR||NKAT/G HB|NON-PATHOLOGICAL||NCI|NOT DONE|||ELISPOT|Y|U|ADJUDICATOR|RATER 1|Y|5||7||BLINDED TREATMENT|1969-08-25|
TRIAL STUDY 134XCP|TR|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MGEQ|FURTHER ENLARGEMENT||RATIO|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|NA|SIBLING|PATHOLOGIST|Y|1||38||TREATMENT|1968-10-23|
TRIAL STUDY 134XCP|TR|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/10^4|UNCHANGED||KDA|NOT DONE|||CRYOSCOPY|NA|NA|SIBLING|RATER 1|U|2||58||INDUCTION TREATMENT|1971-05-14|
TRIAL STUDY 134XCP|TR|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|3||||||DIAMETER|DIAMETER||ENZYME U/M2|NON-PATHOLOGICAL||MASK|NOT DONE|||HPLC/IEX|N|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|3||39||RUN-IN|1971-11-16|
TRIAL STUDY 134XCP|TR|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|4||||||VOLUME|VOLUME||OHM|NONPALPABLE||WATT|NOT DONE|||TURBIDIMETRY|N|U|INTERVIEWER|NEUROLOGIST 2|U|4||88||BASELINE|1970-02-08|
TRIAL STUDY 134XCP|TR|C34E6498-9F9C-4F9A-82AE-6B7331AD8EE9|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||TSP|PRESENT||HZ/S|NOT DONE|||ANTIBIOTIC AGAR SCREEN|U|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|5||7||SCREENING|1961-07-19|
TRIAL STUDY 134XCP|TR|687E56D1-7E45-4598-819A-A0D8D770F406|1||||||VDIAM|VIABLE DIAMETER||EP U|FURTHER ENLARGEMENT FROM NADIR||BLOCKS|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|NA|Y|INTERVIEWER|INTERNIST|NA|1||38||SCREENING|1964-07-13|
TRIAL STUDY 134XCP|TR|687E56D1-7E45-4598-819A-A0D8D770F406|2||||||ORVERLN|ORGAN VERTICAL LENGTH||GENEQ/ML|UNCHANGED||YEARS|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|NA|N|ADJUDICATOR|READER|Y|2||58||BASELINE|1970-04-11|
TRIAL STUDY 134XCP|TR|687E56D1-7E45-4598-819A-A0D8D770F406|3||||||LESFLIND|LESION FAILURE INDICATOR||DPM/0.5 ML|UNEQUIVOCAL||PMOL/10^9 CELLS|NOT DONE|||SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION|Y|NA|STUDY SUBJECT|MICROSCOPIST|NA|3||39||OPEN LABEL TREATMENT|1962-05-20|
TRIAL STUDY 134XCP|TR|687E56D1-7E45-4598-819A-A0D8D770F406|4||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||G/L|EQUIVOCAL||WAFER|NOT DONE|||ELECTROMYOGRAPHY|N|U|FAMILY MEMBER|MICROSCOPIST 3|U|4||88||CONTINUATION TREATMENT|1967-11-04|
TRIAL STUDY 134XCP|TR|687E56D1-7E45-4598-819A-A0D8D770F406|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||G/U|INCREASED||/LPF|NOT DONE|||DC SHEATH FLOW|U|NA|FRIEND|RADIOLOGIST 1|N|5||7||WASHOUT|1963-08-31|
TRIAL STUDY 134XCP|TR|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|1||||||LNSTATE|LYMPH NODE STATE||JOULE|NON-PATHOLOGICAL||LOG10 CFU/G|NOT DONE|||PH METER MEASUREMENT METHOD|Y|U|VENDOR|UROLOGIST|N|1||38||SCREENING|1966-09-07|
TRIAL STUDY 134XCP|TR|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|2||||||LESFLIND|LESION FAILURE INDICATOR||BEAM BREAKS|NON-PATHOLOGICAL||CD*S/M2|NOT DONE|||SPECT SCAN|U|Y|INVESTIGATOR|NEUROLOGIST|Y|2||58||FOLLOW-UP|1961-10-24|
TRIAL STUDY 134XCP|TR|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|3||||||VDIAM|VIABLE DIAMETER||10^4/HPF|FURTHER ENLARGEMENT FROM NADIR||U/MMOL|NOT DONE|||LYMPHANGIOGRAPHY|NA|N|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|3||39||WASHOUT|1963-04-12|
TRIAL STUDY 134XCP|TR|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||BQ/KG|DECREASED||U/L|NOT DONE|||WHOLE GENOME SEQUENCING|Y|Y|SIBLING|HEMATOLOGIST|Y|4||88||TREATMENT|1965-12-06|
TRIAL STUDY 134XCP|TR|FA25647C-7E2D-4FD8-9A76-83B8CF8AB849|5||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||M3|NORMAL||PMOL/G|NOT DONE|||ECHOCARDIOGRAPHY|NA|N|CHILD|OPHTHALMOLOGIST|U|5||7||BLINDED TREATMENT|1966-12-25|
TRIAL STUDY 134XCP|TR|F536FDD9-881B-41AD-B863-FE8AB14062A1|1||||||ORSTATE|ORGAN STATE||CCID 50/ML|FURTHER ENLARGEMENT||MG2/DL2|NOT DONE|||CINEANGIOGRAPHY|N|U|GUARDIAN|PATHOLOGIST|N|1||38||CONTINUATION TREATMENT|1965-09-11|
TRIAL STUDY 134XCP|TR|F536FDD9-881B-41AD-B863-FE8AB14062A1|2||||||LESSCIND|LESION SUCCESS INDICATOR||UG/DAY|UNEQUIVOCAL||ABSORBANCE U/ML|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|N|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2||58||OPEN LABEL TREATMENT|1973-03-22|
TRIAL STUDY 134XCP|TR|F536FDD9-881B-41AD-B863-FE8AB14062A1|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||KCAL/DAY|PATHOLOGICAL||G/MOL|NOT DONE|||PULSE OXIMETRY|Y|Y|INVESTIGATOR|RATER 2|Y|3||39||FOLLOW-UP|1970-01-23|
TRIAL STUDY 134XCP|TR|F536FDD9-881B-41AD-B863-FE8AB14062A1|4||||||RADIODEN|RADIODENSITY||CFU/G|NON-PATHOLOGICAL||NMOL/L|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|U|N|STUDY SUBJECT|RATER 1|N|4||88||FOLLOW-UP|1963-08-02|
TRIAL STUDY 134XCP|TR|F536FDD9-881B-41AD-B863-FE8AB14062A1|5||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||LOG10 ELISA UNIT|ENLARGEMENT FROM NADIR||10^9 ORGANISMS/ML|NOT DONE|||ELISA|U|NA|SIBLING|MICROSCOPIST 1|N|5||7||LONG-TERM FOLLOW-UP|1962-04-15|
TRIAL STUDY 134XCP|TR|CB726766-A812-45B3-95CA-D1AD8F697FD3|1||||||SUMDIAM|SUM OF DIAMETER||VG/ML|ABSENT||MG/ML/MIN|NOT DONE|||PHOROPTER|NA|NA|GUARDIAN|UROLOGIST|N|1||38||INDUCTION TREATMENT|1972-04-07|
TRIAL STUDY 134XCP|TR|CB726766-A812-45B3-95CA-D1AD8F697FD3|2||||||LESSCIND|LESION SUCCESS INDICATOR||NKAT|ENLARGEMENT||MG/ML/MIN|NOT DONE|||CALCOFLUOR WHITE STAIN|N|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||WASHOUT|1972-04-16|
TRIAL STUDY 134XCP|TR|CB726766-A812-45B3-95CA-D1AD8F697FD3|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||MEQ/KG|ENLARGEMENT FROM NADIR||OI50|NOT DONE|||INFRARED SPECTROMETRY|U|Y|CHILD|RADIOLOGIST 2|Y|3||39||WASHOUT|1964-11-26|
TRIAL STUDY 134XCP|TR|CB726766-A812-45B3-95CA-D1AD8F697FD3|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||MG|PALPABLE||UMOL/MIN|NOT DONE|||BETA LACTAMASE|U|Y|INDEPENDENT ASSESSOR|READER 3|Y|4||88||RUN-IN|1967-05-05|
TRIAL STUDY 134XCP|TR|CB726766-A812-45B3-95CA-D1AD8F697FD3|5||||||VDIAM|VIABLE DIAMETER||IU/MMOL|TUMOR MERGED||10^4/HPF|NOT DONE|||GRADIENT DIFFUSION|U|Y|FRIEND|READER 2|Y|5||7||TREATMENT|1961-02-14|
TRIAL STUDY 134XCP|TR|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|1||||||LPERP|LONGEST PERPENDICULAR||MG/DOSE|INCREASED||FMOL/L/SEC|NOT DONE|||REAL-TIME POLYMERASE CHAIN REACTION ASSAY|NA|N|GUARDIAN|PHYSIOTHERAPIST|U|1||38||LONG-TERM FOLLOW-UP|1968-08-24|
TRIAL STUDY 134XCP|TR|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|2||||||PCHGNAD|PERCENT CHANGE FROM NADIR||GBQ/G|INCREASED||ML/G/H|NOT DONE|||IMMUNOFLUORESCENT STAIN|N|N|INVESTIGATOR|HEMATOLOGIST|Y|2||58||OBSERVATION|1971-07-20|
TRIAL STUDY 134XCP|TR|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|3||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||10^6/EJACULATE U|ABSENT||L/S|NOT DONE|||HEMAGGLUTINATION ASSAY|N|NA|DOMESTIC PARTNER|MICROSCOPIST 1|NA|3||39||OBSERVATION|1972-04-18|
TRIAL STUDY 134XCP|TR|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|4||||||NEWCONF|NEW TUMOR CONFIRMED||BREATHS/30S|ABSENT||MG/KG/MIN|NOT DONE|||COULOMETRIC TITRATION|NA|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|4||88||OBSERVATION|1964-03-11|
TRIAL STUDY 134XCP|TR|1CC00AA0-6D99-4C72-B211-A2DD3F36D830|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||PMOL/10^10 CELLS|INCREASED||DROP|NOT DONE|||KINYOUN STAIN|Y|N|INVESTIGATOR|PATHOLOGIST 1|N|5||7||WASHOUT|1966-10-27|
TRIAL STUDY 134XCP|TR|20DC654F-595C-410D-A340-465A23434D42|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||TITER|FURTHER ENLARGEMENT||TABLET|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|N|Y|SIBLING|RATER 2|N|1||38||BLINDED TREATMENT|1964-06-25|
TRIAL STUDY 134XCP|TR|20DC654F-595C-410D-A340-465A23434D42|2||||||SUMVOL|SUM OF VOLUME||V|NON-PATHOLOGICAL||KALLIKREIN INHIBITOR UNIT|NOT DONE|||SMEAR|N|U|FAMILY MEMBER|ADJUDICATOR|NA|2||58||FOLLOW-UP|1969-08-27|
TRIAL STUDY 134XCP|TR|20DC654F-595C-410D-A340-465A23434D42|3||||||VDIAM|VIABLE DIAMETER||SQU/ML|PRESENT||CYLINDER|NOT DONE|||FREEZING POINT DEPRESSION|N|U|SPOUSE|ADJUDICATOR 2|Y|3||39||BASELINE|1972-03-10|
TRIAL STUDY 134XCP|TR|20DC654F-595C-410D-A340-465A23434D42|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||GAUSS|NON-PATHOLOGICAL||ML/CM3/MIN|NOT DONE|||MICRONEUTRALIZATION ASSAY|NA|U|PROXY|UROLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1964-10-26|
TRIAL STUDY 134XCP|TR|20DC654F-595C-410D-A340-465A23434D42|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||ML/BREATH|NON-PATHOLOGICAL||GLOBULE|NOT DONE|||BALLPOINT PEN TECHNIQUE|NA|U|FAMILY MEMBER|NEUROLOGIST 1|U|5||7||OPEN LABEL TREATMENT|1965-05-19|
TRIAL STUDY 134XCP|TR|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|1||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||M|TUMOR MERGED||PACK|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|NA|Y|VENDOR|MICROSCOPIST 3|N|1||38||SCREENING|1960-10-13|
TRIAL STUDY 134XCP|TR|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PPTH|PALPABLE||ML/M2|NOT DONE|||TOLUIDINE BLUE STAIN|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|2||58||SCREENING|1965-11-04|
TRIAL STUDY 134XCP|TR|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|3||||||ORSTATE|ORGAN STATE||/200 HPFS|DIFFUSELY INCREASED||/10^5|NOT DONE|||SLIT LAMP PHOTOGRAPHY|N|U|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|3||39||BLINDED TREATMENT|1964-12-15|
TRIAL STUDY 134XCP|TR|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|4||||||PALPSTAT|PALPABLE STATE||DPM/ML|DECREASED||ML/ANIMAL|NOT DONE|||ELECTROGASTROGRAPHY|NA|N|CAREGIVER|MICROSCOPIST 2|U|4||88||WASHOUT|1963-12-04|
TRIAL STUDY 134XCP|TR|3AFCED00-B717-49B6-ADA0-5E321C97D0A1|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||GPL U|FURTHER ENLARGEMENT||PPTR|NOT DONE|||CINEANGIOGRAPHY|NA|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|5||7||BASELINE|1968-03-17|
TRIAL STUDY 134XCP|TR|4EA8DC88-09C8-4954-A469-D8E12F01CB56|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UL|INCREASED||APL U/ML|NOT DONE|||IMMUNORADIOMETRIC ASSAY|U|U|INTERVIEWER|OPTOMETRIST|U|1||38||OPEN LABEL TREATMENT|1964-10-08|
TRIAL STUDY 134XCP|TR|4EA8DC88-09C8-4954-A469-D8E12F01CB56|2||||||CALCFIND|CALCIFICATION INDICATOR||UG/M2/DAY|UNEQUIVOCAL||UG/M2|NOT DONE|||MICROSCOPY|Y|U|PROXY|READER 1|Y|2||58||BLINDED TREATMENT|1971-04-22|
TRIAL STUDY 134XCP|TR|4EA8DC88-09C8-4954-A469-D8E12F01CB56|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||GY|ENLARGEMENT FROM NADIR||VP/DOSE|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|NA|U|CAREGIVER|READER 1|N|3||39||WASHOUT|1960-07-29|
TRIAL STUDY 134XCP|TR|4EA8DC88-09C8-4954-A469-D8E12F01CB56|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||UM|PATHOLOGICAL||AMFI|NOT DONE|||LANDOLT RING|Y|U|CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|4||88||BASELINE|1973-08-09|
TRIAL STUDY 134XCP|TR|4EA8DC88-09C8-4954-A469-D8E12F01CB56|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||G/CAGE|DIFFUSELY INCREASED||MEQ/UL|NOT DONE|||HIGH RESOLUTION CT|N|NA|CAREGIVER|MICROSCOPIST 1|NA|5||7||INDUCTION TREATMENT|1970-07-07|
TRIAL STUDY 134XCP|TR|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|1||||||LESFLIND|LESION FAILURE INDICATOR||/DAY|FURTHER ENLARGEMENT||CMOL|NOT DONE|||HILLMEN COLOR CHART|Y|NA|ADJUDICATION COMMITTEE|INTERNIST|NA|1||38||RUN-IN|1970-11-13|
TRIAL STUDY 134XCP|TR|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|2||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UV*SEC|TUMOR MERGED||10^4 CFU/ML|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|Y|INVESTIGATOR|PATHOLOGIST|Y|2||58||RUN-IN|1965-05-08|
TRIAL STUDY 134XCP|TR|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|3||||||CALCFIND|CALCIFICATION INDICATOR||PACK|PALPABLE||FT|NOT DONE|||SPECTROPHOTOMETRY|Y|NA|ADJUDICATION COMMITTEE|RATER 1|Y|3||39||OPEN LABEL TREATMENT|1963-10-20|
TRIAL STUDY 134XCP|TR|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|4||||||LMBFLIND|LIMB FAILURE INDICATOR||QUANTITY SUFFICIENT|DIFFUSELY INCREASED||ML/MMHG|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|NA|Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|4||88||TREATMENT|1971-01-19|
TRIAL STUDY 134XCP|TR|4D4868E9-3CAA-4BF1-A3BE-1BE3664DE6B7|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||NG/L|NORMAL||CFU/ML|NOT DONE|||TONOMETRY|N|N|SIBLING|ONCOLOGIST 1|U|5||7||INDUCTION TREATMENT|1965-10-22|
TRIAL STUDY 134XCP|TR|521B1614-9092-4F89-A47F-728C66E01B23|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||BQ/ML|DIFFUSELY INCREASED||UG/H|NOT DONE|||DUCTOGRAPHY|U|N|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|1||38||RUN-IN|1973-05-23|
TRIAL STUDY 134XCP|TR|521B1614-9092-4F89-A47F-728C66E01B23|2||||||VOLUME|VOLUME||IU/DAY|ABSENT||UMOL/KG/MIN|NOT DONE|||ENZYMATIC COLORIMETRY|U|U|FAMILY MEMBER|MICROSCOPIST 3|N|2||58||OBSERVATION|1961-10-09|
TRIAL STUDY 134XCP|TR|521B1614-9092-4F89-A47F-728C66E01B23|3||||||CALCFIND|CALCIFICATION INDICATOR||/MONTH|DIFFUSELY INCREASED||BOTTLE|NOT DONE|||LC-FL|N|NA|SIBLING|CLINICAL PATHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1967-01-01|
TRIAL STUDY 134XCP|TR|521B1614-9092-4F89-A47F-728C66E01B23|4||||||SUMVOL|SUM OF VOLUME||/40 HPFS|FURTHER ENLARGEMENT||10^11/L|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|NA|U|SPOUSE|PHYSIOTHERAPIST|U|4||88||CONTINUATION TREATMENT|1964-07-28|
TRIAL STUDY 134XCP|TR|521B1614-9092-4F89-A47F-728C66E01B23|5||||||SUMDIAM|SUM OF DIAMETER||10^6 U|PRESENT||U/KG/H|NOT DONE|||SNP ARRAY|Y|N|FRIEND|PHYSIOTHERAPIST|NA|5||7||OPEN LABEL TREATMENT|1969-02-09|
TRIAL STUDY 134XCP|TR|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||G/KG/DAY|ABSENT||SFC/10^6 PBMC|NOT DONE|||CLIP SEQUENCING|NA|N|CLINICAL RESEARCH COORDINATOR|RATER|NA|1||38||OPEN LABEL TREATMENT|1965-06-19|
TRIAL STUDY 134XCP|TR|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|2||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||KG|FOCALLY INCREASED||CM H2O|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|Y|U|FAMILY MEMBER|ADJUDICATOR 1|N|2||58||BASELINE|1967-04-10|
TRIAL STUDY 134XCP|TR|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||OZ EQ|EQUIVOCAL||RNA COPIES/ML|NOT DONE|||SNP ARRAY|NA|Y|INVESTIGATOR|RADIOLOGIST 1|N|3||39||WASHOUT|1967-01-07|
TRIAL STUDY 134XCP|TR|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|4||||||PALPSTAT|PALPABLE STATE||MU/G|UNEQUIVOCAL||H*%|NOT DONE|||MICRONEUTRALIZATION ASSAY|N|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|4||88||OPEN LABEL TREATMENT|1962-08-11|
TRIAL STUDY 134XCP|TR|3DB9B1C5-47C4-4684-96B6-334C9C33CD0D|5||||||VDIAM|VIABLE DIAMETER||CI/ML|NON-PATHOLOGICAL||VP/ML|NOT DONE|||GC/MS-CI|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|5||7||FOLLOW-UP|1963-08-07|
TRIAL STUDY 134XCP|TR|FF6B8B49-3C82-459D-A35D-61136FC594D2|1||||||SUMVOL|SUM OF VOLUME||ML/100G/MIN|ABSENT||BQ/ML|NOT DONE|||IMMUNOFLUORESCENT STAIN|U|U|ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|1||38||BASELINE|1969-04-25|
TRIAL STUDY 134XCP|TR|FF6B8B49-3C82-459D-A35D-61136FC594D2|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PMOL/DAY|NONPALPABLE||POUCH|NOT DONE|||CONTACT SPECULAR MICROSCOPY|NA|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|N|2||58||LONG-TERM FOLLOW-UP|1973-06-20|
TRIAL STUDY 134XCP|TR|FF6B8B49-3C82-459D-A35D-61136FC594D2|3||||||LESFLIND|LESION FAILURE INDICATOR||MMHG/L/MIN|PRESENT||MM/H|NOT DONE|||ECHOCARDIOGRAPHY|Y|U|CHILD|ADJUDICATOR 3|Y|3||39||BASELINE|1970-08-17|
TRIAL STUDY 134XCP|TR|FF6B8B49-3C82-459D-A35D-61136FC594D2|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MMHG*MIN/L|NON-PATHOLOGICAL||FMOL|NOT DONE|||MICROARRAY|N|NA|VENDOR|RADIOLOGIST 1|N|4||88||BASELINE|1970-04-03|
TRIAL STUDY 134XCP|TR|FF6B8B49-3C82-459D-A35D-61136FC594D2|5||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||EU|PALPABLE||RNA COPIES/ML|NOT DONE|||MICROBIAL CONCENTRATION|NA|U|CAREGIVER|ONCOLOGIST|N|5||7||INDUCTION TREATMENT|1964-09-22|
TRIAL STUDY 134XCP|TR|2196D9F4-937A-4662-B24B-AC9D472E0393|1||||||VDIAM|VIABLE DIAMETER||EID 50/DOSE|ENLARGEMENT||G/U|NOT DONE|||NUCLEIC ACID BASED METHOD|N|NA|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|1||38||BLINDED TREATMENT|1962-09-24|
TRIAL STUDY 134XCP|TR|2196D9F4-937A-4662-B24B-AC9D472E0393|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||10^10/L|INCREASED||UG/L DDU|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|U|Y|CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|2||58||TREATMENT|1972-10-12|
TRIAL STUDY 134XCP|TR|2196D9F4-937A-4662-B24B-AC9D472E0393|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||MEQ/ML|DECREASED||FRAMES/S|NOT DONE|||GC/MS/MS|U|NA|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|3||39||BLINDED TREATMENT|1962-07-31|
TRIAL STUDY 134XCP|TR|2196D9F4-937A-4662-B24B-AC9D472E0393|4||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||G/ANIMAL|NON-PATHOLOGICAL||MMOL/S|NOT DONE|||WHOLE GENOME SEQUENCING|Y|NA|PROXY|MICROSCOPIST 3|N|4||88||BLINDED TREATMENT|1960-06-17|
TRIAL STUDY 134XCP|TR|2196D9F4-937A-4662-B24B-AC9D472E0393|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||BOX|DECREASED||G/M2/DAY|NOT DONE|||FLOCCULATION|NA|N|CHILD|PHYSIOTHERAPIST|U|5||7||OPEN LABEL TREATMENT|1963-12-06|
TRIAL STUDY 134XCP|TR|F192452A-4088-46AA-9DD1-8D14809E18F6|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MOSM/L|PALPABLE||/100 HPFS|NOT DONE|||IMPULSE OSCILLOMETRY|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|1||38||LONG-TERM FOLLOW-UP|1963-05-23|
TRIAL STUDY 134XCP|TR|F192452A-4088-46AA-9DD1-8D14809E18F6|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CARTRIDGE|DECREASED||DEG/S|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|2||58||BASELINE|1973-02-06|
TRIAL STUDY 134XCP|TR|F192452A-4088-46AA-9DD1-8D14809E18F6|3||||||LPERP|LONGEST PERPENDICULAR||CMH2O*S/ML|FURTHER ENLARGEMENT||MMHG*MIN/L|NOT DONE|||CT SCAN WITHOUT CONTRAST|U|Y|PARENT|ONCOLOGIST|U|3||39||WASHOUT|1962-06-05|
TRIAL STUDY 134XCP|TR|F192452A-4088-46AA-9DD1-8D14809E18F6|4||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||NMOL/L/H|PALPABLE||PMOL/DAY|NOT DONE|||MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|N|N|SIBLING|OPTOMETRIST|U|4||88||BLINDED TREATMENT|1965-08-07|
TRIAL STUDY 134XCP|TR|F192452A-4088-46AA-9DD1-8D14809E18F6|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||%/MIN|NORMAL||OZ EQ|NOT DONE|||RADIOIMMUNOPRECIPITATION ASSAY|U|N|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|5||7||RUN-IN|1968-02-09|
TRIAL STUDY 134XCP|TR|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||STEPS|NORMAL||FFU|NOT DONE|||EPSILOMETER|Y|NA|STUDY SUBJECT|ADJUDICATOR 2|NA|1||38||WASHOUT|1960-02-27|
TRIAL STUDY 134XCP|TR|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||PPTR|ENLARGEMENT FROM NADIR||MNFI|NOT DONE|||PHASE CONTRAST MICROSCOPY|Y|U|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|2||58||OPEN LABEL TREATMENT|1964-08-20|
TRIAL STUDY 134XCP|TR|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|3||||||RADIODEN|RADIODENSITY||KCAL|DIFFUSELY INCREASED||MEQ|NOT DONE|||TOTAL BODY IRRADIATION|N|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|Y|3||39||TREATMENT|1962-05-02|
TRIAL STUDY 134XCP|TR|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||BQ/UL|INCREASED||UG/L|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|N|NA|VENDOR|PEDIATRIC NEUROLOGIST|N|4||88||RUN-IN|1969-09-02|
TRIAL STUDY 134XCP|TR|02FCAF7E-984A-4EF7-95C1-EF545DDFD2C5|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||U/10^12 RBC|FOCALLY INCREASED||/LSQN|NOT DONE|||ICC|N|Y|PARENT|OPHTHALMOLOGIST|Y|5||7||SCREENING|1967-06-28|
TRIAL STUDY 134XCP|TR|0D51A87E-2597-4B2D-A7B5-E533790E917D|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MG/MIN|ENLARGEMENT FROM NADIR||AGU/ML|NOT DONE|||OSCILLOMETRY|NA|U|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|1||38||INDUCTION TREATMENT|1960-06-08|
TRIAL STUDY 134XCP|TR|0D51A87E-2597-4B2D-A7B5-E533790E917D|2||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||KPA/L/SEC|ABSENT||UU/DL|NOT DONE|||CLIP|Y|Y|INDEPENDENT ASSESSOR|UROLOGIST|N|2||58||BASELINE|1971-07-20|
TRIAL STUDY 134XCP|TR|0D51A87E-2597-4B2D-A7B5-E533790E917D|3||||||ORSTATE|ORGAN STATE||HR/DAY|ENLARGEMENT||BOWL|NOT DONE|||CELLULAR PROLIFERATION ASSAY|U|Y|INDEPENDENT ASSESSOR|ADJUDICATOR|U|3||39||OPEN LABEL TREATMENT|1961-10-14|
TRIAL STUDY 134XCP|TR|0D51A87E-2597-4B2D-A7B5-E533790E917D|4||||||LPERP|LONGEST PERPENDICULAR||GLOBULE|UNCHANGED||MU/G|NOT DONE|||CONTRAST ENHANCED MRI|U|N|INTERVIEWER|ADJUDICATOR 3|N|4||88||CONTINUATION TREATMENT|1967-03-28|
TRIAL STUDY 134XCP|TR|0D51A87E-2597-4B2D-A7B5-E533790E917D|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||S*KPA|NORMAL||MV/SEC|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|Y|N|SPOUSE|MICROSCOPIST 2|NA|5||7||WASHOUT|1967-02-18|
TRIAL STUDY 134XCP|TR|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||WEEKS|ENLARGEMENT FROM NADIR||K|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|U|N|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|U|1||38||RUN-IN|1971-10-01|
TRIAL STUDY 134XCP|TR|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||10^12/L|INCREASED||CONTAINER|NOT DONE|||RADIOGRAPHY|U|N|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||BASELINE|1965-09-10|
TRIAL STUDY 134XCP|TR|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|3||||||SUMDIAM|SUM OF DIAMETER||UG/G/H|NORMAL||U/G/H|NOT DONE|||POPULATION SEQUENCING|U|U|SIGNIFICANT OTHER|HEMATOLOGIST|NA|3||39||BASELINE|1968-07-31|
TRIAL STUDY 134XCP|TR|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|4||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||KCAL/DAY|NORMAL||CIGARETTE|NOT DONE|||SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|U|N|SIGNIFICANT OTHER|HEMATOLOGIST|NA|4||88||WASHOUT|1967-06-26|
TRIAL STUDY 134XCP|TR|3CD8C9A3-A0A4-4BE5-8DA9-6FDA02FC85D4|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ENZYME U/G HB|ABSENT||USIEMENS|NOT DONE|||ISHIHARA COLOR PLATES|N|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|5||7||LONG-TERM FOLLOW-UP|1963-11-20|
TRIAL STUDY 134XCP|TR|16075684-F04D-4CB8-970A-0819378790EB|1||||||FDPL5PS|FDG PET LYMPHOMA 5PS SCORE||MV/SEC|INCREASED||KIT|NOT DONE|||PAP STAIN|Y|Y|GUARDIAN|ADJUDICATOR 2|NA|1||38||INDUCTION TREATMENT|1972-09-29|
TRIAL STUDY 134XCP|TR|16075684-F04D-4CB8-970A-0819378790EB|2||||||CALCFIND|CALCIFICATION INDICATOR||10^9/G|FOCALLY INCREASED||MDFI|NOT DONE|||ELISPOT|NA|NA|CHILD|RATER|NA|2||58||WASHOUT|1962-11-06|
TRIAL STUDY 134XCP|TR|16075684-F04D-4CB8-970A-0819378790EB|3||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||ML/S|NON-PATHOLOGICAL||PMOL|NOT DONE|||KLEIHAUER-BETKE|U|Y|PROXY|UROLOGIST|N|3||39||WASHOUT|1963-04-13|
TRIAL STUDY 134XCP|TR|16075684-F04D-4CB8-970A-0819378790EB|4||||||DIAMETER|DIAMETER||DAYS|INCREASED||PACKAGE|NOT DONE|||DIGITAL PCR|N|N|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|4||88||BASELINE|1960-08-22|
TRIAL STUDY 134XCP|TR|16075684-F04D-4CB8-970A-0819378790EB|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ELISA UNIT|FOCALLY INCREASED||L/S/KPA|NOT DONE|||IN SITU HYBRIDIZATION|N|U|DOMESTIC PARTNER|RADIOLOGIST 1|U|5||7||WASHOUT|1963-07-08|
TRIAL STUDY 134XCP|TR|3527E844-D4D5-480A-B6D6-04C5DC0A3380|1||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||KA_U/DL|ABSENT||M3|NOT DONE|||CISH|U|NA|FRIEND|CLINICAL PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1971-09-12|
TRIAL STUDY 134XCP|TR|3527E844-D4D5-480A-B6D6-04C5DC0A3380|2||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||MEQ/KG|PRESENT||DNA COPIES/UG|NOT DONE|||CT SCAN WITHOUT CONTRAST|N|NA|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|2||58||INDUCTION TREATMENT|1971-04-03|
TRIAL STUDY 134XCP|TR|3527E844-D4D5-480A-B6D6-04C5DC0A3380|3||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MG/KG/WEEK|PRESENT||/LPF|NOT DONE|||TRANSVAGINAL ULTRASOUND|NA|U|INTERVIEWER|DERMATOLOGIST|NA|3||39||RUN-IN|1970-04-25|
TRIAL STUDY 134XCP|TR|3527E844-D4D5-480A-B6D6-04C5DC0A3380|4||||||AREA|AREA||PKAT/L|FOCALLY INCREASED||CFU/ML|NOT DONE|||THERMAL IONIZATION MASS SPECTROMETRY|N|N|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|4||88||BLINDED TREATMENT|1971-10-01|
TRIAL STUDY 134XCP|TR|3527E844-D4D5-480A-B6D6-04C5DC0A3380|5||||||LPERP|LONGEST PERPENDICULAR||10^3 DNA COPIES/ML|INCREASED||LB|NOT DONE|||ETDRS EYE CHART|U|Y|CHILD|MICROSCOPIST 1|N|5||7||CONTINUATION TREATMENT|1960-11-06|
TRIAL STUDY 134XCP|TR|DFB0DF52-4D95-4A26-B28F-071774D78426|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||ANTI-XA IU|INCREASED||10^6 IU/ML|NOT DONE|||RULER MEASUREMENT METHOD|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|1||38||CONTINUATION TREATMENT|1972-05-11|
TRIAL STUDY 134XCP|TR|DFB0DF52-4D95-4A26-B28F-071774D78426|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||UEQ|FURTHER ENLARGEMENT||UV|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|NA|Y|ADJUDICATOR|HEMATOLOGIST|NA|2||58||TREATMENT|1963-10-04|
TRIAL STUDY 134XCP|TR|DFB0DF52-4D95-4A26-B28F-071774D78426|3||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||UKAT/10^12 RBC|DIFFUSELY INCREASED||M|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|U|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|3||39||WASHOUT|1967-01-22|
TRIAL STUDY 134XCP|TR|DFB0DF52-4D95-4A26-B28F-071774D78426|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ML/KG|ENLARGEMENT FROM NADIR||PRESSOR UNITS|NOT DONE|||TEST STRIP|N|U|INTERVIEWER|ONCOLOGIST 1|Y|4||88||OPEN LABEL TREATMENT|1970-02-10|
TRIAL STUDY 134XCP|TR|DFB0DF52-4D95-4A26-B28F-071774D78426|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||COPIES/UL|PALPABLE||G/ANIMAL|NOT DONE|||LASER CAPTURE MICRODISSECTION|NA|N|CLINICAL STUDY SPONSOR|ONCOLOGIST|NA|5||7||OPEN LABEL TREATMENT|1969-04-09|
TRIAL STUDY 134XCP|TR|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|1||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||DEG|FOCALLY INCREASED||EP U|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|N|VENDOR|MICROSCOPIST 2|NA|1||38||INDUCTION TREATMENT|1971-05-15|
TRIAL STUDY 134XCP|TR|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|2||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||GBQ|FURTHER ENLARGEMENT||UG|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|NA|U|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|2||58||TREATMENT|1964-11-14|
TRIAL STUDY 134XCP|TR|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||TORR|NON-PATHOLOGICAL||/7.5 ML|NOT DONE|||THICK SMEAR|Y|U|FRIEND|READER|NA|3||39||OBSERVATION|1970-09-11|
TRIAL STUDY 134XCP|TR|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MPA|EQUIVOCAL||L/S|NOT DONE|||INTRAVASCULAR ULTRASOUND|N|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|4||88||OBSERVATION|1968-09-27|
TRIAL STUDY 134XCP|TR|7F7EFCD6-CFE3-4C15-B25B-0843C02CB439|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ANSON U|DECREASED||ELISA UNIT/ML|NOT DONE|||IMMUNO-PET SCAN|U|U|FAMILY MEMBER|ENDOCRINOLOGIST|NA|5||7||OBSERVATION|1966-11-01|
TRIAL STUDY 134XCP|TR|CFF20837-0091-467E-ABDE-72645BAFC849|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ABSORBANCE U|PATHOLOGICAL||DIOPTER|NOT DONE|||ELECTROGASTROGRAPHY|N|N|FAMILY MEMBER|HEMATOLOGIST|N|1||38||OBSERVATION|1970-11-30|
TRIAL STUDY 134XCP|TR|CFF20837-0091-467E-ABDE-72645BAFC849|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||AMPULE|TUMOR MERGED||BQ/G|NOT DONE|||DC SHEATH FLOW|U|NA|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|2||58||FOLLOW-UP|1963-04-04|
TRIAL STUDY 134XCP|TR|CFF20837-0091-467E-ABDE-72645BAFC849|3||||||RADIODEN|RADIODENSITY||PG|NORMAL||LOG10 IU/ML|NOT DONE|||FUNCTIONAL MRI|Y|U|DOMESTIC PARTNER|ADJUDICATOR 2|U|3||39||LONG-TERM FOLLOW-UP|1963-05-10|
TRIAL STUDY 134XCP|TR|CFF20837-0091-467E-ABDE-72645BAFC849|4||||||LESSCIND|LESION SUCCESS INDICATOR||MG/M2|NON-PATHOLOGICAL||K|NOT DONE|||MICROSCOPY|NA|U|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|4||88||LONG-TERM FOLLOW-UP|1961-06-07|
TRIAL STUDY 134XCP|TR|CFF20837-0091-467E-ABDE-72645BAFC849|5||||||LPERP|LONGEST PERPENDICULAR||DB|PRESENT||MMU/ML|NOT DONE|||URANYL ACETATE STAIN|Y|N|PROXY|OTOLARYNGOLOGIST|N|5||7||INDUCTION TREATMENT|1963-03-29|
TRIAL STUDY 134XCP|TR|C79756C8-8601-4770-8BC2-7A530428BA82|1||||||DIAMETER|DIAMETER||WAFER|TUMOR MERGED||BAU|NOT DONE|||CALCULATION|Y|U|CAREGIVER|OPHTHALMOLOGIST|U|1||38||RUN-IN|1964-08-19|
TRIAL STUDY 134XCP|TR|C79756C8-8601-4770-8BC2-7A530428BA82|2||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||G/KG/DAY|TUMOR MERGED||MMOL/MOL|NOT DONE|||DIGITAL PCR ARRAY|U|N|INVESTIGATOR|ADJUDICATOR 2|U|2||58||TREATMENT|1970-10-27|
TRIAL STUDY 134XCP|TR|C79756C8-8601-4770-8BC2-7A530428BA82|3||||||SUMVOL|SUM OF VOLUME||BOX|EQUIVOCAL||MS2|NOT DONE|||MECHANICAL CLOT DETECTION|N|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|3||39||RUN-IN|1965-05-10|
TRIAL STUDY 134XCP|TR|C79756C8-8601-4770-8BC2-7A530428BA82|4||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PLUG|PALPABLE||10^3 CFU/ML|NOT DONE|||NUCLEIC ACID SEQUENCING|N|NA|STUDY SUBJECT|ADJUDICATOR 1|N|4||88||RUN-IN|1963-05-21|
TRIAL STUDY 134XCP|TR|C79756C8-8601-4770-8BC2-7A530428BA82|5||||||SUMDIAM|SUM OF DIAMETER||UU/DL|DECREASED||DAGU/ML|NOT DONE|||FORCED OSCILLATION TECHNIQUE|Y|N|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|5||7||WASHOUT|1961-07-18|
TRIAL STUDY 134XCP|TR|5533A669-828B-4CA3-BEC3-849CE7384167|1||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||RPM|EQUIVOCAL||LOG10 TCID 50/UL|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|N|N|PROXY|PATHOLOGIST 2|Y|1||38||FOLLOW-UP|1969-08-15|
TRIAL STUDY 134XCP|TR|5533A669-828B-4CA3-BEC3-849CE7384167|2||||||NEWCONF|NEW TUMOR CONFIRMED||CCID 50/DOSE|NONPALPABLE||UCI/KG|NOT DONE|||LIGHT SCATTERING SPECTROSCOPY|N|N|PARENT|DERMATOLOGIST|N|2||58||TREATMENT|1961-10-30|
TRIAL STUDY 134XCP|TR|5533A669-828B-4CA3-BEC3-849CE7384167|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||10^6 ORGANISMS|NONPALPABLE||10^9/G|NOT DONE|||LINE PROBE ASSAY|NA|N|SPOUSE|READER 2|Y|3||39||BLINDED TREATMENT|1973-04-03|
TRIAL STUDY 134XCP|TR|5533A669-828B-4CA3-BEC3-849CE7384167|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||MEQ/ML|INCREASED||10^7 TCID 50/DOSE|NOT DONE|||ALCIAN BLUE STAIN|N|U|INVESTIGATOR|MICROSCOPIST 1|U|4||88||BLINDED TREATMENT|1965-08-28|
TRIAL STUDY 134XCP|TR|5533A669-828B-4CA3-BEC3-849CE7384167|5||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||TITER|UNEQUIVOCAL||1/(S*KPA)|NOT DONE|||PLETHYSMOGRAPHY|Y|N|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|5||7||OBSERVATION|1965-05-02|
TRIAL STUDY 134XCP|TR|C711ADD3-F398-4161-BE13-B75BEDF91402|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||SACHET|FURTHER ENLARGEMENT FROM NADIR||MG/L FEU|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|Y|INTERVIEWER|CLINICAL PATHOLOGIST|Y|1||38||CONTINUATION TREATMENT|1972-07-21|
TRIAL STUDY 134XCP|TR|C711ADD3-F398-4161-BE13-B75BEDF91402|2||||||SUMDIAM|SUM OF DIAMETER||SV|DECREASED||LM|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|N|SIBLING|CARDIOLOGIST|N|2||58||BLINDED TREATMENT|1966-09-19|
TRIAL STUDY 134XCP|TR|C711ADD3-F398-4161-BE13-B75BEDF91402|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||NG/MOL|TUMOR MERGED||RPM|NOT DONE|||IN SITU HYBRIDIZATION|NA|U|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|3||39||BLINDED TREATMENT|1973-08-07|
TRIAL STUDY 134XCP|TR|C711ADD3-F398-4161-BE13-B75BEDF91402|4||||||LPERP|LONGEST PERPENDICULAR||10^4/L|TUMOR MERGED||AMP|NOT DONE|||PALPATION|NA|N|CAREGIVER|OPTOMETRIST|Y|4||88||TREATMENT|1962-06-22|
TRIAL STUDY 134XCP|TR|C711ADD3-F398-4161-BE13-B75BEDF91402|5||||||CALCFIND|CALCIFICATION INDICATOR||PELLET|TUMOR MERGED||1/(S*KPA)|NOT DONE|||ORCHIDOMETERY|NA|NA|DOMESTIC PARTNER|DERMATOLOGIST|N|5||7||SCREENING|1973-02-03|
TRIAL STUDY 134XCP|TR|2CD70FFA-5977-4718-961B-6D67368F99B8|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||VP/DOSE|NON-PATHOLOGICAL||HOUNSFIELD UNIT|NOT DONE|||URANYL ACETATE STAIN|NA|NA|PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||OBSERVATION|1966-12-01|
TRIAL STUDY 134XCP|TR|2CD70FFA-5977-4718-961B-6D67368F99B8|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||MMHG|ENLARGEMENT||MHZ|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|N|N|VENDOR|ADJUDICATOR 1|NA|2||58||RUN-IN|1973-04-25|
TRIAL STUDY 134XCP|TR|2CD70FFA-5977-4718-961B-6D67368F99B8|3||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||ML/M2/MIN|ENLARGEMENT||DAGU/ML|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|N|ADJUDICATOR|READER 3|U|3||39||TREATMENT|1962-08-10|
TRIAL STUDY 134XCP|TR|2CD70FFA-5977-4718-961B-6D67368F99B8|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||BREATHS/30S|NON-PATHOLOGICAL||CFU/G|NOT DONE|||GC/MS|U|N|DOMESTIC PARTNER|RADIOLOGIST 2|N|4||88||SCREENING|1967-07-01|
TRIAL STUDY 134XCP|TR|2CD70FFA-5977-4718-961B-6D67368F99B8|5||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||SPRAY|DECREASED||INHALATION|NOT DONE|||TRANSTHORACIC ECHOCARDIOGRAPHY|NA|N|FRIEND|RADIOLOGIST|N|5||7||INDUCTION TREATMENT|1968-07-01|
TRIAL STUDY 134XCP|TR|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|1||||||LNSTATE|LYMPH NODE STATE||RPM|PATHOLOGICAL||UMOL/L/MIN|NOT DONE|||SMEAR|U|NA|ADJUDICATOR|FORENSIC PATHOLOGIST|U|1||38||RUN-IN|1966-07-05|
TRIAL STUDY 134XCP|TR|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|2||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||L/H/M2|UNCHANGED||MCI/KG|NOT DONE|||OBSERVATION|N|U|INTERVIEWER|PHYSIOTHERAPIST|NA|2||58||WASHOUT|1967-08-11|
TRIAL STUDY 134XCP|TR|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|3||||||RADIODEN|RADIODENSITY||UGEQ/L|FURTHER ENLARGEMENT||BU/ML|NOT DONE|||EPSILOMETER|U|U|SIBLING|RADIOLOGIST 1|NA|3||39||CONTINUATION TREATMENT|1961-07-18|
TRIAL STUDY 134XCP|TR|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|4||||||LDIAM|LONGEST DIAMETER||ENZYME U/M2|UNCHANGED||MCI/KG|NOT DONE|||TOTAL BODY IRRADIATION|U|NA|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|4||88||CONTINUATION TREATMENT|1973-03-11|
TRIAL STUDY 134XCP|TR|F01FF884-E12B-4C43-BB7B-5E8918B19A4A|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||APPLICATION|EQUIVOCAL||TRACE|NOT DONE|||PERFUSION MRI|U|U|INTERVIEWER|MICROSCOPIST 2|U|5||7||CONTINUATION TREATMENT|1965-01-29|
TRIAL STUDY 134XCP|TR|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|1||||||ORVERLN|ORGAN VERTICAL LENGTH||ENZYME U/M2|UNCHANGED||CCID 50/ML|NOT DONE|||WRIGHT STAIN|N|NA|SPOUSE|ADJUDICATOR 2|U|1||38||WASHOUT|1972-05-06|
TRIAL STUDY 134XCP|TR|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|2||||||RADIODEN|RADIODENSITY||10^9/G|PATHOLOGICAL||UM/S|NOT DONE|||TRICHROME STAIN|U|U|DOMESTIC PARTNER|MICROSCOPIST|Y|2||58||CONTINUATION TREATMENT|1961-09-25|
TRIAL STUDY 134XCP|TR|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|3||||||ORSTATE|ORGAN STATE||10^7 CFU/ML|INCREASED||ML/MIN/MMHG|NOT DONE|||PET SCAN|U|U|CAREGIVER|RATER 1|Y|3||39||LONG-TERM FOLLOW-UP|1960-10-15|
TRIAL STUDY 134XCP|TR|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||100 IU/ML|PRESENT||ML/DL|NOT DONE|||CINEANGIOGRAPHY|NA|U|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|4||88||INDUCTION TREATMENT|1964-10-15|
TRIAL STUDY 134XCP|TR|F82601ED-4E74-4349-8F01-2F0DA9AE4BD7|5||||||VSLPIND|VESSEL PATENCY INDICATOR||/2500 WBC|PALPABLE||AMP|NOT DONE|||PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|U|NA|VENDOR|OTOLARYNGOLOGIST|Y|5||7||SCREENING|1965-03-14|
TRIAL STUDY 134XCP|TR|43E00B7D-684F-4BAC-A135-E65C22B191AD|1||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||ML/ANIMAL|NONPALPABLE||UG/DOSE|NOT DONE|||DIFFUSION TENSOR MRI|U|U|PROXY|NEUROLOGIST 1|Y|1||38||INDUCTION TREATMENT|1965-05-22|
TRIAL STUDY 134XCP|TR|43E00B7D-684F-4BAC-A135-E65C22B191AD|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||GMFI|TUMOR MERGED||/2000 RBC|NOT DONE|||CALCOFLUOR WHITE STAIN|U|NA|CLINICAL STUDY SPONSOR|READER 1|U|2||58||OBSERVATION|1972-06-25|
TRIAL STUDY 134XCP|TR|43E00B7D-684F-4BAC-A135-E65C22B191AD|3||||||ORVERLN|ORGAN VERTICAL LENGTH||UG/DOSE|PALPABLE||ECL UNIT|NOT DONE|||MRI WITHOUT CONTRAST|N|Y|ADJUDICATOR|RATER 2|NA|3||39||TREATMENT|1968-01-24|
TRIAL STUDY 134XCP|TR|43E00B7D-684F-4BAC-A135-E65C22B191AD|4||||||AREA|AREA||AMU|UNEQUIVOCAL||ATM|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|NA|N|INTERVIEWER|ADJUDICATOR|Y|4||88||TREATMENT|1963-10-16|
TRIAL STUDY 134XCP|TR|43E00B7D-684F-4BAC-A135-E65C22B191AD|5||||||CALCFIND|CALCIFICATION INDICATOR||SIEMENS|FOCALLY INCREASED||UG/L|NOT DONE|||KNEMOMETRY|U|NA|PROXY|PEDIATRIC NEUROLOGIST|NA|5||7||CONTINUATION TREATMENT|1971-03-15|
TRIAL STUDY 134XCP|TR|25680BE0-7CE5-4B76-A48E-2D977A07E749|1||||||LNSTATE|LYMPH NODE STATE||UL/ML|EQUIVOCAL||PFU/ANIMAL|NOT DONE|||FARR ASSAY|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR|N|1||38||OPEN LABEL TREATMENT|1961-10-14|
TRIAL STUDY 134XCP|TR|25680BE0-7CE5-4B76-A48E-2D977A07E749|2||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||/2000 RBC|FURTHER ENLARGEMENT FROM NADIR||CCID 50/ML|NOT DONE|||COLORIMETRY|N|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2||58||OPEN LABEL TREATMENT|1973-05-04|
TRIAL STUDY 134XCP|TR|25680BE0-7CE5-4B76-A48E-2D977A07E749|3||||||AREA|AREA||UG/DOSE|DIFFUSELY INCREASED||AFU|NOT DONE|||SICKLE CELL SOLUBILITY TEST|NA|N|CHILD|HEMATOLOGIST|N|3||39||BASELINE|1966-09-04|
TRIAL STUDY 134XCP|TR|25680BE0-7CE5-4B76-A48E-2D977A07E749|4||||||AREA|AREA||IU/G HB|FOCALLY INCREASED||G/ANIMAL/DAY|NOT DONE|||RADIATION DOSIMETRY|NA|N|SIGNIFICANT OTHER|ADJUDICATOR 1|Y|4||88||WASHOUT|1960-05-11|
TRIAL STUDY 134XCP|TR|25680BE0-7CE5-4B76-A48E-2D977A07E749|5||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||U/M2/H|UNEQUIVOCAL||KIT|NOT DONE|||COMPUTERIZED CORNEAL TOPOGRAPHY|NA|U|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|5||7||OPEN LABEL TREATMENT|1967-10-09|
TRIAL STUDY 134XCP|TR|67CA2619-351F-493E-93B2-5CDC9AF99C8B|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||ML/M2/DAY|NON-PATHOLOGICAL||STEPS/MIN|NOT DONE|||WESTERN BLOT|N|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|1||38||RUN-IN|1961-05-25|
TRIAL STUDY 134XCP|TR|67CA2619-351F-493E-93B2-5CDC9AF99C8B|2||||||SUMVOL|SUM OF VOLUME||NL|ENLARGEMENT||/MIN|NOT DONE|||COULOMETRIC TITRATION|N|Y|DOMESTIC PARTNER|ADJUDICATOR 1|Y|2||58||SCREENING|1960-07-05|
TRIAL STUDY 134XCP|TR|67CA2619-351F-493E-93B2-5CDC9AF99C8B|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^6 ORGANISMS|NONPALPABLE||AU/ML|NOT DONE|||DIGITAL PCR|NA|N|ADJUDICATION COMMITTEE|READER 2|Y|3||39||BASELINE|1963-05-26|
TRIAL STUDY 134XCP|TR|67CA2619-351F-493E-93B2-5CDC9AF99C8B|4||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||10^11/L|ENLARGEMENT||MG/DAY|NOT DONE|||INTRAVASCULAR ULTRASOUND|NA|NA|ADJUDICATOR|MICROSCOPIST 2|NA|4||88||OPEN LABEL TREATMENT|1971-10-04|
TRIAL STUDY 134XCP|TR|67CA2619-351F-493E-93B2-5CDC9AF99C8B|5||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||MG/KG/WEEK|FURTHER ENLARGEMENT||ML/S/M2|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|Y|N|FRIEND|MICROSCOPIST|U|5||7||FOLLOW-UP|1965-10-16|
TRIAL STUDY 134XCP|TR|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|1||||||ORVERLN|ORGAN VERTICAL LENGTH||UG/M2/MIN|FURTHER ENLARGEMENT||ENZYME U/M2|NOT DONE|||AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|U|SPOUSE|CLINICAL PATHOLOGIST|N|1||38||BLINDED TREATMENT|1968-09-17|
TRIAL STUDY 134XCP|TR|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|2||||||BNLNUM|NUMBER OF BONE LESIONS||YEARS|DECREASED||USEC|NOT DONE|||IVY INCISION METHOD|N|U|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2||58||OPEN LABEL TREATMENT|1966-10-30|
TRIAL STUDY 134XCP|TR|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|3||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||L|NORMAL||MPH|NOT DONE|||SMEAR|U|U|DOMESTIC PARTNER|MICROSCOPIST 1|Y|3||39||FOLLOW-UP|1960-02-06|
TRIAL STUDY 134XCP|TR|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|4||||||RADIODEN|RADIODENSITY||MG/KG/WEEK|PRESENT||/2500 WBC|NOT DONE|||AUSCULTATION|N|NA|FAMILY MEMBER|ONCOLOGIST|N|4||88||OBSERVATION|1966-09-06|
TRIAL STUDY 134XCP|TR|A4E6FC7C-719C-4891-8C08-E5907F07A4EA|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MAC50|ABSENT||GPS U|NOT DONE|||FLOCCULATION|Y|N|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5||7||FOLLOW-UP|1973-09-01|
TRIAL STUDY 134XCP|TR|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||ML/BREATH|UNCHANGED||/HPF|NOT DONE|||LC/MS|U|N|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1||38||CONTINUATION TREATMENT|1968-03-20|
TRIAL STUDY 134XCP|TR|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|2||||||LESSCIND|LESION SUCCESS INDICATOR||CI/UG|TUMOR MERGED||MG/KG|NOT DONE|||IRON HEMATOXYLIN STAIN|N|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|2||58||WASHOUT|1965-07-16|
TRIAL STUDY 134XCP|TR|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||UMOL/L/SEC|ABSENT||ML/BEAT|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3||39||OBSERVATION|1960-10-13|
TRIAL STUDY 134XCP|TR|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|4||||||SUMDIAM|SUM OF DIAMETER||G/ANIMAL|EQUIVOCAL||CMH2O*S/ML|NOT DONE|||IMMUNOCHROMATOGRAPHY|NA|U|ADJUDICATOR|RADIOLOGIST 1|U|4||88||RUN-IN|1965-11-11|
TRIAL STUDY 134XCP|TR|890AFEEA-4AC7-4F32-B18F-2FBD860F7B86|5||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||G/DAY|ENLARGEMENT||G/ANIMAL|NOT DONE|||POLYGRAPHY|N|NA|SPOUSE|ONCOLOGIST 2|NA|5||7||INDUCTION TREATMENT|1968-03-30|
TRIAL STUDY 134XCP|TR|51B01BE3-230D-4AE0-A229-81EF519EA932|1||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||GPS U|INCREASED||NKAT/L|NOT DONE|||CONTACT SPECULAR MICROSCOPY|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER|Y|1||38||LONG-TERM FOLLOW-UP|1963-02-10|
TRIAL STUDY 134XCP|TR|51B01BE3-230D-4AE0-A229-81EF519EA932|2||||||SUMLDIAM|SUM OF LONGEST DIAMETER||SIEMENS|ENLARGEMENT FROM NADIR||UMOL/DL|NOT DONE|||IMMUNOTURBIDIMETRY|N|N|SIGNIFICANT OTHER|NEUROLOGIST 1|N|2||58||OBSERVATION|1960-12-26|
TRIAL STUDY 134XCP|TR|51B01BE3-230D-4AE0-A229-81EF519EA932|3||||||SUMDIAM|SUM OF DIAMETER||DEG/MM|NON-PATHOLOGICAL||S/H|NOT DONE|||MALDI|N|Y|PROXY|MICROSCOPIST 3|U|3||39||CONTINUATION TREATMENT|1966-12-08|
TRIAL STUDY 134XCP|TR|51B01BE3-230D-4AE0-A229-81EF519EA932|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||ELISA UNIT/ML|PRESENT||10^3 DNA COPIES/ML|NOT DONE|||HIGH RESOLUTION CT|U|U|PROXY|ONCOLOGIST 1|Y|4||88||LONG-TERM FOLLOW-UP|1961-04-10|
TRIAL STUDY 134XCP|TR|51B01BE3-230D-4AE0-A229-81EF519EA932|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||VIRTUAL PIXEL|INCREASED||MG/G/MIN|NOT DONE|||REFRACTOMETRY|N|U|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|5||7||BASELINE|1972-07-07|
TRIAL STUDY 134XCP|TR|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|1||||||SUMVOL|SUM OF VOLUME||DRINK|DECREASED||IN2|NOT DONE|||SCINTIGRAPHY|NA|NA|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1||38||RUN-IN|1964-12-29|
TRIAL STUDY 134XCP|TR|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|2||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MMOL/DAY|FURTHER ENLARGEMENT||PFU/ML|NOT DONE|||CHROMATOGRAPHY|U|N|ADJUDICATOR|PATHOLOGIST 1|NA|2||58||RUN-IN|1971-09-01|
TRIAL STUDY 134XCP|TR|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|3||||||ORVERLN|ORGAN VERTICAL LENGTH||CM/S|PRESENT||U/L|NOT DONE|||IODINE STAIN|NA|U|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|3||39||INDUCTION TREATMENT|1961-06-02|
TRIAL STUDY 134XCP|TR|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|4||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MG/M2/MIN|PALPABLE||KG/M2|NOT DONE|||FLUORESCEIN STAIN|NA|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|4||88||FOLLOW-UP|1970-02-10|
TRIAL STUDY 134XCP|TR|5665DA4F-6C20-46F3-A00B-E9688DCBF4DE|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||EVENTS|FURTHER ENLARGEMENT FROM NADIR||MEQ/ML|NOT DONE|||PHASE CONTRAST MICROSCOPY|Y|Y|INVESTIGATOR|RADIOLOGIST|N|5||7||LONG-TERM FOLLOW-UP|1973-06-11|
TRIAL STUDY 134XCP|TR|01FD66DA-C67B-48A7-9320-F29C6C226155|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||G/KG/DAY|FOCALLY INCREASED||EVENTS|NOT DONE|||MULTIPLEXED BEAD BASED IMMUNOASSAY|NA|Y|SIGNIFICANT OTHER|ADJUDICATOR 2|U|1||38||WASHOUT|1968-10-05|
TRIAL STUDY 134XCP|TR|01FD66DA-C67B-48A7-9320-F29C6C226155|2||||||NEWCONF|NEW TUMOR CONFIRMED||10^3 ORGANISMS|PATHOLOGICAL||MIU/L|NOT DONE|||LAPAROSCOPY|U|U|FRIEND|ADJUDICATOR 2|Y|2||58||LONG-TERM FOLLOW-UP|1965-10-29|
TRIAL STUDY 134XCP|TR|01FD66DA-C67B-48A7-9320-F29C6C226155|3||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||G/L|FURTHER ENLARGEMENT FROM NADIR||PA|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|NA|ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|3||39||OPEN LABEL TREATMENT|1964-04-18|
TRIAL STUDY 134XCP|TR|01FD66DA-C67B-48A7-9320-F29C6C226155|4||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||PT_BR|PALPABLE||MPL U/ML|NOT DONE|||REFLECTANCE SPECTROSCOPY|U|NA|CLINICAL STUDY SPONSOR|RATER|NA|4||88||BASELINE|1969-11-29|
TRIAL STUDY 134XCP|TR|01FD66DA-C67B-48A7-9320-F29C6C226155|5||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||MKAT|INCREASED||KPA/L/SEC|NOT DONE|||ENDPOINT DILUTION ASSAY|N|NA|STUDY SUBJECT|NEUROLOGIST 1|Y|5||7||OPEN LABEL TREATMENT|1972-04-18|
TRIAL STUDY 134XCP|TR|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||GTT|EQUIVOCAL||CM H2O|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|U|FRIEND|MICROSCOPIST 3|NA|1||38||BASELINE|1962-06-16|
TRIAL STUDY 134XCP|TR|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|2||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MOL/G|UNCHANGED||PFU/DOSE|NOT DONE|||ICC|N|Y|SPOUSE|ONCOLOGIST 1|N|2||58||BASELINE|1961-10-02|
TRIAL STUDY 134XCP|TR|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|3||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UMOL/L|PRESENT||/200 HPFS|NOT DONE|||CALIPER MEASUREMENT METHOD|U|N|STUDY SUBJECT|MICROSCOPIST 1|N|3||39||OPEN LABEL TREATMENT|1967-03-24|
TRIAL STUDY 134XCP|TR|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|4||||||DIAMETER|DIAMETER||U/10^12 RBC|TUMOR MERGED||TORR|NOT DONE|||GRAM STAIN|Y|U|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|4||88||BLINDED TREATMENT|1967-04-28|
TRIAL STUDY 134XCP|TR|DCBA9A22-BC7B-4EA1-9441-AD40D064233C|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MPL U/ML|PATHOLOGICAL||MPH|NOT DONE|||CALCOFLUOR WHITE STAIN|Y|U|CAREGIVER|INTERNIST|NA|5||7||BASELINE|1971-01-25|
TRIAL STUDY 134XCP|TR|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|1||||||OTRCUPCB|OVERALL TRACER UPTAKE COMPARED TO BL||/10^3|TUMOR MERGED||VIRTUAL PIXEL|NOT DONE|||CONTRAST ENHANCED X-RAY|Y|N|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|Y|1||38||OBSERVATION|1973-08-26|
TRIAL STUDY 134XCP|TR|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|2||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||MCI/KG|DIFFUSELY INCREASED||MG/ML/DAY|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|U|N|CAREGIVER|HEMATOLOGIST|U|2||58||CONTINUATION TREATMENT|1971-08-31|
TRIAL STUDY 134XCP|TR|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||LB|TUMOR MERGED||CI|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|Y|FAMILY MEMBER|ADJUDICATOR 2|U|3||39||BASELINE|1972-09-05|
TRIAL STUDY 134XCP|TR|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|4||||||AVMETSUV|AVERAGE METABOLIC STANDARD UPTAKE VALUE||V/V|NONPALPABLE||BOLUS|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|U|SIBLING|UROLOGIST|N|4||88||INDUCTION TREATMENT|1965-09-07|
TRIAL STUDY 134XCP|TR|5D7626F9-604F-4D8B-8D39-1ACD1363CFE2|5||||||SUMDIAM|SUM OF DIAMETER||UG/L FEU|PALPABLE||UM|NOT DONE|||MALDI|NA|NA|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5||7||RUN-IN|1972-04-29|
TRIAL STUDY 134XCP|TR|81E3641F-6145-4B3C-9E26-8DEC1200509D|1||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||KBQ|ENLARGEMENT FROM NADIR||/CMH2O|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|N|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|1||38||TREATMENT|1969-10-01|
TRIAL STUDY 134XCP|TR|81E3641F-6145-4B3C-9E26-8DEC1200509D|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||U/G|FOCALLY INCREASED||G/G|NOT DONE|||CLINICAL EVALUATION|NA|N|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|2||58||LONG-TERM FOLLOW-UP|1972-02-24|
TRIAL STUDY 134XCP|TR|81E3641F-6145-4B3C-9E26-8DEC1200509D|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||U|FURTHER ENLARGEMENT||UG/M2|NOT DONE|||CONTRAST ENHANCED CT SCAN|Y|Y|ADJUDICATOR|READER|NA|3||39||SCREENING|1969-04-13|
TRIAL STUDY 134XCP|TR|81E3641F-6145-4B3C-9E26-8DEC1200509D|4||||||LMBFLIND|LIMB FAILURE INDICATOR||FG|NONPALPABLE||U/M2/DAY|NOT DONE|||HPLC|NA|NA|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|4||88||OBSERVATION|1962-12-13|
TRIAL STUDY 134XCP|TR|81E3641F-6145-4B3C-9E26-8DEC1200509D|5||||||VSLPIND|VESSEL PATENCY INDICATOR||L/DAY|ENLARGEMENT||ML/G/DAY|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|U|NA|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|5||7||INDUCTION TREATMENT|1968-10-16|
TRIAL STUDY 134XCP|TR|8F3D0A71-FD09-4E43-BC54-0562AF99306E|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||/500 WBC|TUMOR MERGED||MBQ|NOT DONE|||CAPILLARY ELECTROPHORESIS|N|N|INVESTIGATOR|RADIOLOGIST|N|1||38||BLINDED TREATMENT|1963-04-18|
TRIAL STUDY 134XCP|TR|8F3D0A71-FD09-4E43-BC54-0562AF99306E|2||||||TUMSTATE|TUMOR STATE||DPM/ML|FURTHER ENLARGEMENT||NEEDLE GAUGE|NOT DONE|||SXA SCAN|U|N|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|2||58||CONTINUATION TREATMENT|1970-11-18|
TRIAL STUDY 134XCP|TR|8F3D0A71-FD09-4E43-BC54-0562AF99306E|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||KPA/L/SEC|DECREASED||IU/L|NOT DONE|||SEQUENCING|U|N|STUDY SUBJECT|RADIOLOGIST|NA|3||39||WASHOUT|1960-04-15|
TRIAL STUDY 134XCP|TR|8F3D0A71-FD09-4E43-BC54-0562AF99306E|4||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||ML/M2/MIN|FOCALLY INCREASED||LOG10 PFU|NOT DONE|||FUNDUS PHOTOGRAPHY|N|U|SPOUSE|NEUROLOGIST|Y|4||88||CONTINUATION TREATMENT|1966-05-26|
TRIAL STUDY 134XCP|TR|8F3D0A71-FD09-4E43-BC54-0562AF99306E|5||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||WEBER|NON-PATHOLOGICAL||UMOL/MG/MIN|NOT DONE|||PERCUSSION|N|N|VENDOR|NEUROLOGIST|Y|5||7||WASHOUT|1960-11-26|
TRIAL STUDY 134XCP|TR|BE750F04-5992-42B5-A084-A33D6FBBFD2E|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UG/M2/DAY|FURTHER ENLARGEMENT FROM NADIR||TUBE|NOT DONE|||PHOTOGRAPHY|N|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|1||38||BASELINE|1971-07-20|
TRIAL STUDY 134XCP|TR|BE750F04-5992-42B5-A084-A33D6FBBFD2E|2||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||KM|UNCHANGED||ATM|NOT DONE|||LINE PROBE ASSAY|N|NA|GUARDIAN|OTOLARYNGOLOGIST|NA|2||58||WASHOUT|1966-10-14|
TRIAL STUDY 134XCP|TR|BE750F04-5992-42B5-A084-A33D6FBBFD2E|3||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||LOG10 PFU|FURTHER ENLARGEMENT FROM NADIR||UV|NOT DONE|||MANUAL COUNT|U|Y|FAMILY MEMBER|OPHTHALMOLOGIST|U|3||39||FOLLOW-UP|1969-03-09|
TRIAL STUDY 134XCP|TR|BE750F04-5992-42B5-A084-A33D6FBBFD2E|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||AG|ABSENT||MET*MIN|NOT DONE|||FUNDUS PHOTOGRAPHY|U|Y|FRIEND|RATER 2|N|4||88||SCREENING|1963-10-18|
TRIAL STUDY 134XCP|TR|BE750F04-5992-42B5-A084-A33D6FBBFD2E|5||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||DPM/MG|PRESENT||PELLET|NOT DONE|||POLYGRAPHY|NA|NA|PARENT|NEUROLOGIST 1|N|5||7||LONG-TERM FOLLOW-UP|1971-04-26|
TRIAL STUDY 134XCP|TR|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|1||||||LMBFLIND|LIMB FAILURE INDICATOR||BQ/UG|ENLARGEMENT||DL|NOT DONE|||SLOAN LETTER EYE CHART 100%|Y|N|CHILD|CARDIOLOGIST|Y|1||38||RUN-IN|1968-03-20|
TRIAL STUDY 134XCP|TR|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|2||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||CMH2O/ML|DECREASED||10^9/G|NOT DONE|||LISSAMINE GREEN STAIN|N|NA|STUDY SUBJECT|RATER 2|NA|2||58||INDUCTION TREATMENT|1973-02-06|
TRIAL STUDY 134XCP|TR|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||H*%|ENLARGEMENT||GAUSS|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|NA|Y|VENDOR|OTOLARYNGOLOGIST|Y|3||39||RUN-IN|1971-10-28|
TRIAL STUDY 134XCP|TR|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|4||||||CALCFIND|CALCIFICATION INDICATOR||10^8/L|ENLARGEMENT||10^3 ORGANISMS/ML|NOT DONE|||TELLER ACUITY CARDS|N|NA|CHILD|RATER|Y|4||88||WASHOUT|1970-10-14|
TRIAL STUDY 134XCP|TR|4926DCA5-2DA6-4A16-8CDB-A92ABDB66B89|5||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||G/CAGE/DAY|UNCHANGED||GRAIN|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|U|N|GUARDIAN|MICROSCOPIST 1|Y|5||7||LONG-TERM FOLLOW-UP|1968-07-07|
TRIAL STUDY 134XCP|TR|8417B146-336C-4777-A566-C1D086F39430|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||V/SEC|FURTHER ENLARGEMENT||CAN|NOT DONE|||SLIT LAMP|U|N|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1971-04-18|
TRIAL STUDY 134XCP|TR|8417B146-336C-4777-A566-C1D086F39430|2||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||STEPS/MIN|DIFFUSELY INCREASED||10^6 RNA COPIES/ML|NOT DONE|||PHOTOMETRY|U|N|FRIEND|MICROSCOPIST 2|N|2||58||BLINDED TREATMENT|1972-02-09|
TRIAL STUDY 134XCP|TR|8417B146-336C-4777-A566-C1D086F39430|3||||||PALPSTAT|PALPABLE STATE||INHALATION|FURTHER ENLARGEMENT||SIEMENS|NOT DONE|||ANGIOGRAPHY|NA|NA|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|3||39||OBSERVATION|1964-03-11|
TRIAL STUDY 134XCP|TR|8417B146-336C-4777-A566-C1D086F39430|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||10^3/L|TUMOR MERGED||%/MIN|NOT DONE|||IMMUNORADIOMETRIC ASSAY|N|NA|SIGNIFICANT OTHER|ONCOLOGIST 1|N|4||88||FOLLOW-UP|1968-10-05|
TRIAL STUDY 134XCP|TR|8417B146-336C-4777-A566-C1D086F39430|5||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||MG/KG/DAY|UNCHANGED||UG/M2/MIN|NOT DONE|||PANENDOSCOPY|U|U|SPOUSE|MICROSCOPIST 1|Y|5||7||OBSERVATION|1973-05-05|
TRIAL STUDY 134XCP|TR|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|1||||||DIAMETER|DIAMETER||TABLET|PATHOLOGICAL||AG|NOT DONE|||WHOLE GENOME SEQUENCING|N|U|SIGNIFICANT OTHER|MICROSCOPIST|NA|1||38||BASELINE|1969-01-12|
TRIAL STUDY 134XCP|TR|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||MG/G/H|UNCHANGED||UKAT/10^12 RBC|NOT DONE|||WESTERN BLOT|NA|U|STUDY SUBJECT|NEUROLOGIST 1|Y|2||58||OPEN LABEL TREATMENT|1969-09-09|
TRIAL STUDY 134XCP|TR|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MG/L|FOCALLY INCREASED||KA_U/DL|NOT DONE|||MACRO BROTH DILUTION|Y|U|INVESTIGATOR|MICROSCOPIST 1|U|3||39||OBSERVATION|1972-10-30|
TRIAL STUDY 134XCP|TR|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MG/ML/MIN|FURTHER ENLARGEMENT FROM NADIR||ML/CM3/MIN|NOT DONE|||NEXT GENERATION TARGETED SEQUENCING|Y|Y|VENDOR|CARDIOLOGIST|U|4||88||BASELINE|1963-07-01|
TRIAL STUDY 134XCP|TR|FB8D36FD-B57F-4D93-AA64-2BFD130B39C7|5||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||NSEC|NONPALPABLE||UG/CM2|NOT DONE|||SURFACE PLASMON RESONANCE|Y|NA|SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|5||7||OPEN LABEL TREATMENT|1960-01-29|
TRIAL STUDY 134XCP|TR|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|1||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||/VF|DIFFUSELY INCREASED||MEQ/MMOL|NOT DONE|||PHOTOMETRY|Y|U|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|1||38||OBSERVATION|1972-12-04|
TRIAL STUDY 134XCP|TR|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||BOX|UNCHANGED||/MONTH|NOT DONE|||PERIPHERAL ANGIOGRAPHY|Y|N|ADJUDICATOR|ONCOLOGIST 2|U|2||58||RUN-IN|1972-02-15|
TRIAL STUDY 134XCP|TR|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|3||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||KG/M2|DIFFUSELY INCREASED||NU/CL|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|U|Y|SIGNIFICANT OTHER|UROLOGIST|Y|3||39||RUN-IN|1963-10-11|
TRIAL STUDY 134XCP|TR|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|4||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KBQ|UNCHANGED||MM/2H|NOT DONE|||ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|U|NA|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|4||88||INDUCTION TREATMENT|1972-07-02|
TRIAL STUDY 134XCP|TR|1B82113D-E76E-45BC-8CC8-EBE3D5FB10EE|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||NGEQ/L|FOCALLY INCREASED||GPELISA UNIT/ML|NOT DONE|||FLUORIMETRY|N|U|SPOUSE|ONCOLOGIST 2|N|5||7||LONG-TERM FOLLOW-UP|1973-05-19|
TRIAL STUDY 134XCP|TR|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||ENZYME U/G HB|FURTHER ENLARGEMENT||DEG/MM|NOT DONE|||DIPSTICK|U|NA|STUDY SUBJECT|DERMATOLOGIST|U|1||38||LONG-TERM FOLLOW-UP|1967-02-22|
TRIAL STUDY 134XCP|TR|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|2||||||LESSCIND|LESION SUCCESS INDICATOR||KA_U/DL|FURTHER ENLARGEMENT||NCI|NOT DONE|||IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|N|Y|DOMESTIC PARTNER|MICROSCOPIST|Y|2||58||BLINDED TREATMENT|1962-06-15|
TRIAL STUDY 134XCP|TR|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|3||||||PALPSTAT|PALPABLE STATE||L/MIN|FURTHER ENLARGEMENT||DAGU|NOT DONE|||OPTICAL COHERENCE TOMOGRAPHY|N|N|ADJUDICATOR|ADJUDICATOR 2|N|3||39||WASHOUT|1968-03-01|
TRIAL STUDY 134XCP|TR|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|4||||||SUMDIAM|SUM OF DIAMETER||FMOL|PALPABLE||WEEKS|NOT DONE|||TARGETED GENOME SEQUENCING|U|U|GUARDIAN|READER 1|Y|4||88||INDUCTION TREATMENT|1972-06-20|
TRIAL STUDY 134XCP|TR|7F6F9ECF-978B-49D7-ADD2-8403D813DFEB|5||||||LMBFLIND|LIMB FAILURE INDICATOR||UG/M2/H|ENLARGEMENT||/MM2|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|NA|CAREGIVER|UROLOGIST|N|5||7||TREATMENT|1960-07-11|
TRIAL STUDY 134XCP|TR|2926D795-9C17-4440-8411-68525E93E78D|1||||||PCHGNAD|PERCENT CHANGE FROM NADIR||/MONTH|PALPABLE||FOZ_US|NOT DONE|||ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|U|Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|1||38||FOLLOW-UP|1967-11-15|
TRIAL STUDY 134XCP|TR|2926D795-9C17-4440-8411-68525E93E78D|2||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||ENZYME U/M2|ENLARGEMENT||10^5/HPF|NOT DONE|||MAGNETIC RESONANCE ANGIOGRAPHY|N|N|DOMESTIC PARTNER|ONCOLOGIST|Y|2||58||FOLLOW-UP|1967-03-20|
TRIAL STUDY 134XCP|TR|2926D795-9C17-4440-8411-68525E93E78D|3||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||ENZYME U|UNEQUIVOCAL||UG/L/H|NOT DONE|||AMSLER GRID|N|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|3||39||LONG-TERM FOLLOW-UP|1963-02-09|
TRIAL STUDY 134XCP|TR|2926D795-9C17-4440-8411-68525E93E78D|4||||||ACPPDNLP|ABSOLUTE CHANGE FROM PPD NADIR IN LPERP||HOMEOPATHIC DILUTION|UNEQUIVOCAL||L/L|NOT DONE|||CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|U|Y|SIBLING|READER|NA|4||88||BLINDED TREATMENT|1961-02-21|
TRIAL STUDY 134XCP|TR|2926D795-9C17-4440-8411-68525E93E78D|5||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||BAU/ML|ENLARGEMENT||NMOL/L|NOT DONE|||AURAMINE STAIN|Y|NA|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|NA|5||7||BLINDED TREATMENT|1966-04-18|
TRIAL STUDY 134XCP|TR|BA3378F3-C308-469F-9818-9AD811086548|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||NM|ENLARGEMENT FROM NADIR||BAU|NOT DONE|||INDIA INK STAIN|N|U|INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|1||38||INDUCTION TREATMENT|1961-11-09|
TRIAL STUDY 134XCP|TR|BA3378F3-C308-469F-9818-9AD811086548|2||||||CALCFIND|CALCIFICATION INDICATOR||ML/H|NON-PATHOLOGICAL||PL|NOT DONE|||PERCUSSION|U|N|PARENT|OPTOMETRIST|N|2||58||SCREENING|1964-05-11|
TRIAL STUDY 134XCP|TR|BA3378F3-C308-469F-9818-9AD811086548|3||||||LPERP|LONGEST PERPENDICULAR||CGY|EQUIVOCAL||PM|NOT DONE|||EPSILOMETER|NA|N|PROXY|ONCOLOGIST|NA|3||39||RUN-IN|1963-12-23|
TRIAL STUDY 134XCP|TR|BA3378F3-C308-469F-9818-9AD811086548|4||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||CIGAR|EQUIVOCAL||UM|NOT DONE|||DC SHEATH FLOW|NA|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|4||88||OPEN LABEL TREATMENT|1970-04-28|
TRIAL STUDY 134XCP|TR|BA3378F3-C308-469F-9818-9AD811086548|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||LOG10 COPIES/ML|PATHOLOGICAL||UMOL/H/MMOL|NOT DONE|||DNA MICROARRAY|U|N|PROXY|ONCOLOGIST 1|NA|5||7||BASELINE|1970-12-18|
TRIAL STUDY 134XCP|TR|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|1||||||SUMVDIAM|SUM OF VIABLE DIAMETER||LOG10 CCID 50/DOSE|DIFFUSELY INCREASED||L/KG|NOT DONE|||ISHIHARA COLOR PLATES|U|NA|PROXY|NEUROLOGIST|Y|1||38||BLINDED TREATMENT|1966-01-24|
TRIAL STUDY 134XCP|TR|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||IMPLANT|INCREASED||IU/KG|NOT DONE|||ECHOCARDIOGRAPHY|N|U|CAREGIVER|PATHOLOGIST 1|U|2||58||OPEN LABEL TREATMENT|1966-10-03|
TRIAL STUDY 134XCP|TR|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|3||||||PALPSTAT|PALPABLE STATE||CI/KG|ENLARGEMENT FROM NADIR||KAT|NOT DONE|||THICK SMEAR|U|Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|3||39||BASELINE|1971-11-28|
TRIAL STUDY 134XCP|TR|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|4||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||ML/MIN|NONPALPABLE||UG/L/H|NOT DONE|||AMSLER GRID|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|4||88||BASELINE|1963-04-27|
TRIAL STUDY 134XCP|TR|D9CABD49-D3C9-4792-8110-3D48D0D11DBA|5||||||LPERP|LONGEST PERPENDICULAR||HOMEOPATHIC DILUTION|INCREASED||PIXELS/IN|NOT DONE|||IN VITRO GENE EXPRESSION ASSAY|NA|Y|DOMESTIC PARTNER|ADJUDICATOR 3|U|5||7||BASELINE|1967-02-12|
TRIAL STUDY 134XCP|TR|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|1||||||RADIODEN|RADIODENSITY||CI/MG|EQUIVOCAL||UIU/DL|NOT DONE|||CONTRAST ENHANCED PET/CT SCAN|NA|U|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|1||38||FOLLOW-UP|1963-09-20|
TRIAL STUDY 134XCP|TR|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|2||||||AREA|AREA||UG/DOSE|PALPABLE||PMOL/DL|NOT DONE|||HPLC|N|N|DOMESTIC PARTNER|DERMATOLOGIST|Y|2||58||WASHOUT|1973-09-08|
TRIAL STUDY 134XCP|TR|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|3||||||SUMDIAM|SUM OF DIAMETER||DPM/MG|UNEQUIVOCAL||M/SEC2|NOT DONE|||PLETHYSMOGRAPHY|Y|NA|SIGNIFICANT OTHER|READER 2|N|3||39||FOLLOW-UP|1964-11-02|
TRIAL STUDY 134XCP|TR|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||ML/CM|PALPABLE||C|NOT DONE|||IMMUNOASSAY|N|N|SIGNIFICANT OTHER|PATHOLOGIST 1|U|4||88||LONG-TERM FOLLOW-UP|1965-08-06|
TRIAL STUDY 134XCP|TR|C9F6564B-D41D-406B-ABD3-5F453B66F1C6|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KG/MOL|NON-PATHOLOGICAL||GY|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|N|NA|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|5||7||WASHOUT|1961-06-11|
TRIAL STUDY 134XCP|TR|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|1||||||BNLNUM|NUMBER OF BONE LESIONS||FG|TUMOR MERGED||ML/100G/MIN|NOT DONE|||IMPULSE OSCILLOMETRY|Y|NA|STUDY SUBJECT|ADJUDICATOR|Y|1||38||LONG-TERM FOLLOW-UP|1970-02-01|
TRIAL STUDY 134XCP|TR|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UG/H|INCREASED||ML/M2/H|NOT DONE|||MICROSCOPY|N|N|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|2||58||BASELINE|1971-02-05|
TRIAL STUDY 134XCP|TR|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||MG/M2/DAY|UNEQUIVOCAL||P|NOT DONE|||ULTRASONOGRAPHIC ELASTOGRAPHY|NA|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|3||39||LONG-TERM FOLLOW-UP|1964-10-08|
TRIAL STUDY 134XCP|TR|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|4||||||TUMSTATE|TUMOR STATE||UMOL/L|PRESENT||VIAL|NOT DONE|||DXA SCAN|N|NA|CLINICAL STUDY SPONSOR|INTERNIST|NA|4||88||INDUCTION TREATMENT|1962-06-13|
TRIAL STUDY 134XCP|TR|02AE6CFC-BC7C-49D1-8B5C-E57147B147B7|5||||||ORSTATE|ORGAN STATE||MG|DIFFUSELY INCREASED||PIXELS/IN|NOT DONE|||PERCUSSION|Y|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5||7||LONG-TERM FOLLOW-UP|1964-09-22|
TRIAL STUDY 134XCP|TR|15594D4E-1DAE-449F-AA52-9B0A926D9985|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||UIU/L|ENLARGEMENT FROM NADIR||UG/ANIMAL|NOT DONE|||CONTRAST ENHANCED CT SCAN|Y|NA|HEALTH CARE PROFESSIONAL|UROLOGIST|U|1||38||RUN-IN|1972-04-05|
TRIAL STUDY 134XCP|TR|15594D4E-1DAE-449F-AA52-9B0A926D9985|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||V|DECREASED||U/G HB|NOT DONE|||BALLPOINT PEN TECHNIQUE|NA|NA|SPOUSE|MICROSCOPIST 1|N|2||58||BLINDED TREATMENT|1970-03-10|
TRIAL STUDY 134XCP|TR|15594D4E-1DAE-449F-AA52-9B0A926D9985|3||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||PACK YEAR|INCREASED||MG/DAY|NOT DONE|||DYNAMIC LIGHT SCATTERING|NA|NA|ADJUDICATOR|NEUROLOGIST|U|3||39||BLINDED TREATMENT|1973-04-29|
TRIAL STUDY 134XCP|TR|15594D4E-1DAE-449F-AA52-9B0A926D9985|4||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||MMOL|NORMAL||BOLUS|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|NA|U|INVESTIGATOR|MICROSCOPIST|Y|4||88||BLINDED TREATMENT|1970-02-15|
TRIAL STUDY 134XCP|TR|15594D4E-1DAE-449F-AA52-9B0A926D9985|5||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||BOLUS|FURTHER ENLARGEMENT||UMOL/L/H|NOT DONE|||ICC|NA|NA|SIBLING|INTERNIST|NA|5||7||LONG-TERM FOLLOW-UP|1968-06-09|
TRIAL STUDY 134XCP|TR|079DEA7B-A617-4787-9872-025F4248ABFF|1||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||G/L|DECREASED||G/ANIMAL|NOT DONE|||DOPPLER ULTRASOUND|N|NA|INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|1||38||RUN-IN|1961-07-02|
TRIAL STUDY 134XCP|TR|079DEA7B-A617-4787-9872-025F4248ABFF|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||G/CAGE/WK|ABSENT||PHERESIS UNIT|NOT DONE|||AGAR DILUTION|U|N|PROXY|PHYSIOTHERAPIST|U|2||58||BLINDED TREATMENT|1964-07-19|
TRIAL STUDY 134XCP|TR|079DEA7B-A617-4787-9872-025F4248ABFF|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||U/KG|FOCALLY INCREASED||MMOL/MIN/KPA|NOT DONE|||MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|NA|N|INVESTIGATOR|READER 1|Y|3||39||BLINDED TREATMENT|1960-11-07|
TRIAL STUDY 134XCP|TR|079DEA7B-A617-4787-9872-025F4248ABFF|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||PFU/ML|UNEQUIVOCAL||UMOL/L/SEC|NOT DONE|||CYSTOSCOPY|N|U|SPOUSE|READER 2|U|4||88||OBSERVATION|1960-11-05|
TRIAL STUDY 134XCP|TR|079DEA7B-A617-4787-9872-025F4248ABFF|5||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||10^4/L|FURTHER ENLARGEMENT FROM NADIR||ML/KG|NOT DONE|||PHOROPTER|NA|N|SIBLING|RADIOLOGIST 2|U|5||7||BASELINE|1961-12-10|
TRIAL STUDY 134XCP|TR|3178AE30-9653-4470-84E4-FB0E4587DF6B|1||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||UG/DOSE|PALPABLE||NG/MOL|NOT DONE|||CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|U|N|CAREGIVER|ONCOLOGIST 1|N|1||38||CONTINUATION TREATMENT|1968-02-27|
TRIAL STUDY 134XCP|TR|3178AE30-9653-4470-84E4-FB0E4587DF6B|2||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MS2|INCREASED||MBQ/UL|NOT DONE|||KINETIC MICROPARTICLE IMMUNOASSAY|Y|Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|2||58||BASELINE|1967-01-09|
TRIAL STUDY 134XCP|TR|3178AE30-9653-4470-84E4-FB0E4587DF6B|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||/MM2|ENLARGEMENT||JDF UNIT|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|Y|NA|DOMESTIC PARTNER|ADJUDICATOR 3|N|3||39||BASELINE|1962-10-21|
TRIAL STUDY 134XCP|TR|3178AE30-9653-4470-84E4-FB0E4587DF6B|4||||||LPERP|LONGEST PERPENDICULAR||S*KPA|ENLARGEMENT||PMOL/DAY|NOT DONE|||ENZYMATIC ULTRACENTRIFUGATION|N|NA|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|4||88||INDUCTION TREATMENT|1969-10-10|
TRIAL STUDY 134XCP|TR|3178AE30-9653-4470-84E4-FB0E4587DF6B|5||||||SUMVOL|SUM OF VOLUME||L/H|DIFFUSELY INCREASED||KS|NOT DONE|||TOLUIDINE BLUE STAIN|Y|Y|FRIEND|CARDIOLOGIST|NA|5||7||FOLLOW-UP|1971-04-02|
TRIAL STUDY 134XCP|TR|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||BQ/G|PATHOLOGICAL||PSEC|NOT DONE|||LUXOL FAST BLUE AND CRESYL VIOLET STAIN|U|U|GUARDIAN|INTERNIST|NA|1||38||INDUCTION TREATMENT|1972-07-28|
TRIAL STUDY 134XCP|TR|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||AMFI|ABSENT||ML/ANIMAL/WK|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|NA|N|SPOUSE|RADIOLOGIST 1|Y|2||58||OBSERVATION|1971-12-30|
TRIAL STUDY 134XCP|TR|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|3||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||GPS U|UNEQUIVOCAL||DPM|NOT DONE|||SXA SCAN|N|N|VENDOR|DERMATOLOGIST|NA|3||39||CONTINUATION TREATMENT|1969-02-16|
TRIAL STUDY 134XCP|TR|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||TABLET|DIFFUSELY INCREASED||QUANTITY SUFFICIENT|NOT DONE|||TRANSMISSION ELECTRON MICROSCOPY|NA|Y|STUDY SUBJECT|RATER 1|Y|4||88||INDUCTION TREATMENT|1961-12-14|
TRIAL STUDY 134XCP|TR|921EE2AA-D4FB-49E1-A3CD-05B064D0E83A|5||||||LMNDPNUM|NUMBER OF LYMPH NODES POSITIVE||MM/SEC|NON-PATHOLOGICAL||KAT|NOT DONE|||CLAUSS METHOD|NA|Y|CHILD|READER|Y|5||7||RUN-IN|1966-10-17|
TRIAL STUDY 134XCP|TR|D274C760-A607-4DA8-ACD3-346EF6E191D2|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||ANSON U|DIFFUSELY INCREASED||FT3|NOT DONE|||REBOUND TONOMETRY|N|N|SIBLING|OPTOMETRIST|U|1||38||BASELINE|1966-08-26|
TRIAL STUDY 134XCP|TR|D274C760-A607-4DA8-ACD3-346EF6E191D2|2||||||CALCFIND|CALCIFICATION INDICATOR||MEQ/MMOL|FURTHER ENLARGEMENT FROM NADIR||MMOL2/L2|NOT DONE|||DIFFUSION TENSOR MRI|Y|N|ADJUDICATOR|CARDIOLOGIST|Y|2||58||OPEN LABEL TREATMENT|1962-03-12|
TRIAL STUDY 134XCP|TR|D274C760-A607-4DA8-ACD3-346EF6E191D2|3||||||VOLUME|VOLUME||OZ|UNEQUIVOCAL||/CMH2O|NOT DONE|||CARDIAC THERMODILUTION|Y|N|CAREGIVER|ADJUDICATOR 1|N|3||39||OBSERVATION|1972-06-11|
TRIAL STUDY 134XCP|TR|D274C760-A607-4DA8-ACD3-346EF6E191D2|4||||||LRISCIND|LESION REVAS ISCHEMIA INDICATOR||MIN|FURTHER ENLARGEMENT||V/SEC|NOT DONE|||IMMUNOCHEMILUMINOMETRIC ASSAY|Y|NA|CAREGIVER|OTOLARYNGOLOGIST|Y|4||88||CONTINUATION TREATMENT|1967-01-08|
TRIAL STUDY 134XCP|TR|D274C760-A607-4DA8-ACD3-346EF6E191D2|5||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MG/L FEU|INCREASED||10^9 CFU/G|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|N|NA|CHILD|PHYSIOTHERAPIST|N|5||7||FOLLOW-UP|1964-08-31|
TRIAL STUDY 134XCP|TR|F5B7E82D-49AD-422E-9C38-5681105094AA|1||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||NMOL/L/H|ABSENT||TCID 50/DOSE|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|U|Y|SIBLING|OTOLARYNGOLOGIST|N|1||38||FOLLOW-UP|1968-06-30|
TRIAL STUDY 134XCP|TR|F5B7E82D-49AD-422E-9C38-5681105094AA|2||||||PALPSTAT|PALPABLE STATE||NMOL/L/H|PALPABLE||MMOL/DAY|NOT DONE|||SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|N|NA|STUDY SUBJECT|PATHOLOGIST 2|U|2||58||OBSERVATION|1969-06-19|
TRIAL STUDY 134XCP|TR|F5B7E82D-49AD-422E-9C38-5681105094AA|3||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||PA|FOCALLY INCREASED||MG/KG/DAY|NOT DONE|||OPHTHALMOSCOPY|NA|NA|PROXY|NEUROLOGIST 2|Y|3||39||RUN-IN|1960-09-01|
TRIAL STUDY 134XCP|TR|F5B7E82D-49AD-422E-9C38-5681105094AA|4||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||PPB|EQUIVOCAL||NMOL/L|NOT DONE|||DIFFUSION TENSOR MRI|N|NA|PROXY|HEMATOLOGIST|NA|4||88||RUN-IN|1973-05-07|
TRIAL STUDY 134XCP|TR|F5B7E82D-49AD-422E-9C38-5681105094AA|5||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||CPM|NONPALPABLE||UMOL/L|NOT DONE|||SIZE EXCLUSION CHROMATOGRAPHY|NA|NA|INTERVIEWER|RADIOLOGIST 1|NA|5||7||OPEN LABEL TREATMENT|1964-04-18|
TRIAL STUDY 134XCP|TR|AF8D32B4-B2CC-4EE3-A612-179814C691B8|1||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||LOZENGE|UNCHANGED||FOZ_US|NOT DONE|||MECHANICAL CLOT DETECTION|Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|1||38||BLINDED TREATMENT|1963-06-29|
TRIAL STUDY 134XCP|TR|AF8D32B4-B2CC-4EE3-A612-179814C691B8|2||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||UMOL|NON-PATHOLOGICAL||NCI|NOT DONE|||IMMUNOBLOT|NA|N|ADJUDICATOR|DERMATOLOGIST|U|2||58||LONG-TERM FOLLOW-UP|1968-01-12|
TRIAL STUDY 134XCP|TR|AF8D32B4-B2CC-4EE3-A612-179814C691B8|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||MS2|DIFFUSELY INCREASED||L/DAY|NOT DONE|||RADIOGRAPHY|NA|U|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|3||39||BLINDED TREATMENT|1969-12-25|
TRIAL STUDY 134XCP|TR|AF8D32B4-B2CC-4EE3-A612-179814C691B8|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||LOG10 CFU/G|NONPALPABLE||MS/MMHG|NOT DONE|||MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y|N|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4||88||TREATMENT|1966-02-20|
TRIAL STUDY 134XCP|TR|AF8D32B4-B2CC-4EE3-A612-179814C691B8|5||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||GPS U|TUMOR MERGED||NCI|NOT DONE|||PULMONARY ANGIOGRAPHY|U|NA|INVESTIGATOR|OPTOMETRIST|NA|5||7||TREATMENT|1968-03-01|
TRIAL STUDY 134XCP|TR|64153B43-9DDC-473D-97E1-0E2E8C3E8116|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||TITER|FURTHER ENLARGEMENT||10^4/HPF|NOT DONE|||SECONDARY ION MASS SPECTOMETRY|NA|U|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|1||38||WASHOUT|1961-02-06|
TRIAL STUDY 134XCP|TR|64153B43-9DDC-473D-97E1-0E2E8C3E8116|2||||||LMBFLIND|LIMB FAILURE INDICATOR||MV|DIFFUSELY INCREASED||CMH2O*S2/ML|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|N|INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|2||58||INDUCTION TREATMENT|1967-11-03|
TRIAL STUDY 134XCP|TR|64153B43-9DDC-473D-97E1-0E2E8C3E8116|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||YD|UNEQUIVOCAL||FINGERTIP UNIT|NOT DONE|||POLYGRAPHY|NA|Y|VENDOR|CARDIOLOGIST|N|3||39||WASHOUT|1968-04-29|
TRIAL STUDY 134XCP|TR|64153B43-9DDC-473D-97E1-0E2E8C3E8116|4||||||ORSTATE|ORGAN STATE||GRAIN|UNEQUIVOCAL||MM/H|NOT DONE|||PET/CT SCAN WITHOUT CONTRAST|U|U|PARENT|PEDIATRIC NEUROLOGIST|NA|4||88||LONG-TERM FOLLOW-UP|1965-01-31|
TRIAL STUDY 134XCP|TR|64153B43-9DDC-473D-97E1-0E2E8C3E8116|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||KN/CM2|NON-PATHOLOGICAL||FG|NOT DONE|||CONTRAST ENHANCED X-RAY|NA|U|PARENT|UROLOGIST|N|5||7||INDUCTION TREATMENT|1969-12-05|
TRIAL STUDY 134XCP|TR|0F5775AD-1D20-4B59-8558-8A41C12E03D0|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||10^6 DNA COPIES/ML|UNEQUIVOCAL||MOL/DAY|NOT DONE|||FARNSWORTH-MUNSELL 100 HUE TEST|NA|Y|SPOUSE|RATER 1|NA|1||38||TREATMENT|1972-04-08|
TRIAL STUDY 134XCP|TR|0F5775AD-1D20-4B59-8558-8A41C12E03D0|2||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||UG/DL|FURTHER ENLARGEMENT||MBQ|NOT DONE|||KINETIC CHROMOGENIC ASSAY|U|U|INVESTIGATOR|PHYSIOTHERAPIST|U|2||58||TREATMENT|1973-03-03|
TRIAL STUDY 134XCP|TR|0F5775AD-1D20-4B59-8558-8A41C12E03D0|3||||||NEWCONF|NEW TUMOR CONFIRMED||UCI/L|EQUIVOCAL||APL U|NOT DONE|||MYELOPEROXIDASE STAIN|N|U|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|3||39||BLINDED TREATMENT|1964-03-13|
TRIAL STUDY 134XCP|TR|0F5775AD-1D20-4B59-8558-8A41C12E03D0|4||||||ORSTATE|ORGAN STATE||OHM|DIFFUSELY INCREASED||KG/CM2|NOT DONE|||FUNCTIONAL MRI|Y|NA|PROXY|MICROSCOPIST 1|Y|4||88||BLINDED TREATMENT|1972-07-13|
TRIAL STUDY 134XCP|TR|0F5775AD-1D20-4B59-8558-8A41C12E03D0|5||||||PCHGBL|PERCENT CHANGE FROM BASELINE||CMOL/L|EQUIVOCAL||HOMEOPATHIC DILUTION|NOT DONE|||ANGIOGRAPHY|N|N|NON-HEALTH CARE PROFESSIONAL|READER 3|N|5||7||LONG-TERM FOLLOW-UP|1963-05-17|
TRIAL STUDY 134XCP|TR|DF533087-690C-489A-9163-9D4503B7BCC9|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||RFU|ENLARGEMENT||CCID 50/ML|NOT DONE|||TONOMETRY|N|N|ADJUDICATION COMMITTEE|PATHOLOGIST|NA|1||38||FOLLOW-UP|1970-06-23|
TRIAL STUDY 134XCP|TR|DF533087-690C-489A-9163-9D4503B7BCC9|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||UMOL/L/H|DIFFUSELY INCREASED||TITER|NOT DONE|||SPECT SCAN|NA|Y|GUARDIAN|UROLOGIST|N|2||58||BASELINE|1971-09-30|
TRIAL STUDY 134XCP|TR|DF533087-690C-489A-9163-9D4503B7BCC9|3||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||VIAL|FOCALLY INCREASED||FG|NOT DONE|||CT SCAN WITHOUT CONTRAST|U|NA|INTERVIEWER|ONCOLOGIST|NA|3||39||BASELINE|1966-10-21|
TRIAL STUDY 134XCP|TR|DF533087-690C-489A-9163-9D4503B7BCC9|4||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||RPM|NONPALPABLE||GTT|NOT DONE|||GRADIENT DIFFUSION|U|NA|DOMESTIC PARTNER|ADJUDICATOR|N|4||88||RUN-IN|1963-12-27|
TRIAL STUDY 134XCP|TR|DF533087-690C-489A-9163-9D4503B7BCC9|5||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||UG/G/MIN|ABSENT||HZ/S|NOT DONE|||EPSILOMETER|Y|NA|INTERVIEWER|ADJUDICATOR|NA|5||7||BLINDED TREATMENT|1968-12-20|
TRIAL STUDY 134XCP|TR|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|1||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||CMH2O*S2/ML|ABSENT||TSP EQ|NOT DONE|||FLUORIMETRY|Y|NA|INTERVIEWER|ONCOLOGIST 2|Y|1||38||LONG-TERM FOLLOW-UP|1960-08-02|
TRIAL STUDY 134XCP|TR|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|2||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||ECL UNIT|EQUIVOCAL||TROCHE|NOT DONE|||ATOMIC ABSORPTION SPECTROMETRY|U|N|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|2||58||BLINDED TREATMENT|1968-01-07|
TRIAL STUDY 134XCP|TR|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|3||||||ORVERLN|ORGAN VERTICAL LENGTH||ML/G/DAY|PALPABLE||ML/CM|NOT DONE|||HANSEL STAIN|Y|NA|CAREGIVER|UROLOGIST|U|3||39||FOLLOW-UP|1965-05-06|
TRIAL STUDY 134XCP|TR|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|4||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||UIU/L|NONPALPABLE||MDFI|NOT DONE|||ELISPOT|NA|N|INVESTIGATOR|MICROSCOPIST 3|N|4||88||FOLLOW-UP|1970-04-04|
TRIAL STUDY 134XCP|TR|D4FE3C52-9E91-47D4-89B2-E9458C6F5919|5||||||SUMVOL|SUM OF VOLUME||LOG10 ELISA UNIT/DOSE|DECREASED||CMH2O*S/ML|NOT DONE|||DNA MICROARRAY|Y|Y|DOMESTIC PARTNER|PATHOLOGIST 2|Y|5||7||LONG-TERM FOLLOW-UP|1960-03-22|
TRIAL STUDY 134XCP|TR|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|1||||||ORSTATE|ORGAN STATE||FT2|FURTHER ENLARGEMENT FROM NADIR||%|NOT DONE|||MS/MS|Y|N|SIBLING|INTERNIST|NA|1||38||OPEN LABEL TREATMENT|1960-07-06|
TRIAL STUDY 134XCP|TR|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||UMOL/L|DECREASED||MKAT|NOT DONE|||REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|NA|Y|CAREGIVER|ONCOLOGIST 1|N|2||58||LONG-TERM FOLLOW-UP|1972-10-09|
TRIAL STUDY 134XCP|TR|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|3||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||UEQ|INCREASED||MG/DOSE|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|U|N|CHILD|UROLOGIST|NA|3||39||OBSERVATION|1970-04-08|
TRIAL STUDY 134XCP|TR|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|4||||||SUMDIAM|SUM OF DIAMETER||PIPE|EQUIVOCAL||GPL U|NOT DONE|||HEMATOXYLIN AND EOSIN STAIN|Y|NA|GUARDIAN|MICROSCOPIST|U|4||88||LONG-TERM FOLLOW-UP|1972-03-24|
TRIAL STUDY 134XCP|TR|D4D4EEF1-9188-4969-A704-4EB2DAF625B5|5||||||SUMDIAM|SUM OF DIAMETER||MPA|FURTHER ENLARGEMENT||BEL|NOT DONE|||PERIODIC ACID SCHIFF STAIN|NA|Y|VENDOR|HEMATOLOGIST|Y|5||7||TREATMENT|1961-09-25|
TRIAL STUDY 134XCP|TR|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|1||||||LESELESV|LESION ELEVATION SEVERITY/INTENSITY||DAGU/ML|TUMOR MERGED||MPS U|NOT DONE|||WRIGHT-GIEMSA STAIN|Y|N|INVESTIGATOR|OPHTHALMOLOGIST|U|1||38||CONTINUATION TREATMENT|1973-08-09|
TRIAL STUDY 134XCP|TR|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|2||||||BNLNUM|NUMBER OF BONE LESIONS||SV|PRESENT||MG/KG/DOSE|NOT DONE|||NON-INVASIVE DIELECTRIC SENSING|N|N|SIBLING|OPTOMETRIST|U|2||58||BASELINE|1961-11-16|
TRIAL STUDY 134XCP|TR|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||GBQ/G|PRESENT||MM2|NOT DONE|||PALM METHOD|Y|U|SPOUSE|CLINICAL PATHOLOGIST|Y|3||39||OBSERVATION|1962-03-31|
TRIAL STUDY 134XCP|TR|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|4||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||SHOCK WAVE|ENLARGEMENT||TSP|NOT DONE|||ACRIDINE ORANGE STAIN|NA|N|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|4||88||WASHOUT|1960-02-28|
TRIAL STUDY 134XCP|TR|0456B11C-D064-4E92-AA2D-12DA09F3FAF4|5||||||BNLNUM|NUMBER OF BONE LESIONS||MKAT|UNCHANGED||RNA COPIES/ML|NOT DONE|||MULTIPLE BREATH WASHOUT|Y|Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|5||7||RUN-IN|1964-11-19|
TRIAL STUDY 134XCP|TR|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|1||||||NEWCONF|NEW TUMOR CONFIRMED||MPS U|EQUIVOCAL||UG/H|NOT DONE|||MICRONEUTRALIZATION ASSAY|Y|U|CAREGIVER|ONCOLOGIST|Y|1||38||WASHOUT|1967-02-28|
TRIAL STUDY 134XCP|TR|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|2||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||LM|EQUIVOCAL||NMOL/G|NOT DONE|||SLOAN LETTER EYE CHART 2.5%|Y|U|FRIEND|FORENSIC PATHOLOGIST|N|2||58||OPEN LABEL TREATMENT|1971-09-21|
TRIAL STUDY 134XCP|TR|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|3||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||S*KPA|NON-PATHOLOGICAL||/VF|NOT DONE|||LEAD CITRATE STAIN|NA|Y|ADJUDICATION COMMITTEE|READER 1|Y|3||39||RUN-IN|1968-10-16|
TRIAL STUDY 134XCP|TR|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|4||||||PCHGNAD|PERCENT CHANGE FROM NADIR||SCM|UNEQUIVOCAL||MG/M2/DAY|NOT DONE|||CELL BASED BIOASSAY|N|NA|PROXY|READER 3|U|4||88||FOLLOW-UP|1968-01-03|
TRIAL STUDY 134XCP|TR|D0C56E07-2ECA-4990-B7AB-6B06E5616C9F|5||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PG/DL|PALPABLE||DRINK|NOT DONE|||DIGITAL PCR ARRAY|NA|NA|SIGNIFICANT OTHER|ADJUDICATOR 1|NA|5||7||BLINDED TREATMENT|1965-06-19|
TRIAL STUDY 134XCP|TR|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|1||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||PL|FURTHER ENLARGEMENT FROM NADIR||ML/H|NOT DONE|||KINETIC CHROMOGENIC ASSAY|N|Y|CHILD|DERMATOLOGIST|N|1||38||FOLLOW-UP|1972-12-25|
TRIAL STUDY 134XCP|TR|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|2||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||PELLET|ENLARGEMENT FROM NADIR||GLOBULE|NOT DONE|||SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|Y|CHILD|MICROSCOPIST 2|U|2||58||TREATMENT|1964-12-08|
TRIAL STUDY 134XCP|TR|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|3||||||SUMVOL|SUM OF VOLUME||BAG|EQUIVOCAL||10^8 PFU|NOT DONE|||PLAQUE REDUCTION NEUTRALIZATION ASSAY|U|NA|PROXY|RATER 1|N|3||39||INDUCTION TREATMENT|1965-10-12|
TRIAL STUDY 134XCP|TR|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|4||||||SUMNLNLD|SUM DIAMETERS OF NON LYMPH NODE TUMORS||CI/MG|FOCALLY INCREASED||LENS|NOT DONE|||NUCLEIC ACID AMPLIFICATION TEST|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|4||88||RUN-IN|1968-09-15|
TRIAL STUDY 134XCP|TR|BCAF5E7C-8A2E-43E6-9292-95021AFDAB1E|5||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||KBQ/UL|UNCHANGED||MEQ/KG|NOT DONE|||LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|U|N|PROXY|OTOLARYNGOLOGIST|Y|5||7||RUN-IN|1967-07-05|
TRIAL STUDY 134XCP|TR|219A70B2-48A6-407C-B901-9847583DB5F4|1||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||GPL U|DIFFUSELY INCREASED||MOL/MG|NOT DONE|||QUANTITATIVE PERIPHERAL ANGIOGRAPHY|N|Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|1||38||FOLLOW-UP|1962-12-27|
TRIAL STUDY 134XCP|TR|219A70B2-48A6-407C-B901-9847583DB5F4|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||KG|FURTHER ENLARGEMENT||% INHIBITION|NOT DONE|||NON-CONTACT SPECULAR MICROSCOPY|NA|U|ADJUDICATION COMMITTEE|READER 2|NA|2||58||WASHOUT|1970-10-13|
TRIAL STUDY 134XCP|TR|219A70B2-48A6-407C-B901-9847583DB5F4|3||||||VDIAM|VIABLE DIAMETER||SCM|UNCHANGED||ABSORBANCE U|NOT DONE|||PULMONARY ANGIOGRAPHY|NA|Y|SPOUSE|READER 3|Y|3||39||LONG-TERM FOLLOW-UP|1972-07-28|
TRIAL STUDY 134XCP|TR|219A70B2-48A6-407C-B901-9847583DB5F4|4||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||MEQ|FOCALLY INCREASED||LINEAR FT*LB|NOT DONE|||PAP STAIN|N|U|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|4||88||SCREENING|1962-07-15|
TRIAL STUDY 134XCP|TR|219A70B2-48A6-407C-B901-9847583DB5F4|5||||||BNLNUM|NUMBER OF BONE LESIONS||VP/ML|ENLARGEMENT FROM NADIR||VIRTUAL PIXEL|NOT DONE|||PHOTOGRAPHY|NA|U|CHILD|ADJUDICATOR 3|N|5||7||TREATMENT|1971-06-03|
TRIAL STUDY 134XCP|TR|CF3AC42D-DFBA-448E-A688-46A87D6264EB|1||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||ML/MIN/MMHG|FOCALLY INCREASED||KG|NOT DONE|||MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|NA|VENDOR|MICROSCOPIST 3|U|1||38||LONG-TERM FOLLOW-UP|1971-07-04|
TRIAL STUDY 134XCP|TR|CF3AC42D-DFBA-448E-A688-46A87D6264EB|2||||||BNLNUM|NUMBER OF BONE LESIONS||MAMP|DIFFUSELY INCREASED||%(V/V)|NOT DONE|||QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|NA|Y|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||WASHOUT|1972-07-14|
TRIAL STUDY 134XCP|TR|CF3AC42D-DFBA-448E-A688-46A87D6264EB|3||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||GY|NON-PATHOLOGICAL||ML/SEC/1.73M2|NOT DONE|||MAGNETIC RESONANCE ELASTOGRAPHY|Y|U|PARENT|ADJUDICATOR 2|U|3||39||SCREENING|1969-12-12|
TRIAL STUDY 134XCP|TR|CF3AC42D-DFBA-448E-A688-46A87D6264EB|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||USIEMENS|FOCALLY INCREASED||WATT|NOT DONE|||SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|INVESTIGATOR|ADJUDICATOR 1|NA|4||88||BASELINE|1968-02-26|
TRIAL STUDY 134XCP|TR|CF3AC42D-DFBA-448E-A688-46A87D6264EB|5||||||SUMPPD|SUM OF PRODUCTS OF PERPENDICULAR DIAM||MET*H|NONPALPABLE||SV|NOT DONE|||SLIT LAMP PHOTOGRAPHY|N|NA|CLINICAL RESEARCH COORDINATOR|RATER|NA|5||7||CONTINUATION TREATMENT|1965-06-28|
TRIAL STUDY 134XCP|TR|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|1||||||SUMLPERP|SUM OF LONGEST PERPENDICULAR||/MM2|FURTHER ENLARGEMENT||KG/MOL|NOT DONE|||FLUORIMETRY|U|N|SIGNIFICANT OTHER|RATER 1|NA|1||38||SCREENING|1973-08-13|
TRIAL STUDY 134XCP|TR|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|2||||||LPERP|LONGEST PERPENDICULAR||IMPLANT|PATHOLOGICAL||U/MMOL|NOT DONE|||SPIRAL CT SCAN WITHOUT CONTRAST|N|NA|SPOUSE|RATER 1|N|2||58||LONG-TERM FOLLOW-UP|1964-08-30|
TRIAL STUDY 134XCP|TR|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|3||||||VDIAM|VIABLE DIAMETER||DROP|FURTHER ENLARGEMENT FROM NADIR||PATCH|NOT DONE|||MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|N|U|ADJUDICATOR|PHYSIOTHERAPIST|NA|3||39||OBSERVATION|1964-05-15|
TRIAL STUDY 134XCP|TR|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|4||||||ACNSD|ABSOLUTE CHANGE NADIR IN SUM OF DIAM||AMPULE|DECREASED||/LSQN|NOT DONE|||TRANSCRIPTION-MEDIATED AMPLIFICATION|N|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|4||88||FOLLOW-UP|1964-03-18|
TRIAL STUDY 134XCP|TR|0FB5E37C-B78E-4EE2-A55E-9E850D680BB4|5||||||LESFLIND|LESION FAILURE INDICATOR||SEC|NONPALPABLE||UG/ANIMAL|NOT DONE|||NEURAMINIDASE INHIBITION ASSAY|Y|N|SPOUSE|ENDOCRINOLOGIST|NA|5||7||WASHOUT|1968-12-22|
TRIAL STUDY 134XCP|TR|D19D43A5-DFE6-415D-86B7-6A767A357BC9|1||||||OTRCUPCN|OVERALL TRACER UPTAKE COMPARED TO NADIR||UEQ/L|ENLARGEMENT FROM NADIR||HEP|NOT DONE|||ACCELERATOR MASS SPECTROMETRY|NA|Y|CLINICAL RESEARCH COORDINATOR|READER 3|U|1||38||OBSERVATION|1970-11-05|
TRIAL STUDY 134XCP|TR|D19D43A5-DFE6-415D-86B7-6A767A357BC9|2||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||UMOL/MG/MIN|ENLARGEMENT FROM NADIR||10^9 ORGANISMS/ML|NOT DONE|||HEMAGGLUTINATION INHIBITION ASSAY|NA|NA|CLINICAL STUDY SPONSOR|READER|NA|2||58||BLINDED TREATMENT|1972-03-26|
TRIAL STUDY 134XCP|TR|D19D43A5-DFE6-415D-86B7-6A767A357BC9|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^12 IU/L|NONPALPABLE||IU/MG|NOT DONE|||LASER CAPTURE MICRODISSECTION|Y|N|INVESTIGATOR|NEUROLOGIST 1|Y|3||39||LONG-TERM FOLLOW-UP|1960-01-13|
TRIAL STUDY 134XCP|TR|D19D43A5-DFE6-415D-86B7-6A767A357BC9|4||||||NBNL2IND|TWO OR MORE NEW BONE LESIONS INDICATOR||10^9 ORGANISMS|ABSENT||NMOL/L/MIN|NOT DONE|||CARDIAC THERMODILUTION|Y|Y|CAREGIVER|NEUROLOGIST 1|NA|4||88||OBSERVATION|1968-11-08|
TRIAL STUDY 134XCP|TR|D19D43A5-DFE6-415D-86B7-6A767A357BC9|5||||||TUMSTATE|TUMOR STATE||/DAY|PALPABLE||EU|NOT DONE|||REFLECTANCE SPECTROSCOPY|N|U|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|Y|5||7||BLINDED TREATMENT|1971-11-22|
TRIAL STUDY 134XCP|TR|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|1||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||G/ANIMAL|DECREASED||%(V/V)|NOT DONE|||QUANTITATIVE CORONARY ANGIOGRAPHY|N|N|VENDOR|OPHTHALMOLOGIST|NA|1||38||WASHOUT|1965-12-23|
TRIAL STUDY 134XCP|TR|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|2||||||RADIODEN|RADIODENSITY||PT_US|DIFFUSELY INCREASED||LENS|NOT DONE|||MAMMOGRAPHY|NA|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|2||58||CONTINUATION TREATMENT|1961-03-06|
TRIAL STUDY 134XCP|TR|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|3||||||BNLNUM|NUMBER OF BONE LESIONS||BREATHS/MIN|ABSENT||LOG10 CFU/ML|NOT DONE|||DXA SCAN|N|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3||39||RUN-IN|1962-02-14|
TRIAL STUDY 134XCP|TR|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|4||||||LDIAM|LONGEST DIAMETER||NMOL|ENLARGEMENT||PPTH|NOT DONE|||SNP ARRAY|U|N|GUARDIAN|MICROSCOPIST 3|NA|4||88||FOLLOW-UP|1967-01-12|
TRIAL STUDY 134XCP|TR|B9DDBCB0-91F7-4C06-B1E7-5577928C799F|5||||||SUMVDIAM|SUM OF VIABLE DIAMETER||TABLET|FURTHER ENLARGEMENT FROM NADIR||U.CARR|NOT DONE|||VENTILATION PERFUSION LUNG SCAN|U|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|5||7||OBSERVATION|1972-11-26|
TRIAL STUDY 134XCP|TR|7D307F63-4A25-4E7D-9980-16764AE5C4A4|1||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||KA_U/DL|EQUIVOCAL||KG/CM2|NOT DONE|||FLOCCULATION, CHARCOAL ENHANCED|U|U|INVESTIGATOR|CARDIOLOGIST|N|1||38||WASHOUT|1970-07-23|
TRIAL STUDY 134XCP|TR|7D307F63-4A25-4E7D-9980-16764AE5C4A4|2||||||DIAMETER|DIAMETER||GPL U/ML|INCREASED||ANTI-XA IU|NOT DONE|||DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|NA|U|INTERVIEWER|MICROSCOPIST 2|N|2||58||SCREENING|1962-12-28|
TRIAL STUDY 134XCP|TR|7D307F63-4A25-4E7D-9980-16764AE5C4A4|3||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||MIN|FURTHER ENLARGEMENT||MS/MMHG|NOT DONE|||NUCLEIC ACID SEQUENCING|N|Y|ADJUDICATOR|RADIOLOGIST 1|U|3||39||FOLLOW-UP|1968-03-23|
TRIAL STUDY 134XCP|TR|7D307F63-4A25-4E7D-9980-16764AE5C4A4|4||||||BNLNUM|NUMBER OF BONE LESIONS||10^6 ORGANISMS/ML|FOCALLY INCREASED||%/S|NOT DONE|||SLOAN LETTER EYE CHART 1.25%|U|Y|SIBLING|PATHOLOGIST 1|NA|4||88||INDUCTION TREATMENT|1960-07-24|
TRIAL STUDY 134XCP|TR|7D307F63-4A25-4E7D-9980-16764AE5C4A4|5||||||PCBSOREN|PERCENT CHANGE BASELINE IN ORGAN ENLARGE||ENZYME U/L|FOCALLY INCREASED||TABLET|NOT DONE|||INTRAVASCULAR ULTRASOUND|Y|U|FRIEND|READER 3|NA|5||7||BLINDED TREATMENT|1965-10-01|
TRIAL STUDY 134XCP|TR|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|1||||||PCNSLD|PERCENT CHANGE NADIR IN SUM LONGEST DIAM||PT_US|DECREASED||UG/KG/DAY|NOT DONE|||PERCUSSION|Y|Y|SIGNIFICANT OTHER|READER 2|N|1||38||INDUCTION TREATMENT|1973-04-19|
TRIAL STUDY 134XCP|TR|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|2||||||ACNDOREN|ABSOLUTE CHANGE NADIR IN ORGAN ENLARGE||10^11/L|ENLARGEMENT||GTT|NOT DONE|||HANSEL STAIN|U|NA|DOMESTIC PARTNER|NEUROLOGIST 2|NA|2||58||FOLLOW-UP|1972-01-25|
TRIAL STUDY 134XCP|TR|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|3||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||FARAD|TUMOR MERGED||SYRINGE|NOT DONE|||GRADIENT DIFFUSION|U|N|PROXY|OTOLARYNGOLOGIST|Y|3||39||OPEN LABEL TREATMENT|1965-10-16|
TRIAL STUDY 134XCP|TR|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|4||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MOL/G|ENLARGEMENT FROM NADIR||/MM|NOT DONE|||MICROSCOPY|Y|Y|PARENT|NEUROLOGIST 1|U|4||88||BASELINE|1968-06-16|
TRIAL STUDY 134XCP|TR|C651B2EE-281E-4CC6-ACC6-E91B19138A7D|5||||||VSLPIND|VESSEL PATENCY INDICATOR||CAPLET|NON-PATHOLOGICAL||MG/M2/MIN|NOT DONE|||QUANTITATIVE COMPUTED TOMOGRAPHY|U|N|ADJUDICATOR|PATHOLOGIST|U|5||7||OPEN LABEL TREATMENT|1965-11-13|
TRIAL STUDY 134XCP|TR|F4718E0D-4DD9-442E-8907-076551C83AEE|1||||||LESERYSV|LESION ERYTHEMA SEVERITY/INTENSITY||DL|DIFFUSELY INCREASED||MEQ/G|NOT DONE|||ENDOSCOPY|U|U|ADJUDICATOR|READER 3|U|1||38||LONG-TERM FOLLOW-UP|1966-06-26|
TRIAL STUDY 134XCP|TR|F4718E0D-4DD9-442E-8907-076551C83AEE|2||||||PCBSV|PERCENT CHANGE BASELINE IN SUM OF VOLUME||MMHG/L/MIN|NONPALPABLE||MM3/MM2/YEAR|NOT DONE|||DARK FIELD MICROSCOPY|U|U|DOMESTIC PARTNER|READER|N|2||58||RUN-IN|1970-03-05|
TRIAL STUDY 134XCP|TR|F4718E0D-4DD9-442E-8907-076551C83AEE|3||||||SUMLDIAM|SUM OF LONGEST DIAMETER||G/ANIMAL/WK|FOCALLY INCREASED||MG/L|NOT DONE|||OPTICAL MAPPING|Y|Y|CHILD|ADJUDICATOR 2|U|3||39||SCREENING|1966-03-07|
TRIAL STUDY 134XCP|TR|F4718E0D-4DD9-442E-8907-076551C83AEE|4||||||PCNDOREN|PERCENT CHANGE NADIR IN ORGAN ENLARGE||CI/ML|ENLARGEMENT FROM NADIR||MKAT|NOT DONE|||POTENTIOMETRY|U|N|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|4||88||BLINDED TREATMENT|1961-12-11|
TRIAL STUDY 134XCP|TR|F4718E0D-4DD9-442E-8907-076551C83AEE|5||||||LRVCLIND|LESION REVAS CLINICAL INDICATOR||MM|ABSENT||VP/DOSE|NOT DONE|||FLUORESCENT IMMUNOASSAY|NA|N|VENDOR|CLINICAL PATHOLOGIST|NA|5||7||BASELINE|1972-08-23|
TRIAL STUDY 134XCP|TR|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|1||||||SUMLDIAM|SUM OF LONGEST DIAMETER||STRIP|UNEQUIVOCAL||NKAT|NOT DONE|||DIRECT SEQUENCING|Y|N|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|1||38||OPEN LABEL TREATMENT|1961-10-22|
TRIAL STUDY 134XCP|TR|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|2||||||NBNLNUM|NUMBER OF NEW BONE LESIONS||HOUNSFIELD UNIT|FURTHER ENLARGEMENT FROM NADIR||MMAL|NOT DONE|||CONGO RED STAIN|NA|U|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|2||58||BASELINE|1967-12-07|
TRIAL STUDY 134XCP|TR|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|3||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||10^11/L|NON-PATHOLOGICAL||U/ML|NOT DONE|||TWO-COLOR MICROARRAY|N|N|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|3||39||SCREENING|1970-02-23|
TRIAL STUDY 134XCP|TR|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|4||||||SUMVDIAM|SUM OF VIABLE DIAMETER||MG/H|ENLARGEMENT FROM NADIR||/100 HPFS|NOT DONE|||CINEANGIOGRAPHY|U|U|FAMILY MEMBER|RATER 1|Y|4||88||RUN-IN|1961-11-28|
TRIAL STUDY 134XCP|TR|AC095369-9EEF-47F5-938C-DAF5D4FAF7C9|5||||||ORSTATE|ORGAN STATE||ML/G/H|UNCHANGED||IN|NOT DONE|||HIGH RESOLUTION CT|N|NA|FRIEND|MICROSCOPIST 3|Y|5||7||INDUCTION TREATMENT|1960-12-09|
TRIAL STUDY 134XCP|TR|E86F996D-3A96-4C36-82B2-1AC4B4906F49|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||FEU|DIFFUSELY INCREASED||YEARS|NOT DONE|||RADIAL IMMUNODIFFUSION|NA|N|VENDOR|MICROSCOPIST|NA|1||38||BLINDED TREATMENT|1962-01-29|
TRIAL STUDY 134XCP|TR|E86F996D-3A96-4C36-82B2-1AC4B4906F49|2||||||DIAMETER|DIAMETER||DRINK|ENLARGEMENT||PG|NOT DONE|||MICROPARTICLE ENZYME IMMUNOASSAY|N|NA|CLINICAL RESEARCH ASSOCIATE|RATER 2|U|2||58||SCREENING|1973-04-30|
TRIAL STUDY 134XCP|TR|E86F996D-3A96-4C36-82B2-1AC4B4906F49|3||||||PCHGNAD|PERCENT CHANGE FROM NADIR||NMOL|NONPALPABLE||PIXEL|NOT DONE|||ICP-MS|U|NA|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3||39||INDUCTION TREATMENT|1967-05-18|
TRIAL STUDY 134XCP|TR|E86F996D-3A96-4C36-82B2-1AC4B4906F49|4||||||LESSCIND|LESION SUCCESS INDICATOR||TESLA|ABSENT||EID 50/DOSE|NOT DONE|||PHYSICAL EXAMINATION|NA|NA|STUDY SUBJECT|PATHOLOGIST|NA|4||88||CONTINUATION TREATMENT|1965-06-04|
TRIAL STUDY 134XCP|TR|E86F996D-3A96-4C36-82B2-1AC4B4906F49|5||||||DIAMETER|DIAMETER||DNA COPIES/ML|ABSENT||NG/DL|NOT DONE|||FLUORESCENT LIFETIME IMAGING MICROSCOPY|NA|U|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|5||7||BASELINE|1972-04-16|
TRIAL STUDY 134XCP|TR|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|1||||||VDIAM|VIABLE DIAMETER||UG/ML/H|PALPABLE||MM3/MM2/YEAR|NOT DONE|||IMMUNOCHROMATOGRAPHY|U|NA|INVESTIGATOR|UROLOGIST|N|1||38||SCREENING|1967-12-10|
TRIAL STUDY 134XCP|TR|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|2||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||MV/SEC|FURTHER ENLARGEMENT||OI50|NOT DONE|||ELLA|U|N|INTERVIEWER|ONCOLOGIST 2|Y|2||58||CONTINUATION TREATMENT|1969-01-16|
TRIAL STUDY 134XCP|TR|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|3||||||LESSCLSV|LESION SCALING SEVERITY/INTENSITY||PMOL/L|PATHOLOGICAL||CCID 50/DOSE|NOT DONE|||PULSE OXIMETRY|N|Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|3||39||WASHOUT|1973-07-04|
TRIAL STUDY 134XCP|TR|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|4||||||NEWCONF|NEW TUMOR CONFIRMED||TUBERCULIN UNIT|UNEQUIVOCAL||UV|NOT DONE|||GC/FID|Y|U|FAMILY MEMBER|CARDIOLOGIST|Y|4||88||BLINDED TREATMENT|1963-10-26|
TRIAL STUDY 134XCP|TR|10DEC5CB-7A18-4A1D-9138-4F2C83A7737C|5||||||LPERP|LONGEST PERPENDICULAR||LOG10 IU/ML|DECREASED||G/DAY|NOT DONE|||MYELOPEROXIDASE STAIN|NA|U|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|5||7||LONG-TERM FOLLOW-UP|1961-12-08|
TRIAL STUDY 134XCP|TR|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|1||||||LMNDEXAM|NUMBER OF LYMPH NODES EXAMINED||U/KG/H|UNEQUIVOCAL||TUBE|NOT DONE|||SLIT LAMP PHOTOGRAPHY|Y|NA|GUARDIAN|PATHOLOGIST 1|N|1||38||OBSERVATION|1967-09-01|
TRIAL STUDY 134XCP|TR|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|2||||||LESFLIND|LESION FAILURE INDICATOR||KCAL|INCREASED||CUP|NOT DONE|||THICK SMEAR|NA|NA|PROXY|OPTOMETRIST|N|2||58||CONTINUATION TREATMENT|1972-10-23|
TRIAL STUDY 134XCP|TR|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|3||||||VSLFLIND|VESSEL FAILURE INDICATOR||10^3 CFU/G|NON-PATHOLOGICAL||ABSORBANCE U/ML|NOT DONE|||MRI WITHOUT CONTRAST|NA|U|INVESTIGATOR|READER 1|U|3||39||INDUCTION TREATMENT|1967-10-01|
TRIAL STUDY 134XCP|TR|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|4||||||TUMSTATE|TUMOR STATE||% INHIBITION|FURTHER ENLARGEMENT FROM NADIR||U/G HB|NOT DONE|||REFRACTOMETRY|U|N|ADJUDICATION COMMITTEE|READER 3|U|4||88||CONTINUATION TREATMENT|1968-12-23|
TRIAL STUDY 134XCP|TR|5E3C9256-B0B9-4221-B5B6-FB2B76DA9BEF|5||||||VSLRVIND|VESSEL REVASCULARIZATION INDICATOR||ML/S|FURTHER ENLARGEMENT||NMOL/G|NOT DONE|||IMMUNE REPERTOIRE DEEP SEQUENCING|Y|N|SIBLING|OPHTHALMOLOGIST|Y|5||7||FOLLOW-UP|1969-12-12|
TRIAL STUDY 134XCP|TR|28E9B15E-4757-42F5-8AE7-2C868904F88B|1||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||ML/KG/DAY|ABSENT||10^9 CFU/ML|NOT DONE|||IMMUNOFIXATION ELECTROPHORESIS|N|Y|SIGNIFICANT OTHER|ONCOLOGIST 2|Y|1||38||OBSERVATION|1961-01-06|
TRIAL STUDY 134XCP|TR|28E9B15E-4757-42F5-8AE7-2C868904F88B|2||||||VDIAM|VIABLE DIAMETER||AGU/ML|FURTHER ENLARGEMENT||DPM|NOT DONE|||TEST STRIP|N|Y|CLINICAL STUDY SPONSOR|INTERNIST|NA|2||58||BLINDED TREATMENT|1961-10-25|
TRIAL STUDY 134XCP|TR|28E9B15E-4757-42F5-8AE7-2C868904F88B|3||||||ORENLQN|ORGAN ENLARGEMENT, QUANTITATIVE||RAD|EQUIVOCAL||MOL/DAY|NOT DONE|||WESTERN BLOT|N|N|CAREGIVER|OPHTHALMOLOGIST|NA|3||39||RUN-IN|1970-08-04|
TRIAL STUDY 134XCP|TR|28E9B15E-4757-42F5-8AE7-2C868904F88B|4||||||BMUPTAKE|BONE MARROW TRACER UPTAKE||LOG10 CFU/ML|UNEQUIVOCAL||ML/M2|NOT DONE|||INCISION-INDUCED BLEEDING METHOD|Y|Y|FAMILY MEMBER|RADIOLOGIST|Y|4||88||TREATMENT|1973-05-25|
TRIAL STUDY 134XCP|TR|28E9B15E-4757-42F5-8AE7-2C868904F88B|5||||||ORVERLN|ORGAN VERTICAL LENGTH||DRAM|ABSENT||UG/M2|NOT DONE|||RYAN BLUE STAIN|U|NA|VENDOR|OPHTHALMOLOGIST|Y|5||7||BASELINE|1973-03-20|
TRIAL STUDY 134XCP|TR|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|1||||||PCBSLD|PERCENT CHANGE BASELINE SUM LONGEST DIAM||AG|NON-PATHOLOGICAL||MMOL/MOL|NOT DONE|||DIGITAL PCR|NA|NA|PROXY|READER 3|U|1||38||SCREENING|1971-04-21|
TRIAL STUDY 134XCP|TR|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|2||||||PCHGBL|PERCENT CHANGE FROM BASELINE||HOURS|UNCHANGED||ML/KG/H|NOT DONE|||WESTERN BLOT|Y|U|CAREGIVER|FORENSIC PATHOLOGIST|U|2||58||FOLLOW-UP|1968-06-03|
TRIAL STUDY 134XCP|TR|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|3||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||MBQ/UL|FURTHER ENLARGEMENT FROM NADIR||UL/DOSE|NOT DONE|||POPULATION SEQUENCING|NA|Y|SIBLING|MICROSCOPIST|Y|3||39||CONTINUATION TREATMENT|1961-02-23|
TRIAL STUDY 134XCP|TR|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|4||||||PCNSD|PERCENT CHANGE NADIR IN SUM OF DIAM||MEQ/DAY|FURTHER ENLARGEMENT||ABSORBANCE U|NOT DONE|||MICROBIAL BIOCHEMICAL IDENTIFICATION|NA|NA|FAMILY MEMBER|PATHOLOGIST 2|U|4||88||INDUCTION TREATMENT|1970-11-28|
TRIAL STUDY 134XCP|TR|1547C5B8-C63D-4A54-8FCF-8BC022E0A52B|5||||||PPD|PRODUCT OF PERPENDICULAR DIAMETERS||CD*S/M2|DIFFUSELY INCREASED||SQU/ML|NOT DONE|||TRIPLE-PHASE MRI SCAN|Y|U|PARENT|ONCOLOGIST 1|Y|5||7||WASHOUT|1963-09-15|
TRIAL STUDY 134XCP|TR|2E1011F1-A091-4E7E-B661-477A1F6DD39A|1||||||VSLPIND|VESSEL PATENCY INDICATOR||PSI|FURTHER ENLARGEMENT FROM NADIR||CP|NOT DONE|||IMMUNOTURBIDIMETRY|U|Y|SIBLING|ONCOLOGIST 2|NA|1||38||SCREENING|1967-04-17|
TRIAL STUDY 134XCP|TR|2E1011F1-A091-4E7E-B661-477A1F6DD39A|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||ML/(MIN*100ML)|PATHOLOGICAL||MIN/DAY|NOT DONE|||TOTAL BODY RADIOGRAPHY|Y|Y|INTERVIEWER|READER 1|NA|2||58||WASHOUT|1972-04-23|
TRIAL STUDY 134XCP|TR|2E1011F1-A091-4E7E-B661-477A1F6DD39A|3||||||PCNSPPD|PERCENT CHANGE NADIR IN SUM OF PPD||10^6 ORGANISMS/G|UNCHANGED||PFU/DOSE|NOT DONE|||IHC|Y|Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|3||39||OPEN LABEL TREATMENT|1972-10-10|
TRIAL STUDY 134XCP|TR|2E1011F1-A091-4E7E-B661-477A1F6DD39A|4||||||ACHNAD|ABSOLUTE CHANGE FROM NADIR||UG/L DDU|PRESENT||OZ|NOT DONE|||OBSERVATION|N|Y|PROXY|ADJUDICATOR 2|Y|4||88||SCREENING|1966-12-27|
TRIAL STUDY 134XCP|TR|2E1011F1-A091-4E7E-B661-477A1F6DD39A|5||||||LESRVIND|LESION REVASCULARIZATION INDICATOR||UMOL/H/MMOL|PRESENT||ABSORBANCE U/MIN|NOT DONE|||IN SITU HYBRIDIZATION|U|NA|SPOUSE|INTERNIST|Y|5||7||OBSERVATION|1965-03-20|
TRIAL STUDY 134XCP|TR|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|1||||||BNLNUM|NUMBER OF BONE LESIONS||DIOPTER|FURTHER ENLARGEMENT||BOWL|NOT DONE|||APPLANATION TONOMETRY|NA|NA|CLINICAL STUDY SPONSOR|READER 3|U|1||38||CONTINUATION TREATMENT|1961-11-04|
TRIAL STUDY 134XCP|TR|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|2||||||LMBFLIND|LIMB FAILURE INDICATOR||LOG10 TCID 50/DOSE|NORMAL||ML|NOT DONE|||CONTRAST ENHANCED SPIRAL CT SCAN|Y|NA|ADJUDICATOR|PATHOLOGIST 2|NA|2||58||SCREENING|1965-01-01|
TRIAL STUDY 134XCP|TR|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|3||||||NEWCONF|NEW TUMOR CONFIRMED||USP U|NON-PATHOLOGICAL||AMFI|NOT DONE|||CHROMOGENIC ASSAY|NA|N|CAREGIVER|FORENSIC PATHOLOGIST|U|3||39||INDUCTION TREATMENT|1962-11-20|
TRIAL STUDY 134XCP|TR|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|4||||||ACPPDNLD|ABSOLUTE CHANGE FROM PPD NADIR IN LDIAM||ML/G/DAY|FOCALLY INCREASED||IU/G|NOT DONE|||MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|U|U|INVESTIGATOR|MICROSCOPIST 1|U|4||88||CONTINUATION TREATMENT|1960-07-22|
TRIAL STUDY 134XCP|TR|7227F990-6CFE-49BD-BB46-5B2DDAD9CB49|5||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||PFU|INCREASED||UM|NOT DONE|||PLETHYSMOGRAPHY|U|NA|SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|5||7||INDUCTION TREATMENT|1968-11-10|
TRIAL STUDY 134XCP|TR|176B6882-0C9E-435E-9842-FF8714BC9CAF|1||||||PCBSD|PERCENT CHANGE BASELINE IN SUM OF DIAM||UG/MIN|FOCALLY INCREASED||ML/MIN/1.73M2|NOT DONE|||AGAR DILUTION|NA|U|GUARDIAN|ONCOLOGIST|NA|1||38||INDUCTION TREATMENT|1971-05-28|
TRIAL STUDY 134XCP|TR|176B6882-0C9E-435E-9842-FF8714BC9CAF|2||||||PCBSPPD|PERCENT CHANGE BASELINE IN SUM OF PPD||10^8 PFU|DIFFUSELY INCREASED||MOL/MG|NOT DONE|||FLUORESCENCE ANGIOGRAPHY|U|N|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|2||58||FOLLOW-UP|1971-10-12|
TRIAL STUDY 134XCP|TR|176B6882-0C9E-435E-9842-FF8714BC9CAF|3||||||PBNL2IND|TWO OR MORE PERSIST NEW BONE LESIONS IND||MONTHS|ABSENT||PUFF|NOT DONE|||AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|N|ADJUDICATOR|OPTOMETRIST|NA|3||39||LONG-TERM FOLLOW-UP|1960-09-16|
TRIAL STUDY 134XCP|TR|176B6882-0C9E-435E-9842-FF8714BC9CAF|4||||||LMBFLIND|LIMB FAILURE INDICATOR||VIAL|PRESENT||10^12/L|NOT DONE|||SPIROMETRY|N|U|INDEPENDENT ASSESSOR|MICROSCOPIST|Y|4||88||OPEN LABEL TREATMENT|1971-10-02|
TRIAL STUDY 134XCP|TR|176B6882-0C9E-435E-9842-FF8714BC9CAF|5||||||PCNPPD|PERCENT CHANGE NADIR IN PPD||10^6 ORGANISMS/MG|UNEQUIVOCAL||UM/S|NOT DONE|||ELECTROCHEMILUMINESCENCE IMMUNOASSAY|N|NA|SIGNIFICANT OTHER|NEUROLOGIST 2|U|5||7||OBSERVATION|1962-09-09|
